<?xml version="1.0" encoding="utf-8"?>
<feed xmlns="http://www.w3.org/2005/Atom">
    <id>https://macwaneric.github.io/cancer.rss.feed/index.html</id>
    <title>CancerFeed</title>
    <updated>2023-09-25T00:50:20.886Z</updated>
    <generator>osmosfeed 1.15.1</generator>
    <link rel="alternate" href="https://macwaneric.github.io/cancer.rss.feed/index.html"/>
    <link rel="self" href="https://macwaneric.github.io/cancer.rss.feed/feed.atom"/>
    <entry>
        <title type="html"><![CDATA[Clonal evolution of long-term expanding head and neck cancer organoid: Impact on treatment response for personalized therapeutic screening]]></title>
        <id>pubmed:37741019</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37741019/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230924205014&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-09-23T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSIONS: We report the establishment of HNCO lines derived from 27 patients and demonstrate their genetic concordance with corresponding parental tumors. Furthermore, we show serial changes in mutational profiles of HNCO along with long passage culture and the impact of these clonal evolutions on response to radiotherapy.]]></summary>
        <author>
            <name>Sung Yong Choi</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clonal Hematopoiesis as a Molecular Risk Factor for Doxorubicin-Induced Cardiotoxicity: A Proof-of-Concept Study]]></title>
        <id>pubmed:37738545</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37738545/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230924205014&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-09-22T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSION: This study provides preliminary evidence for CH as a predictive risk factor for DIC, which, with further investigation, could serve as an important precision medicine biomarker for the large number of patients with cancer who have CH.]]></summary>
        <author>
            <name>Jamila Mammadova</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clonal Hematopoiesis as a Molecular Risk Factor for Doxorubicin-Induced Cardiotoxicity: A Proof-of-Concept Study]]></title>
        <id>pubmed:37738545</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37738545/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230923205208&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-09-22T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSION: This study provides preliminary evidence for CH as a predictive risk factor for DIC, which, with further investigation, could serve as an important precision medicine biomarker for the large number of patients with cancer who have CH.]]></summary>
        <author>
            <name>Jamila Mammadova</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clonal Hematopoiesis as a Molecular Risk Factor for Doxorubicin-Induced Cardiotoxicity: A Proof-of-Concept Study]]></title>
        <id>pubmed:37738545</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37738545/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230922204741&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-09-22T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSION: This study provides preliminary evidence for CH as a predictive risk factor for DIC, which, with further investigation, could serve as an important precision medicine biomarker for the large number of patients with cancer who have CH.]]></summary>
        <author>
            <name>Jamila Mammadova</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[CD45-antibody-drug conjugate clears tissue resident myeloid cells from their niches enabling therapeutic adoptive cell transfer]]></title>
        <id>pubmed:37732224</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37732224/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230924205014&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-09-21T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Tissue resident myeloid cells (TRM) in adults have highly variable lifespans and may be derived from early embryonic yolk sac, fetal liver or bone marrow. Some of these TRM are known pathogenic participants in congenital and acquired diseases. Myeloablative conditioning and hematopoietic stem cell transplant can replace long-lived brain TRM resulting in clinical improvements in metabolic storage diseases. With the advent of antibody-drug-conjugate (ADC) targeted cell killing as a cell selective...]]></summary>
        <author>
            <name>Karin Gustafsson</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Long-term longitudinal analysis of 4,187 participants reveals new insights into determinants of incident clonal hematopoiesis]]></title>
        <id>pubmed:37732181</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37732181/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230924205014&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-09-21T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Clonal hematopoiesis (CH), characterized by blood cells predominantly originating from a single mutated hematopoietic stem cell, is linked to diverse aging-related diseases, including hematologic malignancy and atherosclerotic cardiovascular disease (ASCVD). While CH is common among older adults, the underlying factors driving its development are largely unknown. To address this, we performed whole-exome sequencing on 8,374 blood DNA samples collected from 4,187 Atherosclerosis Risk in...]]></summary>
        <author>
            <name>Md Mesbah Uddin</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[CD45-antibody-drug conjugate clears tissue resident myeloid cells from their niches enabling therapeutic adoptive cell transfer]]></title>
        <id>pubmed:37732224</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37732224/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230923205208&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-09-21T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Tissue resident myeloid cells (TRM) in adults have highly variable lifespans and may be derived from early embryonic yolk sac, fetal liver or bone marrow. Some of these TRM are known pathogenic participants in congenital and acquired diseases. Myeloablative conditioning and hematopoietic stem cell transplant can replace long-lived brain TRM resulting in clinical improvements in metabolic storage diseases. With the advent of antibody-drug-conjugate (ADC) targeted cell killing as a cell selective...]]></summary>
        <author>
            <name>Karin Gustafsson</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Long-term longitudinal analysis of 4,187 participants reveals new insights into determinants of incident clonal hematopoiesis]]></title>
        <id>pubmed:37732181</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37732181/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230923205208&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-09-21T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Clonal hematopoiesis (CH), characterized by blood cells predominantly originating from a single mutated hematopoietic stem cell, is linked to diverse aging-related diseases, including hematologic malignancy and atherosclerotic cardiovascular disease (ASCVD). While CH is common among older adults, the underlying factors driving its development are largely unknown. To address this, we performed whole-exome sequencing on 8,374 blood DNA samples collected from 4,187 Atherosclerosis Risk in...]]></summary>
        <author>
            <name>Md Mesbah Uddin</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[CD45-antibody-drug conjugate clears tissue resident myeloid cells from their niches enabling therapeutic adoptive cell transfer]]></title>
        <id>pubmed:37732224</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37732224/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230922204741&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-09-21T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Tissue resident myeloid cells (TRM) in adults have highly variable lifespans and may be derived from early embryonic yolk sac, fetal liver or bone marrow. Some of these TRM are known pathogenic participants in congenital and acquired diseases. Myeloablative conditioning and hematopoietic stem cell transplant can replace long-lived brain TRM resulting in clinical improvements in metabolic storage diseases. With the advent of antibody-drug-conjugate (ADC) targeted cell killing as a cell selective...]]></summary>
        <author>
            <name>Karin Gustafsson</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Long-term longitudinal analysis of 4,187 participants reveals new insights into determinants of incident clonal hematopoiesis]]></title>
        <id>pubmed:37732181</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37732181/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230922204741&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-09-21T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Clonal hematopoiesis (CH), characterized by blood cells predominantly originating from a single mutated hematopoietic stem cell, is linked to diverse aging-related diseases, including hematologic malignancy and atherosclerotic cardiovascular disease (ASCVD). While CH is common among older adults, the underlying factors driving its development are largely unknown. To address this, we performed whole-exome sequencing on 8,374 blood DNA samples collected from 4,187 Atherosclerosis Risk in...]]></summary>
        <author>
            <name>Md Mesbah Uddin</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[CD45-antibody-drug conjugate clears tissue resident myeloid cells from their niches enabling therapeutic adoptive cell transfer]]></title>
        <id>pubmed:37732224</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37732224/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230921204936&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-09-21T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Tissue resident myeloid cells (TRM) in adults have highly variable lifespans and may be derived from early embryonic yolk sac, fetal liver or bone marrow. Some of these TRM are known pathogenic participants in congenital and acquired diseases. Myeloablative conditioning and hematopoietic stem cell transplant can replace long-lived brain TRM resulting in clinical improvements in metabolic storage diseases. With the advent of antibody-drug-conjugate (ADC) targeted cell killing as a cell selective...]]></summary>
        <author>
            <name>Karin Gustafsson</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Long-term longitudinal analysis of 4,187 participants reveals new insights into determinants of incident clonal hematopoiesis]]></title>
        <id>pubmed:37732181</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37732181/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230921204936&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-09-21T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Clonal hematopoiesis (CH), characterized by blood cells predominantly originating from a single mutated hematopoietic stem cell, is linked to diverse aging-related diseases, including hematologic malignancy and atherosclerotic cardiovascular disease (ASCVD). While CH is common among older adults, the underlying factors driving its development are largely unknown. To address this, we performed whole-exome sequencing on 8,374 blood DNA samples collected from 4,187 Atherosclerosis Risk in...]]></summary>
        <author>
            <name>Md Mesbah Uddin</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Impact of Preexisting Autoimmune Disease on Myelodysplastic Syndromes Outcomes: A population Analysis]]></title>
        <id>pubmed:37729616</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37729616/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230924205014&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-09-20T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Preexisting autoimmune disease affects 10-30% of patients with myelodysplastic syndromes (MDS). Studies comparing outcomes in MDS patients with and without autoimmune disease show discordant results. Using Surveillance, Epidemiology, and End Results (SEER)-Medicare, we conducted a population analysis to define the impact of autoimmunity on MDS outcomes. Cases were ascertained between 2007 - 2017 and claim algorithms employed to identify autoimmune disease, demographic characteristics,...]]></summary>
        <author>
            <name>Diego Andres Adrianzen-Herrera</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Single-cell genotypic and phenotypic analysis of measurable residual disease in acute myeloid leukemia]]></title>
        <id>pubmed:37729414</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37729414/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230924205014&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-09-20T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Measurable residual disease (MRD), defined as the population of cancer cells that persist following therapy, serves as the critical reservoir for disease relapse in acute myeloid leukemia and other malignancies. Understanding the biology enabling MRD clones to resist therapy is necessary to guide the development of more effective curative treatments. Discriminating between residual leukemic clones, preleukemic clones, and normal precursors remains a challenge with current MRD tools. Here, we...]]></summary>
        <author>
            <name>Troy M Robinson</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Impact of Preexisting Autoimmune Disease on Myelodysplastic Syndromes Outcomes: A population Analysis]]></title>
        <id>pubmed:37729616</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37729616/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230923205208&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-09-20T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Preexisting autoimmune disease affects 10-30% of patients with myelodysplastic syndromes (MDS). Studies comparing outcomes in MDS patients with and without autoimmune disease show discordant results. Using Surveillance, Epidemiology, and End Results (SEER)-Medicare, we conducted a population analysis to define the impact of autoimmunity on MDS outcomes. Cases were ascertained between 2007 - 2017 and claim algorithms employed to identify autoimmune disease, demographic characteristics,...]]></summary>
        <author>
            <name>Diego Andres Adrianzen-Herrera</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Single-cell genotypic and phenotypic analysis of measurable residual disease in acute myeloid leukemia]]></title>
        <id>pubmed:37729414</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37729414/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230923205208&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-09-20T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Measurable residual disease (MRD), defined as the population of cancer cells that persist following therapy, serves as the critical reservoir for disease relapse in acute myeloid leukemia and other malignancies. Understanding the biology enabling MRD clones to resist therapy is necessary to guide the development of more effective curative treatments. Discriminating between residual leukemic clones, preleukemic clones, and normal precursors remains a challenge with current MRD tools. Here, we...]]></summary>
        <author>
            <name>Troy M Robinson</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Impact of Preexisting Autoimmune Disease on Myelodysplastic Syndromes Outcomes: A population Analysis]]></title>
        <id>pubmed:37729616</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37729616/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230922204741&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-09-20T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Preexisting autoimmune disease affects 10-30% of patients with myelodysplastic syndromes (MDS). Studies comparing outcomes in MDS patients with and without autoimmune disease show discordant results. Using Surveillance, Epidemiology, and End Results (SEER)-Medicare, we conducted a population analysis to define the impact of autoimmunity on MDS outcomes. Cases were ascertained between 2007 - 2017 and claim algorithms employed to identify autoimmune disease, demographic characteristics,...]]></summary>
        <author>
            <name>Diego Andres Adrianzen-Herrera</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Single-cell genotypic and phenotypic analysis of measurable residual disease in acute myeloid leukemia]]></title>
        <id>pubmed:37729414</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37729414/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230922204741&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-09-20T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Measurable residual disease (MRD), defined as the population of cancer cells that persist following therapy, serves as the critical reservoir for disease relapse in acute myeloid leukemia and other malignancies. Understanding the biology enabling MRD clones to resist therapy is necessary to guide the development of more effective curative treatments. Discriminating between residual leukemic clones, preleukemic clones, and normal precursors remains a challenge with current MRD tools. Here, we...]]></summary>
        <author>
            <name>Troy M Robinson</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Impact of Preexisting Autoimmune Disease on Myelodysplastic Syndromes Outcomes: A population Analysis]]></title>
        <id>pubmed:37729616</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37729616/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230921204936&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-09-20T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Preexisting autoimmune disease affects 10-30% of patients with myelodysplastic syndromes (MDS). Studies comparing outcomes in MDS patients with and without autoimmune disease show discordant results. Using Surveillance, Epidemiology, and End Results (SEER)-Medicare, we conducted a population analysis to define the impact of autoimmunity on MDS outcomes. Cases were ascertained between 2007 - 2017 and claim algorithms employed to identify autoimmune disease, demographic characteristics,...]]></summary>
        <author>
            <name>Diego Andres Adrianzen-Herrera</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Single-cell genotypic and phenotypic analysis of measurable residual disease in acute myeloid leukemia]]></title>
        <id>pubmed:37729414</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37729414/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230921204936&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-09-20T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Measurable residual disease (MRD), defined as the population of cancer cells that persist following therapy, serves as the critical reservoir for disease relapse in acute myeloid leukemia and other malignancies. Understanding the biology enabling MRD clones to resist therapy is necessary to guide the development of more effective curative treatments. Discriminating between residual leukemic clones, preleukemic clones, and normal precursors remains a challenge with current MRD tools. Here, we...]]></summary>
        <author>
            <name>Troy M Robinson</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Impact of Preexisting Autoimmune Disease on Myelodysplastic Syndromes Outcomes: A population Analysis]]></title>
        <id>pubmed:37729616</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37729616/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230920204905&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-09-20T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Preexisting autoimmune disease affects 10-30% of patients with myelodysplastic syndromes (MDS). Studies comparing outcomes in MDS patients with and without autoimmune disease show discordant results. Using Surveillance, Epidemiology, and End Results (SEER)-Medicare, we conducted a population analysis to define the impact of autoimmunity on MDS outcomes. Cases were ascertained between 2007 - 2017 and claim algorithms employed to identify autoimmune disease, demographic characteristics,...]]></summary>
        <author>
            <name>Diego Andres Adrianzen-Herrera</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Single-cell genotypic and phenotypic analysis of measurable residual disease in acute myeloid leukemia]]></title>
        <id>pubmed:37729414</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37729414/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230920204905&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-09-20T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Measurable residual disease (MRD), defined as the population of cancer cells that persist following therapy, serves as the critical reservoir for disease relapse in acute myeloid leukemia and other malignancies. Understanding the biology enabling MRD clones to resist therapy is necessary to guide the development of more effective curative treatments. Discriminating between residual leukemic clones, preleukemic clones, and normal precursors remains a challenge with current MRD tools. Here, we...]]></summary>
        <author>
            <name>Troy M Robinson</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Large T cell clones expressing immune checkpoints increase during multiple myeloma evolution and predict treatment resistance]]></title>
        <id>pubmed:37730678</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37730678/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230924205014&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-09-20T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Tumor recognition by T cells is essential for antitumor immunity. A comprehensive characterization of T cell diversity may be key to understanding the success of immunomodulatory drugs and failure of PD-1 blockade in tumors such as multiple myeloma (MM). Here, we use single-cell RNA and T cell receptor sequencing to characterize bone marrow T cells from healthy adults (n = 4) and patients with precursor (n = 8) and full-blown MM (n = 10). Large T cell clones from patients with MM expressed...]]></summary>
        <author>
            <name>Cirino Botta</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Large T cell clones expressing immune checkpoints increase during multiple myeloma evolution and predict treatment resistance]]></title>
        <id>pubmed:37730678</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37730678/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230923205208&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-09-20T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Tumor recognition by T cells is essential for antitumor immunity. A comprehensive characterization of T cell diversity may be key to understanding the success of immunomodulatory drugs and failure of PD-1 blockade in tumors such as multiple myeloma (MM). Here, we use single-cell RNA and T cell receptor sequencing to characterize bone marrow T cells from healthy adults (n = 4) and patients with precursor (n = 8) and full-blown MM (n = 10). Large T cell clones from patients with MM expressed...]]></summary>
        <author>
            <name>Cirino Botta</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Large T cell clones expressing immune checkpoints increase during multiple myeloma evolution and predict treatment resistance]]></title>
        <id>pubmed:37730678</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37730678/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230922204741&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-09-20T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Tumor recognition by T cells is essential for antitumor immunity. A comprehensive characterization of T cell diversity may be key to understanding the success of immunomodulatory drugs and failure of PD-1 blockade in tumors such as multiple myeloma (MM). Here, we use single-cell RNA and T cell receptor sequencing to characterize bone marrow T cells from healthy adults (n = 4) and patients with precursor (n = 8) and full-blown MM (n = 10). Large T cell clones from patients with MM expressed...]]></summary>
        <author>
            <name>Cirino Botta</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Large T cell clones expressing immune checkpoints increase during multiple myeloma evolution and predict treatment resistance]]></title>
        <id>pubmed:37730678</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37730678/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230921204936&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-09-20T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Tumor recognition by T cells is essential for antitumor immunity. A comprehensive characterization of T cell diversity may be key to understanding the success of immunomodulatory drugs and failure of PD-1 blockade in tumors such as multiple myeloma (MM). Here, we use single-cell RNA and T cell receptor sequencing to characterize bone marrow T cells from healthy adults (n = 4) and patients with precursor (n = 8) and full-blown MM (n = 10). Large T cell clones from patients with MM expressed...]]></summary>
        <author>
            <name>Cirino Botta</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[The heterogeneity and clonal evolution analysis of the advanced prostate cancer with castration resistance]]></title>
        <id>pubmed:37726835</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37726835/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230924205014&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-09-19T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSION: Our findings revealed potential genetic regulators to predict the castration resistance and provide insights into the castration resistance processes in advanced prostate cancer. The crosstalk between clonal evolution patterns and tumor microenvironment may also play a role in castration resistance. A multicenter-research including larger populations with different background are needed to confirm our conclusion in the future.]]></summary>
        <author>
            <name>Ao Liu</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Microfluidic design in single-cell sequencing and application to cancer precision medicine]]></title>
        <id>pubmed:37725985</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37725985/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230924205014&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-09-19T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Single-cell sequencing (SCS) is a crucial tool to reveal the genetic and functional heterogeneity of tumors, providing unique insights into the clonal evolution, microenvironment, drug resistance, and metastatic progression of cancers. Microfluidics is a critical component of many SCS technologies and workflows, conferring advantages in throughput, economy, and automation. Here, we review the current landscape of microfluidic architectures and sequencing techniques for single-cell omics analysis...]]></summary>
        <author>
            <name>Xin Han</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[The heterogeneity and clonal evolution analysis of the advanced prostate cancer with castration resistance]]></title>
        <id>pubmed:37726835</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37726835/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230923205208&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-09-19T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSION: Our findings revealed potential genetic regulators to predict the castration resistance and provide insights into the castration resistance processes in advanced prostate cancer. The crosstalk between clonal evolution patterns and tumor microenvironment may also play a role in castration resistance. A multicenter-research including larger populations with different background are needed to confirm our conclusion in the future.]]></summary>
        <author>
            <name>Ao Liu</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Microfluidic design in single-cell sequencing and application to cancer precision medicine]]></title>
        <id>pubmed:37725985</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37725985/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230923205208&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-09-19T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Single-cell sequencing (SCS) is a crucial tool to reveal the genetic and functional heterogeneity of tumors, providing unique insights into the clonal evolution, microenvironment, drug resistance, and metastatic progression of cancers. Microfluidics is a critical component of many SCS technologies and workflows, conferring advantages in throughput, economy, and automation. Here, we review the current landscape of microfluidic architectures and sequencing techniques for single-cell omics analysis...]]></summary>
        <author>
            <name>Xin Han</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[The heterogeneity and clonal evolution analysis of the advanced prostate cancer with castration resistance]]></title>
        <id>pubmed:37726835</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37726835/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230922204741&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-09-19T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSION: Our findings revealed potential genetic regulators to predict the castration resistance and provide insights into the castration resistance processes in advanced prostate cancer. The crosstalk between clonal evolution patterns and tumor microenvironment may also play a role in castration resistance. A multicenter-research including larger populations with different background are needed to confirm our conclusion in the future.]]></summary>
        <author>
            <name>Ao Liu</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Microfluidic design in single-cell sequencing and application to cancer precision medicine]]></title>
        <id>pubmed:37725985</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37725985/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230922204741&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-09-19T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Single-cell sequencing (SCS) is a crucial tool to reveal the genetic and functional heterogeneity of tumors, providing unique insights into the clonal evolution, microenvironment, drug resistance, and metastatic progression of cancers. Microfluidics is a critical component of many SCS technologies and workflows, conferring advantages in throughput, economy, and automation. Here, we review the current landscape of microfluidic architectures and sequencing techniques for single-cell omics analysis...]]></summary>
        <author>
            <name>Xin Han</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[The heterogeneity and clonal evolution analysis of the advanced prostate cancer with castration resistance]]></title>
        <id>pubmed:37726835</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37726835/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230921204936&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-09-19T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSION: Our findings revealed potential genetic regulators to predict the castration resistance and provide insights into the castration resistance processes in advanced prostate cancer. The crosstalk between clonal evolution patterns and tumor microenvironment may also play a role in castration resistance. A multicenter-research including larger populations with different background are needed to confirm our conclusion in the future.]]></summary>
        <author>
            <name>Ao Liu</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Microfluidic design in single-cell sequencing and application to cancer precision medicine]]></title>
        <id>pubmed:37725985</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37725985/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230921204936&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-09-19T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Single-cell sequencing (SCS) is a crucial tool to reveal the genetic and functional heterogeneity of tumors, providing unique insights into the clonal evolution, microenvironment, drug resistance, and metastatic progression of cancers. Microfluidics is a critical component of many SCS technologies and workflows, conferring advantages in throughput, economy, and automation. Here, we review the current landscape of microfluidic architectures and sequencing techniques for single-cell omics analysis...]]></summary>
        <author>
            <name>Xin Han</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[The heterogeneity and clonal evolution analysis of the advanced prostate cancer with castration resistance]]></title>
        <id>pubmed:37726835</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37726835/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230920204904&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-09-19T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSION: Our findings revealed potential genetic regulators to predict the castration resistance and provide insights into the castration resistance processes in advanced prostate cancer. The crosstalk between clonal evolution patterns and tumor microenvironment may also play a role in castration resistance. A multicenter-research including larger populations with different background are needed to confirm our conclusion in the future.]]></summary>
        <author>
            <name>Ao Liu</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Microfluidic design in single-cell sequencing and application to cancer precision medicine]]></title>
        <id>pubmed:37725985</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37725985/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230920204904&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-09-19T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Single-cell sequencing (SCS) is a crucial tool to reveal the genetic and functional heterogeneity of tumors, providing unique insights into the clonal evolution, microenvironment, drug resistance, and metastatic progression of cancers. Microfluidics is a critical component of many SCS technologies and workflows, conferring advantages in throughput, economy, and automation. Here, we review the current landscape of microfluidic architectures and sequencing techniques for single-cell omics analysis...]]></summary>
        <author>
            <name>Xin Han</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Genetic intra-tumour heterogeneity remodels the immune microenvironment and induces immune evasion in brain metastasis of lung cancer]]></title>
        <id>pubmed:37717855</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37717855/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230924205014&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-09-17T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSIONS: Our findings provide novel insights into the metastatic process and immune escape mechanisms of brain metastasis and pave the way for precise immunotherapeutic strategies for lung cancer patients with brain metastasis.]]></summary>
        <author>
            <name>Xin Wang</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Genetic intra-tumour heterogeneity remodels the immune microenvironment and induces immune evasion in brain metastasis of lung cancer]]></title>
        <id>pubmed:37717855</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37717855/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230923205208&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-09-17T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSIONS: Our findings provide novel insights into the metastatic process and immune escape mechanisms of brain metastasis and pave the way for precise immunotherapeutic strategies for lung cancer patients with brain metastasis.]]></summary>
        <author>
            <name>Xin Wang</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Genetic intra-tumour heterogeneity remodels the immune microenvironment and induces immune evasion in brain metastasis of lung cancer]]></title>
        <id>pubmed:37717855</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37717855/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230922204741&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-09-17T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSIONS: Our findings provide novel insights into the metastatic process and immune escape mechanisms of brain metastasis and pave the way for precise immunotherapeutic strategies for lung cancer patients with brain metastasis.]]></summary>
        <author>
            <name>Xin Wang</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Genetic intra-tumour heterogeneity remodels the immune microenvironment and induces immune evasion in brain metastasis of lung cancer]]></title>
        <id>pubmed:37717855</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37717855/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230921204936&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-09-17T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSIONS: Our findings provide novel insights into the metastatic process and immune escape mechanisms of brain metastasis and pave the way for precise immunotherapeutic strategies for lung cancer patients with brain metastasis.]]></summary>
        <author>
            <name>Xin Wang</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Genetic intra-tumour heterogeneity remodels the immune microenvironment and induces immune evasion in brain metastasis of lung cancer]]></title>
        <id>pubmed:37717855</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37717855/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230920204904&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-09-17T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSIONS: Our findings provide novel insights into the metastatic process and immune escape mechanisms of brain metastasis and pave the way for precise immunotherapeutic strategies for lung cancer patients with brain metastasis.]]></summary>
        <author>
            <name>Xin Wang</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Genetic intra-tumour heterogeneity remodels the immune microenvironment and induces immune evasion in brain metastasis of lung cancer]]></title>
        <id>pubmed:37717855</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37717855/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230919204929&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-09-17T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSIONS: Our findings provide novel insights into the metastatic process and immune escape mechanisms of brain metastasis and pave the way for precise immunotherapeutic strategies for lung cancer patients with brain metastasis.]]></summary>
        <author>
            <name>Xin Wang</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Genetic intra-tumour heterogeneity remodels the immune microenvironment and induces immune evasion in brain metastasis of lung cancer]]></title>
        <id>pubmed:37717855</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37717855/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230918204942&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-09-17T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSIONS: Our findings provide novel insights into the metastatic process and immune escape mechanisms of brain metastasis and pave the way for precise immunotherapeutic strategies for lung cancer patients with brain metastasis.]]></summary>
        <author>
            <name>Xin Wang</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[An Update on Inflammation in Atherosclerosis: How to Effectively Treat Residual Risk]]></title>
        <id>pubmed:37716836</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37716836/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230924205014&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-09-16T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[PURPOSE: This study reviewed the contribution of inflammation to atherosclerotic cardiovascular disease (ASCVD), which has gained widespread recognition in recent years.]]></summary>
        <author>
            <name>N Mohammadnia</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Interpretation of ambiguous TP53 test results: Mosaicism, clonal hematopoiesis, and variants of uncertain significance]]></title>
        <id>pubmed:37715966</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37715966/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230924205014&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-09-16T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[The increased use of next-generation sequencing has led to the detection of pathogenic TP53 variants in the germline setting in patients without a personal or family history consistent with Li-Fraumeni syndrome (LFS). These variants can represent low-penetrance LFS, mosaic LFS, or clonal hematopoiesis of indeterminate potential. Additionally, TP53 variants of uncertain significance can be detected in patients with a history suspicious for LFS. The interpretation of the significance of these...]]></summary>
        <author>
            <name>Darcy K Berry</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[An Update on Inflammation in Atherosclerosis: How to Effectively Treat Residual Risk]]></title>
        <id>pubmed:37716836</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37716836/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230923205208&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-09-16T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[PURPOSE: This study reviewed the contribution of inflammation to atherosclerotic cardiovascular disease (ASCVD), which has gained widespread recognition in recent years.]]></summary>
        <author>
            <name>N Mohammadnia</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Interpretation of ambiguous TP53 test results: Mosaicism, clonal hematopoiesis, and variants of uncertain significance]]></title>
        <id>pubmed:37715966</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37715966/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230923205208&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-09-16T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[The increased use of next-generation sequencing has led to the detection of pathogenic TP53 variants in the germline setting in patients without a personal or family history consistent with Li-Fraumeni syndrome (LFS). These variants can represent low-penetrance LFS, mosaic LFS, or clonal hematopoiesis of indeterminate potential. Additionally, TP53 variants of uncertain significance can be detected in patients with a history suspicious for LFS. The interpretation of the significance of these...]]></summary>
        <author>
            <name>Darcy K Berry</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[An Update on Inflammation in Atherosclerosis: How to Effectively Treat Residual Risk]]></title>
        <id>pubmed:37716836</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37716836/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230922204741&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-09-16T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[PURPOSE: This study reviewed the contribution of inflammation to atherosclerotic cardiovascular disease (ASCVD), which has gained widespread recognition in recent years.]]></summary>
        <author>
            <name>N Mohammadnia</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Interpretation of ambiguous TP53 test results: Mosaicism, clonal hematopoiesis, and variants of uncertain significance]]></title>
        <id>pubmed:37715966</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37715966/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230922204741&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-09-16T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[The increased use of next-generation sequencing has led to the detection of pathogenic TP53 variants in the germline setting in patients without a personal or family history consistent with Li-Fraumeni syndrome (LFS). These variants can represent low-penetrance LFS, mosaic LFS, or clonal hematopoiesis of indeterminate potential. Additionally, TP53 variants of uncertain significance can be detected in patients with a history suspicious for LFS. The interpretation of the significance of these...]]></summary>
        <author>
            <name>Darcy K Berry</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[An Update on Inflammation in Atherosclerosis: How to Effectively Treat Residual Risk]]></title>
        <id>pubmed:37716836</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37716836/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230921204936&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-09-16T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[PURPOSE: This study reviewed the contribution of inflammation to atherosclerotic cardiovascular disease (ASCVD), which has gained widespread recognition in recent years.]]></summary>
        <author>
            <name>N Mohammadnia</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Interpretation of ambiguous TP53 test results: Mosaicism, clonal hematopoiesis, and variants of uncertain significance]]></title>
        <id>pubmed:37715966</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37715966/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230921204936&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-09-16T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[The increased use of next-generation sequencing has led to the detection of pathogenic TP53 variants in the germline setting in patients without a personal or family history consistent with Li-Fraumeni syndrome (LFS). These variants can represent low-penetrance LFS, mosaic LFS, or clonal hematopoiesis of indeterminate potential. Additionally, TP53 variants of uncertain significance can be detected in patients with a history suspicious for LFS. The interpretation of the significance of these...]]></summary>
        <author>
            <name>Darcy K Berry</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[An Update on Inflammation in Atherosclerosis: How to Effectively Treat Residual Risk]]></title>
        <id>pubmed:37716836</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37716836/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230920204905&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-09-16T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[PURPOSE: This study reviewed the contribution of inflammation to atherosclerotic cardiovascular disease (ASCVD), which has gained widespread recognition in recent years.]]></summary>
        <author>
            <name>N Mohammadnia</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Interpretation of ambiguous TP53 test results: Mosaicism, clonal hematopoiesis, and variants of uncertain significance]]></title>
        <id>pubmed:37715966</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37715966/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230920204905&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-09-16T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[The increased use of next-generation sequencing has led to the detection of pathogenic TP53 variants in the germline setting in patients without a personal or family history consistent with Li-Fraumeni syndrome (LFS). These variants can represent low-penetrance LFS, mosaic LFS, or clonal hematopoiesis of indeterminate potential. Additionally, TP53 variants of uncertain significance can be detected in patients with a history suspicious for LFS. The interpretation of the significance of these...]]></summary>
        <author>
            <name>Darcy K Berry</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[An Update on Inflammation in Atherosclerosis: How to Effectively Treat Residual Risk]]></title>
        <id>pubmed:37716836</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37716836/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230919204929&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-09-16T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[PURPOSE: This study reviewed the contribution of inflammation to atherosclerotic cardiovascular disease (ASCVD), which has gained widespread recognition in recent years.]]></summary>
        <author>
            <name>N Mohammadnia</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Interpretation of ambiguous TP53 test results: Mosaicism, clonal hematopoiesis, and variants of uncertain significance]]></title>
        <id>pubmed:37715966</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37715966/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230919204929&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-09-16T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[The increased use of next-generation sequencing has led to the detection of pathogenic TP53 variants in the germline setting in patients without a personal or family history consistent with Li-Fraumeni syndrome (LFS). These variants can represent low-penetrance LFS, mosaic LFS, or clonal hematopoiesis of indeterminate potential. Additionally, TP53 variants of uncertain significance can be detected in patients with a history suspicious for LFS. The interpretation of the significance of these...]]></summary>
        <author>
            <name>Darcy K Berry</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[An Update on Inflammation in Atherosclerosis: How to Effectively Treat Residual Risk]]></title>
        <id>pubmed:37716836</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37716836/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230918204942&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-09-16T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[PURPOSE: This study reviewed the contribution of inflammation to atherosclerotic cardiovascular disease (ASCVD), which has gained widespread recognition in recent years.]]></summary>
        <author>
            <name>N Mohammadnia</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Interpretation of ambiguous TP53 test results: Mosaicism, clonal hematopoiesis, and variants of uncertain significance]]></title>
        <id>pubmed:37715966</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37715966/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230918204942&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-09-16T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[The increased use of next-generation sequencing has led to the detection of pathogenic TP53 variants in the germline setting in patients without a personal or family history consistent with Li-Fraumeni syndrome (LFS). These variants can represent low-penetrance LFS, mosaic LFS, or clonal hematopoiesis of indeterminate potential. Additionally, TP53 variants of uncertain significance can be detected in patients with a history suspicious for LFS. The interpretation of the significance of these...]]></summary>
        <author>
            <name>Darcy K Berry</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[An Update on Inflammation in Atherosclerosis: How to Effectively Treat Residual Risk]]></title>
        <id>pubmed:37716836</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37716836/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230917204935&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-09-16T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[PURPOSE: This study reviewed the contribution of inflammation to atherosclerotic cardiovascular disease (ASCVD), which has gained widespread recognition in recent years.]]></summary>
        <author>
            <name>N Mohammadnia</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Interpretation of ambiguous TP53 test results: Mosaicism, clonal hematopoiesis, and variants of uncertain significance]]></title>
        <id>pubmed:37715966</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37715966/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230917204935&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-09-16T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[The increased use of next-generation sequencing has led to the detection of pathogenic TP53 variants in the germline setting in patients without a personal or family history consistent with Li-Fraumeni syndrome (LFS). These variants can represent low-penetrance LFS, mosaic LFS, or clonal hematopoiesis of indeterminate potential. Additionally, TP53 variants of uncertain significance can be detected in patients with a history suspicious for LFS. The interpretation of the significance of these...]]></summary>
        <author>
            <name>Darcy K Berry</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Interpretation of ambiguous TP53 test results: Mosaicism, clonal hematopoiesis, and variants of uncertain significance]]></title>
        <id>pubmed:37715966</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37715966/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230916205201&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-09-16T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[The increased use of next-generation sequencing has led to the detection of pathogenic TP53 variants in the germline setting in patients without a personal or family history consistent with Li-Fraumeni syndrome (LFS). These variants can represent low-penetrance LFS, mosaic LFS, or clonal hematopoiesis of indeterminate potential. Additionally, TP53 variants of uncertain significance can be detected in patients with a history suspicious for LFS. The interpretation of the significance of these...]]></summary>
        <author>
            <name>Darcy K Berry</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clonal cooperation through soluble metabolite exchange facilitates metastatic outgrowth by modulating Allee effect]]></title>
        <id>pubmed:37713487</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37713487/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230924205014&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-09-15T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Cancers feature substantial intratumoral heterogeneity of genetic and phenotypically distinct lineages. Although interactions between coexisting lineages are emerging as a potential contributor to tumor evolution, the extent and nature of these interactions remain largely unknown. We postulated that tumors develop ecological interactions that sustain diversity and facilitate metastasis. Using a combination of fluorescent barcoding, mathematical modeling, metabolic analysis, and in vivo models,...]]></summary>
        <author>
            <name>Benjamin J Hershey</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clonal cooperation through soluble metabolite exchange facilitates metastatic outgrowth by modulating Allee effect]]></title>
        <id>pubmed:37713487</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37713487/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230923205208&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-09-15T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Cancers feature substantial intratumoral heterogeneity of genetic and phenotypically distinct lineages. Although interactions between coexisting lineages are emerging as a potential contributor to tumor evolution, the extent and nature of these interactions remain largely unknown. We postulated that tumors develop ecological interactions that sustain diversity and facilitate metastasis. Using a combination of fluorescent barcoding, mathematical modeling, metabolic analysis, and in vivo models,...]]></summary>
        <author>
            <name>Benjamin J Hershey</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clonal cooperation through soluble metabolite exchange facilitates metastatic outgrowth by modulating Allee effect]]></title>
        <id>pubmed:37713487</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37713487/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230922204741&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-09-15T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Cancers feature substantial intratumoral heterogeneity of genetic and phenotypically distinct lineages. Although interactions between coexisting lineages are emerging as a potential contributor to tumor evolution, the extent and nature of these interactions remain largely unknown. We postulated that tumors develop ecological interactions that sustain diversity and facilitate metastasis. Using a combination of fluorescent barcoding, mathematical modeling, metabolic analysis, and in vivo models,...]]></summary>
        <author>
            <name>Benjamin J Hershey</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clonal cooperation through soluble metabolite exchange facilitates metastatic outgrowth by modulating Allee effect]]></title>
        <id>pubmed:37713487</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37713487/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230921204936&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-09-15T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Cancers feature substantial intratumoral heterogeneity of genetic and phenotypically distinct lineages. Although interactions between coexisting lineages are emerging as a potential contributor to tumor evolution, the extent and nature of these interactions remain largely unknown. We postulated that tumors develop ecological interactions that sustain diversity and facilitate metastasis. Using a combination of fluorescent barcoding, mathematical modeling, metabolic analysis, and in vivo models,...]]></summary>
        <author>
            <name>Benjamin J Hershey</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clonal cooperation through soluble metabolite exchange facilitates metastatic outgrowth by modulating Allee effect]]></title>
        <id>pubmed:37713487</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37713487/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230920204904&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-09-15T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Cancers feature substantial intratumoral heterogeneity of genetic and phenotypically distinct lineages. Although interactions between coexisting lineages are emerging as a potential contributor to tumor evolution, the extent and nature of these interactions remain largely unknown. We postulated that tumors develop ecological interactions that sustain diversity and facilitate metastasis. Using a combination of fluorescent barcoding, mathematical modeling, metabolic analysis, and in vivo models,...]]></summary>
        <author>
            <name>Benjamin J Hershey</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clonal cooperation through soluble metabolite exchange facilitates metastatic outgrowth by modulating Allee effect]]></title>
        <id>pubmed:37713487</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37713487/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230919204929&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-09-15T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Cancers feature substantial intratumoral heterogeneity of genetic and phenotypically distinct lineages. Although interactions between coexisting lineages are emerging as a potential contributor to tumor evolution, the extent and nature of these interactions remain largely unknown. We postulated that tumors develop ecological interactions that sustain diversity and facilitate metastasis. Using a combination of fluorescent barcoding, mathematical modeling, metabolic analysis, and in vivo models,...]]></summary>
        <author>
            <name>Benjamin J Hershey</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clonal cooperation through soluble metabolite exchange facilitates metastatic outgrowth by modulating Allee effect]]></title>
        <id>pubmed:37713487</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37713487/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230918204942&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-09-15T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Cancers feature substantial intratumoral heterogeneity of genetic and phenotypically distinct lineages. Although interactions between coexisting lineages are emerging as a potential contributor to tumor evolution, the extent and nature of these interactions remain largely unknown. We postulated that tumors develop ecological interactions that sustain diversity and facilitate metastasis. Using a combination of fluorescent barcoding, mathematical modeling, metabolic analysis, and in vivo models,...]]></summary>
        <author>
            <name>Benjamin J Hershey</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clonal cooperation through soluble metabolite exchange facilitates metastatic outgrowth by modulating Allee effect]]></title>
        <id>pubmed:37713487</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37713487/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230917204936&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-09-15T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Cancers feature substantial intratumoral heterogeneity of genetic and phenotypically distinct lineages. Although interactions between coexisting lineages are emerging as a potential contributor to tumor evolution, the extent and nature of these interactions remain largely unknown. We postulated that tumors develop ecological interactions that sustain diversity and facilitate metastasis. Using a combination of fluorescent barcoding, mathematical modeling, metabolic analysis, and in vivo models,...]]></summary>
        <author>
            <name>Benjamin J Hershey</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clonal cooperation through soluble metabolite exchange facilitates metastatic outgrowth by modulating Allee effect]]></title>
        <id>pubmed:37713487</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37713487/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230916205201&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-09-15T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Cancers feature substantial intratumoral heterogeneity of genetic and phenotypically distinct lineages. Although interactions between coexisting lineages are emerging as a potential contributor to tumor evolution, the extent and nature of these interactions remain largely unknown. We postulated that tumors develop ecological interactions that sustain diversity and facilitate metastasis. Using a combination of fluorescent barcoding, mathematical modeling, metabolic analysis, and in vivo models,...]]></summary>
        <author>
            <name>Benjamin J Hershey</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clonal cooperation through soluble metabolite exchange facilitates metastatic outgrowth by modulating Allee effect]]></title>
        <id>pubmed:37713487</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37713487/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230915204741&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-09-15T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Cancers feature substantial intratumoral heterogeneity of genetic and phenotypically distinct lineages. Although interactions between coexisting lineages are emerging as a potential contributor to tumor evolution, the extent and nature of these interactions remain largely unknown. We postulated that tumors develop ecological interactions that sustain diversity and facilitate metastasis. Using a combination of fluorescent barcoding, mathematical modeling, metabolic analysis, and in vivo models,...]]></summary>
        <author>
            <name>Benjamin J Hershey</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Ppm1d truncating mutations promote the development of genotoxic stress-induced AML]]></title>
        <id>pubmed:37709843</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37709843/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230924205014&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-09-14T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Hematopoietic stem cells (HSCs) ensure blood cell production during the life-time of an organism, and to do so they need to balance self-renewal, proliferation, differentiation, and migration in a steady state as well as in response to stress or injury. Importantly, aberrant proliferation of HSCs leads to hematological malignancies, and thus, tight regulation by various tumor suppressor pathways, including p53, is essential. Protein phosphatase magnesium-dependent 1 delta (PPM1D) is a negative...]]></summary>
        <author>
            <name>Monika Burocziova</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Bone Marrow Microenvironment Involvement in t-MN: Focus on Mesenchymal Stem Cells]]></title>
        <id>pubmed:37705521</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37705521/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230924205014&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-09-14T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Therapy-related myeloid neoplasms (t-MN) are a late complication of cytotoxic therapy (CT) used in the treatment of both malignant and non-malignant diseases. Historically, t-MN has been considered to be a direct consequence of DNA damage induced in normal hematopoietic stem or progenitor cells (HSPC) by CT. However, we now know that treatment-induced mutations in HSC are not the only players involved in t-MN development, but additional factors may contribute to the onset of t-MN. One of the...]]></summary>
        <author>
            <name>Giulia Falconi</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Myelodysplasia after clonal hematopoiesis with APOBEC3-mediated CYBB inactivation in retroviral gene therapy for X-CGD]]></title>
        <id>pubmed:37705244</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37705244/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230924205014&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-09-14T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Stem cell gene therapy using the MFGS-gp91^(phox) retroviral vector was performed on a 27-year-old patient with X-linked chronic granulomatous disease (X-CGD) in 2014. The patient's refractory infections were resolved, whereas the oxidase-positive neutrophils disappeared within 6 months. Thirty-two months after gene therapy, the patient developed myelodysplastic syndrome (MDS), and vector integration into the MECOM locus was identified in blast cells. The vector integration into MECOM was...]]></summary>
        <author>
            <name>Toru Uchiyama</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Ppm1d truncating mutations promote the development of genotoxic stress-induced AML]]></title>
        <id>pubmed:37709843</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37709843/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230923205208&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-09-14T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Hematopoietic stem cells (HSCs) ensure blood cell production during the life-time of an organism, and to do so they need to balance self-renewal, proliferation, differentiation, and migration in a steady state as well as in response to stress or injury. Importantly, aberrant proliferation of HSCs leads to hematological malignancies, and thus, tight regulation by various tumor suppressor pathways, including p53, is essential. Protein phosphatase magnesium-dependent 1 delta (PPM1D) is a negative...]]></summary>
        <author>
            <name>Monika Burocziova</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Bone Marrow Microenvironment Involvement in t-MN: Focus on Mesenchymal Stem Cells]]></title>
        <id>pubmed:37705521</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37705521/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230923205208&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-09-14T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Therapy-related myeloid neoplasms (t-MN) are a late complication of cytotoxic therapy (CT) used in the treatment of both malignant and non-malignant diseases. Historically, t-MN has been considered to be a direct consequence of DNA damage induced in normal hematopoietic stem or progenitor cells (HSPC) by CT. However, we now know that treatment-induced mutations in HSC are not the only players involved in t-MN development, but additional factors may contribute to the onset of t-MN. One of the...]]></summary>
        <author>
            <name>Giulia Falconi</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Myelodysplasia after clonal hematopoiesis with APOBEC3-mediated CYBB inactivation in retroviral gene therapy for X-CGD]]></title>
        <id>pubmed:37705244</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37705244/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230923205208&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-09-14T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Stem cell gene therapy using the MFGS-gp91^(phox) retroviral vector was performed on a 27-year-old patient with X-linked chronic granulomatous disease (X-CGD) in 2014. The patient's refractory infections were resolved, whereas the oxidase-positive neutrophils disappeared within 6 months. Thirty-two months after gene therapy, the patient developed myelodysplastic syndrome (MDS), and vector integration into the MECOM locus was identified in blast cells. The vector integration into MECOM was...]]></summary>
        <author>
            <name>Toru Uchiyama</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Ppm1d truncating mutations promote the development of genotoxic stress-induced AML]]></title>
        <id>pubmed:37709843</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37709843/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230922204741&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-09-14T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Hematopoietic stem cells (HSCs) ensure blood cell production during the life-time of an organism, and to do so they need to balance self-renewal, proliferation, differentiation, and migration in a steady state as well as in response to stress or injury. Importantly, aberrant proliferation of HSCs leads to hematological malignancies, and thus, tight regulation by various tumor suppressor pathways, including p53, is essential. Protein phosphatase magnesium-dependent 1 delta (PPM1D) is a negative...]]></summary>
        <author>
            <name>Monika Burocziova</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Bone Marrow Microenvironment Involvement in t-MN: Focus on Mesenchymal Stem Cells]]></title>
        <id>pubmed:37705521</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37705521/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230922204741&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-09-14T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Therapy-related myeloid neoplasms (t-MN) are a late complication of cytotoxic therapy (CT) used in the treatment of both malignant and non-malignant diseases. Historically, t-MN has been considered to be a direct consequence of DNA damage induced in normal hematopoietic stem or progenitor cells (HSPC) by CT. However, we now know that treatment-induced mutations in HSC are not the only players involved in t-MN development, but additional factors may contribute to the onset of t-MN. One of the...]]></summary>
        <author>
            <name>Giulia Falconi</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Myelodysplasia after clonal hematopoiesis with APOBEC3-mediated CYBB inactivation in retroviral gene therapy for X-CGD]]></title>
        <id>pubmed:37705244</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37705244/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230922204741&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-09-14T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Stem cell gene therapy using the MFGS-gp91^(phox) retroviral vector was performed on a 27-year-old patient with X-linked chronic granulomatous disease (X-CGD) in 2014. The patient's refractory infections were resolved, whereas the oxidase-positive neutrophils disappeared within 6 months. Thirty-two months after gene therapy, the patient developed a myelodysplastic syndrome (MDS), and vector integration into the MECOM locus was identified in blast cells. The vector integration into MECOM was...]]></summary>
        <author>
            <name>Toru Uchiyama</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Ppm1d truncating mutations promote the development of genotoxic stress-induced AML]]></title>
        <id>pubmed:37709843</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37709843/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230921204936&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-09-14T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Hematopoietic stem cells (HSCs) ensure blood cell production during the life-time of an organism, and to do so they need to balance self-renewal, proliferation, differentiation, and migration in a steady state as well as in response to stress or injury. Importantly, aberrant proliferation of HSCs leads to hematological malignancies, and thus, tight regulation by various tumor suppressor pathways, including p53, is essential. Protein phosphatase magnesium-dependent 1 delta (PPM1D) is a negative...]]></summary>
        <author>
            <name>Monika Burocziova</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Bone Marrow Microenvironment Involvement in t-MN: Focus on Mesenchymal Stem Cells]]></title>
        <id>pubmed:37705521</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37705521/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230921204936&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-09-14T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Therapy-related myeloid neoplasms (t-MN) are a late complication of cytotoxic therapy (CT) used in the treatment of both malignant and non-malignant diseases. Historically, t-MN has been considered to be a direct consequence of DNA damage induced in normal hematopoietic stem or progenitor cells (HSPC) by CT. However, we now know that treatment-induced mutations in HSC are not the only players involved in t-MN development, but additional factors may contribute to the onset of t-MN. One of the...]]></summary>
        <author>
            <name>Giulia Falconi</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Myelodysplasia after clonal hematopoiesis with APOBEC3-mediated CYBB inactivation in retroviral gene therapy for X-CGD]]></title>
        <id>pubmed:37705244</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37705244/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230921204936&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-09-14T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Stem cell gene therapy using the MFGS-gp91^(phox) retroviral vector was performed on a 27-year-old patient with X-linked chronic granulomatous disease (X-CGD) in 2014. The patient's refractory infections were resolved, whereas the oxidase-positive neutrophils disappeared within 6 months. Thirty-two months after gene therapy, the patient developed a myelodysplastic syndrome (MDS), and vector integration into the MECOM locus was identified in blast cells. The vector integration into MECOM was...]]></summary>
        <author>
            <name>Toru Uchiyama</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Ppm1d truncating mutations promote the development of genotoxic stress-induced AML]]></title>
        <id>pubmed:37709843</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37709843/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230920204905&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-09-14T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Hematopoietic stem cells (HSCs) ensure blood cell production during the life-time of an organism, and to do so they need to balance self-renewal, proliferation, differentiation, and migration in a steady state as well as in response to stress or injury. Importantly, aberrant proliferation of HSCs leads to hematological malignancies, and thus, tight regulation by various tumor suppressor pathways, including p53, is essential. Protein phosphatase magnesium-dependent 1 delta (PPM1D) is a negative...]]></summary>
        <author>
            <name>Monika Burocziova</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Bone Marrow Microenvironment Involvement in t-MN: Focus on Mesenchymal Stem Cells]]></title>
        <id>pubmed:37705521</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37705521/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230920204905&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-09-14T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Therapy-related myeloid neoplasms (t-MN) are a late complication of cytotoxic therapy (CT) used in the treatment of both malignant and non-malignant diseases. Historically, t-MN has been considered to be a direct consequence of DNA damage induced in normal hematopoietic stem or progenitor cells (HSPC) by CT. However, we now know that treatment-induced mutations in HSC are not the only players involved in t-MN development, but additional factors may contribute to the onset of t-MN. One of the...]]></summary>
        <author>
            <name>Giulia Falconi</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Myelodysplasia after clonal hematopoiesis with APOBEC3-mediated CYBB inactivation in retroviral gene therapy for X-CGD]]></title>
        <id>pubmed:37705244</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37705244/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230920204905&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-09-14T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Stem cell gene therapy using the MFGS-gp91^(phox) retroviral vector was performed on a 27-year-old patient with X-linked chronic granulomatous disease (X-CGD) in 2014. The patient's refractory infections were resolved, whereas the oxidase-positive neutrophils disappeared within 6 months. Thirty-two months after gene therapy, the patient developed a myelodysplastic syndrome (MDS), and vector integration into the MECOM locus was identified in blast cells. The vector integration into MECOM was...]]></summary>
        <author>
            <name>Toru Uchiyama</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Ppm1d truncating mutations promote the development of genotoxic stress-induced AML]]></title>
        <id>pubmed:37709843</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37709843/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230919204929&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-09-14T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Hematopoietic stem cells (HSCs) ensure blood cell production during the life-time of an organism, and to do so they need to balance self-renewal, proliferation, differentiation, and migration in a steady state as well as in response to stress or injury. Importantly, aberrant proliferation of HSCs leads to hematological malignancies, and thus, tight regulation by various tumor suppressor pathways, including p53, is essential. Protein phosphatase magnesium-dependent 1 delta (PPM1D) is a negative...]]></summary>
        <author>
            <name>Monika Burocziova</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Bone Marrow Microenvironment Involvement in t-MN: Focus on Mesenchymal Stem Cells]]></title>
        <id>pubmed:37705521</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37705521/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230919204929&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-09-14T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Therapy-related myeloid neoplasms (t-MN) are a late complication of cytotoxic therapy (CT) used in the treatment of both malignant and non-malignant diseases. Historically, t-MN has been considered to be a direct consequence of DNA damage induced in normal hematopoietic stem or progenitor cells (HSPC) by CT. However, we now know that treatment-induced mutations in HSC are not the only players involved in t-MN development, but additional factors may contribute to the onset of t-MN. One of the...]]></summary>
        <author>
            <name>Giulia Falconi</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Myelodysplasia after clonal hematopoiesis with APOBEC3-mediated CYBB inactivation in retroviral gene therapy for X-CGD]]></title>
        <id>pubmed:37705244</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37705244/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230919204929&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-09-14T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Stem cell gene therapy using the MFGS-gp91^(phox) retroviral vector was performed on a 27-year-old patient with X-linked chronic granulomatous disease (X-CGD) in 2014. The patient's refractory infections were resolved, whereas the oxidase-positive neutrophils disappeared within 6 months. Thirty-two months after gene therapy, the patient developed a myelodysplastic syndrome (MDS), and vector integration into the MECOM locus was identified in blast cells. The vector integration into MECOM was...]]></summary>
        <author>
            <name>Toru Uchiyama</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Ppm1d truncating mutations promote the development of genotoxic stress-induced AML]]></title>
        <id>pubmed:37709843</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37709843/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230918204942&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-09-14T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Hematopoietic stem cells (HSCs) ensure blood cell production during the life-time of an organism, and to do so they need to balance self-renewal, proliferation, differentiation, and migration in a steady state as well as in response to stress or injury. Importantly, aberrant proliferation of HSCs leads to hematological malignancies, and thus, tight regulation by various tumor suppressor pathways, including p53, is essential. Protein phosphatase magnesium-dependent 1 delta (PPM1D) is a negative...]]></summary>
        <author>
            <name>Monika Burocziova</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Bone Marrow Microenvironment Involvement in t-MN: Focus on Mesenchymal Stem Cells]]></title>
        <id>pubmed:37705521</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37705521/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230918204942&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-09-14T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Therapy-related myeloid neoplasms (t-MN) are a late complication of cytotoxic therapy (CT) used in the treatment of both malignant and non-malignant diseases. Historically, t-MN has been considered to be a direct consequence of DNA damage induced in normal hematopoietic stem or progenitor cells (HSPC) by CT. However, we now know that treatment-induced mutations in HSC are not the only players involved in t-MN development, but additional factors may contribute to the onset of t-MN. One of the...]]></summary>
        <author>
            <name>Giulia Falconi</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Myelodysplasia after clonal hematopoiesis with APOBEC3-mediated CYBB inactivation in retroviral gene therapy for X-CGD]]></title>
        <id>pubmed:37705244</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37705244/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230918204942&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-09-14T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Stem cell gene therapy using the MFGS-gp91^(phox) retroviral vector was performed on a 27-year-old patient with X-linked chronic granulomatous disease (X-CGD) in 2014. The patient's refractory infections were resolved, whereas the oxidase-positive neutrophils disappeared within 6 months. Thirty-two months after gene therapy, the patient developed a myelodysplastic syndrome (MDS), and vector integration into the MECOM locus was identified in blast cells. The vector integration into MECOM was...]]></summary>
        <author>
            <name>Toru Uchiyama</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Ppm1d truncating mutations promote the development of genotoxic stress-induced AML]]></title>
        <id>pubmed:37709843</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37709843/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230917204935&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-09-14T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Hematopoietic stem cells (HSCs) ensure blood cell production during the life-time of an organism, and to do so they need to balance self-renewal, proliferation, differentiation, and migration in a steady state as well as in response to stress or injury. Importantly, aberrant proliferation of HSCs leads to hematological malignancies, and thus, tight regulation by various tumor suppressor pathways, including p53, is essential. Protein phosphatase magnesium-dependent 1 delta (PPM1D) is a negative...]]></summary>
        <author>
            <name>Monika Burocziova</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Bone Marrow Microenvironment Involvement in t-MN: Focus on Mesenchymal Stem Cells]]></title>
        <id>pubmed:37705521</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37705521/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230917204935&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-09-14T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Therapy-related myeloid neoplasms (t-MN) are a late complication of cytotoxic therapy (CT) used in the treatment of both malignant and non-malignant diseases. Historically, t-MN has been considered to be a direct consequence of DNA damage induced in normal hematopoietic stem or progenitor cells (HSPC) by CT. However, we now know that treatment-induced mutations in HSC are not the only players involved in t-MN development, but additional factors may contribute to the onset of t-MN. One of the...]]></summary>
        <author>
            <name>Giulia Falconi</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Myelodysplasia after clonal hematopoiesis with APOBEC3-mediated CYBB inactivation in retroviral gene therapy for X-CGD]]></title>
        <id>pubmed:37705244</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37705244/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230917204935&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-09-14T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Stem cell gene therapy using the MFGS-gp91^(phox) retroviral vector was performed on a 27-year-old patient with X-linked chronic granulomatous disease (X-CGD) in 2014. The patient's refractory infections were resolved, whereas the oxidase-positive neutrophils disappeared within 6 months. Thirty-two months after gene therapy, the patient developed a myelodysplastic syndrome (MDS), and vector integration into the MECOM locus was identified in blast cells. The vector integration into MECOM was...]]></summary>
        <author>
            <name>Toru Uchiyama</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Ppm1d truncating mutations promote the development of genotoxic stress-induced AML]]></title>
        <id>pubmed:37709843</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37709843/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230916205201&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-09-14T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Hematopoietic stem cells (HSCs) ensure blood cell production during the life-time of an organism, and to do so they need to balance self-renewal, proliferation, differentiation, and migration in a steady state as well as in response to stress or injury. Importantly, aberrant proliferation of HSCs leads to hematological malignancies, and thus, tight regulation by various tumor suppressor pathways, including p53, is essential. Protein phosphatase magnesium-dependent 1 delta (PPM1D) is a negative...]]></summary>
        <author>
            <name>Monika Burocziova</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Bone Marrow Microenvironment Involvement in t-MN: Focus on Mesenchymal Stem Cells]]></title>
        <id>pubmed:37705521</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37705521/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230916205201&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-09-14T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Therapy-related myeloid neoplasms (t-MN) are a late complication of cytotoxic therapy (CT) used in the treatment of both malignant and non-malignant diseases. Historically, t-MN has been considered to be a direct consequence of DNA damage induced in normal hematopoietic stem or progenitor cells (HSPC) by CT. However, we now know that treatment-induced mutations in HSC are not the only players involved in t-MN development, but additional factors may contribute to the onset of t-MN. One of the...]]></summary>
        <author>
            <name>Giulia Falconi</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Myelodysplasia after clonal hematopoiesis with APOBEC3-mediated CYBB inactivation in retroviral gene therapy for X-CGD]]></title>
        <id>pubmed:37705244</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37705244/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230916205201&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-09-14T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Stem cell gene therapy using the MFGS-gp91^(phox) retroviral vector was performed on a 27-year-old patient with X-linked chronic granulomatous disease (X-CGD) in 2014. The patient's refractory infections were resolved, whereas the oxidase-positive neutrophils disappeared within 6 months. Thirty-two months after gene therapy, the patient developed a myelodysplastic syndrome (MDS), and vector integration into the MECOM locus was identified in blast cells. The vector integration into MECOM was...]]></summary>
        <author>
            <name>Toru Uchiyama</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Ppm1d truncating mutations promote the development of genotoxic stress-induced AML]]></title>
        <id>pubmed:37709843</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37709843/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230915204741&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-09-14T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Hematopoietic stem cells (HSCs) ensure blood cell production during the life-time of an organism, and to do so they need to balance self-renewal, proliferation, differentiation, and migration in a steady state as well as in response to stress or injury. Importantly, aberrant proliferation of HSCs leads to hematological malignancies, and thus, tight regulation by various tumor suppressor pathways, including p53, is essential. Protein phosphatase magnesium-dependent 1 delta (PPM1D) is a negative...]]></summary>
        <author>
            <name>Monika Burocziova</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Bone Marrow Microenvironment Involvement in t-MN: Focus on Mesenchymal Stem Cells]]></title>
        <id>pubmed:37705521</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37705521/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230915204741&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-09-14T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Therapy-related myeloid neoplasms (t-MN) are a late complication of cytotoxic therapy (CT) used in the treatment of both malignant and non-malignant diseases. Historically, t-MN has been considered to be a direct consequence of DNA damage induced in normal hematopoietic stem or progenitor cells (HSPC) by CT. However, we now know that treatment-induced mutations in HSC are not the only players involved in t-MN development, but additional factors may contribute to the onset of t-MN. One of the...]]></summary>
        <author>
            <name>Giulia Falconi</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Myelodysplasia after clonal hematopoiesis with APOBEC3-mediated CYBB inactivation in retroviral gene therapy for X-CGD]]></title>
        <id>pubmed:37705244</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37705244/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230915204741&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-09-14T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Stem cell gene therapy using the MFGS-gp91^(phox) retroviral vector was performed on a 27-year-old patient with X-linked chronic granulomatous disease (X-CGD) in 2014. The patient's refractory infections were resolved, whereas the oxidase-positive neutrophils disappeared within 6 months. Thirty-two months after gene therapy, the patient developed a myelodysplastic syndrome (MDS), and vector integration into the MECOM locus was identified in blast cells. The vector integration into MECOM was...]]></summary>
        <author>
            <name>Toru Uchiyama</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Bone Marrow Microenvironment Involvement in t-MN: Focus on Mesenchymal Stem Cells]]></title>
        <id>pubmed:37705521</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37705521/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230914204950&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-09-14T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Therapy-related myeloid neoplasms (t-MN) are a late complication of cytotoxic therapy (CT) used in the treatment of both malignant and non-malignant diseases. Historically, t-MN has been considered to be a direct consequence of DNA damage induced in normal hematopoietic stem or progenitor cells (HSPC) by CT. However, we now know that treatment-induced mutations in HSC are not the only players involved in t-MN development, but additional factors may contribute to the onset of t-MN. One of the...]]></summary>
        <author>
            <name>Giulia Falconi</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Myelodysplasia after clonal hematopoiesis with APOBEC3-mediated CYBB inactivation in retroviral gene therapy for X-CGD]]></title>
        <id>pubmed:37705244</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37705244/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230914204950&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-09-14T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Stem cell gene therapy using the MFGS-gp91^(phox) retroviral vector was performed on a 27-year-old patient with X-linked chronic granulomatous disease (X-CGD) in 2014. The patient's refractory infections were resolved, whereas the oxidase-positive neutrophils disappeared within 6 months. Thirty-two months after gene therapy, the patient developed a myelodysplastic syndrome (MDS), and vector integration into the MECOM locus was identified in blast cells. The vector integration into MECOM was...]]></summary>
        <author>
            <name>Toru Uchiyama</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[cloneRate: fast estimation of single-cell clonal dynamics using coalescent theory]]></title>
        <id>pubmed:37699006</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37699006/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230924205014&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-09-12T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[MOTIVATION: While evolutionary approaches to medicine show promise, measuring evolution itself is difficult due to experimental constraints and the dynamic nature of body systems. In cancer evolution, continuous observation of clonal architecture is impossible, and longitudinal samples from multiple timepoints are rare. Increasingly available DNA sequencing datasets at single-cell resolution enable the reconstruction of past evolution using mutational history, allowing for a better understanding...]]></summary>
        <author>
            <name>Brian Johnson</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[cloneRate: fast estimation of single-cell clonal dynamics using coalescent theory]]></title>
        <id>pubmed:37699006</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37699006/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230923205208&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-09-12T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[MOTIVATION: While evolutionary approaches to medicine show promise, measuring evolution itself is difficult due to experimental constraints and the dynamic nature of body systems. In cancer evolution, continuous observation of clonal architecture is impossible, and longitudinal samples from multiple timepoints are rare. Increasingly available DNA sequencing datasets at single-cell resolution enable the reconstruction of past evolution using mutational history, allowing for a better understanding...]]></summary>
        <author>
            <name>Brian Johnson</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[cloneRate: fast estimation of single-cell clonal dynamics using coalescent theory]]></title>
        <id>pubmed:37699006</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37699006/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230922204741&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-09-12T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[MOTIVATION: While evolutionary approaches to medicine show promise, measuring evolution itself is difficult due to experimental constraints and the dynamic nature of body systems. In cancer evolution, continuous observation of clonal architecture is impossible, and longitudinal samples from multiple timepoints are rare. Increasingly available DNA sequencing datasets at single-cell resolution enable the reconstruction of past evolution using mutational history, allowing for a better understanding...]]></summary>
        <author>
            <name>Brian Johnson</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[cloneRate: fast estimation of single-cell clonal dynamics using coalescent theory]]></title>
        <id>pubmed:37699006</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37699006/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230921204936&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-09-12T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[MOTIVATION: While evolutionary approaches to medicine show promise, measuring evolution itself is difficult due to experimental constraints and the dynamic nature of body systems. In cancer evolution, continuous observation of clonal architecture is impossible, and longitudinal samples from multiple timepoints are rare. Increasingly available DNA sequencing datasets at single-cell resolution enable the reconstruction of past evolution using mutational history, allowing for a better understanding...]]></summary>
        <author>
            <name>Brian Johnson</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[cloneRate: fast estimation of single-cell clonal dynamics using coalescent theory]]></title>
        <id>pubmed:37699006</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37699006/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230920204905&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-09-12T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[MOTIVATION: While evolutionary approaches to medicine show promise, measuring evolution itself is difficult due to experimental constraints and the dynamic nature of body systems. In cancer evolution, continuous observation of clonal architecture is impossible, and longitudinal samples from multiple timepoints are rare. Increasingly available DNA sequencing datasets at single-cell resolution enable the reconstruction of past evolution using mutational history, allowing for a better understanding...]]></summary>
        <author>
            <name>Brian Johnson</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[cloneRate: fast estimation of single-cell clonal dynamics using coalescent theory]]></title>
        <id>pubmed:37699006</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37699006/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230919204929&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-09-12T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[MOTIVATION: While evolutionary approaches to medicine show promise, measuring evolution itself is difficult due to experimental constraints and the dynamic nature of body systems. In cancer evolution, continuous observation of clonal architecture is impossible, and longitudinal samples from multiple timepoints are rare. Increasingly available DNA sequencing datasets at single-cell resolution enable the reconstruction of past evolution using mutational history, allowing for a better understanding...]]></summary>
        <author>
            <name>Brian Johnson</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[cloneRate: fast estimation of single-cell clonal dynamics using coalescent theory]]></title>
        <id>pubmed:37699006</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37699006/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230918204942&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-09-12T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[MOTIVATION: While evolutionary approaches to medicine show promise, measuring evolution itself is difficult due to experimental constraints and the dynamic nature of body systems. In cancer evolution, continuous observation of clonal architecture is impossible, and longitudinal samples from multiple timepoints are rare. Increasingly available DNA sequencing datasets at single-cell resolution enable the reconstruction of past evolution using mutational history, allowing for a better understanding...]]></summary>
        <author>
            <name>Brian Johnson</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[cloneRate: fast estimation of single-cell clonal dynamics using coalescent theory]]></title>
        <id>pubmed:37699006</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37699006/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230917204935&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-09-12T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[MOTIVATION: While evolutionary approaches to medicine show promise, measuring evolution itself is difficult due to experimental constraints and the dynamic nature of body systems. In cancer evolution, continuous observation of clonal architecture is impossible, and longitudinal samples from multiple timepoints are rare. Increasingly available DNA sequencing datasets at single-cell resolution enable the reconstruction of past evolution using mutational history, allowing for a better understanding...]]></summary>
        <author>
            <name>Brian Johnson</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[cloneRate: fast estimation of single-cell clonal dynamics using coalescent theory]]></title>
        <id>pubmed:37699006</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37699006/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230916205201&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-09-12T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[MOTIVATION: While evolutionary approaches to medicine show promise, measuring evolution itself is difficult due to experimental constraints and the dynamic nature of body systems. In cancer evolution, continuous observation of clonal architecture is impossible, and longitudinal samples from multiple timepoints are rare. Increasingly available DNA sequencing datasets at single-cell resolution enable the reconstruction of past evolution using mutational history, allowing for a better understanding...]]></summary>
        <author>
            <name>Brian Johnson</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[cloneRate: fast estimation of single-cell clonal dynamics using coalescent theory]]></title>
        <id>pubmed:37699006</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37699006/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230915204741&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-09-12T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[MOTIVATION: While evolutionary approaches to medicine show promise, measuring evolution itself is difficult due to experimental constraints and the dynamic nature of body systems. In cancer evolution, continuous observation of clonal architecture is impossible, and longitudinal samples from multiple timepoints are rare. Increasingly available DNA sequencing datasets at single-cell resolution enable the reconstruction of past evolution using mutational history, allowing for a better understanding...]]></summary>
        <author>
            <name>Brian Johnson</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[cloneRate: fast estimation of single-cell clonal dynamics using coalescent theory]]></title>
        <id>pubmed:37699006</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37699006/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230914204950&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-09-12T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[MOTIVATION: While evolutionary approaches to medicine show promise, measuring evolution itself is difficult due to experimental constraints and the dynamic nature of body systems. In cancer evolution, continuous observation of clonal architecture is impossible, and longitudinal samples from multiple timepoints are rare. Increasingly available DNA sequencing datasets at single-cell resolution enable the reconstruction of past evolution using mutational history, allowing for a better understanding...]]></summary>
        <author>
            <name>Brian Johnson</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[cloneRate: fast estimation of single-cell clonal dynamics using coalescent theory]]></title>
        <id>pubmed:37699006</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37699006/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230913204840&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-09-12T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[MOTIVATION: While evolutionary approaches to medicine show promise, measuring evolution itself is difficult due to experimental constraints and the dynamic nature of body systems. In cancer evolution, continuous observation of clonal architecture is impossible, and longitudinal samples from multiple timepoints are rare. Increasingly available DNA sequencing datasets at single-cell resolution enable the reconstruction of past evolution using mutational history, allowing for a better understanding...]]></summary>
        <author>
            <name>Brian Johnson</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[cloneRate: fast estimation of single-cell clonal dynamics using coalescent theory]]></title>
        <id>pubmed:37699006</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37699006/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230912205016&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-09-12T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[MOTIVATION: While evolutionary approaches to medicine show promise, measuring evolution itself is difficult due to experimental constraints and the dynamic nature of body systems. In cancer evolution, continuous observation of clonal architecture is impossible, and longitudinal samples from multiple timepoints are rare. Increasingly available DNA sequencing datasets at single-cell resolution enable the reconstruction of past evolution using mutational history, allowing for a better understanding...]]></summary>
        <author>
            <name>Brian Johnson</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Fully accessible fitness landscape of oncogene-negative lung adenocarcinoma]]></title>
        <id>pubmed:37695905</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37695905/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230924205014&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-09-11T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Cancer genomes are almost invariably complex with genomic alterations cooperating during each step of carcinogenesis. In cancers that lack a single dominant oncogene mutation, cooperation between the inactivation of multiple tumor suppressor genes can drive tumor initiation and growth. Here, we shed light on how the sequential acquisition of genomic alterations generates oncogene-negative lung tumors. We couple tumor barcoding with combinatorial and multiplexed somatic genome editing to...]]></summary>
        <author>
            <name>Maryam Yousefi</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Fully accessible fitness landscape of oncogene-negative lung adenocarcinoma]]></title>
        <id>pubmed:37695905</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37695905/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230923205208&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-09-11T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Cancer genomes are almost invariably complex with genomic alterations cooperating during each step of carcinogenesis. In cancers that lack a single dominant oncogene mutation, cooperation between the inactivation of multiple tumor suppressor genes can drive tumor initiation and growth. Here, we shed light on how the sequential acquisition of genomic alterations generates oncogene-negative lung tumors. We couple tumor barcoding with combinatorial and multiplexed somatic genome editing to...]]></summary>
        <author>
            <name>Maryam Yousefi</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Fully accessible fitness landscape of oncogene-negative lung adenocarcinoma]]></title>
        <id>pubmed:37695905</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37695905/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230922204741&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-09-11T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Cancer genomes are almost invariably complex with genomic alterations cooperating during each step of carcinogenesis. In cancers that lack a single dominant oncogene mutation, cooperation between the inactivation of multiple tumor suppressor genes can drive tumor initiation and growth. Here, we shed light on how the sequential acquisition of genomic alterations generates oncogene-negative lung tumors. We couple tumor barcoding with combinatorial and multiplexed somatic genome editing to...]]></summary>
        <author>
            <name>Maryam Yousefi</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Fully accessible fitness landscape of oncogene-negative lung adenocarcinoma]]></title>
        <id>pubmed:37695905</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37695905/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230921204936&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-09-11T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Cancer genomes are almost invariably complex with genomic alterations cooperating during each step of carcinogenesis. In cancers that lack a single dominant oncogene mutation, cooperation between the inactivation of multiple tumor suppressor genes can drive tumor initiation and growth. Here, we shed light on how the sequential acquisition of genomic alterations generates oncogene-negative lung tumors. We couple tumor barcoding with combinatorial and multiplexed somatic genome editing to...]]></summary>
        <author>
            <name>Maryam Yousefi</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Fully accessible fitness landscape of oncogene-negative lung adenocarcinoma]]></title>
        <id>pubmed:37695905</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37695905/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230920204904&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-09-11T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Cancer genomes are almost invariably complex with genomic alterations cooperating during each step of carcinogenesis. In cancers that lack a single dominant oncogene mutation, cooperation between the inactivation of multiple tumor suppressor genes can drive tumor initiation and growth. Here, we shed light on how the sequential acquisition of genomic alterations generates oncogene-negative lung tumors. We couple tumor barcoding with combinatorial and multiplexed somatic genome editing to...]]></summary>
        <author>
            <name>Maryam Yousefi</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Fully accessible fitness landscape of oncogene-negative lung adenocarcinoma]]></title>
        <id>pubmed:37695905</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37695905/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230919204929&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-09-11T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Cancer genomes are almost invariably complex with genomic alterations cooperating during each step of carcinogenesis. In cancers that lack a single dominant oncogene mutation, cooperation between the inactivation of multiple tumor suppressor genes can drive tumor initiation and growth. Here, we shed light on how the sequential acquisition of genomic alterations generates oncogene-negative lung tumors. We couple tumor barcoding with combinatorial and multiplexed somatic genome editing to...]]></summary>
        <author>
            <name>Maryam Yousefi</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Fully accessible fitness landscape of oncogene-negative lung adenocarcinoma]]></title>
        <id>pubmed:37695905</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37695905/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230918204942&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-09-11T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Cancer genomes are almost invariably complex with genomic alterations cooperating during each step of carcinogenesis. In cancers that lack a single dominant oncogene mutation, cooperation between the inactivation of multiple tumor suppressor genes can drive tumor initiation and growth. Here, we shed light on how the sequential acquisition of genomic alterations generates oncogene-negative lung tumors. We couple tumor barcoding with combinatorial and multiplexed somatic genome editing to...]]></summary>
        <author>
            <name>Maryam Yousefi</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Fully accessible fitness landscape of oncogene-negative lung adenocarcinoma]]></title>
        <id>pubmed:37695905</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37695905/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230917204936&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-09-11T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Cancer genomes are almost invariably complex with genomic alterations cooperating during each step of carcinogenesis. In cancers that lack a single dominant oncogene mutation, cooperation between the inactivation of multiple tumor suppressor genes can drive tumor initiation and growth. Here, we shed light on how the sequential acquisition of genomic alterations generates oncogene-negative lung tumors. We couple tumor barcoding with combinatorial and multiplexed somatic genome editing to...]]></summary>
        <author>
            <name>Maryam Yousefi</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Fully accessible fitness landscape of oncogene-negative lung adenocarcinoma]]></title>
        <id>pubmed:37695905</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37695905/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230916205201&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-09-11T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Cancer genomes are almost invariably complex with genomic alterations cooperating during each step of carcinogenesis. In cancers that lack a single dominant oncogene mutation, cooperation between the inactivation of multiple tumor suppressor genes can drive tumor initiation and growth. Here, we shed light on how the sequential acquisition of genomic alterations generates oncogene-negative lung tumors. We couple tumor barcoding with combinatorial and multiplexed somatic genome editing to...]]></summary>
        <author>
            <name>Maryam Yousefi</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Fully accessible fitness landscape of oncogene-negative lung adenocarcinoma]]></title>
        <id>pubmed:37695905</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37695905/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230915204741&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-09-11T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Cancer genomes are almost invariably complex with genomic alterations cooperating during each step of carcinogenesis. In cancers that lack a single dominant oncogene mutation, cooperation between the inactivation of multiple tumor suppressor genes can drive tumor initiation and growth. Here, we shed light on how the sequential acquisition of genomic alterations generates oncogene-negative lung tumors. We couple tumor barcoding with combinatorial and multiplexed somatic genome editing to...]]></summary>
        <author>
            <name>Maryam Yousefi</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Fully accessible fitness landscape of oncogene-negative lung adenocarcinoma]]></title>
        <id>pubmed:37695905</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37695905/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230914204950&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-09-11T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Cancer genomes are almost invariably complex with genomic alterations cooperating during each step of carcinogenesis. In cancers that lack a single dominant oncogene mutation, cooperation between the inactivation of multiple tumor suppressor genes can drive tumor initiation and growth. Here, we shed light on how the sequential acquisition of genomic alterations generates oncogene-negative lung tumors. We couple tumor barcoding with combinatorial and multiplexed somatic genome editing to...]]></summary>
        <author>
            <name>Maryam Yousefi</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Fully accessible fitness landscape of oncogene-negative lung adenocarcinoma]]></title>
        <id>pubmed:37695905</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37695905/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230913204840&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-09-11T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Cancer genomes are almost invariably complex with genomic alterations cooperating during each step of carcinogenesis. In cancers that lack a single dominant oncogene mutation, cooperation between the inactivation of multiple tumor suppressor genes can drive tumor initiation and growth. Here, we shed light on how the sequential acquisition of genomic alterations generates oncogene-negative lung tumors. We couple tumor barcoding with combinatorial and multiplexed somatic genome editing to...]]></summary>
        <author>
            <name>Maryam Yousefi</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Fully accessible fitness landscape of oncogene-negative lung adenocarcinoma]]></title>
        <id>pubmed:37695905</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37695905/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230912205015&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-09-11T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Cancer genomes are almost invariably complex with genomic alterations cooperating during each step of carcinogenesis. In cancers that lack a single dominant oncogene mutation, cooperation between the inactivation of multiple tumor suppressor genes can drive tumor initiation and growth. Here, we shed light on how the sequential acquisition of genomic alterations generates oncogene-negative lung tumors. We couple tumor barcoding with combinatorial and multiplexed somatic genome editing to...]]></summary>
        <author>
            <name>Maryam Yousefi</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Fully accessible fitness landscape of oncogene-negative lung adenocarcinoma]]></title>
        <id>pubmed:37695905</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37695905/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230911204717&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-09-11T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Cancer genomes are almost invariably complex with genomic alterations cooperating during each step of carcinogenesis. In cancers that lack a single dominant oncogene mutation, cooperation between the inactivation of multiple tumor suppressor genes can drive tumor initiation and growth. Here, we shed light on how the sequential acquisition of genomic alterations generates oncogene-negative lung tumors. We couple tumor barcoding with combinatorial and multiplexed somatic genome editing to...]]></summary>
        <author>
            <name>Maryam Yousefi</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Challenges and Prospects of Patient-Derived Xenografts for Cancer Research]]></title>
        <id>pubmed:37686627</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37686627/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230924205014&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-09-09T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[We discuss the importance of the in vivo models in elucidating cancer biology, focusing on the patient-derived xenograft (PDX) models, which are classic and standard functional in vivo platforms for preclinical evaluation. We provide an overview of the most representative models, including cell-derived xenografts (CDX), tumor and metastatic cell-derived xenografts, and PDX models utilizing humanized mice (HM). The orthotopic models, which could reproduce the cancer environment and its...]]></summary>
        <author>
            <name>Jiankang Jin</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[A Leukemic Target with a Thousand Faces: The Mitochondria]]></title>
        <id>pubmed:37685874</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37685874/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230924205014&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-09-09T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[In the era of personalized medicine greatly improved by molecular diagnosis and tailor-made therapies, the survival rate of acute myeloid leukemia (AML) at 5 years remains unfortunately low. Indeed, the high heterogeneity of AML clones with distinct metabolic and molecular profiles allows them to survive the chemotherapy-induced changes, thus leading to resistance, clonal evolution, and relapse. Moreover, leukemic stem cells (LSCs), the quiescent reservoir of residual disease, can persist for a...]]></summary>
        <author>
            <name>Beatrice Maffeo</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Challenges and Prospects of Patient-Derived Xenografts for Cancer Research]]></title>
        <id>pubmed:37686627</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37686627/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230923205208&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-09-09T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[We discuss the importance of the in vivo models in elucidating cancer biology, focusing on the patient-derived xenograft (PDX) models, which are classic and standard functional in vivo platforms for preclinical evaluation. We provide an overview of the most representative models, including cell-derived xenografts (CDX), tumor and metastatic cell-derived xenografts, and PDX models utilizing humanized mice (HM). The orthotopic models, which could reproduce the cancer environment and its...]]></summary>
        <author>
            <name>Jiankang Jin</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[A Leukemic Target with a Thousand Faces: The Mitochondria]]></title>
        <id>pubmed:37685874</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37685874/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230923205208&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-09-09T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[In the era of personalized medicine greatly improved by molecular diagnosis and tailor-made therapies, the survival rate of acute myeloid leukemia (AML) at 5 years remains unfortunately low. Indeed, the high heterogeneity of AML clones with distinct metabolic and molecular profiles allows them to survive the chemotherapy-induced changes, thus leading to resistance, clonal evolution, and relapse. Moreover, leukemic stem cells (LSCs), the quiescent reservoir of residual disease, can persist for a...]]></summary>
        <author>
            <name>Beatrice Maffeo</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Challenges and Prospects of Patient-Derived Xenografts for Cancer Research]]></title>
        <id>pubmed:37686627</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37686627/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230922204741&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-09-09T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[We discuss the importance of the in vivo models in elucidating cancer biology, focusing on the patient-derived xenograft (PDX) models, which are classic and standard functional in vivo platforms for preclinical evaluation. We provide an overview of the most representative models, including cell-derived xenografts (CDX), tumor and metastatic cell-derived xenografts, and PDX models utilizing humanized mice (HM). The orthotopic models, which could reproduce the cancer environment and its...]]></summary>
        <author>
            <name>Jiankang Jin</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[A Leukemic Target with a Thousand Faces: The Mitochondria]]></title>
        <id>pubmed:37685874</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37685874/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230922204741&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-09-09T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[In the era of personalized medicine greatly improved by molecular diagnosis and tailor-made therapies, the survival rate of acute myeloid leukemia (AML) at 5 years remains unfortunately low. Indeed, the high heterogeneity of AML clones with distinct metabolic and molecular profiles allows them to survive the chemotherapy-induced changes, thus leading to resistance, clonal evolution, and relapse. Moreover, leukemic stem cells (LSCs), the quiescent reservoir of residual disease, can persist for a...]]></summary>
        <author>
            <name>Beatrice Maffeo</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Challenges and Prospects of Patient-Derived Xenografts for Cancer Research]]></title>
        <id>pubmed:37686627</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37686627/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230921204936&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-09-09T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[We discuss the importance of the in vivo models in elucidating cancer biology, focusing on the patient-derived xenograft (PDX) models, which are classic and standard functional in vivo platforms for preclinical evaluation. We provide an overview of the most representative models, including cell-derived xenografts (CDX), tumor and metastatic cell-derived xenografts, and PDX models utilizing humanized mice (HM). The orthotopic models, which could reproduce the cancer environment and its...]]></summary>
        <author>
            <name>Jiankang Jin</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[A Leukemic Target with a Thousand Faces: The Mitochondria]]></title>
        <id>pubmed:37685874</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37685874/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230921204936&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-09-09T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[In the era of personalized medicine greatly improved by molecular diagnosis and tailor-made therapies, the survival rate of acute myeloid leukemia (AML) at 5 years remains unfortunately low. Indeed, the high heterogeneity of AML clones with distinct metabolic and molecular profiles allows them to survive the chemotherapy-induced changes, thus leading to resistance, clonal evolution, and relapse. Moreover, leukemic stem cells (LSCs), the quiescent reservoir of residual disease, can persist for a...]]></summary>
        <author>
            <name>Beatrice Maffeo</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Challenges and Prospects of Patient-Derived Xenografts for Cancer Research]]></title>
        <id>pubmed:37686627</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37686627/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230920204904&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-09-09T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[We discuss the importance of the in vivo models in elucidating cancer biology, focusing on the patient-derived xenograft (PDX) models, which are classic and standard functional in vivo platforms for preclinical evaluation. We provide an overview of the most representative models, including cell-derived xenografts (CDX), tumor and metastatic cell-derived xenografts, and PDX models utilizing humanized mice (HM). The orthotopic models, which could reproduce the cancer environment and its...]]></summary>
        <author>
            <name>Jiankang Jin</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[A Leukemic Target with a Thousand Faces: The Mitochondria]]></title>
        <id>pubmed:37685874</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37685874/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230920204904&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-09-09T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[In the era of personalized medicine greatly improved by molecular diagnosis and tailor-made therapies, the survival rate of acute myeloid leukemia (AML) at 5 years remains unfortunately low. Indeed, the high heterogeneity of AML clones with distinct metabolic and molecular profiles allows them to survive the chemotherapy-induced changes, thus leading to resistance, clonal evolution, and relapse. Moreover, leukemic stem cells (LSCs), the quiescent reservoir of residual disease, can persist for a...]]></summary>
        <author>
            <name>Beatrice Maffeo</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Challenges and Prospects of Patient-Derived Xenografts for Cancer Research]]></title>
        <id>pubmed:37686627</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37686627/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230919204929&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-09-09T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[We discuss the importance of the in vivo models in elucidating cancer biology, focusing on the patient-derived xenograft (PDX) models, which are classic and standard functional in vivo platforms for preclinical evaluation. We provide an overview of the most representative models, including cell-derived xenografts (CDX), tumor and metastatic cell-derived xenografts, and PDX models utilizing humanized mice (HM). The orthotopic models, which could reproduce the cancer environment and its...]]></summary>
        <author>
            <name>Jiankang Jin</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[A Leukemic Target with a Thousand Faces: The Mitochondria]]></title>
        <id>pubmed:37685874</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37685874/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230919204929&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-09-09T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[In the era of personalized medicine greatly improved by molecular diagnosis and tailor-made therapies, the survival rate of acute myeloid leukemia (AML) at 5 years remains unfortunately low. Indeed, the high heterogeneity of AML clones with distinct metabolic and molecular profiles allows them to survive the chemotherapy-induced changes, thus leading to resistance, clonal evolution, and relapse. Moreover, leukemic stem cells (LSCs), the quiescent reservoir of residual disease, can persist for a...]]></summary>
        <author>
            <name>Beatrice Maffeo</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Challenges and Prospects of Patient-Derived Xenografts for Cancer Research]]></title>
        <id>pubmed:37686627</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37686627/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230918204942&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-09-09T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[We discuss the importance of the in vivo models in elucidating cancer biology, focusing on the patient-derived xenograft (PDX) models, which are classic and standard functional in vivo platforms for preclinical evaluation. We provide an overview of the most representative models, including cell-derived xenografts (CDX), tumor and metastatic cell-derived xenografts, and PDX models utilizing humanized mice (HM). The orthotopic models, which could reproduce the cancer environment and its...]]></summary>
        <author>
            <name>Jiankang Jin</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[A Leukemic Target with a Thousand Faces: The Mitochondria]]></title>
        <id>pubmed:37685874</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37685874/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230918204942&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-09-09T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[In the era of personalized medicine greatly improved by molecular diagnosis and tailor-made therapies, the survival rate of acute myeloid leukemia (AML) at 5 years remains unfortunately low. Indeed, the high heterogeneity of AML clones with distinct metabolic and molecular profiles allows them to survive the chemotherapy-induced changes, thus leading to resistance, clonal evolution, and relapse. Moreover, leukemic stem cells (LSCs), the quiescent reservoir of residual disease, can persist for a...]]></summary>
        <author>
            <name>Beatrice Maffeo</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Challenges and Prospects of Patient-Derived Xenografts for Cancer Research]]></title>
        <id>pubmed:37686627</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37686627/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230917204936&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-09-09T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[We discuss the importance of the in vivo models in elucidating cancer biology, focusing on the patient-derived xenograft (PDX) models, which are classic and standard functional in vivo platforms for preclinical evaluation. We provide an overview of the most representative models, including cell-derived xenografts (CDX), tumor and metastatic cell-derived xenografts, and PDX models utilizing humanized mice (HM). The orthotopic models, which could reproduce the cancer environment and its...]]></summary>
        <author>
            <name>Jiankang Jin</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[A Leukemic Target with a Thousand Faces: The Mitochondria]]></title>
        <id>pubmed:37685874</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37685874/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230917204936&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-09-09T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[In the era of personalized medicine greatly improved by molecular diagnosis and tailor-made therapies, the survival rate of acute myeloid leukemia (AML) at 5 years remains unfortunately low. Indeed, the high heterogeneity of AML clones with distinct metabolic and molecular profiles allows them to survive the chemotherapy-induced changes, thus leading to resistance, clonal evolution, and relapse. Moreover, leukemic stem cells (LSCs), the quiescent reservoir of residual disease, can persist for a...]]></summary>
        <author>
            <name>Beatrice Maffeo</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Challenges and Prospects of Patient-Derived Xenografts for Cancer Research]]></title>
        <id>pubmed:37686627</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37686627/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230916205201&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-09-09T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[We discuss the importance of the in vivo models in elucidating cancer biology, focusing on the patient-derived xenograft (PDX) models, which are classic and standard functional in vivo platforms for preclinical evaluation. We provide an overview of the most representative models, including cell-derived xenografts (CDX), tumor and metastatic cell-derived xenografts, and PDX models utilizing humanized mice (HM). The orthotopic models, which could reproduce the cancer environment and its...]]></summary>
        <author>
            <name>Jiankang Jin</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[A Leukemic Target with a Thousand Faces: The Mitochondria]]></title>
        <id>pubmed:37685874</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37685874/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230916205201&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-09-09T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[In the era of personalized medicine greatly improved by molecular diagnosis and tailor-made therapies, the survival rate of acute myeloid leukemia (AML) at 5 years remains unfortunately low. Indeed, the high heterogeneity of AML clones with distinct metabolic and molecular profiles allows them to survive the chemotherapy-induced changes, thus leading to resistance, clonal evolution, and relapse. Moreover, leukemic stem cells (LSCs), the quiescent reservoir of residual disease, can persist for a...]]></summary>
        <author>
            <name>Beatrice Maffeo</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Challenges and Prospects of Patient-Derived Xenografts for Cancer Research]]></title>
        <id>pubmed:37686627</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37686627/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230915204741&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-09-09T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[We discuss the importance of the in vivo models in elucidating cancer biology, focusing on the patient-derived xenograft (PDX) models, which are classic and standard functional in vivo platforms for preclinical evaluation. We provide an overview of the most representative models, including cell-derived xenografts (CDX), tumor and metastatic cell-derived xenografts, and PDX models utilizing humanized mice (HM). The orthotopic models, which could reproduce the cancer environment and its...]]></summary>
        <author>
            <name>Jiankang Jin</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[A Leukemic Target with a Thousand Faces: The Mitochondria]]></title>
        <id>pubmed:37685874</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37685874/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230915204741&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-09-09T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[In the era of personalized medicine greatly improved by molecular diagnosis and tailor-made therapies, the survival rate of acute myeloid leukemia (AML) at 5 years remains unfortunately low. Indeed, the high heterogeneity of AML clones with distinct metabolic and molecular profiles allows them to survive the chemotherapy-induced changes, thus leading to resistance, clonal evolution, and relapse. Moreover, leukemic stem cells (LSCs), the quiescent reservoir of residual disease, can persist for a...]]></summary>
        <author>
            <name>Beatrice Maffeo</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Challenges and Prospects of Patient-Derived Xenografts for Cancer Research]]></title>
        <id>pubmed:37686627</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37686627/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230914204950&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-09-09T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[We discuss the importance of the in vivo models in elucidating cancer biology, focusing on the patient-derived xenograft (PDX) models, which are classic and standard functional in vivo platforms for preclinical evaluation. We provide an overview of the most representative models, including cell-derived xenografts (CDX), tumor and metastatic cell-derived xenografts, and PDX models utilizing humanized mice (HM). The orthotopic models, which could reproduce the cancer environment and its...]]></summary>
        <author>
            <name>Jiankang Jin</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[A Leukemic Target with a Thousand Faces: The Mitochondria]]></title>
        <id>pubmed:37685874</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37685874/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230914204950&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-09-09T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[In the era of personalized medicine greatly improved by molecular diagnosis and tailor-made therapies, the survival rate of acute myeloid leukemia (AML) at 5 years remains unfortunately low. Indeed, the high heterogeneity of AML clones with distinct metabolic and molecular profiles allows them to survive the chemotherapy-induced changes, thus leading to resistance, clonal evolution, and relapse. Moreover, leukemic stem cells (LSCs), the quiescent reservoir of residual disease, can persist for a...]]></summary>
        <author>
            <name>Beatrice Maffeo</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Challenges and Prospects of Patient-Derived Xenografts for Cancer Research]]></title>
        <id>pubmed:37686627</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37686627/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230913204840&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-09-09T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[We discuss the importance of the in vivo models in elucidating cancer biology, focusing on the patient-derived xenograft (PDX) models, which are classic and standard functional in vivo platforms for preclinical evaluation. We provide an overview of the most representative models, including cell-derived xenografts (CDX), tumor and metastatic cell-derived xenografts, and PDX models utilizing humanized mice (HM). The orthotopic models, which could reproduce the cancer environment and its...]]></summary>
        <author>
            <name>Jiankang Jin</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[A Leukemic Target with a Thousand Faces: The Mitochondria]]></title>
        <id>pubmed:37685874</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37685874/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230913204840&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-09-09T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[In the era of personalized medicine greatly improved by molecular diagnosis and tailor-made therapies, the survival rate of acute myeloid leukemia (AML) at 5 years remains unfortunately low. Indeed, the high heterogeneity of AML clones with distinct metabolic and molecular profiles allows them to survive the chemotherapy-induced changes, thus leading to resistance, clonal evolution, and relapse. Moreover, leukemic stem cells (LSCs), the quiescent reservoir of residual disease, can persist for a...]]></summary>
        <author>
            <name>Beatrice Maffeo</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Challenges and Prospects of Patient-Derived Xenografts for Cancer Research]]></title>
        <id>pubmed:37686627</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37686627/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230912205015&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-09-09T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[We discuss the importance of the in vivo models in elucidating cancer biology, focusing on the patient-derived xenograft (PDX) models, which are classic and standard functional in vivo platforms for preclinical evaluation. We provide an overview of the most representative models, including cell-derived xenografts (CDX), tumor and metastatic cell-derived xenografts, and PDX models utilizing humanized mice (HM). The orthotopic models, which could reproduce the cancer environment and its...]]></summary>
        <author>
            <name>Jiankang Jin</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[A Leukemic Target with a Thousand Faces: The Mitochondria]]></title>
        <id>pubmed:37685874</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37685874/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230912205015&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-09-09T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[In the era of personalized medicine greatly improved by molecular diagnosis and tailor-made therapies, the survival rate of acute myeloid leukemia (AML) at 5 years remains unfortunately low. Indeed, the high heterogeneity of AML clones with distinct metabolic and molecular profiles allows them to survive the chemotherapy-induced changes, thus leading to resistance, clonal evolution, and relapse. Moreover, leukemic stem cells (LSCs), the quiescent reservoir of residual disease, can persist for a...]]></summary>
        <author>
            <name>Beatrice Maffeo</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Challenges and Prospects of Patient-Derived Xenografts for Cancer Research]]></title>
        <id>pubmed:37686627</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37686627/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230911204717&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-09-09T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[We discuss the importance of the in vivo models in elucidating cancer biology, focusing on the patient-derived xenograft (PDX) models, which are classic and standard functional in vivo platforms for preclinical evaluation. We provide an overview of the most representative models, including cell-derived xenografts (CDX), tumor and metastatic cell-derived xenografts, and PDX models utilizing humanized mice (HM). The orthotopic models, which could reproduce the cancer environment and its...]]></summary>
        <author>
            <name>Jiankang Jin</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[A Leukemic Target with a Thousand Faces: The Mitochondria]]></title>
        <id>pubmed:37685874</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37685874/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230911204717&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-09-09T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[In the era of personalized medicine greatly improved by molecular diagnosis and tailor-made therapies, the survival rate of acute myeloid leukemia (AML) at 5 years remains unfortunately low. Indeed, the high heterogeneity of AML clones with distinct metabolic and molecular profiles allows them to survive the chemotherapy-induced changes, thus leading to resistance, clonal evolution, and relapse. Moreover, leukemic stem cells (LSCs), the quiescent reservoir of residual disease, can persist for a...]]></summary>
        <author>
            <name>Beatrice Maffeo</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Challenges and Prospects of Patient-Derived Xenografts for Cancer Research]]></title>
        <id>pubmed:37686627</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37686627/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230910204912&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-09-09T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[We discuss the importance of the in vivo models in elucidating cancer biology, focusing on the patient-derived xenograft (PDX) models, which are classic and standard functional in vivo platforms for preclinical evaluation. We provide an overview of the most representative models, including cell-derived xenografts (CDX), tumor and metastatic cell-derived xenografts, and PDX models utilizing humanized mice (HM). The orthotopic models, which could reproduce the cancer environment and its...]]></summary>
        <author>
            <name>Jiankang Jin</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Challenges and Prospects of Patient-Derived Xenografts for Cancer Research]]></title>
        <id>pubmed:37686627</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37686627/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230909205145&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-09-09T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[We discuss the importance of the in vivo models in elucidating cancer biology, focusing on the patient-derived xenograft (PDX) models, which are classic and standard functional in vivo platforms for preclinical evaluation. We provide an overview of the most representative models, including cell-derived xenografts (CDX), tumor and metastatic cell-derived xenografts, and PDX models utilizing humanized mice (HM). The orthotopic models, which could reproduce the cancer environment and its...]]></summary>
        <author>
            <name>Jiankang Jin</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Shared and distinct genetic etiologies for different types of clonal hematopoiesis]]></title>
        <id>pubmed:37684235</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37684235/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230924205014&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-09-08T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Clonal hematopoiesis (CH)-age-related expansion of mutated hematopoietic clones-can differ in frequency and cellular fitness by CH type (e.g., mutations in driver genes (CHIP), gains/losses and copy-neutral loss of chromosomal segments (mCAs), and loss of sex chromosomes). Co-occurring CH raises questions as to their origin, selection, and impact. We integrate sequence and genotype array data in up to 482,378 UK Biobank participants to demonstrate shared genetic architecture across CH types. Our...]]></summary>
        <author>
            <name>Derek W Brown</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clonal Hematopoiesis in Clinical and Experimental Heart Failure With Preserved Ejection Fraction]]></title>
        <id>pubmed:37681311</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37681311/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230924205014&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-09-08T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSIONS: CH is associated with worse heart function and prognosis in patients with HFpEF, and a murine experimental model of Tet2-mediated CH displays greater features of HFpEF.]]></summary>
        <author>
            <name>Jesse Cochran</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Shared and distinct genetic etiologies for different types of clonal hematopoiesis]]></title>
        <id>pubmed:37684235</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37684235/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230923205208&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-09-08T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Clonal hematopoiesis (CH)-age-related expansion of mutated hematopoietic clones-can differ in frequency and cellular fitness by CH type (e.g., mutations in driver genes (CHIP), gains/losses and copy-neutral loss of chromosomal segments (mCAs), and loss of sex chromosomes). Co-occurring CH raises questions as to their origin, selection, and impact. We integrate sequence and genotype array data in up to 482,378 UK Biobank participants to demonstrate shared genetic architecture across CH types. Our...]]></summary>
        <author>
            <name>Derek W Brown</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clonal Hematopoiesis in Clinical and Experimental Heart Failure With Preserved Ejection Fraction]]></title>
        <id>pubmed:37681311</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37681311/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230923205208&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-09-08T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSIONS: CH is associated with worse heart function and prognosis in patients with HFpEF, and a murine experimental model of Tet2-mediated CH displays greater features of HFpEF.]]></summary>
        <author>
            <name>Jesse Cochran</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Shared and distinct genetic etiologies for different types of clonal hematopoiesis]]></title>
        <id>pubmed:37684235</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37684235/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230922204741&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-09-08T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Clonal hematopoiesis (CH)-age-related expansion of mutated hematopoietic clones-can differ in frequency and cellular fitness by CH type (e.g., mutations in driver genes (CHIP), gains/losses and copy-neutral loss of chromosomal segments (mCAs), and loss of sex chromosomes). Co-occurring CH raises questions as to their origin, selection, and impact. We integrate sequence and genotype array data in up to 482,378 UK Biobank participants to demonstrate shared genetic architecture across CH types. Our...]]></summary>
        <author>
            <name>Derek W Brown</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clonal Hematopoiesis in Clinical and Experimental Heart Failure With Preserved Ejection Fraction]]></title>
        <id>pubmed:37681311</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37681311/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230922204741&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-09-08T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSIONS: CH is associated with worse heart function and prognosis in patients with HFpEF, and a murine experimental model of Tet2-mediated CH displays greater features of HFpEF.]]></summary>
        <author>
            <name>Jesse Cochran</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Shared and distinct genetic etiologies for different types of clonal hematopoiesis]]></title>
        <id>pubmed:37684235</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37684235/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230921204936&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-09-08T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Clonal hematopoiesis (CH)-age-related expansion of mutated hematopoietic clones-can differ in frequency and cellular fitness by CH type (e.g., mutations in driver genes (CHIP), gains/losses and copy-neutral loss of chromosomal segments (mCAs), and loss of sex chromosomes). Co-occurring CH raises questions as to their origin, selection, and impact. We integrate sequence and genotype array data in up to 482,378 UK Biobank participants to demonstrate shared genetic architecture across CH types. Our...]]></summary>
        <author>
            <name>Derek W Brown</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clonal Hematopoiesis in Clinical and Experimental Heart Failure With Preserved Ejection Fraction]]></title>
        <id>pubmed:37681311</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37681311/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230921204936&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-09-08T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSIONS: CH is associated with worse heart function and prognosis in patients with HFpEF, and a murine experimental model of Tet2-mediated CH displays greater features of HFpEF.]]></summary>
        <author>
            <name>Jesse Cochran</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Shared and distinct genetic etiologies for different types of clonal hematopoiesis]]></title>
        <id>pubmed:37684235</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37684235/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230920204905&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-09-08T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Clonal hematopoiesis (CH)-age-related expansion of mutated hematopoietic clones-can differ in frequency and cellular fitness by CH type (e.g., mutations in driver genes (CHIP), gains/losses and copy-neutral loss of chromosomal segments (mCAs), and loss of sex chromosomes). Co-occurring CH raises questions as to their origin, selection, and impact. We integrate sequence and genotype array data in up to 482,378 UK Biobank participants to demonstrate shared genetic architecture across CH types. Our...]]></summary>
        <author>
            <name>Derek W Brown</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clonal Hematopoiesis in Clinical and Experimental Heart Failure With Preserved Ejection Fraction]]></title>
        <id>pubmed:37681311</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37681311/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230920204905&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-09-08T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSIONS: CH is associated with worse heart function and prognosis in patients with HFpEF, and a murine experimental model of Tet2-mediated CH displays greater features of HFpEF.]]></summary>
        <author>
            <name>Jesse Cochran</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Shared and distinct genetic etiologies for different types of clonal hematopoiesis]]></title>
        <id>pubmed:37684235</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37684235/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230919204929&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-09-08T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Clonal hematopoiesis (CH)-age-related expansion of mutated hematopoietic clones-can differ in frequency and cellular fitness by CH type (e.g., mutations in driver genes (CHIP), gains/losses and copy-neutral loss of chromosomal segments (mCAs), and loss of sex chromosomes). Co-occurring CH raises questions as to their origin, selection, and impact. We integrate sequence and genotype array data in up to 482,378 UK Biobank participants to demonstrate shared genetic architecture across CH types. Our...]]></summary>
        <author>
            <name>Derek W Brown</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clonal Hematopoiesis in Clinical and Experimental Heart Failure With Preserved Ejection Fraction]]></title>
        <id>pubmed:37681311</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37681311/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230919204929&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-09-08T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSIONS: CH is associated with worse heart function and prognosis in patients with HFpEF, and a murine experimental model of Tet2-mediated CH displays greater features of HFpEF.]]></summary>
        <author>
            <name>Jesse Cochran</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Shared and distinct genetic etiologies for different types of clonal hematopoiesis]]></title>
        <id>pubmed:37684235</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37684235/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230918204942&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-09-08T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Clonal hematopoiesis (CH)-age-related expansion of mutated hematopoietic clones-can differ in frequency and cellular fitness by CH type (e.g., mutations in driver genes (CHIP), gains/losses and copy-neutral loss of chromosomal segments (mCAs), and loss of sex chromosomes). Co-occurring CH raises questions as to their origin, selection, and impact. We integrate sequence and genotype array data in up to 482,378 UK Biobank participants to demonstrate shared genetic architecture across CH types. Our...]]></summary>
        <author>
            <name>Derek W Brown</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clonal Hematopoiesis in Clinical and Experimental Heart Failure With Preserved Ejection Fraction]]></title>
        <id>pubmed:37681311</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37681311/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230918204942&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-09-08T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSIONS: CH is associated with worse heart function and prognosis in patients with HFpEF, and a murine experimental model of Tet2-mediated CH displays greater features of HFpEF.]]></summary>
        <author>
            <name>Jesse Cochran</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Shared and distinct genetic etiologies for different types of clonal hematopoiesis]]></title>
        <id>pubmed:37684235</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37684235/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230917204935&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-09-08T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Clonal hematopoiesis (CH)-age-related expansion of mutated hematopoietic clones-can differ in frequency and cellular fitness by CH type (e.g., mutations in driver genes (CHIP), gains/losses and copy-neutral loss of chromosomal segments (mCAs), and loss of sex chromosomes). Co-occurring CH raises questions as to their origin, selection, and impact. We integrate sequence and genotype array data in up to 482,378 UK Biobank participants to demonstrate shared genetic architecture across CH types. Our...]]></summary>
        <author>
            <name>Derek W Brown</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clonal Hematopoiesis in Clinical and Experimental Heart Failure With Preserved Ejection Fraction]]></title>
        <id>pubmed:37681311</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37681311/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230917204935&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-09-08T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSIONS: CH is associated with worse heart function and prognosis in patients with HFpEF, and a murine experimental model of Tet2-mediated CH displays greater features of HFpEF.]]></summary>
        <author>
            <name>Jesse Cochran</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Shared and distinct genetic etiologies for different types of clonal hematopoiesis]]></title>
        <id>pubmed:37684235</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37684235/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230916205201&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-09-08T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Clonal hematopoiesis (CH)-age-related expansion of mutated hematopoietic clones-can differ in frequency and cellular fitness by CH type (e.g., mutations in driver genes (CHIP), gains/losses and copy-neutral loss of chromosomal segments (mCAs), and loss of sex chromosomes). Co-occurring CH raises questions as to their origin, selection, and impact. We integrate sequence and genotype array data in up to 482,378 UK Biobank participants to demonstrate shared genetic architecture across CH types. Our...]]></summary>
        <author>
            <name>Derek W Brown</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clonal Hematopoiesis in Clinical and Experimental Heart Failure With Preserved Ejection Fraction]]></title>
        <id>pubmed:37681311</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37681311/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230916205201&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-09-08T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSIONS: CH is associated with worse heart function and prognosis in patients with HFpEF, and a murine experimental model of Tet2-mediated CH displays greater features of HFpEF.]]></summary>
        <author>
            <name>Jesse Cochran</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Shared and distinct genetic etiologies for different types of clonal hematopoiesis]]></title>
        <id>pubmed:37684235</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37684235/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230915204741&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-09-08T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Clonal hematopoiesis (CH)-age-related expansion of mutated hematopoietic clones-can differ in frequency and cellular fitness by CH type (e.g., mutations in driver genes (CHIP), gains/losses and copy-neutral loss of chromosomal segments (mCAs), and loss of sex chromosomes). Co-occurring CH raises questions as to their origin, selection, and impact. We integrate sequence and genotype array data in up to 482,378 UK Biobank participants to demonstrate shared genetic architecture across CH types. Our...]]></summary>
        <author>
            <name>Derek W Brown</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clonal Hematopoiesis in Clinical and Experimental Heart Failure With Preserved Ejection Fraction]]></title>
        <id>pubmed:37681311</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37681311/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230915204741&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-09-08T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSIONS: CH is associated with worse heart function and prognosis in patients with HFpEF, and a murine experimental model of Tet2-mediated CH displays greater features of HFpEF.]]></summary>
        <author>
            <name>Jesse Cochran</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Shared and distinct genetic etiologies for different types of clonal hematopoiesis]]></title>
        <id>pubmed:37684235</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37684235/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230914204950&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-09-08T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Clonal hematopoiesis (CH)-age-related expansion of mutated hematopoietic clones-can differ in frequency and cellular fitness by CH type (e.g., mutations in driver genes (CHIP), gains/losses and copy-neutral loss of chromosomal segments (mCAs), and loss of sex chromosomes). Co-occurring CH raises questions as to their origin, selection, and impact. We integrate sequence and genotype array data in up to 482,378 UK Biobank participants to demonstrate shared genetic architecture across CH types. Our...]]></summary>
        <author>
            <name>Derek W Brown</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clonal Hematopoiesis in Clinical and Experimental Heart Failure With Preserved Ejection Fraction]]></title>
        <id>pubmed:37681311</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37681311/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230914204950&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-09-08T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSIONS: CH is associated with worse heart function and prognosis in patients with HFpEF, and a murine experimental model of Tet2-mediated CH displays greater features of HFpEF.]]></summary>
        <author>
            <name>Jesse Cochran</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Shared and distinct genetic etiologies for different types of clonal hematopoiesis]]></title>
        <id>pubmed:37684235</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37684235/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230913204840&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-09-08T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Clonal hematopoiesis (CH)-age-related expansion of mutated hematopoietic clones-can differ in frequency and cellular fitness by CH type (e.g., mutations in driver genes (CHIP), gains/losses and copy-neutral loss of chromosomal segments (mCAs), and loss of sex chromosomes). Co-occurring CH raises questions as to their origin, selection, and impact. We integrate sequence and genotype array data in up to 482,378 UK Biobank participants to demonstrate shared genetic architecture across CH types. Our...]]></summary>
        <author>
            <name>Derek W Brown</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clonal Hematopoiesis in Clinical and Experimental Heart Failure With Preserved Ejection Fraction]]></title>
        <id>pubmed:37681311</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37681311/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230913204840&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-09-08T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSIONS: CH is associated with worse heart function and prognosis in patients with HFpEF, and a murine experimental model of Tet2-mediated CH displays greater features of HFpEF.]]></summary>
        <author>
            <name>Jesse Cochran</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Shared and distinct genetic etiologies for different types of clonal hematopoiesis]]></title>
        <id>pubmed:37684235</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37684235/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230912205016&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-09-08T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Clonal hematopoiesis (CH)-age-related expansion of mutated hematopoietic clones-can differ in frequency and cellular fitness by CH type (e.g., mutations in driver genes (CHIP), gains/losses and copy-neutral loss of chromosomal segments (mCAs), and loss of sex chromosomes). Co-occurring CH raises questions as to their origin, selection, and impact. We integrate sequence and genotype array data in up to 482,378 UK Biobank participants to demonstrate shared genetic architecture across CH types. Our...]]></summary>
        <author>
            <name>Derek W Brown</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clonal Hematopoiesis in Clinical and Experimental Heart Failure With Preserved Ejection Fraction]]></title>
        <id>pubmed:37681311</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37681311/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230912205016&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-09-08T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSIONS: CH is associated with worse heart function and prognosis in patients with HFpEF, and a murine experimental model of Tet2-mediated CH displays greater features of HFpEF.]]></summary>
        <author>
            <name>Jesse Cochran</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Shared and distinct genetic etiologies for different types of clonal hematopoiesis]]></title>
        <id>pubmed:37684235</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37684235/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230911204717&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-09-08T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Clonal hematopoiesis (CH)-age-related expansion of mutated hematopoietic clones-can differ in frequency and cellular fitness by CH type (e.g., mutations in driver genes (CHIP), gains/losses and copy-neutral loss of chromosomal segments (mCAs), and loss of sex chromosomes). Co-occurring CH raises questions as to their origin, selection, and impact. We integrate sequence and genotype array data in up to 482,378 UK Biobank participants to demonstrate shared genetic architecture across CH types. Our...]]></summary>
        <author>
            <name>Derek W Brown</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clonal Hematopoiesis in Clinical and Experimental Heart Failure With Preserved Ejection Fraction]]></title>
        <id>pubmed:37681311</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37681311/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230911204717&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-09-08T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSIONS: CH is associated with worse heart function and prognosis in patients with HFpEF, and a murine experimental model of Tet2-mediated CH displays greater features of HFpEF.]]></summary>
        <author>
            <name>Jesse Cochran</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Shared and distinct genetic etiologies for different types of clonal hematopoiesis]]></title>
        <id>pubmed:37684235</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37684235/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230910204912&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-09-08T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Clonal hematopoiesis (CH)-age-related expansion of mutated hematopoietic clones-can differ in frequency and cellular fitness by CH type (e.g., mutations in driver genes (CHIP), gains/losses and copy-neutral loss of chromosomal segments (mCAs), and loss of sex chromosomes). Co-occurring CH raises questions as to their origin, selection, and impact. We integrate sequence and genotype array data in up to 482,378 UK Biobank participants to demonstrate shared genetic architecture across CH types. Our...]]></summary>
        <author>
            <name>Derek W Brown</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clonal Hematopoiesis in Clinical and Experimental Heart Failure With Preserved Ejection Fraction]]></title>
        <id>pubmed:37681311</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37681311/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230910204912&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-09-08T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSIONS: CH is associated with worse heart function and prognosis in patients with HFpEF, and a murine experimental model of Tet2-mediated CH displays greater features of HFpEF.]]></summary>
        <author>
            <name>Jesse Cochran</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Shared and distinct genetic etiologies for different types of clonal hematopoiesis]]></title>
        <id>pubmed:37684235</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37684235/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230909205145&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-09-08T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Clonal hematopoiesis (CH)-age-related expansion of mutated hematopoietic clones-can differ in frequency and cellular fitness by CH type (e.g., mutations in driver genes (CHIP), gains/losses and copy-neutral loss of chromosomal segments (mCAs), and loss of sex chromosomes). Co-occurring CH raises questions as to their origin, selection, and impact. We integrate sequence and genotype array data in up to 482,378 UK Biobank participants to demonstrate shared genetic architecture across CH types. Our...]]></summary>
        <author>
            <name>Derek W Brown</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clonal Hematopoiesis in Clinical and Experimental Heart Failure With Preserved Ejection Fraction]]></title>
        <id>pubmed:37681311</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37681311/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230909205145&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-09-08T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSIONS: CH is associated with worse heart function and prognosis in patients with HFpEF, and a murine experimental model of Tet2-mediated CH displays greater features of HFpEF.]]></summary>
        <author>
            <name>Jesse Cochran</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clonal Hematopoiesis in Clinical and Experimental Heart Failure With Preserved Ejection Fraction]]></title>
        <id>pubmed:37681311</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37681311/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230908204701&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-09-08T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSIONS: CH is associated with worse heart function and prognosis in patients with HFpEF, and a murine experimental model of Tet2-mediated CH displays greater features of HFpEF.]]></summary>
        <author>
            <name>Jesse Cochran</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Potential value of high-throughput single-cell DNA sequencing of Juvenile myelomonocytic leukemia: report of two cases]]></title>
        <id>pubmed:37684264</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37684264/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230924205014&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-09-08T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Juvenile myelomonocytic leukemia (JMML) is a rare myeloproliferative disease of early childhood that develops due to mutations in the genes of the RAS-signaling pathway. Next-generation high throughput sequencing (NGS) enables identification of various secondary molecular genetic events that can facilitate JMML progression and transformation into secondary acute myeloid leukemia (sAML). The methods of single-cell DNA sequencing (scDNA-seq) enable overcoming limitations of bulk NGS and exploring...]]></summary>
        <author>
            <name>E V Volchkov</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Potential value of high-throughput single-cell DNA sequencing of Juvenile myelomonocytic leukemia: report of two cases]]></title>
        <id>pubmed:37684264</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37684264/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230923205208&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-09-08T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Juvenile myelomonocytic leukemia (JMML) is a rare myeloproliferative disease of early childhood that develops due to mutations in the genes of the RAS-signaling pathway. Next-generation high throughput sequencing (NGS) enables identification of various secondary molecular genetic events that can facilitate JMML progression and transformation into secondary acute myeloid leukemia (sAML). The methods of single-cell DNA sequencing (scDNA-seq) enable overcoming limitations of bulk NGS and exploring...]]></summary>
        <author>
            <name>E V Volchkov</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Potential value of high-throughput single-cell DNA sequencing of Juvenile myelomonocytic leukemia: report of two cases]]></title>
        <id>pubmed:37684264</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37684264/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230922204741&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-09-08T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Juvenile myelomonocytic leukemia (JMML) is a rare myeloproliferative disease of early childhood that develops due to mutations in the genes of the RAS-signaling pathway. Next-generation high throughput sequencing (NGS) enables identification of various secondary molecular genetic events that can facilitate JMML progression and transformation into secondary acute myeloid leukemia (sAML). The methods of single-cell DNA sequencing (scDNA-seq) enable overcoming limitations of bulk NGS and exploring...]]></summary>
        <author>
            <name>E V Volchkov</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Potential value of high-throughput single-cell DNA sequencing of Juvenile myelomonocytic leukemia: report of two cases]]></title>
        <id>pubmed:37684264</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37684264/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230921204936&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-09-08T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Juvenile myelomonocytic leukemia (JMML) is a rare myeloproliferative disease of early childhood that develops due to mutations in the genes of the RAS-signaling pathway. Next-generation high throughput sequencing (NGS) enables identification of various secondary molecular genetic events that can facilitate JMML progression and transformation into secondary acute myeloid leukemia (sAML). The methods of single-cell DNA sequencing (scDNA-seq) enable overcoming limitations of bulk NGS and exploring...]]></summary>
        <author>
            <name>E V Volchkov</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Potential value of high-throughput single-cell DNA sequencing of Juvenile myelomonocytic leukemia: report of two cases]]></title>
        <id>pubmed:37684264</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37684264/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230920204904&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-09-08T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Juvenile myelomonocytic leukemia (JMML) is a rare myeloproliferative disease of early childhood that develops due to mutations in the genes of the RAS-signaling pathway. Next-generation high throughput sequencing (NGS) enables identification of various secondary molecular genetic events that can facilitate JMML progression and transformation into secondary acute myeloid leukemia (sAML). The methods of single-cell DNA sequencing (scDNA-seq) enable overcoming limitations of bulk NGS and exploring...]]></summary>
        <author>
            <name>E V Volchkov</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Potential value of high-throughput single-cell DNA sequencing of Juvenile myelomonocytic leukemia: report of two cases]]></title>
        <id>pubmed:37684264</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37684264/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230919204929&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-09-08T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Juvenile myelomonocytic leukemia (JMML) is a rare myeloproliferative disease of early childhood that develops due to mutations in the genes of the RAS-signaling pathway. Next-generation high throughput sequencing (NGS) enables identification of various secondary molecular genetic events that can facilitate JMML progression and transformation into secondary acute myeloid leukemia (sAML). The methods of single-cell DNA sequencing (scDNA-seq) enable overcoming limitations of bulk NGS and exploring...]]></summary>
        <author>
            <name>E V Volchkov</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Potential value of high-throughput single-cell DNA sequencing of Juvenile myelomonocytic leukemia: report of two cases]]></title>
        <id>pubmed:37684264</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37684264/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230918204942&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-09-08T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Juvenile myelomonocytic leukemia (JMML) is a rare myeloproliferative disease of early childhood that develops due to mutations in the genes of the RAS-signaling pathway. Next-generation high throughput sequencing (NGS) enables identification of various secondary molecular genetic events that can facilitate JMML progression and transformation into secondary acute myeloid leukemia (sAML). The methods of single-cell DNA sequencing (scDNA-seq) enable overcoming limitations of bulk NGS and exploring...]]></summary>
        <author>
            <name>E V Volchkov</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Potential value of high-throughput single-cell DNA sequencing of Juvenile myelomonocytic leukemia: report of two cases]]></title>
        <id>pubmed:37684264</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37684264/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230917204936&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-09-08T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Juvenile myelomonocytic leukemia (JMML) is a rare myeloproliferative disease of early childhood that develops due to mutations in the genes of the RAS-signaling pathway. Next-generation high throughput sequencing (NGS) enables identification of various secondary molecular genetic events that can facilitate JMML progression and transformation into secondary acute myeloid leukemia (sAML). The methods of single-cell DNA sequencing (scDNA-seq) enable overcoming limitations of bulk NGS and exploring...]]></summary>
        <author>
            <name>E V Volchkov</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Potential value of high-throughput single-cell DNA sequencing of Juvenile myelomonocytic leukemia: report of two cases]]></title>
        <id>pubmed:37684264</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37684264/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230916205201&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-09-08T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Juvenile myelomonocytic leukemia (JMML) is a rare myeloproliferative disease of early childhood that develops due to mutations in the genes of the RAS-signaling pathway. Next-generation high throughput sequencing (NGS) enables identification of various secondary molecular genetic events that can facilitate JMML progression and transformation into secondary acute myeloid leukemia (sAML). The methods of single-cell DNA sequencing (scDNA-seq) enable overcoming limitations of bulk NGS and exploring...]]></summary>
        <author>
            <name>E V Volchkov</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Potential value of high-throughput single-cell DNA sequencing of Juvenile myelomonocytic leukemia: report of two cases]]></title>
        <id>pubmed:37684264</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37684264/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230915204741&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-09-08T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Juvenile myelomonocytic leukemia (JMML) is a rare myeloproliferative disease of early childhood that develops due to mutations in the genes of the RAS-signaling pathway. Next-generation high throughput sequencing (NGS) enables identification of various secondary molecular genetic events that can facilitate JMML progression and transformation into secondary acute myeloid leukemia (sAML). The methods of single-cell DNA sequencing (scDNA-seq) enable overcoming limitations of bulk NGS and exploring...]]></summary>
        <author>
            <name>E V Volchkov</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Potential value of high-throughput single-cell DNA sequencing of Juvenile myelomonocytic leukemia: report of two cases]]></title>
        <id>pubmed:37684264</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37684264/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230914204950&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-09-08T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Juvenile myelomonocytic leukemia (JMML) is a rare myeloproliferative disease of early childhood that develops due to mutations in the genes of the RAS-signaling pathway. Next-generation high throughput sequencing (NGS) enables identification of various secondary molecular genetic events that can facilitate JMML progression and transformation into secondary acute myeloid leukemia (sAML). The methods of single-cell DNA sequencing (scDNA-seq) enable overcoming limitations of bulk NGS and exploring...]]></summary>
        <author>
            <name>E V Volchkov</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Potential value of high-throughput single-cell DNA sequencing of Juvenile myelomonocytic leukemia: report of two cases]]></title>
        <id>pubmed:37684264</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37684264/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230913204840&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-09-08T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Juvenile myelomonocytic leukemia (JMML) is a rare myeloproliferative disease of early childhood that develops due to mutations in the genes of the RAS-signaling pathway. Next-generation high throughput sequencing (NGS) enables identification of various secondary molecular genetic events that can facilitate JMML progression and transformation into secondary acute myeloid leukemia (sAML). The methods of single-cell DNA sequencing (scDNA-seq) enable overcoming limitations of bulk NGS and exploring...]]></summary>
        <author>
            <name>E V Volchkov</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Potential value of high-throughput single-cell DNA sequencing of Juvenile myelomonocytic leukemia: report of two cases]]></title>
        <id>pubmed:37684264</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37684264/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230912205015&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-09-08T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Juvenile myelomonocytic leukemia (JMML) is a rare myeloproliferative disease of early childhood that develops due to mutations in the genes of the RAS-signaling pathway. Next-generation high throughput sequencing (NGS) enables identification of various secondary molecular genetic events that can facilitate JMML progression and transformation into secondary acute myeloid leukemia (sAML). The methods of single-cell DNA sequencing (scDNA-seq) enable overcoming limitations of bulk NGS and exploring...]]></summary>
        <author>
            <name>E V Volchkov</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Potential value of high-throughput single-cell DNA sequencing of Juvenile myelomonocytic leukemia: report of two cases]]></title>
        <id>pubmed:37684264</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37684264/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230911204717&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-09-08T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Juvenile myelomonocytic leukemia (JMML) is a rare myeloproliferative disease of early childhood that develops due to mutations in the genes of the RAS-signaling pathway. Next-generation high throughput sequencing (NGS) enables identification of various secondary molecular genetic events that can facilitate JMML progression and transformation into secondary acute myeloid leukemia (sAML). The methods of single-cell DNA sequencing (scDNA-seq) enable overcoming limitations of bulk NGS and exploring...]]></summary>
        <author>
            <name>E V Volchkov</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Potential value of high-throughput single-cell DNA sequencing of Juvenile myelomonocytic leukemia: report of two cases]]></title>
        <id>pubmed:37684264</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37684264/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230910204912&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-09-08T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Juvenile myelomonocytic leukemia (JMML) is a rare myeloproliferative disease of early childhood that develops due to mutations in the genes of the RAS-signaling pathway. Next-generation high throughput sequencing (NGS) enables identification of various secondary molecular genetic events that can facilitate JMML progression and transformation into secondary acute myeloid leukemia (sAML). The methods of single-cell DNA sequencing (scDNA-seq) enable overcoming limitations of bulk NGS and exploring...]]></summary>
        <author>
            <name>E V Volchkov</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Potential value of high-throughput single-cell DNA sequencing of Juvenile myelomonocytic leukemia: report of two cases]]></title>
        <id>pubmed:37684264</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37684264/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230909205145&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-09-08T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Juvenile myelomonocytic leukemia (JMML) is a rare myeloproliferative disease of early childhood that develops due to mutations in the genes of the RAS-signaling pathway. Next-generation high throughput sequencing (NGS) enables identification of various secondary molecular genetic events that can facilitate JMML progression and transformation into secondary acute myeloid leukemia (sAML). The methods of single-cell DNA sequencing (scDNA-seq) enable overcoming limitations of bulk NGS and exploring...]]></summary>
        <author>
            <name>E V Volchkov</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Pathogenesis and treatment of immune dysregulation associated with myelodysplastic syndromes]]></title>
        <id>pubmed:37673628</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37673628/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230924205014&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-09-06T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Myelodysplastic syndromes (MDS) are a clonal disorder based on genomic mutations in hematopoietic stem cells. They are categorized as lower-risk MDS, characterized by peripheral cytopenia; and higher-risk MDS, characterized by progression to acute myeloid leukemia. Previous studies reported that inflammation and immune activation are deeply involved in the pathogenesis of lower-risk MDS. Recent studies elucidated the molecular basis for the activation of inflammatory pathways via dysregulated...]]></summary>
        <author>
            <name>Hideaki Nakajima</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Pathogenesis and treatment of immune dysregulation associated with myelodysplastic syndromes]]></title>
        <id>pubmed:37673628</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37673628/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230923205208&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-09-06T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Myelodysplastic syndromes (MDS) are a clonal disorder based on genomic mutations in hematopoietic stem cells. They are categorized as lower-risk MDS, characterized by peripheral cytopenia; and higher-risk MDS, characterized by progression to acute myeloid leukemia. Previous studies reported that inflammation and immune activation are deeply involved in the pathogenesis of lower-risk MDS. Recent studies elucidated the molecular basis for the activation of inflammatory pathways via dysregulated...]]></summary>
        <author>
            <name>Hideaki Nakajima</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Pathogenesis and treatment of immune dysregulation associated with myelodysplastic syndromes]]></title>
        <id>pubmed:37673628</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37673628/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230922204741&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-09-06T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Myelodysplastic syndromes (MDS) are a clonal disorder based on genomic mutations in hematopoietic stem cells. They are categorized as lower-risk MDS, characterized by peripheral cytopenia; and higher-risk MDS, characterized by progression to acute myeloid leukemia. Previous studies reported that inflammation and immune activation are deeply involved in the pathogenesis of lower-risk MDS. Recent studies elucidated the molecular basis for the activation of inflammatory pathways via dysregulated...]]></summary>
        <author>
            <name>Hideaki Nakajima</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Pathogenesis and treatment of immune dysregulation associated with myelodysplastic syndromes]]></title>
        <id>pubmed:37673628</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37673628/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230921204936&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-09-06T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Myelodysplastic syndromes (MDS) are a clonal disorder based on genomic mutations in hematopoietic stem cells. They are categorized as lower-risk MDS, characterized by peripheral cytopenia; and higher-risk MDS, characterized by progression to acute myeloid leukemia. Previous studies reported that inflammation and immune activation are deeply involved in the pathogenesis of lower-risk MDS. Recent studies elucidated the molecular basis for the activation of inflammatory pathways via dysregulated...]]></summary>
        <author>
            <name>Hideaki Nakajima</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Pathogenesis and treatment of immune dysregulation associated with myelodysplastic syndromes]]></title>
        <id>pubmed:37673628</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37673628/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230920204905&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-09-06T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Myelodysplastic syndromes (MDS) are a clonal disorder based on genomic mutations in hematopoietic stem cells. They are categorized as lower-risk MDS, characterized by peripheral cytopenia; and higher-risk MDS, characterized by progression to acute myeloid leukemia. Previous studies reported that inflammation and immune activation are deeply involved in the pathogenesis of lower-risk MDS. Recent studies elucidated the molecular basis for the activation of inflammatory pathways via dysregulated...]]></summary>
        <author>
            <name>Hideaki Nakajima</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Pathogenesis and treatment of immune dysregulation associated with myelodysplastic syndromes]]></title>
        <id>pubmed:37673628</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37673628/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230919204929&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-09-06T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Myelodysplastic syndromes (MDS) are a clonal disorder based on genomic mutations in hematopoietic stem cells. They are categorized as lower-risk MDS, characterized by peripheral cytopenia; and higher-risk MDS, characterized by progression to acute myeloid leukemia. Previous studies reported that inflammation and immune activation are deeply involved in the pathogenesis of lower-risk MDS. Recent studies elucidated the molecular basis for the activation of inflammatory pathways via dysregulated...]]></summary>
        <author>
            <name>Hideaki Nakajima</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Pathogenesis and treatment of immune dysregulation associated with myelodysplastic syndromes]]></title>
        <id>pubmed:37673628</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37673628/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230918204942&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-09-06T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Myelodysplastic syndromes (MDS) are a clonal disorder based on genomic mutations in hematopoietic stem cells. They are categorized as lower-risk MDS, characterized by peripheral cytopenia; and higher-risk MDS, characterized by progression to acute myeloid leukemia. Previous studies reported that inflammation and immune activation are deeply involved in the pathogenesis of lower-risk MDS. Recent studies elucidated the molecular basis for the activation of inflammatory pathways via dysregulated...]]></summary>
        <author>
            <name>Hideaki Nakajima</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Pathogenesis and treatment of immune dysregulation associated with myelodysplastic syndromes]]></title>
        <id>pubmed:37673628</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37673628/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230917204935&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-09-06T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Myelodysplastic syndromes (MDS) are a clonal disorder based on genomic mutations in hematopoietic stem cells. They are categorized as lower-risk MDS, characterized by peripheral cytopenia; and higher-risk MDS, characterized by progression to acute myeloid leukemia. Previous studies reported that inflammation and immune activation are deeply involved in the pathogenesis of lower-risk MDS. Recent studies elucidated the molecular basis for the activation of inflammatory pathways via dysregulated...]]></summary>
        <author>
            <name>Hideaki Nakajima</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Pathogenesis and treatment of immune dysregulation associated with myelodysplastic syndromes]]></title>
        <id>pubmed:37673628</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37673628/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230916205201&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-09-06T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Myelodysplastic syndromes (MDS) are a clonal disorder based on genomic mutations in hematopoietic stem cells. They are categorized as lower-risk MDS, characterized by peripheral cytopenia; and higher-risk MDS, characterized by progression to acute myeloid leukemia. Previous studies reported that inflammation and immune activation are deeply involved in the pathogenesis of lower-risk MDS. Recent studies elucidated the molecular basis for the activation of inflammatory pathways via dysregulated...]]></summary>
        <author>
            <name>Hideaki Nakajima</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Pathogenesis and treatment of immune dysregulation associated with myelodysplastic syndromes]]></title>
        <id>pubmed:37673628</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37673628/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230915204741&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-09-06T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Myelodysplastic syndromes (MDS) are a clonal disorder based on genomic mutations in hematopoietic stem cells. They are categorized as lower-risk MDS, characterized by peripheral cytopenia; and higher-risk MDS, characterized by progression to acute myeloid leukemia. Previous studies reported that inflammation and immune activation are deeply involved in the pathogenesis of lower-risk MDS. Recent studies elucidated the molecular basis for the activation of inflammatory pathways via dysregulated...]]></summary>
        <author>
            <name>Hideaki Nakajima</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Pathogenesis and treatment of immune dysregulation associated with myelodysplastic syndromes]]></title>
        <id>pubmed:37673628</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37673628/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230914204950&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-09-06T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Myelodysplastic syndromes (MDS) are a clonal disorder based on genomic mutations in hematopoietic stem cells. They are categorized as lower-risk MDS, characterized by peripheral cytopenia; and higher-risk MDS, characterized by progression to acute myeloid leukemia. Previous studies reported that inflammation and immune activation are deeply involved in the pathogenesis of lower-risk MDS. Recent studies elucidated the molecular basis for the activation of inflammatory pathways via dysregulated...]]></summary>
        <author>
            <name>Hideaki Nakajima</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Pathogenesis and treatment of immune dysregulation associated with myelodysplastic syndromes]]></title>
        <id>pubmed:37673628</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37673628/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230913204840&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-09-06T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Myelodysplastic syndromes (MDS) are a clonal disorder based on genomic mutations in hematopoietic stem cells. They are categorized as lower-risk MDS, characterized by peripheral cytopenia; and higher-risk MDS, characterized by progression to acute myeloid leukemia. Previous studies reported that inflammation and immune activation are deeply involved in the pathogenesis of lower-risk MDS. Recent studies elucidated the molecular basis for the activation of inflammatory pathways via dysregulated...]]></summary>
        <author>
            <name>Hideaki Nakajima</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Pathogenesis and treatment of immune dysregulation associated with myelodysplastic syndromes]]></title>
        <id>pubmed:37673628</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37673628/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230912205016&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-09-06T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Myelodysplastic syndromes (MDS) are a clonal disorder based on genomic mutations in hematopoietic stem cells. They are categorized as lower-risk MDS, characterized by peripheral cytopenia; and higher-risk MDS, characterized by progression to acute myeloid leukemia. Previous studies reported that inflammation and immune activation are deeply involved in the pathogenesis of lower-risk MDS. Recent studies elucidated the molecular basis for the activation of inflammatory pathways via dysregulated...]]></summary>
        <author>
            <name>Hideaki Nakajima</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Pathogenesis and treatment of immune dysregulation associated with myelodysplastic syndromes]]></title>
        <id>pubmed:37673628</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37673628/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230911204717&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-09-06T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Myelodysplastic syndromes (MDS) are a clonal disorder based on genomic mutations in hematopoietic stem cells. They are categorized as lower-risk MDS, characterized by peripheral cytopenia; and higher-risk MDS, characterized by progression to acute myeloid leukemia. Previous studies reported that inflammation and immune activation are deeply involved in the pathogenesis of lower-risk MDS. Recent studies elucidated the molecular basis for the activation of inflammatory pathways via dysregulated...]]></summary>
        <author>
            <name>Hideaki Nakajima</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Pathogenesis and treatment of immune dysregulation associated with myelodysplastic syndromes]]></title>
        <id>pubmed:37673628</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37673628/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230910204912&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-09-06T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Myelodysplastic syndromes (MDS) are a clonal disorder based on genomic mutations in hematopoietic stem cells. They are categorized as lower-risk MDS, characterized by peripheral cytopenia; and higher-risk MDS, characterized by progression to acute myeloid leukemia. Previous studies reported that inflammation and immune activation are deeply involved in the pathogenesis of lower-risk MDS. Recent studies elucidated the molecular basis for the activation of inflammatory pathways via dysregulated...]]></summary>
        <author>
            <name>Hideaki Nakajima</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Pathogenesis and treatment of immune dysregulation associated with myelodysplastic syndromes]]></title>
        <id>pubmed:37673628</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37673628/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230909205145&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-09-06T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Myelodysplastic syndromes (MDS) are a clonal disorder based on genomic mutations in hematopoietic stem cells. They are categorized as lower-risk MDS, characterized by peripheral cytopenia; and higher-risk MDS, characterized by progression to acute myeloid leukemia. Previous studies reported that inflammation and immune activation are deeply involved in the pathogenesis of lower-risk MDS. Recent studies elucidated the molecular basis for the activation of inflammatory pathways via dysregulated...]]></summary>
        <author>
            <name>Hideaki Nakajima</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Pathogenesis and treatment of immune dysregulation associated with myelodysplastic syndromes]]></title>
        <id>pubmed:37673628</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37673628/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230908204701&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-09-06T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Myelodysplastic syndromes (MDS) are a clonal disorder based on genomic mutations in hematopoietic stem cells. They are categorized as lower-risk MDS, characterized by peripheral cytopenia; and higher-risk MDS, characterized by progression to acute myeloid leukemia. Previous studies reported that inflammation and immune activation are deeply involved in the pathogenesis of lower-risk MDS. Recent studies elucidated the molecular basis for the activation of inflammatory pathways via dysregulated...]]></summary>
        <author>
            <name>Hideaki Nakajima</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Pathogenesis and treatment of immune dysregulation associated with myelodysplastic syndromes]]></title>
        <id>pubmed:37673628</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37673628/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230907204816&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-09-06T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Myelodysplastic syndromes (MDS) are a clonal disorder based on genomic mutations in hematopoietic stem cells. They are categorized as lower-risk MDS, characterized by peripheral cytopenia; and higher-risk MDS, characterized by progression to acute myeloid leukemia. Previous studies reported that inflammation and immune activation are deeply involved in the pathogenesis of lower-risk MDS. Recent studies elucidated the molecular basis for the activation of inflammatory pathways via dysregulated...]]></summary>
        <author>
            <name>Hideaki Nakajima</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[RNA binding protein IGF2BP1 synergizes with ETV6-RUNX1 to drive oncogenic signaling in B-cell Acute Lymphoblastic Leukemia]]></title>
        <id>pubmed:37670323</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37670323/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230924205014&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-09-05T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSION: Our data suggest a combined impact of the ETV6::RUNX1 fusion protein and RNA binding protein, IGF2BP1 in activating multiple oncogenic pathways in B-ALL which makes IGF2BP1 and these pathways as attractive therapeutic targets and biomarkers.]]></summary>
        <author>
            <name>Gunjan Sharma</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[RNA binding protein IGF2BP1 synergizes with ETV6-RUNX1 to drive oncogenic signaling in B-cell Acute Lymphoblastic Leukemia]]></title>
        <id>pubmed:37670323</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37670323/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230923205208&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-09-05T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSION: Our data suggest a combined impact of the ETV6::RUNX1 fusion protein and RNA binding protein, IGF2BP1 in activating multiple oncogenic pathways in B-ALL which makes IGF2BP1 and these pathways as attractive therapeutic targets and biomarkers.]]></summary>
        <author>
            <name>Gunjan Sharma</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[RNA binding protein IGF2BP1 synergizes with ETV6-RUNX1 to drive oncogenic signaling in B-cell Acute Lymphoblastic Leukemia]]></title>
        <id>pubmed:37670323</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37670323/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230922204741&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-09-05T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSION: Our data suggest a combined impact of the ETV6::RUNX1 fusion protein and RNA binding protein, IGF2BP1 in activating multiple oncogenic pathways in B-ALL which makes IGF2BP1 and these pathways as attractive therapeutic targets and biomarkers.]]></summary>
        <author>
            <name>Gunjan Sharma</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[RNA binding protein IGF2BP1 synergizes with ETV6-RUNX1 to drive oncogenic signaling in B-cell Acute Lymphoblastic Leukemia]]></title>
        <id>pubmed:37670323</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37670323/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230921204936&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-09-05T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSION: Our data suggest a combined impact of the ETV6::RUNX1 fusion protein and RNA binding protein, IGF2BP1 in activating multiple oncogenic pathways in B-ALL which makes IGF2BP1 and these pathways as attractive therapeutic targets and biomarkers.]]></summary>
        <author>
            <name>Gunjan Sharma</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Colorimetric Barcoding to Track, Isolate, and Analyze Hematopoietic Stem Cell Clones]]></title>
        <id>pubmed:37668919</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37668919/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230921204936&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-09-05T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[In zebrafish, hematopoietic stem cells (HSCs) are born in the developing aorta during embryogenesis. From the definitive wave of hematopoiesis onward, blood homeostasis relies on self-renewal and differentiation of progeny of existing HSCs, or clones, rather than de novo generation. Here, we describe an approach to quantify the number and size of HSC clones at various times throughout the lifespan of the animal using a fluorescent, multicolor labeling strategy. The system is based on combining...]]></summary>
        <author>
            <name>Dorothee Bornhorst</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[RNA binding protein IGF2BP1 synergizes with ETV6-RUNX1 to drive oncogenic signaling in B-cell Acute Lymphoblastic Leukemia]]></title>
        <id>pubmed:37670323</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37670323/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230920204905&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-09-05T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSION: Our data suggest a combined impact of the ETV6::RUNX1 fusion protein and RNA binding protein, IGF2BP1 in activating multiple oncogenic pathways in B-ALL which makes IGF2BP1 and these pathways as attractive therapeutic targets and biomarkers.]]></summary>
        <author>
            <name>Gunjan Sharma</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Colorimetric Barcoding to Track, Isolate, and Analyze Hematopoietic Stem Cell Clones]]></title>
        <id>pubmed:37668919</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37668919/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230920204905&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-09-05T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[In zebrafish, hematopoietic stem cells (HSCs) are born in the developing aorta during embryogenesis. From the definitive wave of hematopoiesis onward, blood homeostasis relies on self-renewal and differentiation of progeny of existing HSCs, or clones, rather than de novo generation. Here, we describe an approach to quantify the number and size of HSC clones at various times throughout the lifespan of the animal using a fluorescent, multicolor labeling strategy. The system is based on combining...]]></summary>
        <author>
            <name>Dorothee Bornhorst</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[RNA binding protein IGF2BP1 synergizes with ETV6-RUNX1 to drive oncogenic signaling in B-cell Acute Lymphoblastic Leukemia]]></title>
        <id>pubmed:37670323</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37670323/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230919204929&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-09-05T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSION: Our data suggest a combined impact of the ETV6::RUNX1 fusion protein and RNA binding protein, IGF2BP1 in activating multiple oncogenic pathways in B-ALL which makes IGF2BP1 and these pathways as attractive therapeutic targets and biomarkers.]]></summary>
        <author>
            <name>Gunjan Sharma</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Colorimetric Barcoding to Track, Isolate, and Analyze Hematopoietic Stem Cell Clones]]></title>
        <id>pubmed:37668919</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37668919/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230919204929&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-09-05T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[In zebrafish, hematopoietic stem cells (HSCs) are born in the developing aorta during embryogenesis. From the definitive wave of hematopoiesis onward, blood homeostasis relies on self-renewal and differentiation of progeny of existing HSCs, or clones, rather than de novo generation. Here, we describe an approach to quantify the number and size of HSC clones at various times throughout the lifespan of the animal using a fluorescent, multicolor labeling strategy. The system is based on combining...]]></summary>
        <author>
            <name>Dorothee Bornhorst</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[RNA binding protein IGF2BP1 synergizes with ETV6-RUNX1 to drive oncogenic signaling in B-cell Acute Lymphoblastic Leukemia]]></title>
        <id>pubmed:37670323</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37670323/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230918204942&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-09-05T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSION: Our data suggest a combined impact of the ETV6::RUNX1 fusion protein and RNA binding protein, IGF2BP1 in activating multiple oncogenic pathways in B-ALL which makes IGF2BP1 and these pathways as attractive therapeutic targets and biomarkers.]]></summary>
        <author>
            <name>Gunjan Sharma</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Colorimetric Barcoding to Track, Isolate, and Analyze Hematopoietic Stem Cell Clones]]></title>
        <id>pubmed:37668919</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37668919/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230918204942&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-09-05T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[In zebrafish, hematopoietic stem cells (HSCs) are born in the developing aorta during embryogenesis. From the definitive wave of hematopoiesis onward, blood homeostasis relies on self-renewal and differentiation of progeny of existing HSCs, or clones, rather than de novo generation. Here, we describe an approach to quantify the number and size of HSC clones at various times throughout the lifespan of the animal using a fluorescent, multicolor labeling strategy. The system is based on combining...]]></summary>
        <author>
            <name>Dorothee Bornhorst</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[RNA binding protein IGF2BP1 synergizes with ETV6-RUNX1 to drive oncogenic signaling in B-cell Acute Lymphoblastic Leukemia]]></title>
        <id>pubmed:37670323</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37670323/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230917204935&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-09-05T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSION: Our data suggest a combined impact of the ETV6::RUNX1 fusion protein and RNA binding protein, IGF2BP1 in activating multiple oncogenic pathways in B-ALL which makes IGF2BP1 and these pathways as attractive therapeutic targets and biomarkers.]]></summary>
        <author>
            <name>Gunjan Sharma</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Colorimetric Barcoding to Track, Isolate, and Analyze Hematopoietic Stem Cell Clones]]></title>
        <id>pubmed:37668919</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37668919/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230917204935&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-09-05T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[In zebrafish, hematopoietic stem cells (HSCs) are born in the developing aorta during embryogenesis. From the definitive wave of hematopoiesis onward, blood homeostasis relies on self-renewal and differentiation of progeny of existing HSCs, or clones, rather than de novo generation. Here, we describe an approach to quantify the number and size of HSC clones at various times throughout the lifespan of the animal using a fluorescent, multicolor labeling strategy. The system is based on combining...]]></summary>
        <author>
            <name>Dorothee Bornhorst</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[RNA binding protein IGF2BP1 synergizes with ETV6-RUNX1 to drive oncogenic signaling in B-cell Acute Lymphoblastic Leukemia]]></title>
        <id>pubmed:37670323</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37670323/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230916205201&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-09-05T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSION: Our data suggest a combined impact of the ETV6::RUNX1 fusion protein and RNA binding protein, IGF2BP1 in activating multiple oncogenic pathways in B-ALL which makes IGF2BP1 and these pathways as attractive therapeutic targets and biomarkers.]]></summary>
        <author>
            <name>Gunjan Sharma</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Colorimetric Barcoding to Track, Isolate, and Analyze Hematopoietic Stem Cell Clones]]></title>
        <id>pubmed:37668919</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37668919/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230916205201&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-09-05T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[In zebrafish, hematopoietic stem cells (HSCs) are born in the developing aorta during embryogenesis. From the definitive wave of hematopoiesis onward, blood homeostasis relies on self-renewal and differentiation of progeny of existing HSCs, or clones, rather than de novo generation. Here, we describe an approach to quantify the number and size of HSC clones at various times throughout the lifespan of the animal using a fluorescent, multicolor labeling strategy. The system is based on combining...]]></summary>
        <author>
            <name>Dorothee Bornhorst</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[RNA binding protein IGF2BP1 synergizes with ETV6-RUNX1 to drive oncogenic signaling in B-cell Acute Lymphoblastic Leukemia]]></title>
        <id>pubmed:37670323</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37670323/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230915204741&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-09-05T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSION: Our data suggest a combined impact of the ETV6::RUNX1 fusion protein and RNA binding protein, IGF2BP1 in activating multiple oncogenic pathways in B-ALL which makes IGF2BP1 and these pathways as attractive therapeutic targets and biomarkers.]]></summary>
        <author>
            <name>Gunjan Sharma</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Colorimetric Barcoding to Track, Isolate, and Analyze Hematopoietic Stem Cell Clones]]></title>
        <id>pubmed:37668919</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37668919/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230915204741&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-09-05T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[In zebrafish, hematopoietic stem cells (HSCs) are born in the developing aorta during embryogenesis. From the definitive wave of hematopoiesis onward, blood homeostasis relies on self-renewal and differentiation of progeny of existing HSCs, or clones, rather than de novo generation. Here, we describe an approach to quantify the number and size of HSC clones at various times throughout the lifespan of the animal using a fluorescent, multicolor labeling strategy. The system is based on combining...]]></summary>
        <author>
            <name>Dorothee Bornhorst</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[RNA binding protein IGF2BP1 synergizes with ETV6-RUNX1 to drive oncogenic signaling in B-cell Acute Lymphoblastic Leukemia]]></title>
        <id>pubmed:37670323</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37670323/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230914204950&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-09-05T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSION: Our data suggest a combined impact of the ETV6::RUNX1 fusion protein and RNA binding protein, IGF2BP1 in activating multiple oncogenic pathways in B-ALL which makes IGF2BP1 and these pathways as attractive therapeutic targets and biomarkers.]]></summary>
        <author>
            <name>Gunjan Sharma</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Colorimetric Barcoding to Track, Isolate, and Analyze Hematopoietic Stem Cell Clones]]></title>
        <id>pubmed:37668919</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37668919/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230914204950&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-09-05T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[In zebrafish, hematopoietic stem cells (HSCs) are born in the developing aorta during embryogenesis. From the definitive wave of hematopoiesis onward, blood homeostasis relies on self-renewal and differentiation of progeny of existing HSCs, or clones, rather than de novo generation. Here, we describe an approach to quantify the number and size of HSC clones at various times throughout the lifespan of the animal using a fluorescent, multicolor labeling strategy. The system is based on combining...]]></summary>
        <author>
            <name>Dorothee Bornhorst</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[RNA binding protein IGF2BP1 synergizes with ETV6-RUNX1 to drive oncogenic signaling in B-cell Acute Lymphoblastic Leukemia]]></title>
        <id>pubmed:37670323</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37670323/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230913204840&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-09-05T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSION: Our data suggest a combined impact of the ETV6::RUNX1 fusion protein and RNA binding protein, IGF2BP1 in activating multiple oncogenic pathways in B-ALL which makes IGF2BP1 and these pathways as attractive therapeutic targets and biomarkers.]]></summary>
        <author>
            <name>Gunjan Sharma</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Colorimetric Barcoding to Track, Isolate, and Analyze Hematopoietic Stem Cell Clones]]></title>
        <id>pubmed:37668919</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37668919/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230913204840&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-09-05T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[In zebrafish, hematopoietic stem cells (HSCs) are born in the developing aorta during embryogenesis. From the definitive wave of hematopoiesis onward, blood homeostasis relies on self-renewal and differentiation of progeny of existing HSCs, or clones, rather than de novo generation. Here, we describe an approach to quantify the number and size of HSC clones at various times throughout the lifespan of the animal using a fluorescent, multicolor labeling strategy. The system is based on combining...]]></summary>
        <author>
            <name>Dorothee Bornhorst</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[RNA binding protein IGF2BP1 synergizes with ETV6-RUNX1 to drive oncogenic signaling in B-cell Acute Lymphoblastic Leukemia]]></title>
        <id>pubmed:37670323</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37670323/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230912205016&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-09-05T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSION: Our data suggest a combined impact of the ETV6::RUNX1 fusion protein and RNA binding protein, IGF2BP1 in activating multiple oncogenic pathways in B-ALL which makes IGF2BP1 and these pathways as attractive therapeutic targets and biomarkers.]]></summary>
        <author>
            <name>Gunjan Sharma</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Colorimetric Barcoding to Track, Isolate, and Analyze Hematopoietic Stem Cell Clones]]></title>
        <id>pubmed:37668919</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37668919/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230912205016&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-09-05T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[In zebrafish, hematopoietic stem cells (HSCs) are born in the developing aorta during embryogenesis. From the definitive wave of hematopoiesis onward, blood homeostasis relies on self-renewal and differentiation of progeny of existing HSCs, or clones, rather than de novo generation. Here, we describe an approach to quantify the number and size of HSC clones at various times throughout the lifespan of the animal using a fluorescent, multicolor labeling strategy. The system is based on combining...]]></summary>
        <author>
            <name>Dorothee Bornhorst</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[RNA binding protein IGF2BP1 synergizes with ETV6-RUNX1 to drive oncogenic signaling in B-cell Acute Lymphoblastic Leukemia]]></title>
        <id>pubmed:37670323</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37670323/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230911204717&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-09-05T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSION: Our data suggest a combined impact of the ETV6::RUNX1 fusion protein and RNA binding protein, IGF2BP1 in activating multiple oncogenic pathways in B-ALL which makes IGF2BP1 and these pathways as attractive therapeutic targets and biomarkers.]]></summary>
        <author>
            <name>Gunjan Sharma</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Colorimetric Barcoding to Track, Isolate, and Analyze Hematopoietic Stem Cell Clones]]></title>
        <id>pubmed:37668919</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37668919/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230911204717&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-09-05T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[In zebrafish, hematopoietic stem cells (HSCs) are born in the developing aorta during embryogenesis. From the definitive wave of hematopoiesis onward, blood homeostasis relies on self-renewal and differentiation of progeny of existing HSCs, or clones, rather than de novo generation. Here, we describe an approach to quantify the number and size of HSC clones at various times throughout the lifespan of the animal using a fluorescent, multicolor labeling strategy. The system is based on combining...]]></summary>
        <author>
            <name>Dorothee Bornhorst</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[RNA binding protein IGF2BP1 synergizes with ETV6-RUNX1 to drive oncogenic signaling in B-cell Acute Lymphoblastic Leukemia]]></title>
        <id>pubmed:37670323</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37670323/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230910204912&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-09-05T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSION: Our data suggest a combined impact of the ETV6::RUNX1 fusion protein and RNA binding protein, IGF2BP1 in activating multiple oncogenic pathways in B-ALL which makes IGF2BP1 and these pathways as attractive therapeutic targets and biomarkers.]]></summary>
        <author>
            <name>Gunjan Sharma</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Colorimetric Barcoding to Track, Isolate, and Analyze Hematopoietic Stem Cell Clones]]></title>
        <id>pubmed:37668919</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37668919/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230910204912&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-09-05T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[In zebrafish, hematopoietic stem cells (HSCs) are born in the developing aorta during embryogenesis. From the definitive wave of hematopoiesis onward, blood homeostasis relies on self-renewal and differentiation of progeny of existing HSCs, or clones, rather than de novo generation. Here, we describe an approach to quantify the number and size of HSC clones at various times throughout the lifespan of the animal using a fluorescent, multicolor labeling strategy. The system is based on combining...]]></summary>
        <author>
            <name>Dorothee Bornhorst</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[RNA binding protein IGF2BP1 synergizes with ETV6-RUNX1 to drive oncogenic signaling in B-cell Acute Lymphoblastic Leukemia]]></title>
        <id>pubmed:37670323</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37670323/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230909205145&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-09-05T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSION: Our data suggest a combined impact of the ETV6::RUNX1 fusion protein and RNA binding protein, IGF2BP1 in activating multiple oncogenic pathways in B-ALL which makes IGF2BP1 and these pathways as attractive therapeutic targets and biomarkers.]]></summary>
        <author>
            <name>Gunjan Sharma</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Colorimetric Barcoding to Track, Isolate, and Analyze Hematopoietic Stem Cell Clones]]></title>
        <id>pubmed:37668919</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37668919/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230909205145&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-09-05T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[In zebrafish, hematopoietic stem cells (HSCs) are born in the developing aorta during embryogenesis. From the definitive wave of hematopoiesis onward, blood homeostasis relies on self-renewal and differentiation of progeny of existing HSCs, or clones, rather than de novo generation. Here, we describe an approach to quantify the number and size of HSC clones at various times throughout the lifespan of the animal using a fluorescent, multicolor labeling strategy. The system is based on combining...]]></summary>
        <author>
            <name>Dorothee Bornhorst</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[RNA binding protein IGF2BP1 synergizes with ETV6-RUNX1 to drive oncogenic signaling in B-cell Acute Lymphoblastic Leukemia]]></title>
        <id>pubmed:37670323</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37670323/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230908204701&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-09-05T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSION: Our data suggest a combined impact of the ETV6::RUNX1 fusion protein and RNA binding protein, IGF2BP1 in activating multiple oncogenic pathways in B-ALL which makes IGF2BP1 and these pathways as attractive therapeutic targets and biomarkers.]]></summary>
        <author>
            <name>Gunjan Sharma</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Colorimetric Barcoding to Track, Isolate, and Analyze Hematopoietic Stem Cell Clones]]></title>
        <id>pubmed:37668919</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37668919/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230908204701&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-09-05T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[In zebrafish, hematopoietic stem cells (HSCs) are born in the developing aorta during embryogenesis. From the definitive wave of hematopoiesis onward, blood homeostasis relies on self-renewal and differentiation of progeny of existing HSCs, or clones, rather than de novo generation. Here, we describe an approach to quantify the number and size of HSC clones at various times throughout the lifespan of the animal using a fluorescent, multicolor labeling strategy. The system is based on combining...]]></summary>
        <author>
            <name>Dorothee Bornhorst</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[RNA binding protein IGF2BP1 synergizes with ETV6-RUNX1 to drive oncogenic signaling in B-cell Acute Lymphoblastic Leukemia]]></title>
        <id>pubmed:37670323</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37670323/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230907204816&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-09-05T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSION: Our data suggest a combined impact of the ETV6::RUNX1 fusion protein and RNA binding protein, IGF2BP1 in activating multiple oncogenic pathways in B-ALL which makes IGF2BP1 and these pathways as attractive therapeutic targets and biomarkers.]]></summary>
        <author>
            <name>Gunjan Sharma</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Colorimetric Barcoding to Track, Isolate, and Analyze Hematopoietic Stem Cell Clones]]></title>
        <id>pubmed:37668919</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37668919/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230907204816&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-09-05T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[In zebrafish, hematopoietic stem cells (HSCs) are born in the developing aorta during embryogenesis. From the definitive wave of hematopoiesis onward, blood homeostasis relies on self-renewal and differentiation of progeny of existing HSCs, or clones, rather than de novo generation. Here, we describe an approach to quantify the number and size of HSC clones at various times throughout the lifespan of the animal using a fluorescent, multicolor labeling strategy. The system is based on combining...]]></summary>
        <author>
            <name>Dorothee Bornhorst</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[RNA binding protein IGF2BP1 synergizes with ETV6-RUNX1 to drive oncogenic signaling in B-cell Acute Lymphoblastic Leukemia]]></title>
        <id>pubmed:37670323</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37670323/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230906204801&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-09-05T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSION: Our data suggest a combined impact of the ETV6::RUNX1 fusion protein and RNA binding protein, IGF2BP1 in activating multiple oncogenic pathways in B-ALL which makes IGF2BP1 and these pathways as attractive therapeutic targets and biomarkers.]]></summary>
        <author>
            <name>Gunjan Sharma</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Colorimetric Barcoding to Track, Isolate, and Analyze Hematopoietic Stem Cell Clones]]></title>
        <id>pubmed:37668919</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37668919/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230906204801&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-09-05T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[In zebrafish, hematopoietic stem cells (HSCs) are born in the developing aorta during embryogenesis. From the definitive wave of hematopoiesis onward, blood homeostasis relies on self-renewal and differentiation of progeny of existing HSCs, or clones, rather than de novo generation. Here, we describe an approach to quantify the number and size of HSC clones at various times throughout the lifespan of the animal using a fluorescent, multicolor labeling strategy. The system is based on combining...]]></summary>
        <author>
            <name>Dorothee Bornhorst</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Colorimetric Barcoding to Track, Isolate, and Analyze Hematopoietic Stem Cell Clones]]></title>
        <id>pubmed:37668919</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37668919/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230905204848&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-09-05T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[In zebrafish, hematopoietic stem cells (HSCs) are born in the developing aorta during embryogenesis. From the definitive wave of hematopoiesis onward, blood homeostasis relies on self-renewal and differentiation of progeny of existing HSCs, or clones, rather than de novo generation. Here, we describe an approach to quantify the number and size of HSC clones at various times throughout the lifespan of the animal using a fluorescent, multicolor labeling strategy. The system is based on combining...]]></summary>
        <author>
            <name>Dorothee Bornhorst</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Defining the single base importance of human mRNAs and lncRNAs]]></title>
        <id>pubmed:37668090</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37668090/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230924205014&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-09-05T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[As the fundamental unit of a gene and its transcripts, nucleotides have enormous impacts on the gene function and evolution, and thus on phenotypes and diseases. In order to identify the key nucleotides of one specific gene, it is quite crucial to quantitatively measure the importance of each base on the gene. However, there are still no sequence-based methods of doing that. Here, we proposed Base Importance Calculator (BIC), an algorithm to calculate the importance score of each single base...]]></summary>
        <author>
            <name>Rui Fan</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Defining the single base importance of human mRNAs and lncRNAs]]></title>
        <id>pubmed:37668090</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37668090/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230923205208&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-09-05T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[As the fundamental unit of a gene and its transcripts, nucleotides have enormous impacts on the gene function and evolution, and thus on phenotypes and diseases. In order to identify the key nucleotides of one specific gene, it is quite crucial to quantitatively measure the importance of each base on the gene. However, there are still no sequence-based methods of doing that. Here, we proposed Base Importance Calculator (BIC), an algorithm to calculate the importance score of each single base...]]></summary>
        <author>
            <name>Rui Fan</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Defining the single base importance of human mRNAs and lncRNAs]]></title>
        <id>pubmed:37668090</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37668090/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230922204741&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-09-05T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[As the fundamental unit of a gene and its transcripts, nucleotides have enormous impacts on the gene function and evolution, and thus on phenotypes and diseases. In order to identify the key nucleotides of one specific gene, it is quite crucial to quantitatively measure the importance of each base on the gene. However, there are still no sequence-based methods of doing that. Here, we proposed Base Importance Calculator (BIC), an algorithm to calculate the importance score of each single base...]]></summary>
        <author>
            <name>Rui Fan</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Defining the single base importance of human mRNAs and lncRNAs]]></title>
        <id>pubmed:37668090</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37668090/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230921204936&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-09-05T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[As the fundamental unit of a gene and its transcripts, nucleotides have enormous impacts on the gene function and evolution, and thus on phenotypes and diseases. In order to identify the key nucleotides of one specific gene, it is quite crucial to quantitatively measure the importance of each base on the gene. However, there are still no sequence-based methods of doing that. Here, we proposed Base Importance Calculator (BIC), an algorithm to calculate the importance score of each single base...]]></summary>
        <author>
            <name>Rui Fan</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Defining the single base importance of human mRNAs and lncRNAs]]></title>
        <id>pubmed:37668090</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37668090/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230920204904&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-09-05T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[As the fundamental unit of a gene and its transcripts, nucleotides have enormous impacts on the gene function and evolution, and thus on phenotypes and diseases. In order to identify the key nucleotides of one specific gene, it is quite crucial to quantitatively measure the importance of each base on the gene. However, there are still no sequence-based methods of doing that. Here, we proposed Base Importance Calculator (BIC), an algorithm to calculate the importance score of each single base...]]></summary>
        <author>
            <name>Rui Fan</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Defining the single base importance of human mRNAs and lncRNAs]]></title>
        <id>pubmed:37668090</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37668090/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230919204929&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-09-05T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[As the fundamental unit of a gene and its transcripts, nucleotides have enormous impacts on the gene function and evolution, and thus on phenotypes and diseases. In order to identify the key nucleotides of one specific gene, it is quite crucial to quantitatively measure the importance of each base on the gene. However, there are still no sequence-based methods of doing that. Here, we proposed Base Importance Calculator (BIC), an algorithm to calculate the importance score of each single base...]]></summary>
        <author>
            <name>Rui Fan</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Defining the single base importance of human mRNAs and lncRNAs]]></title>
        <id>pubmed:37668090</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37668090/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230918204942&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-09-05T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[As the fundamental unit of a gene and its transcripts, nucleotides have enormous impacts on the gene function and evolution, and thus on phenotypes and diseases. In order to identify the key nucleotides of one specific gene, it is quite crucial to quantitatively measure the importance of each base on the gene. However, there are still no sequence-based methods of doing that. Here, we proposed Base Importance Calculator (BIC), an algorithm to calculate the importance score of each single base...]]></summary>
        <author>
            <name>Rui Fan</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Defining the single base importance of human mRNAs and lncRNAs]]></title>
        <id>pubmed:37668090</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37668090/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230917204936&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-09-05T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[As the fundamental unit of a gene and its transcripts, nucleotides have enormous impacts on the gene function and evolution, and thus on phenotypes and diseases. In order to identify the key nucleotides of one specific gene, it is quite crucial to quantitatively measure the importance of each base on the gene. However, there are still no sequence-based methods of doing that. Here, we proposed Base Importance Calculator (BIC), an algorithm to calculate the importance score of each single base...]]></summary>
        <author>
            <name>Rui Fan</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Defining the single base importance of human mRNAs and lncRNAs]]></title>
        <id>pubmed:37668090</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37668090/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230916205201&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-09-05T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[As the fundamental unit of a gene and its transcripts, nucleotides have enormous impacts on the gene function and evolution, and thus on phenotypes and diseases. In order to identify the key nucleotides of one specific gene, it is quite crucial to quantitatively measure the importance of each base on the gene. However, there are still no sequence-based methods of doing that. Here, we proposed Base Importance Calculator (BIC), an algorithm to calculate the importance score of each single base...]]></summary>
        <author>
            <name>Rui Fan</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Defining the single base importance of human mRNAs and lncRNAs]]></title>
        <id>pubmed:37668090</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37668090/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230915204741&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-09-05T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[As the fundamental unit of a gene and its transcripts, nucleotides have enormous impacts on the gene function and evolution, and thus on phenotypes and diseases. In order to identify the key nucleotides of one specific gene, it is quite crucial to quantitatively measure the importance of each base on the gene. However, there are still no sequence-based methods of doing that. Here, we proposed Base Importance Calculator (BIC), an algorithm to calculate the importance score of each single base...]]></summary>
        <author>
            <name>Rui Fan</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Defining the single base importance of human mRNAs and lncRNAs]]></title>
        <id>pubmed:37668090</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37668090/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230914204950&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-09-05T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[As the fundamental unit of a gene and its transcripts, nucleotides have enormous impacts on the gene function and evolution, and thus on phenotypes and diseases. In order to identify the key nucleotides of one specific gene, it is quite crucial to quantitatively measure the importance of each base on the gene. However, there are still no sequence-based methods of doing that. Here, we proposed Base Importance Calculator (BIC), an algorithm to calculate the importance score of each single base...]]></summary>
        <author>
            <name>Rui Fan</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Defining the single base importance of human mRNAs and lncRNAs]]></title>
        <id>pubmed:37668090</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37668090/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230913204840&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-09-05T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[As the fundamental unit of a gene and its transcripts, nucleotides have enormous impacts on the gene function and evolution, and thus on phenotypes and diseases. In order to identify the key nucleotides of one specific gene, it is quite crucial to quantitatively measure the importance of each base on the gene. However, there are still no sequence-based methods of doing that. Here, we proposed Base Importance Calculator (BIC), an algorithm to calculate the importance score of each single base...]]></summary>
        <author>
            <name>Rui Fan</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Defining the single base importance of human mRNAs and lncRNAs]]></title>
        <id>pubmed:37668090</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37668090/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230912205015&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-09-05T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[As the fundamental unit of a gene and its transcripts, nucleotides have enormous impacts on the gene function and evolution, and thus on phenotypes and diseases. In order to identify the key nucleotides of one specific gene, it is quite crucial to quantitatively measure the importance of each base on the gene. However, there are still no sequence-based methods of doing that. Here, we proposed Base Importance Calculator (BIC), an algorithm to calculate the importance score of each single base...]]></summary>
        <author>
            <name>Rui Fan</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Defining the single base importance of human mRNAs and lncRNAs]]></title>
        <id>pubmed:37668090</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37668090/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230911204717&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-09-05T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[As the fundamental unit of a gene and its transcripts, nucleotides have enormous impacts on the gene function and evolution, and thus on phenotypes and diseases. In order to identify the key nucleotides of one specific gene, it is quite crucial to quantitatively measure the importance of each base on the gene. However, there are still no sequence-based methods of doing that. Here, we proposed Base Importance Calculator (BIC), an algorithm to calculate the importance score of each single base...]]></summary>
        <author>
            <name>Rui Fan</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Defining the single base importance of human mRNAs and lncRNAs]]></title>
        <id>pubmed:37668090</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37668090/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230910204912&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-09-05T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[As the fundamental unit of a gene and its transcripts, nucleotides have enormous impacts on the gene function and evolution, and thus on phenotypes and diseases. In order to identify the key nucleotides of one specific gene, it is quite crucial to quantitatively measure the importance of each base on the gene. However, there are still no sequence-based methods of doing that. Here, we proposed Base Importance Calculator (BIC), an algorithm to calculate the importance score of each single base...]]></summary>
        <author>
            <name>Rui Fan</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Defining the single base importance of human mRNAs and lncRNAs]]></title>
        <id>pubmed:37668090</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37668090/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230909205145&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-09-05T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[As the fundamental unit of a gene and its transcripts, nucleotides have enormous impacts on the gene function and evolution, and thus on phenotypes and diseases. In order to identify the key nucleotides of one specific gene, it is quite crucial to quantitatively measure the importance of each base on the gene. However, there are still no sequence-based methods of doing that. Here, we proposed Base Importance Calculator (BIC), an algorithm to calculate the importance score of each single base...]]></summary>
        <author>
            <name>Rui Fan</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Defining the single base importance of human mRNAs and lncRNAs]]></title>
        <id>pubmed:37668090</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37668090/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230908204701&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-09-05T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[As the fundamental unit of a gene and its transcripts, nucleotides have enormous impacts on the gene function and evolution, and thus on phenotypes and diseases. In order to identify the key nucleotides of one specific gene, it is quite crucial to quantitatively measure the importance of each base on the gene. However, there are still no sequence-based methods of doing that. Here, we proposed Base Importance Calculator (BIC), an algorithm to calculate the importance score of each single base...]]></summary>
        <author>
            <name>Rui Fan</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Defining the single base importance of human mRNAs and lncRNAs]]></title>
        <id>pubmed:37668090</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37668090/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230907204816&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-09-05T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[As the fundamental unit of a gene and its transcripts, nucleotides have enormous impacts on the gene function and evolution, and thus on phenotypes and diseases. In order to identify the key nucleotides of one specific gene, it is quite crucial to quantitatively measure the importance of each base on the gene. However, there are still no sequence-based methods of doing that. Here, we proposed Base Importance Calculator (BIC), an algorithm to calculate the importance score of each single base...]]></summary>
        <author>
            <name>Rui Fan</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Defining the single base importance of human mRNAs and lncRNAs]]></title>
        <id>pubmed:37668090</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37668090/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230906204801&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-09-05T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[As the fundamental unit of a gene and its transcripts, nucleotides have enormous impacts on the gene function and evolution, and thus on phenotypes and diseases. In order to identify the key nucleotides of one specific gene, it is quite crucial to quantitatively measure the importance of each base on the gene. However, there are still no sequence-based methods of doing that. Here, we proposed Base Importance Calculator (BIC), an algorithm to calculate the importance score of each single base...]]></summary>
        <author>
            <name>Rui Fan</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Defining the single base importance of human mRNAs and lncRNAs]]></title>
        <id>pubmed:37668090</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37668090/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230905204848&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-09-05T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[As the fundamental unit of a gene and its transcripts, nucleotides have enormous impacts on the gene function and evolution, and thus on phenotypes and diseases. In order to identify the key nucleotides of one specific gene, it is quite crucial to quantitatively measure the importance of each base on the gene. However, there are still no sequence-based methods of doing that. Here, we proposed Base Importance Calculator (BIC), an algorithm to calculate the importance score of each single base...]]></summary>
        <author>
            <name>Rui Fan</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Single-cell multi-omics identifies chronic inflammation as a driver of TP53-mutant leukemic evolution]]></title>
        <id>pubmed:37666991</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37666991/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230924205014&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-09-04T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Understanding the genetic and nongenetic determinants of tumor protein 53 (TP53)-mutation-driven clonal evolution and subsequent transformation is a crucial step toward the design of rational therapeutic strategies. Here we carry out allelic resolution single-cell multi-omic analysis of hematopoietic stem/progenitor cells (HSPCs) from patients with a myeloproliferative neoplasm who transform to TP53-mutant secondary acute myeloid leukemia (sAML). All patients showed dominant TP53 'multihit' HSPC...]]></summary>
        <author>
            <name>Alba Rodriguez-Meira</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Case report: PIK3CA somatic mutation leading to Klippel Trenaunay Syndrome and multiple tumors]]></title>
        <id>pubmed:37662840</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37662840/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230924205014&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-09-04T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[We report a case of Klippel Trenaunay Syndrome that was monitored both clinically and molecularly over a period of 9 years. A somatic mosaic mutation of PIK3CA (p(E545G)) was identified using both cfDNA NGS liquid biopsy and tissue biopsy. At the age of 56, due to intervening clonal mutations in PIK3CA background, she developed a squamous cell carcinoma in the right affected leg which was treated surgically. Nine years later, lung bilateral adenocarcinoma arose on PIK3CA mutated tissues...]]></summary>
        <author>
            <name>Viola Bianca Serio</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Single-cell multi-omics identifies chronic inflammation as a driver of TP53-mutant leukemic evolution]]></title>
        <id>pubmed:37666991</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37666991/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230923205208&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-09-04T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Understanding the genetic and nongenetic determinants of tumor protein 53 (TP53)-mutation-driven clonal evolution and subsequent transformation is a crucial step toward the design of rational therapeutic strategies. Here we carry out allelic resolution single-cell multi-omic analysis of hematopoietic stem/progenitor cells (HSPCs) from patients with a myeloproliferative neoplasm who transform to TP53-mutant secondary acute myeloid leukemia (sAML). All patients showed dominant TP53 'multihit' HSPC...]]></summary>
        <author>
            <name>Alba Rodriguez-Meira</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Case report: PIK3CA somatic mutation leading to Klippel Trenaunay Syndrome and multiple tumors]]></title>
        <id>pubmed:37662840</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37662840/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230923205208&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-09-04T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[We report a case of Klippel Trenaunay Syndrome that was monitored both clinically and molecularly over a period of 9 years. A somatic mosaic mutation of PIK3CA (p(E545G)) was identified using both cfDNA NGS liquid biopsy and tissue biopsy. At the age of 56, due to intervening clonal mutations in PIK3CA background, she developed a squamous cell carcinoma in the right affected leg which was treated surgically. Nine years later, lung bilateral adenocarcinoma arose on PIK3CA mutated tissues...]]></summary>
        <author>
            <name>Viola Bianca Serio</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Single-cell multi-omics identifies chronic inflammation as a driver of TP53-mutant leukemic evolution]]></title>
        <id>pubmed:37666991</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37666991/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230922204741&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-09-04T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Understanding the genetic and nongenetic determinants of tumor protein 53 (TP53)-mutation-driven clonal evolution and subsequent transformation is a crucial step toward the design of rational therapeutic strategies. Here we carry out allelic resolution single-cell multi-omic analysis of hematopoietic stem/progenitor cells (HSPCs) from patients with a myeloproliferative neoplasm who transform to TP53-mutant secondary acute myeloid leukemia (sAML). All patients showed dominant TP53 'multihit' HSPC...]]></summary>
        <author>
            <name>Alba Rodriguez-Meira</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Case report: PIK3CA somatic mutation leading to Klippel Trenaunay Syndrome and multiple tumors]]></title>
        <id>pubmed:37662840</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37662840/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230922204741&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-09-04T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[We report a case of Klippel Trenaunay Syndrome that was monitored both clinically and molecularly over a period of 9 years. A somatic mosaic mutation of PIK3CA (p(E545G)) was identified using both cfDNA NGS liquid biopsy and tissue biopsy. At the age of 56, due to intervening clonal mutations in PIK3CA background, she developed a squamous cell carcinoma in the right affected leg which was treated surgically. Nine years later, lung bilateral adenocarcinoma arose on PIK3CA mutated tissues...]]></summary>
        <author>
            <name>Viola Bianca Serio</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Single-cell multi-omics identifies chronic inflammation as a driver of TP53-mutant leukemic evolution]]></title>
        <id>pubmed:37666991</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37666991/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230921204936&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-09-04T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Understanding the genetic and nongenetic determinants of tumor protein 53 (TP53)-mutation-driven clonal evolution and subsequent transformation is a crucial step toward the design of rational therapeutic strategies. Here we carry out allelic resolution single-cell multi-omic analysis of hematopoietic stem/progenitor cells (HSPCs) from patients with a myeloproliferative neoplasm who transform to TP53-mutant secondary acute myeloid leukemia (sAML). All patients showed dominant TP53 'multihit' HSPC...]]></summary>
        <author>
            <name>Alba Rodriguez-Meira</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Case report: PIK3CA somatic mutation leading to Klippel Trenaunay Syndrome and multiple tumors]]></title>
        <id>pubmed:37662840</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37662840/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230921204936&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-09-04T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[We report a case of Klippel Trenaunay Syndrome that was monitored both clinically and molecularly over a period of 9 years. A somatic mosaic mutation of PIK3CA (p(E545G)) was identified using both cfDNA NGS liquid biopsy and tissue biopsy. At the age of 56, due to intervening clonal mutations in PIK3CA background, she developed a squamous cell carcinoma in the right affected leg which was treated surgically. Nine years later, lung bilateral adenocarcinoma arose on PIK3CA mutated tissues...]]></summary>
        <author>
            <name>Viola Bianca Serio</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Single-cell multi-omics identifies chronic inflammation as a driver of TP53-mutant leukemic evolution]]></title>
        <id>pubmed:37666991</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37666991/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230920204904&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-09-04T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Understanding the genetic and nongenetic determinants of tumor protein 53 (TP53)-mutation-driven clonal evolution and subsequent transformation is a crucial step toward the design of rational therapeutic strategies. Here we carry out allelic resolution single-cell multi-omic analysis of hematopoietic stem/progenitor cells (HSPCs) from patients with a myeloproliferative neoplasm who transform to TP53-mutant secondary acute myeloid leukemia (sAML). All patients showed dominant TP53 'multihit' HSPC...]]></summary>
        <author>
            <name>Alba Rodriguez-Meira</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Case report: PIK3CA somatic mutation leading to Klippel Trenaunay Syndrome and multiple tumors]]></title>
        <id>pubmed:37662840</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37662840/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230920204904&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-09-04T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[We report a case of Klippel Trenaunay Syndrome that was monitored both clinically and molecularly over a period of 9 years. A somatic mosaic mutation of PIK3CA (p(E545G)) was identified using both cfDNA NGS liquid biopsy and tissue biopsy. At the age of 56, due to intervening clonal mutations in PIK3CA background, she developed a squamous cell carcinoma in the right affected leg which was treated surgically. Nine years later, lung bilateral adenocarcinoma arose on PIK3CA mutated tissues...]]></summary>
        <author>
            <name>Viola Bianca Serio</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Single-cell multi-omics identifies chronic inflammation as a driver of TP53-mutant leukemic evolution]]></title>
        <id>pubmed:37666991</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37666991/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230919204929&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-09-04T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Understanding the genetic and nongenetic determinants of tumor protein 53 (TP53)-mutation-driven clonal evolution and subsequent transformation is a crucial step toward the design of rational therapeutic strategies. Here we carry out allelic resolution single-cell multi-omic analysis of hematopoietic stem/progenitor cells (HSPCs) from patients with a myeloproliferative neoplasm who transform to TP53-mutant secondary acute myeloid leukemia (sAML). All patients showed dominant TP53 'multihit' HSPC...]]></summary>
        <author>
            <name>Alba Rodriguez-Meira</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Case report: PIK3CA somatic mutation leading to Klippel Trenaunay Syndrome and multiple tumors]]></title>
        <id>pubmed:37662840</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37662840/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230919204929&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-09-04T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[We report a case of Klippel Trenaunay Syndrome that was monitored both clinically and molecularly over a period of 9 years. A somatic mosaic mutation of PIK3CA (p(E545G)) was identified using both cfDNA NGS liquid biopsy and tissue biopsy. At the age of 56, due to intervening clonal mutations in PIK3CA background, she developed a squamous cell carcinoma in the right affected leg which was treated surgically. Nine years later, lung bilateral adenocarcinoma arose on PIK3CA mutated tissues...]]></summary>
        <author>
            <name>Viola Bianca Serio</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Single-cell multi-omics identifies chronic inflammation as a driver of TP53-mutant leukemic evolution]]></title>
        <id>pubmed:37666991</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37666991/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230918204942&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-09-04T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Understanding the genetic and nongenetic determinants of tumor protein 53 (TP53)-mutation-driven clonal evolution and subsequent transformation is a crucial step toward the design of rational therapeutic strategies. Here we carry out allelic resolution single-cell multi-omic analysis of hematopoietic stem/progenitor cells (HSPCs) from patients with a myeloproliferative neoplasm who transform to TP53-mutant secondary acute myeloid leukemia (sAML). All patients showed dominant TP53 'multihit' HSPC...]]></summary>
        <author>
            <name>Alba Rodriguez-Meira</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Case report: PIK3CA somatic mutation leading to Klippel Trenaunay Syndrome and multiple tumors]]></title>
        <id>pubmed:37662840</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37662840/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230918204942&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-09-04T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[We report a case of Klippel Trenaunay Syndrome that was monitored both clinically and molecularly over a period of 9 years. A somatic mosaic mutation of PIK3CA (p(E545G)) was identified using both cfDNA NGS liquid biopsy and tissue biopsy. At the age of 56, due to intervening clonal mutations in PIK3CA background, she developed a squamous cell carcinoma in the right affected leg which was treated surgically. Nine years later, lung bilateral adenocarcinoma arose on PIK3CA mutated tissues...]]></summary>
        <author>
            <name>Viola Bianca Serio</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Single-cell multi-omics identifies chronic inflammation as a driver of TP53-mutant leukemic evolution]]></title>
        <id>pubmed:37666991</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37666991/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230917204936&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-09-04T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Understanding the genetic and nongenetic determinants of tumor protein 53 (TP53)-mutation-driven clonal evolution and subsequent transformation is a crucial step toward the design of rational therapeutic strategies. Here we carry out allelic resolution single-cell multi-omic analysis of hematopoietic stem/progenitor cells (HSPCs) from patients with a myeloproliferative neoplasm who transform to TP53-mutant secondary acute myeloid leukemia (sAML). All patients showed dominant TP53 'multihit' HSPC...]]></summary>
        <author>
            <name>Alba Rodriguez-Meira</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Case report: PIK3CA somatic mutation leading to Klippel Trenaunay Syndrome and multiple tumors]]></title>
        <id>pubmed:37662840</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37662840/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230917204936&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-09-04T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[We report a case of Klippel Trenaunay Syndrome that was monitored both clinically and molecularly over a period of 9 years. A somatic mosaic mutation of PIK3CA (p(E545G)) was identified using both cfDNA NGS liquid biopsy and tissue biopsy. At the age of 56, due to intervening clonal mutations in PIK3CA background, she developed a squamous cell carcinoma in the right affected leg which was treated surgically. Nine years later, lung bilateral adenocarcinoma arose on PIK3CA mutated tissues...]]></summary>
        <author>
            <name>Viola Bianca Serio</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Single-cell multi-omics identifies chronic inflammation as a driver of TP53-mutant leukemic evolution]]></title>
        <id>pubmed:37666991</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37666991/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230916205201&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-09-04T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Understanding the genetic and nongenetic determinants of tumor protein 53 (TP53)-mutation-driven clonal evolution and subsequent transformation is a crucial step toward the design of rational therapeutic strategies. Here we carry out allelic resolution single-cell multi-omic analysis of hematopoietic stem/progenitor cells (HSPCs) from patients with a myeloproliferative neoplasm who transform to TP53-mutant secondary acute myeloid leukemia (sAML). All patients showed dominant TP53 'multihit' HSPC...]]></summary>
        <author>
            <name>Alba Rodriguez-Meira</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Case report: PIK3CA somatic mutation leading to Klippel Trenaunay Syndrome and multiple tumors]]></title>
        <id>pubmed:37662840</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37662840/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230916205201&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-09-04T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[We report a case of Klippel Trenaunay Syndrome that was monitored both clinically and molecularly over a period of 9 years. A somatic mosaic mutation of PIK3CA (p(E545G)) was identified using both cfDNA NGS liquid biopsy and tissue biopsy. At the age of 56, due to intervening clonal mutations in PIK3CA background, she developed a squamous cell carcinoma in the right affected leg which was treated surgically. Nine years later, lung bilateral adenocarcinoma arose on PIK3CA mutated tissues...]]></summary>
        <author>
            <name>Viola Bianca Serio</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Single-cell multi-omics identifies chronic inflammation as a driver of TP53-mutant leukemic evolution]]></title>
        <id>pubmed:37666991</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37666991/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230915204741&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-09-04T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Understanding the genetic and nongenetic determinants of tumor protein 53 (TP53)-mutation-driven clonal evolution and subsequent transformation is a crucial step toward the design of rational therapeutic strategies. Here we carry out allelic resolution single-cell multi-omic analysis of hematopoietic stem/progenitor cells (HSPCs) from patients with a myeloproliferative neoplasm who transform to TP53-mutant secondary acute myeloid leukemia (sAML). All patients showed dominant TP53 'multihit' HSPC...]]></summary>
        <author>
            <name>Alba Rodriguez-Meira</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Case report: PIK3CA somatic mutation leading to Klippel Trenaunay Syndrome and multiple tumors]]></title>
        <id>pubmed:37662840</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37662840/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230915204741&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-09-04T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[We report a case of Klippel Trenaunay Syndrome that was monitored both clinically and molecularly over a period of 9 years. A somatic mosaic mutation of PIK3CA (p(E545G)) was identified using both cfDNA NGS liquid biopsy and tissue biopsy. At the age of 56, due to intervening clonal mutations in PIK3CA background, she developed a squamous cell carcinoma in the right affected leg which was treated surgically. Nine years later, lung bilateral adenocarcinoma arose on PIK3CA mutated tissues...]]></summary>
        <author>
            <name>Viola Bianca Serio</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Single-cell multi-omics identifies chronic inflammation as a driver of TP53-mutant leukemic evolution]]></title>
        <id>pubmed:37666991</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37666991/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230914204950&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-09-04T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Understanding the genetic and nongenetic determinants of tumor protein 53 (TP53)-mutation-driven clonal evolution and subsequent transformation is a crucial step toward the design of rational therapeutic strategies. Here we carry out allelic resolution single-cell multi-omic analysis of hematopoietic stem/progenitor cells (HSPCs) from patients with a myeloproliferative neoplasm who transform to TP53-mutant secondary acute myeloid leukemia (sAML). All patients showed dominant TP53 'multihit' HSPC...]]></summary>
        <author>
            <name>Alba Rodriguez-Meira</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Case report: PIK3CA somatic mutation leading to Klippel Trenaunay Syndrome and multiple tumors]]></title>
        <id>pubmed:37662840</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37662840/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230914204950&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-09-04T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[We report a case of Klippel Trenaunay Syndrome that was monitored both clinically and molecularly over a period of 9 years. A somatic mosaic mutation of PIK3CA (p(E545G)) was identified using both cfDNA NGS liquid biopsy and tissue biopsy. At the age of 56, due to intervening clonal mutations in PIK3CA background, she developed a squamous cell carcinoma in the right affected leg which was treated surgically. Nine years later, lung bilateral adenocarcinoma arose on PIK3CA mutated tissues...]]></summary>
        <author>
            <name>Viola Bianca Serio</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Single-cell multi-omics identifies chronic inflammation as a driver of TP53-mutant leukemic evolution]]></title>
        <id>pubmed:37666991</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37666991/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230913204840&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-09-04T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Understanding the genetic and nongenetic determinants of tumor protein 53 (TP53)-mutation-driven clonal evolution and subsequent transformation is a crucial step toward the design of rational therapeutic strategies. Here we carry out allelic resolution single-cell multi-omic analysis of hematopoietic stem/progenitor cells (HSPCs) from patients with a myeloproliferative neoplasm who transform to TP53-mutant secondary acute myeloid leukemia (sAML). All patients showed dominant TP53 'multihit' HSPC...]]></summary>
        <author>
            <name>Alba Rodriguez-Meira</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Case report: PIK3CA somatic mutation leading to Klippel Trenaunay Syndrome and multiple tumors]]></title>
        <id>pubmed:37662840</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37662840/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230913204840&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-09-04T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[We report a case of Klippel Trenaunay Syndrome that was monitored both clinically and molecularly over a period of 9 years. A somatic mosaic mutation of PIK3CA (p(E545G)) was identified using both cfDNA NGS liquid biopsy and tissue biopsy. At the age of 56, due to intervening clonal mutations in PIK3CA background, she developed a squamous cell carcinoma in the right affected leg which was treated surgically. Nine years later, lung bilateral adenocarcinoma arose on PIK3CA mutated tissues...]]></summary>
        <author>
            <name>Viola Bianca Serio</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Single-cell multi-omics identifies chronic inflammation as a driver of TP53-mutant leukemic evolution]]></title>
        <id>pubmed:37666991</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37666991/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230912205015&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-09-04T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Understanding the genetic and nongenetic determinants of tumor protein 53 (TP53)-mutation-driven clonal evolution and subsequent transformation is a crucial step toward the design of rational therapeutic strategies. Here we carry out allelic resolution single-cell multi-omic analysis of hematopoietic stem/progenitor cells (HSPCs) from patients with a myeloproliferative neoplasm who transform to TP53-mutant secondary acute myeloid leukemia (sAML). All patients showed dominant TP53 'multihit' HSPC...]]></summary>
        <author>
            <name>Alba Rodriguez-Meira</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Case report: PIK3CA somatic mutation leading to Klippel Trenaunay Syndrome and multiple tumors]]></title>
        <id>pubmed:37662840</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37662840/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230912205015&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-09-04T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[We report a case of Klippel Trenaunay Syndrome that was monitored both clinically and molecularly over a period of 9 years. A somatic mosaic mutation of PIK3CA (p(E545G)) was identified using both cfDNA NGS liquid biopsy and tissue biopsy. At the age of 56, due to intervening clonal mutations in PIK3CA background, she developed a squamous cell carcinoma in the right affected leg which was treated surgically. Nine years later, lung bilateral adenocarcinoma arose on PIK3CA mutated tissues...]]></summary>
        <author>
            <name>Viola Bianca Serio</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Single-cell multi-omics identifies chronic inflammation as a driver of TP53-mutant leukemic evolution]]></title>
        <id>pubmed:37666991</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37666991/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230911204717&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-09-04T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Understanding the genetic and nongenetic determinants of tumor protein 53 (TP53)-mutation-driven clonal evolution and subsequent transformation is a crucial step toward the design of rational therapeutic strategies. Here we carry out allelic resolution single-cell multi-omic analysis of hematopoietic stem/progenitor cells (HSPCs) from patients with a myeloproliferative neoplasm who transform to TP53-mutant secondary acute myeloid leukemia (sAML). All patients showed dominant TP53 'multihit' HSPC...]]></summary>
        <author>
            <name>Alba Rodriguez-Meira</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Case report: PIK3CA somatic mutation leading to Klippel Trenaunay Syndrome and multiple tumors]]></title>
        <id>pubmed:37662840</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37662840/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230911204717&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-09-04T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[We report a case of Klippel Trenaunay Syndrome that was monitored both clinically and molecularly over a period of 9 years. A somatic mosaic mutation of PIK3CA (p(E545G)) was identified using both cfDNA NGS liquid biopsy and tissue biopsy. At the age of 56, due to intervening clonal mutations in PIK3CA background, she developed a squamous cell carcinoma in the right affected leg which was treated surgically. Nine years later, lung bilateral adenocarcinoma arose on PIK3CA mutated tissues...]]></summary>
        <author>
            <name>Viola Bianca Serio</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Single-cell multi-omics identifies chronic inflammation as a driver of TP53-mutant leukemic evolution]]></title>
        <id>pubmed:37666991</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37666991/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230910204912&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-09-04T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Understanding the genetic and nongenetic determinants of tumor protein 53 (TP53)-mutation-driven clonal evolution and subsequent transformation is a crucial step toward the design of rational therapeutic strategies. Here we carry out allelic resolution single-cell multi-omic analysis of hematopoietic stem/progenitor cells (HSPCs) from patients with a myeloproliferative neoplasm who transform to TP53-mutant secondary acute myeloid leukemia (sAML). All patients showed dominant TP53 'multihit' HSPC...]]></summary>
        <author>
            <name>Alba Rodriguez-Meira</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Case report: PIK3CA somatic mutation leading to Klippel Trenaunay Syndrome and multiple tumors]]></title>
        <id>pubmed:37662840</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37662840/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230910204912&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-09-04T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[We report a case of Klippel Trenaunay Syndrome that was monitored both clinically and molecularly over a period of 9 years. A somatic mosaic mutation of PIK3CA (p(E545G)) was identified using both cfDNA NGS liquid biopsy and tissue biopsy. At the age of 56, due to intervening clonal mutations in PIK3CA background, she developed a squamous cell carcinoma in the right affected leg which was treated surgically. Nine years later, lung bilateral adenocarcinoma arose on PIK3CA mutated tissues...]]></summary>
        <author>
            <name>Viola Bianca Serio</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Single-cell multi-omics identifies chronic inflammation as a driver of TP53-mutant leukemic evolution]]></title>
        <id>pubmed:37666991</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37666991/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230909205145&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-09-04T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Understanding the genetic and nongenetic determinants of tumor protein 53 (TP53)-mutation-driven clonal evolution and subsequent transformation is a crucial step toward the design of rational therapeutic strategies. Here we carry out allelic resolution single-cell multi-omic analysis of hematopoietic stem/progenitor cells (HSPCs) from patients with a myeloproliferative neoplasm who transform to TP53-mutant secondary acute myeloid leukemia (sAML). All patients showed dominant TP53 'multihit' HSPC...]]></summary>
        <author>
            <name>Alba Rodriguez-Meira</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Case report: PIK3CA somatic mutation leading to Klippel Trenaunay Syndrome and multiple tumors]]></title>
        <id>pubmed:37662840</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37662840/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230909205145&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-09-04T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[We report a case of Klippel Trenaunay Syndrome that was monitored both clinically and molecularly over a period of 9 years. A somatic mosaic mutation of PIK3CA (p(E545G)) was identified using both cfDNA NGS liquid biopsy and tissue biopsy. At the age of 56, due to intervening clonal mutations in PIK3CA background, she developed a squamous cell carcinoma in the right affected leg which was treated surgically. Nine years later, lung bilateral adenocarcinoma arose on PIK3CA mutated tissues...]]></summary>
        <author>
            <name>Viola Bianca Serio</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Single-cell multi-omics identifies chronic inflammation as a driver of TP53-mutant leukemic evolution]]></title>
        <id>pubmed:37666991</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37666991/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230908204701&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-09-04T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Understanding the genetic and nongenetic determinants of tumor protein 53 (TP53)-mutation-driven clonal evolution and subsequent transformation is a crucial step toward the design of rational therapeutic strategies. Here we carry out allelic resolution single-cell multi-omic analysis of hematopoietic stem/progenitor cells (HSPCs) from patients with a myeloproliferative neoplasm who transform to TP53-mutant secondary acute myeloid leukemia (sAML). All patients showed dominant TP53 'multihit' HSPC...]]></summary>
        <author>
            <name>Alba Rodriguez-Meira</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Case report: PIK3CA somatic mutation leading to Klippel Trenaunay Syndrome and multiple tumors]]></title>
        <id>pubmed:37662840</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37662840/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230908204701&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-09-04T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[We report a case of Klippel Trenaunay Syndrome that was monitored both clinically and molecularly over a period of 9 years. A somatic mosaic mutation of PIK3CA (p(E545G)) was identified using both cfDNA NGS liquid biopsy and tissue biopsy. At the age of 56, due to intervening clonal mutations in PIK3CA background, she developed a squamous cell carcinoma in the right affected leg which was treated surgically. Nine years later, lung bilateral adenocarcinoma arose on PIK3CA mutated tissues...]]></summary>
        <author>
            <name>Viola Bianca Serio</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Single-cell multi-omics identifies chronic inflammation as a driver of TP53-mutant leukemic evolution]]></title>
        <id>pubmed:37666991</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37666991/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230907204816&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-09-04T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Understanding the genetic and nongenetic determinants of tumor protein 53 (TP53)-mutation-driven clonal evolution and subsequent transformation is a crucial step toward the design of rational therapeutic strategies. Here we carry out allelic resolution single-cell multi-omic analysis of hematopoietic stem/progenitor cells (HSPCs) from patients with a myeloproliferative neoplasm who transform to TP53-mutant secondary acute myeloid leukemia (sAML). All patients showed dominant TP53 'multihit' HSPC...]]></summary>
        <author>
            <name>Alba Rodriguez-Meira</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Case report: PIK3CA somatic mutation leading to Klippel Trenaunay Syndrome and multiple tumors]]></title>
        <id>pubmed:37662840</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37662840/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230907204816&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-09-04T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[We report a case of Klippel Trenaunay Syndrome that was monitored both clinically and molecularly over a period of 9 years. A somatic mosaic mutation of PIK3CA (p(E545G)) was identified using both cfDNA NGS liquid biopsy and tissue biopsy. At the age of 56, due to intervening clonal mutations in PIK3CA background, she developed a squamous cell carcinoma in the right affected leg which was treated surgically. Nine years later, lung bilateral adenocarcinoma arose on PIK3CA mutated tissues...]]></summary>
        <author>
            <name>Viola Bianca Serio</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Single-cell multi-omics identifies chronic inflammation as a driver of TP53-mutant leukemic evolution]]></title>
        <id>pubmed:37666991</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37666991/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230906204801&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-09-04T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Understanding the genetic and nongenetic determinants of tumor protein 53 (TP53)-mutation-driven clonal evolution and subsequent transformation is a crucial step toward the design of rational therapeutic strategies. Here we carry out allelic resolution single-cell multi-omic analysis of hematopoietic stem/progenitor cells (HSPCs) from patients with a myeloproliferative neoplasm who transform to TP53-mutant secondary acute myeloid leukemia (sAML). All patients showed dominant TP53 'multihit' HSPC...]]></summary>
        <author>
            <name>Alba Rodriguez-Meira</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Case report: PIK3CA somatic mutation leading to Klippel Trenaunay Syndrome and multiple tumors]]></title>
        <id>pubmed:37662840</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37662840/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230906204801&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-09-04T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[We report a case of Klippel Trenaunay Syndrome that was monitored both clinically and molecularly over a period of 9 years. A somatic mosaic mutation of PIK3CA (p(E545G)) was identified using both cfDNA NGS liquid biopsy and tissue biopsy. At the age of 56, due to intervening clonal mutations in PIK3CA background, she developed a squamous cell carcinoma in the right affected leg which was treated surgically. Nine years later, lung bilateral adenocarcinoma arose on PIK3CA mutated tissues...]]></summary>
        <author>
            <name>Viola Bianca Serio</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Single-cell multi-omics identifies chronic inflammation as a driver of TP53-mutant leukemic evolution]]></title>
        <id>pubmed:37666991</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37666991/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230905204848&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-09-04T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Understanding the genetic and nongenetic determinants of tumor protein 53 (TP53)-mutation-driven clonal evolution and subsequent transformation is a crucial step toward the design of rational therapeutic strategies. Here we carry out allelic resolution single-cell multi-omic analysis of hematopoietic stem/progenitor cells (HSPCs) from patients with a myeloproliferative neoplasm who transform to TP53-mutant secondary acute myeloid leukemia (sAML). All patients showed dominant TP53 'multihit' HSPC...]]></summary>
        <author>
            <name>Alba Rodriguez-Meira</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Case report: PIK3CA somatic mutation leading to Klippel Trenaunay Syndrome and multiple tumors]]></title>
        <id>pubmed:37662840</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37662840/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230905204848&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-09-04T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[We report a case of Klippel Trenaunay Syndrome that was monitored both clinically and molecularly over a period of 9 years. A somatic mosaic mutation of PIK3CA (p(E545G)) was identified using both cfDNA NGS liquid biopsy and tissue biopsy. At the age of 56, due to intervening clonal mutations in PIK3CA background, she developed a squamous cell carcinoma in the right affected leg which was treated surgically. Nine years later, lung bilateral adenocarcinoma arose on PIK3CA mutated tissues...]]></summary>
        <author>
            <name>Viola Bianca Serio</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Case report: PIK3CA somatic mutation leading to Klippel Trenaunay Syndrome and multiple tumors]]></title>
        <id>pubmed:37662840</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37662840/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230904204751&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-09-04T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[We report a case of Klippel Trenaunay Syndrome that was monitored both clinically and molecularly over a period of 9 years. A somatic mosaic mutation of PIK3CA (p(E545G)) was identified using both cfDNA NGS liquid biopsy and tissue biopsy. At the age of 56, due to intervening clonal mutations in PIK3CA background, she developed a squamous cell carcinoma in the right affected leg which was treated surgically. Nine years later, lung bilateral adenocarcinoma arose on PIK3CA mutated tissues...]]></summary>
        <author>
            <name>Viola Bianca Serio</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[VEXAS syndrome, a new kid on the block of auto-inflammatory diseases: A hematologist's point of view]]></title>
        <id>pubmed:37652853</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37652853/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230920204905&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-08-31T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[The recently discovered VEXAS syndrome is caused by the clonal expansion of hematopoietic stem or progenitor cells with acquired mutations in UBA1 gene, which encodes for a key enzyme of the ubiquitylation proteasome system. As a result, a shorter cytoplasmic isoform of UBA1 is transcribed, which is non-functional. The disease is characterized by non-specific and highly heterogeneous inflammatory manifestations and macrocytic anemia. VEXAS syndrome is a unique acquired hematological monogenic...]]></summary>
        <author>
            <name>Mal Heiblig</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Mural cell-derived chemokines provide a protective niche to safeguard vascular macrophages and limit chronic inflammation]]></title>
        <id>pubmed:37652021</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37652021/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230920204905&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-08-31T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Maladaptive, non-resolving inflammation contributes to chronic inflammatory diseases such as atherosclerosis. Because macrophages remove necrotic cells, defective macrophage programs can promote chronic inflammation with persistent tissue injury. Here, we investigated the mechanisms sustaining vascular macrophages. Intravital imaging revealed a spatiotemporal macrophage niche across vascular beds alongside mural cells (MCs)-pericytes and smooth muscle cells. Single-cell transcriptomics,...]]></summary>
        <author>
            <name>Kami Pekayvaz</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[VEXAS syndrome, a new kid on the block of auto-inflammatory diseases: A hematologist's point of view]]></title>
        <id>pubmed:37652853</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37652853/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230919204929&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-08-31T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[The recently discovered VEXAS syndrome is caused by the clonal expansion of hematopoietic stem or progenitor cells with acquired mutations in UBA1 gene, which encodes for a key enzyme of the ubiquitylation proteasome system. As a result, a shorter cytoplasmic isoform of UBA1 is transcribed, which is non-functional. The disease is characterized by non-specific and highly heterogeneous inflammatory manifestations and macrocytic anemia. VEXAS syndrome is a unique acquired hematological monogenic...]]></summary>
        <author>
            <name>Mal Heiblig</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Mural cell-derived chemokines provide a protective niche to safeguard vascular macrophages and limit chronic inflammation]]></title>
        <id>pubmed:37652021</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37652021/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230919204929&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-08-31T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Maladaptive, non-resolving inflammation contributes to chronic inflammatory diseases such as atherosclerosis. Because macrophages remove necrotic cells, defective macrophage programs can promote chronic inflammation with persistent tissue injury. Here, we investigated the mechanisms sustaining vascular macrophages. Intravital imaging revealed a spatiotemporal macrophage niche across vascular beds alongside mural cells (MCs)-pericytes and smooth muscle cells. Single-cell transcriptomics,...]]></summary>
        <author>
            <name>Kami Pekayvaz</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Cutaneous involvement in Ph-negative myeloproliferative neoplasms: from extramedullary hematopoiesis to myeloid metastasis with histiocytic differentiation. A systematic review of the literature]]></title>
        <id>pubmed:37649236</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37649236/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230919204929&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-08-31T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Myeloid neoplasms may metastasize to the skin, presenting a wide range of clinical-pathological features that often lead to a reduction in patients' survival. The presentation varies depending on the category of myeloid neoplasm and its prognostic significance. The literature has specifically focused on the features of acute myeloid leukemia (AML), myelodysplastic syndrome (MDS), and chronic myelomonocytic leukemia (CMML). In this article, we aimed to uncover the peculiarities of clonal skin...]]></summary>
        <author>
            <name>Arturo Bonometti</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[VEXAS syndrome, a new kid on the block of auto-inflammatory diseases: A hematologist's point of view]]></title>
        <id>pubmed:37652853</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37652853/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230918204942&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-08-31T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[The recently discovered VEXAS syndrome is caused by the clonal expansion of hematopoietic stem or progenitor cells with acquired mutations in UBA1 gene, which encodes for a key enzyme of the ubiquitylation proteasome system. As a result, a shorter cytoplasmic isoform of UBA1 is transcribed, which is non-functional. The disease is characterized by non-specific and highly heterogeneous inflammatory manifestations and macrocytic anemia. VEXAS syndrome is a unique acquired hematological monogenic...]]></summary>
        <author>
            <name>Mal Heiblig</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Mural cell-derived chemokines provide a protective niche to safeguard vascular macrophages and limit chronic inflammation]]></title>
        <id>pubmed:37652021</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37652021/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230918204942&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-08-31T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Maladaptive, non-resolving inflammation contributes to chronic inflammatory diseases such as atherosclerosis. Because macrophages remove necrotic cells, defective macrophage programs can promote chronic inflammation with persistent tissue injury. Here, we investigated the mechanisms sustaining vascular macrophages. Intravital imaging revealed a spatiotemporal macrophage niche across vascular beds alongside mural cells (MCs)-pericytes and smooth muscle cells. Single-cell transcriptomics,...]]></summary>
        <author>
            <name>Kami Pekayvaz</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Cutaneous involvement in Ph-negative myeloproliferative neoplasms: from extramedullary hematopoiesis to myeloid metastasis with histiocytic differentiation. A systematic review of the literature]]></title>
        <id>pubmed:37649236</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37649236/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230918204942&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-08-31T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Myeloid neoplasms may metastasize to the skin, presenting a wide range of clinical-pathological features that often lead to a reduction in patients' survival. The presentation varies depending on the category of myeloid neoplasm and its prognostic significance. The literature has specifically focused on the features of acute myeloid leukemia (AML), myelodysplastic syndrome (MDS), and chronic myelomonocytic leukemia (CMML). In this article, we aimed to uncover the peculiarities of clonal skin...]]></summary>
        <author>
            <name>Arturo Bonometti</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[VEXAS syndrome, a new kid on the block of auto-inflammatory diseases: A hematologist's point of view]]></title>
        <id>pubmed:37652853</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37652853/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230917204935&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-08-31T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[The recently discovered VEXAS syndrome is caused by the clonal expansion of hematopoietic stem or progenitor cells with acquired mutations in UBA1 gene, which encodes for a key enzyme of the ubiquitylation proteasome system. As a result, a shorter cytoplasmic isoform of UBA1 is transcribed, which is non-functional. The disease is characterized by non-specific and highly heterogeneous inflammatory manifestations and macrocytic anemia. VEXAS syndrome is a unique acquired hematological monogenic...]]></summary>
        <author>
            <name>Mal Heiblig</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Mural cell-derived chemokines provide a protective niche to safeguard vascular macrophages and limit chronic inflammation]]></title>
        <id>pubmed:37652021</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37652021/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230917204935&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-08-31T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Maladaptive, non-resolving inflammation contributes to chronic inflammatory diseases such as atherosclerosis. Because macrophages remove necrotic cells, defective macrophage programs can promote chronic inflammation with persistent tissue injury. Here, we investigated the mechanisms sustaining vascular macrophages. Intravital imaging revealed a spatiotemporal macrophage niche across vascular beds alongside mural cells (MCs)-pericytes and smooth muscle cells. Single-cell transcriptomics,...]]></summary>
        <author>
            <name>Kami Pekayvaz</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Cutaneous involvement in Ph-negative myeloproliferative neoplasms: from extramedullary hematopoiesis to myeloid metastasis with histiocytic differentiation. A systematic review of the literature]]></title>
        <id>pubmed:37649236</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37649236/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230917204935&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-08-31T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Myeloid neoplasms may metastasize to the skin, presenting a wide range of clinical-pathological features that often lead to a reduction in patients' survival. The presentation varies depending on the category of myeloid neoplasm and its prognostic significance. The literature has specifically focused on the features of acute myeloid leukemia (AML), myelodysplastic syndrome (MDS), and chronic myelomonocytic leukemia (CMML). In this article, we aimed to uncover the peculiarities of clonal skin...]]></summary>
        <author>
            <name>Arturo Bonometti</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[VEXAS syndrome, a new kid on the block of auto-inflammatory diseases: A hematologist's point of view]]></title>
        <id>pubmed:37652853</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37652853/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230916205201&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-08-31T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[The recently discovered VEXAS syndrome is caused by the clonal expansion of hematopoietic stem or progenitor cells with acquired mutations in UBA1 gene, which encodes for a key enzyme of the ubiquitylation proteasome system. As a result, a shorter cytoplasmic isoform of UBA1 is transcribed, which is non-functional. The disease is characterized by non-specific and highly heterogeneous inflammatory manifestations and macrocytic anemia. VEXAS syndrome is a unique acquired hematological monogenic...]]></summary>
        <author>
            <name>Mal Heiblig</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Mural cell-derived chemokines provide a protective niche to safeguard vascular macrophages and limit chronic inflammation]]></title>
        <id>pubmed:37652021</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37652021/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230916205201&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-08-31T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Maladaptive, non-resolving inflammation contributes to chronic inflammatory diseases such as atherosclerosis. Because macrophages remove necrotic cells, defective macrophage programs can promote chronic inflammation with persistent tissue injury. Here, we investigated the mechanisms sustaining vascular macrophages. Intravital imaging revealed a spatiotemporal macrophage niche across vascular beds alongside mural cells (MCs)-pericytes and smooth muscle cells. Single-cell transcriptomics,...]]></summary>
        <author>
            <name>Kami Pekayvaz</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Cutaneous involvement in Ph-negative myeloproliferative neoplasms: from extramedullary hematopoiesis to myeloid metastasis with histiocytic differentiation. A systematic review of the literature]]></title>
        <id>pubmed:37649236</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37649236/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230916205201&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-08-31T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Myeloid neoplasms may metastasize to the skin, presenting a wide range of clinical-pathological features that often lead to a reduction in patients' survival. The presentation varies depending on the category of myeloid neoplasm and its prognostic significance. The literature has specifically focused on the features of acute myeloid leukemia (AML), myelodysplastic syndrome (MDS), and chronic myelomonocytic leukemia (CMML). In this article, we aimed to uncover the peculiarities of clonal skin...]]></summary>
        <author>
            <name>Arturo Bonometti</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[VEXAS syndrome, a new kid on the block of auto-inflammatory diseases: A hematologist's point of view]]></title>
        <id>pubmed:37652853</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37652853/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230915204741&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-08-31T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[The recently discovered VEXAS syndrome is caused by the clonal expansion of hematopoietic stem or progenitor cells with acquired mutations in UBA1 gene, which encodes for a key enzyme of the ubiquitylation proteasome system. As a result, a shorter cytoplasmic isoform of UBA1 is transcribed, which is non-functional. The disease is characterized by non-specific and highly heterogeneous inflammatory manifestations and macrocytic anemia. VEXAS syndrome is a unique acquired hematological monogenic...]]></summary>
        <author>
            <name>Mal Heiblig</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Mural cell-derived chemokines provide a protective niche to safeguard vascular macrophages and limit chronic inflammation]]></title>
        <id>pubmed:37652021</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37652021/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230915204741&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-08-31T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Maladaptive, non-resolving inflammation contributes to chronic inflammatory diseases such as atherosclerosis. Because macrophages remove necrotic cells, defective macrophage programs can promote chronic inflammation with persistent tissue injury. Here, we investigated the mechanisms sustaining vascular macrophages. Intravital imaging revealed a spatiotemporal macrophage niche across vascular beds alongside mural cells (MCs)-pericytes and smooth muscle cells. Single-cell transcriptomics,...]]></summary>
        <author>
            <name>Kami Pekayvaz</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Cutaneous involvement in Ph-negative myeloproliferative neoplasms: from extramedullary hematopoiesis to myeloid metastasis with histiocytic differentiation. A systematic review of the literature]]></title>
        <id>pubmed:37649236</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37649236/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230915204741&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-08-31T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Myeloid neoplasms may metastasize to the skin, presenting a wide range of clinical-pathological features that often lead to a reduction in patients' survival. The presentation varies depending on the category of myeloid neoplasm and its prognostic significance. The literature has specifically focused on the features of acute myeloid leukemia (AML), myelodysplastic syndrome (MDS), and chronic myelomonocytic leukemia (CMML). In this article, we aimed to uncover the peculiarities of clonal skin...]]></summary>
        <author>
            <name>Arturo Bonometti</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[VEXAS syndrome, a new kid on the block of auto-inflammatory diseases: A hematologist's point of view]]></title>
        <id>pubmed:37652853</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37652853/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230914204950&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-08-31T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[The recently discovered VEXAS syndrome is caused by the clonal expansion of hematopoietic stem or progenitor cells with acquired mutations in UBA1 gene, which encodes for a key enzyme of the ubiquitylation proteasome system. As a result, a shorter cytoplasmic isoform of UBA1 is transcribed, which is non-functional. The disease is characterized by non-specific and highly heterogeneous inflammatory manifestations and macrocytic anemia. VEXAS syndrome is a unique acquired hematological monogenic...]]></summary>
        <author>
            <name>Mal Heiblig</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Mural cell-derived chemokines provide a protective niche to safeguard vascular macrophages and limit chronic inflammation]]></title>
        <id>pubmed:37652021</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37652021/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230914204950&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-08-31T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Maladaptive, non-resolving inflammation contributes to chronic inflammatory diseases such as atherosclerosis. Because macrophages remove necrotic cells, defective macrophage programs can promote chronic inflammation with persistent tissue injury. Here, we investigated the mechanisms sustaining vascular macrophages. Intravital imaging revealed a spatiotemporal macrophage niche across vascular beds alongside mural cells (MCs)-pericytes and smooth muscle cells. Single-cell transcriptomics,...]]></summary>
        <author>
            <name>Kami Pekayvaz</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Cutaneous involvement in Ph-negative myeloproliferative neoplasms: from extramedullary hematopoiesis to myeloid metastasis with histiocytic differentiation. A systematic review of the literature]]></title>
        <id>pubmed:37649236</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37649236/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230914204950&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-08-31T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Myeloid neoplasms may metastasize to the skin, presenting a wide range of clinical-pathological features that often lead to a reduction in patients' survival. The presentation varies depending on the category of myeloid neoplasm and its prognostic significance. The literature has specifically focused on the features of acute myeloid leukemia (AML), myelodysplastic syndrome (MDS), and chronic myelomonocytic leukemia (CMML). In this article, we aimed to uncover the peculiarities of clonal skin...]]></summary>
        <author>
            <name>Arturo Bonometti</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[VEXAS syndrome, a new kid on the block of auto-inflammatory diseases: A hematologist's point of view]]></title>
        <id>pubmed:37652853</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37652853/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230913204840&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-08-31T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[The recently discovered VEXAS syndrome is caused by the clonal expansion of hematopoietic stem or progenitor cells with acquired mutations in UBA1 gene, which encodes for a key enzyme of the ubiquitylation proteasome system. As a result, a shorter cytoplasmic isoform of UBA1 is transcribed, which is non-functional. The disease is characterized by non-specific and highly heterogeneous inflammatory manifestations and macrocytic anemia. VEXAS syndrome is a unique acquired hematological monogenic...]]></summary>
        <author>
            <name>Mal Heiblig</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Mural cell-derived chemokines provide a protective niche to safeguard vascular macrophages and limit chronic inflammation]]></title>
        <id>pubmed:37652021</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37652021/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230913204840&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-08-31T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Maladaptive, non-resolving inflammation contributes to chronic inflammatory diseases such as atherosclerosis. Because macrophages remove necrotic cells, defective macrophage programs can promote chronic inflammation with persistent tissue injury. Here, we investigated the mechanisms sustaining vascular macrophages. Intravital imaging revealed a spatiotemporal macrophage niche across vascular beds alongside mural cells (MCs)-pericytes and smooth muscle cells. Single-cell transcriptomics,...]]></summary>
        <author>
            <name>Kami Pekayvaz</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Cutaneous involvement in Ph-negative myeloproliferative neoplasms: from extramedullary hematopoiesis to myeloid metastasis with histiocytic differentiation. A systematic review of the literature]]></title>
        <id>pubmed:37649236</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37649236/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230913204840&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-08-31T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Myeloid neoplasms may metastasize to the skin, presenting a wide range of clinical-pathological features that often lead to a reduction in patients' survival. The presentation varies depending on the category of myeloid neoplasm and its prognostic significance. The literature has specifically focused on the features of acute myeloid leukemia (AML), myelodysplastic syndrome (MDS), and chronic myelomonocytic leukemia (CMML). In this article, we aimed to uncover the peculiarities of clonal skin...]]></summary>
        <author>
            <name>Arturo Bonometti</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[VEXAS syndrome, a new kid on the block of auto-inflammatory diseases: A hematologist's point of view]]></title>
        <id>pubmed:37652853</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37652853/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230912205016&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-08-31T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[The recently discovered VEXAS syndrome is caused by the clonal expansion of hematopoietic stem or progenitor cells with acquired mutations in UBA1 gene, which encodes for a key enzyme of the ubiquitylation proteasome system. As a result, a shorter cytoplasmic isoform of UBA1 is transcribed, which is non-functional. The disease is characterized by non-specific and highly heterogeneous inflammatory manifestations and macrocytic anemia. VEXAS syndrome is a unique acquired hematological monogenic...]]></summary>
        <author>
            <name>Mal Heiblig</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Mural cell-derived chemokines provide a protective niche to safeguard vascular macrophages and limit chronic inflammation]]></title>
        <id>pubmed:37652021</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37652021/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230912205016&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-08-31T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Maladaptive, non-resolving inflammation contributes to chronic inflammatory diseases such as atherosclerosis. Because macrophages remove necrotic cells, defective macrophage programs can promote chronic inflammation with persistent tissue injury. Here, we investigated the mechanisms sustaining vascular macrophages. Intravital imaging revealed a spatiotemporal macrophage niche across vascular beds alongside mural cells (MCs)-pericytes and smooth muscle cells. Single-cell transcriptomics,...]]></summary>
        <author>
            <name>Kami Pekayvaz</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Cutaneous involvement in Ph-negative myeloproliferative neoplasms: from extramedullary hematopoiesis to myeloid metastasis with histiocytic differentiation. A systematic review of the literature]]></title>
        <id>pubmed:37649236</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37649236/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230912205016&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-08-31T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Myeloid neoplasms may metastasize to the skin, presenting a wide range of clinical-pathological features that often lead to a reduction in patients' survival. The presentation varies depending on the category of myeloid neoplasm and its prognostic significance. The literature has specifically focused on the features of acute myeloid leukemia (AML), myelodysplastic syndrome (MDS), and chronic myelomonocytic leukemia (CMML). In this article, we aimed to uncover the peculiarities of clonal skin...]]></summary>
        <author>
            <name>Arturo Bonometti</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[VEXAS syndrome, a new kid on the block of auto-inflammatory diseases: A hematologist's point of view]]></title>
        <id>pubmed:37652853</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37652853/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230911204717&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-08-31T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[The recently discovered VEXAS syndrome is caused by the clonal expansion of hematopoietic stem or progenitor cells with acquired mutations in UBA1 gene, which encodes for a key enzyme of the ubiquitylation proteasome system. As a result, a shorter cytoplasmic isoform of UBA1 is transcribed, which is non-functional. The disease is characterized by non-specific and highly heterogeneous inflammatory manifestations and macrocytic anemia. VEXAS syndrome is a unique acquired hematological monogenic...]]></summary>
        <author>
            <name>Mal Heiblig</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Mural cell-derived chemokines provide a protective niche to safeguard vascular macrophages and limit chronic inflammation]]></title>
        <id>pubmed:37652021</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37652021/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230911204717&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-08-31T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Maladaptive, non-resolving inflammation contributes to chronic inflammatory diseases such as atherosclerosis. Because macrophages remove necrotic cells, defective macrophage programs can promote chronic inflammation with persistent tissue injury. Here, we investigated the mechanisms sustaining vascular macrophages. Intravital imaging revealed a spatiotemporal macrophage niche across vascular beds alongside mural cells (MCs)-pericytes and smooth muscle cells. Single-cell transcriptomics,...]]></summary>
        <author>
            <name>Kami Pekayvaz</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Cutaneous involvement in Ph-negative myeloproliferative neoplasms: from extramedullary hematopoiesis to myeloid metastasis with histiocytic differentiation. A systematic review of the literature]]></title>
        <id>pubmed:37649236</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37649236/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230911204717&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-08-31T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Myeloid neoplasms may metastasize to the skin, presenting a wide range of clinical-pathological features that often lead to a reduction in patients' survival. The presentation varies depending on the category of myeloid neoplasm and its prognostic significance. The literature has specifically focused on the features of acute myeloid leukemia (AML), myelodysplastic syndrome (MDS), and chronic myelomonocytic leukemia (CMML). In this article, we aimed to uncover the peculiarities of clonal skin...]]></summary>
        <author>
            <name>Arturo Bonometti</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[VEXAS syndrome, a new kid on the block of auto-inflammatory diseases: A hematologist's point of view]]></title>
        <id>pubmed:37652853</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37652853/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230910204912&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-08-31T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[The recently discovered VEXAS syndrome is caused by the clonal expansion of hematopoietic stem or progenitor cells with acquired mutations in UBA1 gene, which encodes for a key enzyme of the ubiquitylation proteasome system. As a result, a shorter cytoplasmic isoform of UBA1 is transcribed, which is non-functional. The disease is characterized by non-specific and highly heterogeneous inflammatory manifestations and macrocytic anemia. VEXAS syndrome is a unique acquired hematological monogenic...]]></summary>
        <author>
            <name>Mal Heiblig</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Mural cell-derived chemokines provide a protective niche to safeguard vascular macrophages and limit chronic inflammation]]></title>
        <id>pubmed:37652021</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37652021/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230910204912&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-08-31T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Maladaptive, non-resolving inflammation contributes to chronic inflammatory diseases such as atherosclerosis. Because macrophages remove necrotic cells, defective macrophage programs can promote chronic inflammation with persistent tissue injury. Here, we investigated the mechanisms sustaining vascular macrophages. Intravital imaging revealed a spatiotemporal macrophage niche across vascular beds alongside mural cells (MCs)-pericytes and smooth muscle cells. Single-cell transcriptomics,...]]></summary>
        <author>
            <name>Kami Pekayvaz</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Cutaneous involvement in Ph-negative myeloproliferative neoplasms: from extramedullary hematopoiesis to myeloid metastasis with histiocytic differentiation. A systematic review of the literature]]></title>
        <id>pubmed:37649236</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37649236/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230910204912&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-08-31T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Myeloid neoplasms may metastasize to the skin, presenting a wide range of clinical-pathological features that often lead to a reduction in patients' survival. The presentation varies depending on the category of myeloid neoplasm and its prognostic significance. The literature has specifically focused on the features of acute myeloid leukemia (AML), myelodysplastic syndrome (MDS), and chronic myelomonocytic leukemia (CMML). In this article, we aimed to uncover the peculiarities of clonal skin...]]></summary>
        <author>
            <name>Arturo Bonometti</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[VEXAS syndrome, a new kid on the block of auto-inflammatory diseases: A hematologist's point of view]]></title>
        <id>pubmed:37652853</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37652853/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230909205145&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-08-31T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[The recently discovered VEXAS syndrome is caused by the clonal expansion of hematopoietic stem or progenitor cells with acquired mutations in UBA1 gene, which encodes for a key enzyme of the ubiquitylation proteasome system. As a result, a shorter cytoplasmic isoform of UBA1 is transcribed, which is non-functional. The disease is characterized by non-specific and highly heterogeneous inflammatory manifestations and macrocytic anemia. VEXAS syndrome is a unique acquired hematological monogenic...]]></summary>
        <author>
            <name>Mal Heiblig</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Mural cell-derived chemokines provide a protective niche to safeguard vascular macrophages and limit chronic inflammation]]></title>
        <id>pubmed:37652021</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37652021/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230909205145&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-08-31T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Maladaptive, non-resolving inflammation contributes to chronic inflammatory diseases such as atherosclerosis. Because macrophages remove necrotic cells, defective macrophage programs can promote chronic inflammation with persistent tissue injury. Here, we investigated the mechanisms sustaining vascular macrophages. Intravital imaging revealed a spatiotemporal macrophage niche across vascular beds alongside mural cells (MCs)-pericytes and smooth muscle cells. Single-cell transcriptomics,...]]></summary>
        <author>
            <name>Kami Pekayvaz</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Cutaneous involvement in Ph-negative myeloproliferative neoplasms: from extramedullary hematopoiesis to myeloid metastasis with histiocytic differentiation. A systematic review of the literature]]></title>
        <id>pubmed:37649236</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37649236/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230909205145&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-08-31T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Myeloid neoplasms may metastasize to the skin, presenting a wide range of clinical-pathological features that often lead to a reduction in patients' survival. The presentation varies depending on the category of myeloid neoplasm and its prognostic significance. The literature has specifically focused on the features of acute myeloid leukemia (AML), myelodysplastic syndrome (MDS), and chronic myelomonocytic leukemia (CMML). In this article, we aimed to uncover the peculiarities of clonal skin...]]></summary>
        <author>
            <name>Arturo Bonometti</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[VEXAS syndrome, a new kid on the block of auto-inflammatory diseases: A hematologist's point of view]]></title>
        <id>pubmed:37652853</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37652853/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230908204701&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-08-31T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[The recently discovered VEXAS syndrome is caused by the clonal expansion of hematopoietic stem or progenitor cells with acquired mutations in UBA1 gene, which encodes for a key enzyme of the ubiquitylation proteasome system. As a result, a shorter cytoplasmic isoform of UBA1 is transcribed, which is non-functional. The disease is characterized by non-specific and highly heterogeneous inflammatory manifestations and macrocytic anemia. VEXAS syndrome is a unique acquired hematological monogenic...]]></summary>
        <author>
            <name>Mal Heiblig</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Mural cell-derived chemokines provide a protective niche to safeguard vascular macrophages and limit chronic inflammation]]></title>
        <id>pubmed:37652021</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37652021/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230908204701&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-08-31T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Maladaptive, non-resolving inflammation contributes to chronic inflammatory diseases such as atherosclerosis. Because macrophages remove necrotic cells, defective macrophage programs can promote chronic inflammation with persistent tissue injury. Here, we investigated the mechanisms sustaining vascular macrophages. Intravital imaging revealed a spatiotemporal macrophage niche across vascular beds alongside mural cells (MCs)-pericytes and smooth muscle cells. Single-cell transcriptomics,...]]></summary>
        <author>
            <name>Kami Pekayvaz</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Cutaneous involvement in Ph-negative myeloproliferative neoplasms: from extramedullary hematopoiesis to myeloid metastasis with histiocytic differentiation. A systematic review of the literature]]></title>
        <id>pubmed:37649236</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37649236/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230908204701&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-08-31T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Myeloid neoplasms may metastasize to the skin, presenting a wide range of clinical-pathological features that often lead to a reduction in patients' survival. The presentation varies depending on the category of myeloid neoplasm and its prognostic significance. The literature has specifically focused on the features of acute myeloid leukemia (AML), myelodysplastic syndrome (MDS), and chronic myelomonocytic leukemia (CMML). In this article, we aimed to uncover the peculiarities of clonal skin...]]></summary>
        <author>
            <name>Arturo Bonometti</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[VEXAS syndrome, a new kid on the block of auto-inflammatory diseases: A hematologist's point of view]]></title>
        <id>pubmed:37652853</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37652853/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230907204816&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-08-31T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[The recently discovered VEXAS syndrome is caused by the clonal expansion of hematopoietic stem or progenitor cells with acquired mutations in UBA1 gene, which encodes for a key enzyme of the ubiquitylation proteasome system. As a result, a shorter cytoplasmic isoform of UBA1 is transcribed, which is non-functional. The disease is characterized by non-specific and highly heterogeneous inflammatory manifestations and macrocytic anemia. VEXAS syndrome is a unique acquired hematological monogenic...]]></summary>
        <author>
            <name>Mal Heiblig</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Mural cell-derived chemokines provide a protective niche to safeguard vascular macrophages and limit chronic inflammation]]></title>
        <id>pubmed:37652021</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37652021/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230907204816&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-08-31T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Maladaptive, non-resolving inflammation contributes to chronic inflammatory diseases such as atherosclerosis. Because macrophages remove necrotic cells, defective macrophage programs can promote chronic inflammation with persistent tissue injury. Here, we investigated the mechanisms sustaining vascular macrophages. Intravital imaging revealed a spatiotemporal macrophage niche across vascular beds alongside mural cells (MCs)-pericytes and smooth muscle cells. Single-cell transcriptomics,...]]></summary>
        <author>
            <name>Kami Pekayvaz</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Cutaneous involvement in Ph-negative myeloproliferative neoplasms: from extramedullary hematopoiesis to myeloid metastasis with histiocytic differentiation. A systematic review of the literature]]></title>
        <id>pubmed:37649236</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37649236/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230907204816&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-08-31T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Myeloid neoplasms may metastasize to the skin, presenting a wide range of clinical-pathological features that often lead to a reduction in patients' survival. The presentation varies depending on the category of myeloid neoplasm and its prognostic significance. The literature has specifically focused on the features of acute myeloid leukemia (AML), myelodysplastic syndrome (MDS), and chronic myelomonocytic leukemia (CMML). In this article, we aimed to uncover the peculiarities of clonal skin...]]></summary>
        <author>
            <name>Arturo Bonometti</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[VEXAS syndrome, a new kid on the block of auto-inflammatory diseases: A hematologist's point of view]]></title>
        <id>pubmed:37652853</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37652853/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230906204801&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-08-31T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[The recently discovered VEXAS syndrome is caused by the clonal expansion of hematopoietic stem or progenitor cells with acquired mutations in UBA1 gene, which encodes for a key enzyme of the ubiquitylation proteasome system. As a result, a shorter cytoplasmic isoform of UBA1 is transcribed, which is non-functional. The disease is characterized by non-specific and highly heterogeneous inflammatory manifestations and macrocytic anemia. VEXAS syndrome is a unique acquired hematological monogenic...]]></summary>
        <author>
            <name>Mal Heiblig</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Mural cell-derived chemokines provide a protective niche to safeguard vascular macrophages and limit chronic inflammation]]></title>
        <id>pubmed:37652021</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37652021/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230906204801&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-08-31T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Maladaptive, non-resolving inflammation contributes to chronic inflammatory diseases such as atherosclerosis. Because macrophages remove necrotic cells, defective macrophage programs can promote chronic inflammation with persistent tissue injury. Here, we investigated the mechanisms sustaining vascular macrophages. Intravital imaging revealed a spatiotemporal macrophage niche across vascular beds alongside mural cells (MCs)-pericytes and smooth muscle cells. Single-cell transcriptomics,...]]></summary>
        <author>
            <name>Kami Pekayvaz</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Cutaneous involvement in Ph-negative myeloproliferative neoplasms: from extramedullary hematopoiesis to myeloid metastasis with histiocytic differentiation. A systematic review of the literature]]></title>
        <id>pubmed:37649236</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37649236/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230906204801&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-08-31T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Myeloid neoplasms may metastasize to the skin, presenting a wide range of clinical-pathological features that often lead to a reduction in patients' survival. The presentation varies depending on the category of myeloid neoplasm and its prognostic significance. The literature has specifically focused on the features of acute myeloid leukemia (AML), myelodysplastic syndrome (MDS), and chronic myelomonocytic leukemia (CMML). In this article, we aimed to uncover the peculiarities of clonal skin...]]></summary>
        <author>
            <name>Arturo Bonometti</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[VEXAS syndrome, a new kid on the block of auto-inflammatory diseases: A hematologist's point of view]]></title>
        <id>pubmed:37652853</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37652853/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230905204848&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-08-31T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[The recently discovered VEXAS syndrome is caused by the clonal expansion of hematopoietic stem or progenitor cells with acquired mutations in UBA1 gene, which encodes for a key enzyme of the ubiquitylation proteasome system. As a result, a shorter cytoplasmic isoform of UBA1 is transcribed, which is non-functional. The disease is characterized by non-specific and highly heterogeneous inflammatory manifestations and macrocytic anemia. VEXAS syndrome is a unique acquired hematological monogenic...]]></summary>
        <author>
            <name>Mal Heiblig</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Mural cell-derived chemokines provide a protective niche to safeguard vascular macrophages and limit chronic inflammation]]></title>
        <id>pubmed:37652021</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37652021/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230905204848&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-08-31T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Maladaptive, non-resolving inflammation contributes to chronic inflammatory diseases such as atherosclerosis. Because macrophages remove necrotic cells, defective macrophage programs can promote chronic inflammation with persistent tissue injury. Here, we investigated the mechanisms sustaining vascular macrophages. Intravital imaging revealed a spatiotemporal macrophage niche across vascular beds alongside mural cells (MCs)-pericytes and smooth muscle cells. Single-cell transcriptomics,...]]></summary>
        <author>
            <name>Kami Pekayvaz</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Cutaneous involvement in Ph-negative myeloproliferative neoplasms: from extramedullary hematopoiesis to myeloid metastasis with histiocytic differentiation. A systematic review of the literature]]></title>
        <id>pubmed:37649236</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37649236/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230905204848&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-08-31T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Myeloid neoplasms may metastasize to the skin, presenting a wide range of clinical-pathological features that often lead to a reduction in patients' survival. The presentation varies depending on the category of myeloid neoplasm and its prognostic significance. The literature has specifically focused on the features of acute myeloid leukemia (AML), myelodysplastic syndrome (MDS), and chronic myelomonocytic leukemia (CMML). In this article, we aimed to uncover the peculiarities of clonal skin...]]></summary>
        <author>
            <name>Arturo Bonometti</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[VEXAS syndrome, a new kid on the block of auto-inflammatory diseases: A hematologist's point of view]]></title>
        <id>pubmed:37652853</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37652853/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230904204751&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-08-31T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[The recently discovered VEXAS syndrome is caused by the clonal expansion of hematopoietic stem or progenitor cells with acquired mutations in UBA1 gene, which encodes for a key enzyme of the ubiquitylation proteasome system. As a result, a shorter cytoplasmic isoform of UBA1 is transcribed, which is non-functional. The disease is characterized by non-specific and highly heterogeneous inflammatory manifestations and macrocytic anemia. VEXAS syndrome is a unique acquired hematological monogenic...]]></summary>
        <author>
            <name>Mal Heiblig</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Mural cell-derived chemokines provide a protective niche to safeguard vascular macrophages and limit chronic inflammation]]></title>
        <id>pubmed:37652021</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37652021/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230904204751&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-08-31T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Maladaptive, non-resolving inflammation contributes to chronic inflammatory diseases such as atherosclerosis. Because macrophages remove necrotic cells, defective macrophage programs can promote chronic inflammation with persistent tissue injury. Here, we investigated the mechanisms sustaining vascular macrophages. Intravital imaging revealed a spatiotemporal macrophage niche across vascular beds alongside mural cells (MCs)-pericytes and smooth muscle cells. Single-cell transcriptomics,...]]></summary>
        <author>
            <name>Kami Pekayvaz</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Cutaneous involvement in Ph-negative myeloproliferative neoplasms: from extramedullary hematopoiesis to myeloid metastasis with histiocytic differentiation. A systematic review of the literature]]></title>
        <id>pubmed:37649236</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37649236/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230904204751&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-08-31T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Myeloid neoplasms may metastasize to the skin, presenting a wide range of clinical-pathological features that often lead to a reduction in patients' survival. The presentation varies depending on the category of myeloid neoplasm and its prognostic significance. The literature has specifically focused on the features of acute myeloid leukemia (AML), myelodysplastic syndrome (MDS), and chronic myelomonocytic leukemia (CMML). In this article, we aimed to uncover the peculiarities of clonal skin...]]></summary>
        <author>
            <name>Arturo Bonometti</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[VEXAS syndrome, a new kid on the block of auto-inflammatory diseases: A hematologist's point of view]]></title>
        <id>pubmed:37652853</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37652853/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230903204939&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-08-31T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[The recently discovered VEXAS syndrome is caused by the clonal expansion of hematopoietic stem or progenitor cells with acquired mutations in UBA1 gene, which encodes for a key enzyme of the ubiquitylation proteasome system. As a result, a shorter cytoplasmic isoform of UBA1 is transcribed, which is non-functional. The disease is characterized by non-specific and highly heterogeneous inflammatory manifestations and macrocytic anemia. VEXAS syndrome is a unique acquired hematological monogenic...]]></summary>
        <author>
            <name>Mal Heiblig</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Mural cell-derived chemokines provide a protective niche to safeguard vascular macrophages and limit chronic inflammation]]></title>
        <id>pubmed:37652021</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37652021/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230903204939&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-08-31T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Maladaptive, non-resolving inflammation contributes to chronic inflammatory diseases such as atherosclerosis. Because macrophages remove necrotic cells, defective macrophage programs can promote chronic inflammation with persistent tissue injury. Here, we investigated the mechanisms sustaining vascular macrophages. Intravital imaging revealed a spatiotemporal macrophage niche across vascular beds alongside mural cells (MCs)-pericytes and smooth muscle cells. Single-cell transcriptomics,...]]></summary>
        <author>
            <name>Kami Pekayvaz</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Cutaneous involvement in Ph-negative myeloproliferative neoplasms: from extramedullary hematopoiesis to myeloid metastasis with histiocytic differentiation. A systematic review of the literature]]></title>
        <id>pubmed:37649236</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37649236/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230903204939&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-08-31T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Myeloid neoplasms may metastasize to the skin, presenting a wide range of clinical-pathological features that often lead to a reduction in patients' survival. The presentation varies depending on the category of myeloid neoplasm and its prognostic significance. The literature has specifically focused on the features of acute myeloid leukemia (AML), myelodysplastic syndrome (MDS), and chronic myelomonocytic leukemia (CMML). In this article, we aimed to uncover the peculiarities of clonal skin...]]></summary>
        <author>
            <name>Arturo Bonometti</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[VEXAS syndrome, a new kid on the block of auto-inflammatory diseases: A hematologist's point of view]]></title>
        <id>pubmed:37652853</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37652853/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230902205121&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-08-31T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[The recently discovered VEXAS syndrome is caused by the clonal expansion of hematopoietic stem or progenitor cells with acquired mutations in UBA1 gene, which encodes for a key enzyme of the ubiquitylation proteasome system. As a result, a shorter cytoplasmic isoform of UBA1 is transcribed, which is non-functional. The disease is characterized by non-specific and highly heterogeneous inflammatory manifestations and macrocytic anemia. VEXAS syndrome is a unique acquired hematological monogenic...]]></summary>
        <author>
            <name>Mal Heiblig</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Mural cell-derived chemokines provide a protective niche to safeguard vascular macrophages and limit chronic inflammation]]></title>
        <id>pubmed:37652021</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37652021/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230902205121&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-08-31T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Maladaptive, non-resolving inflammation contributes to chronic inflammatory diseases such as atherosclerosis. Because macrophages remove necrotic cells, defective macrophage programs can promote chronic inflammation with persistent tissue injury. Here, we investigated the mechanisms sustaining vascular macrophages. Intravital imaging revealed a spatiotemporal macrophage niche across vascular beds alongside mural cells (MCs)-pericytes and smooth muscle cells. Single-cell transcriptomics,...]]></summary>
        <author>
            <name>Kami Pekayvaz</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Cutaneous involvement in Ph-negative myeloproliferative neoplasms: from extramedullary hematopoiesis to myeloid metastasis with histiocytic differentiation. A systematic review of the literature]]></title>
        <id>pubmed:37649236</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37649236/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230902205121&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-08-31T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Myeloid neoplasms may metastasize to the skin, presenting a wide range of clinical-pathological features that often lead to a reduction in patients' survival. The presentation varies depending on the category of myeloid neoplasm and its prognostic significance. The literature has specifically focused on the features of acute myeloid leukemia (AML), myelodysplastic syndrome (MDS), and chronic myelomonocytic leukemia (CMML). In this article, we aimed to uncover the peculiarities of clonal skin...]]></summary>
        <author>
            <name>Arturo Bonometti</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[VEXAS syndrome, a new kid on the block of auto-inflammatory diseases: A hematologist's point of view]]></title>
        <id>pubmed:37652853</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37652853/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230901204619&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-08-31T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[The recently discovered VEXAS syndrome is caused by the clonal expansion of hematopoietic stem or progenitor cells with acquired mutations in UBA1 gene, which encodes for a key enzyme of the ubiquitylation proteasome system. As a result, a shorter cytoplasmic isoform of UBA1 is transcribed, which is non-functional. The disease is characterized by non-specific and highly heterogeneous inflammatory manifestations and macrocytic anemia. VEXAS syndrome is a unique acquired hematological monogenic...]]></summary>
        <author>
            <name>Mal Heiblig</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Mural cell-derived chemokines provide a protective niche to safeguard vascular macrophages and limit chronic inflammation]]></title>
        <id>pubmed:37652021</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37652021/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230901204619&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-08-31T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Maladaptive, non-resolving inflammation contributes to chronic inflammatory diseases such as atherosclerosis. Because macrophages remove necrotic cells, defective macrophage programs can promote chronic inflammation with persistent tissue injury. Here, we investigated the mechanisms sustaining vascular macrophages. Intravital imaging revealed a spatiotemporal macrophage niche across vascular beds alongside mural cells (MCs)-pericytes and smooth muscle cells. Single-cell transcriptomics,...]]></summary>
        <author>
            <name>Kami Pekayvaz</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Cutaneous involvement in Ph-negative myeloproliferative neoplasms: from extramedullary hematopoiesis to myeloid metastasis with histiocytic differentiation. A systematic review of the literature]]></title>
        <id>pubmed:37649236</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37649236/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230901204619&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-08-31T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Myeloid neoplasms may metastasize to the skin, presenting a wide range of clinical-pathological features that often lead to a reduction in patients' survival. The presentation varies depending on the category of myeloid neoplasm and its prognostic significance. The literature has specifically focused on the features of acute myeloid leukemia (AML), myelodysplastic syndrome (MDS), and chronic myelomonocytic leukemia (CMML). In this article, we aimed to uncover the peculiarities of clonal skin...]]></summary>
        <author>
            <name>Arturo Bonometti</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Cutaneous involvement in Ph-negative myeloproliferative neoplasms: from extramedullary hematopoiesis to myeloid metastasis with histiocytic differentiation. A systematic review of the literature]]></title>
        <id>pubmed:37649236</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37649236/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230831205203&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-08-31T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Myeloid neoplasms may metastasize to the skin, presenting a wide range of clinical-pathological features that often lead to a reduction in patients' survival. The presentation varies depending on the category of myeloid neoplasm and its prognostic significance. The literature has specifically focused on the features of acute myeloid leukemia (AML), myelodysplastic syndrome (MDS), and chronic myelomonocytic leukemia (CMML). In this article, we aimed to uncover the peculiarities of clonal skin...]]></summary>
        <author>
            <name>Arturo Bonometti</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Mechanisms of antigen escape from BCMA- or GPRC5D-targeted immunotherapies in multiple myeloma]]></title>
        <id>pubmed:37653344</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37653344/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230924205014&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-08-31T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[B cell maturation antigen (BCMA) target loss is considered to be a rare event that mediates multiple myeloma (MM) resistance to anti-BCMA chimeric antigen receptor T cell (CAR T) or bispecific T cell engager (TCE) therapies. Emerging data report that downregulation of G-protein-coupled receptor family C group 5 member D (GPRC5D) protein often occurs at relapse after anti-GPRC5D CAR T therapy. To examine the tumor-intrinsic factors that promote MM antigen escape, we performed combined bulk and...]]></summary>
        <author>
            <name>Holly Lee</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Molecular and clonal evolution <em>invivo</em> reveal a common pathway of distant relapse gliomas]]></title>
        <id>pubmed:37649695</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37649695/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230924205014&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-08-31T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[The evolutionary trajectories of genomic alterations underlying distant recurrence in glioma remain largely unknown. To elucidate glioma evolution, we analyzed the evolutionary trajectories of matched pairs of primary tumors and relapse tumors or tumor in situ fluid (TISF) based on deep whole-genome sequencing data (ctDNA). We found that MMR gene mutations occurred in the late stage in IDH-mutant glioma during gene evolution, which activates multiple signaling pathways and significantly...]]></summary>
        <author>
            <name>Guanzheng Liu</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Mechanisms of antigen escape from BCMA- or GPRC5D-targeted immunotherapies in multiple myeloma]]></title>
        <id>pubmed:37653344</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37653344/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230923205208&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-08-31T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[B cell maturation antigen (BCMA) target loss is considered to be a rare event that mediates multiple myeloma (MM) resistance to anti-BCMA chimeric antigen receptor T cell (CAR T) or bispecific T cell engager (TCE) therapies. Emerging data report that downregulation of G-protein-coupled receptor family C group 5 member D (GPRC5D) protein often occurs at relapse after anti-GPRC5D CAR T therapy. To examine the tumor-intrinsic factors that promote MM antigen escape, we performed combined bulk and...]]></summary>
        <author>
            <name>Holly Lee</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Molecular and clonal evolution <em>invivo</em> reveal a common pathway of distant relapse gliomas]]></title>
        <id>pubmed:37649695</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37649695/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230923205208&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-08-31T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[The evolutionary trajectories of genomic alterations underlying distant recurrence in glioma remain largely unknown. To elucidate glioma evolution, we analyzed the evolutionary trajectories of matched pairs of primary tumors and relapse tumors or tumor in situ fluid (TISF) based on deep whole-genome sequencing data (ctDNA). We found that MMR gene mutations occurred in the late stage in IDH-mutant glioma during gene evolution, which activates multiple signaling pathways and significantly...]]></summary>
        <author>
            <name>Guanzheng Liu</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Mechanisms of antigen escape from BCMA- or GPRC5D-targeted immunotherapies in multiple myeloma]]></title>
        <id>pubmed:37653344</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37653344/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230922204741&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-08-31T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[B cell maturation antigen (BCMA) target loss is considered to be a rare event that mediates multiple myeloma (MM) resistance to anti-BCMA chimeric antigen receptor T cell (CAR T) or bispecific T cell engager (TCE) therapies. Emerging data report that downregulation of G-protein-coupled receptor family C group 5 member D (GPRC5D) protein often occurs at relapse after anti-GPRC5D CAR T therapy. To examine the tumor-intrinsic factors that promote MM antigen escape, we performed combined bulk and...]]></summary>
        <author>
            <name>Holly Lee</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Molecular and clonal evolution <em>invivo</em> reveal a common pathway of distant relapse gliomas]]></title>
        <id>pubmed:37649695</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37649695/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230922204741&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-08-31T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[The evolutionary trajectories of genomic alterations underlying distant recurrence in glioma remain largely unknown. To elucidate glioma evolution, we analyzed the evolutionary trajectories of matched pairs of primary tumors and relapse tumors or tumor in situ fluid (TISF) based on deep whole-genome sequencing data (ctDNA). We found that MMR gene mutations occurred in the late stage in IDH-mutant glioma during gene evolution, which activates multiple signaling pathways and significantly...]]></summary>
        <author>
            <name>Guanzheng Liu</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Mechanisms of antigen escape from BCMA- or GPRC5D-targeted immunotherapies in multiple myeloma]]></title>
        <id>pubmed:37653344</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37653344/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230921204936&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-08-31T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[B cell maturation antigen (BCMA) target loss is considered to be a rare event that mediates multiple myeloma (MM) resistance to anti-BCMA chimeric antigen receptor T cell (CAR T) or bispecific T cell engager (TCE) therapies. Emerging data report that downregulation of G-protein-coupled receptor family C group 5 member D (GPRC5D) protein often occurs at relapse after anti-GPRC5D CAR T therapy. To examine the tumor-intrinsic factors that promote MM antigen escape, we performed combined bulk and...]]></summary>
        <author>
            <name>Holly Lee</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Molecular and clonal evolution <em>invivo</em> reveal a common pathway of distant relapse gliomas]]></title>
        <id>pubmed:37649695</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37649695/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230921204936&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-08-31T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[The evolutionary trajectories of genomic alterations underlying distant recurrence in glioma remain largely unknown. To elucidate glioma evolution, we analyzed the evolutionary trajectories of matched pairs of primary tumors and relapse tumors or tumor in situ fluid (TISF) based on deep whole-genome sequencing data (ctDNA). We found that MMR gene mutations occurred in the late stage in IDH-mutant glioma during gene evolution, which activates multiple signaling pathways and significantly...]]></summary>
        <author>
            <name>Guanzheng Liu</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Mechanisms of antigen escape from BCMA- or GPRC5D-targeted immunotherapies in multiple myeloma]]></title>
        <id>pubmed:37653344</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37653344/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230920204904&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-08-31T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[B cell maturation antigen (BCMA) target loss is considered to be a rare event that mediates multiple myeloma (MM) resistance to anti-BCMA chimeric antigen receptor T cell (CAR T) or bispecific T cell engager (TCE) therapies. Emerging data report that downregulation of G-protein-coupled receptor family C group 5 member D (GPRC5D) protein often occurs at relapse after anti-GPRC5D CAR T therapy. To examine the tumor-intrinsic factors that promote MM antigen escape, we performed combined bulk and...]]></summary>
        <author>
            <name>Holly Lee</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Molecular and clonal evolution <em>invivo</em> reveal a common pathway of distant relapse gliomas]]></title>
        <id>pubmed:37649695</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37649695/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230920204904&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-08-31T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[The evolutionary trajectories of genomic alterations underlying distant recurrence in glioma remain largely unknown. To elucidate glioma evolution, we analyzed the evolutionary trajectories of matched pairs of primary tumors and relapse tumors or tumor in situ fluid (TISF) based on deep whole-genome sequencing data (ctDNA). We found that MMR gene mutations occurred in the late stage in IDH-mutant glioma during gene evolution, which activates multiple signaling pathways and significantly...]]></summary>
        <author>
            <name>Guanzheng Liu</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Mechanisms of antigen escape from BCMA- or GPRC5D-targeted immunotherapies in multiple myeloma]]></title>
        <id>pubmed:37653344</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37653344/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230919204929&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-08-31T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[B cell maturation antigen (BCMA) target loss is considered to be a rare event that mediates multiple myeloma (MM) resistance to anti-BCMA chimeric antigen receptor T cell (CAR T) or bispecific T cell engager (TCE) therapies. Emerging data report that downregulation of G-protein-coupled receptor family C group 5 member D (GPRC5D) protein often occurs at relapse after anti-GPRC5D CAR T therapy. To examine the tumor-intrinsic factors that promote MM antigen escape, we performed combined bulk and...]]></summary>
        <author>
            <name>Holly Lee</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Molecular and clonal evolution <em>invivo</em> reveal a common pathway of distant relapse gliomas]]></title>
        <id>pubmed:37649695</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37649695/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230919204929&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-08-31T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[The evolutionary trajectories of genomic alterations underlying distant recurrence in glioma remain largely unknown. To elucidate glioma evolution, we analyzed the evolutionary trajectories of matched pairs of primary tumors and relapse tumors or tumor in situ fluid (TISF) based on deep whole-genome sequencing data (ctDNA). We found that MMR gene mutations occurred in the late stage in IDH-mutant glioma during gene evolution, which activates multiple signaling pathways and significantly...]]></summary>
        <author>
            <name>Guanzheng Liu</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Mechanisms of antigen escape from BCMA- or GPRC5D-targeted immunotherapies in multiple myeloma]]></title>
        <id>pubmed:37653344</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37653344/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230918204942&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-08-31T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[B cell maturation antigen (BCMA) target loss is considered to be a rare event that mediates multiple myeloma (MM) resistance to anti-BCMA chimeric antigen receptor T cell (CAR T) or bispecific T cell engager (TCE) therapies. Emerging data report that downregulation of G-protein-coupled receptor family C group 5 member D (GPRC5D) protein often occurs at relapse after anti-GPRC5D CAR T therapy. To examine the tumor-intrinsic factors that promote MM antigen escape, we performed combined bulk and...]]></summary>
        <author>
            <name>Holly Lee</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Molecular and clonal evolution <em>invivo</em> reveal a common pathway of distant relapse gliomas]]></title>
        <id>pubmed:37649695</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37649695/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230918204942&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-08-31T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[The evolutionary trajectories of genomic alterations underlying distant recurrence in glioma remain largely unknown. To elucidate glioma evolution, we analyzed the evolutionary trajectories of matched pairs of primary tumors and relapse tumors or tumor in situ fluid (TISF) based on deep whole-genome sequencing data (ctDNA). We found that MMR gene mutations occurred in the late stage in IDH-mutant glioma during gene evolution, which activates multiple signaling pathways and significantly...]]></summary>
        <author>
            <name>Guanzheng Liu</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Mechanisms of antigen escape from BCMA- or GPRC5D-targeted immunotherapies in multiple myeloma]]></title>
        <id>pubmed:37653344</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37653344/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230917204936&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-08-31T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[B cell maturation antigen (BCMA) target loss is considered to be a rare event that mediates multiple myeloma (MM) resistance to anti-BCMA chimeric antigen receptor T cell (CAR T) or bispecific T cell engager (TCE) therapies. Emerging data report that downregulation of G-protein-coupled receptor family C group 5 member D (GPRC5D) protein often occurs at relapse after anti-GPRC5D CAR T therapy. To examine the tumor-intrinsic factors that promote MM antigen escape, we performed combined bulk and...]]></summary>
        <author>
            <name>Holly Lee</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Molecular and clonal evolution <em>invivo</em> reveal a common pathway of distant relapse gliomas]]></title>
        <id>pubmed:37649695</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37649695/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230917204936&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-08-31T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[The evolutionary trajectories of genomic alterations underlying distant recurrence in glioma remain largely unknown. To elucidate glioma evolution, we analyzed the evolutionary trajectories of matched pairs of primary tumors and relapse tumors or tumor in situ fluid (TISF) based on deep whole-genome sequencing data (ctDNA). We found that MMR gene mutations occurred in the late stage in IDH-mutant glioma during gene evolution, which activates multiple signaling pathways and significantly...]]></summary>
        <author>
            <name>Guanzheng Liu</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Mechanisms of antigen escape from BCMA- or GPRC5D-targeted immunotherapies in multiple myeloma]]></title>
        <id>pubmed:37653344</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37653344/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230916205201&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-08-31T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[B cell maturation antigen (BCMA) target loss is considered to be a rare event that mediates multiple myeloma (MM) resistance to anti-BCMA chimeric antigen receptor T cell (CAR T) or bispecific T cell engager (TCE) therapies. Emerging data report that downregulation of G-protein-coupled receptor family C group 5 member D (GPRC5D) protein often occurs at relapse after anti-GPRC5D CAR T therapy. To examine the tumor-intrinsic factors that promote MM antigen escape, we performed combined bulk and...]]></summary>
        <author>
            <name>Holly Lee</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Molecular and clonal evolution <em>invivo</em> reveal a common pathway of distant relapse gliomas]]></title>
        <id>pubmed:37649695</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37649695/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230916205201&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-08-31T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[The evolutionary trajectories of genomic alterations underlying distant recurrence in glioma remain largely unknown. To elucidate glioma evolution, we analyzed the evolutionary trajectories of matched pairs of primary tumors and relapse tumors or tumor in situ fluid (TISF) based on deep whole-genome sequencing data (ctDNA). We found that MMR gene mutations occurred in the late stage in IDH-mutant glioma during gene evolution, which activates multiple signaling pathways and significantly...]]></summary>
        <author>
            <name>Guanzheng Liu</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Mechanisms of antigen escape from BCMA- or GPRC5D-targeted immunotherapies in multiple myeloma]]></title>
        <id>pubmed:37653344</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37653344/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230915204741&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-08-31T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[B cell maturation antigen (BCMA) target loss is considered to be a rare event that mediates multiple myeloma (MM) resistance to anti-BCMA chimeric antigen receptor T cell (CAR T) or bispecific T cell engager (TCE) therapies. Emerging data report that downregulation of G-protein-coupled receptor family C group 5 member D (GPRC5D) protein often occurs at relapse after anti-GPRC5D CAR T therapy. To examine the tumor-intrinsic factors that promote MM antigen escape, we performed combined bulk and...]]></summary>
        <author>
            <name>Holly Lee</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Molecular and clonal evolution <em>invivo</em> reveal a common pathway of distant relapse gliomas]]></title>
        <id>pubmed:37649695</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37649695/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230915204741&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-08-31T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[The evolutionary trajectories of genomic alterations underlying distant recurrence in glioma remain largely unknown. To elucidate glioma evolution, we analyzed the evolutionary trajectories of matched pairs of primary tumors and relapse tumors or tumor in situ fluid (TISF) based on deep whole-genome sequencing data (ctDNA). We found that MMR gene mutations occurred in the late stage in IDH-mutant glioma during gene evolution, which activates multiple signaling pathways and significantly...]]></summary>
        <author>
            <name>Guanzheng Liu</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Mechanisms of antigen escape from BCMA- or GPRC5D-targeted immunotherapies in multiple myeloma]]></title>
        <id>pubmed:37653344</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37653344/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230914204950&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-08-31T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[B cell maturation antigen (BCMA) target loss is considered to be a rare event that mediates multiple myeloma (MM) resistance to anti-BCMA chimeric antigen receptor T cell (CAR T) or bispecific T cell engager (TCE) therapies. Emerging data report that downregulation of G-protein-coupled receptor family C group 5 member D (GPRC5D) protein often occurs at relapse after anti-GPRC5D CAR T therapy. To examine the tumor-intrinsic factors that promote MM antigen escape, we performed combined bulk and...]]></summary>
        <author>
            <name>Holly Lee</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Molecular and clonal evolution <em>invivo</em> reveal a common pathway of distant relapse gliomas]]></title>
        <id>pubmed:37649695</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37649695/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230914204950&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-08-31T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[The evolutionary trajectories of genomic alterations underlying distant recurrence in glioma remain largely unknown. To elucidate glioma evolution, we analyzed the evolutionary trajectories of matched pairs of primary tumors and relapse tumors or tumor in situ fluid (TISF) based on deep whole-genome sequencing data (ctDNA). We found that MMR gene mutations occurred in the late stage in IDH-mutant glioma during gene evolution, which activates multiple signaling pathways and significantly...]]></summary>
        <author>
            <name>Guanzheng Liu</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Mechanisms of antigen escape from BCMA- or GPRC5D-targeted immunotherapies in multiple myeloma]]></title>
        <id>pubmed:37653344</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37653344/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230913204840&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-08-31T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[B cell maturation antigen (BCMA) target loss is considered to be a rare event that mediates multiple myeloma (MM) resistance to anti-BCMA chimeric antigen receptor T cell (CAR T) or bispecific T cell engager (TCE) therapies. Emerging data report that downregulation of G-protein-coupled receptor family C group 5 member D (GPRC5D) protein often occurs at relapse after anti-GPRC5D CAR T therapy. To examine the tumor-intrinsic factors that promote MM antigen escape, we performed combined bulk and...]]></summary>
        <author>
            <name>Holly Lee</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Molecular and clonal evolution <em>invivo</em> reveal a common pathway of distant relapse gliomas]]></title>
        <id>pubmed:37649695</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37649695/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230913204840&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-08-31T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[The evolutionary trajectories of genomic alterations underlying distant recurrence in glioma remain largely unknown. To elucidate glioma evolution, we analyzed the evolutionary trajectories of matched pairs of primary tumors and relapse tumors or tumor in situ fluid (TISF) based on deep whole-genome sequencing data (ctDNA). We found that MMR gene mutations occurred in the late stage in IDH-mutant glioma during gene evolution, which activates multiple signaling pathways and significantly...]]></summary>
        <author>
            <name>Guanzheng Liu</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Mechanisms of antigen escape from BCMA- or GPRC5D-targeted immunotherapies in multiple myeloma]]></title>
        <id>pubmed:37653344</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37653344/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230912205015&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-08-31T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[B cell maturation antigen (BCMA) target loss is considered to be a rare event that mediates multiple myeloma (MM) resistance to anti-BCMA chimeric antigen receptor T cell (CAR T) or bispecific T cell engager (TCE) therapies. Emerging data report that downregulation of G-protein-coupled receptor family C group 5 member D (GPRC5D) protein often occurs at relapse after anti-GPRC5D CAR T therapy. To examine the tumor-intrinsic factors that promote MM antigen escape, we performed combined bulk and...]]></summary>
        <author>
            <name>Holly Lee</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Molecular and clonal evolution <em>invivo</em> reveal a common pathway of distant relapse gliomas]]></title>
        <id>pubmed:37649695</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37649695/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230912205015&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-08-31T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[The evolutionary trajectories of genomic alterations underlying distant recurrence in glioma remain largely unknown. To elucidate glioma evolution, we analyzed the evolutionary trajectories of matched pairs of primary tumors and relapse tumors or tumor in situ fluid (TISF) based on deep whole-genome sequencing data (ctDNA). We found that MMR gene mutations occurred in the late stage in IDH-mutant glioma during gene evolution, which activates multiple signaling pathways and significantly...]]></summary>
        <author>
            <name>Guanzheng Liu</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Mechanisms of antigen escape from BCMA- or GPRC5D-targeted immunotherapies in multiple myeloma]]></title>
        <id>pubmed:37653344</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37653344/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230911204717&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-08-31T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[B cell maturation antigen (BCMA) target loss is considered to be a rare event that mediates multiple myeloma (MM) resistance to anti-BCMA chimeric antigen receptor T cell (CAR T) or bispecific T cell engager (TCE) therapies. Emerging data report that downregulation of G-protein-coupled receptor family C group 5 member D (GPRC5D) protein often occurs at relapse after anti-GPRC5D CAR T therapy. To examine the tumor-intrinsic factors that promote MM antigen escape, we performed combined bulk and...]]></summary>
        <author>
            <name>Holly Lee</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Molecular and clonal evolution <em>invivo</em> reveal a common pathway of distant relapse gliomas]]></title>
        <id>pubmed:37649695</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37649695/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230911204717&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-08-31T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[The evolutionary trajectories of genomic alterations underlying distant recurrence in glioma remain largely unknown. To elucidate glioma evolution, we analyzed the evolutionary trajectories of matched pairs of primary tumors and relapse tumors or tumor in situ fluid (TISF) based on deep whole-genome sequencing data (ctDNA). We found that MMR gene mutations occurred in the late stage in IDH-mutant glioma during gene evolution, which activates multiple signaling pathways and significantly...]]></summary>
        <author>
            <name>Guanzheng Liu</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Mechanisms of antigen escape from BCMA- or GPRC5D-targeted immunotherapies in multiple myeloma]]></title>
        <id>pubmed:37653344</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37653344/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230910204912&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-08-31T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[B cell maturation antigen (BCMA) target loss is considered to be a rare event that mediates multiple myeloma (MM) resistance to anti-BCMA chimeric antigen receptor T cell (CAR T) or bispecific T cell engager (TCE) therapies. Emerging data report that downregulation of G-protein-coupled receptor family C group 5 member D (GPRC5D) protein often occurs at relapse after anti-GPRC5D CAR T therapy. To examine the tumor-intrinsic factors that promote MM antigen escape, we performed combined bulk and...]]></summary>
        <author>
            <name>Holly Lee</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Molecular and clonal evolution <em>invivo</em> reveal a common pathway of distant relapse gliomas]]></title>
        <id>pubmed:37649695</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37649695/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230910204912&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-08-31T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[The evolutionary trajectories of genomic alterations underlying distant recurrence in glioma remain largely unknown. To elucidate glioma evolution, we analyzed the evolutionary trajectories of matched pairs of primary tumors and relapse tumors or tumor in situ fluid (TISF) based on deep whole-genome sequencing data (ctDNA). We found that MMR gene mutations occurred in the late stage in IDH-mutant glioma during gene evolution, which activates multiple signaling pathways and significantly...]]></summary>
        <author>
            <name>Guanzheng Liu</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Mechanisms of antigen escape from BCMA- or GPRC5D-targeted immunotherapies in multiple myeloma]]></title>
        <id>pubmed:37653344</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37653344/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230909205145&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-08-31T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[B cell maturation antigen (BCMA) target loss is considered to be a rare event that mediates multiple myeloma (MM) resistance to anti-BCMA chimeric antigen receptor T cell (CAR T) or bispecific T cell engager (TCE) therapies. Emerging data report that downregulation of G-protein-coupled receptor family C group 5 member D (GPRC5D) protein often occurs at relapse after anti-GPRC5D CAR T therapy. To examine the tumor-intrinsic factors that promote MM antigen escape, we performed combined bulk and...]]></summary>
        <author>
            <name>Holly Lee</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Molecular and clonal evolution <em>invivo</em> reveal a common pathway of distant relapse gliomas]]></title>
        <id>pubmed:37649695</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37649695/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230909205145&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-08-31T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[The evolutionary trajectories of genomic alterations underlying distant recurrence in glioma remain largely unknown. To elucidate glioma evolution, we analyzed the evolutionary trajectories of matched pairs of primary tumors and relapse tumors or tumor in situ fluid (TISF) based on deep whole-genome sequencing data (ctDNA). We found that MMR gene mutations occurred in the late stage in IDH-mutant glioma during gene evolution, which activates multiple signaling pathways and significantly...]]></summary>
        <author>
            <name>Guanzheng Liu</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Mechanisms of antigen escape from BCMA- or GPRC5D-targeted immunotherapies in multiple myeloma]]></title>
        <id>pubmed:37653344</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37653344/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230908204701&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-08-31T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[B cell maturation antigen (BCMA) target loss is considered to be a rare event that mediates multiple myeloma (MM) resistance to anti-BCMA chimeric antigen receptor T cell (CAR T) or bispecific T cell engager (TCE) therapies. Emerging data report that downregulation of G-protein-coupled receptor family C group 5 member D (GPRC5D) protein often occurs at relapse after anti-GPRC5D CAR T therapy. To examine the tumor-intrinsic factors that promote MM antigen escape, we performed combined bulk and...]]></summary>
        <author>
            <name>Holly Lee</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Molecular and clonal evolution <em>invivo</em> reveal a common pathway of distant relapse gliomas]]></title>
        <id>pubmed:37649695</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37649695/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230908204701&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-08-31T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[The evolutionary trajectories of genomic alterations underlying distant recurrence in glioma remain largely unknown. To elucidate glioma evolution, we analyzed the evolutionary trajectories of matched pairs of primary tumors and relapse tumors or tumor in situ fluid (TISF) based on deep whole-genome sequencing data (ctDNA). We found that MMR gene mutations occurred in the late stage in IDH-mutant glioma during gene evolution, which activates multiple signaling pathways and significantly...]]></summary>
        <author>
            <name>Guanzheng Liu</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Mechanisms of antigen escape from BCMA- or GPRC5D-targeted immunotherapies in multiple myeloma]]></title>
        <id>pubmed:37653344</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37653344/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230907204816&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-08-31T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[B cell maturation antigen (BCMA) target loss is considered to be a rare event that mediates multiple myeloma (MM) resistance to anti-BCMA chimeric antigen receptor T cell (CAR T) or bispecific T cell engager (TCE) therapies. Emerging data report that downregulation of G-protein-coupled receptor family C group 5 member D (GPRC5D) protein often occurs at relapse after anti-GPRC5D CAR T therapy. To examine the tumor-intrinsic factors that promote MM antigen escape, we performed combined bulk and...]]></summary>
        <author>
            <name>Holly Lee</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Molecular and clonal evolution <em>invivo</em> reveal a common pathway of distant relapse gliomas]]></title>
        <id>pubmed:37649695</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37649695/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230907204816&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-08-31T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[The evolutionary trajectories of genomic alterations underlying distant recurrence in glioma remain largely unknown. To elucidate glioma evolution, we analyzed the evolutionary trajectories of matched pairs of primary tumors and relapse tumors or tumor in situ fluid (TISF) based on deep whole-genome sequencing data (ctDNA). We found that MMR gene mutations occurred in the late stage in IDH-mutant glioma during gene evolution, which activates multiple signaling pathways and significantly...]]></summary>
        <author>
            <name>Guanzheng Liu</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Mechanisms of antigen escape from BCMA- or GPRC5D-targeted immunotherapies in multiple myeloma]]></title>
        <id>pubmed:37653344</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37653344/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230906204801&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-08-31T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[B cell maturation antigen (BCMA) target loss is considered to be a rare event that mediates multiple myeloma (MM) resistance to anti-BCMA chimeric antigen receptor T cell (CAR T) or bispecific T cell engager (TCE) therapies. Emerging data report that downregulation of G-protein-coupled receptor family C group 5 member D (GPRC5D) protein often occurs at relapse after anti-GPRC5D CAR T therapy. To examine the tumor-intrinsic factors that promote MM antigen escape, we performed combined bulk and...]]></summary>
        <author>
            <name>Holly Lee</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Molecular and clonal evolution <em>invivo</em> reveal a common pathway of distant relapse gliomas]]></title>
        <id>pubmed:37649695</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37649695/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230906204801&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-08-31T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[The evolutionary trajectories of genomic alterations underlying distant recurrence in glioma remain largely unknown. To elucidate glioma evolution, we analyzed the evolutionary trajectories of matched pairs of primary tumors and relapse tumors or tumor in situ fluid (TISF) based on deep whole-genome sequencing data (ctDNA). We found that MMR gene mutations occurred in the late stage in IDH-mutant glioma during gene evolution, which activates multiple signaling pathways and significantly...]]></summary>
        <author>
            <name>Guanzheng Liu</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Mechanisms of antigen escape from BCMA- or GPRC5D-targeted immunotherapies in multiple myeloma]]></title>
        <id>pubmed:37653344</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37653344/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230905204848&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-08-31T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[B cell maturation antigen (BCMA) target loss is considered to be a rare event that mediates multiple myeloma (MM) resistance to anti-BCMA chimeric antigen receptor T cell (CAR T) or bispecific T cell engager (TCE) therapies. Emerging data report that downregulation of G-protein-coupled receptor family C group 5 member D (GPRC5D) protein often occurs at relapse after anti-GPRC5D CAR T therapy. To examine the tumor-intrinsic factors that promote MM antigen escape, we performed combined bulk and...]]></summary>
        <author>
            <name>Holly Lee</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Molecular and clonal evolution <em>invivo</em> reveal a common pathway of distant relapse gliomas]]></title>
        <id>pubmed:37649695</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37649695/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230905204848&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-08-31T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[The evolutionary trajectories of genomic alterations underlying distant recurrence in glioma remain largely unknown. To elucidate glioma evolution, we analyzed the evolutionary trajectories of matched pairs of primary tumors and relapse tumors or tumor in situ fluid (TISF) based on deep whole-genome sequencing data (ctDNA). We found that MMR gene mutations occurred in the late stage in IDH-mutant glioma during gene evolution, which activates multiple signaling pathways and significantly...]]></summary>
        <author>
            <name>Guanzheng Liu</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Mechanisms of antigen escape from BCMA- or GPRC5D-targeted immunotherapies in multiple myeloma]]></title>
        <id>pubmed:37653344</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37653344/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230904204751&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-08-31T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[B cell maturation antigen (BCMA) target loss is considered to be a rare event that mediates multiple myeloma (MM) resistance to anti-BCMA chimeric antigen receptor T cell (CAR T) or bispecific T cell engager (TCE) therapies. Emerging data report that downregulation of G-protein-coupled receptor family C group 5 member D (GPRC5D) protein often occurs at relapse after anti-GPRC5D CAR T therapy. To examine the tumor-intrinsic factors that promote MM antigen escape, we performed combined bulk and...]]></summary>
        <author>
            <name>Holly Lee</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Molecular and clonal evolution <em>invivo</em> reveal a common pathway of distant relapse gliomas]]></title>
        <id>pubmed:37649695</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37649695/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230904204751&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-08-31T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[The evolutionary trajectories of genomic alterations underlying distant recurrence in glioma remain largely unknown. To elucidate glioma evolution, we analyzed the evolutionary trajectories of matched pairs of primary tumors and relapse tumors or tumor in situ fluid (TISF) based on deep whole-genome sequencing data (ctDNA). We found that MMR gene mutations occurred in the late stage in IDH-mutant glioma during gene evolution, which activates multiple signaling pathways and significantly...]]></summary>
        <author>
            <name>Guanzheng Liu</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Mechanisms of antigen escape from BCMA- or GPRC5D-targeted immunotherapies in multiple myeloma]]></title>
        <id>pubmed:37653344</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37653344/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230903204939&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-08-31T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[B cell maturation antigen (BCMA) target loss is considered to be a rare event that mediates multiple myeloma (MM) resistance to anti-BCMA chimeric antigen receptor T cell (CAR T) or bispecific T cell engager (TCE) therapies. Emerging data report that downregulation of G-protein-coupled receptor family C group 5 member D (GPRC5D) protein often occurs at relapse after anti-GPRC5D CAR T therapy. To examine the tumor-intrinsic factors that promote MM antigen escape, we performed combined bulk and...]]></summary>
        <author>
            <name>Holly Lee</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Molecular and clonal evolution <em>invivo</em> reveal a common pathway of distant relapse gliomas]]></title>
        <id>pubmed:37649695</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37649695/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230903204939&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-08-31T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[The evolutionary trajectories of genomic alterations underlying distant recurrence in glioma remain largely unknown. To elucidate glioma evolution, we analyzed the evolutionary trajectories of matched pairs of primary tumors and relapse tumors or tumor in situ fluid (TISF) based on deep whole-genome sequencing data (ctDNA). We found that MMR gene mutations occurred in the late stage in IDH-mutant glioma during gene evolution, which activates multiple signaling pathways and significantly...]]></summary>
        <author>
            <name>Guanzheng Liu</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Mechanisms of antigen escape from BCMA- or GPRC5D-targeted immunotherapies in multiple myeloma]]></title>
        <id>pubmed:37653344</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37653344/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230902205121&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-08-31T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[B cell maturation antigen (BCMA) target loss is considered to be a rare event that mediates multiple myeloma (MM) resistance to anti-BCMA chimeric antigen receptor T cell (CAR T) or bispecific T cell engager (TCE) therapies. Emerging data report that downregulation of G-protein-coupled receptor family C group 5 member D (GPRC5D) protein often occurs at relapse after anti-GPRC5D CAR T therapy. To examine the tumor-intrinsic factors that promote MM antigen escape, we performed combined bulk and...]]></summary>
        <author>
            <name>Holly Lee</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Molecular and clonal evolution <em>invivo</em> reveal a common pathway of distant relapse gliomas]]></title>
        <id>pubmed:37649695</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37649695/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230902205121&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-08-31T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[The evolutionary trajectories of genomic alterations underlying distant recurrence in glioma remain largely unknown. To elucidate glioma evolution, we analyzed the evolutionary trajectories of matched pairs of primary tumors and relapse tumors or tumor in situ fluid (TISF) based on deep whole-genome sequencing data (ctDNA). We found that MMR gene mutations occurred in the late stage in IDH-mutant glioma during gene evolution, which activates multiple signaling pathways and significantly...]]></summary>
        <author>
            <name>Guanzheng Liu</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Mechanisms of antigen escape from BCMA- or GPRC5D-targeted immunotherapies in multiple myeloma]]></title>
        <id>pubmed:37653344</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37653344/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230901204619&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-08-31T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[B cell maturation antigen (BCMA) target loss is considered to be a rare event that mediates multiple myeloma (MM) resistance to anti-BCMA chimeric antigen receptor T cell (CAR T) or bispecific T cell engager (TCE) therapies. Emerging data report that downregulation of G-protein-coupled receptor family C group 5 member D (GPRC5D) protein often occurs at relapse after anti-GPRC5D CAR T therapy. To examine the tumor-intrinsic factors that promote MM antigen escape, we performed combined bulk and...]]></summary>
        <author>
            <name>Holly Lee</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Molecular and clonal evolution <em>invivo</em> reveal a common pathway of distant relapse gliomas]]></title>
        <id>pubmed:37649695</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37649695/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230901204619&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-08-31T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[The evolutionary trajectories of genomic alterations underlying distant recurrence in glioma remain largely unknown. To elucidate glioma evolution, we analyzed the evolutionary trajectories of matched pairs of primary tumors and relapse tumors or tumor in situ fluid (TISF) based on deep whole-genome sequencing data (ctDNA). We found that MMR gene mutations occurred in the late stage in IDH-mutant glioma during gene evolution, which activates multiple signaling pathways and significantly...]]></summary>
        <author>
            <name>Guanzheng Liu</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Molecular and clonal evolution <em>invivo</em> reveal a common pathway of distant relapse gliomas]]></title>
        <id>pubmed:37649695</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37649695/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230831205203&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-08-31T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[The evolutionary trajectories of genomic alterations underlying distant recurrence in glioma remain largely unknown. To elucidate glioma evolution, we analyzed the evolutionary trajectories of matched pairs of primary tumors and relapse tumors or tumor in situ fluid (TISF) based on deep whole-genome sequencing data (ctDNA). We found that MMR gene mutations occurred in the late stage in IDH-mutant glioma during gene evolution, which activates multiple signaling pathways and significantly...]]></summary>
        <author>
            <name>Guanzheng Liu</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Cytotoxic peripheral T-cell lymphomas and EBV-positive T/NK-cell lymphoproliferative diseases: emerging concepts, recent advances, and the putative role of clonal hematopoiesis. A report of the 2022 EA4HP/SH lymphoma workshop]]></title>
        <id>pubmed:37646869</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37646869/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230919204929&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-08-30T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Cytotoxic peripheral T-cell lymphomas and EBV-positive T/NK-cell lymphoproliferative diseases were discussed at the 2022 European Association for Haematopathology/Society for Hematopathology lymphoma workshop held in Florence, Italy. This session focused on (i) primary nodal EBV-positive T and NK-cell lymphomas (primary nodal-EBV-TNKL), (ii) extranodal EBV-positive T/NK lymphoproliferative diseases (LPD) in children and adults, (iii) cytotoxic peripheral T-cell lymphomas, NOS (cPTCL-NOS),...]]></summary>
        <author>
            <name>Fina Climent</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Cytotoxic peripheral T-cell lymphomas and EBV-positive T/NK-cell lymphoproliferative diseases: emerging concepts, recent advances, and the putative role of clonal hematopoiesis. A report of the 2022 EA4HP/SH lymphoma workshop]]></title>
        <id>pubmed:37646869</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37646869/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230918204942&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-08-30T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Cytotoxic peripheral T-cell lymphomas and EBV-positive T/NK-cell lymphoproliferative diseases were discussed at the 2022 European Association for Haematopathology/Society for Hematopathology lymphoma workshop held in Florence, Italy. This session focused on (i) primary nodal EBV-positive T and NK-cell lymphomas (primary nodal-EBV-TNKL), (ii) extranodal EBV-positive T/NK lymphoproliferative diseases (LPD) in children and adults, (iii) cytotoxic peripheral T-cell lymphomas, NOS (cPTCL-NOS),...]]></summary>
        <author>
            <name>Fina Climent</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Cytotoxic peripheral T-cell lymphomas and EBV-positive T/NK-cell lymphoproliferative diseases: emerging concepts, recent advances, and the putative role of clonal hematopoiesis. A report of the 2022 EA4HP/SH lymphoma workshop]]></title>
        <id>pubmed:37646869</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37646869/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230917204935&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-08-30T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Cytotoxic peripheral T-cell lymphomas and EBV-positive T/NK-cell lymphoproliferative diseases were discussed at the 2022 European Association for Haematopathology/Society for Hematopathology lymphoma workshop held in Florence, Italy. This session focused on (i) primary nodal EBV-positive T and NK-cell lymphomas (primary nodal-EBV-TNKL), (ii) extranodal EBV-positive T/NK lymphoproliferative diseases (LPD) in children and adults, (iii) cytotoxic peripheral T-cell lymphomas, NOS (cPTCL-NOS),...]]></summary>
        <author>
            <name>Fina Climent</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Cytotoxic peripheral T-cell lymphomas and EBV-positive T/NK-cell lymphoproliferative diseases: emerging concepts, recent advances, and the putative role of clonal hematopoiesis. A report of the 2022 EA4HP/SH lymphoma workshop]]></title>
        <id>pubmed:37646869</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37646869/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230916205201&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-08-30T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Cytotoxic peripheral T-cell lymphomas and EBV-positive T/NK-cell lymphoproliferative diseases were discussed at the 2022 European Association for Haematopathology/Society for Hematopathology lymphoma workshop held in Florence, Italy. This session focused on (i) primary nodal EBV-positive T and NK-cell lymphomas (primary nodal-EBV-TNKL), (ii) extranodal EBV-positive T/NK lymphoproliferative diseases (LPD) in children and adults, (iii) cytotoxic peripheral T-cell lymphomas, NOS (cPTCL-NOS),...]]></summary>
        <author>
            <name>Fina Climent</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Prognostic relevance of clonal hematopoiesis in myeloid neoplastic transformation in patients with follicular lymphoma treated with radioimmunotherapy]]></title>
        <id>pubmed:37646653</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37646653/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230916205201&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-08-30T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[While novel radioisotope therapies continue to advance cancer care, reports of therapy-related myeloid neoplasms (t-MN) have generated concern. The prevalence and role of clonal hematopoiesis (CH) in this process remain to be defined. We hypothesized that (1) CH is prevalent in relapsed follicular lymphoma (FL) and is associated with t-MN transformation. (2) Radiation in the form of radioimmunotherapy (RIT) plays a role in clonal progression. In this retrospective cohort study, we evaluated the...]]></summary>
        <author>
            <name>Zhuoer Xie</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Cytotoxic peripheral T-cell lymphomas and EBV-positive T/NK-cell lymphoproliferative diseases: emerging concepts, recent advances, and the putative role of clonal hematopoiesis. A report of the 2022 EA4HP/SH lymphoma workshop]]></title>
        <id>pubmed:37646869</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37646869/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230915204741&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-08-30T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Cytotoxic peripheral T-cell lymphomas and EBV-positive T/NK-cell lymphoproliferative diseases were discussed at the 2022 European Association for Haematopathology/Society for Hematopathology lymphoma workshop held in Florence, Italy. This session focused on (i) primary nodal EBV-positive T and NK-cell lymphomas (primary nodal-EBV-TNKL), (ii) extranodal EBV-positive T/NK lymphoproliferative diseases (LPD) in children and adults, (iii) cytotoxic peripheral T-cell lymphomas, NOS (cPTCL-NOS),...]]></summary>
        <author>
            <name>Fina Climent</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Prognostic relevance of clonal hematopoiesis in myeloid neoplastic transformation in patients with follicular lymphoma treated with radioimmunotherapy]]></title>
        <id>pubmed:37646653</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37646653/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230915204741&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-08-30T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[While novel radioisotope therapies continue to advance cancer care, reports of therapy-related myeloid neoplasms (t-MN) have generated concern. The prevalence and role of clonal hematopoiesis (CH) in this process remain to be defined. We hypothesized that (1) CH is prevalent in relapsed follicular lymphoma (FL) and is associated with t-MN transformation. (2) Radiation in the form of radioimmunotherapy (RIT) plays a role in clonal progression. In this retrospective cohort study, we evaluated the...]]></summary>
        <author>
            <name>Zhuoer Xie</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Cytotoxic peripheral T-cell lymphomas and EBV-positive T/NK-cell lymphoproliferative diseases: emerging concepts, recent advances, and the putative role of clonal hematopoiesis. A report of the 2022 EA4HP/SH lymphoma workshop]]></title>
        <id>pubmed:37646869</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37646869/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230914204950&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-08-30T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Cytotoxic peripheral T-cell lymphomas and EBV-positive T/NK-cell lymphoproliferative diseases were discussed at the 2022 European Association for Haematopathology/Society for Hematopathology lymphoma workshop held in Florence, Italy. This session focused on (i) primary nodal EBV-positive T and NK-cell lymphomas (primary nodal-EBV-TNKL), (ii) extranodal EBV-positive T/NK lymphoproliferative diseases (LPD) in children and adults, (iii) cytotoxic peripheral T-cell lymphomas, NOS (cPTCL-NOS),...]]></summary>
        <author>
            <name>Fina Climent</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Prognostic relevance of clonal hematopoiesis in myeloid neoplastic transformation in patients with follicular lymphoma treated with radioimmunotherapy]]></title>
        <id>pubmed:37646653</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37646653/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230914204950&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-08-30T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[While novel radioisotope therapies continue to advance cancer care, reports of therapy-related myeloid neoplasms (t-MN) have generated concern. The prevalence and role of clonal hematopoiesis (CH) in this process remain to be defined. We hypothesized that (1) CH is prevalent in relapsed follicular lymphoma (FL) and is associated with t-MN transformation. (2) Radiation in the form of radioimmunotherapy (RIT) plays a role in clonal progression. In this retrospective cohort study, we evaluated the...]]></summary>
        <author>
            <name>Zhuoer Xie</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Cytotoxic peripheral T-cell lymphomas and EBV-positive T/NK-cell lymphoproliferative diseases: emerging concepts, recent advances, and the putative role of clonal hematopoiesis. A report of the 2022 EA4HP/SH lymphoma workshop]]></title>
        <id>pubmed:37646869</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37646869/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230913204840&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-08-30T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Cytotoxic peripheral T-cell lymphomas and EBV-positive T/NK-cell lymphoproliferative diseases were discussed at the 2022 European Association for Haematopathology/Society for Hematopathology lymphoma workshop held in Florence, Italy. This session focused on (i) primary nodal EBV-positive T and NK-cell lymphomas (primary nodal-EBV-TNKL), (ii) extranodal EBV-positive T/NK lymphoproliferative diseases (LPD) in children and adults, (iii) cytotoxic peripheral T-cell lymphomas, NOS (cPTCL-NOS),...]]></summary>
        <author>
            <name>Fina Climent</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Prognostic relevance of clonal hematopoiesis in myeloid neoplastic transformation in patients with follicular lymphoma treated with radioimmunotherapy]]></title>
        <id>pubmed:37646653</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37646653/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230913204840&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-08-30T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[While novel radioisotope therapies continue to advance cancer care, reports of therapy-related myeloid neoplasms (t-MN) have generated concern. The prevalence and role of clonal hematopoiesis (CH) in this process remain to be defined. We hypothesized that (1) CH is prevalent in relapsed follicular lymphoma (FL) and is associated with t-MN transformation. (2) Radiation in the form of radioimmunotherapy (RIT) plays a role in clonal progression. In this retrospective cohort study, we evaluated the...]]></summary>
        <author>
            <name>Zhuoer Xie</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Cytotoxic peripheral T-cell lymphomas and EBV-positive T/NK-cell lymphoproliferative diseases: emerging concepts, recent advances, and the putative role of clonal hematopoiesis. A report of the 2022 EA4HP/SH lymphoma workshop]]></title>
        <id>pubmed:37646869</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37646869/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230912205016&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-08-30T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Cytotoxic peripheral T-cell lymphomas and EBV-positive T/NK-cell lymphoproliferative diseases were discussed at the 2022 European Association for Haematopathology/Society for Hematopathology lymphoma workshop held in Florence, Italy. This session focused on (i) primary nodal EBV-positive T and NK-cell lymphomas (primary nodal-EBV-TNKL), (ii) extranodal EBV-positive T/NK lymphoproliferative diseases (LPD) in children and adults, (iii) cytotoxic peripheral T-cell lymphomas, NOS (cPTCL-NOS),...]]></summary>
        <author>
            <name>Fina Climent</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Prognostic relevance of clonal hematopoiesis in myeloid neoplastic transformation in patients with follicular lymphoma treated with radioimmunotherapy]]></title>
        <id>pubmed:37646653</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37646653/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230912205016&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-08-30T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[While novel radioisotope therapies continue to advance cancer care, reports of therapy-related myeloid neoplasms (t-MN) have generated concern. The prevalence and role of clonal hematopoiesis (CH) in this process remain to be defined. We hypothesized that (1) CH is prevalent in relapsed follicular lymphoma (FL) and is associated with t-MN transformation. (2) Radiation in the form of radioimmunotherapy (RIT) plays a role in clonal progression. In this retrospective cohort study, we evaluated the...]]></summary>
        <author>
            <name>Zhuoer Xie</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Cytotoxic peripheral T-cell lymphomas and EBV-positive T/NK-cell lymphoproliferative diseases: emerging concepts, recent advances, and the putative role of clonal hematopoiesis. A report of the 2022 EA4HP/SH lymphoma workshop]]></title>
        <id>pubmed:37646869</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37646869/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230911204717&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-08-30T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Cytotoxic peripheral T-cell lymphomas and EBV-positive T/NK-cell lymphoproliferative diseases were discussed at the 2022 European Association for Haematopathology/Society for Hematopathology lymphoma workshop held in Florence, Italy. This session focused on (i) primary nodal EBV-positive T and NK-cell lymphomas (primary nodal-EBV-TNKL), (ii) extranodal EBV-positive T/NK lymphoproliferative diseases (LPD) in children and adults, (iii) cytotoxic peripheral T-cell lymphomas, NOS (cPTCL-NOS),...]]></summary>
        <author>
            <name>Fina Climent</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Prognostic relevance of clonal hematopoiesis in myeloid neoplastic transformation in patients with follicular lymphoma treated with radioimmunotherapy]]></title>
        <id>pubmed:37646653</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37646653/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230911204717&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-08-30T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[While novel radioisotope therapies continue to advance cancer care, reports of therapy-related myeloid neoplasms (t-MN) have generated concern. The prevalence and role of clonal hematopoiesis (CH) in this process remain to be defined. We hypothesized that (1) CH is prevalent in relapsed follicular lymphoma (FL) and is associated with t-MN transformation. (2) Radiation in the form of radioimmunotherapy (RIT) plays a role in clonal progression. In this retrospective cohort study, we evaluated the...]]></summary>
        <author>
            <name>Zhuoer Xie</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Cytotoxic peripheral T-cell lymphomas and EBV-positive T/NK-cell lymphoproliferative diseases: emerging concepts, recent advances, and the putative role of clonal hematopoiesis. A report of the 2022 EA4HP/SH lymphoma workshop]]></title>
        <id>pubmed:37646869</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37646869/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230910204912&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-08-30T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Cytotoxic peripheral T-cell lymphomas and EBV-positive T/NK-cell lymphoproliferative diseases were discussed at the 2022 European Association for Haematopathology/Society for Hematopathology lymphoma workshop held in Florence, Italy. This session focused on (i) primary nodal EBV-positive T and NK-cell lymphomas (primary nodal-EBV-TNKL), (ii) extranodal EBV-positive T/NK lymphoproliferative diseases (LPD) in children and adults, (iii) cytotoxic peripheral T-cell lymphomas, NOS (cPTCL-NOS),...]]></summary>
        <author>
            <name>Fina Climent</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Prognostic relevance of clonal hematopoiesis in myeloid neoplastic transformation in patients with follicular lymphoma treated with radioimmunotherapy]]></title>
        <id>pubmed:37646653</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37646653/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230910204912&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-08-30T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[While novel radioisotope therapies continue to advance cancer care, reports of therapy-related myeloid neoplasms (t-MN) have generated concern. The prevalence and role of clonal hematopoiesis (CH) in this process remain to be defined. We hypothesized that (1) CH is prevalent in relapsed follicular lymphoma (FL) and is associated with t-MN transformation. (2) Radiation in the form of radioimmunotherapy (RIT) plays a role in clonal progression. In this retrospective cohort study, we evaluated the...]]></summary>
        <author>
            <name>Zhuoer Xie</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Cytotoxic peripheral T-cell lymphomas and EBV-positive T/NK-cell lymphoproliferative diseases: emerging concepts, recent advances, and the putative role of clonal hematopoiesis. A report of the 2022 EA4HP/SH lymphoma workshop]]></title>
        <id>pubmed:37646869</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37646869/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230909205145&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-08-30T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Cytotoxic peripheral T-cell lymphomas and EBV-positive T/NK-cell lymphoproliferative diseases were discussed at the 2022 European Association for Haematopathology/Society for Hematopathology lymphoma workshop held in Florence, Italy. This session focused on (i) primary nodal EBV-positive T and NK-cell lymphomas (primary nodal-EBV-TNKL), (ii) extranodal EBV-positive T/NK lymphoproliferative diseases (LPD) in children and adults, (iii) cytotoxic peripheral T-cell lymphomas, NOS (cPTCL-NOS),...]]></summary>
        <author>
            <name>Fina Climent</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Prognostic relevance of clonal hematopoiesis in myeloid neoplastic transformation in patients with follicular lymphoma treated with radioimmunotherapy]]></title>
        <id>pubmed:37646653</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37646653/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230909205145&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-08-30T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[While novel radioisotope therapies continue to advance cancer care, reports of therapy-related myeloid neoplasms (t-MN) have generated concern. The prevalence and role of clonal hematopoiesis (CH) in this process remain to be defined. We hypothesized that (1) CH is prevalent in relapsed follicular lymphoma (FL) and is associated with t-MN transformation. (2) Radiation in the form of radioimmunotherapy (RIT) plays a role in clonal progression. In this retrospective cohort study, we evaluated the...]]></summary>
        <author>
            <name>Zhuoer Xie</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Cytotoxic peripheral T-cell lymphomas and EBV-positive T/NK-cell lymphoproliferative diseases: emerging concepts, recent advances, and the putative role of clonal hematopoiesis. A report of the 2022 EA4HP/SH lymphoma workshop]]></title>
        <id>pubmed:37646869</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37646869/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230908204701&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-08-30T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Cytotoxic peripheral T-cell lymphomas and EBV-positive T/NK-cell lymphoproliferative diseases were discussed at the 2022 European Association for Haematopathology/Society for Hematopathology lymphoma workshop held in Florence, Italy. This session focused on (i) primary nodal EBV-positive T and NK-cell lymphomas (primary nodal-EBV-TNKL), (ii) extranodal EBV-positive T/NK lymphoproliferative diseases (LPD) in children and adults, (iii) cytotoxic peripheral T-cell lymphomas, NOS (cPTCL-NOS),...]]></summary>
        <author>
            <name>Fina Climent</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Prognostic relevance of clonal hematopoiesis in myeloid neoplastic transformation in patients with follicular lymphoma treated with radioimmunotherapy]]></title>
        <id>pubmed:37646653</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37646653/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230908204701&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-08-30T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[While novel radioisotope therapies continue to advance cancer care, reports of therapy-related myeloid neoplasms (t-MN) have generated concern. The prevalence and role of clonal hematopoiesis (CH) in this process remain to be defined. We hypothesized that (1) CH is prevalent in relapsed follicular lymphoma (FL) and is associated with t-MN transformation. (2) Radiation in the form of radioimmunotherapy (RIT) plays a role in clonal progression. In this retrospective cohort study, we evaluated the...]]></summary>
        <author>
            <name>Zhuoer Xie</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Cytotoxic peripheral T-cell lymphomas and EBV-positive T/NK-cell lymphoproliferative diseases: emerging concepts, recent advances, and the putative role of clonal hematopoiesis. A report of the 2022 EA4HP/SH lymphoma workshop]]></title>
        <id>pubmed:37646869</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37646869/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230907204816&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-08-30T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Cytotoxic peripheral T-cell lymphomas and EBV-positive T/NK-cell lymphoproliferative diseases were discussed at the 2022 European Association for Haematopathology/Society for Hematopathology lymphoma workshop held in Florence, Italy. This session focused on (i) primary nodal EBV-positive T and NK-cell lymphomas (primary nodal-EBV-TNKL), (ii) extranodal EBV-positive T/NK lymphoproliferative diseases (LPD) in children and adults, (iii) cytotoxic peripheral T-cell lymphomas, NOS (cPTCL-NOS),...]]></summary>
        <author>
            <name>Fina Climent</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Prognostic relevance of clonal hematopoiesis in myeloid neoplastic transformation in patients with follicular lymphoma treated with radioimmunotherapy]]></title>
        <id>pubmed:37646653</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37646653/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230907204816&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-08-30T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[While novel radioisotope therapies continue to advance cancer care, reports of therapy-related myeloid neoplasms (t-MN) have generated concern. The prevalence and role of clonal hematopoiesis (CH) in this process remain to be defined. We hypothesized that (1) CH is prevalent in relapsed follicular lymphoma (FL) and is associated with t-MN transformation. (2) Radiation in the form of radioimmunotherapy (RIT) plays a role in clonal progression. In this retrospective cohort study, we evaluated the...]]></summary>
        <author>
            <name>Zhuoer Xie</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Cytotoxic peripheral T-cell lymphomas and EBV-positive T/NK-cell lymphoproliferative diseases: emerging concepts, recent advances, and the putative role of clonal hematopoiesis. A report of the 2022 EA4HP/SH lymphoma workshop]]></title>
        <id>pubmed:37646869</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37646869/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230906204801&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-08-30T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Cytotoxic peripheral T-cell lymphomas and EBV-positive T/NK-cell lymphoproliferative diseases were discussed at the 2022 European Association for Haematopathology/Society for Hematopathology lymphoma workshop held in Florence, Italy. This session focused on (i) primary nodal EBV-positive T and NK-cell lymphomas (primary nodal-EBV-TNKL), (ii) extranodal EBV-positive T/NK lymphoproliferative diseases (LPD) in children and adults, (iii) cytotoxic peripheral T-cell lymphomas, NOS (cPTCL-NOS),...]]></summary>
        <author>
            <name>Fina Climent</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Prognostic relevance of clonal hematopoiesis in myeloid neoplastic transformation in patients with follicular lymphoma treated with radioimmunotherapy]]></title>
        <id>pubmed:37646653</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37646653/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230906204801&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-08-30T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[While novel radioisotope therapies continue to advance cancer care, reports of therapy-related myeloid neoplasms (t-MN) have generated concern. The prevalence and role of clonal hematopoiesis (CH) in this process remain to be defined. We hypothesized that (1) CH is prevalent in relapsed follicular lymphoma (FL) and is associated with t-MN transformation. (2) Radiation in the form of radioimmunotherapy (RIT) plays a role in clonal progression. In this retrospective cohort study, we evaluated the...]]></summary>
        <author>
            <name>Zhuoer Xie</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Cytotoxic peripheral T-cell lymphomas and EBV-positive T/NK-cell lymphoproliferative diseases: emerging concepts, recent advances, and the putative role of clonal hematopoiesis. A report of the 2022 EA4HP/SH lymphoma workshop]]></title>
        <id>pubmed:37646869</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37646869/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230905204848&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-08-30T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Cytotoxic peripheral T-cell lymphomas and EBV-positive T/NK-cell lymphoproliferative diseases were discussed at the 2022 European Association for Haematopathology/Society for Hematopathology lymphoma workshop held in Florence, Italy. This session focused on (i) primary nodal EBV-positive T and NK-cell lymphomas (primary nodal-EBV-TNKL), (ii) extranodal EBV-positive T/NK lymphoproliferative diseases (LPD) in children and adults, (iii) cytotoxic peripheral T-cell lymphomas, NOS (cPTCL-NOS),...]]></summary>
        <author>
            <name>Fina Climent</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Prognostic relevance of clonal hematopoiesis in myeloid neoplastic transformation in patients with follicular lymphoma treated with radioimmunotherapy]]></title>
        <id>pubmed:37646653</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37646653/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230905204848&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-08-30T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[While novel radioisotope therapies continue to advance cancer care, reports of therapy-related myeloid neoplasms (t-MN) have generated concern. The prevalence and role of clonal hematopoiesis (CH) in this process remain to be defined. We hypothesized that (1) CH is prevalent in relapsed follicular lymphoma (FL) and is associated with t-MN transformation. (2) Radiation in the form of radioimmunotherapy (RIT) plays a role in clonal progression. In this retrospective cohort study, we evaluated the...]]></summary>
        <author>
            <name>Zhuoer Xie</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Cytotoxic peripheral T-cell lymphomas and EBV-positive T/NK-cell lymphoproliferative diseases: emerging concepts, recent advances, and the putative role of clonal hematopoiesis. A report of the 2022 EA4HP/SH lymphoma workshop]]></title>
        <id>pubmed:37646869</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37646869/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230904204751&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-08-30T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Cytotoxic peripheral T-cell lymphomas and EBV-positive T/NK-cell lymphoproliferative diseases were discussed at the 2022 European Association for Haematopathology/Society for Hematopathology lymphoma workshop held in Florence, Italy. This session focused on (i) primary nodal EBV-positive T and NK-cell lymphomas (primary nodal-EBV-TNKL), (ii) extranodal EBV-positive T/NK lymphoproliferative diseases (LPD) in children and adults, (iii) cytotoxic peripheral T-cell lymphomas, NOS (cPTCL-NOS),...]]></summary>
        <author>
            <name>Fina Climent</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Prognostic relevance of clonal hematopoiesis in myeloid neoplastic transformation in patients with follicular lymphoma treated with radioimmunotherapy]]></title>
        <id>pubmed:37646653</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37646653/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230904204751&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-08-30T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[While novel radioisotope therapies continue to advance cancer care, reports of therapy-related myeloid neoplasms (t-MN) have generated concern. The prevalence and role of clonal hematopoiesis (CH) in this process remain to be defined. We hypothesized that (1) CH is prevalent in relapsed follicular lymphoma (FL) and is associated with t-MN transformation. (2) Radiation in the form of radioimmunotherapy (RIT) plays a role in clonal progression. In this retrospective cohort study, we evaluated the...]]></summary>
        <author>
            <name>Zhuoer Xie</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Cytotoxic peripheral T-cell lymphomas and EBV-positive T/NK-cell lymphoproliferative diseases: emerging concepts, recent advances, and the putative role of clonal hematopoiesis. A report of the 2022 EA4HP/SH lymphoma workshop]]></title>
        <id>pubmed:37646869</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37646869/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230903204939&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-08-30T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Cytotoxic peripheral T-cell lymphomas and EBV-positive T/NK-cell lymphoproliferative diseases were discussed at the 2022 European Association for Haematopathology/Society for Hematopathology lymphoma workshop held in Florence, Italy. This session focused on (i) primary nodal EBV-positive T and NK-cell lymphomas (primary nodal-EBV-TNKL), (ii) extranodal EBV-positive T/NK lymphoproliferative diseases (LPD) in children and adults, (iii) cytotoxic peripheral T-cell lymphomas, NOS (cPTCL-NOS),...]]></summary>
        <author>
            <name>Fina Climent</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Prognostic relevance of clonal hematopoiesis in myeloid neoplastic transformation in patients with follicular lymphoma treated with radioimmunotherapy]]></title>
        <id>pubmed:37646653</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37646653/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230903204939&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-08-30T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[While novel radioisotope therapies continue to advance cancer care, reports of therapy-related myeloid neoplasms (t-MN) have generated concern. The prevalence and role of clonal hematopoiesis (CH) in this process remain to be defined. We hypothesized that (1) CH is prevalent in relapsed follicular lymphoma (FL) and is associated with t-MN transformation. (2) Radiation in the form of radioimmunotherapy (RIT) plays a role in clonal progression. In this retrospective cohort study, we evaluated the...]]></summary>
        <author>
            <name>Zhuoer Xie</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Cytotoxic peripheral T-cell lymphomas and EBV-positive T/NK-cell lymphoproliferative diseases: emerging concepts, recent advances, and the putative role of clonal hematopoiesis. A report of the 2022 EA4HP/SH lymphoma workshop]]></title>
        <id>pubmed:37646869</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37646869/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230902205121&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-08-30T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Cytotoxic peripheral T-cell lymphomas and EBV-positive T/NK-cell lymphoproliferative diseases were discussed at the 2022 European Association for Haematopathology/Society for Hematopathology lymphoma workshop held in Florence, Italy. This session focused on (i) primary nodal EBV-positive T and NK-cell lymphomas (primary nodal-EBV-TNKL), (ii) extranodal EBV-positive T/NK lymphoproliferative diseases (LPD) in children and adults, (iii) cytotoxic peripheral T-cell lymphomas, NOS (cPTCL-NOS),...]]></summary>
        <author>
            <name>Fina Climent</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Prognostic relevance of clonal hematopoiesis in myeloid neoplastic transformation in patients with follicular lymphoma treated with radioimmunotherapy]]></title>
        <id>pubmed:37646653</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37646653/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230902205121&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-08-30T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[While novel radioisotope therapies continue to advance cancer care, reports of therapy-related myeloid neoplasms (t-MN) have generated concern. The prevalence and role of clonal hematopoiesis (CH) in this process remain to be defined. We hypothesized that (1) CH is prevalent in relapsed follicular lymphoma (FL) and is associated with t-MN transformation. (2) Radiation in the form of radioimmunotherapy (RIT) plays a role in clonal progression. In this retrospective cohort study, we evaluated the...]]></summary>
        <author>
            <name>Zhuoer Xie</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Cytotoxic peripheral T-cell lymphomas and EBV-positive T/NK-cell lymphoproliferative diseases: emerging concepts, recent advances, and the putative role of clonal hematopoiesis. A report of the 2022 EA4HP/SH lymphoma workshop]]></title>
        <id>pubmed:37646869</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37646869/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230901204619&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-08-30T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Cytotoxic peripheral T-cell lymphomas and EBV-positive T/NK-cell lymphoproliferative diseases were discussed at the 2022 European Association for Haematopathology/Society for Hematopathology lymphoma workshop held in Florence, Italy. This session focused on (i) primary nodal EBV-positive T and NK-cell lymphomas (primary nodal-EBV-TNKL), (ii) extranodal EBV-positive T/NK lymphoproliferative diseases (LPD) in children and adults, (iii) cytotoxic peripheral T-cell lymphomas, NOS (cPTCL-NOS),...]]></summary>
        <author>
            <name>Fina Climent</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Prognostic relevance of clonal hematopoiesis in myeloid neoplastic transformation in patients with follicular lymphoma treated with radioimmunotherapy]]></title>
        <id>pubmed:37646653</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37646653/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230901204619&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-08-30T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[While novel radioisotope therapies continue to advance cancer care, reports of therapy-related myeloid neoplasms (t-MN) have generated concern. The prevalence and role of clonal hematopoiesis (CH) in this process remain to be defined. We hypothesized that (1) CH is prevalent in relapsed follicular lymphoma (FL) and is associated with t-MN transformation. (2) Radiation in the form of radioimmunotherapy (RIT) plays a role in clonal progression. In this retrospective cohort study, we evaluated the...]]></summary>
        <author>
            <name>Zhuoer Xie</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Cytotoxic peripheral T-cell lymphomas and EBV-positive T/NK-cell lymphoproliferative diseases: emerging concepts, recent advances, and the putative role of clonal hematopoiesis. A report of the 2022 EA4HP/SH lymphoma workshop]]></title>
        <id>pubmed:37646869</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37646869/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230831205203&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-08-30T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Cytotoxic peripheral T-cell lymphomas and EBV-positive T/NK-cell lymphoproliferative diseases were discussed at the 2022 European Association for Haematopathology/Society for Hematopathology lymphoma workshop held in Florence, Italy. This session focused on (i) primary nodal EBV-positive T and NK-cell lymphomas (primary nodal-EBV-TNKL), (ii) extranodal EBV-positive T/NK lymphoproliferative diseases (LPD) in children and adults, (iii) cytotoxic peripheral T-cell lymphomas, NOS (cPTCL-NOS),...]]></summary>
        <author>
            <name>Fina Climent</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Prognostic relevance of clonal hematopoiesis in myeloid neoplastic transformation in patients with follicular lymphoma treated with radioimmunotherapy]]></title>
        <id>pubmed:37646653</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37646653/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230831205203&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-08-30T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[While novel radioisotope therapies continue to advance cancer care, reports of therapy-related myeloid neoplasms (t-MN) have generated concern. The prevalence and role of clonal hematopoiesis (CH) in this process remain to be defined. We hypothesized that (1) CH is prevalent in relapsed follicular lymphoma (FL) and is associated with t-MN transformation. (2) Radiation in the form of radioimmunotherapy (RIT) plays a role in clonal progression. In this retrospective cohort study, we evaluated the...]]></summary>
        <author>
            <name>Zhuoer Xie</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Cytotoxic peripheral T-cell lymphomas and EBV-positive T/NK-cell lymphoproliferative diseases: emerging concepts, recent advances, and the putative role of clonal hematopoiesis. A report of the 2022 EA4HP/SH lymphoma workshop]]></title>
        <id>pubmed:37646869</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37646869/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230830204850&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-08-30T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Cytotoxic peripheral T-cell lymphomas and EBV-positive T/NK-cell lymphoproliferative diseases were discussed at the 2022 European Association for Haematopathology/Society for Hematopathology lymphoma workshop held in Florence, Italy. This session focused on (i) primary nodal EBV-positive T and NK-cell lymphomas (primary nodal-EBV-TNKL), (ii) extranodal EBV-positive T/NK lymphoproliferative diseases (LPD) in children and adults, (iii) cytotoxic peripheral T-cell lymphomas, NOS (cPTCL-NOS),...]]></summary>
        <author>
            <name>Fina Climent</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Prognostic relevance of clonal hematopoiesis in myeloid neoplastic transformation in patients with follicular lymphoma treated with radioimmunotherapy]]></title>
        <id>pubmed:37646653</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37646653/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230830204850&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-08-30T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[While novel radioisotope therapies continue to advance cancer care, reports of therapy-related myeloid neoplasms (t-MN) have generated concern. The prevalence and role of clonal hematopoiesis (CH) in this process remain to be defined. We hypothesized that (1) CH is prevalent in relapsed follicular lymphoma (FL) and is associated with t-MN transformation. (2) Radiation in the form of radioimmunotherapy (RIT) plays a role in clonal progression. In this retrospective cohort study, we evaluated the...]]></summary>
        <author>
            <name>Zhuoer Xie</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clonal Hematopoiesis Has Prognostic Value in Dilated Cardiomyopathy Independent of Age and Clone Size]]></title>
        <id>pubmed:37638520</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37638520/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230915204741&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-08-28T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSIONS: CH predicts cardiac death and all-cause mortality in DCM patients with optimal thresholds for clone size of 0.36% and 0.06%, respectively. Therefore, CH is prognostically relevant, independent of clone size in patients with DCM.]]></summary>
        <author>
            <name>Maurits A Sikking</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clonal Hematopoiesis Has Prognostic Value in Dilated Cardiomyopathy Independent of Age and Clone Size]]></title>
        <id>pubmed:37638520</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37638520/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230914204950&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-08-28T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSIONS: CH predicts cardiac death and all-cause mortality in DCM patients with optimal thresholds for clone size of 0.36% and 0.06%, respectively. Therefore, CH is prognostically relevant, independent of clone size in patients with DCM.]]></summary>
        <author>
            <name>Maurits A Sikking</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clonal Hematopoiesis Has Prognostic Value in Dilated Cardiomyopathy Independent of Age and Clone Size]]></title>
        <id>pubmed:37638520</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37638520/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230913204840&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-08-28T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSIONS: CH predicts cardiac death and all-cause mortality in DCM patients with optimal thresholds for clone size of 0.36% and 0.06%, respectively. Therefore, CH is prognostically relevant, independent of clone size in patients with DCM.]]></summary>
        <author>
            <name>Maurits A Sikking</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clonal Hematopoiesis Has Prognostic Value in Dilated Cardiomyopathy Independent of Age and Clone Size]]></title>
        <id>pubmed:37638520</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37638520/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230912205016&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-08-28T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSIONS: CH predicts cardiac death and all-cause mortality in DCM patients with optimal thresholds for clone size of 0.36% and 0.06%, respectively. Therefore, CH is prognostically relevant, independent of clone size in patients with DCM.]]></summary>
        <author>
            <name>Maurits A Sikking</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clonal Hematopoiesis Has Prognostic Value in Dilated Cardiomyopathy Independent of Age and Clone Size]]></title>
        <id>pubmed:37638520</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37638520/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230911204717&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-08-28T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSIONS: CH predicts cardiac death and all-cause mortality in DCM patients with optimal thresholds for clone size of 0.36% and 0.06%, respectively. Therefore, CH is prognostically relevant, independent of clone size in patients with DCM.]]></summary>
        <author>
            <name>Maurits A Sikking</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clonal Hematopoiesis Has Prognostic Value in Dilated Cardiomyopathy Independent of Age and Clone Size]]></title>
        <id>pubmed:37638520</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37638520/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230910204912&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-08-28T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSIONS: CH predicts cardiac death and all-cause mortality in DCM patients with optimal thresholds for clone size of 0.36% and 0.06%, respectively. Therefore, CH is prognostically relevant, independent of clone size in patients with DCM.]]></summary>
        <author>
            <name>Maurits A Sikking</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clonal Hematopoiesis Has Prognostic Value in Dilated Cardiomyopathy Independent of Age and Clone Size]]></title>
        <id>pubmed:37638520</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37638520/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230909205145&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-08-28T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSIONS: CH predicts cardiac death and all-cause mortality in DCM patients with optimal thresholds for clone size of 0.36% and 0.06%, respectively. Therefore, CH is prognostically relevant, independent of clone size in patients with DCM.]]></summary>
        <author>
            <name>Maurits A Sikking</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clonal Hematopoiesis Has Prognostic Value in Dilated Cardiomyopathy Independent of Age and Clone Size]]></title>
        <id>pubmed:37638520</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37638520/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230908204701&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-08-28T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSIONS: CH predicts cardiac death and all-cause mortality in DCM patients with optimal thresholds for clone size of 0.36% and 0.06%, respectively. Therefore, CH is prognostically relevant, independent of clone size in patients with DCM.]]></summary>
        <author>
            <name>Maurits A Sikking</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clonal Hematopoiesis Has Prognostic Value in Dilated Cardiomyopathy Independent of Age and Clone Size]]></title>
        <id>pubmed:37638520</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37638520/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230907204816&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-08-28T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSIONS: CH predicts cardiac death and all-cause mortality in DCM patients with optimal thresholds for clone size of 0.36% and 0.06%, respectively. Therefore, CH is prognostically relevant, independent of clone size in patients with DCM.]]></summary>
        <author>
            <name>Maurits A Sikking</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clonal Hematopoiesis has Prognostic Value in Dilated Cardiomyopathy independent of Age and Clone Size]]></title>
        <id>pubmed:37638520</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37638520/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230906204801&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-08-28T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSION: CH predicts cardiac death and all-cause mortality in DCM patients with an optimal threshold for clone size of 0.36% and 0.06%, respectively. Therefore, CH is prognostically relevant independent of clone size in patients with DCM.]]></summary>
        <author>
            <name>Maurits A Sikking</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clonal Hematopoiesis has Prognostic Value in Dilated Cardiomyopathy independent of Age and Clone Size]]></title>
        <id>pubmed:37638520</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37638520/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230905204848&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-08-28T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSION: CH predicts cardiac death and all-cause mortality in DCM patients with an optimal threshold for clone size of 0.36% and 0.06%, respectively. Therefore, CH is prognostically relevant independent of clone size in patients with DCM.]]></summary>
        <author>
            <name>Maurits A Sikking</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clonal Hematopoiesis has Prognostic Value in Dilated Cardiomyopathy independent of Age and Clone Size]]></title>
        <id>pubmed:37638520</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37638520/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230904204751&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-08-28T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSION: CH predicts cardiac death and all-cause mortality in DCM patients with an optimal threshold for clone size of 0.36% and 0.06%, respectively. Therefore, CH is prognostically relevant independent of clone size in patients with DCM.]]></summary>
        <author>
            <name>Maurits A Sikking</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clonal Hematopoiesis has Prognostic Value in Dilated Cardiomyopathy independent of Age and Clone Size]]></title>
        <id>pubmed:37638520</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37638520/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230903204939&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-08-28T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSION: CH predicts cardiac death and all-cause mortality in DCM patients with an optimal threshold for clone size of 0.36% and 0.06%, respectively. Therefore, CH is prognostically relevant independent of clone size in patients with DCM.]]></summary>
        <author>
            <name>Maurits A Sikking</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clonal Hematopoiesis has Prognostic Value in Dilated Cardiomyopathy independent of Age and Clone Size]]></title>
        <id>pubmed:37638520</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37638520/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230902205121&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-08-28T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSION: CH predicts cardiac death and all-cause mortality in DCM patients with an optimal threshold for clone size of 0.36% and 0.06%, respectively. Therefore, CH is prognostically relevant independent of clone size in patients with DCM.]]></summary>
        <author>
            <name>Maurits A Sikking</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clonal Hematopoiesis has Prognostic Value in Dilated Cardiomyopathy independent of Age and Clone Size]]></title>
        <id>pubmed:37638520</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37638520/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230901204619&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-08-28T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSION: CH predicts cardiac death and all-cause mortality in DCM patients with an optimal threshold for clone size of 0.36% and 0.06%, respectively. Therefore, CH is prognostically relevant independent of clone size in patients with DCM.]]></summary>
        <author>
            <name>Maurits A Sikking</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clonal Hematopoiesis has Prognostic Value in Dilated Cardiomyopathy independent of Age and Clone Size]]></title>
        <id>pubmed:37638520</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37638520/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230831205203&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-08-28T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSION: CH predicts cardiac death and all-cause mortality in DCM patients with an optimal threshold for clone size of 0.36% and 0.06%, respectively. Therefore, CH is prognostically relevant independent of clone size in patients with DCM.]]></summary>
        <author>
            <name>Maurits A Sikking</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clonal Hematopoiesis has Prognostic Value in Dilated Cardiomyopathy independent of Age and Clone Size]]></title>
        <id>pubmed:37638520</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37638520/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230830204850&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-08-28T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSION: CH predicts cardiac death and all-cause mortality in DCM patients with an optimal threshold for clone size of 0.36% and 0.06%, respectively. Therefore, CH is prognostically relevant independent of clone size in patients with DCM.]]></summary>
        <author>
            <name>Maurits A Sikking</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clonal Hematopoiesis has Prognostic Value in Dilated Cardiomyopathy independent of Age and Clone Size]]></title>
        <id>pubmed:37638520</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37638520/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230829204824&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-08-28T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSION: CH predicts cardiac death and all-cause mortality in DCM patients with an optimal threshold for clone size of 0.36% and 0.06%, respectively. Therefore, CH is prognostically relevant independent of clone size in patients with DCM.]]></summary>
        <author>
            <name>Maurits A Sikking</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clonal Hematopoiesis has Prognostic Value in Dilated Cardiomyopathy independent of Age and Clone Size]]></title>
        <id>pubmed:37638520</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37638520/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230828204854&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-08-28T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSION: CH predicts cardiac death and all-cause mortality in DCM patients with an optimal threshold for clone size of 0.36% and 0.06%, respectively. Therefore, CH is prognostically relevant independent of clone size in patients with DCM.]]></summary>
        <author>
            <name>Maurits A Sikking</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Whole blood transcriptional profiling reveals highly deregulated atherosclerosis genes in Philadelphia-chromosome negative myeloproliferative neoplasms]]></title>
        <id>pubmed:37640394</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37640394/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230923205208&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-08-28T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSIONS: We have for the first time shown massive deregulation of atherosclerosis genes in MPNs, likely reflecting the inflammatory state in MPNs in association with in vivo activation of leukocytes, platelets, and endothelial cells being deeply involved in the atherosclerotic process.]]></summary>
        <author>
            <name>Vibe Skov</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Whole blood transcriptional profiling reveals highly deregulated atherosclerosis genes in Philadelphia-chromosome negative myeloproliferative neoplasms]]></title>
        <id>pubmed:37640394</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37640394/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230922204741&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-08-28T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSIONS: We have for the first time shown massive deregulation of atherosclerosis genes in MPNs, likely reflecting the inflammatory state in MPNs in association with in vivo activation of leukocytes, platelets, and endothelial cells being deeply involved in the atherosclerotic process.]]></summary>
        <author>
            <name>Vibe Skov</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Whole blood transcriptional profiling reveals highly deregulated atherosclerosis genes in Philadelphia-chromosome negative myeloproliferative neoplasms]]></title>
        <id>pubmed:37640394</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37640394/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230921204936&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-08-28T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSIONS: We have for the first time shown massive deregulation of atherosclerosis genes in MPNs, likely reflecting the inflammatory state in MPNs in association with in vivo activation of leukocytes, platelets, and endothelial cells being deeply involved in the atherosclerotic process.]]></summary>
        <author>
            <name>Vibe Skov</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Whole blood transcriptional profiling reveals highly deregulated atherosclerosis genes in Philadelphia-chromosome negative myeloproliferative neoplasms]]></title>
        <id>pubmed:37640394</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37640394/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230920204904&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-08-28T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSIONS: We have for the first time shown massive deregulation of atherosclerosis genes in MPNs, likely reflecting the inflammatory state in MPNs in association with in vivo activation of leukocytes, platelets, and endothelial cells being deeply involved in the atherosclerotic process.]]></summary>
        <author>
            <name>Vibe Skov</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Diagnostic significance of dysregulated miRNAs in T-cell malignancies and their metabolic roles]]></title>
        <id>pubmed:37637043</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37637043/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230920204904&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-08-28T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[T-cell malignancy is a broad term used for a diverse group of disease subtypes representing dysfunctional malignant T cells transformed at various stages of their clonal evolution. Despite having similar clinical manifestations, these disease groups have different disease progressions and diagnostic parameters. The effective diagnosis and prognosis of such a diverse disease group demands testing of molecular entities that capture footprints of the disease physiology in its entirety. MicroRNAs...]]></summary>
        <author>
            <name>Deepankar Mondal</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Whole blood transcriptional profiling reveals highly deregulated atherosclerosis genes in Philadelphia-chromosome negative myeloproliferative neoplasms]]></title>
        <id>pubmed:37640394</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37640394/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230919204929&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-08-28T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSIONS: We have for the first time shown massive deregulation of atherosclerosis genes in MPNs, likely reflecting the inflammatory state in MPNs in association with in vivo activation of leukocytes, platelets, and endothelial cells being deeply involved in the atherosclerotic process.]]></summary>
        <author>
            <name>Vibe Skov</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Diagnostic significance of dysregulated miRNAs in T-cell malignancies and their metabolic roles]]></title>
        <id>pubmed:37637043</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37637043/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230919204929&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-08-28T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[T-cell malignancy is a broad term used for a diverse group of disease subtypes representing dysfunctional malignant T cells transformed at various stages of their clonal evolution. Despite having similar clinical manifestations, these disease groups have different disease progressions and diagnostic parameters. The effective diagnosis and prognosis of such a diverse disease group demands testing of molecular entities that capture footprints of the disease physiology in its entirety. MicroRNAs...]]></summary>
        <author>
            <name>Deepankar Mondal</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Whole blood transcriptional profiling reveals highly deregulated atherosclerosis genes in Philadelphia-chromosome negative myeloproliferative neoplasms]]></title>
        <id>pubmed:37640394</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37640394/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230918204942&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-08-28T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSIONS: We have for the first time shown massive deregulation of atherosclerosis genes in MPNs, likely reflecting the inflammatory state in MPNs in association with in vivo activation of leukocytes, platelets, and endothelial cells being deeply involved in the atherosclerotic process.]]></summary>
        <author>
            <name>Vibe Skov</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Diagnostic significance of dysregulated miRNAs in T-cell malignancies and their metabolic roles]]></title>
        <id>pubmed:37637043</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37637043/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230918204942&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-08-28T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[T-cell malignancy is a broad term used for a diverse group of disease subtypes representing dysfunctional malignant T cells transformed at various stages of their clonal evolution. Despite having similar clinical manifestations, these disease groups have different disease progressions and diagnostic parameters. The effective diagnosis and prognosis of such a diverse disease group demands testing of molecular entities that capture footprints of the disease physiology in its entirety. MicroRNAs...]]></summary>
        <author>
            <name>Deepankar Mondal</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Whole blood transcriptional profiling reveals highly deregulated atherosclerosis genes in Philadelphia-chromosome negative myeloproliferative neoplasms]]></title>
        <id>pubmed:37640394</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37640394/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230917204936&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-08-28T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSIONS: We have for the first time shown massive deregulation of atherosclerosis genes in MPNs, likely reflecting the inflammatory state in MPNs in association with in vivo activation of leukocytes, platelets, and endothelial cells being deeply involved in the atherosclerotic process.]]></summary>
        <author>
            <name>Vibe Skov</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Diagnostic significance of dysregulated miRNAs in T-cell malignancies and their metabolic roles]]></title>
        <id>pubmed:37637043</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37637043/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230917204936&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-08-28T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[T-cell malignancy is a broad term used for a diverse group of disease subtypes representing dysfunctional malignant T cells transformed at various stages of their clonal evolution. Despite having similar clinical manifestations, these disease groups have different disease progressions and diagnostic parameters. The effective diagnosis and prognosis of such a diverse disease group demands testing of molecular entities that capture footprints of the disease physiology in its entirety. MicroRNAs...]]></summary>
        <author>
            <name>Deepankar Mondal</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Whole blood transcriptional profiling reveals highly deregulated atherosclerosis genes in Philadelphia-chromosome negative myeloproliferative neoplasms]]></title>
        <id>pubmed:37640394</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37640394/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230916205201&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-08-28T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSIONS: We have for the first time shown massive deregulation of atherosclerosis genes in MPNs, likely reflecting the inflammatory state in MPNs in association with in vivo activation of leukocytes, platelets, and endothelial cells being deeply involved in the atherosclerotic process.]]></summary>
        <author>
            <name>Vibe Skov</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Diagnostic significance of dysregulated miRNAs in T-cell malignancies and their metabolic roles]]></title>
        <id>pubmed:37637043</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37637043/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230916205201&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-08-28T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[T-cell malignancy is a broad term used for a diverse group of disease subtypes representing dysfunctional malignant T cells transformed at various stages of their clonal evolution. Despite having similar clinical manifestations, these disease groups have different disease progressions and diagnostic parameters. The effective diagnosis and prognosis of such a diverse disease group demands testing of molecular entities that capture footprints of the disease physiology in its entirety. MicroRNAs...]]></summary>
        <author>
            <name>Deepankar Mondal</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Whole blood transcriptional profiling reveals highly deregulated atherosclerosis genes in Philadelphia-chromosome negative myeloproliferative neoplasms]]></title>
        <id>pubmed:37640394</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37640394/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230915204741&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-08-28T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSIONS: We have for the first time shown massive deregulation of atherosclerosis genes in MPNs, likely reflecting the inflammatory state in MPNs in association with in vivo activation of leukocytes, platelets, and endothelial cells being deeply involved in the atherosclerotic process.]]></summary>
        <author>
            <name>Vibe Skov</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Diagnostic significance of dysregulated miRNAs in T-cell malignancies and their metabolic roles]]></title>
        <id>pubmed:37637043</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37637043/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230915204741&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-08-28T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[T-cell malignancy is a broad term used for a diverse group of disease subtypes representing dysfunctional malignant T cells transformed at various stages of their clonal evolution. Despite having similar clinical manifestations, these disease groups have different disease progressions and diagnostic parameters. The effective diagnosis and prognosis of such a diverse disease group demands testing of molecular entities that capture footprints of the disease physiology in its entirety. MicroRNAs...]]></summary>
        <author>
            <name>Deepankar Mondal</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Whole blood transcriptional profiling reveals highly deregulated atherosclerosis genes in Philadelphia-chromosome negative myeloproliferative neoplasms]]></title>
        <id>pubmed:37640394</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37640394/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230914204950&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-08-28T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSIONS: We have for the first time shown massive deregulation of atherosclerosis genes in MPNs, likely reflecting the inflammatory state in MPNs in association with in vivo activation of leukocytes, platelets, and endothelial cells being deeply involved in the atherosclerotic process.]]></summary>
        <author>
            <name>Vibe Skov</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Diagnostic significance of dysregulated miRNAs in T-cell malignancies and their metabolic roles]]></title>
        <id>pubmed:37637043</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37637043/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230914204950&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-08-28T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[T-cell malignancy is a broad term used for a diverse group of disease subtypes representing dysfunctional malignant T cells transformed at various stages of their clonal evolution. Despite having similar clinical manifestations, these disease groups have different disease progressions and diagnostic parameters. The effective diagnosis and prognosis of such a diverse disease group demands testing of molecular entities that capture footprints of the disease physiology in its entirety. MicroRNAs...]]></summary>
        <author>
            <name>Deepankar Mondal</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Whole blood transcriptional profiling reveals highly deregulated atherosclerosis genes in Philadelphia-chromosome negative myeloproliferative neoplasms]]></title>
        <id>pubmed:37640394</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37640394/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230913204840&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-08-28T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSIONS: We have for the first time shown massive deregulation of atherosclerosis genes in MPNs, likely reflecting the inflammatory state in MPNs in association with in vivo activation of leukocytes, platelets, and endothelial cells being deeply involved in the atherosclerotic process.]]></summary>
        <author>
            <name>Vibe Skov</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Diagnostic significance of dysregulated miRNAs in T-cell malignancies and their metabolic roles]]></title>
        <id>pubmed:37637043</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37637043/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230913204840&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-08-28T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[T-cell malignancy is a broad term used for a diverse group of disease subtypes representing dysfunctional malignant T cells transformed at various stages of their clonal evolution. Despite having similar clinical manifestations, these disease groups have different disease progressions and diagnostic parameters. The effective diagnosis and prognosis of such a diverse disease group demands testing of molecular entities that capture footprints of the disease physiology in its entirety. MicroRNAs...]]></summary>
        <author>
            <name>Deepankar Mondal</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Whole blood transcriptional profiling reveals highly deregulated atherosclerosis genes in Philadelphia-chromosome negative myeloproliferative neoplasms]]></title>
        <id>pubmed:37640394</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37640394/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230912205015&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-08-28T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSIONS: We have for the first time shown massive deregulation of atherosclerosis genes in MPNs, likely reflecting the inflammatory state in MPNs in association with in vivo activation of leukocytes, platelets, and endothelial cells being deeply involved in the atherosclerotic process.]]></summary>
        <author>
            <name>Vibe Skov</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Diagnostic significance of dysregulated miRNAs in T-cell malignancies and their metabolic roles]]></title>
        <id>pubmed:37637043</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37637043/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230912205015&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-08-28T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[T-cell malignancy is a broad term used for a diverse group of disease subtypes representing dysfunctional malignant T cells transformed at various stages of their clonal evolution. Despite having similar clinical manifestations, these disease groups have different disease progressions and diagnostic parameters. The effective diagnosis and prognosis of such a diverse disease group demands testing of molecular entities that capture footprints of the disease physiology in its entirety. MicroRNAs...]]></summary>
        <author>
            <name>Deepankar Mondal</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Whole blood transcriptional profiling reveals highly deregulated atherosclerosis genes in Philadelphia-chromosome negative myeloproliferative neoplasms]]></title>
        <id>pubmed:37640394</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37640394/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230911204717&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-08-28T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSIONS: We have for the first time shown massive deregulation of atherosclerosis genes in MPNs, likely reflecting the inflammatory state in MPNs in association with in vivo activation of leukocytes, platelets, and endothelial cells being deeply involved in the atherosclerotic process.]]></summary>
        <author>
            <name>Vibe Skov</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Diagnostic significance of dysregulated miRNAs in T-cell malignancies and their metabolic roles]]></title>
        <id>pubmed:37637043</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37637043/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230911204717&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-08-28T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[T-cell malignancy is a broad term used for a diverse group of disease subtypes representing dysfunctional malignant T cells transformed at various stages of their clonal evolution. Despite having similar clinical manifestations, these disease groups have different disease progressions and diagnostic parameters. The effective diagnosis and prognosis of such a diverse disease group demands testing of molecular entities that capture footprints of the disease physiology in its entirety. MicroRNAs...]]></summary>
        <author>
            <name>Deepankar Mondal</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Whole blood transcriptional profiling reveals highly deregulated atherosclerosis genes in Philadelphia-chromosome negative myeloproliferative neoplasms]]></title>
        <id>pubmed:37640394</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37640394/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230910204912&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-08-28T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSIONS: We have for the first time shown massive deregulation of atherosclerosis genes in MPNs, likely reflecting the inflammatory state in MPNs in association with in vivo activation of leukocytes, platelets, and endothelial cells being deeply involved in the atherosclerotic process.]]></summary>
        <author>
            <name>Vibe Skov</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Diagnostic significance of dysregulated miRNAs in T-cell malignancies and their metabolic roles]]></title>
        <id>pubmed:37637043</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37637043/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230910204912&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-08-28T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[T-cell malignancy is a broad term used for a diverse group of disease subtypes representing dysfunctional malignant T cells transformed at various stages of their clonal evolution. Despite having similar clinical manifestations, these disease groups have different disease progressions and diagnostic parameters. The effective diagnosis and prognosis of such a diverse disease group demands testing of molecular entities that capture footprints of the disease physiology in its entirety. MicroRNAs...]]></summary>
        <author>
            <name>Deepankar Mondal</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Whole blood transcriptional profiling reveals highly deregulated atherosclerosis genes in Philadelphia-chromosome negative myeloproliferative neoplasms]]></title>
        <id>pubmed:37640394</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37640394/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230909205145&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-08-28T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSIONS: We have for the first time shown massive deregulation of atherosclerosis genes in MPNs, likely reflecting the inflammatory state in MPNs in association with in vivo activation of leukocytes, platelets, and endothelial cells being deeply involved in the atherosclerotic process.]]></summary>
        <author>
            <name>Vibe Skov</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Diagnostic significance of dysregulated miRNAs in T-cell malignancies and their metabolic roles]]></title>
        <id>pubmed:37637043</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37637043/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230909205145&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-08-28T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[T-cell malignancy is a broad term used for a diverse group of disease subtypes representing dysfunctional malignant T cells transformed at various stages of their clonal evolution. Despite having similar clinical manifestations, these disease groups have different disease progressions and diagnostic parameters. The effective diagnosis and prognosis of such a diverse disease group demands testing of molecular entities that capture footprints of the disease physiology in its entirety. MicroRNAs...]]></summary>
        <author>
            <name>Deepankar Mondal</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Whole blood transcriptional profiling reveals highly deregulated atherosclerosis genes in Philadelphia-chromosome negative myeloproliferative neoplasms]]></title>
        <id>pubmed:37640394</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37640394/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230908204701&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-08-28T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSIONS: We have for the first time shown massive deregulation of atherosclerosis genes in MPNs, likely reflecting the inflammatory state in MPNs in association with in vivo activation of leukocytes, platelets, and endothelial cells being deeply involved in the atherosclerotic process.]]></summary>
        <author>
            <name>Vibe Skov</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Diagnostic significance of dysregulated miRNAs in T-cell malignancies and their metabolic roles]]></title>
        <id>pubmed:37637043</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37637043/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230908204701&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-08-28T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[T-cell malignancy is a broad term used for a diverse group of disease subtypes representing dysfunctional malignant T cells transformed at various stages of their clonal evolution. Despite having similar clinical manifestations, these disease groups have different disease progressions and diagnostic parameters. The effective diagnosis and prognosis of such a diverse disease group demands testing of molecular entities that capture footprints of the disease physiology in its entirety. MicroRNAs...]]></summary>
        <author>
            <name>Deepankar Mondal</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Whole blood transcriptional profiling reveals highly deregulated atherosclerosis genes in Philadelphia-chromosome negative myeloproliferative neoplasms]]></title>
        <id>pubmed:37640394</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37640394/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230907204816&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-08-28T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSIONS: We have for the first time shown massive deregulation of atherosclerosis genes in MPNs, likely reflecting the inflammatory state in MPNs in association with in vivo activation of leukocytes, platelets, and endothelial cells being deeply involved in the atherosclerotic process.]]></summary>
        <author>
            <name>Vibe Skov</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Diagnostic significance of dysregulated miRNAs in T-cell malignancies and their metabolic roles]]></title>
        <id>pubmed:37637043</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37637043/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230907204816&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-08-28T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[T-cell malignancy is a broad term used for a diverse group of disease subtypes representing dysfunctional malignant T cells transformed at various stages of their clonal evolution. Despite having similar clinical manifestations, these disease groups have different disease progressions and diagnostic parameters. The effective diagnosis and prognosis of such a diverse disease group demands testing of molecular entities that capture footprints of the disease physiology in its entirety. MicroRNAs...]]></summary>
        <author>
            <name>Deepankar Mondal</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Whole blood transcriptional profiling reveals highly deregulated atherosclerosis genes in Philadelphia-chromosome negative myeloproliferative neoplasms]]></title>
        <id>pubmed:37640394</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37640394/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230906204801&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-08-28T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSIONS: We have for the first time shown massive deregulation of atherosclerosis genes in MPNs, likely reflecting the inflammatory state in MPNs in association with in vivo activation of leukocytes, platelets, and endothelial cells being deeply involved in the atherosclerotic process.]]></summary>
        <author>
            <name>Vibe Skov</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Diagnostic significance of dysregulated miRNAs in T-cell malignancies and their metabolic roles]]></title>
        <id>pubmed:37637043</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37637043/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230906204801&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-08-28T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[T-cell malignancy is a broad term used for a diverse group of disease subtypes representing dysfunctional malignant T cells transformed at various stages of their clonal evolution. Despite having similar clinical manifestations, these disease groups have different disease progressions and diagnostic parameters. The effective diagnosis and prognosis of such a diverse disease group demands testing of molecular entities that capture footprints of the disease physiology in its entirety. MicroRNAs...]]></summary>
        <author>
            <name>Deepankar Mondal</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Whole blood transcriptional profiling reveals highly deregulated atherosclerosis genes in Philadelphia-chromosome negative myeloproliferative neoplasms]]></title>
        <id>pubmed:37640394</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37640394/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230905204848&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-08-28T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSIONS: We have for the first time shown massive deregulation of atherosclerosis genes in MPNs, likely reflecting the inflammatory state in MPNs in association with in vivo activation of leukocytes, platelets, and endothelial cells being deeply involved in the atherosclerotic process.]]></summary>
        <author>
            <name>Vibe Skov</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Diagnostic significance of dysregulated miRNAs in T-cell malignancies and their metabolic roles]]></title>
        <id>pubmed:37637043</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37637043/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230905204848&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-08-28T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[T-cell malignancy is a broad term used for a diverse group of disease subtypes representing dysfunctional malignant T cells transformed at various stages of their clonal evolution. Despite having similar clinical manifestations, these disease groups have different disease progressions and diagnostic parameters. The effective diagnosis and prognosis of such a diverse disease group demands testing of molecular entities that capture footprints of the disease physiology in its entirety. MicroRNAs...]]></summary>
        <author>
            <name>Deepankar Mondal</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Whole blood transcriptional profiling reveals highly deregulated atherosclerosis genes in Philadelphia-chromosome negative myeloproliferative neoplasms]]></title>
        <id>pubmed:37640394</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37640394/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230904204751&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-08-28T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSIONS: We have for the first time shown massive deregulation of atherosclerosis genes in MPNs, likely reflecting the inflammatory state in MPNs in association with in vivo activation of leukocytes, platelets, and endothelial cells being deeply involved in the atherosclerotic process.]]></summary>
        <author>
            <name>Vibe Skov</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Diagnostic significance of dysregulated miRNAs in T-cell malignancies and their metabolic roles]]></title>
        <id>pubmed:37637043</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37637043/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230904204751&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-08-28T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[T-cell malignancy is a broad term used for a diverse group of disease subtypes representing dysfunctional malignant T cells transformed at various stages of their clonal evolution. Despite having similar clinical manifestations, these disease groups have different disease progressions and diagnostic parameters. The effective diagnosis and prognosis of such a diverse disease group demands testing of molecular entities that capture footprints of the disease physiology in its entirety. MicroRNAs...]]></summary>
        <author>
            <name>Deepankar Mondal</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Whole blood transcriptional profiling reveals highly deregulated atherosclerosis genes in Philadelphia-chromosome negative myeloproliferative neoplasms]]></title>
        <id>pubmed:37640394</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37640394/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230903204939&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-08-28T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSIONS: We have for the first time shown massive deregulation of atherosclerosis genes in MPNs, likely reflecting the inflammatory state in MPNs in association with in vivo activation of leukocytes, platelets, and endothelial cells being deeply involved in the atherosclerotic process.]]></summary>
        <author>
            <name>Vibe Skov</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Diagnostic significance of dysregulated miRNAs in T-cell malignancies and their metabolic roles]]></title>
        <id>pubmed:37637043</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37637043/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230903204939&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-08-28T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[T-cell malignancy is a broad term used for a diverse group of disease subtypes representing dysfunctional malignant T cells transformed at various stages of their clonal evolution. Despite having similar clinical manifestations, these disease groups have different disease progressions and diagnostic parameters. The effective diagnosis and prognosis of such a diverse disease group demands testing of molecular entities that capture footprints of the disease physiology in its entirety. MicroRNAs...]]></summary>
        <author>
            <name>Deepankar Mondal</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Whole blood transcriptional profiling reveals highly deregulated atherosclerosis genes in Philadelphia-chromosome negative myeloproliferative neoplasms]]></title>
        <id>pubmed:37640394</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37640394/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230902205121&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-08-28T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSIONS: We have for the first time shown massive deregulation of atherosclerosis genes in MPNs, likely reflecting the inflammatory state in MPNs in association with in vivo activation of leukocytes, platelets, and endothelial cells being deeply involved in the atherosclerotic process.]]></summary>
        <author>
            <name>Vibe Skov</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Diagnostic significance of dysregulated miRNAs in T-cell malignancies and their metabolic roles]]></title>
        <id>pubmed:37637043</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37637043/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230902205121&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-08-28T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[T-cell malignancy is a broad term used for a diverse group of disease subtypes representing dysfunctional malignant T cells transformed at various stages of their clonal evolution. Despite having similar clinical manifestations, these disease groups have different disease progressions and diagnostic parameters. The effective diagnosis and prognosis of such a diverse disease group demands testing of molecular entities that capture footprints of the disease physiology in its entirety. MicroRNAs...]]></summary>
        <author>
            <name>Deepankar Mondal</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Whole blood transcriptional profiling reveals highly deregulated atherosclerosis genes in Philadelphia-chromosome negative myeloproliferative neoplasms]]></title>
        <id>pubmed:37640394</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37640394/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230901204619&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-08-28T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSIONS: We have for the first time shown massive deregulation of atherosclerosis genes in MPNs, likely reflecting the inflammatory state in MPNs in association with in vivo activation of leukocytes, platelets, and endothelial cells being deeply involved in the atherosclerotic process.]]></summary>
        <author>
            <name>Vibe Skov</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Diagnostic significance of dysregulated miRNAs in T-cell malignancies and their metabolic roles]]></title>
        <id>pubmed:37637043</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37637043/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230901204619&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-08-28T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[T-cell malignancy is a broad term used for a diverse group of disease subtypes representing dysfunctional malignant T cells transformed at various stages of their clonal evolution. Despite having similar clinical manifestations, these disease groups have different disease progressions and diagnostic parameters. The effective diagnosis and prognosis of such a diverse disease group demands testing of molecular entities that capture footprints of the disease physiology in its entirety. MicroRNAs...]]></summary>
        <author>
            <name>Deepankar Mondal</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Whole blood transcriptional profiling reveals highly deregulated atherosclerosis genes in Philadelphia-chromosome negative myeloproliferative neoplasms]]></title>
        <id>pubmed:37640394</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37640394/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230831205203&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-08-28T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSIONS: We have for the first time shown massive deregulation of atherosclerosis genes in MPNs, likely reflecting the inflammatory state in MPNs in association with in vivo activation of leukocytes, platelets, and endothelial cells being deeply involved in the atherosclerotic process.]]></summary>
        <author>
            <name>Vibe Skov</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Diagnostic significance of dysregulated miRNAs in T-cell malignancies and their metabolic roles]]></title>
        <id>pubmed:37637043</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37637043/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230831205203&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-08-28T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[T-cell malignancy is a broad term used for a diverse group of disease subtypes representing dysfunctional malignant T cells transformed at various stages of their clonal evolution. Despite having similar clinical manifestations, these disease groups have different disease progressions and diagnostic parameters. The effective diagnosis and prognosis of such a diverse disease group demands testing of molecular entities that capture footprints of the disease physiology in its entirety. MicroRNAs...]]></summary>
        <author>
            <name>Deepankar Mondal</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Whole blood transcriptional profiling reveals highly deregulated atherosclerosis genes in Philadelphia-chromosome negative myeloproliferative neoplasms]]></title>
        <id>pubmed:37640394</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37640394/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230830204850&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-08-28T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSIONS: We have for the first time shown massive deregulation of atherosclerosis genes in MPNs, likely reflecting the inflammatory state in MPNs in association with in vivo activation of leukocytes, platelets, and endothelial cells being deeply involved in the atherosclerotic process.]]></summary>
        <author>
            <name>Vibe Skov</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Diagnostic significance of dysregulated miRNAs in T-cell malignancies and their metabolic roles]]></title>
        <id>pubmed:37637043</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37637043/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230830204850&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-08-28T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[T-cell malignancy is a broad term used for a diverse group of disease subtypes representing dysfunctional malignant T cells transformed at various stages of their clonal evolution. Despite having similar clinical manifestations, these disease groups have different disease progressions and diagnostic parameters. The effective diagnosis and prognosis of such a diverse disease group demands testing of molecular entities that capture footprints of the disease physiology in its entirety. MicroRNAs...]]></summary>
        <author>
            <name>Deepankar Mondal</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Whole blood transcriptional profiling reveals highly deregulated atherosclerosis genes in Philadelphia-chromosome negative myeloproliferative neoplasms]]></title>
        <id>pubmed:37640394</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37640394/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230829204824&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-08-28T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSIONS: We have for the first time shown massive deregulation of atherosclerosis genes in MPNs, likely reflecting the inflammatory state in MPNs in association with in vivo activation of leukocytes, platelets, and endothelial cells being deeply involved in the atherosclerotic process.]]></summary>
        <author>
            <name>Vibe Skov</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Diagnostic significance of dysregulated miRNAs in T-cell malignancies and their metabolic roles]]></title>
        <id>pubmed:37637043</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37637043/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230829204824&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-08-28T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[T-cell malignancy is a broad term used for a diverse group of disease subtypes representing dysfunctional malignant T cells transformed at various stages of their clonal evolution. Despite having similar clinical manifestations, these disease groups have different disease progressions and diagnostic parameters. The effective diagnosis and prognosis of such a diverse disease group demands testing of molecular entities that capture footprints of the disease physiology in its entirety. MicroRNAs...]]></summary>
        <author>
            <name>Deepankar Mondal</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Diagnostic significance of dysregulated miRNAs in T-cell malignancies and their metabolic roles]]></title>
        <id>pubmed:37637043</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37637043/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230828204854&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-08-28T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[T-cell malignancy is a broad term used for a diverse group of disease subtypes representing dysfunctional malignant T cells transformed at various stages of their clonal evolution. Despite having similar clinical manifestations, these disease groups have different disease progressions and diagnostic parameters. The effective diagnosis and prognosis of such a diverse disease group demands testing of molecular entities that capture footprints of the disease physiology in its entirety. MicroRNAs...]]></summary>
        <author>
            <name>Deepankar Mondal</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Molecular Studies for the Early Detection of Philadelphia-Negative Myeloproliferative Neoplasms]]></title>
        <id>pubmed:37628880</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37628880/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230914204950&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-08-26T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[JAK2 V617F is the predominant driver mutation in patients with Philadelphia-negative myeloproliferative neoplasms (MPN). JAK2 mutations are also frequent in clonal hematopoiesis of indeterminate potential (CHIP) in otherwise "healthy" individuals. However, the period between mutation acquisition and MPN diagnosis (known as latency) varies widely between individuals, with JAK2 mutations detectable several decades before diagnosis and even from birth in some individuals. Here, we will review the...]]></summary>
        <author>
            <name>Ruth Stuckey</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Molecular Studies for the Early Detection of Philadelphia-Negative Myeloproliferative Neoplasms]]></title>
        <id>pubmed:37628880</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37628880/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230913204840&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-08-26T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[JAK2 V617F is the predominant driver mutation in patients with Philadelphia-negative myeloproliferative neoplasms (MPN). JAK2 mutations are also frequent in clonal hematopoiesis of indeterminate potential (CHIP) in otherwise "healthy" individuals. However, the period between mutation acquisition and MPN diagnosis (known as latency) varies widely between individuals, with JAK2 mutations detectable several decades before diagnosis and even from birth in some individuals. Here, we will review the...]]></summary>
        <author>
            <name>Ruth Stuckey</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Unveiling the Genetic Footprint: Exploring Somatic Mutations in Peripheral Arterial Disease Progression]]></title>
        <id>pubmed:37626784</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37626784/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230913204840&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-08-26T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Peripheral arterial diseases (PADs) are complex cardiovascular conditions influenced by environmental factors and somatic mutations in multiple genes involved in hematopoiesis and inflammation. While traditional risk factors, such as smoking, hypercholesterolemia, and hypertension, have been extensively studied, the role of somatic mutations in PAD progression remains underexplored. The present article intends to provide a comprehensive commentary of the molecular mechanisms, genetic landscape,...]]></summary>
        <author>
            <name>Amankeldi A Salybekov</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Molecular Studies for the Early Detection of Philadelphia-Negative Myeloproliferative Neoplasms]]></title>
        <id>pubmed:37628880</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37628880/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230912205016&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-08-26T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[JAK2 V617F is the predominant driver mutation in patients with Philadelphia-negative myeloproliferative neoplasms (MPN). JAK2 mutations are also frequent in clonal hematopoiesis of indeterminate potential (CHIP) in otherwise "healthy" individuals. However, the period between mutation acquisition and MPN diagnosis (known as latency) varies widely between individuals, with JAK2 mutations detectable several decades before diagnosis and even from birth in some individuals. Here, we will review the...]]></summary>
        <author>
            <name>Ruth Stuckey</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Unveiling the Genetic Footprint: Exploring Somatic Mutations in Peripheral Arterial Disease Progression]]></title>
        <id>pubmed:37626784</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37626784/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230912205016&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-08-26T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Peripheral arterial diseases (PADs) are complex cardiovascular conditions influenced by environmental factors and somatic mutations in multiple genes involved in hematopoiesis and inflammation. While traditional risk factors, such as smoking, hypercholesterolemia, and hypertension, have been extensively studied, the role of somatic mutations in PAD progression remains underexplored. The present article intends to provide a comprehensive commentary of the molecular mechanisms, genetic landscape,...]]></summary>
        <author>
            <name>Amankeldi A Salybekov</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Molecular Studies for the Early Detection of Philadelphia-Negative Myeloproliferative Neoplasms]]></title>
        <id>pubmed:37628880</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37628880/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230911204717&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-08-26T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[JAK2 V617F is the predominant driver mutation in patients with Philadelphia-negative myeloproliferative neoplasms (MPN). JAK2 mutations are also frequent in clonal hematopoiesis of indeterminate potential (CHIP) in otherwise "healthy" individuals. However, the period between mutation acquisition and MPN diagnosis (known as latency) varies widely between individuals, with JAK2 mutations detectable several decades before diagnosis and even from birth in some individuals. Here, we will review the...]]></summary>
        <author>
            <name>Ruth Stuckey</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Unveiling the Genetic Footprint: Exploring Somatic Mutations in Peripheral Arterial Disease Progression]]></title>
        <id>pubmed:37626784</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37626784/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230911204717&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-08-26T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Peripheral arterial diseases (PADs) are complex cardiovascular conditions influenced by environmental factors and somatic mutations in multiple genes involved in hematopoiesis and inflammation. While traditional risk factors, such as smoking, hypercholesterolemia, and hypertension, have been extensively studied, the role of somatic mutations in PAD progression remains underexplored. The present article intends to provide a comprehensive commentary of the molecular mechanisms, genetic landscape,...]]></summary>
        <author>
            <name>Amankeldi A Salybekov</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Molecular Studies for the Early Detection of Philadelphia-Negative Myeloproliferative Neoplasms]]></title>
        <id>pubmed:37628880</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37628880/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230910204912&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-08-26T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[JAK2 V617F is the predominant driver mutation in patients with Philadelphia-negative myeloproliferative neoplasms (MPN). JAK2 mutations are also frequent in clonal hematopoiesis of indeterminate potential (CHIP) in otherwise "healthy" individuals. However, the period between mutation acquisition and MPN diagnosis (known as latency) varies widely between individuals, with JAK2 mutations detectable several decades before diagnosis and even from birth in some individuals. Here, we will review the...]]></summary>
        <author>
            <name>Ruth Stuckey</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Unveiling the Genetic Footprint: Exploring Somatic Mutations in Peripheral Arterial Disease Progression]]></title>
        <id>pubmed:37626784</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37626784/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230910204912&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-08-26T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Peripheral arterial diseases (PADs) are complex cardiovascular conditions influenced by environmental factors and somatic mutations in multiple genes involved in hematopoiesis and inflammation. While traditional risk factors, such as smoking, hypercholesterolemia, and hypertension, have been extensively studied, the role of somatic mutations in PAD progression remains underexplored. The present article intends to provide a comprehensive commentary of the molecular mechanisms, genetic landscape,...]]></summary>
        <author>
            <name>Amankeldi A Salybekov</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Molecular Studies for the Early Detection of Philadelphia-Negative Myeloproliferative Neoplasms]]></title>
        <id>pubmed:37628880</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37628880/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230909205145&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-08-26T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[JAK2 V617F is the predominant driver mutation in patients with Philadelphia-negative myeloproliferative neoplasms (MPN). JAK2 mutations are also frequent in clonal hematopoiesis of indeterminate potential (CHIP) in otherwise "healthy" individuals. However, the period between mutation acquisition and MPN diagnosis (known as latency) varies widely between individuals, with JAK2 mutations detectable several decades before diagnosis and even from birth in some individuals. Here, we will review the...]]></summary>
        <author>
            <name>Ruth Stuckey</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Unveiling the Genetic Footprint: Exploring Somatic Mutations in Peripheral Arterial Disease Progression]]></title>
        <id>pubmed:37626784</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37626784/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230909205145&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-08-26T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Peripheral arterial diseases (PADs) are complex cardiovascular conditions influenced by environmental factors and somatic mutations in multiple genes involved in hematopoiesis and inflammation. While traditional risk factors, such as smoking, hypercholesterolemia, and hypertension, have been extensively studied, the role of somatic mutations in PAD progression remains underexplored. The present article intends to provide a comprehensive commentary of the molecular mechanisms, genetic landscape,...]]></summary>
        <author>
            <name>Amankeldi A Salybekov</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Molecular Studies for the Early Detection of Philadelphia-Negative Myeloproliferative Neoplasms]]></title>
        <id>pubmed:37628880</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37628880/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230908204701&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-08-26T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[JAK2 V617F is the predominant driver mutation in patients with Philadelphia-negative myeloproliferative neoplasms (MPN). JAK2 mutations are also frequent in clonal hematopoiesis of indeterminate potential (CHIP) in otherwise "healthy" individuals. However, the period between mutation acquisition and MPN diagnosis (known as latency) varies widely between individuals, with JAK2 mutations detectable several decades before diagnosis and even from birth in some individuals. Here, we will review the...]]></summary>
        <author>
            <name>Ruth Stuckey</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Unveiling the Genetic Footprint: Exploring Somatic Mutations in Peripheral Arterial Disease Progression]]></title>
        <id>pubmed:37626784</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37626784/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230908204701&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-08-26T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Peripheral arterial diseases (PADs) are complex cardiovascular conditions influenced by environmental factors and somatic mutations in multiple genes involved in hematopoiesis and inflammation. While traditional risk factors, such as smoking, hypercholesterolemia, and hypertension, have been extensively studied, the role of somatic mutations in PAD progression remains underexplored. The present article intends to provide a comprehensive commentary of the molecular mechanisms, genetic landscape,...]]></summary>
        <author>
            <name>Amankeldi A Salybekov</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Molecular Studies for the Early Detection of Philadelphia-Negative Myeloproliferative Neoplasms]]></title>
        <id>pubmed:37628880</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37628880/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230907204816&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-08-26T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[JAK2 V617F is the predominant driver mutation in patients with Philadelphia-negative myeloproliferative neoplasms (MPN). JAK2 mutations are also frequent in clonal hematopoiesis of indeterminate potential (CHIP) in otherwise "healthy" individuals. However, the period between mutation acquisition and MPN diagnosis (known as latency) varies widely between individuals, with JAK2 mutations detectable several decades before diagnosis and even from birth in some individuals. Here, we will review the...]]></summary>
        <author>
            <name>Ruth Stuckey</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Unveiling the Genetic Footprint: Exploring Somatic Mutations in Peripheral Arterial Disease Progression]]></title>
        <id>pubmed:37626784</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37626784/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230907204816&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-08-26T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Peripheral arterial diseases (PADs) are complex cardiovascular conditions influenced by environmental factors and somatic mutations in multiple genes involved in hematopoiesis and inflammation. While traditional risk factors, such as smoking, hypercholesterolemia, and hypertension, have been extensively studied, the role of somatic mutations in PAD progression remains underexplored. The present article intends to provide a comprehensive commentary of the molecular mechanisms, genetic landscape,...]]></summary>
        <author>
            <name>Amankeldi A Salybekov</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Molecular Studies for the Early Detection of Philadelphia-Negative Myeloproliferative Neoplasms]]></title>
        <id>pubmed:37628880</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37628880/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230906204801&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-08-26T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[JAK2 V617F is the predominant driver mutation in patients with Philadelphia-negative myeloproliferative neoplasms (MPN). JAK2 mutations are also frequent in clonal hematopoiesis of indeterminate potential (CHIP) in otherwise "healthy" individuals. However, the period between mutation acquisition and MPN diagnosis (known as latency) varies widely between individuals, with JAK2 mutations detectable several decades before diagnosis and even from birth in some individuals. Here, we will review the...]]></summary>
        <author>
            <name>Ruth Stuckey</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Unveiling the Genetic Footprint: Exploring Somatic Mutations in Peripheral Arterial Disease Progression]]></title>
        <id>pubmed:37626784</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37626784/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230906204801&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-08-26T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Peripheral arterial diseases (PADs) are complex cardiovascular conditions influenced by environmental factors and somatic mutations in multiple genes involved in hematopoiesis and inflammation. While traditional risk factors, such as smoking, hypercholesterolemia, and hypertension, have been extensively studied, the role of somatic mutations in PAD progression remains underexplored. The present article intends to provide a comprehensive commentary of the molecular mechanisms, genetic landscape,...]]></summary>
        <author>
            <name>Amankeldi A Salybekov</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Molecular Studies for the Early Detection of Philadelphia-Negative Myeloproliferative Neoplasms]]></title>
        <id>pubmed:37628880</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37628880/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230905204848&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-08-26T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[JAK2 V617F is the predominant driver mutation in patients with Philadelphia-negative myeloproliferative neoplasms (MPN). JAK2 mutations are also frequent in clonal hematopoiesis of indeterminate potential (CHIP) in otherwise "healthy" individuals. However, the period between mutation acquisition and MPN diagnosis (known as latency) varies widely between individuals, with JAK2 mutations detectable several decades before diagnosis and even from birth in some individuals. Here, we will review the...]]></summary>
        <author>
            <name>Ruth Stuckey</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Unveiling the Genetic Footprint: Exploring Somatic Mutations in Peripheral Arterial Disease Progression]]></title>
        <id>pubmed:37626784</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37626784/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230905204848&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-08-26T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Peripheral arterial diseases (PADs) are complex cardiovascular conditions influenced by environmental factors and somatic mutations in multiple genes involved in hematopoiesis and inflammation. While traditional risk factors, such as smoking, hypercholesterolemia, and hypertension, have been extensively studied, the role of somatic mutations in PAD progression remains underexplored. The present article intends to provide a comprehensive commentary of the molecular mechanisms, genetic landscape,...]]></summary>
        <author>
            <name>Amankeldi A Salybekov</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Molecular Studies for the Early Detection of Philadelphia-Negative Myeloproliferative Neoplasms]]></title>
        <id>pubmed:37628880</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37628880/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230904204751&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-08-26T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[JAK2 V617F is the predominant driver mutation in patients with Philadelphia-negative myeloproliferative neoplasms (MPN). JAK2 mutations are also frequent in clonal hematopoiesis of indeterminate potential (CHIP) in otherwise "healthy" individuals. However, the period between mutation acquisition and MPN diagnosis (known as latency) varies widely between individuals, with JAK2 mutations detectable several decades before diagnosis and even from birth in some individuals. Here, we will review the...]]></summary>
        <author>
            <name>Ruth Stuckey</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Unveiling the Genetic Footprint: Exploring Somatic Mutations in Peripheral Arterial Disease Progression]]></title>
        <id>pubmed:37626784</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37626784/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230904204751&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-08-26T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Peripheral arterial diseases (PADs) are complex cardiovascular conditions influenced by environmental factors and somatic mutations in multiple genes involved in hematopoiesis and inflammation. While traditional risk factors, such as smoking, hypercholesterolemia, and hypertension, have been extensively studied, the role of somatic mutations in PAD progression remains underexplored. The present article intends to provide a comprehensive commentary of the molecular mechanisms, genetic landscape,...]]></summary>
        <author>
            <name>Amankeldi A Salybekov</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Molecular Studies for the Early Detection of Philadelphia-Negative Myeloproliferative Neoplasms]]></title>
        <id>pubmed:37628880</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37628880/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230903204939&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-08-26T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[JAK2 V617F is the predominant driver mutation in patients with Philadelphia-negative myeloproliferative neoplasms (MPN). JAK2 mutations are also frequent in clonal hematopoiesis of indeterminate potential (CHIP) in otherwise "healthy" individuals. However, the period between mutation acquisition and MPN diagnosis (known as latency) varies widely between individuals, with JAK2 mutations detectable several decades before diagnosis and even from birth in some individuals. Here, we will review the...]]></summary>
        <author>
            <name>Ruth Stuckey</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Unveiling the Genetic Footprint: Exploring Somatic Mutations in Peripheral Arterial Disease Progression]]></title>
        <id>pubmed:37626784</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37626784/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230903204939&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-08-26T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Peripheral arterial diseases (PADs) are complex cardiovascular conditions influenced by environmental factors and somatic mutations in multiple genes involved in hematopoiesis and inflammation. While traditional risk factors, such as smoking, hypercholesterolemia, and hypertension, have been extensively studied, the role of somatic mutations in PAD progression remains underexplored. The present article intends to provide a comprehensive commentary of the molecular mechanisms, genetic landscape,...]]></summary>
        <author>
            <name>Amankeldi A Salybekov</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Molecular Studies for the Early Detection of Philadelphia-Negative Myeloproliferative Neoplasms]]></title>
        <id>pubmed:37628880</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37628880/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230902205121&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-08-26T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[JAK2 V617F is the predominant driver mutation in patients with Philadelphia-negative myeloproliferative neoplasms (MPN). JAK2 mutations are also frequent in clonal hematopoiesis of indeterminate potential (CHIP) in otherwise "healthy" individuals. However, the period between mutation acquisition and MPN diagnosis (known as latency) varies widely between individuals, with JAK2 mutations detectable several decades before diagnosis and even from birth in some individuals. Here, we will review the...]]></summary>
        <author>
            <name>Ruth Stuckey</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Unveiling the Genetic Footprint: Exploring Somatic Mutations in Peripheral Arterial Disease Progression]]></title>
        <id>pubmed:37626784</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37626784/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230902205121&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-08-26T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Peripheral arterial diseases (PADs) are complex cardiovascular conditions influenced by environmental factors and somatic mutations in multiple genes involved in hematopoiesis and inflammation. While traditional risk factors, such as smoking, hypercholesterolemia, and hypertension, have been extensively studied, the role of somatic mutations in PAD progression remains underexplored. The present article intends to provide a comprehensive commentary of the molecular mechanisms, genetic landscape,...]]></summary>
        <author>
            <name>Amankeldi A Salybekov</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Molecular Studies for the Early Detection of Philadelphia-Negative Myeloproliferative Neoplasms]]></title>
        <id>pubmed:37628880</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37628880/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230901204619&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-08-26T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[JAK2 V617F is the predominant driver mutation in patients with Philadelphia-negative myeloproliferative neoplasms (MPN). JAK2 mutations are also frequent in clonal hematopoiesis of indeterminate potential (CHIP) in otherwise "healthy" individuals. However, the period between mutation acquisition and MPN diagnosis (known as latency) varies widely between individuals, with JAK2 mutations detectable several decades before diagnosis and even from birth in some individuals. Here, we will review the...]]></summary>
        <author>
            <name>Ruth Stuckey</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Unveiling the Genetic Footprint: Exploring Somatic Mutations in Peripheral Arterial Disease Progression]]></title>
        <id>pubmed:37626784</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37626784/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230901204619&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-08-26T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Peripheral arterial diseases (PADs) are complex cardiovascular conditions influenced by environmental factors and somatic mutations in multiple genes involved in hematopoiesis and inflammation. While traditional risk factors, such as smoking, hypercholesterolemia, and hypertension, have been extensively studied, the role of somatic mutations in PAD progression remains underexplored. The present article intends to provide a comprehensive commentary of the molecular mechanisms, genetic landscape,...]]></summary>
        <author>
            <name>Amankeldi A Salybekov</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Molecular Studies for the Early Detection of Philadelphia-Negative Myeloproliferative Neoplasms]]></title>
        <id>pubmed:37628880</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37628880/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230831205203&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-08-26T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[JAK2 V617F is the predominant driver mutation in patients with Philadelphia-negative myeloproliferative neoplasms (MPN). JAK2 mutations are also frequent in clonal hematopoiesis of indeterminate potential (CHIP) in otherwise "healthy" individuals. However, the period between mutation acquisition and MPN diagnosis (known as latency) varies widely between individuals, with JAK2 mutations detectable several decades before diagnosis and even from birth in some individuals. Here, we will review the...]]></summary>
        <author>
            <name>Ruth Stuckey</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Unveiling the Genetic Footprint: Exploring Somatic Mutations in Peripheral Arterial Disease Progression]]></title>
        <id>pubmed:37626784</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37626784/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230831205203&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-08-26T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Peripheral arterial diseases (PADs) are complex cardiovascular conditions influenced by environmental factors and somatic mutations in multiple genes involved in hematopoiesis and inflammation. While traditional risk factors, such as smoking, hypercholesterolemia, and hypertension, have been extensively studied, the role of somatic mutations in PAD progression remains underexplored. The present article intends to provide a comprehensive commentary of the molecular mechanisms, genetic landscape,...]]></summary>
        <author>
            <name>Amankeldi A Salybekov</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Molecular Studies for the Early Detection of Philadelphia-Negative Myeloproliferative Neoplasms]]></title>
        <id>pubmed:37628880</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37628880/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230830204850&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-08-26T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[JAK2 V617F is the predominant driver mutation in patients with Philadelphia-negative myeloproliferative neoplasms (MPN). JAK2 mutations are also frequent in clonal hematopoiesis of indeterminate potential (CHIP) in otherwise "healthy" individuals. However, the period between mutation acquisition and MPN diagnosis (known as latency) varies widely between individuals, with JAK2 mutations detectable several decades before diagnosis and even from birth in some individuals. Here, we will review the...]]></summary>
        <author>
            <name>Ruth Stuckey</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Unveiling the Genetic Footprint: Exploring Somatic Mutations in Peripheral Arterial Disease Progression]]></title>
        <id>pubmed:37626784</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37626784/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230830204850&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-08-26T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Peripheral arterial diseases (PADs) are complex cardiovascular conditions influenced by environmental factors and somatic mutations in multiple genes involved in hematopoiesis and inflammation. While traditional risk factors, such as smoking, hypercholesterolemia, and hypertension, have been extensively studied, the role of somatic mutations in PAD progression remains underexplored. The present article intends to provide a comprehensive commentary of the molecular mechanisms, genetic landscape,...]]></summary>
        <author>
            <name>Amankeldi A Salybekov</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Molecular Studies for the Early Detection of Philadelphia-Negative Myeloproliferative Neoplasms]]></title>
        <id>pubmed:37628880</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37628880/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230829204824&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-08-26T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[JAK2 V617F is the predominant driver mutation in patients with Philadelphia-negative myeloproliferative neoplasms (MPN). JAK2 mutations are also frequent in clonal hematopoiesis of indeterminate potential (CHIP) in otherwise "healthy" individuals. However, the period between mutation acquisition and MPN diagnosis (known as latency) varies widely between individuals, with JAK2 mutations detectable several decades before diagnosis and even from birth in some individuals. Here, we will review the...]]></summary>
        <author>
            <name>Ruth Stuckey</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Unveiling the Genetic Footprint: Exploring Somatic Mutations in Peripheral Arterial Disease Progression]]></title>
        <id>pubmed:37626784</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37626784/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230829204824&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-08-26T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Peripheral arterial diseases (PADs) are complex cardiovascular conditions influenced by environmental factors and somatic mutations in multiple genes involved in hematopoiesis and inflammation. While traditional risk factors, such as smoking, hypercholesterolemia, and hypertension, have been extensively studied, the role of somatic mutations in PAD progression remains underexplored. The present article intends to provide a comprehensive commentary of the molecular mechanisms, genetic landscape,...]]></summary>
        <author>
            <name>Amankeldi A Salybekov</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Molecular Studies for the Early Detection of Philadelphia-Negative Myeloproliferative Neoplasms]]></title>
        <id>pubmed:37628880</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37628880/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230828204854&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-08-26T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[JAK2 V617F is the predominant driver mutation in patients with Philadelphia-negative myeloproliferative neoplasms (MPN). JAK2 mutations are also frequent in clonal hematopoiesis of indeterminate potential (CHIP) in otherwise "healthy" individuals. However, the period between mutation acquisition and MPN diagnosis (known as latency) varies widely between individuals, with JAK2 mutations detectable several decades before diagnosis and even from birth in some individuals. Here, we will review the...]]></summary>
        <author>
            <name>Ruth Stuckey</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Unveiling the Genetic Footprint: Exploring Somatic Mutations in Peripheral Arterial Disease Progression]]></title>
        <id>pubmed:37626784</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37626784/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230828204854&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-08-26T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Peripheral arterial diseases (PADs) are complex cardiovascular conditions influenced by environmental factors and somatic mutations in multiple genes involved in hematopoiesis and inflammation. While traditional risk factors, such as smoking, hypercholesterolemia, and hypertension, have been extensively studied, the role of somatic mutations in PAD progression remains underexplored. The present article intends to provide a comprehensive commentary of the molecular mechanisms, genetic landscape,...]]></summary>
        <author>
            <name>Amankeldi A Salybekov</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Molecular Studies for the Early Detection of Philadelphia-Negative Myeloproliferative Neoplasms]]></title>
        <id>pubmed:37628880</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37628880/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230827204908&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-08-26T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[JAK2 V617F is the predominant driver mutation in patients with Philadelphia-negative myeloproliferative neoplasms (MPN). JAK2 mutations are also frequent in clonal hematopoiesis of indeterminate potential (CHIP) in otherwise "healthy" individuals. However, the period between mutation acquisition and MPN diagnosis (known as latency) varies widely between individuals, with JAK2 mutations detectable several decades before diagnosis and even from birth in some individuals. Here, we will review the...]]></summary>
        <author>
            <name>Ruth Stuckey</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Unveiling the Genetic Footprint: Exploring Somatic Mutations in Peripheral Arterial Disease Progression]]></title>
        <id>pubmed:37626784</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37626784/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230827204908&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-08-26T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Peripheral arterial diseases (PADs) are complex cardiovascular conditions influenced by environmental factors and somatic mutations in multiple genes involved in hematopoiesis and inflammation. While traditional risk factors, such as smoking, hypercholesterolemia, and hypertension, have been extensively studied, the role of somatic mutations in PAD progression remains underexplored. The present article intends to provide a comprehensive commentary of the molecular mechanisms, genetic landscape,...]]></summary>
        <author>
            <name>Amankeldi A Salybekov</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Molecular Studies for the Early Detection of Philadelphia-Negative Myeloproliferative Neoplasms]]></title>
        <id>pubmed:37628880</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37628880/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230826205107&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-08-26T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[JAK2 V617F is the predominant driver mutation in patients with Philadelphia-negative myeloproliferative neoplasms (MPN). JAK2 mutations are also frequent in clonal hematopoiesis of indeterminate potential (CHIP) in otherwise "healthy" individuals. However, the period between mutation acquisition and MPN diagnosis (known as latency) varies widely between individuals, with JAK2 mutations detectable several decades before diagnosis and even from birth in some individuals. Here, we will review the...]]></summary>
        <author>
            <name>Ruth Stuckey</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Unveiling the Genetic Footprint: Exploring Somatic Mutations in Peripheral Arterial Disease Progression]]></title>
        <id>pubmed:37626784</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37626784/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230826205107&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-08-26T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Peripheral arterial diseases (PADs) are complex cardiovascular conditions influenced by environmental factors and somatic mutations in multiple genes involved in hematopoiesis and inflammation. While traditional risk factors, such as smoking, hypercholesterolemia, and hypertension, have been extensively studied, the role of somatic mutations in PAD progression remains underexplored. The present article intends to provide a comprehensive commentary of the molecular mechanisms, genetic landscape,...]]></summary>
        <author>
            <name>Amankeldi A Salybekov</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Unravelling the Complexity of Colorectal Cancer: Heterogeneity, Clonal Evolution, and Clinical Implications]]></title>
        <id>pubmed:37627048</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37627048/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230919204929&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-08-26T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Colorectal cancer (CRC) is a global health concern and a leading cause of death worldwide. The disease's course and response to treatment are significantly influenced by its heterogeneity, both within a single lesion and between primary and metastatic sites. Biomarkers, such as mutations in KRAS, NRAS, and BRAF, provide valuable guidance for treatment decisions in patients with metastatic CRC. While high concordance exists between mutational status in primary and metastatic lesions, some...]]></summary>
        <author>
            <name>Nadia Saoudi Gonzlez</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Unravelling the Complexity of Colorectal Cancer: Heterogeneity, Clonal Evolution, and Clinical Implications]]></title>
        <id>pubmed:37627048</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37627048/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230918204942&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-08-26T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Colorectal cancer (CRC) is a global health concern and a leading cause of death worldwide. The disease's course and response to treatment are significantly influenced by its heterogeneity, both within a single lesion and between primary and metastatic sites. Biomarkers, such as mutations in KRAS, NRAS, and BRAF, provide valuable guidance for treatment decisions in patients with metastatic CRC. While high concordance exists between mutational status in primary and metastatic lesions, some...]]></summary>
        <author>
            <name>Nadia Saoudi Gonzlez</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Unravelling the Complexity of Colorectal Cancer: Heterogeneity, Clonal Evolution, and Clinical Implications]]></title>
        <id>pubmed:37627048</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37627048/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230917204936&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-08-26T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Colorectal cancer (CRC) is a global health concern and a leading cause of death worldwide. The disease's course and response to treatment are significantly influenced by its heterogeneity, both within a single lesion and between primary and metastatic sites. Biomarkers, such as mutations in KRAS, NRAS, and BRAF, provide valuable guidance for treatment decisions in patients with metastatic CRC. While high concordance exists between mutational status in primary and metastatic lesions, some...]]></summary>
        <author>
            <name>Nadia Saoudi Gonzlez</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Unravelling the Complexity of Colorectal Cancer: Heterogeneity, Clonal Evolution, and Clinical Implications]]></title>
        <id>pubmed:37627048</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37627048/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230916205201&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-08-26T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Colorectal cancer (CRC) is a global health concern and a leading cause of death worldwide. The disease's course and response to treatment are significantly influenced by its heterogeneity, both within a single lesion and between primary and metastatic sites. Biomarkers, such as mutations in KRAS, NRAS, and BRAF, provide valuable guidance for treatment decisions in patients with metastatic CRC. While high concordance exists between mutational status in primary and metastatic lesions, some...]]></summary>
        <author>
            <name>Nadia Saoudi Gonzlez</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Unravelling the Complexity of Colorectal Cancer: Heterogeneity, Clonal Evolution, and Clinical Implications]]></title>
        <id>pubmed:37627048</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37627048/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230915204741&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-08-26T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Colorectal cancer (CRC) is a global health concern and a leading cause of death worldwide. The disease's course and response to treatment are significantly influenced by its heterogeneity, both within a single lesion and between primary and metastatic sites. Biomarkers, such as mutations in KRAS, NRAS, and BRAF, provide valuable guidance for treatment decisions in patients with metastatic CRC. While high concordance exists between mutational status in primary and metastatic lesions, some...]]></summary>
        <author>
            <name>Nadia Saoudi Gonzlez</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Unravelling the Complexity of Colorectal Cancer: Heterogeneity, Clonal Evolution, and Clinical Implications]]></title>
        <id>pubmed:37627048</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37627048/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230914204950&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-08-26T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Colorectal cancer (CRC) is a global health concern and a leading cause of death worldwide. The disease's course and response to treatment are significantly influenced by its heterogeneity, both within a single lesion and between primary and metastatic sites. Biomarkers, such as mutations in KRAS, NRAS, and BRAF, provide valuable guidance for treatment decisions in patients with metastatic CRC. While high concordance exists between mutational status in primary and metastatic lesions, some...]]></summary>
        <author>
            <name>Nadia Saoudi Gonzlez</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Unravelling the Complexity of Colorectal Cancer: Heterogeneity, Clonal Evolution, and Clinical Implications]]></title>
        <id>pubmed:37627048</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37627048/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230913204840&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-08-26T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Colorectal cancer (CRC) is a global health concern and a leading cause of death worldwide. The disease's course and response to treatment are significantly influenced by its heterogeneity, both within a single lesion and between primary and metastatic sites. Biomarkers, such as mutations in KRAS, NRAS, and BRAF, provide valuable guidance for treatment decisions in patients with metastatic CRC. While high concordance exists between mutational status in primary and metastatic lesions, some...]]></summary>
        <author>
            <name>Nadia Saoudi Gonzlez</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Unravelling the Complexity of Colorectal Cancer: Heterogeneity, Clonal Evolution, and Clinical Implications]]></title>
        <id>pubmed:37627048</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37627048/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230912205015&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-08-26T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Colorectal cancer (CRC) is a global health concern and a leading cause of death worldwide. The disease's course and response to treatment are significantly influenced by its heterogeneity, both within a single lesion and between primary and metastatic sites. Biomarkers, such as mutations in KRAS, NRAS, and BRAF, provide valuable guidance for treatment decisions in patients with metastatic CRC. While high concordance exists between mutational status in primary and metastatic lesions, some...]]></summary>
        <author>
            <name>Nadia Saoudi Gonzlez</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Unravelling the Complexity of Colorectal Cancer: Heterogeneity, Clonal Evolution, and Clinical Implications]]></title>
        <id>pubmed:37627048</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37627048/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230911204717&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-08-26T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Colorectal cancer (CRC) is a global health concern and a leading cause of death worldwide. The disease's course and response to treatment are significantly influenced by its heterogeneity, both within a single lesion and between primary and metastatic sites. Biomarkers, such as mutations in KRAS, NRAS, and BRAF, provide valuable guidance for treatment decisions in patients with metastatic CRC. While high concordance exists between mutational status in primary and metastatic lesions, some...]]></summary>
        <author>
            <name>Nadia Saoudi Gonzlez</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Unravelling the Complexity of Colorectal Cancer: Heterogeneity, Clonal Evolution, and Clinical Implications]]></title>
        <id>pubmed:37627048</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37627048/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230910204912&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-08-26T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Colorectal cancer (CRC) is a global health concern and a leading cause of death worldwide. The disease's course and response to treatment are significantly influenced by its heterogeneity, both within a single lesion and between primary and metastatic sites. Biomarkers, such as mutations in KRAS, NRAS, and BRAF, provide valuable guidance for treatment decisions in patients with metastatic CRC. While high concordance exists between mutational status in primary and metastatic lesions, some...]]></summary>
        <author>
            <name>Nadia Saoudi Gonzlez</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Unravelling the Complexity of Colorectal Cancer: Heterogeneity, Clonal Evolution, and Clinical Implications]]></title>
        <id>pubmed:37627048</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37627048/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230909205145&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-08-26T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Colorectal cancer (CRC) is a global health concern and a leading cause of death worldwide. The disease's course and response to treatment are significantly influenced by its heterogeneity, both within a single lesion and between primary and metastatic sites. Biomarkers, such as mutations in KRAS, NRAS, and BRAF, provide valuable guidance for treatment decisions in patients with metastatic CRC. While high concordance exists between mutational status in primary and metastatic lesions, some...]]></summary>
        <author>
            <name>Nadia Saoudi Gonzlez</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Unravelling the Complexity of Colorectal Cancer: Heterogeneity, Clonal Evolution, and Clinical Implications]]></title>
        <id>pubmed:37627048</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37627048/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230908204701&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-08-26T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Colorectal cancer (CRC) is a global health concern and a leading cause of death worldwide. The disease's course and response to treatment are significantly influenced by its heterogeneity, both within a single lesion and between primary and metastatic sites. Biomarkers, such as mutations in KRAS, NRAS, and BRAF, provide valuable guidance for treatment decisions in patients with metastatic CRC. While high concordance exists between mutational status in primary and metastatic lesions, some...]]></summary>
        <author>
            <name>Nadia Saoudi Gonzlez</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Unravelling the Complexity of Colorectal Cancer: Heterogeneity, Clonal Evolution, and Clinical Implications]]></title>
        <id>pubmed:37627048</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37627048/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230907204816&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-08-26T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Colorectal cancer (CRC) is a global health concern and a leading cause of death worldwide. The disease's course and response to treatment are significantly influenced by its heterogeneity, both within a single lesion and between primary and metastatic sites. Biomarkers, such as mutations in KRAS, NRAS, and BRAF, provide valuable guidance for treatment decisions in patients with metastatic CRC. While high concordance exists between mutational status in primary and metastatic lesions, some...]]></summary>
        <author>
            <name>Nadia Saoudi Gonzlez</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Unravelling the Complexity of Colorectal Cancer: Heterogeneity, Clonal Evolution, and Clinical Implications]]></title>
        <id>pubmed:37627048</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37627048/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230906204801&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-08-26T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Colorectal cancer (CRC) is a global health concern and a leading cause of death worldwide. The disease's course and response to treatment are significantly influenced by its heterogeneity, both within a single lesion and between primary and metastatic sites. Biomarkers, such as mutations in KRAS, NRAS, and BRAF, provide valuable guidance for treatment decisions in patients with metastatic CRC. While high concordance exists between mutational status in primary and metastatic lesions, some...]]></summary>
        <author>
            <name>Nadia Saoudi Gonzlez</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Unravelling the Complexity of Colorectal Cancer: Heterogeneity, Clonal Evolution, and Clinical Implications]]></title>
        <id>pubmed:37627048</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37627048/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230905204848&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-08-26T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Colorectal cancer (CRC) is a global health concern and a leading cause of death worldwide. The disease's course and response to treatment are significantly influenced by its heterogeneity, both within a single lesion and between primary and metastatic sites. Biomarkers, such as mutations in KRAS, NRAS, and BRAF, provide valuable guidance for treatment decisions in patients with metastatic CRC. While high concordance exists between mutational status in primary and metastatic lesions, some...]]></summary>
        <author>
            <name>Nadia Saoudi Gonzlez</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Unravelling the Complexity of Colorectal Cancer: Heterogeneity, Clonal Evolution, and Clinical Implications]]></title>
        <id>pubmed:37627048</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37627048/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230904204751&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-08-26T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Colorectal cancer (CRC) is a global health concern and a leading cause of death worldwide. The disease's course and response to treatment are significantly influenced by its heterogeneity, both within a single lesion and between primary and metastatic sites. Biomarkers, such as mutations in KRAS, NRAS, and BRAF, provide valuable guidance for treatment decisions in patients with metastatic CRC. While high concordance exists between mutational status in primary and metastatic lesions, some...]]></summary>
        <author>
            <name>Nadia Saoudi Gonzlez</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Unravelling the Complexity of Colorectal Cancer: Heterogeneity, Clonal Evolution, and Clinical Implications]]></title>
        <id>pubmed:37627048</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37627048/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230903204939&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-08-26T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Colorectal cancer (CRC) is a global health concern and a leading cause of death worldwide. The disease's course and response to treatment are significantly influenced by its heterogeneity, both within a single lesion and between primary and metastatic sites. Biomarkers, such as mutations in KRAS, NRAS, and BRAF, provide valuable guidance for treatment decisions in patients with metastatic CRC. While high concordance exists between mutational status in primary and metastatic lesions, some...]]></summary>
        <author>
            <name>Nadia Saoudi Gonzlez</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Unravelling the Complexity of Colorectal Cancer: Heterogeneity, Clonal Evolution, and Clinical Implications]]></title>
        <id>pubmed:37627048</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37627048/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230902205121&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-08-26T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Colorectal cancer (CRC) is a global health concern and a leading cause of death worldwide. The disease's course and response to treatment are significantly influenced by its heterogeneity, both within a single lesion and between primary and metastatic sites. Biomarkers, such as mutations in KRAS, NRAS, and BRAF, provide valuable guidance for treatment decisions in patients with metastatic CRC. While high concordance exists between mutational status in primary and metastatic lesions, some...]]></summary>
        <author>
            <name>Nadia Saoudi Gonzlez</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Unravelling the Complexity of Colorectal Cancer: Heterogeneity, Clonal Evolution, and Clinical Implications]]></title>
        <id>pubmed:37627048</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37627048/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230901204619&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-08-26T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Colorectal cancer (CRC) is a global health concern and a leading cause of death worldwide. The disease's course and response to treatment are significantly influenced by its heterogeneity, both within a single lesion and between primary and metastatic sites. Biomarkers, such as mutations in KRAS, NRAS, and BRAF, provide valuable guidance for treatment decisions in patients with metastatic CRC. While high concordance exists between mutational status in primary and metastatic lesions, some...]]></summary>
        <author>
            <name>Nadia Saoudi Gonzlez</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Unravelling the Complexity of Colorectal Cancer: Heterogeneity, Clonal Evolution, and Clinical Implications]]></title>
        <id>pubmed:37627048</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37627048/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230831205203&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-08-26T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Colorectal cancer (CRC) is a global health concern and a leading cause of death worldwide. The disease's course and response to treatment are significantly influenced by its heterogeneity, both within a single lesion and between primary and metastatic sites. Biomarkers, such as mutations in KRAS, NRAS, and BRAF, provide valuable guidance for treatment decisions in patients with metastatic CRC. While high concordance exists between mutational status in primary and metastatic lesions, some...]]></summary>
        <author>
            <name>Nadia Saoudi Gonzlez</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Unravelling the Complexity of Colorectal Cancer: Heterogeneity, Clonal Evolution, and Clinical Implications]]></title>
        <id>pubmed:37627048</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37627048/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230830204850&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-08-26T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Colorectal cancer (CRC) is a global health concern and a leading cause of death worldwide. The disease's course and response to treatment are significantly influenced by its heterogeneity, both within a single lesion and between primary and metastatic sites. Biomarkers, such as mutations in KRAS, NRAS, and BRAF, provide valuable guidance for treatment decisions in patients with metastatic CRC. While high concordance exists between mutational status in primary and metastatic lesions, some...]]></summary>
        <author>
            <name>Nadia Saoudi Gonzlez</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Unravelling the Complexity of Colorectal Cancer: Heterogeneity, Clonal Evolution, and Clinical Implications]]></title>
        <id>pubmed:37627048</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37627048/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230829204824&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-08-26T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Colorectal cancer (CRC) is a global health concern and a leading cause of death worldwide. The disease's course and response to treatment are significantly influenced by its heterogeneity, both within a single lesion and between primary and metastatic sites. Biomarkers, such as mutations in KRAS, NRAS, and BRAF, provide valuable guidance for treatment decisions in patients with metastatic CRC. While high concordance exists between mutational status in primary and metastatic lesions, some...]]></summary>
        <author>
            <name>Nadia Saoudi Gonzlez</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Unravelling the Complexity of Colorectal Cancer: Heterogeneity, Clonal Evolution, and Clinical Implications]]></title>
        <id>pubmed:37627048</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37627048/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230828204854&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-08-26T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Colorectal cancer (CRC) is a global health concern and a leading cause of death worldwide. The disease's course and response to treatment are significantly influenced by its heterogeneity, both within a single lesion and between primary and metastatic sites. Biomarkers, such as mutations in KRAS, NRAS, and BRAF, provide valuable guidance for treatment decisions in patients with metastatic CRC. While high concordance exists between mutational status in primary and metastatic lesions, some...]]></summary>
        <author>
            <name>Nadia Saoudi Gonzlez</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Unravelling the Complexity of Colorectal Cancer: Heterogeneity, Clonal Evolution, and Clinical Implications]]></title>
        <id>pubmed:37627048</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37627048/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230827204908&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-08-26T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Colorectal cancer (CRC) is a global health concern and a leading cause of death worldwide. The disease's course and response to treatment are significantly influenced by its heterogeneity, both within a single lesion and between primary and metastatic sites. Biomarkers, such as mutations in KRAS, NRAS, and BRAF, provide valuable guidance for treatment decisions in patients with metastatic CRC. While high concordance exists between mutational status in primary and metastatic lesions, some...]]></summary>
        <author>
            <name>Nadia Saoudi Gonzlez</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Unravelling the Complexity of Colorectal Cancer: Heterogeneity, Clonal Evolution, and Clinical Implications]]></title>
        <id>pubmed:37627048</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37627048/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230826205107&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-08-26T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Colorectal cancer (CRC) is a global health concern and a leading cause of death worldwide. The disease's course and response to treatment are significantly influenced by its heterogeneity, both within a single lesion and between primary and metastatic sites. Biomarkers, such as mutations in KRAS, NRAS, and BRAF, provide valuable guidance for treatment decisions in patients with metastatic CRC. While high concordance exists between mutational status in primary and metastatic lesions, some...]]></summary>
        <author>
            <name>Nadia Saoudi Gonzlez</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Multiparameter prediction of myeloid neoplasia risk]]></title>
        <id>pubmed:37620601</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37620601/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230913204840&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-08-24T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[The myeloid neoplasms encompass acute myeloid leukemia, myelodysplastic syndromes and myeloproliferative neoplasms. Most cases arise from the shared ancestor of clonal hematopoiesis (CH). Here we analyze data from 454,340 UK Biobank participants, of whom 1,808 developed a myeloid neoplasm 0-15 years after recruitment. We describe the differences in CH mutational landscapes and hematology/biochemistry test parameters among individuals that later develop myeloid neoplasms (pre-MN) versus controls,...]]></summary>
        <author>
            <name>Muxin Gu</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Multiparameter prediction of myeloid neoplasia risk]]></title>
        <id>pubmed:37620601</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37620601/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230912205016&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-08-24T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[The myeloid neoplasms encompass acute myeloid leukemia, myelodysplastic syndromes and myeloproliferative neoplasms. Most cases arise from the shared ancestor of clonal hematopoiesis (CH). Here we analyze data from 454,340 UK Biobank participants, of whom 1,808 developed a myeloid neoplasm 0-15 years after recruitment. We describe the differences in CH mutational landscapes and hematology/biochemistry test parameters among individuals that later develop myeloid neoplasms (pre-MN) versus controls,...]]></summary>
        <author>
            <name>Muxin Gu</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Multiparameter prediction of myeloid neoplasia risk]]></title>
        <id>pubmed:37620601</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37620601/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230911204717&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-08-24T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[The myeloid neoplasms encompass acute myeloid leukemia, myelodysplastic syndromes and myeloproliferative neoplasms. Most cases arise from the shared ancestor of clonal hematopoiesis (CH). Here we analyze data from 454,340 UK Biobank participants, of whom 1,808 developed a myeloid neoplasm 0-15 years after recruitment. We describe the differences in CH mutational landscapes and hematology/biochemistry test parameters among individuals that later develop myeloid neoplasms (pre-MN) versus controls,...]]></summary>
        <author>
            <name>Muxin Gu</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Hematopoietic-specific heterozygous loss of Dnmt3a exacerbates colitis-associated colon cancer]]></title>
        <id>pubmed:37615936</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37615936/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230911204717&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-08-24T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Clonal hematopoiesis (CH) is defined as clonal expansion of mutant hematopoietic stem cells absent diagnosis of a hematologic malignancy. Presence of CH in solid tumor patients, including colon cancer, correlates with shorter survival. We hypothesized that bone marrow-derived cells with heterozygous loss-of-function mutations of DNMT3A, the most common genetic alteration in CH, contribute to the pathogenesis of colon cancer. In a mouse model that combines colitis-associated colon cancer (CAC)...]]></summary>
        <author>
            <name>Yang Feng</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Multiparameter prediction of myeloid neoplasia risk]]></title>
        <id>pubmed:37620601</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37620601/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230910204912&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-08-24T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[The myeloid neoplasms encompass acute myeloid leukemia, myelodysplastic syndromes and myeloproliferative neoplasms. Most cases arise from the shared ancestor of clonal hematopoiesis (CH). Here we analyze data from 454,340 UK Biobank participants, of whom 1,808 developed a myeloid neoplasm 0-15 years after recruitment. We describe the differences in CH mutational landscapes and hematology/biochemistry test parameters among individuals that later develop myeloid neoplasms (pre-MN) versus controls,...]]></summary>
        <author>
            <name>Muxin Gu</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Hematopoietic-specific heterozygous loss of Dnmt3a exacerbates colitis-associated colon cancer]]></title>
        <id>pubmed:37615936</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37615936/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230910204912&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-08-24T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Clonal hematopoiesis (CH) is defined as clonal expansion of mutant hematopoietic stem cells absent diagnosis of a hematologic malignancy. Presence of CH in solid tumor patients, including colon cancer, correlates with shorter survival. We hypothesized that bone marrow-derived cells with heterozygous loss-of-function mutations of DNMT3A, the most common genetic alteration in CH, contribute to the pathogenesis of colon cancer. In a mouse model that combines colitis-associated colon cancer (CAC)...]]></summary>
        <author>
            <name>Yang Feng</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Multiparameter prediction of myeloid neoplasia risk]]></title>
        <id>pubmed:37620601</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37620601/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230909205145&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-08-24T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[The myeloid neoplasms encompass acute myeloid leukemia, myelodysplastic syndromes and myeloproliferative neoplasms. Most cases arise from the shared ancestor of clonal hematopoiesis (CH). Here we analyze data from 454,340 UK Biobank participants, of whom 1,808 developed a myeloid neoplasm 0-15 years after recruitment. We describe the differences in CH mutational landscapes and hematology/biochemistry test parameters among individuals that later develop myeloid neoplasms (pre-MN) versus controls,...]]></summary>
        <author>
            <name>Muxin Gu</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Hematopoietic-specific heterozygous loss of Dnmt3a exacerbates colitis-associated colon cancer]]></title>
        <id>pubmed:37615936</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37615936/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230909205145&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-08-24T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Clonal hematopoiesis (CH) is defined as clonal expansion of mutant hematopoietic stem cells absent diagnosis of a hematologic malignancy. Presence of CH in solid tumor patients, including colon cancer, correlates with shorter survival. We hypothesized that bone marrow-derived cells with heterozygous loss-of-function mutations of DNMT3A, the most common genetic alteration in CH, contribute to the pathogenesis of colon cancer. In a mouse model that combines colitis-associated colon cancer (CAC)...]]></summary>
        <author>
            <name>Yang Feng</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Multiparameter prediction of myeloid neoplasia risk]]></title>
        <id>pubmed:37620601</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37620601/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230908204701&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-08-24T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[The myeloid neoplasms encompass acute myeloid leukemia, myelodysplastic syndromes and myeloproliferative neoplasms. Most cases arise from the shared ancestor of clonal hematopoiesis (CH). Here we analyze data from 454,340 UK Biobank participants, of whom 1,808 developed a myeloid neoplasm 0-15 years after recruitment. We describe the differences in CH mutational landscapes and hematology/biochemistry test parameters among individuals that later develop myeloid neoplasms (pre-MN) versus controls,...]]></summary>
        <author>
            <name>Muxin Gu</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Hematopoietic-specific heterozygous loss of Dnmt3a exacerbates colitis-associated colon cancer]]></title>
        <id>pubmed:37615936</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37615936/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230908204701&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-08-24T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Clonal hematopoiesis (CH) is defined as clonal expansion of mutant hematopoietic stem cells absent diagnosis of a hematologic malignancy. Presence of CH in solid tumor patients, including colon cancer, correlates with shorter survival. We hypothesized that bone marrow-derived cells with heterozygous loss-of-function mutations of DNMT3A, the most common genetic alteration in CH, contribute to the pathogenesis of colon cancer. In a mouse model that combines colitis-associated colon cancer (CAC)...]]></summary>
        <author>
            <name>Yang Feng</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Multiparameter prediction of myeloid neoplasia risk]]></title>
        <id>pubmed:37620601</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37620601/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230907204816&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-08-24T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[The myeloid neoplasms encompass acute myeloid leukemia, myelodysplastic syndromes and myeloproliferative neoplasms. Most cases arise from the shared ancestor of clonal hematopoiesis (CH). Here we analyze data from 454,340 UK Biobank participants, of whom 1,808 developed a myeloid neoplasm 0-15 years after recruitment. We describe the differences in CH mutational landscapes and hematology/biochemistry test parameters among individuals that later develop myeloid neoplasms (pre-MN) versus controls,...]]></summary>
        <author>
            <name>Muxin Gu</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Hematopoietic-specific heterozygous loss of Dnmt3a exacerbates colitis-associated colon cancer]]></title>
        <id>pubmed:37615936</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37615936/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230907204816&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-08-24T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Clonal hematopoiesis (CH) is defined as clonal expansion of mutant hematopoietic stem cells absent diagnosis of a hematologic malignancy. Presence of CH in solid tumor patients, including colon cancer, correlates with shorter survival. We hypothesized that bone marrow-derived cells with heterozygous loss-of-function mutations of DNMT3A, the most common genetic alteration in CH, contribute to the pathogenesis of colon cancer. In a mouse model that combines colitis-associated colon cancer (CAC)...]]></summary>
        <author>
            <name>Yang Feng</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Multiparameter prediction of myeloid neoplasia risk]]></title>
        <id>pubmed:37620601</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37620601/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230906204801&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-08-24T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[The myeloid neoplasms encompass acute myeloid leukemia, myelodysplastic syndromes and myeloproliferative neoplasms. Most cases arise from the shared ancestor of clonal hematopoiesis (CH). Here we analyze data from 454,340 UK Biobank participants, of whom 1,808 developed a myeloid neoplasm 0-15 years after recruitment. We describe the differences in CH mutational landscapes and hematology/biochemistry test parameters among individuals that later develop myeloid neoplasms (pre-MN) versus controls,...]]></summary>
        <author>
            <name>Muxin Gu</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Hematopoietic-specific heterozygous loss of Dnmt3a exacerbates colitis-associated colon cancer]]></title>
        <id>pubmed:37615936</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37615936/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230906204801&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-08-24T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Clonal hematopoiesis (CH) is defined as clonal expansion of mutant hematopoietic stem cells absent diagnosis of a hematologic malignancy. Presence of CH in solid tumor patients, including colon cancer, correlates with shorter survival. We hypothesized that bone marrow-derived cells with heterozygous loss-of-function mutations of DNMT3A, the most common genetic alteration in CH, contribute to the pathogenesis of colon cancer. In a mouse model that combines colitis-associated colon cancer (CAC)...]]></summary>
        <author>
            <name>Yang Feng</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Multiparameter prediction of myeloid neoplasia risk]]></title>
        <id>pubmed:37620601</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37620601/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230905204848&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-08-24T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[The myeloid neoplasms encompass acute myeloid leukemia, myelodysplastic syndromes and myeloproliferative neoplasms. Most cases arise from the shared ancestor of clonal hematopoiesis (CH). Here we analyze data from 454,340 UK Biobank participants, of whom 1,808 developed a myeloid neoplasm 0-15 years after recruitment. We describe the differences in CH mutational landscapes and hematology/biochemistry test parameters among individuals that later develop myeloid neoplasms (pre-MN) versus controls,...]]></summary>
        <author>
            <name>Muxin Gu</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Hematopoietic-specific heterozygous loss of Dnmt3a exacerbates colitis-associated colon cancer]]></title>
        <id>pubmed:37615936</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37615936/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230905204848&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-08-24T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Clonal hematopoiesis (CH) is defined as clonal expansion of mutant hematopoietic stem cells absent diagnosis of a hematologic malignancy. Presence of CH in solid tumor patients, including colon cancer, correlates with shorter survival. We hypothesized that bone marrow-derived cells with heterozygous loss-of-function mutations of DNMT3A, the most common genetic alteration in CH, contribute to the pathogenesis of colon cancer. In a mouse model that combines colitis-associated colon cancer (CAC)...]]></summary>
        <author>
            <name>Yang Feng</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Multiparameter prediction of myeloid neoplasia risk]]></title>
        <id>pubmed:37620601</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37620601/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230904204751&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-08-24T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[The myeloid neoplasms encompass acute myeloid leukemia, myelodysplastic syndromes and myeloproliferative neoplasms. Most cases arise from the shared ancestor of clonal hematopoiesis (CH). Here we analyze data from 454,340 UK Biobank participants, of whom 1,808 developed a myeloid neoplasm 0-15 years after recruitment. We describe the differences in CH mutational landscapes and hematology/biochemistry test parameters among individuals that later develop myeloid neoplasms (pre-MN) versus controls,...]]></summary>
        <author>
            <name>Muxin Gu</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Hematopoietic-specific heterozygous loss of Dnmt3a exacerbates colitis-associated colon cancer]]></title>
        <id>pubmed:37615936</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37615936/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230904204751&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-08-24T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Clonal hematopoiesis (CH) is defined as clonal expansion of mutant hematopoietic stem cells absent diagnosis of a hematologic malignancy. Presence of CH in solid tumor patients, including colon cancer, correlates with shorter survival. We hypothesized that bone marrow-derived cells with heterozygous loss-of-function mutations of DNMT3A, the most common genetic alteration in CH, contribute to the pathogenesis of colon cancer. In a mouse model that combines colitis-associated colon cancer (CAC)...]]></summary>
        <author>
            <name>Yang Feng</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Multiparameter prediction of myeloid neoplasia risk]]></title>
        <id>pubmed:37620601</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37620601/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230903204939&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-08-24T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[The myeloid neoplasms encompass acute myeloid leukemia, myelodysplastic syndromes and myeloproliferative neoplasms. Most cases arise from the shared ancestor of clonal hematopoiesis (CH). Here we analyze data from 454,340 UK Biobank participants, of whom 1,808 developed a myeloid neoplasm 0-15 years after recruitment. We describe the differences in CH mutational landscapes and hematology/biochemistry test parameters among individuals that later develop myeloid neoplasms (pre-MN) versus controls,...]]></summary>
        <author>
            <name>Muxin Gu</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Hematopoietic-specific heterozygous loss of Dnmt3a exacerbates colitis-associated colon cancer]]></title>
        <id>pubmed:37615936</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37615936/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230903204939&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-08-24T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Clonal hematopoiesis (CH) is defined as clonal expansion of mutant hematopoietic stem cells absent diagnosis of a hematologic malignancy. Presence of CH in solid tumor patients, including colon cancer, correlates with shorter survival. We hypothesized that bone marrow-derived cells with heterozygous loss-of-function mutations of DNMT3A, the most common genetic alteration in CH, contribute to the pathogenesis of colon cancer. In a mouse model that combines colitis-associated colon cancer (CAC)...]]></summary>
        <author>
            <name>Yang Feng</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Multiparameter prediction of myeloid neoplasia risk]]></title>
        <id>pubmed:37620601</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37620601/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230902205121&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-08-24T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[The myeloid neoplasms encompass acute myeloid leukemia, myelodysplastic syndromes and myeloproliferative neoplasms. Most cases arise from the shared ancestor of clonal hematopoiesis (CH). Here we analyze data from 454,340 UK Biobank participants, of whom 1,808 developed a myeloid neoplasm 0-15 years after recruitment. We describe the differences in CH mutational landscapes and hematology/biochemistry test parameters among individuals that later develop myeloid neoplasms (pre-MN) versus controls,...]]></summary>
        <author>
            <name>Muxin Gu</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Hematopoietic-specific heterozygous loss of Dnmt3a exacerbates colitis-associated colon cancer]]></title>
        <id>pubmed:37615936</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37615936/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230902205121&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-08-24T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Clonal hematopoiesis (CH) is defined as clonal expansion of mutant hematopoietic stem cells absent diagnosis of a hematologic malignancy. Presence of CH in solid tumor patients, including colon cancer, correlates with shorter survival. We hypothesized that bone marrow-derived cells with heterozygous loss-of-function mutations of DNMT3A, the most common genetic alteration in CH, contribute to the pathogenesis of colon cancer. In a mouse model that combines colitis-associated colon cancer (CAC)...]]></summary>
        <author>
            <name>Yang Feng</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Multiparameter prediction of myeloid neoplasia risk]]></title>
        <id>pubmed:37620601</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37620601/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230901204619&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-08-24T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[The myeloid neoplasms encompass acute myeloid leukemia, myelodysplastic syndromes and myeloproliferative neoplasms. Most cases arise from the shared ancestor of clonal hematopoiesis (CH). Here we analyze data from 454,340 UK Biobank participants, of whom 1,808 developed a myeloid neoplasm 0-15 years after recruitment. We describe the differences in CH mutational landscapes and hematology/biochemistry test parameters among individuals that later develop myeloid neoplasms (pre-MN) versus controls,...]]></summary>
        <author>
            <name>Muxin Gu</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Hematopoietic-specific heterozygous loss of Dnmt3a exacerbates colitis-associated colon cancer]]></title>
        <id>pubmed:37615936</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37615936/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230901204619&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-08-24T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Clonal hematopoiesis (CH) is defined as clonal expansion of mutant hematopoietic stem cells absent diagnosis of a hematologic malignancy. Presence of CH in solid tumor patients, including colon cancer, correlates with shorter survival. We hypothesized that bone marrow-derived cells with heterozygous loss-of-function mutations of DNMT3A, the most common genetic alteration in CH, contribute to the pathogenesis of colon cancer. In a mouse model that combines colitis-associated colon cancer (CAC)...]]></summary>
        <author>
            <name>Yang Feng</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Multiparameter prediction of myeloid neoplasia risk]]></title>
        <id>pubmed:37620601</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37620601/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230831205203&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-08-24T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[The myeloid neoplasms encompass acute myeloid leukemia, myelodysplastic syndromes and myeloproliferative neoplasms. Most cases arise from the shared ancestor of clonal hematopoiesis (CH). Here we analyze data from 454,340 UK Biobank participants, of whom 1,808 developed a myeloid neoplasm 0-15 years after recruitment. We describe the differences in CH mutational landscapes and hematology/biochemistry test parameters among individuals that later develop myeloid neoplasms (pre-MN) versus controls,...]]></summary>
        <author>
            <name>Muxin Gu</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Hematopoietic-specific heterozygous loss of Dnmt3a exacerbates colitis-associated colon cancer]]></title>
        <id>pubmed:37615936</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37615936/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230831205203&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-08-24T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Clonal hematopoiesis (CH) is defined as clonal expansion of mutant hematopoietic stem cells absent diagnosis of a hematologic malignancy. Presence of CH in solid tumor patients, including colon cancer, correlates with shorter survival. We hypothesized that bone marrow-derived cells with heterozygous loss-of-function mutations of DNMT3A, the most common genetic alteration in CH, contribute to the pathogenesis of colon cancer. In a mouse model that combines colitis-associated colon cancer (CAC)...]]></summary>
        <author>
            <name>Yang Feng</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Multiparameter prediction of myeloid neoplasia risk]]></title>
        <id>pubmed:37620601</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37620601/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230830204850&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-08-24T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[The myeloid neoplasms encompass acute myeloid leukemia, myelodysplastic syndromes and myeloproliferative neoplasms. Most cases arise from the shared ancestor of clonal hematopoiesis (CH). Here we analyze data from 454,340 UK Biobank participants, of whom 1,808 developed a myeloid neoplasm 0-15 years after recruitment. We describe the differences in CH mutational landscapes and hematology/biochemistry test parameters among individuals that later develop myeloid neoplasms (pre-MN) versus controls,...]]></summary>
        <author>
            <name>Muxin Gu</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Hematopoietic-specific heterozygous loss of Dnmt3a exacerbates colitis-associated colon cancer]]></title>
        <id>pubmed:37615936</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37615936/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230830204850&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-08-24T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Clonal hematopoiesis (CH) is defined as clonal expansion of mutant hematopoietic stem cells absent diagnosis of a hematologic malignancy. Presence of CH in solid tumor patients, including colon cancer, correlates with shorter survival. We hypothesized that bone marrow-derived cells with heterozygous loss-of-function mutations of DNMT3A, the most common genetic alteration in CH, contribute to the pathogenesis of colon cancer. In a mouse model that combines colitis-associated colon cancer (CAC)...]]></summary>
        <author>
            <name>Yang Feng</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Multiparameter prediction of myeloid neoplasia risk]]></title>
        <id>pubmed:37620601</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37620601/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230829204824&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-08-24T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[The myeloid neoplasms encompass acute myeloid leukemia, myelodysplastic syndromes and myeloproliferative neoplasms. Most cases arise from the shared ancestor of clonal hematopoiesis (CH). Here we analyze data from 454,340 UK Biobank participants, of whom 1,808 developed a myeloid neoplasm 0-15 years after recruitment. We describe the differences in CH mutational landscapes and hematology/biochemistry test parameters among individuals that later develop myeloid neoplasms (pre-MN) versus controls,...]]></summary>
        <author>
            <name>Muxin Gu</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Hematopoietic-specific heterozygous loss of Dnmt3a exacerbates colitis-associated colon cancer]]></title>
        <id>pubmed:37615936</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37615936/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230829204824&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-08-24T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Clonal hematopoiesis (CH) is defined as clonal expansion of mutant hematopoietic stem cells absent diagnosis of a hematologic malignancy. Presence of CH in solid tumor patients, including colon cancer, correlates with shorter survival. We hypothesized that bone marrow-derived cells with heterozygous loss-of-function mutations of DNMT3A, the most common genetic alteration in CH, contribute to the pathogenesis of colon cancer. In a mouse model that combines colitis-associated colon cancer (CAC)...]]></summary>
        <author>
            <name>Yang Feng</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Multiparameter prediction of myeloid neoplasia risk]]></title>
        <id>pubmed:37620601</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37620601/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230828204854&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-08-24T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[The myeloid neoplasms encompass acute myeloid leukemia, myelodysplastic syndromes and myeloproliferative neoplasms. Most cases arise from the shared ancestor of clonal hematopoiesis (CH). Here we analyze data from 454,340 UK Biobank participants, of whom 1,808 developed a myeloid neoplasm 0-15 years after recruitment. We describe the differences in CH mutational landscapes and hematology/biochemistry test parameters among individuals that later develop myeloid neoplasms (pre-MN) versus controls,...]]></summary>
        <author>
            <name>Muxin Gu</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Hematopoietic-specific heterozygous loss of Dnmt3a exacerbates colitis-associated colon cancer]]></title>
        <id>pubmed:37615936</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37615936/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230828204854&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-08-24T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Clonal hematopoiesis (CH) is defined as clonal expansion of mutant hematopoietic stem cells absent diagnosis of a hematologic malignancy. Presence of CH in solid tumor patients, including colon cancer, correlates with shorter survival. We hypothesized that bone marrow-derived cells with heterozygous loss-of-function mutations of DNMT3A, the most common genetic alteration in CH, contribute to the pathogenesis of colon cancer. In a mouse model that combines colitis-associated colon cancer (CAC)...]]></summary>
        <author>
            <name>Yang Feng</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Multiparameter prediction of myeloid neoplasia risk]]></title>
        <id>pubmed:37620601</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37620601/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230827204908&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-08-24T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[The myeloid neoplasms encompass acute myeloid leukemia, myelodysplastic syndromes and myeloproliferative neoplasms. Most cases arise from the shared ancestor of clonal hematopoiesis (CH). Here we analyze data from 454,340 UK Biobank participants, of whom 1,808 developed a myeloid neoplasm 0-15 years after recruitment. We describe the differences in CH mutational landscapes and hematology/biochemistry test parameters among individuals that later develop myeloid neoplasms (pre-MN) versus controls,...]]></summary>
        <author>
            <name>Muxin Gu</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Hematopoietic-specific heterozygous loss of Dnmt3a exacerbates colitis-associated colon cancer]]></title>
        <id>pubmed:37615936</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37615936/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230827204908&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-08-24T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Clonal hematopoiesis (CH) is defined as clonal expansion of mutant hematopoietic stem cells absent diagnosis of a hematologic malignancy. Presence of CH in solid tumor patients, including colon cancer, correlates with shorter survival. We hypothesized that bone marrow-derived cells with heterozygous loss-of-function mutations of DNMT3A, the most common genetic alteration in CH, contribute to the pathogenesis of colon cancer. In a mouse model that combines colitis-associated colon cancer (CAC)...]]></summary>
        <author>
            <name>Yang Feng</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Multiparameter prediction of myeloid neoplasia risk]]></title>
        <id>pubmed:37620601</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37620601/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230826205107&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-08-24T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[The myeloid neoplasms encompass acute myeloid leukemia, myelodysplastic syndromes and myeloproliferative neoplasms. Most cases arise from the shared ancestor of clonal hematopoiesis (CH). Here we analyze data from 454,340 UK Biobank participants, of whom 1,808 developed a myeloid neoplasm 0-15 years after recruitment. We describe the differences in CH mutational landscapes and hematology/biochemistry test parameters among individuals that later develop myeloid neoplasms (pre-MN) versus controls,...]]></summary>
        <author>
            <name>Muxin Gu</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Hematopoietic-specific heterozygous loss of Dnmt3a exacerbates colitis-associated colon cancer]]></title>
        <id>pubmed:37615936</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37615936/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230826205107&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-08-24T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Clonal hematopoiesis (CH) is defined as clonal expansion of mutant hematopoietic stem cells absent diagnosis of a hematologic malignancy. Presence of CH in solid tumor patients, including colon cancer, correlates with shorter survival. We hypothesized that bone marrow-derived cells with heterozygous loss-of-function mutations of DNMT3A, the most common genetic alteration in CH, contribute to the pathogenesis of colon cancer. In a mouse model that combines colitis-associated colon cancer (CAC)...]]></summary>
        <author>
            <name>Yang Feng</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Multiparameter prediction of myeloid neoplasia risk]]></title>
        <id>pubmed:37620601</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37620601/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230825204557&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-08-24T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[The myeloid neoplasms encompass acute myeloid leukemia, myelodysplastic syndromes and myeloproliferative neoplasms. Most cases arise from the shared ancestor of clonal hematopoiesis (CH). Here we analyze data from 454,340 UK Biobank participants, of whom 1,808 developed a myeloid neoplasm 0-15 years after recruitment. We describe the differences in CH mutational landscapes and hematology/biochemistry test parameters among individuals that later develop myeloid neoplasms (pre-MN) versus controls,...]]></summary>
        <author>
            <name>Muxin Gu</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Hematopoietic-specific heterozygous loss of Dnmt3a exacerbates colitis-associated colon cancer]]></title>
        <id>pubmed:37615936</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37615936/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230825204557&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-08-24T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Clonal hematopoiesis (CH) is defined as clonal expansion of mutant hematopoietic stem cells absent diagnosis of a hematologic malignancy. Presence of CH in solid tumor patients, including colon cancer, correlates with shorter survival. We hypothesized that bone marrow-derived cells with heterozygous loss-of-function mutations of DNMT3A, the most common genetic alteration in CH, contribute to the pathogenesis of colon cancer. In a mouse model that combines colitis-associated colon cancer (CAC)...]]></summary>
        <author>
            <name>Yang Feng</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Hematopoietic-specific heterozygous loss of Dnmt3a exacerbates colitis-associated colon cancer]]></title>
        <id>pubmed:37615936</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37615936/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230824204823&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-08-24T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Clonal hematopoiesis (CH) is defined as clonal expansion of mutant hematopoietic stem cells absent diagnosis of a hematologic malignancy. Presence of CH in solid tumor patients, including colon cancer, correlates with shorter survival. We hypothesized that bone marrow-derived cells with heterozygous loss-of-function mutations of DNMT3A, the most common genetic alteration in CH, contribute to the pathogenesis of colon cancer. In a mouse model that combines colitis-associated colon cancer (CAC)...]]></summary>
        <author>
            <name>Yang Feng</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Multiparameter prediction of myeloid neoplasia risk]]></title>
        <id>pubmed:37620601</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37620601/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230919204929&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-08-24T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[The myeloid neoplasms encompass acute myeloid leukemia, myelodysplastic syndromes and myeloproliferative neoplasms. Most cases arise from the shared ancestor of clonal hematopoiesis (CH). Here we analyze data from 454,340 UK Biobank participants, of whom 1,808 developed a myeloid neoplasm 0-15 years after recruitment. We describe the differences in CH mutational landscapes and hematology/biochemistry test parameters among individuals that later develop myeloid neoplasms (pre-MN) versus controls,...]]></summary>
        <author>
            <name>Muxin Gu</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Multiparameter prediction of myeloid neoplasia risk]]></title>
        <id>pubmed:37620601</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37620601/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230918204942&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-08-24T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[The myeloid neoplasms encompass acute myeloid leukemia, myelodysplastic syndromes and myeloproliferative neoplasms. Most cases arise from the shared ancestor of clonal hematopoiesis (CH). Here we analyze data from 454,340 UK Biobank participants, of whom 1,808 developed a myeloid neoplasm 0-15 years after recruitment. We describe the differences in CH mutational landscapes and hematology/biochemistry test parameters among individuals that later develop myeloid neoplasms (pre-MN) versus controls,...]]></summary>
        <author>
            <name>Muxin Gu</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Multiparameter prediction of myeloid neoplasia risk]]></title>
        <id>pubmed:37620601</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37620601/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230917204936&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-08-24T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[The myeloid neoplasms encompass acute myeloid leukemia, myelodysplastic syndromes and myeloproliferative neoplasms. Most cases arise from the shared ancestor of clonal hematopoiesis (CH). Here we analyze data from 454,340 UK Biobank participants, of whom 1,808 developed a myeloid neoplasm 0-15 years after recruitment. We describe the differences in CH mutational landscapes and hematology/biochemistry test parameters among individuals that later develop myeloid neoplasms (pre-MN) versus controls,...]]></summary>
        <author>
            <name>Muxin Gu</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Immune stress suppresses innate immune signaling in preleukemic precursor B-cells to provoke leukemia in predisposed mice]]></title>
        <id>pubmed:37620322</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37620322/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230917204936&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-08-24T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[The initial steps of B-cell acute lymphoblastic leukemia (B-ALL) development usually pass unnoticed in children. Several preclinical studies have shown that exposure to immune stressors triggers the transformation of preleukemic B cells to full-blown B-ALL, but how this takes place is still a longstanding and unsolved challenge. Here we show that dysregulation of innate immunity plays a driving role in the clonal evolution of pre-malignant Pax5^(+/-) B-cell precursors toward leukemia....]]></summary>
        <author>
            <name>Marta Isidro-Hernndez</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Multiparameter prediction of myeloid neoplasia risk]]></title>
        <id>pubmed:37620601</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37620601/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230916205201&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-08-24T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[The myeloid neoplasms encompass acute myeloid leukemia, myelodysplastic syndromes and myeloproliferative neoplasms. Most cases arise from the shared ancestor of clonal hematopoiesis (CH). Here we analyze data from 454,340 UK Biobank participants, of whom 1,808 developed a myeloid neoplasm 0-15 years after recruitment. We describe the differences in CH mutational landscapes and hematology/biochemistry test parameters among individuals that later develop myeloid neoplasms (pre-MN) versus controls,...]]></summary>
        <author>
            <name>Muxin Gu</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Immune stress suppresses innate immune signaling in preleukemic precursor B-cells to provoke leukemia in predisposed mice]]></title>
        <id>pubmed:37620322</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37620322/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230916205201&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-08-24T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[The initial steps of B-cell acute lymphoblastic leukemia (B-ALL) development usually pass unnoticed in children. Several preclinical studies have shown that exposure to immune stressors triggers the transformation of preleukemic B cells to full-blown B-ALL, but how this takes place is still a longstanding and unsolved challenge. Here we show that dysregulation of innate immunity plays a driving role in the clonal evolution of pre-malignant Pax5^(+/-) B-cell precursors toward leukemia....]]></summary>
        <author>
            <name>Marta Isidro-Hernndez</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Multiparameter prediction of myeloid neoplasia risk]]></title>
        <id>pubmed:37620601</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37620601/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230915204741&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-08-24T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[The myeloid neoplasms encompass acute myeloid leukemia, myelodysplastic syndromes and myeloproliferative neoplasms. Most cases arise from the shared ancestor of clonal hematopoiesis (CH). Here we analyze data from 454,340 UK Biobank participants, of whom 1,808 developed a myeloid neoplasm 0-15 years after recruitment. We describe the differences in CH mutational landscapes and hematology/biochemistry test parameters among individuals that later develop myeloid neoplasms (pre-MN) versus controls,...]]></summary>
        <author>
            <name>Muxin Gu</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Immune stress suppresses innate immune signaling in preleukemic precursor B-cells to provoke leukemia in predisposed mice]]></title>
        <id>pubmed:37620322</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37620322/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230915204741&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-08-24T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[The initial steps of B-cell acute lymphoblastic leukemia (B-ALL) development usually pass unnoticed in children. Several preclinical studies have shown that exposure to immune stressors triggers the transformation of preleukemic B cells to full-blown B-ALL, but how this takes place is still a longstanding and unsolved challenge. Here we show that dysregulation of innate immunity plays a driving role in the clonal evolution of pre-malignant Pax5^(+/-) B-cell precursors toward leukemia....]]></summary>
        <author>
            <name>Marta Isidro-Hernndez</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Multiparameter prediction of myeloid neoplasia risk]]></title>
        <id>pubmed:37620601</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37620601/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230914204950&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-08-24T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[The myeloid neoplasms encompass acute myeloid leukemia, myelodysplastic syndromes and myeloproliferative neoplasms. Most cases arise from the shared ancestor of clonal hematopoiesis (CH). Here we analyze data from 454,340 UK Biobank participants, of whom 1,808 developed a myeloid neoplasm 0-15 years after recruitment. We describe the differences in CH mutational landscapes and hematology/biochemistry test parameters among individuals that later develop myeloid neoplasms (pre-MN) versus controls,...]]></summary>
        <author>
            <name>Muxin Gu</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Immune stress suppresses innate immune signaling in preleukemic precursor B-cells to provoke leukemia in predisposed mice]]></title>
        <id>pubmed:37620322</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37620322/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230914204950&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-08-24T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[The initial steps of B-cell acute lymphoblastic leukemia (B-ALL) development usually pass unnoticed in children. Several preclinical studies have shown that exposure to immune stressors triggers the transformation of preleukemic B cells to full-blown B-ALL, but how this takes place is still a longstanding and unsolved challenge. Here we show that dysregulation of innate immunity plays a driving role in the clonal evolution of pre-malignant Pax5^(+/-) B-cell precursors toward leukemia....]]></summary>
        <author>
            <name>Marta Isidro-Hernndez</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Multiparameter prediction of myeloid neoplasia risk]]></title>
        <id>pubmed:37620601</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37620601/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230913204840&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-08-24T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[The myeloid neoplasms encompass acute myeloid leukemia, myelodysplastic syndromes and myeloproliferative neoplasms. Most cases arise from the shared ancestor of clonal hematopoiesis (CH). Here we analyze data from 454,340 UK Biobank participants, of whom 1,808 developed a myeloid neoplasm 0-15 years after recruitment. We describe the differences in CH mutational landscapes and hematology/biochemistry test parameters among individuals that later develop myeloid neoplasms (pre-MN) versus controls,...]]></summary>
        <author>
            <name>Muxin Gu</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Immune stress suppresses innate immune signaling in preleukemic precursor B-cells to provoke leukemia in predisposed mice]]></title>
        <id>pubmed:37620322</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37620322/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230913204840&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-08-24T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[The initial steps of B-cell acute lymphoblastic leukemia (B-ALL) development usually pass unnoticed in children. Several preclinical studies have shown that exposure to immune stressors triggers the transformation of preleukemic B cells to full-blown B-ALL, but how this takes place is still a longstanding and unsolved challenge. Here we show that dysregulation of innate immunity plays a driving role in the clonal evolution of pre-malignant Pax5^(+/-) B-cell precursors toward leukemia....]]></summary>
        <author>
            <name>Marta Isidro-Hernndez</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Multiparameter prediction of myeloid neoplasia risk]]></title>
        <id>pubmed:37620601</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37620601/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230912205015&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-08-24T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[The myeloid neoplasms encompass acute myeloid leukemia, myelodysplastic syndromes and myeloproliferative neoplasms. Most cases arise from the shared ancestor of clonal hematopoiesis (CH). Here we analyze data from 454,340 UK Biobank participants, of whom 1,808 developed a myeloid neoplasm 0-15 years after recruitment. We describe the differences in CH mutational landscapes and hematology/biochemistry test parameters among individuals that later develop myeloid neoplasms (pre-MN) versus controls,...]]></summary>
        <author>
            <name>Muxin Gu</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Immune stress suppresses innate immune signaling in preleukemic precursor B-cells to provoke leukemia in predisposed mice]]></title>
        <id>pubmed:37620322</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37620322/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230912205015&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-08-24T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[The initial steps of B-cell acute lymphoblastic leukemia (B-ALL) development usually pass unnoticed in children. Several preclinical studies have shown that exposure to immune stressors triggers the transformation of preleukemic B cells to full-blown B-ALL, but how this takes place is still a longstanding and unsolved challenge. Here we show that dysregulation of innate immunity plays a driving role in the clonal evolution of pre-malignant Pax5^(+/-) B-cell precursors toward leukemia....]]></summary>
        <author>
            <name>Marta Isidro-Hernndez</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Multiparameter prediction of myeloid neoplasia risk]]></title>
        <id>pubmed:37620601</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37620601/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230911204717&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-08-24T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[The myeloid neoplasms encompass acute myeloid leukemia, myelodysplastic syndromes and myeloproliferative neoplasms. Most cases arise from the shared ancestor of clonal hematopoiesis (CH). Here we analyze data from 454,340 UK Biobank participants, of whom 1,808 developed a myeloid neoplasm 0-15 years after recruitment. We describe the differences in CH mutational landscapes and hematology/biochemistry test parameters among individuals that later develop myeloid neoplasms (pre-MN) versus controls,...]]></summary>
        <author>
            <name>Muxin Gu</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Immune stress suppresses innate immune signaling in preleukemic precursor B-cells to provoke leukemia in predisposed mice]]></title>
        <id>pubmed:37620322</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37620322/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230911204717&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-08-24T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[The initial steps of B-cell acute lymphoblastic leukemia (B-ALL) development usually pass unnoticed in children. Several preclinical studies have shown that exposure to immune stressors triggers the transformation of preleukemic B cells to full-blown B-ALL, but how this takes place is still a longstanding and unsolved challenge. Here we show that dysregulation of innate immunity plays a driving role in the clonal evolution of pre-malignant Pax5^(+/-) B-cell precursors toward leukemia....]]></summary>
        <author>
            <name>Marta Isidro-Hernndez</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Immune stress suppresses innate immune signaling in preleukemic precursor B-cells to provoke leukemia in predisposed mice]]></title>
        <id>pubmed:37620322</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37620322/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230910204912&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-08-24T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[The initial steps of B-cell acute lymphoblastic leukemia (B-ALL) development usually pass unnoticed in children. Several preclinical studies have shown that exposure to immune stressors triggers the transformation of preleukemic B cells to full-blown B-ALL, but how this takes place is still a longstanding and unsolved challenge. Here we show that dysregulation of innate immunity plays a driving role in the clonal evolution of pre-malignant Pax5^(+/-) B-cell precursors toward leukemia....]]></summary>
        <author>
            <name>Marta Isidro-Hernndez</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Immune stress suppresses innate immune signaling in preleukemic precursor B-cells to provoke leukemia in predisposed mice]]></title>
        <id>pubmed:37620322</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37620322/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230909205145&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-08-24T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[The initial steps of B-cell acute lymphoblastic leukemia (B-ALL) development usually pass unnoticed in children. Several preclinical studies have shown that exposure to immune stressors triggers the transformation of preleukemic B cells to full-blown B-ALL, but how this takes place is still a longstanding and unsolved challenge. Here we show that dysregulation of innate immunity plays a driving role in the clonal evolution of pre-malignant Pax5^(+/-) B-cell precursors toward leukemia....]]></summary>
        <author>
            <name>Marta Isidro-Hernndez</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Immune stress suppresses innate immune signaling in preleukemic precursor B-cells to provoke leukemia in predisposed mice]]></title>
        <id>pubmed:37620322</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37620322/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230908204701&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-08-24T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[The initial steps of B-cell acute lymphoblastic leukemia (B-ALL) development usually pass unnoticed in children. Several preclinical studies have shown that exposure to immune stressors triggers the transformation of preleukemic B cells to full-blown B-ALL, but how this takes place is still a longstanding and unsolved challenge. Here we show that dysregulation of innate immunity plays a driving role in the clonal evolution of pre-malignant Pax5^(+/-) B-cell precursors toward leukemia....]]></summary>
        <author>
            <name>Marta Isidro-Hernndez</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Immune stress suppresses innate immune signaling in preleukemic precursor B-cells to provoke leukemia in predisposed mice]]></title>
        <id>pubmed:37620322</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37620322/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230907204816&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-08-24T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[The initial steps of B-cell acute lymphoblastic leukemia (B-ALL) development usually pass unnoticed in children. Several preclinical studies have shown that exposure to immune stressors triggers the transformation of preleukemic B cells to full-blown B-ALL, but how this takes place is still a longstanding and unsolved challenge. Here we show that dysregulation of innate immunity plays a driving role in the clonal evolution of pre-malignant Pax5^(+/-) B-cell precursors toward leukemia....]]></summary>
        <author>
            <name>Marta Isidro-Hernndez</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Immune stress suppresses innate immune signaling in preleukemic precursor B-cells to provoke leukemia in predisposed mice]]></title>
        <id>pubmed:37620322</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37620322/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230906204801&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-08-24T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[The initial steps of B-cell acute lymphoblastic leukemia (B-ALL) development usually pass unnoticed in children. Several preclinical studies have shown that exposure to immune stressors triggers the transformation of preleukemic B cells to full-blown B-ALL, but how this takes place is still a longstanding and unsolved challenge. Here we show that dysregulation of innate immunity plays a driving role in the clonal evolution of pre-malignant Pax5^(+/-) B-cell precursors toward leukemia....]]></summary>
        <author>
            <name>Marta Isidro-Hernndez</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Immune stress suppresses innate immune signaling in preleukemic precursor B-cells to provoke leukemia in predisposed mice]]></title>
        <id>pubmed:37620322</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37620322/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230905204848&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-08-24T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[The initial steps of B-cell acute lymphoblastic leukemia (B-ALL) development usually pass unnoticed in children. Several preclinical studies have shown that exposure to immune stressors triggers the transformation of preleukemic B cells to full-blown B-ALL, but how this takes place is still a longstanding and unsolved challenge. Here we show that dysregulation of innate immunity plays a driving role in the clonal evolution of pre-malignant Pax5^(+/-) B-cell precursors toward leukemia....]]></summary>
        <author>
            <name>Marta Isidro-Hernndez</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Immune stress suppresses innate immune signaling in preleukemic precursor B-cells to provoke leukemia in predisposed mice]]></title>
        <id>pubmed:37620322</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37620322/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230904204751&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-08-24T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[The initial steps of B-cell acute lymphoblastic leukemia (B-ALL) development usually pass unnoticed in children. Several preclinical studies have shown that exposure to immune stressors triggers the transformation of preleukemic B cells to full-blown B-ALL, but how this takes place is still a longstanding and unsolved challenge. Here we show that dysregulation of innate immunity plays a driving role in the clonal evolution of pre-malignant Pax5^(+/-) B-cell precursors toward leukemia....]]></summary>
        <author>
            <name>Marta Isidro-Hernndez</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Immune stress suppresses innate immune signaling in preleukemic precursor B-cells to provoke leukemia in predisposed mice]]></title>
        <id>pubmed:37620322</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37620322/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230903204939&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-08-24T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[The initial steps of B-cell acute lymphoblastic leukemia (B-ALL) development usually pass unnoticed in children. Several preclinical studies have shown that exposure to immune stressors triggers the transformation of preleukemic B cells to full-blown B-ALL, but how this takes place is still a longstanding and unsolved challenge. Here we show that dysregulation of innate immunity plays a driving role in the clonal evolution of pre-malignant Pax5^(+/-) B-cell precursors toward leukemia....]]></summary>
        <author>
            <name>Marta Isidro-Hernndez</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Immune stress suppresses innate immune signaling in preleukemic precursor B-cells to provoke leukemia in predisposed mice]]></title>
        <id>pubmed:37620322</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37620322/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230902205121&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-08-24T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[The initial steps of B-cell acute lymphoblastic leukemia (B-ALL) development usually pass unnoticed in children. Several preclinical studies have shown that exposure to immune stressors triggers the transformation of preleukemic B cells to full-blown B-ALL, but how this takes place is still a longstanding and unsolved challenge. Here we show that dysregulation of innate immunity plays a driving role in the clonal evolution of pre-malignant Pax5^(+/-) B-cell precursors toward leukemia....]]></summary>
        <author>
            <name>Marta Isidro-Hernndez</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Immune stress suppresses innate immune signaling in preleukemic precursor B-cells to provoke leukemia in predisposed mice]]></title>
        <id>pubmed:37620322</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37620322/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230901204619&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-08-24T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[The initial steps of B-cell acute lymphoblastic leukemia (B-ALL) development usually pass unnoticed in children. Several preclinical studies have shown that exposure to immune stressors triggers the transformation of preleukemic B cells to full-blown B-ALL, but how this takes place is still a longstanding and unsolved challenge. Here we show that dysregulation of innate immunity plays a driving role in the clonal evolution of pre-malignant Pax5^(+/-) B-cell precursors toward leukemia....]]></summary>
        <author>
            <name>Marta Isidro-Hernndez</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Immune stress suppresses innate immune signaling in preleukemic precursor B-cells to provoke leukemia in predisposed mice]]></title>
        <id>pubmed:37620322</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37620322/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230831205203&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-08-24T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[The initial steps of B-cell acute lymphoblastic leukemia (B-ALL) development usually pass unnoticed in children. Several preclinical studies have shown that exposure to immune stressors triggers the transformation of preleukemic B cells to full-blown B-ALL, but how this takes place is still a longstanding and unsolved challenge. Here we show that dysregulation of innate immunity plays a driving role in the clonal evolution of pre-malignant Pax5^(+/-) B-cell precursors toward leukemia....]]></summary>
        <author>
            <name>Marta Isidro-Hernndez</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Immune stress suppresses innate immune signaling in preleukemic precursor B-cells to provoke leukemia in predisposed mice]]></title>
        <id>pubmed:37620322</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37620322/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230830204850&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-08-24T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[The initial steps of B-cell acute lymphoblastic leukemia (B-ALL) development usually pass unnoticed in children. Several preclinical studies have shown that exposure to immune stressors triggers the transformation of preleukemic B cells to full-blown B-ALL, but how this takes place is still a longstanding and unsolved challenge. Here we show that dysregulation of innate immunity plays a driving role in the clonal evolution of pre-malignant Pax5^(+/-) B-cell precursors toward leukemia....]]></summary>
        <author>
            <name>Marta Isidro-Hernndez</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Immune stress suppresses innate immune signaling in preleukemic precursor B-cells to provoke leukemia in predisposed mice]]></title>
        <id>pubmed:37620322</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37620322/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230829204824&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-08-24T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[The initial steps of B-cell acute lymphoblastic leukemia (B-ALL) development usually pass unnoticed in children. Several preclinical studies have shown that exposure to immune stressors triggers the transformation of preleukemic B cells to full-blown B-ALL, but how this takes place is still a longstanding and unsolved challenge. Here we show that dysregulation of innate immunity plays a driving role in the clonal evolution of pre-malignant Pax5^(+/-) B-cell precursors toward leukemia....]]></summary>
        <author>
            <name>Marta Isidro-Hernndez</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Immune stress suppresses innate immune signaling in preleukemic precursor B-cells to provoke leukemia in predisposed mice]]></title>
        <id>pubmed:37620322</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37620322/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230828204854&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-08-24T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[The initial steps of B-cell acute lymphoblastic leukemia (B-ALL) development usually pass unnoticed in children. Several preclinical studies have shown that exposure to immune stressors triggers the transformation of preleukemic B cells to full-blown B-ALL, but how this takes place is still a longstanding and unsolved challenge. Here we show that dysregulation of innate immunity plays a driving role in the clonal evolution of pre-malignant Pax5^(+/-) B-cell precursors toward leukemia....]]></summary>
        <author>
            <name>Marta Isidro-Hernndez</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Targeted NGS on sequential bone marrow biopsies aids in the evaluation of cytopenias and monocytosis and documents clonal evolution-a proof of principle study]]></title>
        <id>pubmed:37610626</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37610626/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230914204950&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-08-23T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Differential diagnosis of clonal versus reactive cytopenia and monocytosis, respectively, frequently presents a diagnostic challenge. With the two recent classifications of myeloid disorders, mutational analysis has gained importance as a diagnostic tool. However, reports on its utility on trephine bone marrow biopsies (BMB) are sparse. The aim of our proof of principle study was to determine the suitability of targeted sequencing for the longitudinal evaluation of cytopenia and monocytosis and...]]></summary>
        <author>
            <name>Dominik Nann</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Targeted NGS on sequential bone marrow biopsies aids in the evaluation of cytopenias and monocytosis and documents clonal evolution-a proof of principle study]]></title>
        <id>pubmed:37610626</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37610626/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230913204840&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-08-23T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Differential diagnosis of clonal versus reactive cytopenia and monocytosis, respectively, frequently presents a diagnostic challenge. With the two recent classifications of myeloid disorders, mutational analysis has gained importance as a diagnostic tool. However, reports on its utility on trephine bone marrow biopsies (BMB) are sparse. The aim of our proof of principle study was to determine the suitability of targeted sequencing for the longitudinal evaluation of cytopenia and monocytosis and...]]></summary>
        <author>
            <name>Dominik Nann</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Targeted NGS on sequential bone marrow biopsies aids in the evaluation of cytopenias and monocytosis and documents clonal evolution-a proof of principle study]]></title>
        <id>pubmed:37610626</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37610626/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230912205015&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-08-23T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Differential diagnosis of clonal versus reactive cytopenia and monocytosis, respectively, frequently presents a diagnostic challenge. With the two recent classifications of myeloid disorders, mutational analysis has gained importance as a diagnostic tool. However, reports on its utility on trephine bone marrow biopsies (BMB) are sparse. The aim of our proof of principle study was to determine the suitability of targeted sequencing for the longitudinal evaluation of cytopenia and monocytosis and...]]></summary>
        <author>
            <name>Dominik Nann</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Targeted NGS on sequential bone marrow biopsies aids in the evaluation of cytopenias and monocytosis and documents clonal evolution-a proof of principle study]]></title>
        <id>pubmed:37610626</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37610626/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230911204717&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-08-23T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Differential diagnosis of clonal versus reactive cytopenia and monocytosis, respectively, frequently presents a diagnostic challenge. With the two recent classifications of myeloid disorders, mutational analysis has gained importance as a diagnostic tool. However, reports on its utility on trephine bone marrow biopsies (BMB) are sparse. The aim of our proof of principle study was to determine the suitability of targeted sequencing for the longitudinal evaluation of cytopenia and monocytosis and...]]></summary>
        <author>
            <name>Dominik Nann</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Targeted NGS on sequential bone marrow biopsies aids in the evaluation of cytopenias and monocytosis and documents clonal evolution-a proof of principle study]]></title>
        <id>pubmed:37610626</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37610626/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230910204912&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-08-23T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Differential diagnosis of clonal versus reactive cytopenia and monocytosis, respectively, frequently presents a diagnostic challenge. With the two recent classifications of myeloid disorders, mutational analysis has gained importance as a diagnostic tool. However, reports on its utility on trephine bone marrow biopsies (BMB) are sparse. The aim of our proof of principle study was to determine the suitability of targeted sequencing for the longitudinal evaluation of cytopenia and monocytosis and...]]></summary>
        <author>
            <name>Dominik Nann</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Targeted NGS on sequential bone marrow biopsies aids in the evaluation of cytopenias and monocytosis and documents clonal evolution-a proof of principle study]]></title>
        <id>pubmed:37610626</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37610626/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230909205145&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-08-23T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Differential diagnosis of clonal versus reactive cytopenia and monocytosis, respectively, frequently presents a diagnostic challenge. With the two recent classifications of myeloid disorders, mutational analysis has gained importance as a diagnostic tool. However, reports on its utility on trephine bone marrow biopsies (BMB) are sparse. The aim of our proof of principle study was to determine the suitability of targeted sequencing for the longitudinal evaluation of cytopenia and monocytosis and...]]></summary>
        <author>
            <name>Dominik Nann</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Targeted NGS on sequential bone marrow biopsies aids in the evaluation of cytopenias and monocytosis and documents clonal evolution-a proof of principle study]]></title>
        <id>pubmed:37610626</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37610626/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230908204701&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-08-23T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Differential diagnosis of clonal versus reactive cytopenia and monocytosis, respectively, frequently presents a diagnostic challenge. With the two recent classifications of myeloid disorders, mutational analysis has gained importance as a diagnostic tool. However, reports on its utility on trephine bone marrow biopsies (BMB) are sparse. The aim of our proof of principle study was to determine the suitability of targeted sequencing for the longitudinal evaluation of cytopenia and monocytosis and...]]></summary>
        <author>
            <name>Dominik Nann</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Targeted NGS on sequential bone marrow biopsies aids in the evaluation of cytopenias and monocytosis and documents clonal evolution-a proof of principle study]]></title>
        <id>pubmed:37610626</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37610626/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230907204816&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-08-23T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Differential diagnosis of clonal versus reactive cytopenia and monocytosis, respectively, frequently presents a diagnostic challenge. With the two recent classifications of myeloid disorders, mutational analysis has gained importance as a diagnostic tool. However, reports on its utility on trephine bone marrow biopsies (BMB) are sparse. The aim of our proof of principle study was to determine the suitability of targeted sequencing for the longitudinal evaluation of cytopenia and monocytosis and...]]></summary>
        <author>
            <name>Dominik Nann</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Targeted NGS on sequential bone marrow biopsies aids in the evaluation of cytopenias and monocytosis and documents clonal evolution-a proof of principle study]]></title>
        <id>pubmed:37610626</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37610626/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230906204801&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-08-23T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Differential diagnosis of clonal versus reactive cytopenia and monocytosis, respectively, frequently presents a diagnostic challenge. With the two recent classifications of myeloid disorders, mutational analysis has gained importance as a diagnostic tool. However, reports on its utility on trephine bone marrow biopsies (BMB) are sparse. The aim of our proof of principle study was to determine the suitability of targeted sequencing for the longitudinal evaluation of cytopenia and monocytosis and...]]></summary>
        <author>
            <name>Dominik Nann</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Targeted NGS on sequential bone marrow biopsies aids in the evaluation of cytopenias and monocytosis and documents clonal evolution-a proof of principle study]]></title>
        <id>pubmed:37610626</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37610626/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230905204848&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-08-23T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Differential diagnosis of clonal versus reactive cytopenia and monocytosis, respectively, frequently presents a diagnostic challenge. With the two recent classifications of myeloid disorders, mutational analysis has gained importance as a diagnostic tool. However, reports on its utility on trephine bone marrow biopsies (BMB) are sparse. The aim of our proof of principle study was to determine the suitability of targeted sequencing for the longitudinal evaluation of cytopenia and monocytosis and...]]></summary>
        <author>
            <name>Dominik Nann</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Targeted NGS on sequential bone marrow biopsies aids in the evaluation of cytopenias and monocytosis and documents clonal evolution-a proof of principle study]]></title>
        <id>pubmed:37610626</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37610626/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230904204751&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-08-23T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Differential diagnosis of clonal versus reactive cytopenia and monocytosis, respectively, frequently presents a diagnostic challenge. With the two recent classifications of myeloid disorders, mutational analysis has gained importance as a diagnostic tool. However, reports on its utility on trephine bone marrow biopsies (BMB) are sparse. The aim of our proof of principle study was to determine the suitability of targeted sequencing for the longitudinal evaluation of cytopenia and monocytosis and...]]></summary>
        <author>
            <name>Dominik Nann</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Targeted NGS on sequential bone marrow biopsies aids in the evaluation of cytopenias and monocytosis and documents clonal evolution-a proof of principle study]]></title>
        <id>pubmed:37610626</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37610626/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230903204939&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-08-23T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Differential diagnosis of clonal versus reactive cytopenia and monocytosis, respectively, frequently presents a diagnostic challenge. With the two recent classifications of myeloid disorders, mutational analysis has gained importance as a diagnostic tool. However, reports on its utility on trephine bone marrow biopsies (BMB) are sparse. The aim of our proof of principle study was to determine the suitability of targeted sequencing for the longitudinal evaluation of cytopenia and monocytosis and...]]></summary>
        <author>
            <name>Dominik Nann</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Targeted NGS on sequential bone marrow biopsies aids in the evaluation of cytopenias and monocytosis and documents clonal evolution-a proof of principle study]]></title>
        <id>pubmed:37610626</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37610626/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230902205121&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-08-23T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Differential diagnosis of clonal versus reactive cytopenia and monocytosis, respectively, frequently presents a diagnostic challenge. With the two recent classifications of myeloid disorders, mutational analysis has gained importance as a diagnostic tool. However, reports on its utility on trephine bone marrow biopsies (BMB) are sparse. The aim of our proof of principle study was to determine the suitability of targeted sequencing for the longitudinal evaluation of cytopenia and monocytosis and...]]></summary>
        <author>
            <name>Dominik Nann</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Targeted NGS on sequential bone marrow biopsies aids in the evaluation of cytopenias and monocytosis and documents clonal evolution-a proof of principle study]]></title>
        <id>pubmed:37610626</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37610626/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230901204619&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-08-23T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Differential diagnosis of clonal versus reactive cytopenia and monocytosis, respectively, frequently presents a diagnostic challenge. With the two recent classifications of myeloid disorders, mutational analysis has gained importance as a diagnostic tool. However, reports on its utility on trephine bone marrow biopsies (BMB) are sparse. The aim of our proof of principle study was to determine the suitability of targeted sequencing for the longitudinal evaluation of cytopenia and monocytosis and...]]></summary>
        <author>
            <name>Dominik Nann</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Targeted NGS on sequential bone marrow biopsies aids in the evaluation of cytopenias and monocytosis and documents clonal evolution-a proof of principle study]]></title>
        <id>pubmed:37610626</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37610626/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230831205203&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-08-23T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Differential diagnosis of clonal versus reactive cytopenia and monocytosis, respectively, frequently presents a diagnostic challenge. With the two recent classifications of myeloid disorders, mutational analysis has gained importance as a diagnostic tool. However, reports on its utility on trephine bone marrow biopsies (BMB) are sparse. The aim of our proof of principle study was to determine the suitability of targeted sequencing for the longitudinal evaluation of cytopenia and monocytosis and...]]></summary>
        <author>
            <name>Dominik Nann</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Targeted NGS on sequential bone marrow biopsies aids in the evaluation of cytopenias and monocytosis and documents clonal evolution-a proof of principle study]]></title>
        <id>pubmed:37610626</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37610626/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230830204850&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-08-23T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Differential diagnosis of clonal versus reactive cytopenia and monocytosis, respectively, frequently presents a diagnostic challenge. With the two recent classifications of myeloid disorders, mutational analysis has gained importance as a diagnostic tool. However, reports on its utility on trephine bone marrow biopsies (BMB) are sparse. The aim of our proof of principle study was to determine the suitability of targeted sequencing for the longitudinal evaluation of cytopenia and monocytosis and...]]></summary>
        <author>
            <name>Dominik Nann</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Targeted NGS on sequential bone marrow biopsies aids in the evaluation of cytopenias and monocytosis and documents clonal evolution-a proof of principle study]]></title>
        <id>pubmed:37610626</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37610626/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230829204824&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-08-23T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Differential diagnosis of clonal versus reactive cytopenia and monocytosis, respectively, frequently presents a diagnostic challenge. With the two recent classifications of myeloid disorders, mutational analysis has gained importance as a diagnostic tool. However, reports on its utility on trephine bone marrow biopsies (BMB) are sparse. The aim of our proof of principle study was to determine the suitability of targeted sequencing for the longitudinal evaluation of cytopenia and monocytosis and...]]></summary>
        <author>
            <name>Dominik Nann</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Targeted NGS on sequential bone marrow biopsies aids in the evaluation of cytopenias and monocytosis and documents clonal evolution-a proof of principle study]]></title>
        <id>pubmed:37610626</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37610626/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230828204854&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-08-23T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Differential diagnosis of clonal versus reactive cytopenia and monocytosis, respectively, frequently presents a diagnostic challenge. With the two recent classifications of myeloid disorders, mutational analysis has gained importance as a diagnostic tool. However, reports on its utility on trephine bone marrow biopsies (BMB) are sparse. The aim of our proof of principle study was to determine the suitability of targeted sequencing for the longitudinal evaluation of cytopenia and monocytosis and...]]></summary>
        <author>
            <name>Dominik Nann</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Targeted NGS on sequential bone marrow biopsies aids in the evaluation of cytopenias and monocytosis and documents clonal evolution-a proof of principle study]]></title>
        <id>pubmed:37610626</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37610626/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230827204908&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-08-23T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Differential diagnosis of clonal versus reactive cytopenia and monocytosis, respectively, frequently presents a diagnostic challenge. With the two recent classifications of myeloid disorders, mutational analysis has gained importance as a diagnostic tool. However, reports on its utility on trephine bone marrow biopsies (BMB) are sparse. The aim of our proof of principle study was to determine the suitability of targeted sequencing for the longitudinal evaluation of cytopenia and monocytosis and...]]></summary>
        <author>
            <name>Dominik Nann</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Targeted NGS on sequential bone marrow biopsies aids in the evaluation of cytopenias and monocytosis and documents clonal evolution-a proof of principle study]]></title>
        <id>pubmed:37610626</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37610626/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230826205107&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-08-23T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Differential diagnosis of clonal versus reactive cytopenia and monocytosis, respectively, frequently presents a diagnostic challenge. With the two recent classifications of myeloid disorders, mutational analysis has gained importance as a diagnostic tool. However, reports on its utility on trephine bone marrow biopsies (BMB) are sparse. The aim of our proof of principle study was to determine the suitability of targeted sequencing for the longitudinal evaluation of cytopenia and monocytosis and...]]></summary>
        <author>
            <name>Dominik Nann</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Targeted NGS on sequential bone marrow biopsies aids in the evaluation of cytopenias and monocytosis and documents clonal evolution-a proof of principle study]]></title>
        <id>pubmed:37610626</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37610626/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230825204602&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-08-23T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Differential diagnosis of clonal versus reactive cytopenia and monocytosis, respectively, frequently presents a diagnostic challenge. With the two recent classifications of myeloid disorders, mutational analysis has gained importance as a diagnostic tool. However, reports on its utility on trephine bone marrow biopsies (BMB) are sparse. The aim of our proof of principle study was to determine the suitability of targeted sequencing for the longitudinal evaluation of cytopenia and monocytosis and...]]></summary>
        <author>
            <name>Dominik Nann</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Targeted NGS on sequential bone marrow biopsies aids in the evaluation of cytopenias and monocytosis and documents clonal evolution-a proof of principle study]]></title>
        <id>pubmed:37610626</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37610626/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230824204824&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-08-23T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Differential diagnosis of clonal versus reactive cytopenia and monocytosis, respectively, frequently presents a diagnostic challenge. With the two recent classifications of myeloid disorders, mutational analysis has gained importance as a diagnostic tool. However, reports on its utility on trephine bone marrow biopsies (BMB) are sparse. The aim of our proof of principle study was to determine the suitability of targeted sequencing for the longitudinal evaluation of cytopenia and monocytosis and...]]></summary>
        <author>
            <name>Dominik Nann</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Targeted NGS on sequential bone marrow biopsies aids in the evaluation of cytopenias and monocytosis and documents clonal evolution-a proof of principle study]]></title>
        <id>pubmed:37610626</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37610626/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230823204708&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-08-23T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Differential diagnosis of clonal versus reactive cytopenia and monocytosis, respectively, frequently presents a diagnostic challenge. With the two recent classifications of myeloid disorders, mutational analysis has gained importance as a diagnostic tool. However, reports on its utility on trephine bone marrow biopsies (BMB) are sparse. The aim of our proof of principle study was to determine the suitability of targeted sequencing for the longitudinal evaluation of cytopenia and monocytosis and...]]></summary>
        <author>
            <name>Dominik Nann</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Validation of a 12-color flow cytometry assay for acute myeloid leukemia minimal/measurable residual disease detection]]></title>
        <id>pubmed:37605812</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37605812/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230908204701&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-08-22T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSION: The validation met all criteria and obtained FDA IDE (investigational device exemption) approval. This study provides ample technical and professional details in setting up the AML MRD flow cytometry assay and illustrates through the example of the "fit for purpose" validation process. We also highlight the need for further characterization of abnormal blasts bearing the potential for AML relapse.]]></summary>
        <author>
            <name>Sa A Wang</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Validation of a 12-color flow cytometry assay for acute myeloid leukemia minimal/measurable residual disease detection]]></title>
        <id>pubmed:37605812</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37605812/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230907204816&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-08-22T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSION: The validation met all criteria and obtained FDA IDE (investigational device exemption) approval. This study provides ample technical and professional details in setting up the AML MRD flow cytometry assay and illustrates through the example of the "fit for purpose" validation process. We also highlight the need for further characterization of abnormal blasts bearing the potential for AML relapse.]]></summary>
        <author>
            <name>Sa A Wang</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Validation of a 12-color flow cytometry assay for acute myeloid leukemia minimal/measurable residual disease detection]]></title>
        <id>pubmed:37605812</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37605812/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230906204801&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-08-22T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSION: The validation met all criteria and obtained FDA IDE (investigational device exemption) approval. This study provides ample technical and professional details in setting up the AML MRD flow cytometry assay and illustrates through the example of the "fit for purpose" validation process. We also highlight the need for further characterization of abnormal blasts bearing the potential for AML relapse.]]></summary>
        <author>
            <name>Sa A Wang</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Validation of a 12-color flow cytometry assay for acute myeloid leukemia minimal/measurable residual disease detection]]></title>
        <id>pubmed:37605812</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37605812/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230905204848&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-08-22T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSION: The validation met all criteria and obtained FDA IDE (investigational device exemption) approval. This study provides ample technical and professional details in setting up the AML MRD flow cytometry assay and illustrates through the example of the "fit for purpose" validation process. We also highlight the need for further characterization of abnormal blasts bearing the potential for AML relapse.]]></summary>
        <author>
            <name>Sa A Wang</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Validation of a 12-color flow cytometry assay for acute myeloid leukemia minimal/measurable residual disease detection]]></title>
        <id>pubmed:37605812</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37605812/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230904204751&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-08-22T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSION: The validation met all criteria and obtained FDA IDE (investigational device exemption) approval. This study provides ample technical and professional details in setting up the AML MRD flow cytometry assay and illustrates through the example of the "fit for purpose" validation process. We also highlight the need for further characterization of abnormal blasts bearing the potential for AML relapse.]]></summary>
        <author>
            <name>Sa A Wang</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Validation of a 12-color flow cytometry assay for acute myeloid leukemia minimal/measurable residual disease detection]]></title>
        <id>pubmed:37605812</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37605812/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230903204939&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-08-22T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSION: The validation met all criteria and obtained FDA IDE (investigational device exemption) approval. This study provides ample technical and professional details in setting up the AML MRD flow cytometry assay and illustrates through the example of the "fit for purpose" validation process. We also highlight the need for further characterization of abnormal blasts bearing the potential for AML relapse.]]></summary>
        <author>
            <name>Sa A Wang</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Validation of a 12-color flow cytometry assay for acute myeloid leukemia minimal/measurable residual disease detection]]></title>
        <id>pubmed:37605812</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37605812/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230902205121&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-08-22T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSION: The validation met all criteria and obtained FDA IDE (investigational device exemption) approval. This study provides ample technical and professional details in setting up the AML MRD flow cytometry assay and illustrates through the example of the "fit for purpose" validation process. We also highlight the need for further characterization of abnormal blasts bearing the potential for AML relapse.]]></summary>
        <author>
            <name>Sa A Wang</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Validation of a 12-color flow cytometry assay for acute myeloid leukemia minimal/measurable residual disease detection]]></title>
        <id>pubmed:37605812</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37605812/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230901204619&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-08-22T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSION: The validation met all criteria and obtained FDA IDE (investigational device exemption) approval. This study provides ample technical and professional details in setting up the AML MRD flow cytometry assay and illustrates through the example of the "fit for purpose" validation process. We also highlight the need for further characterization of abnormal blasts bearing the potential for AML relapse.]]></summary>
        <author>
            <name>Sa A Wang</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Validation of a 12-color flow cytometry assay for acute myeloid leukemia minimal/measurable residual disease detection]]></title>
        <id>pubmed:37605812</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37605812/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230831205203&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-08-22T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSION: The validation met all criteria and obtained FDA IDE (investigational device exemption) approval. This study provides ample technical and professional details in setting up the AML MRD flow cytometry assay and illustrates through the example of the "fit for purpose" validation process. We also highlight the need for further characterization of abnormal blasts bearing the potential for AML relapse.]]></summary>
        <author>
            <name>Sa A Wang</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Validation of a 12-color flow cytometry assay for acute myeloid leukemia minimal/measurable residual disease detection]]></title>
        <id>pubmed:37605812</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37605812/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230830204850&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-08-22T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSION: The validation met all criteria and obtained FDA IDE (investigational device exemption) approval. This study provides ample technical and professional details in setting up the AML MRD flow cytometry assay and illustrates through the example of the "fit for purpose" validation process. We also highlight the need for further characterization of abnormal blasts bearing the potential for AML relapse.]]></summary>
        <author>
            <name>Sa A Wang</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Validation of a 12-color flow cytometry assay for acute myeloid leukemia minimal/measurable residual disease detection]]></title>
        <id>pubmed:37605812</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37605812/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230829204824&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-08-22T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSION: The validation met all criteria and obtained FDA IDE (investigational device exemption) approval. This study provides ample technical and professional details in setting up the AML MRD flow cytometry assay and illustrates through the example of the "fit for purpose" validation process. We also highlight the need for further characterization of abnormal blasts bearing the potential for AML relapse.]]></summary>
        <author>
            <name>Sa A Wang</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Validation of a 12-color flow cytometry assay for acute myeloid leukemia minimal/measurable residual disease detection]]></title>
        <id>pubmed:37605812</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37605812/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230828204854&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-08-22T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSION: The validation met all criteria and obtained FDA IDE (investigational device exemption) approval. This study provides ample technical and professional details in setting up the AML MRD flow cytometry assay and illustrates through the example of the "fit for purpose" validation process. We also highlight the need for further characterization of abnormal blasts bearing the potential for AML relapse.]]></summary>
        <author>
            <name>Sa A Wang</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Validation of a 12-color flow cytometry assay for acute myeloid leukemia minimal/measurable residual disease detection]]></title>
        <id>pubmed:37605812</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37605812/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230827204908&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-08-22T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSION: The validation met all criteria and obtained FDA IDE (investigational device exemption) approval. This study provides ample technical and professional details in setting up the AML MRD flow cytometry assay and illustrates through the example of the "fit for purpose" validation process. We also highlight the need for further characterization of abnormal blasts bearing the potential for AML relapse.]]></summary>
        <author>
            <name>Sa A Wang</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Validation of a 12-color flow cytometry assay for acute myeloid leukemia minimal/measurable residual disease detection]]></title>
        <id>pubmed:37605812</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37605812/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230826205107&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-08-22T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSION: The validation met all criteria and obtained FDA IDE (investigational device exemption) approval. This study provides ample technical and professional details in setting up the AML MRD flow cytometry assay and illustrates through the example of the "fit for purpose" validation process. We also highlight the need for further characterization of abnormal blasts bearing the potential for AML relapse.]]></summary>
        <author>
            <name>Sa A Wang</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Validation of a 12-color flow cytometry assay for acute myeloid leukemia minimal/measurable residual disease detection]]></title>
        <id>pubmed:37605812</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37605812/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230825204557&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-08-22T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSION: The validation met all criteria and obtained FDA IDE (investigational device exemption) approval. This study provides ample technical and professional details in setting up the AML MRD flow cytometry assay and illustrates through the example of the "fit for purpose" validation process. We also highlight the need for further characterization of abnormal blasts bearing the potential for AML relapse.]]></summary>
        <author>
            <name>Sa A Wang</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Validation of a 12-color flow cytometry assay for acute myeloid leukemia minimal/measurable residual disease detection]]></title>
        <id>pubmed:37605812</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37605812/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230824204823&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-08-22T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSION: The validation met all criteria and obtained FDA IDE (investigational device exemption) approval. This study provides ample technical and professional details in setting up the AML MRD flow cytometry assay and illustrates through the example of the "fit for purpose" validation process. We also highlight the need for further characterization of abnormal blasts bearing the potential for AML relapse.]]></summary>
        <author>
            <name>Sa A Wang</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Validation of a 12-color flow cytometry assay for acute myeloid leukemia minimal/measurable residual disease detection]]></title>
        <id>pubmed:37605812</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37605812/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230823204708&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-08-22T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSION: The validation met all criteria and obtained FDA IDE (investigational device exemption) approval. This study provides ample technical and professional details in setting up the AML MRD flow cytometry assay and illustrates through the example of the "fit for purpose" validation process. We also highlight the need for further characterization of abnormal blasts bearing the potential for AML relapse.]]></summary>
        <author>
            <name>Sa A Wang</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Validation of a 12-color flow cytometry assay for acute myeloid leukemia minimal/measurable residual disease detection]]></title>
        <id>pubmed:37605812</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37605812/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230822204709&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-08-22T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSION: The validation met all criteria and obtained FDA IDE (investigational device exemption) approval. This study provides ample technical and professional details in setting up the AML MRD flow cytometry assay and illustrates through the example of the "fit for purpose" validation process. We also highlight the need for further characterization of abnormal blasts bearing the potential for AML relapse.]]></summary>
        <author>
            <name>Sa A Wang</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Base Editor Scanning Reveals Activating Mutations of DNMT3A]]></title>
        <id>pubmed:37603861</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37603861/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230907204816&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-08-21T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[DNA methyltransferase 3A (DNMT3A) is a de novo cytosine methyltransferase responsible for establishing proper DNA methylation during mammalian development. Loss-of-function (LOF) mutations to DNMT3A, including the hotspot mutation R882H, frequently occur in developmental growth disorders and hematological diseases, including clonal hematopoiesis and acute myeloid leukemia. Accordingly, identifying mechanisms that activate DNMT3A is of both fundamental and therapeutic interest. Here, we applied a...]]></summary>
        <author>
            <name>Emma M Garcia</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Base Editor Scanning Reveals Activating Mutations of DNMT3A]]></title>
        <id>pubmed:37603861</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37603861/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230906204801&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-08-21T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[DNA methyltransferase 3A (DNMT3A) is a de novo cytosine methyltransferase responsible for establishing proper DNA methylation during mammalian development. Loss-of-function (LOF) mutations to DNMT3A, including the hotspot mutation R882H, frequently occur in developmental growth disorders and hematological diseases, including clonal hematopoiesis and acute myeloid leukemia. Accordingly, identifying mechanisms that activate DNMT3A is of both fundamental and therapeutic interest. Here, we applied a...]]></summary>
        <author>
            <name>Emma M Garcia</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Molecular residual disease detection in resected, muscle-invasive urothelial cancer with a tissue-based comprehensive genomic profiling-informed personalized monitoring assay]]></title>
        <id>pubmed:37601688</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37601688/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230906204801&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-08-21T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSION: We present a personalized ctDNA monitoring assay utilizing tissue-based FoundationOne^() CDx CGP, which is a pragmatic and potentially clinically scalable method that can detect low levels of residual ctDNA in patients with resected, muscle-invasive bladder cancer without germline sampling.]]></summary>
        <author>
            <name>Thomas Powles</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Base Editor Scanning Reveals Activating Mutations of DNMT3A]]></title>
        <id>pubmed:37603861</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37603861/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230905204848&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-08-21T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[DNA methyltransferase 3A (DNMT3A) is a de novo cytosine methyltransferase responsible for establishing proper DNA methylation during mammalian development. Loss-of-function (LOF) mutations to DNMT3A, including the hotspot mutation R882H, frequently occur in developmental growth disorders and hematological diseases, including clonal hematopoiesis and acute myeloid leukemia. Accordingly, identifying mechanisms that activate DNMT3A is of both fundamental and therapeutic interest. Here, we applied a...]]></summary>
        <author>
            <name>Emma M Garcia</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Molecular residual disease detection in resected, muscle-invasive urothelial cancer with a tissue-based comprehensive genomic profiling-informed personalized monitoring assay]]></title>
        <id>pubmed:37601688</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37601688/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230905204848&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-08-21T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSION: We present a personalized ctDNA monitoring assay utilizing tissue-based FoundationOne^() CDx CGP, which is a pragmatic and potentially clinically scalable method that can detect low levels of residual ctDNA in patients with resected, muscle-invasive bladder cancer without germline sampling.]]></summary>
        <author>
            <name>Thomas Powles</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[The terminal period findings of late-diagnosed fibrodysplasia ossificans progressiva]]></title>
        <id>pubmed:37599859</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37599859/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230905204848&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-08-21T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Fibrodysplasia ossificans progressiva (FOP) is an autosomal dominant rare disease characterized by foot deformities and concomitant heterotopic ossifications. Theoretically, in the absence of early diagnosis and medication, the patient's outcome will be poor. The patients are usually diagnosed at an early age. Hence, encountering a non-treated and terminal-period patient is rare. Our case was unique because it showed the clinical picture and atypical radiological distribution of a 20-year-old,...]]></summary>
        <author>
            <name>Emrah Doan</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Base Editor Scanning Reveals Activating Mutations of DNMT3A]]></title>
        <id>pubmed:37603861</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37603861/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230904204751&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-08-21T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[DNA methyltransferase 3A (DNMT3A) is a de novo cytosine methyltransferase responsible for establishing proper DNA methylation during mammalian development. Loss-of-function (LOF) mutations to DNMT3A, including the hotspot mutation R882H, frequently occur in developmental growth disorders and hematological diseases, including clonal hematopoiesis and acute myeloid leukemia. Accordingly, identifying mechanisms that activate DNMT3A is of both fundamental and therapeutic interest. Here, we applied a...]]></summary>
        <author>
            <name>Emma M Garcia</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Molecular residual disease detection in resected, muscle-invasive urothelial cancer with a tissue-based comprehensive genomic profiling-informed personalized monitoring assay]]></title>
        <id>pubmed:37601688</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37601688/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230904204751&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-08-21T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSION: We present a personalized ctDNA monitoring assay utilizing tissue-based FoundationOne^() CDx CGP, which is a pragmatic and potentially clinically scalable method that can detect low levels of residual ctDNA in patients with resected, muscle-invasive bladder cancer without germline sampling.]]></summary>
        <author>
            <name>Thomas Powles</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[The terminal period findings of late-diagnosed fibrodysplasia ossificans progressiva]]></title>
        <id>pubmed:37599859</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37599859/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230904204751&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-08-21T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Fibrodysplasia ossificans progressiva (FOP) is an autosomal dominant rare disease characterized by foot deformities and concomitant heterotopic ossifications. Theoretically, in the absence of early diagnosis and medication, the patient's outcome will be poor. The patients are usually diagnosed at an early age. Hence, encountering a non-treated and terminal-period patient is rare. Our case was unique because it showed the clinical picture and atypical radiological distribution of a 20-year-old,...]]></summary>
        <author>
            <name>Emrah Doan</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Base Editor Scanning Reveals Activating Mutations of DNMT3A]]></title>
        <id>pubmed:37603861</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37603861/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230903204939&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-08-21T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[DNA methyltransferase 3A (DNMT3A) is a de novo cytosine methyltransferase responsible for establishing proper DNA methylation during mammalian development. Loss-of-function (LOF) mutations to DNMT3A, including the hotspot mutation R882H, frequently occur in developmental growth disorders and hematological diseases, including clonal hematopoiesis and acute myeloid leukemia. Accordingly, identifying mechanisms that activate DNMT3A is of both fundamental and therapeutic interest. Here, we applied a...]]></summary>
        <author>
            <name>Emma M Garcia</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Molecular residual disease detection in resected, muscle-invasive urothelial cancer with a tissue-based comprehensive genomic profiling-informed personalized monitoring assay]]></title>
        <id>pubmed:37601688</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37601688/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230903204939&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-08-21T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSION: We present a personalized ctDNA monitoring assay utilizing tissue-based FoundationOne^() CDx CGP, which is a pragmatic and potentially clinically scalable method that can detect low levels of residual ctDNA in patients with resected, muscle-invasive bladder cancer without germline sampling.]]></summary>
        <author>
            <name>Thomas Powles</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[The terminal period findings of late-diagnosed fibrodysplasia ossificans progressiva]]></title>
        <id>pubmed:37599859</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37599859/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230903204939&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-08-21T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Fibrodysplasia ossificans progressiva (FOP) is an autosomal dominant rare disease characterized by foot deformities and concomitant heterotopic ossifications. Theoretically, in the absence of early diagnosis and medication, the patient's outcome will be poor. The patients are usually diagnosed at an early age. Hence, encountering a non-treated and terminal-period patient is rare. Our case was unique because it showed the clinical picture and atypical radiological distribution of a 20-year-old,...]]></summary>
        <author>
            <name>Emrah Doan</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Base Editor Scanning Reveals Activating Mutations of DNMT3A]]></title>
        <id>pubmed:37603861</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37603861/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230902205121&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-08-21T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[DNA methyltransferase 3A (DNMT3A) is a de novo cytosine methyltransferase responsible for establishing proper DNA methylation during mammalian development. Loss-of-function (LOF) mutations to DNMT3A, including the hotspot mutation R882H, frequently occur in developmental growth disorders and hematological diseases, including clonal hematopoiesis and acute myeloid leukemia. Accordingly, identifying mechanisms that activate DNMT3A is of both fundamental and therapeutic interest. Here, we applied a...]]></summary>
        <author>
            <name>Emma M Garcia</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Molecular residual disease detection in resected, muscle-invasive urothelial cancer with a tissue-based comprehensive genomic profiling-informed personalized monitoring assay]]></title>
        <id>pubmed:37601688</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37601688/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230902205121&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-08-21T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSION: We present a personalized ctDNA monitoring assay utilizing tissue-based FoundationOne^() CDx CGP, which is a pragmatic and potentially clinically scalable method that can detect low levels of residual ctDNA in patients with resected, muscle-invasive bladder cancer without germline sampling.]]></summary>
        <author>
            <name>Thomas Powles</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[The terminal period findings of late-diagnosed fibrodysplasia ossificans progressiva]]></title>
        <id>pubmed:37599859</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37599859/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230902205121&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-08-21T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Fibrodysplasia ossificans progressiva (FOP) is an autosomal dominant rare disease characterized by foot deformities and concomitant heterotopic ossifications. Theoretically, in the absence of early diagnosis and medication, the patient's outcome will be poor. The patients are usually diagnosed at an early age. Hence, encountering a non-treated and terminal-period patient is rare. Our case was unique because it showed the clinical picture and atypical radiological distribution of a 20-year-old,...]]></summary>
        <author>
            <name>Emrah Doan</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Base Editor Scanning Reveals Activating Mutations of DNMT3A]]></title>
        <id>pubmed:37603861</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37603861/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230901204619&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-08-21T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[DNA methyltransferase 3A (DNMT3A) is a de novo cytosine methyltransferase responsible for establishing proper DNA methylation during mammalian development. Loss-of-function (LOF) mutations to DNMT3A, including the hotspot mutation R882H, frequently occur in developmental growth disorders and hematological diseases, including clonal hematopoiesis and acute myeloid leukemia. Accordingly, identifying mechanisms that activate DNMT3A is of both fundamental and therapeutic interest. Here, we applied a...]]></summary>
        <author>
            <name>Emma M Garcia</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Molecular residual disease detection in resected, muscle-invasive urothelial cancer with a tissue-based comprehensive genomic profiling-informed personalized monitoring assay]]></title>
        <id>pubmed:37601688</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37601688/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230901204619&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-08-21T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSION: We present a personalized ctDNA monitoring assay utilizing tissue-based FoundationOne^() CDx CGP, which is a pragmatic and potentially clinically scalable method that can detect low levels of residual ctDNA in patients with resected, muscle-invasive bladder cancer without germline sampling.]]></summary>
        <author>
            <name>Thomas Powles</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[The terminal period findings of late-diagnosed fibrodysplasia ossificans progressiva]]></title>
        <id>pubmed:37599859</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37599859/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230901204619&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-08-21T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Fibrodysplasia ossificans progressiva (FOP) is an autosomal dominant rare disease characterized by foot deformities and concomitant heterotopic ossifications. Theoretically, in the absence of early diagnosis and medication, the patient's outcome will be poor. The patients are usually diagnosed at an early age. Hence, encountering a non-treated and terminal-period patient is rare. Our case was unique because it showed the clinical picture and atypical radiological distribution of a 20-year-old,...]]></summary>
        <author>
            <name>Emrah Doan</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Base Editor Scanning Reveals Activating Mutations of DNMT3A]]></title>
        <id>pubmed:37603861</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37603861/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230831205203&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-08-21T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[DNA methyltransferase 3A (DNMT3A) is a de novo cytosine methyltransferase responsible for establishing proper DNA methylation during mammalian development. Loss-of-function (LOF) mutations to DNMT3A, including the hotspot mutation R882H, frequently occur in developmental growth disorders and hematological diseases, including clonal hematopoiesis and acute myeloid leukemia. Accordingly, identifying mechanisms that activate DNMT3A is of both fundamental and therapeutic interest. Here, we applied a...]]></summary>
        <author>
            <name>Emma M Garcia</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Molecular residual disease detection in resected, muscle-invasive urothelial cancer with a tissue-based comprehensive genomic profiling-informed personalized monitoring assay]]></title>
        <id>pubmed:37601688</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37601688/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230831205203&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-08-21T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSION: We present a personalized ctDNA monitoring assay utilizing tissue-based FoundationOne^() CDx CGP, which is a pragmatic and potentially clinically scalable method that can detect low levels of residual ctDNA in patients with resected, muscle-invasive bladder cancer without germline sampling.]]></summary>
        <author>
            <name>Thomas Powles</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[The terminal period findings of late-diagnosed fibrodysplasia ossificans progressiva]]></title>
        <id>pubmed:37599859</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37599859/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230831205203&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-08-21T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Fibrodysplasia ossificans progressiva (FOP) is an autosomal dominant rare disease characterized by foot deformities and concomitant heterotopic ossifications. Theoretically, in the absence of early diagnosis and medication, the patient's outcome will be poor. The patients are usually diagnosed at an early age. Hence, encountering a non-treated and terminal-period patient is rare. Our case was unique because it showed the clinical picture and atypical radiological distribution of a 20-year-old,...]]></summary>
        <author>
            <name>Emrah Doan</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Base Editor Scanning Reveals Activating Mutations of DNMT3A]]></title>
        <id>pubmed:37603861</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37603861/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230830204850&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-08-21T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[DNA methyltransferase 3A (DNMT3A) is a de novo cytosine methyltransferase responsible for establishing proper DNA methylation during mammalian development. Loss-of-function (LOF) mutations to DNMT3A, including the hotspot mutation R882H, frequently occur in developmental growth disorders and hematological diseases, including clonal hematopoiesis and acute myeloid leukemia. Accordingly, identifying mechanisms that activate DNMT3A is of both fundamental and therapeutic interest. Here, we applied a...]]></summary>
        <author>
            <name>Emma M Garcia</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Molecular residual disease detection in resected, muscle-invasive urothelial cancer with a tissue-based comprehensive genomic profiling-informed personalized monitoring assay]]></title>
        <id>pubmed:37601688</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37601688/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230830204850&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-08-21T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSION: We present a personalized ctDNA monitoring assay utilizing tissue-based FoundationOne^() CDx CGP, which is a pragmatic and potentially clinically scalable method that can detect low levels of residual ctDNA in patients with resected, muscle-invasive bladder cancer without germline sampling.]]></summary>
        <author>
            <name>Thomas Powles</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[The terminal period findings of late-diagnosed fibrodysplasia ossificans progressiva]]></title>
        <id>pubmed:37599859</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37599859/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230830204850&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-08-21T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Fibrodysplasia ossificans progressiva (FOP) is an autosomal dominant rare disease characterized by foot deformities and concomitant heterotopic ossifications. Theoretically, in the absence of early diagnosis and medication, the patient's outcome will be poor. The patients are usually diagnosed at an early age. Hence, encountering a non-treated and terminal-period patient is rare. Our case was unique because it showed the clinical picture and atypical radiological distribution of a 20-year-old,...]]></summary>
        <author>
            <name>Emrah Doan</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Base Editor Scanning Reveals Activating Mutations of DNMT3A]]></title>
        <id>pubmed:37603861</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37603861/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230829204824&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-08-21T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[DNA methyltransferase 3A (DNMT3A) is a de novo cytosine methyltransferase responsible for establishing proper DNA methylation during mammalian development. Loss-of-function (LOF) mutations to DNMT3A, including the hotspot mutation R882H, frequently occur in developmental growth disorders and hematological diseases, including clonal hematopoiesis and acute myeloid leukemia. Accordingly, identifying mechanisms that activate DNMT3A is of both fundamental and therapeutic interest. Here, we applied a...]]></summary>
        <author>
            <name>Emma M Garcia</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Molecular residual disease detection in resected, muscle-invasive urothelial cancer with a tissue-based comprehensive genomic profiling-informed personalized monitoring assay]]></title>
        <id>pubmed:37601688</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37601688/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230829204824&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-08-21T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSION: We present a personalized ctDNA monitoring assay utilizing tissue-based FoundationOne^() CDx CGP, which is a pragmatic and potentially clinically scalable method that can detect low levels of residual ctDNA in patients with resected, muscle-invasive bladder cancer without germline sampling.]]></summary>
        <author>
            <name>Thomas Powles</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[The terminal period findings of late-diagnosed fibrodysplasia ossificans progressiva]]></title>
        <id>pubmed:37599859</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37599859/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230829204824&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-08-21T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Fibrodysplasia ossificans progressiva (FOP) is an autosomal dominant rare disease characterized by foot deformities and concomitant heterotopic ossifications. Theoretically, in the absence of early diagnosis and medication, the patient's outcome will be poor. The patients are usually diagnosed at an early age. Hence, encountering a non-treated and terminal-period patient is rare. Our case was unique because it showed the clinical picture and atypical radiological distribution of a 20-year-old,...]]></summary>
        <author>
            <name>Emrah Doan</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Base Editor Scanning Reveals Activating Mutations of DNMT3A]]></title>
        <id>pubmed:37603861</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37603861/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230828204854&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-08-21T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[DNA methyltransferase 3A (DNMT3A) is a de novo cytosine methyltransferase responsible for establishing proper DNA methylation during mammalian development. Loss-of-function (LOF) mutations to DNMT3A, including the hotspot mutation R882H, frequently occur in developmental growth disorders and hematological diseases, including clonal hematopoiesis and acute myeloid leukemia. Accordingly, identifying mechanisms that activate DNMT3A is of both fundamental and therapeutic interest. Here, we applied a...]]></summary>
        <author>
            <name>Emma M Garcia</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Molecular residual disease detection in resected, muscle-invasive urothelial cancer with a tissue-based comprehensive genomic profiling-informed personalized monitoring assay]]></title>
        <id>pubmed:37601688</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37601688/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230828204854&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-08-21T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSION: We present a personalized ctDNA monitoring assay utilizing tissue-based FoundationOne^() CDx CGP, which is a pragmatic and potentially clinically scalable method that can detect low levels of residual ctDNA in patients with resected, muscle-invasive bladder cancer without germline sampling.]]></summary>
        <author>
            <name>Thomas Powles</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[The terminal period findings of late-diagnosed fibrodysplasia ossificans progressiva]]></title>
        <id>pubmed:37599859</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37599859/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230828204854&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-08-21T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Fibrodysplasia ossificans progressiva (FOP) is an autosomal dominant rare disease characterized by foot deformities and concomitant heterotopic ossifications. Theoretically, in the absence of early diagnosis and medication, the patient's outcome will be poor. The patients are usually diagnosed at an early age. Hence, encountering a non-treated and terminal-period patient is rare. Our case was unique because it showed the clinical picture and atypical radiological distribution of a 20-year-old,...]]></summary>
        <author>
            <name>Emrah Doan</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Base Editor Scanning Reveals Activating Mutations of DNMT3A]]></title>
        <id>pubmed:37603861</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37603861/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230827204908&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-08-21T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[DNA methyltransferase 3A (DNMT3A) is a de novo cytosine methyltransferase responsible for establishing proper DNA methylation during mammalian development. Loss-of-function (LOF) mutations to DNMT3A, including the hotspot mutation R882H, frequently occur in developmental growth disorders and hematological diseases, including clonal hematopoiesis and acute myeloid leukemia. Accordingly, identifying mechanisms that activate DNMT3A is of both fundamental and therapeutic interest. Here, we applied a...]]></summary>
        <author>
            <name>Emma M Garcia</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Molecular residual disease detection in resected, muscle-invasive urothelial cancer with a tissue-based comprehensive genomic profiling-informed personalized monitoring assay]]></title>
        <id>pubmed:37601688</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37601688/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230827204908&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-08-21T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSION: We present a personalized ctDNA monitoring assay utilizing tissue-based FoundationOne^() CDx CGP, which is a pragmatic and potentially clinically scalable method that can detect low levels of residual ctDNA in patients with resected, muscle-invasive bladder cancer without germline sampling.]]></summary>
        <author>
            <name>Thomas Powles</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[The terminal period findings of late-diagnosed fibrodysplasia ossificans progressiva]]></title>
        <id>pubmed:37599859</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37599859/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230827204908&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-08-21T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Fibrodysplasia ossificans progressiva (FOP) is an autosomal dominant rare disease characterized by foot deformities and concomitant heterotopic ossifications. Theoretically, in the absence of early diagnosis and medication, the patient's outcome will be poor. The patients are usually diagnosed at an early age. Hence, encountering a non-treated and terminal-period patient is rare. Our case was unique because it showed the clinical picture and atypical radiological distribution of a 20-year-old,...]]></summary>
        <author>
            <name>Emrah Doan</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Base Editor Scanning Reveals Activating Mutations of DNMT3A]]></title>
        <id>pubmed:37603861</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37603861/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230826205107&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-08-21T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[DNA methyltransferase 3A (DNMT3A) is a de novo cytosine methyltransferase responsible for establishing proper DNA methylation during mammalian development. Loss-of-function (LOF) mutations to DNMT3A, including the hotspot mutation R882H, frequently occur in developmental growth disorders and hematological diseases, including clonal hematopoiesis and acute myeloid leukemia. Accordingly, identifying mechanisms that activate DNMT3A is of both fundamental and therapeutic interest. Here, we applied a...]]></summary>
        <author>
            <name>Emma M Garcia</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Molecular residual disease detection in resected, muscle-invasive urothelial cancer with a tissue-based comprehensive genomic profiling-informed personalized monitoring assay]]></title>
        <id>pubmed:37601688</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37601688/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230826205107&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-08-21T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSION: We present a personalized ctDNA monitoring assay utilizing tissue-based FoundationOne^() CDx CGP, which is a pragmatic and potentially clinically scalable method that can detect low levels of residual ctDNA in patients with resected, muscle-invasive bladder cancer without germline sampling.]]></summary>
        <author>
            <name>Thomas Powles</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[The terminal period findings of late-diagnosed fibrodysplasia ossificans progressiva]]></title>
        <id>pubmed:37599859</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37599859/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230826205107&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-08-21T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Fibrodysplasia ossificans progressiva (FOP) is an autosomal dominant rare disease characterized by foot deformities and concomitant heterotopic ossifications. Theoretically, in the absence of early diagnosis and medication, the patient's outcome will be poor. The patients are usually diagnosed at an early age. Hence, encountering a non-treated and terminal-period patient is rare. Our case was unique because it showed the clinical picture and atypical radiological distribution of a 20-year-old,...]]></summary>
        <author>
            <name>Emrah Doan</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Base Editor Scanning Reveals Activating Mutations of DNMT3A]]></title>
        <id>pubmed:37603861</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37603861/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230825204557&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-08-21T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[DNA methyltransferase 3A (DNMT3A) is a de novo cytosine methyltransferase responsible for establishing proper DNA methylation during mammalian development. Loss-of-function (LOF) mutations to DNMT3A, including the hotspot mutation R882H, frequently occur in developmental growth disorders and hematological diseases, including clonal hematopoiesis and acute myeloid leukemia. Accordingly, identifying mechanisms that activate DNMT3A is of both fundamental and therapeutic interest. Here, we applied a...]]></summary>
        <author>
            <name>Emma M Garcia</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Molecular residual disease detection in resected, muscle-invasive urothelial cancer with a tissue-based comprehensive genomic profiling-informed personalized monitoring assay]]></title>
        <id>pubmed:37601688</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37601688/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230825204557&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-08-21T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSION: We present a personalized ctDNA monitoring assay utilizing tissue-based FoundationOne^() CDx CGP, which is a pragmatic and potentially clinically scalable method that can detect low levels of residual ctDNA in patients with resected, muscle-invasive bladder cancer without germline sampling.]]></summary>
        <author>
            <name>Thomas Powles</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[The terminal period findings of late-diagnosed fibrodysplasia ossificans progressiva]]></title>
        <id>pubmed:37599859</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37599859/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230825204557&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-08-21T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Fibrodysplasia ossificans progressiva (FOP) is an autosomal dominant rare disease characterized by foot deformities and concomitant heterotopic ossifications. Theoretically, in the absence of early diagnosis and medication, the patient's outcome will be poor. The patients are usually diagnosed at an early age. Hence, encountering a non-treated and terminal-period patient is rare. Our case was unique because it showed the clinical picture and atypical radiological distribution of a 20-year-old,...]]></summary>
        <author>
            <name>Emrah Doan</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Base Editor Scanning Reveals Activating Mutations of DNMT3A]]></title>
        <id>pubmed:37603861</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37603861/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230824204823&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-08-21T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[DNA methyltransferase 3A (DNMT3A) is a de novo cytosine methyltransferase responsible for establishing proper DNA methylation during mammalian development. Loss-of-function (LOF) mutations to DNMT3A, including the hotspot mutation R882H, frequently occur in developmental growth disorders and hematological diseases, including clonal hematopoiesis and acute myeloid leukemia. Accordingly, identifying mechanisms that activate DNMT3A is of both fundamental and therapeutic interest. Here, we applied a...]]></summary>
        <author>
            <name>Emma M Garcia</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Molecular residual disease detection in resected, muscle-invasive urothelial cancer with a tissue-based comprehensive genomic profiling-informed personalized monitoring assay]]></title>
        <id>pubmed:37601688</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37601688/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230824204823&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-08-21T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSION: We present a personalized ctDNA monitoring assay utilizing tissue-based FoundationOne^() CDx CGP, which is a pragmatic and potentially clinically scalable method that can detect low levels of residual ctDNA in patients with resected, muscle-invasive bladder cancer without germline sampling.]]></summary>
        <author>
            <name>Thomas Powles</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[The terminal period findings of late-diagnosed fibrodysplasia ossificans progressiva]]></title>
        <id>pubmed:37599859</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37599859/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230824204823&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-08-21T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Fibrodysplasia ossificans progressiva (FOP) is an autosomal dominant rare disease characterized by foot deformities and concomitant heterotopic ossifications. Theoretically, in the absence of early diagnosis and medication, the patient's outcome will be poor. The patients are usually diagnosed at an early age. Hence, encountering a non-treated and terminal-period patient is rare. Our case was unique because it showed the clinical picture and atypical radiological distribution of a 20-year-old,...]]></summary>
        <author>
            <name>Emrah Doan</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Base Editor Scanning Reveals Activating Mutations of DNMT3A]]></title>
        <id>pubmed:37603861</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37603861/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230823204708&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-08-21T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[DNA methyltransferase 3A (DNMT3A) is a de novo cytosine methyltransferase responsible for establishing proper DNA methylation during mammalian development. Loss-of-function (LOF) mutations to DNMT3A, including the hotspot mutation R882H, frequently occur in developmental growth disorders and hematological diseases, including clonal hematopoiesis and acute myeloid leukemia. Accordingly, identifying mechanisms that activate DNMT3A is of both fundamental and therapeutic interest. Here, we applied a...]]></summary>
        <author>
            <name>Emma M Garcia</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Molecular residual disease detection in resected, muscle-invasive urothelial cancer with a tissue-based comprehensive genomic profiling-informed personalized monitoring assay]]></title>
        <id>pubmed:37601688</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37601688/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230823204708&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-08-21T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSION: We present a personalized ctDNA monitoring assay utilizing tissue-based FoundationOne^() CDx CGP, which is a pragmatic and potentially clinically scalable method that can detect low levels of residual ctDNA in patients with resected, muscle-invasive bladder cancer without germline sampling.]]></summary>
        <author>
            <name>Thomas Powles</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[The terminal period findings of late-diagnosed fibrodysplasia ossificans progressiva]]></title>
        <id>pubmed:37599859</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37599859/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230823204708&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-08-21T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Fibrodysplasia ossificans progressiva (FOP) is an autosomal dominant rare disease characterized by foot deformities and concomitant heterotopic ossifications. Theoretically, in the absence of early diagnosis and medication, the patient's outcome will be poor. The patients are usually diagnosed at an early age. Hence, encountering a non-treated and terminal-period patient is rare. Our case was unique because it showed the clinical picture and atypical radiological distribution of a 20-year-old,...]]></summary>
        <author>
            <name>Emrah Doan</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Base Editor Scanning Reveals Activating Mutations of DNMT3A]]></title>
        <id>pubmed:37603861</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37603861/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230822204709&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-08-21T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[DNA methyltransferase 3A (DNMT3A) is a de novo cytosine methyltransferase responsible for establishing proper DNA methylation during mammalian development. Loss-of-function (LOF) mutations to DNMT3A, including the hotspot mutation R882H, frequently occur in developmental growth disorders and hematological diseases, including clonal hematopoiesis and acute myeloid leukemia. Accordingly, identifying mechanisms that activate DNMT3A is of both fundamental and therapeutic interest. Here, we applied a...]]></summary>
        <author>
            <name>Emma M Garcia</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Molecular residual disease detection in resected, muscle-invasive urothelial cancer with a tissue-based comprehensive genomic profiling-informed personalized monitoring assay]]></title>
        <id>pubmed:37601688</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37601688/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230822204709&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-08-21T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSION: We present a personalized ctDNA monitoring assay utilizing tissue-based FoundationOne^() CDx CGP, which is a pragmatic and potentially clinically scalable method that can detect low levels of residual ctDNA in patients with resected, muscle-invasive bladder cancer without germline sampling.]]></summary>
        <author>
            <name>Thomas Powles</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[The terminal period findings of late-diagnosed fibrodysplasia ossificans progressiva]]></title>
        <id>pubmed:37599859</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37599859/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230822204709&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-08-21T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Fibrodysplasia ossificans progressiva (FOP) is an autosomal dominant rare disease characterized by foot deformities and concomitant heterotopic ossifications. Theoretically, in the absence of early diagnosis and medication, the patient's outcome will be poor. The patients are usually diagnosed at an early age. Hence, encountering a non-treated and terminal-period patient is rare. Our case was unique because it showed the clinical picture and atypical radiological distribution of a 20-year-old,...]]></summary>
        <author>
            <name>Emrah Doan</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Base Editor Scanning Reveals Activating Mutations of DNMT3A]]></title>
        <id>pubmed:37603861</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37603861/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230821204801&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-08-21T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[DNA methyltransferase 3A (DNMT3A) is a de novo cytosine methyltransferase responsible for establishing proper DNA methylation during mammalian development. Loss-of-function (LOF) mutations to DNMT3A, including the hotspot mutation R882H, frequently occur in developmental growth disorders and hematological diseases, including clonal hematopoiesis and acute myeloid leukemia. Accordingly, identifying mechanisms that activate DNMT3A is of both fundamental and therapeutic interest. Here, we applied a...]]></summary>
        <author>
            <name>Emma M Garcia</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Molecular residual disease detection in resected, muscle-invasive urothelial cancer with a tissue-based comprehensive genomic profiling-informed personalized monitoring assay]]></title>
        <id>pubmed:37601688</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37601688/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230821204801&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-08-21T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSION: We present a personalized ctDNA monitoring assay utilizing tissue-based FoundationOne^() CDx CGP, which is a pragmatic and potentially clinically scalable method that can detect low levels of residual ctDNA in patients with resected, muscle-invasive bladder cancer without germline sampling.]]></summary>
        <author>
            <name>Thomas Powles</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Expressed barcoding enables high resolution tracking of the evolution of drug tolerance]]></title>
        <id>pubmed:37603596</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37603596/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230910204912&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-08-21T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[For a majority of non-small cell lung cancer (NSCLC) patients with EGFR mutations, treatment with EGFR inhibitors (EGFRi) induces a clinical response. Despite this initial reduction in tumor size, residual disease persists that leads to disease relapse. Elucidating the pre-existing biological differences between sensitive cells and surviving drug-tolerant persister cells and deciphering how drug-tolerant cells evolve in response to treatment could help identify strategies to improve the efficacy...]]></summary>
        <author>
            <name>Jennifer L Cotton</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Improving cellular phylogenies through the integrated use of mutation order and optimality principles]]></title>
        <id>pubmed:37602230</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37602230/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230910204912&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-08-21T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[The study of tumor evolution is being revolutionalized by single-cell sequencing technologies that survey the somatic variation of cancer cells. In these endeavors, reliable inference of the evolutionary relationship of single cells is a key step. However, single-cell sequences contain many errors and missing bases, which necessitate advancing standard molecular phylogenetics approaches for applications in analyzing these datasets. We have developed a computational approach that integratively...]]></summary>
        <author>
            <name>Sayaka Miura</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Expressed barcoding enables high resolution tracking of the evolution of drug tolerance]]></title>
        <id>pubmed:37603596</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37603596/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230909205145&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-08-21T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[For a majority of non-small cell lung cancer (NSCLC) patients with EGFR mutations, treatment with EGFR inhibitors (EGFRi) induces a clinical response. Despite this initial reduction in tumor size, residual disease persists that leads to disease relapse. Elucidating the pre-existing biological differences between sensitive cells and surviving drug-tolerant persister cells and deciphering how drug-tolerant cells evolve in response to treatment could help identify strategies to improve the efficacy...]]></summary>
        <author>
            <name>Jennifer L Cotton</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Improving cellular phylogenies through the integrated use of mutation order and optimality principles]]></title>
        <id>pubmed:37602230</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37602230/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230909205145&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-08-21T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[The study of tumor evolution is being revolutionalized by single-cell sequencing technologies that survey the somatic variation of cancer cells. In these endeavors, reliable inference of the evolutionary relationship of single cells is a key step. However, single-cell sequences contain many errors and missing bases, which necessitate advancing standard molecular phylogenetics approaches for applications in analyzing these datasets. We have developed a computational approach that integratively...]]></summary>
        <author>
            <name>Sayaka Miura</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Expressed barcoding enables high resolution tracking of the evolution of drug tolerance]]></title>
        <id>pubmed:37603596</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37603596/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230908204701&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-08-21T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[For a majority of non-small cell lung cancer (NSCLC) patients with EGFR mutations, treatment with EGFR inhibitors (EGFRi) induces a clinical response. Despite this initial reduction in tumor size, residual disease persists that leads to disease relapse. Elucidating the pre-existing biological differences between sensitive cells and surviving drug-tolerant persister cells and deciphering how drug-tolerant cells evolve in response to treatment could help identify strategies to improve the efficacy...]]></summary>
        <author>
            <name>Jennifer L Cotton</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Improving cellular phylogenies through the integrated use of mutation order and optimality principles]]></title>
        <id>pubmed:37602230</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37602230/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230908204701&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-08-21T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[The study of tumor evolution is being revolutionalized by single-cell sequencing technologies that survey the somatic variation of cancer cells. In these endeavors, reliable inference of the evolutionary relationship of single cells is a key step. However, single-cell sequences contain many errors and missing bases, which necessitate advancing standard molecular phylogenetics approaches for applications in analyzing these datasets. We have developed a computational approach that integratively...]]></summary>
        <author>
            <name>Sayaka Miura</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Expressed barcoding enables high resolution tracking of the evolution of drug tolerance]]></title>
        <id>pubmed:37603596</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37603596/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230907204816&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-08-21T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[For a majority of non-small cell lung cancer (NSCLC) patients with EGFR mutations, treatment with EGFR inhibitors (EGFRi) induces a clinical response. Despite this initial reduction in tumor size, residual disease persists that leads to disease relapse. Elucidating the pre-existing biological differences between sensitive cells and surviving drug-tolerant persister cells and deciphering how drug-tolerant cells evolve in response to treatment could help identify strategies to improve the efficacy...]]></summary>
        <author>
            <name>Jennifer L Cotton</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Improving cellular phylogenies through the integrated use of mutation order and optimality principles]]></title>
        <id>pubmed:37602230</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37602230/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230907204816&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-08-21T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[The study of tumor evolution is being revolutionalized by single-cell sequencing technologies that survey the somatic variation of cancer cells. In these endeavors, reliable inference of the evolutionary relationship of single cells is a key step. However, single-cell sequences contain many errors and missing bases, which necessitate advancing standard molecular phylogenetics approaches for applications in analyzing these datasets. We have developed a computational approach that integratively...]]></summary>
        <author>
            <name>Sayaka Miura</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Expressed barcoding enables high resolution tracking of the evolution of drug tolerance]]></title>
        <id>pubmed:37603596</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37603596/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230906204801&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-08-21T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[For a majority of non-small cell lung cancer (NSCLC) patients with EGFR mutations, treatment with EGFR inhibitors (EGFRi) induces a clinical response. Despite this initial reduction in tumor size, residual disease persists that leads to disease relapse. Elucidating the pre-existing biological differences between sensitive cells and surviving drug-tolerant persister cells and deciphering how drug-tolerant cells evolve in response to treatment could help identify strategies to improve the efficacy...]]></summary>
        <author>
            <name>Jennifer L Cotton</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Improving cellular phylogenies through the integrated use of mutation order and optimality principles]]></title>
        <id>pubmed:37602230</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37602230/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230906204801&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-08-21T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[The study of tumor evolution is being revolutionalized by single-cell sequencing technologies that survey the somatic variation of cancer cells. In these endeavors, reliable inference of the evolutionary relationship of single cells is a key step. However, single-cell sequences contain many errors and missing bases, which necessitate advancing standard molecular phylogenetics approaches for applications in analyzing these datasets. We have developed a computational approach that integratively...]]></summary>
        <author>
            <name>Sayaka Miura</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Expressed barcoding enables high resolution tracking of the evolution of drug tolerance]]></title>
        <id>pubmed:37603596</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37603596/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230905204848&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-08-21T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[For a majority of non-small cell lung cancer (NSCLC) patients with EGFR mutations, treatment with EGFR inhibitors (EGFRi) induces a clinical response. Despite this initial reduction in tumor size, residual disease persists that leads to disease relapse. Elucidating the pre-existing biological differences between sensitive cells and surviving drug-tolerant persister cells and deciphering how drug-tolerant cells evolve in response to treatment could help identify strategies to improve the efficacy...]]></summary>
        <author>
            <name>Jennifer L Cotton</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Improving cellular phylogenies through the integrated use of mutation order and optimality principles]]></title>
        <id>pubmed:37602230</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37602230/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230905204848&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-08-21T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[The study of tumor evolution is being revolutionalized by single-cell sequencing technologies that survey the somatic variation of cancer cells. In these endeavors, reliable inference of the evolutionary relationship of single cells is a key step. However, single-cell sequences contain many errors and missing bases, which necessitate advancing standard molecular phylogenetics approaches for applications in analyzing these datasets. We have developed a computational approach that integratively...]]></summary>
        <author>
            <name>Sayaka Miura</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Expressed barcoding enables high resolution tracking of the evolution of drug tolerance]]></title>
        <id>pubmed:37603596</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37603596/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230904204751&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-08-21T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[For a majority of non-small cell lung cancer (NSCLC) patients with EGFR mutations, treatment with EGFR inhibitors (EGFRi) induces a clinical response. Despite this initial reduction in tumor size, residual disease persists that leads to disease relapse. Elucidating the pre-existing biological differences between sensitive cells and surviving drug-tolerant persister cells and deciphering how drug-tolerant cells evolve in response to treatment could help identify strategies to improve the efficacy...]]></summary>
        <author>
            <name>Jennifer L Cotton</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Improving cellular phylogenies through the integrated use of mutation order and optimality principles]]></title>
        <id>pubmed:37602230</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37602230/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230904204751&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-08-21T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[The study of tumor evolution is being revolutionalized by single-cell sequencing technologies that survey the somatic variation of cancer cells. In these endeavors, reliable inference of the evolutionary relationship of single cells is a key step. However, single-cell sequences contain many errors and missing bases, which necessitate advancing standard molecular phylogenetics approaches for applications in analyzing these datasets. We have developed a computational approach that integratively...]]></summary>
        <author>
            <name>Sayaka Miura</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Expressed barcoding enables high resolution tracking of the evolution of drug tolerance]]></title>
        <id>pubmed:37603596</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37603596/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230903204939&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-08-21T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[For a majority of non-small cell lung cancer (NSCLC) patients with EGFR mutations, treatment with EGFR inhibitors (EGFRi) induces a clinical response. Despite this initial reduction in tumor size, residual disease persists that leads to disease relapse. Elucidating the pre-existing biological differences between sensitive cells and surviving drug-tolerant persister cells and deciphering how drug-tolerant cells evolve in response to treatment could help identify strategies to improve the efficacy...]]></summary>
        <author>
            <name>Jennifer L Cotton</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Improving cellular phylogenies through the integrated use of mutation order and optimality principles]]></title>
        <id>pubmed:37602230</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37602230/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230903204939&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-08-21T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[The study of tumor evolution is being revolutionalized by single-cell sequencing technologies that survey the somatic variation of cancer cells. In these endeavors, reliable inference of the evolutionary relationship of single cells is a key step. However, single-cell sequences contain many errors and missing bases, which necessitate advancing standard molecular phylogenetics approaches for applications in analyzing these datasets. We have developed a computational approach that integratively...]]></summary>
        <author>
            <name>Sayaka Miura</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Expressed barcoding enables high resolution tracking of the evolution of drug tolerance]]></title>
        <id>pubmed:37603596</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37603596/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230902205121&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-08-21T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[For a majority of non-small cell lung cancer (NSCLC) patients with EGFR mutations, treatment with EGFR inhibitors (EGFRi) induces a clinical response. Despite this initial reduction in tumor size, residual disease persists that leads to disease relapse. Elucidating the pre-existing biological differences between sensitive cells and surviving drug-tolerant persister cells and deciphering how drug-tolerant cells evolve in response to treatment could help identify strategies to improve the efficacy...]]></summary>
        <author>
            <name>Jennifer L Cotton</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Improving cellular phylogenies through the integrated use of mutation order and optimality principles]]></title>
        <id>pubmed:37602230</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37602230/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230902205121&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-08-21T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[The study of tumor evolution is being revolutionalized by single-cell sequencing technologies that survey the somatic variation of cancer cells. In these endeavors, reliable inference of the evolutionary relationship of single cells is a key step. However, single-cell sequences contain many errors and missing bases, which necessitate advancing standard molecular phylogenetics approaches for applications in analyzing these datasets. We have developed a computational approach that integratively...]]></summary>
        <author>
            <name>Sayaka Miura</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Expressed barcoding enables high resolution tracking of the evolution of drug tolerance]]></title>
        <id>pubmed:37603596</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37603596/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230901204619&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-08-21T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[For a majority of non-small cell lung cancer (NSCLC) patients with EGFR mutations, treatment with EGFR inhibitors (EGFRi) induces a clinical response. Despite this initial reduction in tumor size, residual disease persists that leads to disease relapse. Elucidating the pre-existing biological differences between sensitive cells and surviving drug-tolerant persister cells and deciphering how drug-tolerant cells evolve in response to treatment could help identify strategies to improve the efficacy...]]></summary>
        <author>
            <name>Jennifer L Cotton</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Improving cellular phylogenies through the integrated use of mutation order and optimality principles]]></title>
        <id>pubmed:37602230</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37602230/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230901204619&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-08-21T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[The study of tumor evolution is being revolutionalized by single-cell sequencing technologies that survey the somatic variation of cancer cells. In these endeavors, reliable inference of the evolutionary relationship of single cells is a key step. However, single-cell sequences contain many errors and missing bases, which necessitate advancing standard molecular phylogenetics approaches for applications in analyzing these datasets. We have developed a computational approach that integratively...]]></summary>
        <author>
            <name>Sayaka Miura</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Expressed barcoding enables high resolution tracking of the evolution of drug tolerance]]></title>
        <id>pubmed:37603596</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37603596/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230831205203&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-08-21T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[For a majority of non-small cell lung cancer (NSCLC) patients with EGFR mutations, treatment with EGFR inhibitors (EGFRi) induces a clinical response. Despite this initial reduction in tumor size, residual disease persists that leads to disease relapse. Elucidating the pre-existing biological differences between sensitive cells and surviving drug-tolerant persister cells and deciphering how drug-tolerant cells evolve in response to treatment could help identify strategies to improve the efficacy...]]></summary>
        <author>
            <name>Jennifer L Cotton</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Improving cellular phylogenies through the integrated use of mutation order and optimality principles]]></title>
        <id>pubmed:37602230</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37602230/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230831205203&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-08-21T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[The study of tumor evolution is being revolutionalized by single-cell sequencing technologies that survey the somatic variation of cancer cells. In these endeavors, reliable inference of the evolutionary relationship of single cells is a key step. However, single-cell sequences contain many errors and missing bases, which necessitate advancing standard molecular phylogenetics approaches for applications in analyzing these datasets. We have developed a computational approach that integratively...]]></summary>
        <author>
            <name>Sayaka Miura</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Expressed barcoding enables high resolution tracking of the evolution of drug tolerance]]></title>
        <id>pubmed:37603596</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37603596/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230830204850&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-08-21T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[For a majority of non-small cell lung cancer (NSCLC) patients with EGFR mutations, treatment with EGFR inhibitors (EGFRi) induces a clinical response. Despite this initial reduction in tumor size, residual disease persists that leads to disease relapse. Elucidating the pre-existing biological differences between sensitive cells and surviving drug-tolerant persister cells and deciphering how drug-tolerant cells evolve in response to treatment could help identify strategies to improve the efficacy...]]></summary>
        <author>
            <name>Jennifer L Cotton</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Improving cellular phylogenies through the integrated use of mutation order and optimality principles]]></title>
        <id>pubmed:37602230</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37602230/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230830204850&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-08-21T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[The study of tumor evolution is being revolutionalized by single-cell sequencing technologies that survey the somatic variation of cancer cells. In these endeavors, reliable inference of the evolutionary relationship of single cells is a key step. However, single-cell sequences contain many errors and missing bases, which necessitate advancing standard molecular phylogenetics approaches for applications in analyzing these datasets. We have developed a computational approach that integratively...]]></summary>
        <author>
            <name>Sayaka Miura</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Expressed barcoding enables high resolution tracking of the evolution of drug tolerance]]></title>
        <id>pubmed:37603596</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37603596/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230829204824&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-08-21T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[For a majority of non-small cell lung cancer (NSCLC) patients with EGFR mutations, treatment with EGFR inhibitors (EGFRi) induces a clinical response. Despite this initial reduction in tumor size, residual disease persists that leads to disease relapse. Elucidating the pre-existing biological differences between sensitive cells and surviving drug-tolerant persister cells and deciphering how drug-tolerant cells evolve in response to treatment could help identify strategies to improve the efficacy...]]></summary>
        <author>
            <name>Jennifer L Cotton</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Improving cellular phylogenies through the integrated use of mutation order and optimality principles]]></title>
        <id>pubmed:37602230</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37602230/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230829204824&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-08-21T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[The study of tumor evolution is being revolutionalized by single-cell sequencing technologies that survey the somatic variation of cancer cells. In these endeavors, reliable inference of the evolutionary relationship of single cells is a key step. However, single-cell sequences contain many errors and missing bases, which necessitate advancing standard molecular phylogenetics approaches for applications in analyzing these datasets. We have developed a computational approach that integratively...]]></summary>
        <author>
            <name>Sayaka Miura</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Expressed barcoding enables high resolution tracking of the evolution of drug tolerance]]></title>
        <id>pubmed:37603596</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37603596/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230828204854&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-08-21T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[For a majority of non-small cell lung cancer (NSCLC) patients with EGFR mutations, treatment with EGFR inhibitors (EGFRi) induces a clinical response. Despite this initial reduction in tumor size, residual disease persists that leads to disease relapse. Elucidating the pre-existing biological differences between sensitive cells and surviving drug-tolerant persister cells and deciphering how drug-tolerant cells evolve in response to treatment could help identify strategies to improve the efficacy...]]></summary>
        <author>
            <name>Jennifer L Cotton</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Improving cellular phylogenies through the integrated use of mutation order and optimality principles]]></title>
        <id>pubmed:37602230</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37602230/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230828204854&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-08-21T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[The study of tumor evolution is being revolutionalized by single-cell sequencing technologies that survey the somatic variation of cancer cells. In these endeavors, reliable inference of the evolutionary relationship of single cells is a key step. However, single-cell sequences contain many errors and missing bases, which necessitate advancing standard molecular phylogenetics approaches for applications in analyzing these datasets. We have developed a computational approach that integratively...]]></summary>
        <author>
            <name>Sayaka Miura</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Expressed barcoding enables high resolution tracking of the evolution of drug tolerance]]></title>
        <id>pubmed:37603596</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37603596/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230827204908&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-08-21T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[For a majority of non-small cell lung cancer (NSCLC) patients with EGFR mutations, treatment with EGFR inhibitors (EGFRi) induces a clinical response. Despite this initial reduction in tumor size, residual disease persists that leads to disease relapse. Elucidating the pre-existing biological differences between sensitive cells and surviving drug-tolerant persister cells and deciphering how drug-tolerant cells evolve in response to treatment could help identify strategies to improve the efficacy...]]></summary>
        <author>
            <name>Jennifer L Cotton</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Improving cellular phylogenies through the integrated use of mutation order and optimality principles]]></title>
        <id>pubmed:37602230</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37602230/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230827204908&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-08-21T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[The study of tumor evolution is being revolutionalized by single-cell sequencing technologies that survey the somatic variation of cancer cells. In these endeavors, reliable inference of the evolutionary relationship of single cells is a key step. However, single-cell sequences contain many errors and missing bases, which necessitate advancing standard molecular phylogenetics approaches for applications in analyzing these datasets. We have developed a computational approach that integratively...]]></summary>
        <author>
            <name>Sayaka Miura</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Expressed barcoding enables high resolution tracking of the evolution of drug tolerance]]></title>
        <id>pubmed:37603596</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37603596/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230826205107&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-08-21T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[For a majority of non-small cell lung cancer (NSCLC) patients with EGFR mutations, treatment with EGFR inhibitors (EGFRi) induces a clinical response. Despite this initial reduction in tumor size, residual disease persists that leads to disease relapse. Elucidating the pre-existing biological differences between sensitive cells and surviving drug-tolerant persister cells and deciphering how drug-tolerant cells evolve in response to treatment could help identify strategies to improve the efficacy...]]></summary>
        <author>
            <name>Jennifer L Cotton</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Improving cellular phylogenies through the integrated use of mutation order and optimality principles]]></title>
        <id>pubmed:37602230</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37602230/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230826205107&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-08-21T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[The study of tumor evolution is being revolutionalized by single-cell sequencing technologies that survey the somatic variation of cancer cells. In these endeavors, reliable inference of the evolutionary relationship of single cells is a key step. However, single-cell sequences contain many errors and missing bases, which necessitate advancing standard molecular phylogenetics approaches for applications in analyzing these datasets. We have developed a computational approach that integratively...]]></summary>
        <author>
            <name>Sayaka Miura</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Expressed barcoding enables high resolution tracking of the evolution of drug tolerance]]></title>
        <id>pubmed:37603596</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37603596/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230825204602&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-08-21T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[For a majority of non-small cell lung cancer (NSCLC) patients with EGFR mutations, treatment with EGFR inhibitors (EGFRi) induces a clinical response. Despite this initial reduction in tumor size, residual disease persists that leads to disease relapse. Elucidating the pre-existing biological differences between sensitive cells and surviving drug-tolerant persister cells and deciphering how drug-tolerant cells evolve in response to treatment could help identify strategies to improve the efficacy...]]></summary>
        <author>
            <name>Jennifer L Cotton</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Improving cellular phylogenies through the integrated use of mutation order and optimality principles]]></title>
        <id>pubmed:37602230</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37602230/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230825204602&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-08-21T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[The study of tumor evolution is being revolutionalized by single-cell sequencing technologies that survey the somatic variation of cancer cells. In these endeavors, reliable inference of the evolutionary relationship of single cells is a key step. However, single-cell sequences contain many errors and missing bases, which necessitate advancing standard molecular phylogenetics approaches for applications in analyzing these datasets. We have developed a computational approach that integratively...]]></summary>
        <author>
            <name>Sayaka Miura</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Expressed barcoding enables high resolution tracking of the evolution of drug tolerance]]></title>
        <id>pubmed:37603596</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37603596/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230824204824&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-08-21T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[For a majority of non-small cell lung cancer (NSCLC) patients with EGFR mutations, treatment with EGFR inhibitors (EGFRi) induces a clinical response. Despite this initial reduction in tumor size, residual disease persists that leads to disease relapse. Elucidating the pre-existing biological differences between sensitive cells and surviving drug-tolerant persister cells and deciphering how drug-tolerant cells evolve in response to treatment could help identify strategies to improve the efficacy...]]></summary>
        <author>
            <name>Jennifer L Cotton</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Improving cellular phylogenies through the integrated use of mutation order and optimality principles]]></title>
        <id>pubmed:37602230</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37602230/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230824204824&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-08-21T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[The study of tumor evolution is being revolutionalized by single-cell sequencing technologies that survey the somatic variation of cancer cells. In these endeavors, reliable inference of the evolutionary relationship of single cells is a key step. However, single-cell sequences contain many errors and missing bases, which necessitate advancing standard molecular phylogenetics approaches for applications in analyzing these datasets. We have developed a computational approach that integratively...]]></summary>
        <author>
            <name>Sayaka Miura</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Expressed barcoding enables high resolution tracking of the evolution of drug tolerance]]></title>
        <id>pubmed:37603596</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37603596/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230823204708&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-08-21T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[For a majority of non-small cell lung cancer (NSCLC) patients with EGFR mutations, treatment with EGFR inhibitors (EGFRi) induces a clinical response. Despite this initial reduction in tumor size, residual disease persists that leads to disease relapse. Elucidating the pre-existing biological differences between sensitive cells and surviving drug-tolerant persister cells and deciphering how drug-tolerant cells evolve in response to treatment could help identify strategies to improve the efficacy...]]></summary>
        <author>
            <name>Jennifer L Cotton</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Improving cellular phylogenies through the integrated use of mutation order and optimality principles]]></title>
        <id>pubmed:37602230</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37602230/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230823204708&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-08-21T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[The study of tumor evolution is being revolutionalized by single-cell sequencing technologies that survey the somatic variation of cancer cells. In these endeavors, reliable inference of the evolutionary relationship of single cells is a key step. However, single-cell sequences contain many errors and missing bases, which necessitate advancing standard molecular phylogenetics approaches for applications in analyzing these datasets. We have developed a computational approach that integratively...]]></summary>
        <author>
            <name>Sayaka Miura</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Expressed barcoding enables high resolution tracking of the evolution of drug tolerance]]></title>
        <id>pubmed:37603596</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37603596/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230822204709&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-08-21T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[For a majority of non-small cell lung cancer (NSCLC) patients with EGFR mutations, treatment with EGFR inhibitors (EGFRi) induces a clinical response. Despite this initial reduction in tumor size, residual disease persists that leads to disease relapse. Elucidating the pre-existing biological differences between sensitive cells and surviving drug-tolerant persister cells and deciphering how drug-tolerant cells evolve in response to treatment could help identify strategies to improve the efficacy...]]></summary>
        <author>
            <name>Jennifer L Cotton</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Improving cellular phylogenies through the integrated use of mutation order and optimality principles]]></title>
        <id>pubmed:37602230</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37602230/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230822204709&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-08-21T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[The study of tumor evolution is being revolutionalized by single-cell sequencing technologies that survey the somatic variation of cancer cells. In these endeavors, reliable inference of the evolutionary relationship of single cells is a key step. However, single-cell sequences contain many errors and missing bases, which necessitate advancing standard molecular phylogenetics approaches for applications in analyzing these datasets. We have developed a computational approach that integratively...]]></summary>
        <author>
            <name>Sayaka Miura</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Expressed barcoding enables high resolution tracking of the evolution of drug tolerance]]></title>
        <id>pubmed:37603596</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37603596/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230821204801&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-08-21T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[For a majority of non-small cell lung cancer (NSCLC) patients with EGFR mutations, treatment with EGFR inhibitors (EGFRi) induces a clinical response. Despite this initial reduction in tumor size, residual disease persists that leads to disease relapse. Elucidating the pre-existing biological differences between sensitive cells and surviving drug-tolerant persister cells and deciphering how drug-tolerant cells evolve in response to treatment could help identify strategies to improve the efficacy...]]></summary>
        <author>
            <name>Jennifer L Cotton</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Improving cellular phylogenies through the integrated use of mutation order and optimality principles]]></title>
        <id>pubmed:37602230</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37602230/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230821204801&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-08-21T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[The study of tumor evolution is being revolutionalized by single-cell sequencing technologies that survey the somatic variation of cancer cells. In these endeavors, reliable inference of the evolutionary relationship of single cells is a key step. However, single-cell sequences contain many errors and missing bases, which necessitate advancing standard molecular phylogenetics approaches for applications in analyzing these datasets. We have developed a computational approach that integratively...]]></summary>
        <author>
            <name>Sayaka Miura</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Distinct mutational processes shape selection of MHC class I and class II mutations across primary and metastatic tumors]]></title>
        <id>pubmed:37597185</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37597185/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230910204912&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-08-19T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Disruption of antigen presentation via loss of major histocompatibility complex (MHC) expression is a strategy whereby cancer cells escape immune surveillance and develop resistance to immunotherapy. Here, we develop the personalized genomics algorithm Hapster and accurately call somatic mutations within the MHC genes of 10,001 primary and 2,199 metastatic tumors, creating a catalog of 1,663 non-synonymous mutations that provide key insights into MHC mutagenesis. We find that MHC class I genes...]]></summary>
        <author>
            <name>Michael B Mumphrey</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Distinct mutational processes shape selection of MHC class I and class II mutations across primary and metastatic tumors]]></title>
        <id>pubmed:37597185</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37597185/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230909205145&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-08-19T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Disruption of antigen presentation via loss of major histocompatibility complex (MHC) expression is a strategy whereby cancer cells escape immune surveillance and develop resistance to immunotherapy. Here, we develop the personalized genomics algorithm Hapster and accurately call somatic mutations within the MHC genes of 10,001 primary and 2,199 metastatic tumors, creating a catalog of 1,663 non-synonymous mutations that provide key insights into MHC mutagenesis. We find that MHC class I genes...]]></summary>
        <author>
            <name>Michael B Mumphrey</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Distinct mutational processes shape selection of MHC class I and class II mutations across primary and metastatic tumors]]></title>
        <id>pubmed:37597185</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37597185/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230908204701&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-08-19T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Disruption of antigen presentation via loss of major histocompatibility complex (MHC) expression is a strategy whereby cancer cells escape immune surveillance and develop resistance to immunotherapy. Here, we develop the personalized genomics algorithm Hapster and accurately call somatic mutations within the MHC genes of 10,001 primary and 2,199 metastatic tumors, creating a catalog of 1,663 non-synonymous mutations that provide key insights into MHC mutagenesis. We find that MHC class I genes...]]></summary>
        <author>
            <name>Michael B Mumphrey</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Distinct mutational processes shape selection of MHC class I and class II mutations across primary and metastatic tumors]]></title>
        <id>pubmed:37597185</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37597185/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230907204816&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-08-19T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Disruption of antigen presentation via loss of major histocompatibility complex (MHC) expression is a strategy whereby cancer cells escape immune surveillance and develop resistance to immunotherapy. Here, we develop the personalized genomics algorithm Hapster and accurately call somatic mutations within the MHC genes of 10,001 primary and 2,199 metastatic tumors, creating a catalog of 1,663 non-synonymous mutations that provide key insights into MHC mutagenesis. We find that MHC class I genes...]]></summary>
        <author>
            <name>Michael B Mumphrey</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Distinct mutational processes shape selection of MHC class I and class II mutations across primary and metastatic tumors]]></title>
        <id>pubmed:37597185</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37597185/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230906204801&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-08-19T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Disruption of antigen presentation via loss of major histocompatibility complex (MHC) expression is a strategy whereby cancer cells escape immune surveillance and develop resistance to immunotherapy. Here, we develop the personalized genomics algorithm Hapster and accurately call somatic mutations within the MHC genes of 10,001 primary and 2,199 metastatic tumors, creating a catalog of 1,663 non-synonymous mutations that provide key insights into MHC mutagenesis. We find that MHC class I genes...]]></summary>
        <author>
            <name>Michael B Mumphrey</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Distinct mutational processes shape selection of MHC class I and class II mutations across primary and metastatic tumors]]></title>
        <id>pubmed:37597185</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37597185/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230905204848&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-08-19T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Disruption of antigen presentation via loss of major histocompatibility complex (MHC) expression is a strategy whereby cancer cells escape immune surveillance and develop resistance to immunotherapy. Here, we develop the personalized genomics algorithm Hapster and accurately call somatic mutations within the MHC genes of 10,001 primary and 2,199 metastatic tumors, creating a catalog of 1,663 non-synonymous mutations that provide key insights into MHC mutagenesis. We find that MHC class I genes...]]></summary>
        <author>
            <name>Michael B Mumphrey</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Distinct mutational processes shape selection of MHC class I and class II mutations across primary and metastatic tumors]]></title>
        <id>pubmed:37597185</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37597185/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230904204751&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-08-19T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Disruption of antigen presentation via loss of major histocompatibility complex (MHC) expression is a strategy whereby cancer cells escape immune surveillance and develop resistance to immunotherapy. Here, we develop the personalized genomics algorithm Hapster and accurately call somatic mutations within the MHC genes of 10,001 primary and 2,199 metastatic tumors, creating a catalog of 1,663 non-synonymous mutations that provide key insights into MHC mutagenesis. We find that MHC class I genes...]]></summary>
        <author>
            <name>Michael B Mumphrey</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Distinct mutational processes shape selection of MHC class I and class II mutations across primary and metastatic tumors]]></title>
        <id>pubmed:37597185</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37597185/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230903204939&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-08-19T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Disruption of antigen presentation via loss of major histocompatibility complex (MHC) expression is a strategy whereby cancer cells escape immune surveillance and develop resistance to immunotherapy. Here, we develop the personalized genomics algorithm Hapster and accurately call somatic mutations within the MHC genes of 10,001 primary and 2,199 metastatic tumors, creating a catalog of 1,663 non-synonymous mutations that provide key insights into MHC mutagenesis. We find that MHC class I genes...]]></summary>
        <author>
            <name>Michael B Mumphrey</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Distinct mutational processes shape selection of MHC class I and class II mutations across primary and metastatic tumors]]></title>
        <id>pubmed:37597185</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37597185/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230902205121&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-08-19T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Disruption of antigen presentation via loss of major histocompatibility complex (MHC) expression is a strategy whereby cancer cells escape immune surveillance and develop resistance to immunotherapy. Here, we develop the personalized genomics algorithm Hapster and accurately call somatic mutations within the MHC genes of 10,001 primary and 2,199 metastatic tumors, creating a catalog of 1,663 non-synonymous mutations that provide key insights into MHC mutagenesis. We find that MHC class I genes...]]></summary>
        <author>
            <name>Michael B Mumphrey</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Distinct mutational processes shape selection of MHC class I and class II mutations across primary and metastatic tumors]]></title>
        <id>pubmed:37597185</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37597185/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230901204619&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-08-19T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Disruption of antigen presentation via loss of major histocompatibility complex (MHC) expression is a strategy whereby cancer cells escape immune surveillance and develop resistance to immunotherapy. Here, we develop the personalized genomics algorithm Hapster and accurately call somatic mutations within the MHC genes of 10,001 primary and 2,199 metastatic tumors, creating a catalog of 1,663 non-synonymous mutations that provide key insights into MHC mutagenesis. We find that MHC class I genes...]]></summary>
        <author>
            <name>Michael B Mumphrey</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Distinct mutational processes shape selection of MHC class I and class II mutations across primary and metastatic tumors]]></title>
        <id>pubmed:37597185</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37597185/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230831205203&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-08-19T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Disruption of antigen presentation via loss of major histocompatibility complex (MHC) expression is a strategy whereby cancer cells escape immune surveillance and develop resistance to immunotherapy. Here, we develop the personalized genomics algorithm Hapster and accurately call somatic mutations within the MHC genes of 10,001 primary and 2,199 metastatic tumors, creating a catalog of 1,663 non-synonymous mutations that provide key insights into MHC mutagenesis. We find that MHC class I genes...]]></summary>
        <author>
            <name>Michael B Mumphrey</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Distinct mutational processes shape selection of MHC class I and class II mutations across primary and metastatic tumors]]></title>
        <id>pubmed:37597185</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37597185/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230830204850&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-08-19T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Disruption of antigen presentation via loss of major histocompatibility complex (MHC) expression is a strategy whereby cancer cells escape immune surveillance and develop resistance to immunotherapy. Here, we develop the personalized genomics algorithm Hapster and accurately call somatic mutations within the MHC genes of 10,001 primary and 2,199 metastatic tumors, creating a catalog of 1,663 non-synonymous mutations that provide key insights into MHC mutagenesis. We find that MHC class I genes...]]></summary>
        <author>
            <name>Michael B Mumphrey</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Distinct mutational processes shape selection of MHC class I and class II mutations across primary and metastatic tumors]]></title>
        <id>pubmed:37597185</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37597185/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230829204824&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-08-19T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Disruption of antigen presentation via loss of major histocompatibility complex (MHC) expression is a strategy whereby cancer cells escape immune surveillance and develop resistance to immunotherapy. Here, we develop the personalized genomics algorithm Hapster and accurately call somatic mutations within the MHC genes of 10,001 primary and 2,199 metastatic tumors, creating a catalog of 1,663 non-synonymous mutations that provide key insights into MHC mutagenesis. We find that MHC class I genes...]]></summary>
        <author>
            <name>Michael B Mumphrey</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Distinct mutational processes shape selection of MHC class I and class II mutations across primary and metastatic tumors]]></title>
        <id>pubmed:37597185</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37597185/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230828204854&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-08-19T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Disruption of antigen presentation via loss of major histocompatibility complex (MHC) expression is a strategy whereby cancer cells escape immune surveillance and develop resistance to immunotherapy. Here, we develop the personalized genomics algorithm Hapster and accurately call somatic mutations within the MHC genes of 10,001 primary and 2,199 metastatic tumors, creating a catalog of 1,663 non-synonymous mutations that provide key insights into MHC mutagenesis. We find that MHC class I genes...]]></summary>
        <author>
            <name>Michael B Mumphrey</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Distinct mutational processes shape selection of MHC class I and class II mutations across primary and metastatic tumors]]></title>
        <id>pubmed:37597185</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37597185/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230827204908&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-08-19T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Disruption of antigen presentation via loss of major histocompatibility complex (MHC) expression is a strategy whereby cancer cells escape immune surveillance and develop resistance to immunotherapy. Here, we develop the personalized genomics algorithm Hapster and accurately call somatic mutations within the MHC genes of 10,001 primary and 2,199 metastatic tumors, creating a catalog of 1,663 non-synonymous mutations that provide key insights into MHC mutagenesis. We find that MHC class I genes...]]></summary>
        <author>
            <name>Michael B Mumphrey</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Distinct mutational processes shape selection of MHC class I and class II mutations across primary and metastatic tumors]]></title>
        <id>pubmed:37597185</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37597185/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230826205107&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-08-19T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Disruption of antigen presentation via loss of major histocompatibility complex (MHC) expression is a strategy whereby cancer cells escape immune surveillance and develop resistance to immunotherapy. Here, we develop the personalized genomics algorithm Hapster and accurately call somatic mutations within the MHC genes of 10,001 primary and 2,199 metastatic tumors, creating a catalog of 1,663 non-synonymous mutations that provide key insights into MHC mutagenesis. We find that MHC class I genes...]]></summary>
        <author>
            <name>Michael B Mumphrey</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Distinct mutational processes shape selection of MHC class I and class II mutations across primary and metastatic tumors]]></title>
        <id>pubmed:37597185</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37597185/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230825204602&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-08-19T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Disruption of antigen presentation via loss of major histocompatibility complex (MHC) expression is a strategy whereby cancer cells escape immune surveillance and develop resistance to immunotherapy. Here, we develop the personalized genomics algorithm Hapster and accurately call somatic mutations within the MHC genes of 10,001 primary and 2,199 metastatic tumors, creating a catalog of 1,663 non-synonymous mutations that provide key insights into MHC mutagenesis. We find that MHC class I genes...]]></summary>
        <author>
            <name>Michael B Mumphrey</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Distinct mutational processes shape selection of MHC class I and class II mutations across primary and metastatic tumors]]></title>
        <id>pubmed:37597185</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37597185/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230824204824&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-08-19T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Disruption of antigen presentation via loss of major histocompatibility complex (MHC) expression is a strategy whereby cancer cells escape immune surveillance and develop resistance to immunotherapy. Here, we develop the personalized genomics algorithm Hapster and accurately call somatic mutations within the MHC genes of 10,001 primary and 2,199 metastatic tumors, creating a catalog of 1,663 non-synonymous mutations that provide key insights into MHC mutagenesis. We find that MHC class I genes...]]></summary>
        <author>
            <name>Michael B Mumphrey</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Distinct mutational processes shape selection of MHC class I and class II mutations across primary and metastatic tumors]]></title>
        <id>pubmed:37597185</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37597185/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230823204708&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-08-19T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Disruption of antigen presentation via loss of major histocompatibility complex (MHC) expression is a strategy whereby cancer cells escape immune surveillance and develop resistance to immunotherapy. Here, we develop the personalized genomics algorithm Hapster and accurately call somatic mutations within the MHC genes of 10,001 primary and 2,199 metastatic tumors, creating a catalog of 1,663 non-synonymous mutations that provide key insights into MHC mutagenesis. We find that MHC class I genes...]]></summary>
        <author>
            <name>Michael B Mumphrey</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Distinct mutational processes shape selection of MHC class I and class II mutations across primary and metastatic tumors]]></title>
        <id>pubmed:37597185</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37597185/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230822204709&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-08-19T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Disruption of antigen presentation via loss of major histocompatibility complex (MHC) expression is a strategy whereby cancer cells escape immune surveillance and develop resistance to immunotherapy. Here, we develop the personalized genomics algorithm Hapster and accurately call somatic mutations within the MHC genes of 10,001 primary and 2,199 metastatic tumors, creating a catalog of 1,663 non-synonymous mutations that provide key insights into MHC mutagenesis. We find that MHC class I genes...]]></summary>
        <author>
            <name>Michael B Mumphrey</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Distinct mutational processes shape selection of MHC class I and class II mutations across primary and metastatic tumors]]></title>
        <id>pubmed:37597185</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37597185/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230821204801&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-08-19T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Disruption of antigen presentation via loss of major histocompatibility complex (MHC) expression is a strategy whereby cancer cells escape immune surveillance and develop resistance to immunotherapy. Here, we develop the personalized genomics algorithm Hapster and accurately call somatic mutations within the MHC genes of 10,001 primary and 2,199 metastatic tumors, creating a catalog of 1,663 non-synonymous mutations that provide key insights into MHC mutagenesis. We find that MHC class I genes...]]></summary>
        <author>
            <name>Michael B Mumphrey</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Distinct mutational processes shape selection of MHC class I and class II mutations across primary and metastatic tumors]]></title>
        <id>pubmed:37597185</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37597185/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230820204715&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-08-19T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Disruption of antigen presentation via loss of major histocompatibility complex (MHC) expression is a strategy whereby cancer cells escape immune surveillance and develop resistance to immunotherapy. Here, we develop the personalized genomics algorithm Hapster and accurately call somatic mutations within the MHC genes of 10,001 primary and 2,199 metastatic tumors, creating a catalog of 1,663 non-synonymous mutations that provide key insights into MHC mutagenesis. We find that MHC class I genes...]]></summary>
        <author>
            <name>Michael B Mumphrey</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Distinct mutational processes shape selection of MHC class I and class II mutations across primary and metastatic tumors]]></title>
        <id>pubmed:37597185</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37597185/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230819204952&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-08-19T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Disruption of antigen presentation via loss of major histocompatibility complex (MHC) expression is a strategy whereby cancer cells escape immune surveillance and develop resistance to immunotherapy. Here, we develop the personalized genomics algorithm Hapster and accurately call somatic mutations within the MHC genes of 10,001 primary and 2,199 metastatic tumors, creating a catalog of 1,663 non-synonymous mutations that provide key insights into MHC mutagenesis. We find that MHC class I genes...]]></summary>
        <author>
            <name>Michael B Mumphrey</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[PPM1D modulates hematopoietic cell fitness and response to DNA damage and is a therapeutic target in myeloid malignancy]]></title>
        <id>pubmed:37595362</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37595362/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230904204751&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-08-18T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[PPM1D encodes a phosphatase that is recurrently activated across cancer, most notably in therapy-related myeloid neoplasms. However, the function of PPM1D in hematopoiesis and its contribution to tumor cell growth remain incompletely understood. Using conditional mouse models, we uncover a central role for Ppm1d in hematopoiesis and validate its potential as a therapeutic target. We find that Ppm1d regulates the competitive fitness and self-renewal of hematopoietic stem cells (HSCs) with and...]]></summary>
        <author>
            <name>Peter Grant Miller</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[PPM1D modulates hematopoietic cell fitness and response to DNA damage and is a therapeutic target in myeloid malignancy]]></title>
        <id>pubmed:37595362</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37595362/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230903204939&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-08-18T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[PPM1D encodes a phosphatase that is recurrently activated across cancer, most notably in therapy-related myeloid neoplasms. However, the function of PPM1D in hematopoiesis and its contribution to tumor cell growth remain incompletely understood. Using conditional mouse models, we uncover a central role for Ppm1d in hematopoiesis and validate its potential as a therapeutic target. We find that Ppm1d regulates the competitive fitness and self-renewal of hematopoietic stem cells (HSCs) with and...]]></summary>
        <author>
            <name>Peter Grant Miller</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[PPM1D modulates hematopoietic cell fitness and response to DNA damage and is a therapeutic target in myeloid malignancy]]></title>
        <id>pubmed:37595362</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37595362/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230902205121&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-08-18T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[PPM1D encodes a phosphatase that is recurrently activated across cancer, most notably in therapy-related myeloid neoplasms. However, the function of PPM1D in hematopoiesis and its contribution to tumor cell growth remain incompletely understood. Using conditional mouse models, we uncover a central role for Ppm1d in hematopoiesis and validate its potential as a therapeutic target. We find that Ppm1d regulates the competitive fitness and self-renewal of hematopoietic stem cells (HSCs) with and...]]></summary>
        <author>
            <name>Peter Grant Miller</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[PPM1D modulates hematopoietic cell fitness and response to DNA damage and is a therapeutic target in myeloid malignancy]]></title>
        <id>pubmed:37595362</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37595362/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230901204619&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-08-18T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[PPM1D encodes a phosphatase that is recurrently activated across cancer, most notably in therapy-related myeloid neoplasms. However, the function of PPM1D in hematopoiesis and its contribution to tumor cell growth remain incompletely understood. Using conditional mouse models, we uncover a central role for Ppm1d in hematopoiesis and validate its potential as a therapeutic target. We find that Ppm1d regulates the competitive fitness and self-renewal of hematopoietic stem cells (HSCs) with and...]]></summary>
        <author>
            <name>Peter Grant Miller</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[PPM1D modulates hematopoietic cell fitness and response to DNA damage and is a therapeutic target in myeloid malignancy]]></title>
        <id>pubmed:37595362</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37595362/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230831205203&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-08-18T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[PPM1D encodes a phosphatase that is recurrently activated across cancer, most notably in therapy-related myeloid neoplasms. However, the function of PPM1D in hematopoiesis and its contribution to tumor cell growth remain incompletely understood. Using conditional mouse models, we uncover a central role for Ppm1d in hematopoiesis and validate its potential as a therapeutic target. We find that Ppm1d regulates the competitive fitness and self-renewal of hematopoietic stem cells (HSCs) with and...]]></summary>
        <author>
            <name>Peter Grant Miller</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[PPM1D modulates hematopoietic cell fitness and response to DNA damage and is a therapeutic target in myeloid malignancy]]></title>
        <id>pubmed:37595362</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37595362/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230830204850&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-08-18T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[PPM1D encodes a phosphatase that is recurrently activated across cancer, most notably in therapy-related myeloid neoplasms. However, the function of PPM1D in hematopoiesis and its contribution to tumor cell growth remain incompletely understood. Using conditional mouse models, we uncover a central role for Ppm1d in hematopoiesis and validate its potential as a therapeutic target. We find that Ppm1d regulates the competitive fitness and self-renewal of hematopoietic stem cells (HSCs) with and...]]></summary>
        <author>
            <name>Peter Grant Miller</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[PPM1D modulates hematopoietic cell fitness and response to DNA damage and is a therapeutic target in myeloid malignancy]]></title>
        <id>pubmed:37595362</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37595362/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230829204824&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-08-18T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[PPM1D encodes a phosphatase that is recurrently activated across cancer, most notably in therapy-related myeloid neoplasms. However, the function of PPM1D in hematopoiesis and its contribution to tumor cell growth remain incompletely understood. Using conditional mouse models, we uncover a central role for Ppm1d in hematopoiesis and validate its potential as a therapeutic target. We find that Ppm1d regulates the competitive fitness and self-renewal of hematopoietic stem cells (HSCs) with and...]]></summary>
        <author>
            <name>Peter Grant Miller</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[PPM1D modulates hematopoietic cell fitness and response to DNA damage and is a therapeutic target in myeloid malignancy]]></title>
        <id>pubmed:37595362</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37595362/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230828204854&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-08-18T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[PPM1D encodes a phosphatase that is recurrently activated across cancer, most notably in therapy-related myeloid neoplasms. However, the function of PPM1D in hematopoiesis and its contribution to tumor cell growth remain incompletely understood. Using conditional mouse models, we uncover a central role for Ppm1d in hematopoiesis and validate its potential as a therapeutic target. We find that Ppm1d regulates the competitive fitness and self-renewal of hematopoietic stem cells (HSCs) with and...]]></summary>
        <author>
            <name>Peter Grant Miller</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[PPM1D modulates hematopoietic cell fitness and response to DNA damage and is a therapeutic target in myeloid malignancy]]></title>
        <id>pubmed:37595362</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37595362/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230827204908&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-08-18T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[PPM1D encodes a phosphatase that is recurrently activated across cancer, most notably in therapy-related myeloid neoplasms. However, the function of PPM1D in hematopoiesis and its contribution to tumor cell growth remain incompletely understood. Using conditional mouse models, we uncover a central role for Ppm1d in hematopoiesis and validate its potential as a therapeutic target. We find that Ppm1d regulates the competitive fitness and self-renewal of hematopoietic stem cells (HSCs) with and...]]></summary>
        <author>
            <name>Peter Grant Miller</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[PPM1D modulates hematopoietic cell fitness and response to DNA damage and is a therapeutic target in myeloid malignancy]]></title>
        <id>pubmed:37595362</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37595362/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230826205107&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-08-18T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[PPM1D encodes a phosphatase that is recurrently activated across cancer, most notably in therapy-related myeloid neoplasms. However, the function of PPM1D in hematopoiesis and its contribution to tumor cell growth remain incompletely understood. Using conditional mouse models, we uncover a central role for Ppm1d in hematopoiesis and validate its potential as a therapeutic target. We find that Ppm1d regulates the competitive fitness and self-renewal of hematopoietic stem cells (HSCs) with and...]]></summary>
        <author>
            <name>Peter Grant Miller</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[PPM1D modulates hematopoietic cell fitness and response to DNA damage and is a therapeutic target in myeloid malignancy]]></title>
        <id>pubmed:37595362</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37595362/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230825204557&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-08-18T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[PPM1D encodes a phosphatase that is recurrently activated across cancer, most notably in therapy-related myeloid neoplasms. However, the function of PPM1D in hematopoiesis and its contribution to tumor cell growth remain incompletely understood. Using conditional mouse models, we uncover a central role for Ppm1d in hematopoiesis and validate its potential as a therapeutic target. We find that Ppm1d regulates the competitive fitness and self-renewal of hematopoietic stem cells (HSCs) with and...]]></summary>
        <author>
            <name>Peter Grant Miller</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[PPM1D modulates hematopoietic cell fitness and response to DNA damage and is a therapeutic target in myeloid malignancy]]></title>
        <id>pubmed:37595362</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37595362/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230824204823&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-08-18T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[PPM1D encodes a phosphatase that is recurrently activated across cancer, most notably in therapy-related myeloid neoplasms. However, the function of PPM1D in hematopoiesis and its contribution to tumor cell growth remain incompletely understood. Using conditional mouse models, we uncover a central role for Ppm1d in hematopoiesis and validate its potential as a therapeutic target. We find that Ppm1d regulates the competitive fitness and self-renewal of hematopoietic stem cells (HSCs) with and...]]></summary>
        <author>
            <name>Peter Grant Miller</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[PPM1D modulates hematopoietic cell fitness and response to DNA damage and is a therapeutic target in myeloid malignancy]]></title>
        <id>pubmed:37595362</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37595362/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230823204708&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-08-18T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[PPM1D encodes a phosphatase that is recurrently activated across cancer, most notably in therapy-related myeloid neoplasms. However, the function of PPM1D in hematopoiesis and its contribution to tumor cell growth remain incompletely understood. Using conditional mouse models, we uncover a central role for Ppm1d in hematopoiesis and validate its potential as a therapeutic target. We find that Ppm1d regulates the competitive fitness and self-renewal of hematopoietic stem cells (HSCs) with and...]]></summary>
        <author>
            <name>Peter Grant Miller</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[PPM1D modulates hematopoietic cell fitness and response to DNA damage and is a therapeutic target in myeloid malignancy]]></title>
        <id>pubmed:37595362</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37595362/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230822204709&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-08-18T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[PPM1D encodes a phosphatase that is recurrently activated across cancer, most notably in therapy-related myeloid neoplasms. However, the function of PPM1D in hematopoiesis and its contribution to tumor cell growth remain incompletely understood. Using conditional mouse models, we uncover a central role for Ppm1d in hematopoiesis and validate its potential as a therapeutic target. We find that Ppm1d regulates the competitive fitness and self-renewal of hematopoietic stem cells (HSCs) with and...]]></summary>
        <author>
            <name>Peter Grant Miller</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[PPM1D modulates hematopoietic cell fitness and response to DNA damage and is a therapeutic target in myeloid malignancy]]></title>
        <id>pubmed:37595362</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37595362/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230821204801&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-08-18T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[PPM1D encodes a phosphatase that is recurrently activated across cancer, most notably in therapy-related myeloid neoplasms. However, the function of PPM1D in hematopoiesis and its contribution to tumor cell growth remain incompletely understood. Using conditional mouse models, we uncover a central role for Ppm1d in hematopoiesis and validate its potential as a therapeutic target. We find that Ppm1d regulates the competitive fitness and self-renewal of hematopoietic stem cells (HSCs) with and...]]></summary>
        <author>
            <name>Peter Grant Miller</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[PPM1D modulates hematopoietic cell fitness and response to DNA damage and is a therapeutic target in myeloid malignancy]]></title>
        <id>pubmed:37595362</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37595362/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230820204715&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-08-18T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[PPM1D encodes a phosphatase that is recurrently activated across cancer, most notably in therapy-related myeloid neoplasms. However, the function of PPM1D in hematopoiesis and its contribution to tumor cell growth remain incompletely understood. Using conditional mouse models, we uncover a central role for Ppm1d in hematopoiesis and validate its potential as a therapeutic target. We find that Ppm1d regulates the competitive fitness and self-renewal of hematopoietic stem cells (HSCs) with and...]]></summary>
        <author>
            <name>Peter Grant Miller</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[PPM1D modulates hematopoietic cell fitness and response to DNA damage and is a therapeutic target in myeloid malignancy]]></title>
        <id>pubmed:37595362</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37595362/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230819204952&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-08-18T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[PPM1D encodes a phosphatase that is recurrently activated across cancer, most notably in therapy-related myeloid neoplasms. However, the function of PPM1D in hematopoiesis and its contribution to tumor cell growth remain incompletely understood. Using conditional mouse models, we uncover a central role for Ppm1d in hematopoiesis and validate its potential as a therapeutic target. We find that Ppm1d regulates the competitive fitness and self-renewal of hematopoietic stem cells (HSCs) with and...]]></summary>
        <author>
            <name>Peter Grant Miller</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Subclonal accumulation of immune escape mechanisms in microsatellite instability-high colorectal cancers]]></title>
        <id>pubmed:37596408</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37596408/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230908204701&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-08-18T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSIONS: Our results demonstrate the heterogeneous acquisition of immune escape mechanisms in MSI-H CRCs by Darwinian selection, providing novel insights into ICI-based treatment strategies.]]></summary>
        <author>
            <name>Yuta Kobayashi</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Subclonal accumulation of immune escape mechanisms in microsatellite instability-high colorectal cancers]]></title>
        <id>pubmed:37596408</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37596408/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230907204816&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-08-18T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSIONS: Our results demonstrate the heterogeneous acquisition of immune escape mechanisms in MSI-H CRCs by Darwinian selection, providing novel insights into ICI-based treatment strategies.]]></summary>
        <author>
            <name>Yuta Kobayashi</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Subclonal accumulation of immune escape mechanisms in microsatellite instability-high colorectal cancers]]></title>
        <id>pubmed:37596408</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37596408/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230906204801&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-08-18T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSIONS: Our results demonstrate the heterogeneous acquisition of immune escape mechanisms in MSI-H CRCs by Darwinian selection, providing novel insights into ICI-based treatment strategies.]]></summary>
        <author>
            <name>Yuta Kobayashi</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Subclonal accumulation of immune escape mechanisms in microsatellite instability-high colorectal cancers]]></title>
        <id>pubmed:37596408</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37596408/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230905204848&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-08-18T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSIONS: Our results demonstrate the heterogeneous acquisition of immune escape mechanisms in MSI-H CRCs by Darwinian selection, providing novel insights into ICI-based treatment strategies.]]></summary>
        <author>
            <name>Yuta Kobayashi</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Subclonal accumulation of immune escape mechanisms in microsatellite instability-high colorectal cancers]]></title>
        <id>pubmed:37596408</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37596408/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230904204751&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-08-18T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSIONS: Our results demonstrate the heterogeneous acquisition of immune escape mechanisms in MSI-H CRCs by Darwinian selection, providing novel insights into ICI-based treatment strategies.]]></summary>
        <author>
            <name>Yuta Kobayashi</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Subclonal accumulation of immune escape mechanisms in microsatellite instability-high colorectal cancers]]></title>
        <id>pubmed:37596408</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37596408/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230903204939&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-08-18T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSIONS: Our results demonstrate the heterogeneous acquisition of immune escape mechanisms in MSI-H CRCs by Darwinian selection, providing novel insights into ICI-based treatment strategies.]]></summary>
        <author>
            <name>Yuta Kobayashi</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Subclonal accumulation of immune escape mechanisms in microsatellite instability-high colorectal cancers]]></title>
        <id>pubmed:37596408</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37596408/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230902205121&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-08-18T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSIONS: Our results demonstrate the heterogeneous acquisition of immune escape mechanisms in MSI-H CRCs by Darwinian selection, providing novel insights into ICI-based treatment strategies.]]></summary>
        <author>
            <name>Yuta Kobayashi</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Subclonal accumulation of immune escape mechanisms in microsatellite instability-high colorectal cancers]]></title>
        <id>pubmed:37596408</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37596408/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230901204619&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-08-18T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSIONS: Our results demonstrate the heterogeneous acquisition of immune escape mechanisms in MSI-H CRCs by Darwinian selection, providing novel insights into ICI-based treatment strategies.]]></summary>
        <author>
            <name>Yuta Kobayashi</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Subclonal accumulation of immune escape mechanisms in microsatellite instability-high colorectal cancers]]></title>
        <id>pubmed:37596408</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37596408/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230831205203&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-08-18T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSIONS: Our results demonstrate the heterogeneous acquisition of immune escape mechanisms in MSI-H CRCs by Darwinian selection, providing novel insights into ICI-based treatment strategies.]]></summary>
        <author>
            <name>Yuta Kobayashi</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Subclonal accumulation of immune escape mechanisms in microsatellite instability-high colorectal cancers]]></title>
        <id>pubmed:37596408</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37596408/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230830204850&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-08-18T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSIONS: Our results demonstrate the heterogeneous acquisition of immune escape mechanisms in MSI-H CRCs by Darwinian selection, providing novel insights into ICI-based treatment strategies.]]></summary>
        <author>
            <name>Yuta Kobayashi</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Subclonal accumulation of immune escape mechanisms in microsatellite instability-high colorectal cancers]]></title>
        <id>pubmed:37596408</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37596408/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230829204824&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-08-18T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSIONS: Our results demonstrate the heterogeneous acquisition of immune escape mechanisms in MSI-H CRCs by Darwinian selection, providing novel insights into ICI-based treatment strategies.]]></summary>
        <author>
            <name>Yuta Kobayashi</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Subclonal accumulation of immune escape mechanisms in microsatellite instability-high colorectal cancers]]></title>
        <id>pubmed:37596408</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37596408/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230828204854&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-08-18T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSIONS: Our results demonstrate the heterogeneous acquisition of immune escape mechanisms in MSI-H CRCs by Darwinian selection, providing novel insights into ICI-based treatment strategies.]]></summary>
        <author>
            <name>Yuta Kobayashi</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Subclonal accumulation of immune escape mechanisms in microsatellite instability-high colorectal cancers]]></title>
        <id>pubmed:37596408</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37596408/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230827204908&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-08-18T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSIONS: Our results demonstrate the heterogeneous acquisition of immune escape mechanisms in MSI-H CRCs by Darwinian selection, providing novel insights into ICI-based treatment strategies.]]></summary>
        <author>
            <name>Yuta Kobayashi</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Subclonal accumulation of immune escape mechanisms in microsatellite instability-high colorectal cancers]]></title>
        <id>pubmed:37596408</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37596408/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230826205107&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-08-18T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSIONS: Our results demonstrate the heterogeneous acquisition of immune escape mechanisms in MSI-H CRCs by Darwinian selection, providing novel insights into ICI-based treatment strategies.]]></summary>
        <author>
            <name>Yuta Kobayashi</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Subclonal accumulation of immune escape mechanisms in microsatellite instability-high colorectal cancers]]></title>
        <id>pubmed:37596408</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37596408/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230825204602&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-08-18T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSIONS: Our results demonstrate the heterogeneous acquisition of immune escape mechanisms in MSI-H CRCs by Darwinian selection, providing novel insights into ICI-based treatment strategies.]]></summary>
        <author>
            <name>Yuta Kobayashi</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Subclonal accumulation of immune escape mechanisms in microsatellite instability-high colorectal cancers]]></title>
        <id>pubmed:37596408</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37596408/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230824204824&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-08-18T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSIONS: Our results demonstrate the heterogeneous acquisition of immune escape mechanisms in MSI-H CRCs by Darwinian selection, providing novel insights into ICI-based treatment strategies.]]></summary>
        <author>
            <name>Yuta Kobayashi</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Subclonal accumulation of immune escape mechanisms in microsatellite instability-high colorectal cancers]]></title>
        <id>pubmed:37596408</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37596408/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230823204708&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-08-18T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSIONS: Our results demonstrate the heterogeneous acquisition of immune escape mechanisms in MSI-H CRCs by Darwinian selection, providing novel insights into ICI-based treatment strategies.]]></summary>
        <author>
            <name>Yuta Kobayashi</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Subclonal accumulation of immune escape mechanisms in microsatellite instability-high colorectal cancers]]></title>
        <id>pubmed:37596408</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37596408/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230822204709&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-08-18T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSIONS: Our results demonstrate the heterogeneous acquisition of immune escape mechanisms in MSI-H CRCs by Darwinian selection, providing novel insights into ICI-based treatment strategies.]]></summary>
        <author>
            <name>Yuta Kobayashi</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Subclonal accumulation of immune escape mechanisms in microsatellite instability-high colorectal cancers]]></title>
        <id>pubmed:37596408</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37596408/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230821204801&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-08-18T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSIONS: Our results demonstrate the heterogeneous acquisition of immune escape mechanisms in MSI-H CRCs by Darwinian selection, providing novel insights into ICI-based treatment strategies.]]></summary>
        <author>
            <name>Yuta Kobayashi</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Subclonal accumulation of immune escape mechanisms in microsatellite instability-high colorectal cancers]]></title>
        <id>pubmed:37596408</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37596408/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230820204715&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-08-18T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSIONS: Our results demonstrate the heterogeneous acquisition of immune escape mechanisms in MSI-H CRCs by Darwinian selection, providing novel insights into ICI-based treatment strategies.]]></summary>
        <author>
            <name>Yuta Kobayashi</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Subclonal accumulation of immune escape mechanisms in microsatellite instability-high colorectal cancers]]></title>
        <id>pubmed:37596408</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37596408/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230819204952&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-08-18T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSIONS: Our results demonstrate the heterogeneous acquisition of immune escape mechanisms in MSI-H CRCs by Darwinian selection, providing novel insights into ICI-based treatment strategies.]]></summary>
        <author>
            <name>Yuta Kobayashi</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Single-nucleotide variant calling in single-cell sequencing data with Monopogen]]></title>
        <id>pubmed:37592035</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37592035/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230831205203&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-08-17T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Single-cell omics technologies enable molecular characterization of diverse cell types and states, but how the resulting transcriptional and epigenetic profiles depend on the cell's genetic background remains understudied. We describe Monopogen, a computational tool to detect single-nucleotide variants (SNVs) from single-cell sequencing data. Monopogen leverages linkage disequilibrium from external reference panels to identify germline SNVs and detects putative somatic SNVs using allele...]]></summary>
        <author>
            <name>Jinzhuang Dou</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clinical impact of the genomic landscape and leukemogenic trajectories in non-intensively treated elderly acute myeloid leukemia patients]]></title>
        <id>pubmed:37591941</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37591941/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230831205203&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-08-17T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[To characterize the genomic landscape and leukemogenic pathways of older, newly diagnosed, non-intensively treated patients with AML and to study the clinical implications, comprehensive genetics analyses were performed including targeted DNA sequencing of 263 genes in 604 patients treated in a prospective Phase III clinical trial. Leukemic trajectories were delineated using oncogenetic tree modeling and hierarchical clustering, and prognostic groups were derived from multivariable Cox...]]></summary>
        <author>
            <name>Ekaterina Jahn</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Single-nucleotide variant calling in single-cell sequencing data with Monopogen]]></title>
        <id>pubmed:37592035</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37592035/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230830204850&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-08-17T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Single-cell omics technologies enable molecular characterization of diverse cell types and states, but how the resulting transcriptional and epigenetic profiles depend on the cell's genetic background remains understudied. We describe Monopogen, a computational tool to detect single-nucleotide variants (SNVs) from single-cell sequencing data. Monopogen leverages linkage disequilibrium from external reference panels to identify germline SNVs and detects putative somatic SNVs using allele...]]></summary>
        <author>
            <name>Jinzhuang Dou</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clinical impact of the genomic landscape and leukemogenic trajectories in non-intensively treated elderly acute myeloid leukemia patients]]></title>
        <id>pubmed:37591941</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37591941/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230830204850&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-08-17T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[To characterize the genomic landscape and leukemogenic pathways of older, newly diagnosed, non-intensively treated patients with AML and to study the clinical implications, comprehensive genetics analyses were performed including targeted DNA sequencing of 263 genes in 604 patients treated in a prospective Phase III clinical trial. Leukemic trajectories were delineated using oncogenetic tree modeling and hierarchical clustering, and prognostic groups were derived from multivariable Cox...]]></summary>
        <author>
            <name>Ekaterina Jahn</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Single-nucleotide variant calling in single-cell sequencing data with Monopogen]]></title>
        <id>pubmed:37592035</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37592035/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230829204824&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-08-17T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Single-cell omics technologies enable molecular characterization of diverse cell types and states, but how the resulting transcriptional and epigenetic profiles depend on the cell's genetic background remains understudied. We describe Monopogen, a computational tool to detect single-nucleotide variants (SNVs) from single-cell sequencing data. Monopogen leverages linkage disequilibrium from external reference panels to identify germline SNVs and detects putative somatic SNVs using allele...]]></summary>
        <author>
            <name>Jinzhuang Dou</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clinical impact of the genomic landscape and leukemogenic trajectories in non-intensively treated elderly acute myeloid leukemia patients]]></title>
        <id>pubmed:37591941</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37591941/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230829204824&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-08-17T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[To characterize the genomic landscape and leukemogenic pathways of older, newly diagnosed, non-intensively treated patients with AML and to study the clinical implications, comprehensive genetics analyses were performed including targeted DNA sequencing of 263 genes in 604 patients treated in a prospective Phase III clinical trial. Leukemic trajectories were delineated using oncogenetic tree modeling and hierarchical clustering, and prognostic groups were derived from multivariable Cox...]]></summary>
        <author>
            <name>Ekaterina Jahn</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Single-nucleotide variant calling in single-cell sequencing data with Monopogen]]></title>
        <id>pubmed:37592035</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37592035/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230828204854&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-08-17T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Single-cell omics technologies enable molecular characterization of diverse cell types and states, but how the resulting transcriptional and epigenetic profiles depend on the cell's genetic background remains understudied. We describe Monopogen, a computational tool to detect single-nucleotide variants (SNVs) from single-cell sequencing data. Monopogen leverages linkage disequilibrium from external reference panels to identify germline SNVs and detects putative somatic SNVs using allele...]]></summary>
        <author>
            <name>Jinzhuang Dou</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clinical impact of the genomic landscape and leukemogenic trajectories in non-intensively treated elderly acute myeloid leukemia patients]]></title>
        <id>pubmed:37591941</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37591941/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230828204854&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-08-17T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[To characterize the genomic landscape and leukemogenic pathways of older, newly diagnosed, non-intensively treated patients with AML and to study the clinical implications, comprehensive genetics analyses were performed including targeted DNA sequencing of 263 genes in 604 patients treated in a prospective Phase III clinical trial. Leukemic trajectories were delineated using oncogenetic tree modeling and hierarchical clustering, and prognostic groups were derived from multivariable Cox...]]></summary>
        <author>
            <name>Ekaterina Jahn</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Single-nucleotide variant calling in single-cell sequencing data with Monopogen]]></title>
        <id>pubmed:37592035</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37592035/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230827204908&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-08-17T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Single-cell omics technologies enable molecular characterization of diverse cell types and states, but how the resulting transcriptional and epigenetic profiles depend on the cell's genetic background remains understudied. We describe Monopogen, a computational tool to detect single-nucleotide variants (SNVs) from single-cell sequencing data. Monopogen leverages linkage disequilibrium from external reference panels to identify germline SNVs and detects putative somatic SNVs using allele...]]></summary>
        <author>
            <name>Jinzhuang Dou</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clinical impact of the genomic landscape and leukemogenic trajectories in non-intensively treated elderly acute myeloid leukemia patients]]></title>
        <id>pubmed:37591941</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37591941/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230827204908&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-08-17T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[To characterize the genomic landscape and leukemogenic pathways of older, newly diagnosed, non-intensively treated patients with AML and to study the clinical implications, comprehensive genetics analyses were performed including targeted DNA sequencing of 263 genes in 604 patients treated in a prospective Phase III clinical trial. Leukemic trajectories were delineated using oncogenetic tree modeling and hierarchical clustering, and prognostic groups were derived from multivariable Cox...]]></summary>
        <author>
            <name>Ekaterina Jahn</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Single-nucleotide variant calling in single-cell sequencing data with Monopogen]]></title>
        <id>pubmed:37592035</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37592035/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230826205107&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-08-17T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Single-cell omics technologies enable molecular characterization of diverse cell types and states, but how the resulting transcriptional and epigenetic profiles depend on the cell's genetic background remains understudied. We describe Monopogen, a computational tool to detect single-nucleotide variants (SNVs) from single-cell sequencing data. Monopogen leverages linkage disequilibrium from external reference panels to identify germline SNVs and detects putative somatic SNVs using allele...]]></summary>
        <author>
            <name>Jinzhuang Dou</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clinical impact of the genomic landscape and leukemogenic trajectories in non-intensively treated elderly acute myeloid leukemia patients]]></title>
        <id>pubmed:37591941</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37591941/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230826205107&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-08-17T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[To characterize the genomic landscape and leukemogenic pathways of older, newly diagnosed, non-intensively treated patients with AML and to study the clinical implications, comprehensive genetics analyses were performed including targeted DNA sequencing of 263 genes in 604 patients treated in a prospective Phase III clinical trial. Leukemic trajectories were delineated using oncogenetic tree modeling and hierarchical clustering, and prognostic groups were derived from multivariable Cox...]]></summary>
        <author>
            <name>Ekaterina Jahn</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Single-nucleotide variant calling in single-cell sequencing data with Monopogen]]></title>
        <id>pubmed:37592035</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37592035/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230825204557&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-08-17T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Single-cell omics technologies enable molecular characterization of diverse cell types and states, but how the resulting transcriptional and epigenetic profiles depend on the cell's genetic background remains understudied. We describe Monopogen, a computational tool to detect single-nucleotide variants (SNVs) from single-cell sequencing data. Monopogen leverages linkage disequilibrium from external reference panels to identify germline SNVs and detects putative somatic SNVs using allele...]]></summary>
        <author>
            <name>Jinzhuang Dou</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clinical impact of the genomic landscape and leukemogenic trajectories in non-intensively treated elderly acute myeloid leukemia patients]]></title>
        <id>pubmed:37591941</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37591941/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230825204557&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-08-17T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[To characterize the genomic landscape and leukemogenic pathways of older, newly diagnosed, non-intensively treated patients with AML and to study the clinical implications, comprehensive genetics analyses were performed including targeted DNA sequencing of 263 genes in 604 patients treated in a prospective Phase III clinical trial. Leukemic trajectories were delineated using oncogenetic tree modeling and hierarchical clustering, and prognostic groups were derived from multivariable Cox...]]></summary>
        <author>
            <name>Ekaterina Jahn</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Single-nucleotide variant calling in single-cell sequencing data with Monopogen]]></title>
        <id>pubmed:37592035</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37592035/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230824204823&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-08-17T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Single-cell omics technologies enable molecular characterization of diverse cell types and states, but how the resulting transcriptional and epigenetic profiles depend on the cell's genetic background remains understudied. We describe Monopogen, a computational tool to detect single-nucleotide variants (SNVs) from single-cell sequencing data. Monopogen leverages linkage disequilibrium from external reference panels to identify germline SNVs and detects putative somatic SNVs using allele...]]></summary>
        <author>
            <name>Jinzhuang Dou</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clinical impact of the genomic landscape and leukemogenic trajectories in non-intensively treated elderly acute myeloid leukemia patients]]></title>
        <id>pubmed:37591941</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37591941/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230824204823&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-08-17T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[To characterize the genomic landscape and leukemogenic pathways of older, newly diagnosed, non-intensively treated patients with AML and to study the clinical implications, comprehensive genetics analyses were performed including targeted DNA sequencing of 263 genes in 604 patients treated in a prospective Phase III clinical trial. Leukemic trajectories were delineated using oncogenetic tree modeling and hierarchical clustering, and prognostic groups were derived from multivariable Cox...]]></summary>
        <author>
            <name>Ekaterina Jahn</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Single-nucleotide variant calling in single-cell sequencing data with Monopogen]]></title>
        <id>pubmed:37592035</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37592035/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230823204708&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-08-17T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Single-cell omics technologies enable molecular characterization of diverse cell types and states, but how the resulting transcriptional and epigenetic profiles depend on the cell's genetic background remains understudied. We describe Monopogen, a computational tool to detect single-nucleotide variants (SNVs) from single-cell sequencing data. Monopogen leverages linkage disequilibrium from external reference panels to identify germline SNVs and detects putative somatic SNVs using allele...]]></summary>
        <author>
            <name>Jinzhuang Dou</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clinical impact of the genomic landscape and leukemogenic trajectories in non-intensively treated elderly acute myeloid leukemia patients]]></title>
        <id>pubmed:37591941</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37591941/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230823204708&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-08-17T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[To characterize the genomic landscape and leukemogenic pathways of older, newly diagnosed, non-intensively treated patients with AML and to study the clinical implications, comprehensive genetics analyses were performed including targeted DNA sequencing of 263 genes in 604 patients treated in a prospective Phase III clinical trial. Leukemic trajectories were delineated using oncogenetic tree modeling and hierarchical clustering, and prognostic groups were derived from multivariable Cox...]]></summary>
        <author>
            <name>Ekaterina Jahn</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Single-nucleotide variant calling in single-cell sequencing data with Monopogen]]></title>
        <id>pubmed:37592035</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37592035/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230822204709&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-08-17T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Single-cell omics technologies enable molecular characterization of diverse cell types and states, but how the resulting transcriptional and epigenetic profiles depend on the cell's genetic background remains understudied. We describe Monopogen, a computational tool to detect single-nucleotide variants (SNVs) from single-cell sequencing data. Monopogen leverages linkage disequilibrium from external reference panels to identify germline SNVs and detects putative somatic SNVs using allele...]]></summary>
        <author>
            <name>Jinzhuang Dou</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clinical impact of the genomic landscape and leukemogenic trajectories in non-intensively treated elderly acute myeloid leukemia patients]]></title>
        <id>pubmed:37591941</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37591941/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230822204709&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-08-17T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[To characterize the genomic landscape and leukemogenic pathways of older, newly diagnosed, non-intensively treated patients with AML and to study the clinical implications, comprehensive genetics analyses were performed including targeted DNA sequencing of 263 genes in 604 patients treated in a prospective Phase III clinical trial. Leukemic trajectories were delineated using oncogenetic tree modeling and hierarchical clustering, and prognostic groups were derived from multivariable Cox...]]></summary>
        <author>
            <name>Ekaterina Jahn</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Single-nucleotide variant calling in single-cell sequencing data with Monopogen]]></title>
        <id>pubmed:37592035</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37592035/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230821204801&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-08-17T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Single-cell omics technologies enable molecular characterization of diverse cell types and states, but how the resulting transcriptional and epigenetic profiles depend on the cell's genetic background remains understudied. We describe Monopogen, a computational tool to detect single-nucleotide variants (SNVs) from single-cell sequencing data. Monopogen leverages linkage disequilibrium from external reference panels to identify germline SNVs and detects putative somatic SNVs using allele...]]></summary>
        <author>
            <name>Jinzhuang Dou</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clinical impact of the genomic landscape and leukemogenic trajectories in non-intensively treated elderly acute myeloid leukemia patients]]></title>
        <id>pubmed:37591941</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37591941/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230821204801&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-08-17T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[To characterize the genomic landscape and leukemogenic pathways of older, newly diagnosed, non-intensively treated patients with AML and to study the clinical implications, comprehensive genetics analyses were performed including targeted DNA sequencing of 263 genes in 604 patients treated in a prospective Phase III clinical trial. Leukemic trajectories were delineated using oncogenetic tree modeling and hierarchical clustering, and prognostic groups were derived from multivariable Cox...]]></summary>
        <author>
            <name>Ekaterina Jahn</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Single-nucleotide variant calling in single-cell sequencing data with Monopogen]]></title>
        <id>pubmed:37592035</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37592035/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230820204715&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-08-17T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Single-cell omics technologies enable molecular characterization of diverse cell types and states, but how the resulting transcriptional and epigenetic profiles depend on the cell's genetic background remains understudied. We describe Monopogen, a computational tool to detect single-nucleotide variants (SNVs) from single-cell sequencing data. Monopogen leverages linkage disequilibrium from external reference panels to identify germline SNVs and detects putative somatic SNVs using allele...]]></summary>
        <author>
            <name>Jinzhuang Dou</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clinical impact of the genomic landscape and leukemogenic trajectories in non-intensively treated elderly acute myeloid leukemia patients]]></title>
        <id>pubmed:37591941</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37591941/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230820204715&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-08-17T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[To characterize the genomic landscape and leukemogenic pathways of older, newly diagnosed, non-intensively treated patients with AML and to study the clinical implications, comprehensive genetics analyses were performed including targeted DNA sequencing of 263 genes in 604 patients treated in a prospective Phase III clinical trial. Leukemic trajectories were delineated using oncogenetic tree modeling and hierarchical clustering, and prognostic groups were derived from multivariable Cox...]]></summary>
        <author>
            <name>Ekaterina Jahn</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Single-nucleotide variant calling in single-cell sequencing data with Monopogen]]></title>
        <id>pubmed:37592035</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37592035/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230819204952&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-08-17T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Single-cell omics technologies enable molecular characterization of diverse cell types and states, but how the resulting transcriptional and epigenetic profiles depend on the cell's genetic background remains understudied. We describe Monopogen, a computational tool to detect single-nucleotide variants (SNVs) from single-cell sequencing data. Monopogen leverages linkage disequilibrium from external reference panels to identify germline SNVs and detects putative somatic SNVs using allele...]]></summary>
        <author>
            <name>Jinzhuang Dou</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clinical impact of the genomic landscape and leukemogenic trajectories in non-intensively treated elderly acute myeloid leukemia patients]]></title>
        <id>pubmed:37591941</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37591941/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230819204952&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-08-17T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[To characterize the genomic landscape and leukemogenic pathways of older, newly diagnosed, non-intensively treated patients with AML and to study the clinical implications, comprehensive genetics analyses were performed including targeted DNA sequencing of 263 genes in 604 patients treated in a prospective Phase III clinical trial. Leukemic trajectories were delineated using oncogenetic tree modeling and hierarchical clustering, and prognostic groups were derived from multivariable Cox...]]></summary>
        <author>
            <name>Ekaterina Jahn</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Single-nucleotide variant calling in single-cell sequencing data with Monopogen]]></title>
        <id>pubmed:37592035</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37592035/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230818204446&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-08-17T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Single-cell omics technologies enable molecular characterization of diverse cell types and states, but how the resulting transcriptional and epigenetic profiles depend on the cell's genetic background remains understudied. We describe Monopogen, a computational tool to detect single-nucleotide variants (SNVs) from single-cell sequencing data. Monopogen leverages linkage disequilibrium from external reference panels to identify germline SNVs and detects putative somatic SNVs using allele...]]></summary>
        <author>
            <name>Jinzhuang Dou</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clinical impact of the genomic landscape and leukemogenic trajectories in non-intensively treated elderly acute myeloid leukemia patients]]></title>
        <id>pubmed:37591941</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37591941/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230818204446&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-08-17T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[To characterize the genomic landscape and leukemogenic pathways of older, newly diagnosed, non-intensively treated patients with AML and to study the clinical implications, comprehensive genetics analyses were performed including targeted DNA sequencing of 263 genes in 604 patients treated in a prospective Phase III clinical trial. Leukemic trajectories were delineated using oncogenetic tree modeling and hierarchical clustering, and prognostic groups were derived from multivariable Cox...]]></summary>
        <author>
            <name>Ekaterina Jahn</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Early activation of inflammatory pathways in UBA1-mutated hematopoietic stem and progenitor cells in VEXAS]]></title>
        <id>pubmed:37586319</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37586319/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230830204850&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-08-16T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[VEXAS (vacuoles, E1 enzyme, X-linked, autoinflammatory, somatic) syndrome is a pleiotropic, severe autoinflammatory disease caused by somatic mutations in the ubiquitin-like modifier activating enzyme 1 (UBA1) gene. To elucidate VEXAS pathophysiology, we performed transcriptome sequencing of single bone marrow mononuclear cells and hematopoietic stem and progenitor cells (HSPCs) from VEXAS patients. HSPCs are biased toward myeloid (granulocytic) differentiation, and against lymphoid...]]></summary>
        <author>
            <name>Zhijie Wu</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Early activation of inflammatory pathways in UBA1-mutated hematopoietic stem and progenitor cells in VEXAS]]></title>
        <id>pubmed:37586319</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37586319/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230829204824&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-08-16T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[VEXAS (vacuoles, E1 enzyme, X-linked, autoinflammatory, somatic) syndrome is a pleiotropic, severe autoinflammatory disease caused by somatic mutations in the ubiquitin-like modifier activating enzyme 1 (UBA1) gene. To elucidate VEXAS pathophysiology, we performed transcriptome sequencing of single bone marrow mononuclear cells and hematopoietic stem and progenitor cells (HSPCs) from VEXAS patients. HSPCs are biased toward myeloid (granulocytic) differentiation, and against lymphoid...]]></summary>
        <author>
            <name>Zhijie Wu</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Early activation of inflammatory pathways in UBA1-mutated hematopoietic stem and progenitor cells in VEXAS]]></title>
        <id>pubmed:37586319</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37586319/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230828204854&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-08-16T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[VEXAS (vacuoles, E1 enzyme, X-linked, autoinflammatory, somatic) syndrome is a pleiotropic, severe autoinflammatory disease caused by somatic mutations in the ubiquitin-like modifier activating enzyme 1 (UBA1) gene. To elucidate VEXAS pathophysiology, we performed transcriptome sequencing of single bone marrow mononuclear cells and hematopoietic stem and progenitor cells (HSPCs) from VEXAS patients. HSPCs are biased toward myeloid (granulocytic) differentiation, and against lymphoid...]]></summary>
        <author>
            <name>Zhijie Wu</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Early activation of inflammatory pathways in UBA1-mutated hematopoietic stem and progenitor cells in VEXAS]]></title>
        <id>pubmed:37586319</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37586319/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230827204908&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-08-16T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[VEXAS (vacuoles, E1 enzyme, X-linked, autoinflammatory, somatic) syndrome is a pleiotropic, severe autoinflammatory disease caused by somatic mutations in the ubiquitin-like modifier activating enzyme 1 (UBA1) gene. To elucidate VEXAS pathophysiology, we performed transcriptome sequencing of single bone marrow mononuclear cells and hematopoietic stem and progenitor cells (HSPCs) from VEXAS patients. HSPCs are biased toward myeloid (granulocytic) differentiation, and against lymphoid...]]></summary>
        <author>
            <name>Zhijie Wu</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Early activation of inflammatory pathways in UBA1-mutated hematopoietic stem and progenitor cells in VEXAS]]></title>
        <id>pubmed:37586319</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37586319/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230826205107&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-08-16T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[VEXAS (vacuoles, E1 enzyme, X-linked, autoinflammatory, somatic) syndrome is a pleiotropic, severe autoinflammatory disease caused by somatic mutations in the ubiquitin-like modifier activating enzyme 1 (UBA1) gene. To elucidate VEXAS pathophysiology, we performed transcriptome sequencing of single bone marrow mononuclear cells and hematopoietic stem and progenitor cells (HSPCs) from VEXAS patients. HSPCs are biased toward myeloid (granulocytic) differentiation, and against lymphoid...]]></summary>
        <author>
            <name>Zhijie Wu</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Early activation of inflammatory pathways in UBA1-mutated hematopoietic stem and progenitor cells in VEXAS]]></title>
        <id>pubmed:37586319</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37586319/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230825204557&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-08-16T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[VEXAS (vacuoles, E1 enzyme, X-linked, autoinflammatory, somatic) syndrome is a pleiotropic, severe autoinflammatory disease caused by somatic mutations in the ubiquitin-like modifier activating enzyme 1 (UBA1) gene. To elucidate VEXAS pathophysiology, we performed transcriptome sequencing of single bone marrow mononuclear cells and hematopoietic stem and progenitor cells (HSPCs) from VEXAS patients. HSPCs are biased toward myeloid (granulocytic) differentiation, and against lymphoid...]]></summary>
        <author>
            <name>Zhijie Wu</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Early activation of inflammatory pathways in UBA1-mutated hematopoietic stem and progenitor cells in VEXAS]]></title>
        <id>pubmed:37586319</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37586319/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230824204823&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-08-16T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[VEXAS (vacuoles, E1 enzyme, X-linked, autoinflammatory, somatic) syndrome is a pleiotropic, severe autoinflammatory disease caused by somatic mutations in the ubiquitin-like modifier activating enzyme 1 (UBA1) gene. To elucidate VEXAS pathophysiology, we performed transcriptome sequencing of single bone marrow mononuclear cells and hematopoietic stem and progenitor cells (HSPCs) from VEXAS patients. HSPCs are biased toward myeloid (granulocytic) differentiation, and against lymphoid...]]></summary>
        <author>
            <name>Zhijie Wu</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Early activation of inflammatory pathways in UBA1-mutated hematopoietic stem and progenitor cells in VEXAS]]></title>
        <id>pubmed:37586319</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37586319/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230823204708&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-08-16T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[VEXAS (vacuoles, E1 enzyme, X-linked, autoinflammatory, somatic) syndrome is a pleiotropic, severe autoinflammatory disease caused by somatic mutations in the ubiquitin-like modifier activating enzyme 1 (UBA1) gene. To elucidate VEXAS pathophysiology, we performed transcriptome sequencing of single bone marrow mononuclear cells and hematopoietic stem and progenitor cells (HSPCs) from VEXAS patients. HSPCs are biased toward myeloid (granulocytic) differentiation, and against lymphoid...]]></summary>
        <author>
            <name>Zhijie Wu</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Early activation of inflammatory pathways in UBA1-mutated hematopoietic stem and progenitor cells in VEXAS]]></title>
        <id>pubmed:37586319</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37586319/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230822204709&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-08-16T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[VEXAS (vacuoles, E1 enzyme, X-linked, autoinflammatory, somatic) syndrome is a pleiotropic, severe autoinflammatory disease caused by somatic mutations in the ubiquitin-like modifier activating enzyme 1 (UBA1) gene. To elucidate VEXAS pathophysiology, we performed transcriptome sequencing of single bone marrow mononuclear cells and hematopoietic stem and progenitor cells (HSPCs) from VEXAS patients. HSPCs are biased toward myeloid (granulocytic) differentiation, and against lymphoid...]]></summary>
        <author>
            <name>Zhijie Wu</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Early activation of inflammatory pathways in UBA1-mutated hematopoietic stem and progenitor cells in VEXAS]]></title>
        <id>pubmed:37586319</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37586319/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230821204801&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-08-16T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[VEXAS (vacuoles, E1 enzyme, X-linked, autoinflammatory, somatic) syndrome is a pleiotropic, severe autoinflammatory disease caused by somatic mutations in the ubiquitin-like modifier activating enzyme 1 (UBA1) gene. To elucidate VEXAS pathophysiology, we performed transcriptome sequencing of single bone marrow mononuclear cells and hematopoietic stem and progenitor cells (HSPCs) from VEXAS patients. HSPCs are biased toward myeloid (granulocytic) differentiation, and against lymphoid...]]></summary>
        <author>
            <name>Zhijie Wu</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Early activation of inflammatory pathways in UBA1-mutated hematopoietic stem and progenitor cells in VEXAS]]></title>
        <id>pubmed:37586319</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37586319/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230820204715&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-08-16T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[VEXAS (vacuoles, E1 enzyme, X-linked, autoinflammatory, somatic) syndrome is a pleiotropic, severe autoinflammatory disease caused by somatic mutations in the ubiquitin-like modifier activating enzyme 1 (UBA1) gene. To elucidate VEXAS pathophysiology, we performed transcriptome sequencing of single bone marrow mononuclear cells and hematopoietic stem and progenitor cells (HSPCs) from VEXAS patients. HSPCs are biased toward myeloid (granulocytic) differentiation, and against lymphoid...]]></summary>
        <author>
            <name>Zhijie Wu</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Early activation of inflammatory pathways in UBA1-mutated hematopoietic stem and progenitor cells in VEXAS]]></title>
        <id>pubmed:37586319</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37586319/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230819204952&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-08-16T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[VEXAS (vacuoles, E1 enzyme, X-linked, autoinflammatory, somatic) syndrome is a pleiotropic, severe autoinflammatory disease caused by somatic mutations in the ubiquitin-like modifier activating enzyme 1 (UBA1) gene. To elucidate VEXAS pathophysiology, we performed transcriptome sequencing of single bone marrow mononuclear cells and hematopoietic stem and progenitor cells (HSPCs) from VEXAS patients. HSPCs are biased toward myeloid (granulocytic) differentiation, and against lymphoid...]]></summary>
        <author>
            <name>Zhijie Wu</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Early activation of inflammatory pathways in UBA1-mutated hematopoietic stem and progenitor cells in VEXAS]]></title>
        <id>pubmed:37586319</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37586319/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230818204446&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-08-16T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[VEXAS (vacuoles, E1 enzyme, X-linked, autoinflammatory, somatic) syndrome is a pleiotropic, severe autoinflammatory disease caused by somatic mutations in the ubiquitin-like modifier activating enzyme 1 (UBA1) gene. To elucidate VEXAS pathophysiology, we performed transcriptome sequencing of single bone marrow mononuclear cells and hematopoietic stem and progenitor cells (HSPCs) from VEXAS patients. HSPCs are biased toward myeloid (granulocytic) differentiation, and against lymphoid...]]></summary>
        <author>
            <name>Zhijie Wu</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Early activation of inflammatory pathways in UBA1-mutated hematopoietic stem and progenitor cells in VEXAS]]></title>
        <id>pubmed:37586319</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37586319/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230817204642&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-08-16T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[VEXAS (vacuoles, E1 enzyme, X-linked, autoinflammatory, somatic) syndrome is a pleiotropic, severe autoinflammatory disease caused by somatic mutations in the ubiquitin-like modifier activating enzyme 1 (UBA1) gene. To elucidate VEXAS pathophysiology, we performed transcriptome sequencing of single bone marrow mononuclear cells and hematopoietic stem and progenitor cells (HSPCs) from VEXAS patients. HSPCs are biased toward myeloid (granulocytic) differentiation, and against lymphoid...]]></summary>
        <author>
            <name>Zhijie Wu</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Archival single-cell genomics reveals persistent subclones during DCIS progression]]></title>
        <id>pubmed:37586362</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37586362/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230908204701&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-08-16T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Ductal carcinoma in situ (DCIS) is a common precursor of invasive breast cancer. Our understanding of its genomic progression to recurrent disease remains poor, partly due to challenges associated with the genomic profiling of formalin-fixed paraffin-embedded (FFPE) materials. Here, we developed Arc-well, a high-throughput single-cell DNA-sequencing method that is compatible with FFPE materials. We validated our method by profiling 40,330 single cells from cell lines, a frozen tissue, and 27...]]></summary>
        <author>
            <name>Kaile Wang</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Archival single-cell genomics reveals persistent subclones during DCIS progression]]></title>
        <id>pubmed:37586362</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37586362/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230907204816&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-08-16T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Ductal carcinoma in situ (DCIS) is a common precursor of invasive breast cancer. Our understanding of its genomic progression to recurrent disease remains poor, partly due to challenges associated with the genomic profiling of formalin-fixed paraffin-embedded (FFPE) materials. Here, we developed Arc-well, a high-throughput single-cell DNA-sequencing method that is compatible with FFPE materials. We validated our method by profiling 40,330 single cells from cell lines, a frozen tissue, and 27...]]></summary>
        <author>
            <name>Kaile Wang</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Archival single-cell genomics reveals persistent subclones during DCIS progression]]></title>
        <id>pubmed:37586362</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37586362/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230906204801&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-08-16T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Ductal carcinoma in situ (DCIS) is a common precursor of invasive breast cancer. Our understanding of its genomic progression to recurrent disease remains poor, partly due to challenges associated with the genomic profiling of formalin-fixed paraffin-embedded (FFPE) materials. Here, we developed Arc-well, a high-throughput single-cell DNA-sequencing method that is compatible with FFPE materials. We validated our method by profiling 40,330 single cells from cell lines, a frozen tissue, and 27...]]></summary>
        <author>
            <name>Kaile Wang</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Archival single-cell genomics reveals persistent subclones during DCIS progression]]></title>
        <id>pubmed:37586362</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37586362/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230905204848&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-08-16T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Ductal carcinoma in situ (DCIS) is a common precursor of invasive breast cancer. Our understanding of its genomic progression to recurrent disease remains poor, partly due to challenges associated with the genomic profiling of formalin-fixed paraffin-embedded (FFPE) materials. Here, we developed Arc-well, a high-throughput single-cell DNA-sequencing method that is compatible with FFPE materials. We validated our method by profiling 40,330 single cells from cell lines, a frozen tissue, and 27...]]></summary>
        <author>
            <name>Kaile Wang</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Archival single-cell genomics reveals persistent subclones during DCIS progression]]></title>
        <id>pubmed:37586362</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37586362/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230904204751&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-08-16T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Ductal carcinoma in situ (DCIS) is a common precursor of invasive breast cancer. Our understanding of its genomic progression to recurrent disease remains poor, partly due to challenges associated with the genomic profiling of formalin-fixed paraffin-embedded (FFPE) materials. Here, we developed Arc-well, a high-throughput single-cell DNA-sequencing method that is compatible with FFPE materials. We validated our method by profiling 40,330 single cells from cell lines, a frozen tissue, and 27...]]></summary>
        <author>
            <name>Kaile Wang</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Archival single-cell genomics reveals persistent subclones during DCIS progression]]></title>
        <id>pubmed:37586362</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37586362/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230903204939&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-08-16T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Ductal carcinoma in situ (DCIS) is a common precursor of invasive breast cancer. Our understanding of its genomic progression to recurrent disease remains poor, partly due to challenges associated with the genomic profiling of formalin-fixed paraffin-embedded (FFPE) materials. Here, we developed Arc-well, a high-throughput single-cell DNA-sequencing method that is compatible with FFPE materials. We validated our method by profiling 40,330 single cells from cell lines, a frozen tissue, and 27...]]></summary>
        <author>
            <name>Kaile Wang</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Archival single-cell genomics reveals persistent subclones during DCIS progression]]></title>
        <id>pubmed:37586362</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37586362/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230902205121&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-08-16T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Ductal carcinoma in situ (DCIS) is a common precursor of invasive breast cancer. Our understanding of its genomic progression to recurrent disease remains poor, partly due to challenges associated with the genomic profiling of formalin-fixed paraffin-embedded (FFPE) materials. Here, we developed Arc-well, a high-throughput single-cell DNA-sequencing method that is compatible with FFPE materials. We validated our method by profiling 40,330 single cells from cell lines, a frozen tissue, and 27...]]></summary>
        <author>
            <name>Kaile Wang</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Archival single-cell genomics reveals persistent subclones during DCIS progression]]></title>
        <id>pubmed:37586362</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37586362/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230901204619&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-08-16T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Ductal carcinoma in situ (DCIS) is a common precursor of invasive breast cancer. Our understanding of its genomic progression to recurrent disease remains poor, partly due to challenges associated with the genomic profiling of formalin-fixed paraffin-embedded (FFPE) materials. Here, we developed Arc-well, a high-throughput single-cell DNA-sequencing method that is compatible with FFPE materials. We validated our method by profiling 40,330 single cells from cell lines, a frozen tissue, and 27...]]></summary>
        <author>
            <name>Kaile Wang</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Archival single-cell genomics reveals persistent subclones during DCIS progression]]></title>
        <id>pubmed:37586362</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37586362/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230831205203&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-08-16T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Ductal carcinoma in situ (DCIS) is a common precursor of invasive breast cancer. Our understanding of its genomic progression to recurrent disease remains poor, partly due to challenges associated with the genomic profiling of formalin-fixed paraffin-embedded (FFPE) materials. Here, we developed Arc-well, a high-throughput single-cell DNA-sequencing method that is compatible with FFPE materials. We validated our method by profiling 40,330 single cells from cell lines, a frozen tissue, and 27...]]></summary>
        <author>
            <name>Kaile Wang</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Archival single-cell genomics reveals persistent subclones during DCIS progression]]></title>
        <id>pubmed:37586362</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37586362/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230830204850&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-08-16T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Ductal carcinoma in situ (DCIS) is a common precursor of invasive breast cancer. Our understanding of its genomic progression to recurrent disease remains poor, partly due to challenges associated with the genomic profiling of formalin-fixed paraffin-embedded (FFPE) materials. Here, we developed Arc-well, a high-throughput single-cell DNA-sequencing method that is compatible with FFPE materials. We validated our method by profiling 40,330 single cells from cell lines, a frozen tissue, and 27...]]></summary>
        <author>
            <name>Kaile Wang</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Archival single-cell genomics reveals persistent subclones during DCIS progression]]></title>
        <id>pubmed:37586362</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37586362/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230829204824&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-08-16T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Ductal carcinoma in situ (DCIS) is a common precursor of invasive breast cancer. Our understanding of its genomic progression to recurrent disease remains poor, partly due to challenges associated with the genomic profiling of formalin-fixed paraffin-embedded (FFPE) materials. Here, we developed Arc-well, a high-throughput single-cell DNA-sequencing method that is compatible with FFPE materials. We validated our method by profiling 40,330 single cells from cell lines, a frozen tissue, and 27...]]></summary>
        <author>
            <name>Kaile Wang</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Archival single-cell genomics reveals persistent subclones during DCIS progression]]></title>
        <id>pubmed:37586362</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37586362/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230828204854&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-08-16T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Ductal carcinoma in situ (DCIS) is a common precursor of invasive breast cancer. Our understanding of its genomic progression to recurrent disease remains poor, partly due to challenges associated with the genomic profiling of formalin-fixed paraffin-embedded (FFPE) materials. Here, we developed Arc-well, a high-throughput single-cell DNA-sequencing method that is compatible with FFPE materials. We validated our method by profiling 40,330 single cells from cell lines, a frozen tissue, and 27...]]></summary>
        <author>
            <name>Kaile Wang</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Archival single-cell genomics reveals persistent subclones during DCIS progression]]></title>
        <id>pubmed:37586362</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37586362/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230827204908&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-08-16T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Ductal carcinoma in situ (DCIS) is a common precursor of invasive breast cancer. Our understanding of its genomic progression to recurrent disease remains poor, partly due to challenges associated with the genomic profiling of formalin-fixed paraffin-embedded (FFPE) materials. Here, we developed Arc-well, a high-throughput single-cell DNA-sequencing method that is compatible with FFPE materials. We validated our method by profiling 40,330 single cells from cell lines, a frozen tissue, and 27...]]></summary>
        <author>
            <name>Kaile Wang</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Archival single-cell genomics reveals persistent subclones during DCIS progression]]></title>
        <id>pubmed:37586362</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37586362/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230826205107&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-08-16T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Ductal carcinoma in situ (DCIS) is a common precursor of invasive breast cancer. Our understanding of its genomic progression to recurrent disease remains poor, partly due to challenges associated with the genomic profiling of formalin-fixed paraffin-embedded (FFPE) materials. Here, we developed Arc-well, a high-throughput single-cell DNA-sequencing method that is compatible with FFPE materials. We validated our method by profiling 40,330 single cells from cell lines, a frozen tissue, and 27...]]></summary>
        <author>
            <name>Kaile Wang</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Archival single-cell genomics reveals persistent subclones during DCIS progression]]></title>
        <id>pubmed:37586362</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37586362/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230825204602&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-08-16T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Ductal carcinoma in situ (DCIS) is a common precursor of invasive breast cancer. Our understanding of its genomic progression to recurrent disease remains poor, partly due to challenges associated with the genomic profiling of formalin-fixed paraffin-embedded (FFPE) materials. Here, we developed Arc-well, a high-throughput single-cell DNA-sequencing method that is compatible with FFPE materials. We validated our method by profiling 40,330 single cells from cell lines, a frozen tissue, and 27...]]></summary>
        <author>
            <name>Kaile Wang</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Archival single-cell genomics reveals persistent subclones during DCIS progression]]></title>
        <id>pubmed:37586362</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37586362/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230824204824&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-08-16T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Ductal carcinoma in situ (DCIS) is a common precursor of invasive breast cancer. Our understanding of its genomic progression to recurrent disease remains poor, partly due to challenges associated with the genomic profiling of formalin-fixed paraffin-embedded (FFPE) materials. Here, we developed Arc-well, a high-throughput single-cell DNA-sequencing method that is compatible with FFPE materials. We validated our method by profiling 40,330 single cells from cell lines, a frozen tissue, and 27...]]></summary>
        <author>
            <name>Kaile Wang</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Archival single-cell genomics reveals persistent subclones during DCIS progression]]></title>
        <id>pubmed:37586362</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37586362/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230823204708&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-08-16T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Ductal carcinoma in situ (DCIS) is a common precursor of invasive breast cancer. Our understanding of its genomic progression to recurrent disease remains poor, partly due to challenges associated with the genomic profiling of formalin-fixed paraffin-embedded (FFPE) materials. Here, we developed Arc-well, a high-throughput single-cell DNA-sequencing method that is compatible with FFPE materials. We validated our method by profiling 40,330 single cells from cell lines, a frozen tissue, and 27...]]></summary>
        <author>
            <name>Kaile Wang</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Archival single-cell genomics reveals persistent subclones during DCIS progression]]></title>
        <id>pubmed:37586362</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37586362/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230822204709&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-08-16T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Ductal carcinoma in situ (DCIS) is a common precursor of invasive breast cancer. Our understanding of its genomic progression to recurrent disease remains poor, partly due to challenges associated with the genomic profiling of formalin-fixed paraffin-embedded (FFPE) materials. Here, we developed Arc-well, a high-throughput single-cell DNA-sequencing method that is compatible with FFPE materials. We validated our method by profiling 40,330 single cells from cell lines, a frozen tissue, and 27...]]></summary>
        <author>
            <name>Kaile Wang</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Archival single-cell genomics reveals persistent subclones during DCIS progression]]></title>
        <id>pubmed:37586362</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37586362/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230821204801&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-08-16T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Ductal carcinoma in situ (DCIS) is a common precursor of invasive breast cancer. Our understanding of its genomic progression to recurrent disease remains poor, partly due to challenges associated with the genomic profiling of formalin-fixed paraffin-embedded (FFPE) materials. Here, we developed Arc-well, a high-throughput single-cell DNA-sequencing method that is compatible with FFPE materials. We validated our method by profiling 40,330 single cells from cell lines, a frozen tissue, and 27...]]></summary>
        <author>
            <name>Kaile Wang</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Archival single-cell genomics reveals persistent subclones during DCIS progression]]></title>
        <id>pubmed:37586362</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37586362/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230820204715&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-08-16T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Ductal carcinoma in situ (DCIS) is a common precursor of invasive breast cancer. Our understanding of its genomic progression to recurrent disease remains poor, partly due to challenges associated with the genomic profiling of formalin-fixed paraffin-embedded (FFPE) materials. Here, we developed Arc-well, a high-throughput single-cell DNA-sequencing method that is compatible with FFPE materials. We validated our method by profiling 40,330 single cells from cell lines, a frozen tissue, and 27...]]></summary>
        <author>
            <name>Kaile Wang</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Archival single-cell genomics reveals persistent subclones during DCIS progression]]></title>
        <id>pubmed:37586362</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37586362/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230819204952&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-08-16T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Ductal carcinoma in situ (DCIS) is a common precursor of invasive breast cancer. Our understanding of its genomic progression to recurrent disease remains poor, partly due to challenges associated with the genomic profiling of formalin-fixed paraffin-embedded (FFPE) materials. Here, we developed Arc-well, a high-throughput single-cell DNA-sequencing method that is compatible with FFPE materials. We validated our method by profiling 40,330 single cells from cell lines, a frozen tissue, and 27...]]></summary>
        <author>
            <name>Kaile Wang</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Archival single-cell genomics reveals persistent subclones during DCIS progression]]></title>
        <id>pubmed:37586362</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37586362/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230818204446&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-08-16T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Ductal carcinoma in situ (DCIS) is a common precursor of invasive breast cancer. Our understanding of its genomic progression to recurrent disease remains poor, partly due to challenges associated with the genomic profiling of formalin-fixed paraffin-embedded (FFPE) materials. Here, we developed Arc-well, a high-throughput single-cell DNA-sequencing method that is compatible with FFPE materials. We validated our method by profiling 40,330 single cells from cell lines, a frozen tissue, and 27...]]></summary>
        <author>
            <name>Kaile Wang</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Archival single-cell genomics reveals persistent subclones during DCIS progression]]></title>
        <id>pubmed:37586362</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37586362/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230817204642&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-08-16T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Ductal carcinoma in situ (DCIS) is a common precursor of invasive breast cancer. Our understanding of its genomic progression to recurrent disease remains poor, partly due to challenges associated with the genomic profiling of formalin-fixed paraffin-embedded (FFPE) materials. Here, we developed Arc-well, a high-throughput single-cell DNA-sequencing method that is compatible with FFPE materials. We validated our method by profiling 40,330 single cells from cell lines, a frozen tissue, and 27...]]></summary>
        <author>
            <name>Kaile Wang</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Single-cell multi-omics defines the cell-type-specific impact of splicing aberrations in human hematopoietic clonal outgrowths]]></title>
        <id>pubmed:37582363</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37582363/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230829204824&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-08-15T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[RNA splicing factors are recurrently mutated in clonal blood disorders, but the impact of dysregulated splicing in hematopoiesis remains unclear. To overcome technical limitations, we integrated genotyping of transcriptomes (GoT) with long-read single-cell transcriptomics and proteogenomics for single-cell profiling of transcriptomes, surface proteins, somatic mutations, and RNA splicing (GoT-Splice). We applied GoT-Splice to hematopoietic progenitors from myelodysplastic syndrome (MDS) patients...]]></summary>
        <author>
            <name>Mariela Corts-Lpez</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Single-cell multi-omics defines the cell-type-specific impact of splicing aberrations in human hematopoietic clonal outgrowths]]></title>
        <id>pubmed:37582363</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37582363/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230828204854&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-08-15T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[RNA splicing factors are recurrently mutated in clonal blood disorders, but the impact of dysregulated splicing in hematopoiesis remains unclear. To overcome technical limitations, we integrated genotyping of transcriptomes (GoT) with long-read single-cell transcriptomics and proteogenomics for single-cell profiling of transcriptomes, surface proteins, somatic mutations, and RNA splicing (GoT-Splice). We applied GoT-Splice to hematopoietic progenitors from myelodysplastic syndrome (MDS) patients...]]></summary>
        <author>
            <name>Mariela Corts-Lpez</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Single-cell multi-omics defines the cell-type-specific impact of splicing aberrations in human hematopoietic clonal outgrowths]]></title>
        <id>pubmed:37582363</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37582363/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230827204908&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-08-15T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[RNA splicing factors are recurrently mutated in clonal blood disorders, but the impact of dysregulated splicing in hematopoiesis remains unclear. To overcome technical limitations, we integrated genotyping of transcriptomes (GoT) with long-read single-cell transcriptomics and proteogenomics for single-cell profiling of transcriptomes, surface proteins, somatic mutations, and RNA splicing (GoT-Splice). We applied GoT-Splice to hematopoietic progenitors from myelodysplastic syndrome (MDS) patients...]]></summary>
        <author>
            <name>Mariela Corts-Lpez</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Single-cell multi-omics defines the cell-type-specific impact of splicing aberrations in human hematopoietic clonal outgrowths]]></title>
        <id>pubmed:37582363</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37582363/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230826205107&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-08-15T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[RNA splicing factors are recurrently mutated in clonal blood disorders, but the impact of dysregulated splicing in hematopoiesis remains unclear. To overcome technical limitations, we integrated genotyping of transcriptomes (GoT) with long-read single-cell transcriptomics and proteogenomics for single-cell profiling of transcriptomes, surface proteins, somatic mutations, and RNA splicing (GoT-Splice). We applied GoT-Splice to hematopoietic progenitors from myelodysplastic syndrome (MDS) patients...]]></summary>
        <author>
            <name>Mariela Corts-Lpez</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Single-cell multi-omics defines the cell-type-specific impact of splicing aberrations in human hematopoietic clonal outgrowths]]></title>
        <id>pubmed:37582363</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37582363/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230825204557&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-08-15T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[RNA splicing factors are recurrently mutated in clonal blood disorders, but the impact of dysregulated splicing in hematopoiesis remains unclear. To overcome technical limitations, we integrated genotyping of transcriptomes (GoT) with long-read single-cell transcriptomics and proteogenomics for single-cell profiling of transcriptomes, surface proteins, somatic mutations, and RNA splicing (GoT-Splice). We applied GoT-Splice to hematopoietic progenitors from myelodysplastic syndrome (MDS) patients...]]></summary>
        <author>
            <name>Mariela Corts-Lpez</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Single-cell multi-omics defines the cell-type-specific impact of splicing aberrations in human hematopoietic clonal outgrowths]]></title>
        <id>pubmed:37582363</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37582363/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230824204823&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-08-15T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[RNA splicing factors are recurrently mutated in clonal blood disorders, but the impact of dysregulated splicing in hematopoiesis remains unclear. To overcome technical limitations, we integrated genotyping of transcriptomes (GoT) with long-read single-cell transcriptomics and proteogenomics for single-cell profiling of transcriptomes, surface proteins, somatic mutations, and RNA splicing (GoT-Splice). We applied GoT-Splice to hematopoietic progenitors from myelodysplastic syndrome (MDS) patients...]]></summary>
        <author>
            <name>Mariela Corts-Lpez</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Single-cell multi-omics defines the cell-type-specific impact of splicing aberrations in human hematopoietic clonal outgrowths]]></title>
        <id>pubmed:37582363</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37582363/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230823204708&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-08-15T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[RNA splicing factors are recurrently mutated in clonal blood disorders, but the impact of dysregulated splicing in hematopoiesis remains unclear. To overcome technical limitations, we integrated genotyping of transcriptomes (GoT) with long-read single-cell transcriptomics and proteogenomics for single-cell profiling of transcriptomes, surface proteins, somatic mutations, and RNA splicing (GoT-Splice). We applied GoT-Splice to hematopoietic progenitors from myelodysplastic syndrome (MDS) patients...]]></summary>
        <author>
            <name>Mariela Corts-Lpez</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Single-cell multi-omics defines the cell-type-specific impact of splicing aberrations in human hematopoietic clonal outgrowths]]></title>
        <id>pubmed:37582363</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37582363/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230822204709&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-08-15T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[RNA splicing factors are recurrently mutated in clonal blood disorders, but the impact of dysregulated splicing in hematopoiesis remains unclear. To overcome technical limitations, we integrated genotyping of transcriptomes (GoT) with long-read single-cell transcriptomics and proteogenomics for single-cell profiling of transcriptomes, surface proteins, somatic mutations, and RNA splicing (GoT-Splice). We applied GoT-Splice to hematopoietic progenitors from myelodysplastic syndrome (MDS) patients...]]></summary>
        <author>
            <name>Mariela Corts-Lpez</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Single-cell multi-omics defines the cell-type-specific impact of splicing aberrations in human hematopoietic clonal outgrowths]]></title>
        <id>pubmed:37582363</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37582363/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230821204801&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-08-15T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[RNA splicing factors are recurrently mutated in clonal blood disorders, but the impact of dysregulated splicing in hematopoiesis remains unclear. To overcome technical limitations, we integrated genotyping of transcriptomes (GoT) with long-read single-cell transcriptomics and proteogenomics for single-cell profiling of transcriptomes, surface proteins, somatic mutations, and RNA splicing (GoT-Splice). We applied GoT-Splice to hematopoietic progenitors from myelodysplastic syndrome (MDS) patients...]]></summary>
        <author>
            <name>Mariela Corts-Lpez</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Single-cell multi-omics defines the cell-type-specific impact of splicing aberrations in human hematopoietic clonal outgrowths]]></title>
        <id>pubmed:37582363</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37582363/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230820204715&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-08-15T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[RNA splicing factors are recurrently mutated in clonal blood disorders, but the impact of dysregulated splicing in hematopoiesis remains unclear. To overcome technical limitations, we integrated genotyping of transcriptomes (GoT) with long-read single-cell transcriptomics and proteogenomics for single-cell profiling of transcriptomes, surface proteins, somatic mutations, and RNA splicing (GoT-Splice). We applied GoT-Splice to hematopoietic progenitors from myelodysplastic syndrome (MDS) patients...]]></summary>
        <author>
            <name>Mariela Corts-Lpez</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Single-cell multi-omics defines the cell-type-specific impact of splicing aberrations in human hematopoietic clonal outgrowths]]></title>
        <id>pubmed:37582363</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37582363/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230819204952&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-08-15T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[RNA splicing factors are recurrently mutated in clonal blood disorders, but the impact of dysregulated splicing in hematopoiesis remains unclear. To overcome technical limitations, we integrated genotyping of transcriptomes (GoT) with long-read single-cell transcriptomics and proteogenomics for single-cell profiling of transcriptomes, surface proteins, somatic mutations, and RNA splicing (GoT-Splice). We applied GoT-Splice to hematopoietic progenitors from myelodysplastic syndrome (MDS) patients...]]></summary>
        <author>
            <name>Mariela Corts-Lpez</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Single-cell multi-omics defines the cell-type-specific impact of splicing aberrations in human hematopoietic clonal outgrowths]]></title>
        <id>pubmed:37582363</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37582363/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230818204446&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-08-15T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[RNA splicing factors are recurrently mutated in clonal blood disorders, but the impact of dysregulated splicing in hematopoiesis remains unclear. To overcome technical limitations, we integrated genotyping of transcriptomes (GoT) with long-read single-cell transcriptomics and proteogenomics for single-cell profiling of transcriptomes, surface proteins, somatic mutations, and RNA splicing (GoT-Splice). We applied GoT-Splice to hematopoietic progenitors from myelodysplastic syndrome (MDS) patients...]]></summary>
        <author>
            <name>Mariela Corts-Lpez</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Single-cell multi-omics defines the cell-type-specific impact of splicing aberrations in human hematopoietic clonal outgrowths]]></title>
        <id>pubmed:37582363</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37582363/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230817204642&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-08-15T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[RNA splicing factors are recurrently mutated in clonal blood disorders, but the impact of dysregulated splicing in hematopoiesis remains unclear. To overcome technical limitations, we integrated genotyping of transcriptomes (GoT) with long-read single-cell transcriptomics and proteogenomics for single-cell profiling of transcriptomes, surface proteins, somatic mutations, and RNA splicing (GoT-Splice). We applied GoT-Splice to hematopoietic progenitors from myelodysplastic syndrome (MDS) patients...]]></summary>
        <author>
            <name>Mariela Corts-Lpez</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Single-cell multi-omics defines the cell-type-specific impact of splicing aberrations in human hematopoietic clonal outgrowths]]></title>
        <id>pubmed:37582363</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37582363/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230816204601&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-08-15T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[RNA splicing factors are recurrently mutated in clonal blood disorders, but the impact of dysregulated splicing in hematopoiesis remains unclear. To overcome technical limitations, we integrated genotyping of transcriptomes (GoT) with long-read single-cell transcriptomics and proteogenomics for single-cell profiling of transcriptomes, surface proteins, somatic mutations, and RNA splicing (GoT-Splice). We applied GoT-Splice to hematopoietic progenitors from myelodysplastic syndrome (MDS) patients...]]></summary>
        <author>
            <name>Mariela Corts-Lpez</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[COMPASS: joint copy number and mutation phylogeny reconstruction from amplicon single-cell sequencing data]]></title>
        <id>pubmed:37582954</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37582954/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230904204751&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-08-15T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Reconstructing the history of somatic DNA alterations can help understand the evolution of a tumor and predict its resistance to treatment. Single-cell DNA sequencing (scDNAseq) can be used to investigate clonal heterogeneity and to inform phylogeny reconstruction. However, most existing phylogenetic methods for scDNAseq data are designed either for single nucleotide variants (SNVs) or for large copy number alterations (CNAs), or are not applicable to targeted sequencing. Here, we develop...]]></summary>
        <author>
            <name>Etienne Sollier</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[COMPASS: joint copy number and mutation phylogeny reconstruction from amplicon single-cell sequencing data]]></title>
        <id>pubmed:37582954</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37582954/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230903204939&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-08-15T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Reconstructing the history of somatic DNA alterations can help understand the evolution of a tumor and predict its resistance to treatment. Single-cell DNA sequencing (scDNAseq) can be used to investigate clonal heterogeneity and to inform phylogeny reconstruction. However, most existing phylogenetic methods for scDNAseq data are designed either for single nucleotide variants (SNVs) or for large copy number alterations (CNAs), or are not applicable to targeted sequencing. Here, we develop...]]></summary>
        <author>
            <name>Etienne Sollier</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[COMPASS: joint copy number and mutation phylogeny reconstruction from amplicon single-cell sequencing data]]></title>
        <id>pubmed:37582954</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37582954/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230902205121&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-08-15T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Reconstructing the history of somatic DNA alterations can help understand the evolution of a tumor and predict its resistance to treatment. Single-cell DNA sequencing (scDNAseq) can be used to investigate clonal heterogeneity and to inform phylogeny reconstruction. However, most existing phylogenetic methods for scDNAseq data are designed either for single nucleotide variants (SNVs) or for large copy number alterations (CNAs), or are not applicable to targeted sequencing. Here, we develop...]]></summary>
        <author>
            <name>Etienne Sollier</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[COMPASS: joint copy number and mutation phylogeny reconstruction from amplicon single-cell sequencing data]]></title>
        <id>pubmed:37582954</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37582954/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230901204619&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-08-15T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Reconstructing the history of somatic DNA alterations can help understand the evolution of a tumor and predict its resistance to treatment. Single-cell DNA sequencing (scDNAseq) can be used to investigate clonal heterogeneity and to inform phylogeny reconstruction. However, most existing phylogenetic methods for scDNAseq data are designed either for single nucleotide variants (SNVs) or for large copy number alterations (CNAs), or are not applicable to targeted sequencing. Here, we develop...]]></summary>
        <author>
            <name>Etienne Sollier</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[COMPASS: joint copy number and mutation phylogeny reconstruction from amplicon single-cell sequencing data]]></title>
        <id>pubmed:37582954</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37582954/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230831205203&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-08-15T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Reconstructing the history of somatic DNA alterations can help understand the evolution of a tumor and predict its resistance to treatment. Single-cell DNA sequencing (scDNAseq) can be used to investigate clonal heterogeneity and to inform phylogeny reconstruction. However, most existing phylogenetic methods for scDNAseq data are designed either for single nucleotide variants (SNVs) or for large copy number alterations (CNAs), or are not applicable to targeted sequencing. Here, we develop...]]></summary>
        <author>
            <name>Etienne Sollier</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[COMPASS: joint copy number and mutation phylogeny reconstruction from amplicon single-cell sequencing data]]></title>
        <id>pubmed:37582954</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37582954/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230830204850&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-08-15T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Reconstructing the history of somatic DNA alterations can help understand the evolution of a tumor and predict its resistance to treatment. Single-cell DNA sequencing (scDNAseq) can be used to investigate clonal heterogeneity and to inform phylogeny reconstruction. However, most existing phylogenetic methods for scDNAseq data are designed either for single nucleotide variants (SNVs) or for large copy number alterations (CNAs), or are not applicable to targeted sequencing. Here, we develop...]]></summary>
        <author>
            <name>Etienne Sollier</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[COMPASS: joint copy number and mutation phylogeny reconstruction from amplicon single-cell sequencing data]]></title>
        <id>pubmed:37582954</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37582954/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230829204824&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-08-15T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Reconstructing the history of somatic DNA alterations can help understand the evolution of a tumor and predict its resistance to treatment. Single-cell DNA sequencing (scDNAseq) can be used to investigate clonal heterogeneity and to inform phylogeny reconstruction. However, most existing phylogenetic methods for scDNAseq data are designed either for single nucleotide variants (SNVs) or for large copy number alterations (CNAs), or are not applicable to targeted sequencing. Here, we develop...]]></summary>
        <author>
            <name>Etienne Sollier</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[COMPASS: joint copy number and mutation phylogeny reconstruction from amplicon single-cell sequencing data]]></title>
        <id>pubmed:37582954</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37582954/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230828204854&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-08-15T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Reconstructing the history of somatic DNA alterations can help understand the evolution of a tumor and predict its resistance to treatment. Single-cell DNA sequencing (scDNAseq) can be used to investigate clonal heterogeneity and to inform phylogeny reconstruction. However, most existing phylogenetic methods for scDNAseq data are designed either for single nucleotide variants (SNVs) or for large copy number alterations (CNAs), or are not applicable to targeted sequencing. Here, we develop...]]></summary>
        <author>
            <name>Etienne Sollier</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[COMPASS: joint copy number and mutation phylogeny reconstruction from amplicon single-cell sequencing data]]></title>
        <id>pubmed:37582954</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37582954/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230827204908&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-08-15T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Reconstructing the history of somatic DNA alterations can help understand the evolution of a tumor and predict its resistance to treatment. Single-cell DNA sequencing (scDNAseq) can be used to investigate clonal heterogeneity and to inform phylogeny reconstruction. However, most existing phylogenetic methods for scDNAseq data are designed either for single nucleotide variants (SNVs) or for large copy number alterations (CNAs), or are not applicable to targeted sequencing. Here, we develop...]]></summary>
        <author>
            <name>Etienne Sollier</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[COMPASS: joint copy number and mutation phylogeny reconstruction from amplicon single-cell sequencing data]]></title>
        <id>pubmed:37582954</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37582954/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230826205107&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-08-15T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Reconstructing the history of somatic DNA alterations can help understand the evolution of a tumor and predict its resistance to treatment. Single-cell DNA sequencing (scDNAseq) can be used to investigate clonal heterogeneity and to inform phylogeny reconstruction. However, most existing phylogenetic methods for scDNAseq data are designed either for single nucleotide variants (SNVs) or for large copy number alterations (CNAs), or are not applicable to targeted sequencing. Here, we develop...]]></summary>
        <author>
            <name>Etienne Sollier</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[COMPASS: joint copy number and mutation phylogeny reconstruction from amplicon single-cell sequencing data]]></title>
        <id>pubmed:37582954</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37582954/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230825204602&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-08-15T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Reconstructing the history of somatic DNA alterations can help understand the evolution of a tumor and predict its resistance to treatment. Single-cell DNA sequencing (scDNAseq) can be used to investigate clonal heterogeneity and to inform phylogeny reconstruction. However, most existing phylogenetic methods for scDNAseq data are designed either for single nucleotide variants (SNVs) or for large copy number alterations (CNAs), or are not applicable to targeted sequencing. Here, we develop...]]></summary>
        <author>
            <name>Etienne Sollier</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[COMPASS: joint copy number and mutation phylogeny reconstruction from amplicon single-cell sequencing data]]></title>
        <id>pubmed:37582954</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37582954/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230824204824&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-08-15T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Reconstructing the history of somatic DNA alterations can help understand the evolution of a tumor and predict its resistance to treatment. Single-cell DNA sequencing (scDNAseq) can be used to investigate clonal heterogeneity and to inform phylogeny reconstruction. However, most existing phylogenetic methods for scDNAseq data are designed either for single nucleotide variants (SNVs) or for large copy number alterations (CNAs), or are not applicable to targeted sequencing. Here, we develop...]]></summary>
        <author>
            <name>Etienne Sollier</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[COMPASS: joint copy number and mutation phylogeny reconstruction from amplicon single-cell sequencing data]]></title>
        <id>pubmed:37582954</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37582954/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230823204708&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-08-15T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Reconstructing the history of somatic DNA alterations can help understand the evolution of a tumor and predict its resistance to treatment. Single-cell DNA sequencing (scDNAseq) can be used to investigate clonal heterogeneity and to inform phylogeny reconstruction. However, most existing phylogenetic methods for scDNAseq data are designed either for single nucleotide variants (SNVs) or for large copy number alterations (CNAs), or are not applicable to targeted sequencing. Here, we develop...]]></summary>
        <author>
            <name>Etienne Sollier</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[COMPASS: joint copy number and mutation phylogeny reconstruction from amplicon single-cell sequencing data]]></title>
        <id>pubmed:37582954</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37582954/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230822204709&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-08-15T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Reconstructing the history of somatic DNA alterations can help understand the evolution of a tumor and predict its resistance to treatment. Single-cell DNA sequencing (scDNAseq) can be used to investigate clonal heterogeneity and to inform phylogeny reconstruction. However, most existing phylogenetic methods for scDNAseq data are designed either for single nucleotide variants (SNVs) or for large copy number alterations (CNAs), or are not applicable to targeted sequencing. Here, we develop...]]></summary>
        <author>
            <name>Etienne Sollier</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[COMPASS: joint copy number and mutation phylogeny reconstruction from amplicon single-cell sequencing data]]></title>
        <id>pubmed:37582954</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37582954/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230821204801&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-08-15T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Reconstructing the history of somatic DNA alterations can help understand the evolution of a tumor and predict its resistance to treatment. Single-cell DNA sequencing (scDNAseq) can be used to investigate clonal heterogeneity and to inform phylogeny reconstruction. However, most existing phylogenetic methods for scDNAseq data are designed either for single nucleotide variants (SNVs) or for large copy number alterations (CNAs), or are not applicable to targeted sequencing. Here, we develop...]]></summary>
        <author>
            <name>Etienne Sollier</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[COMPASS: joint copy number and mutation phylogeny reconstruction from amplicon single-cell sequencing data]]></title>
        <id>pubmed:37582954</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37582954/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230820204715&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-08-15T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Reconstructing the history of somatic DNA alterations can help understand the evolution of a tumor and predict its resistance to treatment. Single-cell DNA sequencing (scDNAseq) can be used to investigate clonal heterogeneity and to inform phylogeny reconstruction. However, most existing phylogenetic methods for scDNAseq data are designed either for single nucleotide variants (SNVs) or for large copy number alterations (CNAs), or are not applicable to targeted sequencing. Here, we develop...]]></summary>
        <author>
            <name>Etienne Sollier</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[COMPASS: joint copy number and mutation phylogeny reconstruction from amplicon single-cell sequencing data]]></title>
        <id>pubmed:37582954</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37582954/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230819204952&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-08-15T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Reconstructing the history of somatic DNA alterations can help understand the evolution of a tumor and predict its resistance to treatment. Single-cell DNA sequencing (scDNAseq) can be used to investigate clonal heterogeneity and to inform phylogeny reconstruction. However, most existing phylogenetic methods for scDNAseq data are designed either for single nucleotide variants (SNVs) or for large copy number alterations (CNAs), or are not applicable to targeted sequencing. Here, we develop...]]></summary>
        <author>
            <name>Etienne Sollier</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[COMPASS: joint copy number and mutation phylogeny reconstruction from amplicon single-cell sequencing data]]></title>
        <id>pubmed:37582954</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37582954/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230818204446&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-08-15T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Reconstructing the history of somatic DNA alterations can help understand the evolution of a tumor and predict its resistance to treatment. Single-cell DNA sequencing (scDNAseq) can be used to investigate clonal heterogeneity and to inform phylogeny reconstruction. However, most existing phylogenetic methods for scDNAseq data are designed either for single nucleotide variants (SNVs) or for large copy number alterations (CNAs), or are not applicable to targeted sequencing. Here, we develop...]]></summary>
        <author>
            <name>Etienne Sollier</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[COMPASS: joint copy number and mutation phylogeny reconstruction from amplicon single-cell sequencing data]]></title>
        <id>pubmed:37582954</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37582954/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230817204642&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-08-15T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Reconstructing the history of somatic DNA alterations can help understand the evolution of a tumor and predict its resistance to treatment. Single-cell DNA sequencing (scDNAseq) can be used to investigate clonal heterogeneity and to inform phylogeny reconstruction. However, most existing phylogenetic methods for scDNAseq data are designed either for single nucleotide variants (SNVs) or for large copy number alterations (CNAs), or are not applicable to targeted sequencing. Here, we develop...]]></summary>
        <author>
            <name>Etienne Sollier</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[COMPASS: joint copy number and mutation phylogeny reconstruction from amplicon single-cell sequencing data]]></title>
        <id>pubmed:37582954</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37582954/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230816204600&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-08-15T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Reconstructing the history of somatic DNA alterations can help understand the evolution of a tumor and predict its resistance to treatment. Single-cell DNA sequencing (scDNAseq) can be used to investigate clonal heterogeneity and to inform phylogeny reconstruction. However, most existing phylogenetic methods for scDNAseq data are designed either for single nucleotide variants (SNVs) or for large copy number alterations (CNAs), or are not applicable to targeted sequencing. Here, we develop...]]></summary>
        <author>
            <name>Etienne Sollier</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[CRISPR/dCas9 DNA methylation editing is heritable during human hematopoiesis and shapes immune progeny]]></title>
        <id>pubmed:37579157</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37579157/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230829204824&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-08-14T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Aging is associated with an abnormal increase in DNA methylation (DNAm) in human gene promoters, including in bone marrow stem cells. DNAm patterns are further perturbed in hematological malignancies such as acute myeloid leukemia but the physiological significance of such epigenetic changes is unknown. Using epigenetic editing of human stem/progenitor cells (HSPCs), we show that p15 methylation affects hematopoiesis in vivo. We edited the CDKN2B (p15) promoter and ARF (p14) using dCas9-3A3L and...]]></summary>
        <author>
            <name>Emily A Saunderson</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[CRISPR/dCas9 DNA methylation editing is heritable during human hematopoiesis and shapes immune progeny]]></title>
        <id>pubmed:37579157</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37579157/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230828204854&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-08-14T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Aging is associated with an abnormal increase in DNA methylation (DNAm) in human gene promoters, including in bone marrow stem cells. DNAm patterns are further perturbed in hematological malignancies such as acute myeloid leukemia but the physiological significance of such epigenetic changes is unknown. Using epigenetic editing of human stem/progenitor cells (HSPCs), we show that p15 methylation affects hematopoiesis in vivo. We edited the CDKN2B (p15) promoter and ARF (p14) using dCas9-3A3L and...]]></summary>
        <author>
            <name>Emily A Saunderson</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[CRISPR/dCas9 DNA methylation editing is heritable during human hematopoiesis and shapes immune progeny]]></title>
        <id>pubmed:37579157</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37579157/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230827204908&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-08-14T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Aging is associated with an abnormal increase in DNA methylation (DNAm) in human gene promoters, including in bone marrow stem cells. DNAm patterns are further perturbed in hematological malignancies such as acute myeloid leukemia but the physiological significance of such epigenetic changes is unknown. Using epigenetic editing of human stem/progenitor cells (HSPCs), we show that p15 methylation affects hematopoiesis in vivo. We edited the CDKN2B (p15) promoter and ARF (p14) using dCas9-3A3L and...]]></summary>
        <author>
            <name>Emily A Saunderson</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Development of a Mouse Model of Hematopoietic Loss of Y Chromosome]]></title>
        <id>pubmed:37575386</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37575386/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230827204908&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-08-14T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[This protocol describes the generation of chimeric mice in which the Y chromosome is deleted from a proportion of blood cells. This model recapitulates the phenomenon of hematopoietic mosaic loss of Y chromosome (mLOY), which is frequently observed in the blood of aged men. To construct mice with hematopoietic Y chromosome loss, lineage-negative cells are isolated from the bone marrow of ROSA26-Cas9 knock-in mice. These cells are transduced with a lentivirus vector encoding a guide RNA (gRNA)...]]></summary>
        <author>
            <name>Soichi Sano</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[CRISPR/dCas9 DNA methylation editing is heritable during human hematopoiesis and shapes immune progeny]]></title>
        <id>pubmed:37579157</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37579157/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230826205107&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-08-14T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Aging is associated with an abnormal increase in DNA methylation (DNAm) in human gene promoters, including in bone marrow stem cells. DNAm patterns are further perturbed in hematological malignancies such as acute myeloid leukemia but the physiological significance of such epigenetic changes is unknown. Using epigenetic editing of human stem/progenitor cells (HSPCs), we show that p15 methylation affects hematopoiesis in vivo. We edited the CDKN2B (p15) promoter and ARF (p14) using dCas9-3A3L and...]]></summary>
        <author>
            <name>Emily A Saunderson</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Development of a Mouse Model of Hematopoietic Loss of Y Chromosome]]></title>
        <id>pubmed:37575386</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37575386/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230826205107&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-08-14T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[This protocol describes the generation of chimeric mice in which the Y chromosome is deleted from a proportion of blood cells. This model recapitulates the phenomenon of hematopoietic mosaic loss of Y chromosome (mLOY), which is frequently observed in the blood of aged men. To construct mice with hematopoietic Y chromosome loss, lineage-negative cells are isolated from the bone marrow of ROSA26-Cas9 knock-in mice. These cells are transduced with a lentivirus vector encoding a guide RNA (gRNA)...]]></summary>
        <author>
            <name>Soichi Sano</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[CRISPR/dCas9 DNA methylation editing is heritable during human hematopoiesis and shapes immune progeny]]></title>
        <id>pubmed:37579157</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37579157/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230825204557&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-08-14T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Aging is associated with an abnormal increase in DNA methylation (DNAm) in human gene promoters, including in bone marrow stem cells. DNAm patterns are further perturbed in hematological malignancies such as acute myeloid leukemia but the physiological significance of such epigenetic changes is unknown. Using epigenetic editing of human stem/progenitor cells (HSPCs), we show that p15 methylation affects hematopoiesis in vivo. We edited the CDKN2B (p15) promoter and ARF (p14) using dCas9-3A3L and...]]></summary>
        <author>
            <name>Emily A Saunderson</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Development of a Mouse Model of Hematopoietic Loss of Y Chromosome]]></title>
        <id>pubmed:37575386</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37575386/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230825204557&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-08-14T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[This protocol describes the generation of chimeric mice in which the Y chromosome is deleted from a proportion of blood cells. This model recapitulates the phenomenon of hematopoietic mosaic loss of Y chromosome (mLOY), which is frequently observed in the blood of aged men. To construct mice with hematopoietic Y chromosome loss, lineage-negative cells are isolated from the bone marrow of ROSA26-Cas9 knock-in mice. These cells are transduced with a lentivirus vector encoding a guide RNA (gRNA)...]]></summary>
        <author>
            <name>Soichi Sano</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[CRISPR/dCas9 DNA methylation editing is heritable during human hematopoiesis and shapes immune progeny]]></title>
        <id>pubmed:37579157</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37579157/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230824204823&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-08-14T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Aging is associated with an abnormal increase in DNA methylation (DNAm) in human gene promoters, including in bone marrow stem cells. DNAm patterns are further perturbed in hematological malignancies such as acute myeloid leukemia but the physiological significance of such epigenetic changes is unknown. Using epigenetic editing of human stem/progenitor cells (HSPCs), we show that p15 methylation affects hematopoiesis in vivo. We edited the CDKN2B (p15) promoter and ARF (p14) using dCas9-3A3L and...]]></summary>
        <author>
            <name>Emily A Saunderson</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Development of a Mouse Model of Hematopoietic Loss of Y Chromosome]]></title>
        <id>pubmed:37575386</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37575386/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230824204823&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-08-14T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[This protocol describes the generation of chimeric mice in which the Y chromosome is deleted from a proportion of blood cells. This model recapitulates the phenomenon of hematopoietic mosaic loss of Y chromosome (mLOY), which is frequently observed in the blood of aged men. To construct mice with hematopoietic Y chromosome loss, lineage-negative cells are isolated from the bone marrow of ROSA26-Cas9 knock-in mice. These cells are transduced with a lentivirus vector encoding a guide RNA (gRNA)...]]></summary>
        <author>
            <name>Soichi Sano</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[CRISPR/dCas9 DNA methylation editing is heritable during human hematopoiesis and shapes immune progeny]]></title>
        <id>pubmed:37579157</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37579157/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230823204708&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-08-14T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Aging is associated with an abnormal increase in DNA methylation (DNAm) in human gene promoters, including in bone marrow stem cells. DNAm patterns are further perturbed in hematological malignancies such as acute myeloid leukemia but the physiological significance of such epigenetic changes is unknown. Using epigenetic editing of human stem/progenitor cells (HSPCs), we show that p15 methylation affects hematopoiesis in vivo. We edited the CDKN2B (p15) promoter and ARF (p14) using dCas9-3A3L and...]]></summary>
        <author>
            <name>Emily A Saunderson</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Development of a Mouse Model of Hematopoietic Loss of Y Chromosome]]></title>
        <id>pubmed:37575386</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37575386/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230823204708&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-08-14T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[This protocol describes the generation of chimeric mice in which the Y chromosome is deleted from a proportion of blood cells. This model recapitulates the phenomenon of hematopoietic mosaic loss of Y chromosome (mLOY), which is frequently observed in the blood of aged men. To construct mice with hematopoietic Y chromosome loss, lineage-negative cells are isolated from the bone marrow of ROSA26-Cas9 knock-in mice. These cells are transduced with a lentivirus vector encoding a guide RNA (gRNA)...]]></summary>
        <author>
            <name>Soichi Sano</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[CRISPR/dCas9 DNA methylation editing is heritable during human hematopoiesis and shapes immune progeny]]></title>
        <id>pubmed:37579157</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37579157/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230822204709&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-08-14T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Aging is associated with an abnormal increase in DNA methylation (DNAm) in human gene promoters, including in bone marrow stem cells. DNAm patterns are further perturbed in hematological malignancies such as acute myeloid leukemia but the physiological significance of such epigenetic changes is unknown. Using epigenetic editing of human stem/progenitor cells (HSPCs), we show that p15 methylation affects hematopoiesis in vivo. We edited the CDKN2B (p15) promoter and ARF (p14) using dCas9-3A3L and...]]></summary>
        <author>
            <name>Emily A Saunderson</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Development of a Mouse Model of Hematopoietic Loss of Y Chromosome]]></title>
        <id>pubmed:37575386</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37575386/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230822204709&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-08-14T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[This protocol describes the generation of chimeric mice in which the Y chromosome is deleted from a proportion of blood cells. This model recapitulates the phenomenon of hematopoietic mosaic loss of Y chromosome (mLOY), which is frequently observed in the blood of aged men. To construct mice with hematopoietic Y chromosome loss, lineage-negative cells are isolated from the bone marrow of ROSA26-Cas9 knock-in mice. These cells are transduced with a lentivirus vector encoding a guide RNA (gRNA)...]]></summary>
        <author>
            <name>Soichi Sano</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[CRISPR/dCas9 DNA methylation editing is heritable during human hematopoiesis and shapes immune progeny]]></title>
        <id>pubmed:37579157</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37579157/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230821204801&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-08-14T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Aging is associated with an abnormal increase in DNA methylation (DNAm) in human gene promoters, including in bone marrow stem cells. DNAm patterns are further perturbed in hematological malignancies such as acute myeloid leukemia but the physiological significance of such epigenetic changes is unknown. Using epigenetic editing of human stem/progenitor cells (HSPCs), we show that p15 methylation affects hematopoiesis in vivo. We edited the CDKN2B (p15) promoter and ARF (p14) using dCas9-3A3L and...]]></summary>
        <author>
            <name>Emily A Saunderson</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Development of a Mouse Model of Hematopoietic Loss of Y Chromosome]]></title>
        <id>pubmed:37575386</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37575386/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230821204801&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-08-14T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[This protocol describes the generation of chimeric mice in which the Y chromosome is deleted from a proportion of blood cells. This model recapitulates the phenomenon of hematopoietic mosaic loss of Y chromosome (mLOY), which is frequently observed in the blood of aged men. To construct mice with hematopoietic Y chromosome loss, lineage-negative cells are isolated from the bone marrow of ROSA26-Cas9 knock-in mice. These cells are transduced with a lentivirus vector encoding a guide RNA (gRNA)...]]></summary>
        <author>
            <name>Soichi Sano</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[CRISPR/dCas9 DNA methylation editing is heritable during human hematopoiesis and shapes immune progeny]]></title>
        <id>pubmed:37579157</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37579157/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230820204715&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-08-14T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Aging is associated with an abnormal increase in DNA methylation (DNAm) in human gene promoters, including in bone marrow stem cells. DNAm patterns are further perturbed in hematological malignancies such as acute myeloid leukemia but the physiological significance of such epigenetic changes is unknown. Using epigenetic editing of human stem/progenitor cells (HSPCs), we show that p15 methylation affects hematopoiesis in vivo. We edited the CDKN2B (p15) promoter and ARF (p14) using dCas9-3A3L and...]]></summary>
        <author>
            <name>Emily A Saunderson</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Development of a Mouse Model of Hematopoietic Loss of Y Chromosome]]></title>
        <id>pubmed:37575386</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37575386/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230820204715&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-08-14T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[This protocol describes the generation of chimeric mice in which the Y chromosome is deleted from a proportion of blood cells. This model recapitulates the phenomenon of hematopoietic mosaic loss of Y chromosome (mLOY), which is frequently observed in the blood of aged men. To construct mice with hematopoietic Y chromosome loss, lineage-negative cells are isolated from the bone marrow of ROSA26-Cas9 knock-in mice. These cells are transduced with a lentivirus vector encoding a guide RNA (gRNA)...]]></summary>
        <author>
            <name>Soichi Sano</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[CRISPR/dCas9 DNA methylation editing is heritable during human hematopoiesis and shapes immune progeny]]></title>
        <id>pubmed:37579157</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37579157/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230819204952&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-08-14T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Aging is associated with an abnormal increase in DNA methylation (DNAm) in human gene promoters, including in bone marrow stem cells. DNAm patterns are further perturbed in hematological malignancies such as acute myeloid leukemia but the physiological significance of such epigenetic changes is unknown. Using epigenetic editing of human stem/progenitor cells (HSPCs), we show that p15 methylation affects hematopoiesis in vivo. We edited the CDKN2B (p15) promoter and ARF (p14) using dCas9-3A3L and...]]></summary>
        <author>
            <name>Emily A Saunderson</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Development of a Mouse Model of Hematopoietic Loss of Y Chromosome]]></title>
        <id>pubmed:37575386</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37575386/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230819204952&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-08-14T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[This protocol describes the generation of chimeric mice in which the Y chromosome is deleted from a proportion of blood cells. This model recapitulates the phenomenon of hematopoietic mosaic loss of Y chromosome (mLOY), which is frequently observed in the blood of aged men. To construct mice with hematopoietic Y chromosome loss, lineage-negative cells are isolated from the bone marrow of ROSA26-Cas9 knock-in mice. These cells are transduced with a lentivirus vector encoding a guide RNA (gRNA)...]]></summary>
        <author>
            <name>Soichi Sano</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[CRISPR/dCas9 DNA methylation editing is heritable during human hematopoiesis and shapes immune progeny]]></title>
        <id>pubmed:37579157</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37579157/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230818204446&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-08-14T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Aging is associated with an abnormal increase in DNA methylation (DNAm) in human gene promoters, including in bone marrow stem cells. DNAm patterns are further perturbed in hematological malignancies such as acute myeloid leukemia but the physiological significance of such epigenetic changes is unknown. Using epigenetic editing of human stem/progenitor cells (HSPCs), we show that p15 methylation affects hematopoiesis in vivo. We edited the CDKN2B (p15) promoter and ARF (p14) using dCas9-3A3L and...]]></summary>
        <author>
            <name>Emily A Saunderson</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Development of a Mouse Model of Hematopoietic Loss of Y Chromosome]]></title>
        <id>pubmed:37575386</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37575386/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230818204446&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-08-14T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[This protocol describes the generation of chimeric mice in which the Y chromosome is deleted from a proportion of blood cells. This model recapitulates the phenomenon of hematopoietic mosaic loss of Y chromosome (mLOY), which is frequently observed in the blood of aged men. To construct mice with hematopoietic Y chromosome loss, lineage-negative cells are isolated from the bone marrow of ROSA26-Cas9 knock-in mice. These cells are transduced with a lentivirus vector encoding a guide RNA (gRNA)...]]></summary>
        <author>
            <name>Soichi Sano</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[CRISPR/dCas9 DNA methylation editing is heritable during human hematopoiesis and shapes immune progeny]]></title>
        <id>pubmed:37579157</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37579157/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230817204642&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-08-14T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Aging is associated with an abnormal increase in DNA methylation (DNAm) in human gene promoters, including in bone marrow stem cells. DNAm patterns are further perturbed in hematological malignancies such as acute myeloid leukemia but the physiological significance of such epigenetic changes is unknown. Using epigenetic editing of human stem/progenitor cells (HSPCs), we show that p15 methylation affects hematopoiesis in vivo. We edited the CDKN2B (p15) promoter and ARF (p14) using dCas9-3A3L and...]]></summary>
        <author>
            <name>Emily A Saunderson</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Development of a Mouse Model of Hematopoietic Loss of Y Chromosome]]></title>
        <id>pubmed:37575386</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37575386/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230817204642&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-08-14T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[This protocol describes the generation of chimeric mice in which the Y chromosome is deleted from a proportion of blood cells. This model recapitulates the phenomenon of hematopoietic mosaic loss of Y chromosome (mLOY), which is frequently observed in the blood of aged men. To construct mice with hematopoietic Y chromosome loss, lineage-negative cells are isolated from the bone marrow of ROSA26-Cas9 knock-in mice. These cells are transduced with a lentivirus vector encoding a guide RNA (gRNA)...]]></summary>
        <author>
            <name>Soichi Sano</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[CRISPR/dCas9 DNA methylation editing is heritable during human hematopoiesis and shapes immune progeny]]></title>
        <id>pubmed:37579157</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37579157/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230816204601&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-08-14T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Aging is associated with an abnormal increase in DNA methylation (DNAm) in human gene promoters, including in bone marrow stem cells. DNAm patterns are further perturbed in hematological malignancies such as acute myeloid leukemia but the physiological significance of such epigenetic changes is unknown. Using epigenetic editing of human stem/progenitor cells (HSPCs), we show that p15 methylation affects hematopoiesis in vivo. We edited the CDKN2B (p15) promoter and ARF (p14) using dCas9-3A3L and...]]></summary>
        <author>
            <name>Emily A Saunderson</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Development of a Mouse Model of Hematopoietic Loss of Y Chromosome]]></title>
        <id>pubmed:37575386</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37575386/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230816204601&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-08-14T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[This protocol describes the generation of chimeric mice in which the Y chromosome is deleted from a proportion of blood cells. This model recapitulates the phenomenon of hematopoietic mosaic loss of Y chromosome (mLOY), which is frequently observed in the blood of aged men. To construct mice with hematopoietic Y chromosome loss, lineage-negative cells are isolated from the bone marrow of ROSA26-Cas9 knock-in mice. These cells are transduced with a lentivirus vector encoding a guide RNA (gRNA)...]]></summary>
        <author>
            <name>Soichi Sano</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[CRISPR/dCas9 DNA methylation editing is heritable during human hematopoiesis and shapes immune progeny]]></title>
        <id>pubmed:37579157</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37579157/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230815204647&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-08-14T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Aging is associated with an abnormal increase in DNA methylation (DNAm) in human gene promoters, including in bone marrow stem cells. DNAm patterns are further perturbed in hematological malignancies such as acute myeloid leukemia but the physiological significance of such epigenetic changes is unknown. Using epigenetic editing of human stem/progenitor cells (HSPCs), we show that p15 methylation affects hematopoiesis in vivo. We edited the CDKN2B (p15) promoter and ARF (p14) using dCas9-3A3L and...]]></summary>
        <author>
            <name>Emily A Saunderson</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Development of a Mouse Model of Hematopoietic Loss of Y Chromosome]]></title>
        <id>pubmed:37575386</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37575386/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230815204647&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-08-14T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[This protocol describes the generation of chimeric mice in which the Y chromosome is deleted from a proportion of blood cells. This model recapitulates the phenomenon of hematopoietic mosaic loss of Y chromosome (mLOY), which is frequently observed in the blood of aged men. To construct mice with hematopoietic Y chromosome loss, lineage-negative cells are isolated from the bone marrow of ROSA26-Cas9 knock-in mice. These cells are transduced with a lentivirus vector encoding a guide RNA (gRNA)...]]></summary>
        <author>
            <name>Soichi Sano</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[CRISPR/dCas9 DNA methylation editing is heritable during human hematopoiesis and shapes immune progeny]]></title>
        <id>pubmed:37579157</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37579157/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230814204719&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-08-14T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Aging is associated with an abnormal increase in DNA methylation (DNAm) in human gene promoters, including in bone marrow stem cells. DNAm patterns are further perturbed in hematological malignancies such as acute myeloid leukemia but the physiological significance of such epigenetic changes is unknown. Using epigenetic editing of human stem/progenitor cells (HSPCs), we show that p15 methylation affects hematopoiesis in vivo. We edited the CDKN2B (p15) promoter and ARF (p14) using dCas9-3A3L and...]]></summary>
        <author>
            <name>Emily A Saunderson</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Development of a Mouse Model of Hematopoietic Loss of Y Chromosome]]></title>
        <id>pubmed:37575386</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37575386/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230814204719&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-08-14T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[This protocol describes the generation of chimeric mice in which the Y chromosome is deleted from a proportion of blood cells. This model recapitulates the phenomenon of hematopoietic mosaic loss of Y chromosome (mLOY), which is frequently observed in the blood of aged men. To construct mice with hematopoietic Y chromosome loss, lineage-negative cells are isolated from the bone marrow of ROSA26-Cas9 knock-in mice. These cells are transduced with a lentivirus vector encoding a guide RNA (gRNA)...]]></summary>
        <author>
            <name>Soichi Sano</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Potential immunosuppressive clonal hematopoietic mutations in tumor infiltrating immune cells in breast invasive carcinoma]]></title>
        <id>pubmed:37573441</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37573441/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230825204557&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-08-12T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[A hallmark of cancer is a tumor cell's ability to evade immune destruction. Somatic mutations in tumor cells that prevent immune destruction have been extensively studied. However, somatic mutations in tumor infiltrating immune (TII) cells, to our knowledge, have not been previously studied. Understandably so since normal hematopoiesis prevents the accumulation of somatic mutations in immune cells. However, clonal hematopoiesis does result in the accumulation of somatic mutations in immune...]]></summary>
        <author>
            <name>Ramu Anandakrishnan</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Potential immunosuppressive clonal hematopoietic mutations in tumor infiltrating immune cells in breast invasive carcinoma]]></title>
        <id>pubmed:37573441</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37573441/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230824204823&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-08-12T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[A hallmark of cancer is a tumor cell's ability to evade immune destruction. Somatic mutations in tumor cells that prevent immune destruction have been extensively studied. However, somatic mutations in tumor infiltrating immune (TII) cells, to our knowledge, have not been previously studied. Understandably so since normal hematopoiesis prevents the accumulation of somatic mutations in immune cells. However, clonal hematopoiesis does result in the accumulation of somatic mutations in immune...]]></summary>
        <author>
            <name>Ramu Anandakrishnan</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Potential immunosuppressive clonal hematopoietic mutations in tumor infiltrating immune cells in breast invasive carcinoma]]></title>
        <id>pubmed:37573441</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37573441/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230823204708&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-08-12T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[A hallmark of cancer is a tumor cell's ability to evade immune destruction. Somatic mutations in tumor cells that prevent immune destruction have been extensively studied. However, somatic mutations in tumor infiltrating immune (TII) cells, to our knowledge, have not been previously studied. Understandably so since normal hematopoiesis prevents the accumulation of somatic mutations in immune cells. However, clonal hematopoiesis does result in the accumulation of somatic mutations in immune...]]></summary>
        <author>
            <name>Ramu Anandakrishnan</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Potential immunosuppressive clonal hematopoietic mutations in tumor infiltrating immune cells in breast invasive carcinoma]]></title>
        <id>pubmed:37573441</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37573441/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230822204709&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-08-12T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[A hallmark of cancer is a tumor cell's ability to evade immune destruction. Somatic mutations in tumor cells that prevent immune destruction have been extensively studied. However, somatic mutations in tumor infiltrating immune (TII) cells, to our knowledge, have not been previously studied. Understandably so since normal hematopoiesis prevents the accumulation of somatic mutations in immune cells. However, clonal hematopoiesis does result in the accumulation of somatic mutations in immune...]]></summary>
        <author>
            <name>Ramu Anandakrishnan</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Potential immunosuppressive clonal hematopoietic mutations in tumor infiltrating immune cells in breast invasive carcinoma]]></title>
        <id>pubmed:37573441</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37573441/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230821204801&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-08-12T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[A hallmark of cancer is a tumor cell's ability to evade immune destruction. Somatic mutations in tumor cells that prevent immune destruction have been extensively studied. However, somatic mutations in tumor infiltrating immune (TII) cells, to our knowledge, have not been previously studied. Understandably so since normal hematopoiesis prevents the accumulation of somatic mutations in immune cells. However, clonal hematopoiesis does result in the accumulation of somatic mutations in immune...]]></summary>
        <author>
            <name>Ramu Anandakrishnan</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Potential immunosuppressive clonal hematopoietic mutations in tumor infiltrating immune cells in breast invasive carcinoma]]></title>
        <id>pubmed:37573441</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37573441/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230820204715&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-08-12T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[A hallmark of cancer is a tumor cell's ability to evade immune destruction. Somatic mutations in tumor cells that prevent immune destruction have been extensively studied. However, somatic mutations in tumor infiltrating immune (TII) cells, to our knowledge, have not been previously studied. Understandably so since normal hematopoiesis prevents the accumulation of somatic mutations in immune cells. However, clonal hematopoiesis does result in the accumulation of somatic mutations in immune...]]></summary>
        <author>
            <name>Ramu Anandakrishnan</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Potential immunosuppressive clonal hematopoietic mutations in tumor infiltrating immune cells in breast invasive carcinoma]]></title>
        <id>pubmed:37573441</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37573441/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230819204952&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-08-12T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[A hallmark of cancer is a tumor cell's ability to evade immune destruction. Somatic mutations in tumor cells that prevent immune destruction have been extensively studied. However, somatic mutations in tumor infiltrating immune (TII) cells, to our knowledge, have not been previously studied. Understandably so since normal hematopoiesis prevents the accumulation of somatic mutations in immune cells. However, clonal hematopoiesis does result in the accumulation of somatic mutations in immune...]]></summary>
        <author>
            <name>Ramu Anandakrishnan</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Potential immunosuppressive clonal hematopoietic mutations in tumor infiltrating immune cells in breast invasive carcinoma]]></title>
        <id>pubmed:37573441</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37573441/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230818204446&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-08-12T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[A hallmark of cancer is a tumor cell's ability to evade immune destruction. Somatic mutations in tumor cells that prevent immune destruction have been extensively studied. However, somatic mutations in tumor infiltrating immune (TII) cells, to our knowledge, have not been previously studied. Understandably so since normal hematopoiesis prevents the accumulation of somatic mutations in immune cells. However, clonal hematopoiesis does result in the accumulation of somatic mutations in immune...]]></summary>
        <author>
            <name>Ramu Anandakrishnan</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Potential immunosuppressive clonal hematopoietic mutations in tumor infiltrating immune cells in breast invasive carcinoma]]></title>
        <id>pubmed:37573441</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37573441/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230817204642&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-08-12T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[A hallmark of cancer is a tumor cell's ability to evade immune destruction. Somatic mutations in tumor cells that prevent immune destruction have been extensively studied. However, somatic mutations in tumor infiltrating immune (TII) cells, to our knowledge, have not been previously studied. Understandably so since normal hematopoiesis prevents the accumulation of somatic mutations in immune cells. However, clonal hematopoiesis does result in the accumulation of somatic mutations in immune...]]></summary>
        <author>
            <name>Ramu Anandakrishnan</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Potential immunosuppressive clonal hematopoietic mutations in tumor infiltrating immune cells in breast invasive carcinoma]]></title>
        <id>pubmed:37573441</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37573441/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230816204601&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-08-12T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[A hallmark of cancer is a tumor cell's ability to evade immune destruction. Somatic mutations in tumor cells that prevent immune destruction have been extensively studied. However, somatic mutations in tumor infiltrating immune (TII) cells, to our knowledge, have not been previously studied. Understandably so since normal hematopoiesis prevents the accumulation of somatic mutations in immune cells. However, clonal hematopoiesis does result in the accumulation of somatic mutations in immune...]]></summary>
        <author>
            <name>Ramu Anandakrishnan</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Potential immunosuppressive clonal hematopoietic mutations in tumor infiltrating immune cells in breast invasive carcinoma]]></title>
        <id>pubmed:37573441</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37573441/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230815204647&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-08-12T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[A hallmark of cancer is a tumor cell's ability to evade immune destruction. Somatic mutations in tumor cells that prevent immune destruction have been extensively studied. However, somatic mutations in tumor infiltrating immune (TII) cells, to our knowledge, have not been previously studied. Understandably so since normal hematopoiesis prevents the accumulation of somatic mutations in immune cells. However, clonal hematopoiesis does result in the accumulation of somatic mutations in immune...]]></summary>
        <author>
            <name>Ramu Anandakrishnan</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Potential immunosuppressive clonal hematopoietic mutations in tumor infiltrating immune cells in breast invasive carcinoma]]></title>
        <id>pubmed:37573441</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37573441/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230814204719&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-08-12T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[A hallmark of cancer is a tumor cell's ability to evade immune destruction. Somatic mutations in tumor cells that prevent immune destruction have been extensively studied. However, somatic mutations in tumor infiltrating immune (TII) cells, to our knowledge, have not been previously studied. Understandably so since normal hematopoiesis prevents the accumulation of somatic mutations in immune cells. However, clonal hematopoiesis does result in the accumulation of somatic mutations in immune...]]></summary>
        <author>
            <name>Ramu Anandakrishnan</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Potential immunosuppressive clonal hematopoietic mutations in tumor infiltrating immune cells in breast invasive carcinoma]]></title>
        <id>pubmed:37573441</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37573441/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230813204802&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-08-12T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[A hallmark of cancer is a tumor cell's ability to evade immune destruction. Somatic mutations in tumor cells that prevent immune destruction have been extensively studied. However, somatic mutations in tumor infiltrating immune (TII) cells, to our knowledge, have not been previously studied. Understandably so since normal hematopoiesis prevents the accumulation of somatic mutations in immune cells. However, clonal hematopoiesis does result in the accumulation of somatic mutations in immune...]]></summary>
        <author>
            <name>Ramu Anandakrishnan</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Potential immunosuppressive clonal hematopoietic mutations in tumor infiltrating immune cells in breast invasive carcinoma]]></title>
        <id>pubmed:37573441</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37573441/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230904204751&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-08-12T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[A hallmark of cancer is a tumor cell's ability to evade immune destruction. Somatic mutations in tumor cells that prevent immune destruction have been extensively studied. However, somatic mutations in tumor infiltrating immune (TII) cells, to our knowledge, have not been previously studied. Understandably so since normal hematopoiesis prevents the accumulation of somatic mutations in immune cells. However, clonal hematopoiesis does result in the accumulation of somatic mutations in immune...]]></summary>
        <author>
            <name>Ramu Anandakrishnan</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Potential immunosuppressive clonal hematopoietic mutations in tumor infiltrating immune cells in breast invasive carcinoma]]></title>
        <id>pubmed:37573441</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37573441/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230903204939&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-08-12T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[A hallmark of cancer is a tumor cell's ability to evade immune destruction. Somatic mutations in tumor cells that prevent immune destruction have been extensively studied. However, somatic mutations in tumor infiltrating immune (TII) cells, to our knowledge, have not been previously studied. Understandably so since normal hematopoiesis prevents the accumulation of somatic mutations in immune cells. However, clonal hematopoiesis does result in the accumulation of somatic mutations in immune...]]></summary>
        <author>
            <name>Ramu Anandakrishnan</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Potential immunosuppressive clonal hematopoietic mutations in tumor infiltrating immune cells in breast invasive carcinoma]]></title>
        <id>pubmed:37573441</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37573441/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230902205121&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-08-12T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[A hallmark of cancer is a tumor cell's ability to evade immune destruction. Somatic mutations in tumor cells that prevent immune destruction have been extensively studied. However, somatic mutations in tumor infiltrating immune (TII) cells, to our knowledge, have not been previously studied. Understandably so since normal hematopoiesis prevents the accumulation of somatic mutations in immune cells. However, clonal hematopoiesis does result in the accumulation of somatic mutations in immune...]]></summary>
        <author>
            <name>Ramu Anandakrishnan</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Potential immunosuppressive clonal hematopoietic mutations in tumor infiltrating immune cells in breast invasive carcinoma]]></title>
        <id>pubmed:37573441</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37573441/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230901204619&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-08-12T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[A hallmark of cancer is a tumor cell's ability to evade immune destruction. Somatic mutations in tumor cells that prevent immune destruction have been extensively studied. However, somatic mutations in tumor infiltrating immune (TII) cells, to our knowledge, have not been previously studied. Understandably so since normal hematopoiesis prevents the accumulation of somatic mutations in immune cells. However, clonal hematopoiesis does result in the accumulation of somatic mutations in immune...]]></summary>
        <author>
            <name>Ramu Anandakrishnan</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Potential immunosuppressive clonal hematopoietic mutations in tumor infiltrating immune cells in breast invasive carcinoma]]></title>
        <id>pubmed:37573441</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37573441/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230831205203&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-08-12T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[A hallmark of cancer is a tumor cell's ability to evade immune destruction. Somatic mutations in tumor cells that prevent immune destruction have been extensively studied. However, somatic mutations in tumor infiltrating immune (TII) cells, to our knowledge, have not been previously studied. Understandably so since normal hematopoiesis prevents the accumulation of somatic mutations in immune cells. However, clonal hematopoiesis does result in the accumulation of somatic mutations in immune...]]></summary>
        <author>
            <name>Ramu Anandakrishnan</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Potential immunosuppressive clonal hematopoietic mutations in tumor infiltrating immune cells in breast invasive carcinoma]]></title>
        <id>pubmed:37573441</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37573441/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230830204850&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-08-12T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[A hallmark of cancer is a tumor cell's ability to evade immune destruction. Somatic mutations in tumor cells that prevent immune destruction have been extensively studied. However, somatic mutations in tumor infiltrating immune (TII) cells, to our knowledge, have not been previously studied. Understandably so since normal hematopoiesis prevents the accumulation of somatic mutations in immune cells. However, clonal hematopoiesis does result in the accumulation of somatic mutations in immune...]]></summary>
        <author>
            <name>Ramu Anandakrishnan</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Potential immunosuppressive clonal hematopoietic mutations in tumor infiltrating immune cells in breast invasive carcinoma]]></title>
        <id>pubmed:37573441</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37573441/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230829204824&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-08-12T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[A hallmark of cancer is a tumor cell's ability to evade immune destruction. Somatic mutations in tumor cells that prevent immune destruction have been extensively studied. However, somatic mutations in tumor infiltrating immune (TII) cells, to our knowledge, have not been previously studied. Understandably so since normal hematopoiesis prevents the accumulation of somatic mutations in immune cells. However, clonal hematopoiesis does result in the accumulation of somatic mutations in immune...]]></summary>
        <author>
            <name>Ramu Anandakrishnan</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Potential immunosuppressive clonal hematopoietic mutations in tumor infiltrating immune cells in breast invasive carcinoma]]></title>
        <id>pubmed:37573441</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37573441/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230828204854&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-08-12T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[A hallmark of cancer is a tumor cell's ability to evade immune destruction. Somatic mutations in tumor cells that prevent immune destruction have been extensively studied. However, somatic mutations in tumor infiltrating immune (TII) cells, to our knowledge, have not been previously studied. Understandably so since normal hematopoiesis prevents the accumulation of somatic mutations in immune cells. However, clonal hematopoiesis does result in the accumulation of somatic mutations in immune...]]></summary>
        <author>
            <name>Ramu Anandakrishnan</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Potential immunosuppressive clonal hematopoietic mutations in tumor infiltrating immune cells in breast invasive carcinoma]]></title>
        <id>pubmed:37573441</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37573441/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230827204908&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-08-12T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[A hallmark of cancer is a tumor cell's ability to evade immune destruction. Somatic mutations in tumor cells that prevent immune destruction have been extensively studied. However, somatic mutations in tumor infiltrating immune (TII) cells, to our knowledge, have not been previously studied. Understandably so since normal hematopoiesis prevents the accumulation of somatic mutations in immune cells. However, clonal hematopoiesis does result in the accumulation of somatic mutations in immune...]]></summary>
        <author>
            <name>Ramu Anandakrishnan</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Potential immunosuppressive clonal hematopoietic mutations in tumor infiltrating immune cells in breast invasive carcinoma]]></title>
        <id>pubmed:37573441</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37573441/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230826205107&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-08-12T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[A hallmark of cancer is a tumor cell's ability to evade immune destruction. Somatic mutations in tumor cells that prevent immune destruction have been extensively studied. However, somatic mutations in tumor infiltrating immune (TII) cells, to our knowledge, have not been previously studied. Understandably so since normal hematopoiesis prevents the accumulation of somatic mutations in immune cells. However, clonal hematopoiesis does result in the accumulation of somatic mutations in immune...]]></summary>
        <author>
            <name>Ramu Anandakrishnan</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Potential immunosuppressive clonal hematopoietic mutations in tumor infiltrating immune cells in breast invasive carcinoma]]></title>
        <id>pubmed:37573441</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37573441/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230825204602&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-08-12T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[A hallmark of cancer is a tumor cell's ability to evade immune destruction. Somatic mutations in tumor cells that prevent immune destruction have been extensively studied. However, somatic mutations in tumor infiltrating immune (TII) cells, to our knowledge, have not been previously studied. Understandably so since normal hematopoiesis prevents the accumulation of somatic mutations in immune cells. However, clonal hematopoiesis does result in the accumulation of somatic mutations in immune...]]></summary>
        <author>
            <name>Ramu Anandakrishnan</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Potential immunosuppressive clonal hematopoietic mutations in tumor infiltrating immune cells in breast invasive carcinoma]]></title>
        <id>pubmed:37573441</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37573441/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230824204824&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-08-12T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[A hallmark of cancer is a tumor cell's ability to evade immune destruction. Somatic mutations in tumor cells that prevent immune destruction have been extensively studied. However, somatic mutations in tumor infiltrating immune (TII) cells, to our knowledge, have not been previously studied. Understandably so since normal hematopoiesis prevents the accumulation of somatic mutations in immune cells. However, clonal hematopoiesis does result in the accumulation of somatic mutations in immune...]]></summary>
        <author>
            <name>Ramu Anandakrishnan</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Potential immunosuppressive clonal hematopoietic mutations in tumor infiltrating immune cells in breast invasive carcinoma]]></title>
        <id>pubmed:37573441</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37573441/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230823204708&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-08-12T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[A hallmark of cancer is a tumor cell's ability to evade immune destruction. Somatic mutations in tumor cells that prevent immune destruction have been extensively studied. However, somatic mutations in tumor infiltrating immune (TII) cells, to our knowledge, have not been previously studied. Understandably so since normal hematopoiesis prevents the accumulation of somatic mutations in immune cells. However, clonal hematopoiesis does result in the accumulation of somatic mutations in immune...]]></summary>
        <author>
            <name>Ramu Anandakrishnan</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Potential immunosuppressive clonal hematopoietic mutations in tumor infiltrating immune cells in breast invasive carcinoma]]></title>
        <id>pubmed:37573441</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37573441/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230822204709&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-08-12T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[A hallmark of cancer is a tumor cell's ability to evade immune destruction. Somatic mutations in tumor cells that prevent immune destruction have been extensively studied. However, somatic mutations in tumor infiltrating immune (TII) cells, to our knowledge, have not been previously studied. Understandably so since normal hematopoiesis prevents the accumulation of somatic mutations in immune cells. However, clonal hematopoiesis does result in the accumulation of somatic mutations in immune...]]></summary>
        <author>
            <name>Ramu Anandakrishnan</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Potential immunosuppressive clonal hematopoietic mutations in tumor infiltrating immune cells in breast invasive carcinoma]]></title>
        <id>pubmed:37573441</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37573441/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230821204801&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-08-12T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[A hallmark of cancer is a tumor cell's ability to evade immune destruction. Somatic mutations in tumor cells that prevent immune destruction have been extensively studied. However, somatic mutations in tumor infiltrating immune (TII) cells, to our knowledge, have not been previously studied. Understandably so since normal hematopoiesis prevents the accumulation of somatic mutations in immune cells. However, clonal hematopoiesis does result in the accumulation of somatic mutations in immune...]]></summary>
        <author>
            <name>Ramu Anandakrishnan</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Potential immunosuppressive clonal hematopoietic mutations in tumor infiltrating immune cells in breast invasive carcinoma]]></title>
        <id>pubmed:37573441</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37573441/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230820204715&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-08-12T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[A hallmark of cancer is a tumor cell's ability to evade immune destruction. Somatic mutations in tumor cells that prevent immune destruction have been extensively studied. However, somatic mutations in tumor infiltrating immune (TII) cells, to our knowledge, have not been previously studied. Understandably so since normal hematopoiesis prevents the accumulation of somatic mutations in immune cells. However, clonal hematopoiesis does result in the accumulation of somatic mutations in immune...]]></summary>
        <author>
            <name>Ramu Anandakrishnan</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Potential immunosuppressive clonal hematopoietic mutations in tumor infiltrating immune cells in breast invasive carcinoma]]></title>
        <id>pubmed:37573441</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37573441/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230819204952&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-08-12T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[A hallmark of cancer is a tumor cell's ability to evade immune destruction. Somatic mutations in tumor cells that prevent immune destruction have been extensively studied. However, somatic mutations in tumor infiltrating immune (TII) cells, to our knowledge, have not been previously studied. Understandably so since normal hematopoiesis prevents the accumulation of somatic mutations in immune cells. However, clonal hematopoiesis does result in the accumulation of somatic mutations in immune...]]></summary>
        <author>
            <name>Ramu Anandakrishnan</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Potential immunosuppressive clonal hematopoietic mutations in tumor infiltrating immune cells in breast invasive carcinoma]]></title>
        <id>pubmed:37573441</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37573441/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230818204446&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-08-12T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[A hallmark of cancer is a tumor cell's ability to evade immune destruction. Somatic mutations in tumor cells that prevent immune destruction have been extensively studied. However, somatic mutations in tumor infiltrating immune (TII) cells, to our knowledge, have not been previously studied. Understandably so since normal hematopoiesis prevents the accumulation of somatic mutations in immune cells. However, clonal hematopoiesis does result in the accumulation of somatic mutations in immune...]]></summary>
        <author>
            <name>Ramu Anandakrishnan</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Potential immunosuppressive clonal hematopoietic mutations in tumor infiltrating immune cells in breast invasive carcinoma]]></title>
        <id>pubmed:37573441</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37573441/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230817204642&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-08-12T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[A hallmark of cancer is a tumor cell's ability to evade immune destruction. Somatic mutations in tumor cells that prevent immune destruction have been extensively studied. However, somatic mutations in tumor infiltrating immune (TII) cells, to our knowledge, have not been previously studied. Understandably so since normal hematopoiesis prevents the accumulation of somatic mutations in immune cells. However, clonal hematopoiesis does result in the accumulation of somatic mutations in immune...]]></summary>
        <author>
            <name>Ramu Anandakrishnan</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Potential immunosuppressive clonal hematopoietic mutations in tumor infiltrating immune cells in breast invasive carcinoma]]></title>
        <id>pubmed:37573441</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37573441/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230816204600&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-08-12T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[A hallmark of cancer is a tumor cell's ability to evade immune destruction. Somatic mutations in tumor cells that prevent immune destruction have been extensively studied. However, somatic mutations in tumor infiltrating immune (TII) cells, to our knowledge, have not been previously studied. Understandably so since normal hematopoiesis prevents the accumulation of somatic mutations in immune cells. However, clonal hematopoiesis does result in the accumulation of somatic mutations in immune...]]></summary>
        <author>
            <name>Ramu Anandakrishnan</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Potential immunosuppressive clonal hematopoietic mutations in tumor infiltrating immune cells in breast invasive carcinoma]]></title>
        <id>pubmed:37573441</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37573441/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230815204647&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-08-12T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[A hallmark of cancer is a tumor cell's ability to evade immune destruction. Somatic mutations in tumor cells that prevent immune destruction have been extensively studied. However, somatic mutations in tumor infiltrating immune (TII) cells, to our knowledge, have not been previously studied. Understandably so since normal hematopoiesis prevents the accumulation of somatic mutations in immune cells. However, clonal hematopoiesis does result in the accumulation of somatic mutations in immune...]]></summary>
        <author>
            <name>Ramu Anandakrishnan</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Potential immunosuppressive clonal hematopoietic mutations in tumor infiltrating immune cells in breast invasive carcinoma]]></title>
        <id>pubmed:37573441</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37573441/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230814204719&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-08-12T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[A hallmark of cancer is a tumor cell's ability to evade immune destruction. Somatic mutations in tumor cells that prevent immune destruction have been extensively studied. However, somatic mutations in tumor infiltrating immune (TII) cells, to our knowledge, have not been previously studied. Understandably so since normal hematopoiesis prevents the accumulation of somatic mutations in immune cells. However, clonal hematopoiesis does result in the accumulation of somatic mutations in immune...]]></summary>
        <author>
            <name>Ramu Anandakrishnan</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Serum biomarkers are altered in UK biobank participants with mosaic chromosomal alterations]]></title>
        <id>pubmed:37565819</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37565819/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230825204557&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-08-11T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Age-related clonal expansion of cells harboring mosaic chromosomal alterations (mCAs) is one manifestation of clonal hematopoiesis. Identifying factors that influence the generation and promotion of clonal expansion of mCAs are key to investigate the role of mCAs in health and disease. Herein, we report on widely measured serum biomarkers and their possible association with mCAs, which could provide new insights into molecular alterations that promote acquisition and clonal expansion. We...]]></summary>
        <author>
            <name>Aubrey K Hubbard</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Serum biomarkers are altered in UK biobank participants with mosaic chromosomal alterations]]></title>
        <id>pubmed:37565819</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37565819/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230824204823&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-08-11T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Age-related clonal expansion of cells harboring mosaic chromosomal alterations (mCAs) is one manifestation of clonal hematopoiesis. Identifying factors that influence the generation and promotion of clonal expansion of mCAs are key to investigate the role of mCAs in health and disease. Herein, we report on widely measured serum biomarkers and their possible association with mCAs, which could provide new insights into molecular alterations that promote acquisition and clonal expansion. We...]]></summary>
        <author>
            <name>Aubrey K Hubbard</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Serum biomarkers are altered in UK biobank participants with mosaic chromosomal alterations]]></title>
        <id>pubmed:37565819</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37565819/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230823204708&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-08-11T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Age-related clonal expansion of cells harboring mosaic chromosomal alterations (mCAs) is one manifestation of clonal hematopoiesis. Identifying factors that influence the generation and promotion of clonal expansion of mCAs are key to investigate the role of mCAs in health and disease. Herein, we report on widely measured serum biomarkers and their possible association with mCAs, which could provide new insights into molecular alterations that promote acquisition and clonal expansion. We...]]></summary>
        <author>
            <name>Aubrey K Hubbard</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Serum biomarkers are altered in UK biobank participants with mosaic chromosomal alterations]]></title>
        <id>pubmed:37565819</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37565819/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230822204709&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-08-11T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Age-related clonal expansion of cells harboring mosaic chromosomal alterations (mCAs) is one manifestation of clonal hematopoiesis. Identifying factors that influence the generation and promotion of clonal expansion of mCAs are key to investigate the role of mCAs in health and disease. Herein, we report on widely measured serum biomarkers and their possible association with mCAs, which could provide new insights into molecular alterations that promote acquisition and clonal expansion. We...]]></summary>
        <author>
            <name>Aubrey K Hubbard</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Serum biomarkers are altered in UK biobank participants with mosaic chromosomal alterations]]></title>
        <id>pubmed:37565819</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37565819/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230821204801&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-08-11T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Age-related clonal expansion of cells harboring mosaic chromosomal alterations (mCAs) is one manifestation of clonal hematopoiesis. Identifying factors that influence the generation and promotion of clonal expansion of mCAs are key to investigate the role of mCAs in health and disease. Herein, we report on widely measured serum biomarkers and their possible association with mCAs, which could provide new insights into molecular alterations that promote acquisition and clonal expansion. We...]]></summary>
        <author>
            <name>Aubrey K Hubbard</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Serum biomarkers are altered in UK biobank participants with mosaic chromosomal alterations]]></title>
        <id>pubmed:37565819</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37565819/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230820204715&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-08-11T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Age-related clonal expansion of cells harboring mosaic chromosomal alterations (mCAs) is one manifestation of clonal hematopoiesis. Identifying factors that influence the generation and promotion of clonal expansion of mCAs are key to investigate the role of mCAs in health and disease. Herein, we report on widely measured serum biomarkers and their possible association with mCAs, which could provide new insights into molecular alterations that promote acquisition and clonal expansion. We...]]></summary>
        <author>
            <name>Aubrey K Hubbard</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Serum biomarkers are altered in UK biobank participants with mosaic chromosomal alterations]]></title>
        <id>pubmed:37565819</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37565819/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230819204952&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-08-11T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Age-related clonal expansion of cells harboring mosaic chromosomal alterations (mCAs) is one manifestation of clonal hematopoiesis. Identifying factors that influence the generation and promotion of clonal expansion of mCAs are key to investigate the role of mCAs in health and disease. Herein, we report on widely measured serum biomarkers and their possible association with mCAs, which could provide new insights into molecular alterations that promote acquisition and clonal expansion. We...]]></summary>
        <author>
            <name>Aubrey K Hubbard</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Serum biomarkers are altered in UK biobank participants with mosaic chromosomal alterations]]></title>
        <id>pubmed:37565819</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37565819/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230818204446&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-08-11T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Age-related clonal expansion of cells harboring mosaic chromosomal alterations (mCAs) is one manifestation of clonal hematopoiesis. Identifying factors that influence the generation and promotion of clonal expansion of mCAs are key to investigate the role of mCAs in health and disease. Herein, we report on widely measured serum biomarkers and their possible association with mCAs, which could provide new insights into molecular alterations that promote acquisition and clonal expansion. We...]]></summary>
        <author>
            <name>Aubrey K Hubbard</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Serum biomarkers are altered in UK biobank participants with mosaic chromosomal alterations]]></title>
        <id>pubmed:37565819</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37565819/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230817204642&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-08-11T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Age-related clonal expansion of cells harboring mosaic chromosomal alterations (mCAs) is one manifestation of clonal hematopoiesis. Identifying factors that influence the generation and promotion of clonal expansion of mCAs are key to investigate the role of mCAs in health and disease. Herein, we report on widely measured serum biomarkers and their possible association with mCAs, which could provide new insights into molecular alterations that promote acquisition and clonal expansion. We...]]></summary>
        <author>
            <name>Aubrey K Hubbard</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Serum biomarkers are altered in UK biobank participants with mosaic chromosomal alterations]]></title>
        <id>pubmed:37565819</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37565819/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230816204601&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-08-11T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Age-related clonal expansion of cells harboring mosaic chromosomal alterations (mCAs) is one manifestation of clonal hematopoiesis. Identifying factors that influence the generation and promotion of clonal expansion of mCAs are key to investigate the role of mCAs in health and disease. Herein, we report on widely measured serum biomarkers and their possible association with mCAs, which could provide new insights into molecular alterations that promote acquisition and clonal expansion. We...]]></summary>
        <author>
            <name>Aubrey K Hubbard</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Serum biomarkers are altered in UK biobank participants with mosaic chromosomal alterations]]></title>
        <id>pubmed:37565819</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37565819/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230815204647&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-08-11T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Age-related clonal expansion of cells harboring mosaic chromosomal alterations (mCAs) is one manifestation of clonal hematopoiesis. Identifying factors that influence the generation and promotion of clonal expansion of mCAs are key to investigate the role of mCAs in health and disease. Herein, we report on widely measured serum biomarkers and their possible association with mCAs, which could provide new insights into molecular alterations that promote acquisition and clonal expansion. We...]]></summary>
        <author>
            <name>Aubrey K Hubbard</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Serum biomarkers are altered in UK biobank participants with mosaic chromosomal alterations]]></title>
        <id>pubmed:37565819</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37565819/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230814204719&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-08-11T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Age-related clonal expansion of cells harboring mosaic chromosomal alterations (mCAs) is one manifestation of clonal hematopoiesis. Identifying factors that influence the generation and promotion of clonal expansion of mCAs are key to investigate the role of mCAs in health and disease. Herein, we report on widely measured serum biomarkers and their possible association with mCAs, which could provide new insights into molecular alterations that promote acquisition and clonal expansion. We...]]></summary>
        <author>
            <name>Aubrey K Hubbard</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Serum biomarkers are altered in UK biobank participants with mosaic chromosomal alterations]]></title>
        <id>pubmed:37565819</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37565819/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230813204802&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-08-11T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Age-related clonal expansion of cells harboring mosaic chromosomal alterations (mCAs) is one manifestation of clonal hematopoiesis. Identifying factors that influence the generation and promotion of clonal expansion of mCAs are key to investigate the role of mCAs in health and disease. Herein, we report on widely measured serum biomarkers and their possible association with mCAs, which could provide new insights into molecular alterations that promote acquisition and clonal expansion. We...]]></summary>
        <author>
            <name>Aubrey K Hubbard</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Serum biomarkers are altered in UK biobank participants with mosaic chromosomal alterations]]></title>
        <id>pubmed:37565819</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37565819/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230812205008&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-08-11T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Age-related clonal expansion of cells harboring mosaic chromosomal alterations (mCAs) is one manifestation of clonal hematopoiesis. Identifying factors that influence the generation and promotion of clonal expansion of mCAs are key to investigate the role of mCAs in health and disease. Herein, we report on widely measured serum biomarkers and their possible association with mCAs, which could provide new insights into molecular alterations that promote acquisition and clonal expansion. We...]]></summary>
        <author>
            <name>Aubrey K Hubbard</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Serum biomarkers are altered in UK biobank participants with mosaic chromosomal alterations]]></title>
        <id>pubmed:37565819</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37565819/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230811204531&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-08-11T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Age-related clonal expansion of cells harboring mosaic chromosomal alterations (mCAs) is one manifestation of clonal hematopoiesis. Identifying factors that influence the generation and promotion of clonal expansion of mCAs are key to investigate the role of mCAs in health and disease. Herein, we report on widely measured serum biomarkers and their possible association with mCAs, which could provide new insights into molecular alterations that promote acquisition and clonal expansion. We...]]></summary>
        <author>
            <name>Aubrey K Hubbard</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Modulation of bone marrow and peripheral blood cytokine levels by age and clonal hematopoiesis in healthy individuals]]></title>
        <id>pubmed:37562724</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37562724/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230824204823&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-08-10T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Aging is associated with bone marrow (BM) inflammaging and, in some individuals, with the onset of clonal hematopoiesis (CH) of indeterminate potential. In this study conducted on 94 strictly healthy volunteers (18 to 80 yo), we measured BM and peripheral blood (PB) plasma levels of 49 hematopoietic and inflammatory cytokines. With aging, 7 cytokines increased in BM (FLT3L, CXCL9, HGF, FGF-2, CCL27, IL-16, IL-18) and 8 decreased (G-CSF, TNF, IL-2, IL-15, IL-17A, CCL7, IL-4, IL-10). In PB, 10...]]></summary>
        <author>
            <name>Nomie Ravalet</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Modulation of bone marrow and peripheral blood cytokine levels by age and clonal hematopoiesis in healthy individuals]]></title>
        <id>pubmed:37562724</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37562724/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230823204708&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-08-10T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Aging is associated with bone marrow (BM) inflammaging and, in some individuals, with the onset of clonal hematopoiesis (CH) of indeterminate potential. In this study conducted on 94 strictly healthy volunteers (18 to 80 yo), we measured BM and peripheral blood (PB) plasma levels of 49 hematopoietic and inflammatory cytokines. With aging, 7 cytokines increased in BM (FLT3L, CXCL9, HGF, FGF-2, CCL27, IL-16, IL-18) and 8 decreased (G-CSF, TNF, IL-2, IL-15, IL-17A, CCL7, IL-4, IL-10). In PB, 10...]]></summary>
        <author>
            <name>Nomie Ravalet</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Associations Between Cancer Predisposition Mutations and Clonal Hematopoiesis in Patients With Solid Tumors]]></title>
        <id>pubmed:37561983</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37561983/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230823204708&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-08-10T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSION: Our results suggest a close relationship between inherited variants and CH mutations within the DDR genes in patients with solid tumors. Associations identified in this study might translate into enhanced clinical surveillance for CH and associated comorbidities in patients with cancer harboring these germline mutations.]]></summary>
        <author>
            <name>Sebasti Franch-Expsito</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Modulation of bone marrow and peripheral blood cytokine levels by age and clonal hematopoiesis in healthy individuals]]></title>
        <id>pubmed:37562724</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37562724/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230822204709&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-08-10T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Aging is associated with bone marrow (BM) inflammaging and, in some individuals, with the onset of clonal hematopoiesis (CH) of indeterminate potential. In this study conducted on 94 strictly healthy volunteers (18 to 80 yo), we measured BM and peripheral blood (PB) plasma levels of 49 hematopoietic and inflammatory cytokines. With aging, 7 cytokines increased in BM (FLT3L, CXCL9, HGF, FGF-2, CCL27, IL-16, IL-18) and 8 decreased (G-CSF, TNF, IL-2, IL-15, IL-17A, CCL7, IL-4, IL-10). In PB, 10...]]></summary>
        <author>
            <name>Nomie Ravalet</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Associations Between Cancer Predisposition Mutations and Clonal Hematopoiesis in Patients With Solid Tumors]]></title>
        <id>pubmed:37561983</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37561983/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230822204709&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-08-10T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSION: Our results suggest a close relationship between inherited variants and CH mutations within the DDR genes in patients with solid tumors. Associations identified in this study might translate into enhanced clinical surveillance for CH and associated comorbidities in patients with cancer harboring these germline mutations.]]></summary>
        <author>
            <name>Sebasti Franch-Expsito</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Modulation of bone marrow and peripheral blood cytokine levels by age and clonal hematopoiesis in healthy individuals]]></title>
        <id>pubmed:37562724</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37562724/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230821204801&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-08-10T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Aging is associated with bone marrow (BM) inflammaging and, in some individuals, with the onset of clonal hematopoiesis (CH) of indeterminate potential. In this study conducted on 94 strictly healthy volunteers (18 to 80 yo), we measured BM and peripheral blood (PB) plasma levels of 49 hematopoietic and inflammatory cytokines. With aging, 7 cytokines increased in BM (FLT3L, CXCL9, HGF, FGF-2, CCL27, IL-16, IL-18) and 8 decreased (G-CSF, TNF, IL-2, IL-15, IL-17A, CCL7, IL-4, IL-10). In PB, 10...]]></summary>
        <author>
            <name>Nomie Ravalet</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Associations Between Cancer Predisposition Mutations and Clonal Hematopoiesis in Patients With Solid Tumors]]></title>
        <id>pubmed:37561983</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37561983/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230821204801&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-08-10T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSION: Our results suggest a close relationship between inherited variants and CH mutations within the DDR genes in patients with solid tumors. Associations identified in this study might translate into enhanced clinical surveillance for CH and associated comorbidities in patients with cancer harboring these germline mutations.]]></summary>
        <author>
            <name>Sebasti Franch-Expsito</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Transient abnormal myelopoiesis with extramedullary involvement in a down syndrome preemie leading to an unresponsive course despite chemotherapy]]></title>
        <id>pubmed:37560406</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37560406/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230821204801&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-08-10T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[INTRODUCTION: Transient abnormal myelopoiesis (TAM) is a transient, clonal myeloproliferative disorder unique to Down Syndrome (DS) babies. It is characterized by increased peripheral blasts and presence of GATA1 mutation. The clinical spectrum ranges from jaundice and hepatosplenomegaly to multi-organ failure and death. Here we present a case of a premature baby with DS diagnosed to have TAM with extramedullary involvement at birth who had a fatal outcome.]]></summary>
        <author>
            <name>Saroja Devi Geetha</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Modulation of bone marrow and peripheral blood cytokine levels by age and clonal hematopoiesis in healthy individuals]]></title>
        <id>pubmed:37562724</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37562724/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230820204715&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-08-10T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Aging is associated with bone marrow (BM) inflammaging and, in some individuals, with the onset of clonal hematopoiesis (CH) of indeterminate potential. In this study conducted on 94 strictly healthy volunteers (18 to 80 yo), we measured BM and peripheral blood (PB) plasma levels of 49 hematopoietic and inflammatory cytokines. With aging, 7 cytokines increased in BM (FLT3L, CXCL9, HGF, FGF-2, CCL27, IL-16, IL-18) and 8 decreased (G-CSF, TNF, IL-2, IL-15, IL-17A, CCL7, IL-4, IL-10). In PB, 10...]]></summary>
        <author>
            <name>Nomie Ravalet</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Associations Between Cancer Predisposition Mutations and Clonal Hematopoiesis in Patients With Solid Tumors]]></title>
        <id>pubmed:37561983</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37561983/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230820204715&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-08-10T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSION: Our results suggest a close relationship between inherited variants and CH mutations within the DDR genes in patients with solid tumors. Associations identified in this study might translate into enhanced clinical surveillance for CH and associated comorbidities in patients with cancer harboring these germline mutations.]]></summary>
        <author>
            <name>Sebasti Franch-Expsito</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Transient abnormal myelopoiesis with extramedullary involvement in a down syndrome preemie leading to an unresponsive course despite chemotherapy]]></title>
        <id>pubmed:37560406</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37560406/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230820204715&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-08-10T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[INTRODUCTION: Transient abnormal myelopoiesis (TAM) is a transient, clonal myeloproliferative disorder unique to Down Syndrome (DS) babies. It is characterized by increased peripheral blasts and presence of GATA1 mutation. The clinical spectrum ranges from jaundice and hepatosplenomegaly to multi-organ failure and death. Here we present a case of a premature baby with DS diagnosed to have TAM with extramedullary involvement at birth who had a fatal outcome.]]></summary>
        <author>
            <name>Saroja Devi Geetha</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Modulation of bone marrow and peripheral blood cytokine levels by age and clonal hematopoiesis in healthy individuals]]></title>
        <id>pubmed:37562724</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37562724/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230819204952&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-08-10T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Aging is associated with bone marrow (BM) inflammaging and, in some individuals, with the onset of clonal hematopoiesis (CH) of indeterminate potential. In this study conducted on 94 strictly healthy volunteers (18 to 80 yo), we measured BM and peripheral blood (PB) plasma levels of 49 hematopoietic and inflammatory cytokines. With aging, 7 cytokines increased in BM (FLT3L, CXCL9, HGF, FGF-2, CCL27, IL-16, IL-18) and 8 decreased (G-CSF, TNF, IL-2, IL-15, IL-17A, CCL7, IL-4, IL-10). In PB, 10...]]></summary>
        <author>
            <name>Nomie Ravalet</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Associations Between Cancer Predisposition Mutations and Clonal Hematopoiesis in Patients With Solid Tumors]]></title>
        <id>pubmed:37561983</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37561983/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230819204952&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-08-10T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSION: Our results suggest a close relationship between inherited variants and CH mutations within the DDR genes in patients with solid tumors. Associations identified in this study might translate into enhanced clinical surveillance for CH and associated comorbidities in patients with cancer harboring these germline mutations.]]></summary>
        <author>
            <name>Sebasti Franch-Expsito</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Transient abnormal myelopoiesis with extramedullary involvement in a down syndrome preemie leading to an unresponsive course despite chemotherapy]]></title>
        <id>pubmed:37560406</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37560406/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230819204952&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-08-10T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[INTRODUCTION: Transient abnormal myelopoiesis (TAM) is a transient, clonal myeloproliferative disorder unique to Down Syndrome (DS) babies. It is characterized by increased peripheral blasts and presence of GATA1 mutation. The clinical spectrum ranges from jaundice and hepatosplenomegaly to multi-organ failure and death. Here we present a case of a premature baby with DS diagnosed to have TAM with extramedullary involvement at birth who had a fatal outcome.]]></summary>
        <author>
            <name>Saroja Devi Geetha</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Modulation of bone marrow and peripheral blood cytokine levels by age and clonal hematopoiesis in healthy individuals]]></title>
        <id>pubmed:37562724</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37562724/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230818204446&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-08-10T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Aging is associated with bone marrow (BM) inflammaging and, in some individuals, with the onset of clonal hematopoiesis (CH) of indeterminate potential. In this study conducted on 94 strictly healthy volunteers (18 to 80 yo), we measured BM and peripheral blood (PB) plasma levels of 49 hematopoietic and inflammatory cytokines. With aging, 7 cytokines increased in BM (FLT3L, CXCL9, HGF, FGF-2, CCL27, IL-16, IL-18) and 8 decreased (G-CSF, TNF, IL-2, IL-15, IL-17A, CCL7, IL-4, IL-10). In PB, 10...]]></summary>
        <author>
            <name>Nomie Ravalet</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Associations Between Cancer Predisposition Mutations and Clonal Hematopoiesis in Patients With Solid Tumors]]></title>
        <id>pubmed:37561983</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37561983/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230818204446&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-08-10T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSION: Our results suggest a close relationship between inherited variants and CH mutations within the DDR genes in patients with solid tumors. Associations identified in this study might translate into enhanced clinical surveillance for CH and associated comorbidities in patients with cancer harboring these germline mutations.]]></summary>
        <author>
            <name>Sebasti Franch-Expsito</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Transient abnormal myelopoiesis with extramedullary involvement in a down syndrome preemie leading to an unresponsive course despite chemotherapy]]></title>
        <id>pubmed:37560406</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37560406/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230818204446&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-08-10T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[INTRODUCTION: Transient abnormal myelopoiesis (TAM) is a transient, clonal myeloproliferative disorder unique to Down Syndrome (DS) babies. It is characterized by increased peripheral blasts and presence of GATA1 mutation. The clinical spectrum ranges from jaundice and hepatosplenomegaly to multi-organ failure and death. Here we present a case of a premature baby with DS diagnosed to have TAM with extramedullary involvement at birth who had a fatal outcome.]]></summary>
        <author>
            <name>Saroja Devi Geetha</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Modulation of bone marrow and peripheral blood cytokine levels by age and clonal hematopoiesis in healthy individuals]]></title>
        <id>pubmed:37562724</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37562724/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230817204642&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-08-10T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Aging is associated with bone marrow (BM) inflammaging and, in some individuals, with the onset of clonal hematopoiesis (CH) of indeterminate potential. In this study conducted on 94 strictly healthy volunteers (18 to 80 yo), we measured BM and peripheral blood (PB) plasma levels of 49 hematopoietic and inflammatory cytokines. With aging, 7 cytokines increased in BM (FLT3L, CXCL9, HGF, FGF-2, CCL27, IL-16, IL-18) and 8 decreased (G-CSF, TNF, IL-2, IL-15, IL-17A, CCL7, IL-4, IL-10). In PB, 10...]]></summary>
        <author>
            <name>Nomie Ravalet</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Associations Between Cancer Predisposition Mutations and Clonal Hematopoiesis in Patients With Solid Tumors]]></title>
        <id>pubmed:37561983</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37561983/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230817204642&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-08-10T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSION: Our results suggest a close relationship between inherited variants and CH mutations within the DDR genes in patients with solid tumors. Associations identified in this study might translate into enhanced clinical surveillance for CH and associated comorbidities in patients with cancer harboring these germline mutations.]]></summary>
        <author>
            <name>Sebasti Franch-Expsito</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Transient abnormal myelopoiesis with extramedullary involvement in a down syndrome preemie leading to an unresponsive course despite chemotherapy]]></title>
        <id>pubmed:37560406</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37560406/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230817204642&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-08-10T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[INTRODUCTION: Transient abnormal myelopoiesis (TAM) is a transient, clonal myeloproliferative disorder unique to Down Syndrome (DS) babies. It is characterized by increased peripheral blasts and presence of GATA1 mutation. The clinical spectrum ranges from jaundice and hepatosplenomegaly to multi-organ failure and death. Here we present a case of a premature baby with DS diagnosed to have TAM with extramedullary involvement at birth who had a fatal outcome.]]></summary>
        <author>
            <name>Saroja Devi Geetha</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Modulation of bone marrow and peripheral blood cytokine levels by age and clonal hematopoiesis in healthy individuals]]></title>
        <id>pubmed:37562724</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37562724/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230816204601&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-08-10T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Aging is associated with bone marrow (BM) inflammaging and, in some individuals, with the onset of clonal hematopoiesis (CH) of indeterminate potential. In this study conducted on 94 strictly healthy volunteers (18 to 80 yo), we measured BM and peripheral blood (PB) plasma levels of 49 hematopoietic and inflammatory cytokines. With aging, 7 cytokines increased in BM (FLT3L, CXCL9, HGF, FGF-2, CCL27, IL-16, IL-18) and 8 decreased (G-CSF, TNF, IL-2, IL-15, IL-17A, CCL7, IL-4, IL-10). In PB, 10...]]></summary>
        <author>
            <name>Nomie Ravalet</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Associations Between Cancer Predisposition Mutations and Clonal Hematopoiesis in Patients With Solid Tumors]]></title>
        <id>pubmed:37561983</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37561983/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230816204601&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-08-10T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSION: Our results suggest a close relationship between inherited variants and CH mutations within the DDR genes in patients with solid tumors. Associations identified in this study might translate into enhanced clinical surveillance for CH and associated comorbidities in patients with cancer harboring these germline mutations.]]></summary>
        <author>
            <name>Sebasti Franch-Expsito</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Transient abnormal myelopoiesis with extramedullary involvement in a down syndrome preemie leading to an unresponsive course despite chemotherapy]]></title>
        <id>pubmed:37560406</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37560406/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230816204601&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-08-10T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[INTRODUCTION: Transient abnormal myelopoiesis (TAM) is a transient, clonal myeloproliferative disorder unique to Down Syndrome (DS) babies. It is characterized by increased peripheral blasts and presence of GATA1 mutation. The clinical spectrum ranges from jaundice and hepatosplenomegaly to multi-organ failure and death. Here we present a case of a premature baby with DS diagnosed to have TAM with extramedullary involvement at birth who had a fatal outcome.]]></summary>
        <author>
            <name>Saroja Devi Geetha</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Modulation of bone marrow and peripheral blood cytokine levels by age and clonal hematopoiesis in healthy individuals]]></title>
        <id>pubmed:37562724</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37562724/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230815204647&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-08-10T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Aging is associated with bone marrow (BM) inflammaging and, in some individuals, with the onset of clonal hematopoiesis (CH) of indeterminate potential. In this study conducted on 94 strictly healthy volunteers (18 to 80 yo), we measured BM and peripheral blood (PB) plasma levels of 49 hematopoietic and inflammatory cytokines. With aging, 7 cytokines increased in BM (FLT3L, CXCL9, HGF, FGF-2, CCL27, IL-16, IL-18) and 8 decreased (G-CSF, TNF, IL-2, IL-15, IL-17A, CCL7, IL-4, IL-10). In PB, 10...]]></summary>
        <author>
            <name>Nomie Ravalet</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Associations Between Cancer Predisposition Mutations and Clonal Hematopoiesis in Patients With Solid Tumors]]></title>
        <id>pubmed:37561983</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37561983/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230815204647&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-08-10T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSION: Our results suggest a close relationship between inherited variants and CH mutations within the DDR genes in patients with solid tumors. Associations identified in this study might translate into enhanced clinical surveillance for CH and associated comorbidities in patients with cancer harboring these germline mutations.]]></summary>
        <author>
            <name>Sebasti Franch-Expsito</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Transient abnormal myelopoiesis with extramedullary involvement in a down syndrome preemie leading to an unresponsive course despite chemotherapy]]></title>
        <id>pubmed:37560406</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37560406/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230815204647&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-08-10T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[INTRODUCTION: Transient abnormal myelopoiesis (TAM) is a transient, clonal myeloproliferative disorder unique to Down Syndrome (DS) babies. It is characterized by increased peripheral blasts and presence of GATA1 mutation. The clinical spectrum ranges from jaundice and hepatosplenomegaly to multi-organ failure and death. Here we present a case of a premature baby with DS diagnosed to have TAM with extramedullary involvement at birth who had a fatal outcome.]]></summary>
        <author>
            <name>Saroja Devi Geetha</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Modulation of bone marrow and peripheral blood cytokine levels by age and clonal hematopoiesis in healthy individuals]]></title>
        <id>pubmed:37562724</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37562724/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230814204719&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-08-10T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Aging is associated with bone marrow (BM) inflammaging and, in some individuals, with the onset of clonal hematopoiesis (CH) of indeterminate potential. In this study conducted on 94 strictly healthy volunteers (18 to 80 yo), we measured BM and peripheral blood (PB) plasma levels of 49 hematopoietic and inflammatory cytokines. With aging, 7 cytokines increased in BM (FLT3L, CXCL9, HGF, FGF-2, CCL27, IL-16, IL-18) and 8 decreased (G-CSF, TNF, IL-2, IL-15, IL-17A, CCL7, IL-4, IL-10). In PB, 10...]]></summary>
        <author>
            <name>Nomie Ravalet</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Associations Between Cancer Predisposition Mutations and Clonal Hematopoiesis in Patients With Solid Tumors]]></title>
        <id>pubmed:37561983</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37561983/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230814204719&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-08-10T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSION: Our results suggest a close relationship between inherited variants and CH mutations within the DDR genes in patients with solid tumors. Associations identified in this study might translate into enhanced clinical surveillance for CH and associated comorbidities in patients with cancer harboring these germline mutations.]]></summary>
        <author>
            <name>Sebasti Franch-Expsito</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Transient abnormal myelopoiesis with extramedullary involvement in a down syndrome preemie leading to an unresponsive course despite chemotherapy]]></title>
        <id>pubmed:37560406</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37560406/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230814204719&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-08-10T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[INTRODUCTION: Transient abnormal myelopoiesis (TAM) is a transient, clonal myeloproliferative disorder unique to Down Syndrome (DS) babies. It is characterized by increased peripheral blasts and presence of GATA1 mutation. The clinical spectrum ranges from jaundice and hepatosplenomegaly to multi-organ failure and death. Here we present a case of a premature baby with DS diagnosed to have TAM with extramedullary involvement at birth who had a fatal outcome.]]></summary>
        <author>
            <name>Saroja Devi Geetha</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Modulation of bone marrow and peripheral blood cytokine levels by age and clonal hematopoiesis in healthy individuals]]></title>
        <id>pubmed:37562724</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37562724/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230813204802&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-08-10T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Aging is associated with bone marrow (BM) inflammaging and, in some individuals, with the onset of clonal hematopoiesis (CH) of indeterminate potential. In this study conducted on 94 strictly healthy volunteers (18 to 80 yo), we measured BM and peripheral blood (PB) plasma levels of 49 hematopoietic and inflammatory cytokines. With aging, 7 cytokines increased in BM (FLT3L, CXCL9, HGF, FGF-2, CCL27, IL-16, IL-18) and 8 decreased (G-CSF, TNF, IL-2, IL-15, IL-17A, CCL7, IL-4, IL-10). In PB, 10...]]></summary>
        <author>
            <name>Nomie Ravalet</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Associations Between Cancer Predisposition Mutations and Clonal Hematopoiesis in Patients With Solid Tumors]]></title>
        <id>pubmed:37561983</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37561983/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230813204802&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-08-10T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSION: Our results suggest a close relationship between inherited variants and CH mutations within the DDR genes in patients with solid tumors. Associations identified in this study might translate into enhanced clinical surveillance for CH and associated comorbidities in patients with cancer harboring these germline mutations.]]></summary>
        <author>
            <name>Sebasti Franch-Expsito</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Transient abnormal myelopoiesis with extramedullary involvement in a down syndrome preemie leading to an unresponsive course despite chemotherapy]]></title>
        <id>pubmed:37560406</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37560406/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230813204802&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-08-10T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[INTRODUCTION: Transient abnormal myelopoiesis (TAM) is a transient, clonal myeloproliferative disorder unique to Down Syndrome (DS) babies. It is characterized by increased peripheral blasts and presence of GATA1 mutation. The clinical spectrum ranges from jaundice and hepatosplenomegaly to multi-organ failure and death. Here we present a case of a premature baby with DS diagnosed to have TAM with extramedullary involvement at birth who had a fatal outcome.]]></summary>
        <author>
            <name>Saroja Devi Geetha</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Modulation of bone marrow and peripheral blood cytokine levels by age and clonal hematopoiesis in healthy individuals]]></title>
        <id>pubmed:37562724</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37562724/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230812205008&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-08-10T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Aging is associated with bone marrow (BM) inflammaging and, in some individuals, with the onset of clonal hematopoiesis (CH) of indeterminate potential. In this study conducted on 94 strictly healthy volunteers (18 to 80 yo), we measured BM and peripheral blood (PB) plasma levels of 49 hematopoietic and inflammatory cytokines. With aging, 7 cytokines increased in BM (FLT3L, CXCL9, HGF, FGF-2, CCL27, IL-16, IL-18) and 8 decreased (G-CSF, TNF, IL-2, IL-15, IL-17A, CCL7, IL-4, IL-10). In PB, 10...]]></summary>
        <author>
            <name>Nomie Ravalet</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Associations Between Cancer Predisposition Mutations and Clonal Hematopoiesis in Patients With Solid Tumors]]></title>
        <id>pubmed:37561983</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37561983/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230812205008&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-08-10T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSION: Our results suggest a close relationship between inherited variants and CH mutations within the DDR genes in patients with solid tumors. Associations identified in this study might translate into enhanced clinical surveillance for CH and associated comorbidities in patients with cancer harboring these germline mutations.]]></summary>
        <author>
            <name>Sebasti Franch-Expsito</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Transient abnormal myelopoiesis with extramedullary involvement in a down syndrome preemie leading to an unresponsive course despite chemotherapy]]></title>
        <id>pubmed:37560406</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37560406/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230812205008&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-08-10T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[INTRODUCTION: Transient abnormal myelopoiesis (TAM) is a transient, clonal myeloproliferative disorder unique to Down Syndrome (DS) babies. It is characterized by increased peripheral blasts and presence of GATA1 mutation. The clinical spectrum ranges from jaundice and hepatosplenomegaly to multi-organ failure and death. Here we present a case of a premature baby with DS diagnosed to have TAM with extramedullary involvement at birth who had a fatal outcome.]]></summary>
        <author>
            <name>Saroja Devi Geetha</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Modulation of bone marrow and peripheral blood cytokine levels by age and clonal hematopoiesis in healthy individuals]]></title>
        <id>pubmed:37562724</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37562724/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230811204531&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-08-10T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Aging is associated with bone marrow (BM) inflammaging and, in some individuals, with the onset of clonal hematopoiesis (CH) of indeterminate potential. In this study conducted on 94 strictly healthy volunteers (18 to 80 yo), we measured BM and peripheral blood (PB) plasma levels of 49 hematopoietic and inflammatory cytokines. With aging, 7 cytokines increased in BM (FLT3L, CXCL9, HGF, FGF-2, CCL27, IL-16, IL-18) and 8 decreased (G-CSF, TNF, IL-2, IL-15, IL-17A, CCL7, IL-4, IL-10). In PB, 10...]]></summary>
        <author>
            <name>Nomie Ravalet</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Associations Between Cancer Predisposition Mutations and Clonal Hematopoiesis in Patients With Solid Tumors]]></title>
        <id>pubmed:37561983</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37561983/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230811204531&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-08-10T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSION: Our results suggest a close relationship between inherited variants and CH mutations within the DDR genes in patients with solid tumors. Associations identified in this study might translate into enhanced clinical surveillance for CH and associated comorbidities in patients with cancer harboring these germline mutations.]]></summary>
        <author>
            <name>Sebasti Franch-Expsito</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Transient abnormal myelopoiesis with extramedullary involvement in a down syndrome preemie leading to an unresponsive course despite chemotherapy]]></title>
        <id>pubmed:37560406</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37560406/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230811204531&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-08-10T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[INTRODUCTION: Transient abnormal myelopoiesis (TAM) is a transient, clonal myeloproliferative disorder unique to Down Syndrome (DS) babies. It is characterized by increased peripheral blasts and presence of GATA1 mutation. The clinical spectrum ranges from jaundice and hepatosplenomegaly to multi-organ failure and death. Here we present a case of a premature baby with DS diagnosed to have TAM with extramedullary involvement at birth who had a fatal outcome.]]></summary>
        <author>
            <name>Saroja Devi Geetha</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Associations Between Cancer Predisposition Mutations and Clonal Hematopoiesis in Patients With Solid Tumors]]></title>
        <id>pubmed:37561983</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37561983/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230810204637&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-08-10T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSION: Our results suggest a close relationship between inherited variants and CH mutations within the DDR genes in patients with solid tumors. Associations identified in this study might translate into enhanced clinical surveillance for CH and associated comorbidities in patients with cancer harboring these germline mutations.]]></summary>
        <author>
            <name>Sebasti Franch-Expsito</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Transient abnormal myelopoiesis with extramedullary involvement in a down syndrome preemie leading to an unresponsive course despite chemotherapy]]></title>
        <id>pubmed:37560406</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37560406/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230810204637&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-08-10T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[INTRODUCTION: Transient abnormal myelopoiesis (TAM) is a transient, clonal myeloproliferative disorder unique to Down Syndrome (DS) babies. It is characterized by increased peripheral blasts and presence of GATA1 mutation. The clinical spectrum ranges from jaundice and hepatosplenomegaly to multi-organ failure and death. Here we present a case of a premature baby with DS diagnosed to have TAM with extramedullary involvement at birth who had a fatal outcome.]]></summary>
        <author>
            <name>Saroja Devi Geetha</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Associations Between Cancer Predisposition Mutations and Clonal Hematopoiesis in Patients With Solid Tumors]]></title>
        <id>pubmed:37561983</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37561983/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230903204939&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-08-10T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSION: Our results suggest a close relationship between inherited variants and CH mutations within the DDR genes in patients with solid tumors. Associations identified in this study might translate into enhanced clinical surveillance for CH and associated comorbidities in patients with cancer harboring these germline mutations.]]></summary>
        <author>
            <name>Sebasti Franch-Expsito</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Associations Between Cancer Predisposition Mutations and Clonal Hematopoiesis in Patients With Solid Tumors]]></title>
        <id>pubmed:37561983</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37561983/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230902205121&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-08-10T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSION: Our results suggest a close relationship between inherited variants and CH mutations within the DDR genes in patients with solid tumors. Associations identified in this study might translate into enhanced clinical surveillance for CH and associated comorbidities in patients with cancer harboring these germline mutations.]]></summary>
        <author>
            <name>Sebasti Franch-Expsito</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Associations Between Cancer Predisposition Mutations and Clonal Hematopoiesis in Patients With Solid Tumors]]></title>
        <id>pubmed:37561983</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37561983/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230901204619&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-08-10T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSION: Our results suggest a close relationship between inherited variants and CH mutations within the DDR genes in patients with solid tumors. Associations identified in this study might translate into enhanced clinical surveillance for CH and associated comorbidities in patients with cancer harboring these germline mutations.]]></summary>
        <author>
            <name>Sebasti Franch-Expsito</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Associations Between Cancer Predisposition Mutations and Clonal Hematopoiesis in Patients With Solid Tumors]]></title>
        <id>pubmed:37561983</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37561983/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230831205203&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-08-10T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSION: Our results suggest a close relationship between inherited variants and CH mutations within the DDR genes in patients with solid tumors. Associations identified in this study might translate into enhanced clinical surveillance for CH and associated comorbidities in patients with cancer harboring these germline mutations.]]></summary>
        <author>
            <name>Sebasti Franch-Expsito</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Associations Between Cancer Predisposition Mutations and Clonal Hematopoiesis in Patients With Solid Tumors]]></title>
        <id>pubmed:37561983</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37561983/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230830204850&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-08-10T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSION: Our results suggest a close relationship between inherited variants and CH mutations within the DDR genes in patients with solid tumors. Associations identified in this study might translate into enhanced clinical surveillance for CH and associated comorbidities in patients with cancer harboring these germline mutations.]]></summary>
        <author>
            <name>Sebasti Franch-Expsito</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Associations Between Cancer Predisposition Mutations and Clonal Hematopoiesis in Patients With Solid Tumors]]></title>
        <id>pubmed:37561983</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37561983/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230829204824&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-08-10T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSION: Our results suggest a close relationship between inherited variants and CH mutations within the DDR genes in patients with solid tumors. Associations identified in this study might translate into enhanced clinical surveillance for CH and associated comorbidities in patients with cancer harboring these germline mutations.]]></summary>
        <author>
            <name>Sebasti Franch-Expsito</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Associations Between Cancer Predisposition Mutations and Clonal Hematopoiesis in Patients With Solid Tumors]]></title>
        <id>pubmed:37561983</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37561983/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230828204854&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-08-10T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSION: Our results suggest a close relationship between inherited variants and CH mutations within the DDR genes in patients with solid tumors. Associations identified in this study might translate into enhanced clinical surveillance for CH and associated comorbidities in patients with cancer harboring these germline mutations.]]></summary>
        <author>
            <name>Sebasti Franch-Expsito</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Associations Between Cancer Predisposition Mutations and Clonal Hematopoiesis in Patients With Solid Tumors]]></title>
        <id>pubmed:37561983</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37561983/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230827204908&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-08-10T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSION: Our results suggest a close relationship between inherited variants and CH mutations within the DDR genes in patients with solid tumors. Associations identified in this study might translate into enhanced clinical surveillance for CH and associated comorbidities in patients with cancer harboring these germline mutations.]]></summary>
        <author>
            <name>Sebasti Franch-Expsito</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Associations Between Cancer Predisposition Mutations and Clonal Hematopoiesis in Patients With Solid Tumors]]></title>
        <id>pubmed:37561983</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37561983/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230826205107&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-08-10T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSION: Our results suggest a close relationship between inherited variants and CH mutations within the DDR genes in patients with solid tumors. Associations identified in this study might translate into enhanced clinical surveillance for CH and associated comorbidities in patients with cancer harboring these germline mutations.]]></summary>
        <author>
            <name>Sebasti Franch-Expsito</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Associations Between Cancer Predisposition Mutations and Clonal Hematopoiesis in Patients With Solid Tumors]]></title>
        <id>pubmed:37561983</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37561983/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230825204602&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-08-10T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSION: Our results suggest a close relationship between inherited variants and CH mutations within the DDR genes in patients with solid tumors. Associations identified in this study might translate into enhanced clinical surveillance for CH and associated comorbidities in patients with cancer harboring these germline mutations.]]></summary>
        <author>
            <name>Sebasti Franch-Expsito</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Associations Between Cancer Predisposition Mutations and Clonal Hematopoiesis in Patients With Solid Tumors]]></title>
        <id>pubmed:37561983</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37561983/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230824204824&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-08-10T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSION: Our results suggest a close relationship between inherited variants and CH mutations within the DDR genes in patients with solid tumors. Associations identified in this study might translate into enhanced clinical surveillance for CH and associated comorbidities in patients with cancer harboring these germline mutations.]]></summary>
        <author>
            <name>Sebasti Franch-Expsito</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Associations Between Cancer Predisposition Mutations and Clonal Hematopoiesis in Patients With Solid Tumors]]></title>
        <id>pubmed:37561983</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37561983/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230823204708&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-08-10T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSION: Our results suggest a close relationship between inherited variants and CH mutations within the DDR genes in patients with solid tumors. Associations identified in this study might translate into enhanced clinical surveillance for CH and associated comorbidities in patients with cancer harboring these germline mutations.]]></summary>
        <author>
            <name>Sebasti Franch-Expsito</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Associations Between Cancer Predisposition Mutations and Clonal Hematopoiesis in Patients With Solid Tumors]]></title>
        <id>pubmed:37561983</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37561983/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230822204709&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-08-10T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSION: Our results suggest a close relationship between inherited variants and CH mutations within the DDR genes in patients with solid tumors. Associations identified in this study might translate into enhanced clinical surveillance for CH and associated comorbidities in patients with cancer harboring these germline mutations.]]></summary>
        <author>
            <name>Sebasti Franch-Expsito</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Associations Between Cancer Predisposition Mutations and Clonal Hematopoiesis in Patients With Solid Tumors]]></title>
        <id>pubmed:37561983</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37561983/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230821204801&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-08-10T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSION: Our results suggest a close relationship between inherited variants and CH mutations within the DDR genes in patients with solid tumors. Associations identified in this study might translate into enhanced clinical surveillance for CH and associated comorbidities in patients with cancer harboring these germline mutations.]]></summary>
        <author>
            <name>Sebasti Franch-Expsito</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Associations Between Cancer Predisposition Mutations and Clonal Hematopoiesis in Patients With Solid Tumors]]></title>
        <id>pubmed:37561983</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37561983/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230820204715&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-08-10T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSION: Our results suggest a close relationship between inherited variants and CH mutations within the DDR genes in patients with solid tumors. Associations identified in this study might translate into enhanced clinical surveillance for CH and associated comorbidities in patients with cancer harboring these germline mutations.]]></summary>
        <author>
            <name>Sebasti Franch-Expsito</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Associations Between Cancer Predisposition Mutations and Clonal Hematopoiesis in Patients With Solid Tumors]]></title>
        <id>pubmed:37561983</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37561983/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230819204952&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-08-10T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSION: Our results suggest a close relationship between inherited variants and CH mutations within the DDR genes in patients with solid tumors. Associations identified in this study might translate into enhanced clinical surveillance for CH and associated comorbidities in patients with cancer harboring these germline mutations.]]></summary>
        <author>
            <name>Sebasti Franch-Expsito</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Associations Between Cancer Predisposition Mutations and Clonal Hematopoiesis in Patients With Solid Tumors]]></title>
        <id>pubmed:37561983</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37561983/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230818204446&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-08-10T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSION: Our results suggest a close relationship between inherited variants and CH mutations within the DDR genes in patients with solid tumors. Associations identified in this study might translate into enhanced clinical surveillance for CH and associated comorbidities in patients with cancer harboring these germline mutations.]]></summary>
        <author>
            <name>Sebasti Franch-Expsito</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Associations Between Cancer Predisposition Mutations and Clonal Hematopoiesis in Patients With Solid Tumors]]></title>
        <id>pubmed:37561983</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37561983/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230817204642&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-08-10T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSION: Our results suggest a close relationship between inherited variants and CH mutations within the DDR genes in patients with solid tumors. Associations identified in this study might translate into enhanced clinical surveillance for CH and associated comorbidities in patients with cancer harboring these germline mutations.]]></summary>
        <author>
            <name>Sebasti Franch-Expsito</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Associations Between Cancer Predisposition Mutations and Clonal Hematopoiesis in Patients With Solid Tumors]]></title>
        <id>pubmed:37561983</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37561983/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230816204600&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-08-10T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSION: Our results suggest a close relationship between inherited variants and CH mutations within the DDR genes in patients with solid tumors. Associations identified in this study might translate into enhanced clinical surveillance for CH and associated comorbidities in patients with cancer harboring these germline mutations.]]></summary>
        <author>
            <name>Sebasti Franch-Expsito</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Associations Between Cancer Predisposition Mutations and Clonal Hematopoiesis in Patients With Solid Tumors]]></title>
        <id>pubmed:37561983</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37561983/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230815204647&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-08-10T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSION: Our results suggest a close relationship between inherited variants and CH mutations within the DDR genes in patients with solid tumors. Associations identified in this study might translate into enhanced clinical surveillance for CH and associated comorbidities in patients with cancer harboring these germline mutations.]]></summary>
        <author>
            <name>Sebasti Franch-Expsito</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Associations Between Cancer Predisposition Mutations and Clonal Hematopoiesis in Patients With Solid Tumors]]></title>
        <id>pubmed:37561983</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37561983/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230814204719&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-08-10T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSION: Our results suggest a close relationship between inherited variants and CH mutations within the DDR genes in patients with solid tumors. Associations identified in this study might translate into enhanced clinical surveillance for CH and associated comorbidities in patients with cancer harboring these germline mutations.]]></summary>
        <author>
            <name>Sebasti Franch-Expsito</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Different niches for stem cells carrying the same oncogenic driver affect pathogenesis and therapy response in myeloproliferative neoplasms]]></title>
        <id>pubmed:37550517</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37550517/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230821204801&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-08-07T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Aging facilitates the expansion of hematopoietic stem cells (HSCs) carrying clonal hematopoiesis-related somatic mutations and the development of myeloid malignancies, such as myeloproliferative neoplasms (MPNs). While cooperating mutations can cause transformation, it is unclear whether distinct bone marrow (BM) HSC-niches can influence the growth and therapy response of HSCs carrying the same oncogenic driver. Here we found different BM niches for HSCs in MPN subtypes. JAK-STAT signaling...]]></summary>
        <author>
            <name>Elodie Grockowiak</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Different niches for stem cells carrying the same oncogenic driver affect pathogenesis and therapy response in myeloproliferative neoplasms]]></title>
        <id>pubmed:37550517</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37550517/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230820204715&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-08-07T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Aging facilitates the expansion of hematopoietic stem cells (HSCs) carrying clonal hematopoiesis-related somatic mutations and the development of myeloid malignancies, such as myeloproliferative neoplasms (MPNs). While cooperating mutations can cause transformation, it is unclear whether distinct bone marrow (BM) HSC-niches can influence the growth and therapy response of HSCs carrying the same oncogenic driver. Here we found different BM niches for HSCs in MPN subtypes. JAK-STAT signaling...]]></summary>
        <author>
            <name>Elodie Grockowiak</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Short-term western diet causes rapid and lasting alterations of bone marrow physiology]]></title>
        <id>pubmed:37549687</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37549687/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230820204715&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-08-07T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Dietary factors have a significant impact on overall health and western diet (WD) disrupts arterial homeostasis, thereby promoting atherosclerosis. In our study, we investigated the effects of short-term WD on bone marrow vasculature and hematopoiesis in hypercholesterolemic mice. We found that WD rapidly remodels bone marrow arterioles, and these alterations persist even after WD cessation. The proximity between hematopoietic stem cells (HSCs) and arterioles increased with short-term WD, which...]]></summary>
        <author>
            <name>Mariaelvy Bianchini</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Immune dysregulation and potential targeted therapy in myelodysplastic syndrome]]></title>
        <id>pubmed:37547364</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37547364/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230820204715&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-08-07T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Myelodysplastic syndrome (MDS) is a heterogeneous group of clonal hematological diseases and a high risk for transformation to acute myeloid leukemia (AML). The identification of key genetic alterations in MDS has enhanced our understanding of the pathogenesis and evolution. In recent years, it has been found that both innate and adaptive immune signaling are activated in the hematopoietic niche of MDS with aberrant cytokine secretion in the bone marrow microenvironment. It is also clear that...]]></summary>
        <author>
            <name>Xiaoying Zhang</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Different niches for stem cells carrying the same oncogenic driver affect pathogenesis and therapy response in myeloproliferative neoplasms]]></title>
        <id>pubmed:37550517</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37550517/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230819204952&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-08-07T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Aging facilitates the expansion of hematopoietic stem cells (HSCs) carrying clonal hematopoiesis-related somatic mutations and the development of myeloid malignancies, such as myeloproliferative neoplasms (MPNs). While cooperating mutations can cause transformation, it is unclear whether distinct bone marrow (BM) HSC-niches can influence the growth and therapy response of HSCs carrying the same oncogenic driver. Here we found different BM niches for HSCs in MPN subtypes. JAK-STAT signaling...]]></summary>
        <author>
            <name>Elodie Grockowiak</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Short-term western diet causes rapid and lasting alterations of bone marrow physiology]]></title>
        <id>pubmed:37549687</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37549687/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230819204952&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-08-07T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Dietary factors have a significant impact on overall health and western diet (WD) disrupts arterial homeostasis, thereby promoting atherosclerosis. In our study, we investigated the effects of short-term WD on bone marrow vasculature and hematopoiesis in hypercholesterolemic mice. We found that WD rapidly remodels bone marrow arterioles, and these alterations persist even after WD cessation. The proximity between hematopoietic stem cells (HSCs) and arterioles increased with short-term WD, which...]]></summary>
        <author>
            <name>Mariaelvy Bianchini</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Immune dysregulation and potential targeted therapy in myelodysplastic syndrome]]></title>
        <id>pubmed:37547364</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37547364/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230819204952&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-08-07T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Myelodysplastic syndrome (MDS) is a heterogeneous group of clonal hematological diseases and a high risk for transformation to acute myeloid leukemia (AML). The identification of key genetic alterations in MDS has enhanced our understanding of the pathogenesis and evolution. In recent years, it has been found that both innate and adaptive immune signaling are activated in the hematopoietic niche of MDS with aberrant cytokine secretion in the bone marrow microenvironment. It is also clear that...]]></summary>
        <author>
            <name>Xiaoying Zhang</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Different niches for stem cells carrying the same oncogenic driver affect pathogenesis and therapy response in myeloproliferative neoplasms]]></title>
        <id>pubmed:37550517</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37550517/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230818204446&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-08-07T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Aging facilitates the expansion of hematopoietic stem cells (HSCs) carrying clonal hematopoiesis-related somatic mutations and the development of myeloid malignancies, such as myeloproliferative neoplasms (MPNs). While cooperating mutations can cause transformation, it is unclear whether distinct bone marrow (BM) HSC-niches can influence the growth and therapy response of HSCs carrying the same oncogenic driver. Here we found different BM niches for HSCs in MPN subtypes. JAK-STAT signaling...]]></summary>
        <author>
            <name>Elodie Grockowiak</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Short-term western diet causes rapid and lasting alterations of bone marrow physiology]]></title>
        <id>pubmed:37549687</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37549687/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230818204446&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-08-07T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Dietary factors have a significant impact on overall health and western diet (WD) disrupts arterial homeostasis, thereby promoting atherosclerosis. In our study, we investigated the effects of short-term WD on bone marrow vasculature and hematopoiesis in hypercholesterolemic mice. We found that WD rapidly remodels bone marrow arterioles, and these alterations persist even after WD cessation. The proximity between hematopoietic stem cells (HSCs) and arterioles increased with short-term WD, which...]]></summary>
        <author>
            <name>Mariaelvy Bianchini</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Immune dysregulation and potential targeted therapy in myelodysplastic syndrome]]></title>
        <id>pubmed:37547364</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37547364/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230818204446&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-08-07T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Myelodysplastic syndrome (MDS) is a heterogeneous group of clonal hematological diseases and a high risk for transformation to acute myeloid leukemia (AML). The identification of key genetic alterations in MDS has enhanced our understanding of the pathogenesis and evolution. In recent years, it has been found that both innate and adaptive immune signaling are activated in the hematopoietic niche of MDS with aberrant cytokine secretion in the bone marrow microenvironment. It is also clear that...]]></summary>
        <author>
            <name>Xiaoying Zhang</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Leukocytes carrying <em>Clonal Hematopoiesis of Indeterminate Potential</em> (CHIP) Mutations invade Human Atherosclerotic Plaques]]></title>
        <id>pubmed:37546840</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37546840/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230818204446&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-08-07T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSIONS: Deep-DNA-sequencing reveals a high prevalence of CHIP mutations in whole blood of CAD patients. CHIP-affected leukocytes invade plaques in human coronary arteries. RNAseq data obtained from macrophages of CHIP-affected patients suggest that pro-atherosclerotic signaling differs depending on the underlying mutations. Further studies are necessary to understand whether specific pathways affected by CHIP mutations may be targeted for personalized treatment.]]></summary>
        <author>
            <name>Moritz von Scheidt</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Different niches for stem cells carrying the same oncogenic driver affect pathogenesis and therapy response in myeloproliferative neoplasms]]></title>
        <id>pubmed:37550517</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37550517/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230817204642&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-08-07T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Aging facilitates the expansion of hematopoietic stem cells (HSCs) carrying clonal hematopoiesis-related somatic mutations and the development of myeloid malignancies, such as myeloproliferative neoplasms (MPNs). While cooperating mutations can cause transformation, it is unclear whether distinct bone marrow (BM) HSC-niches can influence the growth and therapy response of HSCs carrying the same oncogenic driver. Here we found different BM niches for HSCs in MPN subtypes. JAK-STAT signaling...]]></summary>
        <author>
            <name>Elodie Grockowiak</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Short-term western diet causes rapid and lasting alterations of bone marrow physiology]]></title>
        <id>pubmed:37549687</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37549687/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230817204642&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-08-07T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Dietary factors have a significant impact on overall health and western diet (WD) disrupts arterial homeostasis, thereby promoting atherosclerosis. In our study, we investigated the effects of short-term WD on bone marrow vasculature and hematopoiesis in hypercholesterolemic mice. We found that WD rapidly remodels bone marrow arterioles, and these alterations persist even after WD cessation. The proximity between hematopoietic stem cells (HSCs) and arterioles increased with short-term WD, which...]]></summary>
        <author>
            <name>Mariaelvy Bianchini</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Immune dysregulation and potential targeted therapy in myelodysplastic syndrome]]></title>
        <id>pubmed:37547364</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37547364/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230817204642&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-08-07T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Myelodysplastic syndrome (MDS) is a heterogeneous group of clonal hematological diseases and a high risk for transformation to acute myeloid leukemia (AML). The identification of key genetic alterations in MDS has enhanced our understanding of the pathogenesis and evolution. In recent years, it has been found that both innate and adaptive immune signaling are activated in the hematopoietic niche of MDS with aberrant cytokine secretion in the bone marrow microenvironment. It is also clear that...]]></summary>
        <author>
            <name>Xiaoying Zhang</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Leukocytes carrying <em>Clonal Hematopoiesis of Indeterminate Potential</em> (CHIP) Mutations invade Human Atherosclerotic Plaques]]></title>
        <id>pubmed:37546840</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37546840/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230817204642&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-08-07T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSIONS: Deep-DNA-sequencing reveals a high prevalence of CHIP mutations in whole blood of CAD patients. CHIP-affected leukocytes invade plaques in human coronary arteries. RNAseq data obtained from macrophages of CHIP-affected patients suggest that pro-atherosclerotic signaling differs depending on the underlying mutations. Further studies are necessary to understand whether specific pathways affected by CHIP mutations may be targeted for personalized treatment.]]></summary>
        <author>
            <name>Moritz von Scheidt</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Cigarette smoke stimulates clonal expansion of Jak2<sup>V617F</sup> and Tet2<sup>-/-</sup> cells]]></title>
        <id>pubmed:37546389</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37546389/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230817204642&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-08-07T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSION: Altogether, these findings demonstrate that CS results in an inflamed bone marrow environment that provides a selection pressure for existing CHIP mutations such as Jak2V617F and Tet2 loss-of-function.]]></summary>
        <author>
            <name>Gajalakshmi Ramanathan</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Different niches for stem cells carrying the same oncogenic driver affect pathogenesis and therapy response in myeloproliferative neoplasms]]></title>
        <id>pubmed:37550517</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37550517/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230816204601&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-08-07T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Aging facilitates the expansion of hematopoietic stem cells (HSCs) carrying clonal hematopoiesis-related somatic mutations and the development of myeloid malignancies, such as myeloproliferative neoplasms (MPNs). While cooperating mutations can cause transformation, it is unclear whether distinct bone marrow (BM) HSC-niches can influence the growth and therapy response of HSCs carrying the same oncogenic driver. Here we found different BM niches for HSCs in MPN subtypes. JAK-STAT signaling...]]></summary>
        <author>
            <name>Elodie Grockowiak</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Short-term western diet causes rapid and lasting alterations of bone marrow physiology]]></title>
        <id>pubmed:37549687</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37549687/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230816204601&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-08-07T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Dietary factors have a significant impact on overall health and western diet (WD) disrupts arterial homeostasis, thereby promoting atherosclerosis. In our study, we investigated the effects of short-term WD on bone marrow vasculature and hematopoiesis in hypercholesterolemic mice. We found that WD rapidly remodels bone marrow arterioles, and these alterations persist even after WD cessation. The proximity between hematopoietic stem cells (HSCs) and arterioles increased with short-term WD, which...]]></summary>
        <author>
            <name>Mariaelvy Bianchini</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Immune dysregulation and potential targeted therapy in myelodysplastic syndrome]]></title>
        <id>pubmed:37547364</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37547364/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230816204601&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-08-07T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Myelodysplastic syndrome (MDS) is a heterogeneous group of clonal hematological diseases and a high risk for transformation to acute myeloid leukemia (AML). The identification of key genetic alterations in MDS has enhanced our understanding of the pathogenesis and evolution. In recent years, it has been found that both innate and adaptive immune signaling are activated in the hematopoietic niche of MDS with aberrant cytokine secretion in the bone marrow microenvironment. It is also clear that...]]></summary>
        <author>
            <name>Xiaoying Zhang</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Leukocytes carrying <em>Clonal Hematopoiesis of Indeterminate Potential</em> (CHIP) Mutations invade Human Atherosclerotic Plaques]]></title>
        <id>pubmed:37546840</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37546840/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230816204601&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-08-07T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSIONS: Deep-DNA-sequencing reveals a high prevalence of CHIP mutations in whole blood of CAD patients. CHIP-affected leukocytes invade plaques in human coronary arteries. RNAseq data obtained from macrophages of CHIP-affected patients suggest that pro-atherosclerotic signaling differs depending on the underlying mutations. Further studies are necessary to understand whether specific pathways affected by CHIP mutations may be targeted for personalized treatment.]]></summary>
        <author>
            <name>Moritz von Scheidt</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Cigarette smoke stimulates clonal expansion of Jak2<sup>V617F</sup> and Tet2<sup>-/-</sup> cells]]></title>
        <id>pubmed:37546389</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37546389/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230816204601&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-08-07T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSION: Altogether, these findings demonstrate that CS results in an inflamed bone marrow environment that provides a selection pressure for existing CHIP mutations such as Jak2V617F and Tet2 loss-of-function.]]></summary>
        <author>
            <name>Gajalakshmi Ramanathan</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Different niches for stem cells carrying the same oncogenic driver affect pathogenesis and therapy response in myeloproliferative neoplasms]]></title>
        <id>pubmed:37550517</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37550517/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230815204647&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-08-07T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Aging facilitates the expansion of hematopoietic stem cells (HSCs) carrying clonal hematopoiesis-related somatic mutations and the development of myeloid malignancies, such as myeloproliferative neoplasms (MPNs). While cooperating mutations can cause transformation, it is unclear whether distinct bone marrow (BM) HSC-niches can influence the growth and therapy response of HSCs carrying the same oncogenic driver. Here we found different BM niches for HSCs in MPN subtypes. JAK-STAT signaling...]]></summary>
        <author>
            <name>Elodie Grockowiak</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Short-term western diet causes rapid and lasting alterations of bone marrow physiology]]></title>
        <id>pubmed:37549687</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37549687/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230815204647&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-08-07T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Dietary factors have a significant impact on overall health and western diet (WD) disrupts arterial homeostasis, thereby promoting atherosclerosis. In our study, we investigated the effects of short-term WD on bone marrow vasculature and hematopoiesis in hypercholesterolemic mice. We found that WD rapidly remodels bone marrow arterioles, and these alterations persist even after WD cessation. The proximity between hematopoietic stem cells (HSCs) and arterioles increased with short-term WD, which...]]></summary>
        <author>
            <name>Mariaelvy Bianchini</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Immune dysregulation and potential targeted therapy in myelodysplastic syndrome]]></title>
        <id>pubmed:37547364</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37547364/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230815204647&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-08-07T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Myelodysplastic syndrome (MDS) is a heterogeneous group of clonal hematological diseases and a high risk for transformation to acute myeloid leukemia (AML). The identification of key genetic alterations in MDS has enhanced our understanding of the pathogenesis and evolution. In recent years, it has been found that both innate and adaptive immune signaling are activated in the hematopoietic niche of MDS with aberrant cytokine secretion in the bone marrow microenvironment. It is also clear that...]]></summary>
        <author>
            <name>Xiaoying Zhang</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Leukocytes carrying <em>Clonal Hematopoiesis of Indeterminate Potential</em> (CHIP) Mutations invade Human Atherosclerotic Plaques]]></title>
        <id>pubmed:37546840</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37546840/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230815204647&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-08-07T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSIONS: Deep-DNA-sequencing reveals a high prevalence of CHIP mutations in whole blood of CAD patients. CHIP-affected leukocytes invade plaques in human coronary arteries. RNAseq data obtained from macrophages of CHIP-affected patients suggest that pro-atherosclerotic signaling differs depending on the underlying mutations. Further studies are necessary to understand whether specific pathways affected by CHIP mutations may be targeted for personalized treatment.]]></summary>
        <author>
            <name>Moritz von Scheidt</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Cigarette smoke stimulates clonal expansion of Jak2<sup>V617F</sup> and Tet2<sup>-/-</sup> cells]]></title>
        <id>pubmed:37546389</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37546389/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230815204647&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-08-07T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSION: Altogether, these findings demonstrate that CS results in an inflamed bone marrow environment that provides a selection pressure for existing CHIP mutations such as Jak2V617F and Tet2 loss-of-function.]]></summary>
        <author>
            <name>Gajalakshmi Ramanathan</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Different niches for stem cells carrying the same oncogenic driver affect pathogenesis and therapy response in myeloproliferative neoplasms]]></title>
        <id>pubmed:37550517</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37550517/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230814204719&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-08-07T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Aging facilitates the expansion of hematopoietic stem cells (HSCs) carrying clonal hematopoiesis-related somatic mutations and the development of myeloid malignancies, such as myeloproliferative neoplasms (MPNs). While cooperating mutations can cause transformation, it is unclear whether distinct bone marrow (BM) HSC-niches can influence the growth and therapy response of HSCs carrying the same oncogenic driver. Here we found different BM niches for HSCs in MPN subtypes. JAK-STAT signaling...]]></summary>
        <author>
            <name>Elodie Grockowiak</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Short-term western diet causes rapid and lasting alterations of bone marrow physiology]]></title>
        <id>pubmed:37549687</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37549687/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230814204719&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-08-07T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Dietary factors have a significant impact on overall health and western diet (WD) disrupts arterial homeostasis, thereby promoting atherosclerosis. In our study, we investigated the effects of short-term WD on bone marrow vasculature and hematopoiesis in hypercholesterolemic mice. We found that WD rapidly remodels bone marrow arterioles, and these alterations persist even after WD cessation. The proximity between hematopoietic stem cells (HSCs) and arterioles increased with short-term WD, which...]]></summary>
        <author>
            <name>Mariaelvy Bianchini</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Immune dysregulation and potential targeted therapy in myelodysplastic syndrome]]></title>
        <id>pubmed:37547364</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37547364/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230814204719&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-08-07T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Myelodysplastic syndrome (MDS) is a heterogeneous group of clonal hematological diseases and a high risk for transformation to acute myeloid leukemia (AML). The identification of key genetic alterations in MDS has enhanced our understanding of the pathogenesis and evolution. In recent years, it has been found that both innate and adaptive immune signaling are activated in the hematopoietic niche of MDS with aberrant cytokine secretion in the bone marrow microenvironment. It is also clear that...]]></summary>
        <author>
            <name>Xiaoying Zhang</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Leukocytes carrying <em>Clonal Hematopoiesis of Indeterminate Potential</em> (CHIP) Mutations invade Human Atherosclerotic Plaques]]></title>
        <id>pubmed:37546840</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37546840/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230814204719&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-08-07T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSIONS: Deep-DNA-sequencing reveals a high prevalence of CHIP mutations in whole blood of CAD patients. CHIP-affected leukocytes invade plaques in human coronary arteries. RNAseq data obtained from macrophages of CHIP-affected patients suggest that pro-atherosclerotic signaling differs depending on the underlying mutations. Further studies are necessary to understand whether specific pathways affected by CHIP mutations may be targeted for personalized treatment.]]></summary>
        <author>
            <name>Moritz von Scheidt</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Cigarette smoke stimulates clonal expansion of Jak2<sup>V617F</sup> and Tet2<sup>-/-</sup> cells]]></title>
        <id>pubmed:37546389</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37546389/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230814204719&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-08-07T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSION: Altogether, these findings demonstrate that CS results in an inflamed bone marrow environment that provides a selection pressure for existing CHIP mutations such as Jak2V617F and Tet2 loss-of-function.]]></summary>
        <author>
            <name>Gajalakshmi Ramanathan</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Different niches for stem cells carrying the same oncogenic driver affect pathogenesis and therapy response in myeloproliferative neoplasms]]></title>
        <id>pubmed:37550517</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37550517/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230813204802&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-08-07T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Aging facilitates the expansion of hematopoietic stem cells (HSCs) carrying clonal hematopoiesis-related somatic mutations and the development of myeloid malignancies, such as myeloproliferative neoplasms (MPNs). While cooperating mutations can cause transformation, it is unclear whether distinct bone marrow (BM) HSC-niches can influence the growth and therapy response of HSCs carrying the same oncogenic driver. Here we found different BM niches for HSCs in MPN subtypes. JAK-STAT signaling...]]></summary>
        <author>
            <name>Elodie Grockowiak</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Short-term western diet causes rapid and lasting alterations of bone marrow physiology]]></title>
        <id>pubmed:37549687</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37549687/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230813204802&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-08-07T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Dietary factors have a significant impact on overall health and western diet (WD) disrupts arterial homeostasis, thereby promoting atherosclerosis. In our study, we investigated the effects of short-term WD on bone marrow vasculature and hematopoiesis in hypercholesterolemic mice. We found that WD rapidly remodels bone marrow arterioles, and these alterations persist even after WD cessation. The proximity between hematopoietic stem cells (HSCs) and arterioles increased with short-term WD, which...]]></summary>
        <author>
            <name>Mariaelvy Bianchini</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Immune dysregulation and potential targeted therapy in myelodysplastic syndrome]]></title>
        <id>pubmed:37547364</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37547364/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230813204802&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-08-07T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Myelodysplastic syndrome (MDS) is a heterogeneous group of clonal hematological diseases and a high risk for transformation to acute myeloid leukemia (AML). The identification of key genetic alterations in MDS has enhanced our understanding of the pathogenesis and evolution. In recent years, it has been found that both innate and adaptive immune signaling are activated in the hematopoietic niche of MDS with aberrant cytokine secretion in the bone marrow microenvironment. It is also clear that...]]></summary>
        <author>
            <name>Xiaoying Zhang</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Leukocytes carrying <em>Clonal Hematopoiesis of Indeterminate Potential</em> (CHIP) Mutations invade Human Atherosclerotic Plaques]]></title>
        <id>pubmed:37546840</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37546840/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230813204802&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-08-07T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSIONS: Deep-DNA-sequencing reveals a high prevalence of CHIP mutations in whole blood of CAD patients. CHIP-affected leukocytes invade plaques in human coronary arteries. RNAseq data obtained from macrophages of CHIP-affected patients suggest that pro-atherosclerotic signaling differs depending on the underlying mutations. Further studies are necessary to understand whether specific pathways affected by CHIP mutations may be targeted for personalized treatment.]]></summary>
        <author>
            <name>Moritz von Scheidt</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Cigarette smoke stimulates clonal expansion of Jak2<sup>V617F</sup> and Tet2<sup>-/-</sup> cells]]></title>
        <id>pubmed:37546389</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37546389/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230813204802&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-08-07T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSION: Altogether, these findings demonstrate that CS results in an inflamed bone marrow environment that provides a selection pressure for existing CHIP mutations such as Jak2V617F and Tet2 loss-of-function.]]></summary>
        <author>
            <name>Gajalakshmi Ramanathan</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Different niches for stem cells carrying the same oncogenic driver affect pathogenesis and therapy response in myeloproliferative neoplasms]]></title>
        <id>pubmed:37550517</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37550517/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230812205008&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-08-07T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Aging facilitates the expansion of hematopoietic stem cells (HSCs) carrying clonal hematopoiesis-related somatic mutations and the development of myeloid malignancies, such as myeloproliferative neoplasms (MPNs). While cooperating mutations can cause transformation, it is unclear whether distinct bone marrow (BM) HSC-niches can influence the growth and therapy response of HSCs carrying the same oncogenic driver. Here we found different BM niches for HSCs in MPN subtypes. JAK-STAT signaling...]]></summary>
        <author>
            <name>Elodie Grockowiak</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Short-term western diet causes rapid and lasting alterations of bone marrow physiology]]></title>
        <id>pubmed:37549687</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37549687/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230812205008&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-08-07T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Dietary factors have a significant impact on overall health and western diet (WD) disrupts arterial homeostasis, thereby promoting atherosclerosis. In our study, we investigated the effects of short-term WD on bone marrow vasculature and hematopoiesis in hypercholesterolemic mice. We found that WD rapidly remodels bone marrow arterioles, and these alterations persist even after WD cessation. The proximity between hematopoietic stem cells (HSCs) and arterioles increased with short-term WD, which...]]></summary>
        <author>
            <name>Mariaelvy Bianchini</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Immune dysregulation and potential targeted therapy in myelodysplastic syndrome]]></title>
        <id>pubmed:37547364</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37547364/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230812205008&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-08-07T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Myelodysplastic syndrome (MDS) is a heterogeneous group of clonal hematological diseases and a high risk for transformation to acute myeloid leukemia (AML). The identification of key genetic alterations in MDS has enhanced our understanding of the pathogenesis and evolution. In recent years, it has been found that both innate and adaptive immune signaling are activated in the hematopoietic niche of MDS with aberrant cytokine secretion in the bone marrow microenvironment. It is also clear that...]]></summary>
        <author>
            <name>Xiaoying Zhang</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Leukocytes carrying <em>Clonal Hematopoiesis of Indeterminate Potential</em> (CHIP) Mutations invade Human Atherosclerotic Plaques]]></title>
        <id>pubmed:37546840</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37546840/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230812205008&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-08-07T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSIONS: Deep-DNA-sequencing reveals a high prevalence of CHIP mutations in whole blood of CAD patients. CHIP-affected leukocytes invade plaques in human coronary arteries. RNAseq data obtained from macrophages of CHIP-affected patients suggest that pro-atherosclerotic signaling differs depending on the underlying mutations. Further studies are necessary to understand whether specific pathways affected by CHIP mutations may be targeted for personalized treatment.]]></summary>
        <author>
            <name>Moritz von Scheidt</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Cigarette smoke stimulates clonal expansion of Jak2<sup>V617F</sup> and Tet2<sup>-/-</sup> cells]]></title>
        <id>pubmed:37546389</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37546389/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230812205008&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-08-07T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSION: Altogether, these findings demonstrate that CS results in an inflamed bone marrow environment that provides a selection pressure for existing CHIP mutations such as Jak2V617F and Tet2 loss-of-function.]]></summary>
        <author>
            <name>Gajalakshmi Ramanathan</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Different niches for stem cells carrying the same oncogenic driver affect pathogenesis and therapy response in myeloproliferative neoplasms]]></title>
        <id>pubmed:37550517</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37550517/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230811204531&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-08-07T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Aging facilitates the expansion of hematopoietic stem cells (HSCs) carrying clonal hematopoiesis-related somatic mutations and the development of myeloid malignancies, such as myeloproliferative neoplasms (MPNs). While cooperating mutations can cause transformation, it is unclear whether distinct bone marrow (BM) HSC-niches can influence the growth and therapy response of HSCs carrying the same oncogenic driver. Here we found different BM niches for HSCs in MPN subtypes. JAK-STAT signaling...]]></summary>
        <author>
            <name>Elodie Grockowiak</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Short-term western diet causes rapid and lasting alterations of bone marrow physiology]]></title>
        <id>pubmed:37549687</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37549687/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230811204531&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-08-07T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Dietary factors have a significant impact on overall health and western diet (WD) disrupts arterial homeostasis, thereby promoting atherosclerosis. In our study, we investigated the effects of short-term WD on bone marrow vasculature and hematopoiesis in hypercholesterolemic mice. We found that WD rapidly remodels bone marrow arterioles, and these alterations persist even after WD cessation. The proximity between hematopoietic stem cells (HSCs) and arterioles increased with short-term WD, which...]]></summary>
        <author>
            <name>Mariaelvy Bianchini</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Immune dysregulation and potential targeted therapy in myelodysplastic syndrome]]></title>
        <id>pubmed:37547364</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37547364/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230811204531&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-08-07T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Myelodysplastic syndrome (MDS) is a heterogeneous group of clonal hematological diseases and a high risk for transformation to acute myeloid leukemia (AML). The identification of key genetic alterations in MDS has enhanced our understanding of the pathogenesis and evolution. In recent years, it has been found that both innate and adaptive immune signaling are activated in the hematopoietic niche of MDS with aberrant cytokine secretion in the bone marrow microenvironment. It is also clear that...]]></summary>
        <author>
            <name>Xiaoying Zhang</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Leukocytes carrying <em>Clonal Hematopoiesis of Indeterminate Potential</em> (CHIP) Mutations invade Human Atherosclerotic Plaques]]></title>
        <id>pubmed:37546840</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37546840/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230811204531&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-08-07T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSIONS: Deep-DNA-sequencing reveals a high prevalence of CHIP mutations in whole blood of CAD patients. CHIP-affected leukocytes invade plaques in human coronary arteries. RNAseq data obtained from macrophages of CHIP-affected patients suggest that pro-atherosclerotic signaling differs depending on the underlying mutations. Further studies are necessary to understand whether specific pathways affected by CHIP mutations may be targeted for personalized treatment.]]></summary>
        <author>
            <name>Moritz von Scheidt</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Cigarette smoke stimulates clonal expansion of Jak2<sup>V617F</sup> and Tet2<sup>-/-</sup> cells]]></title>
        <id>pubmed:37546389</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37546389/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230811204531&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-08-07T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSION: Altogether, these findings demonstrate that CS results in an inflamed bone marrow environment that provides a selection pressure for existing CHIP mutations such as Jak2V617F and Tet2 loss-of-function.]]></summary>
        <author>
            <name>Gajalakshmi Ramanathan</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Different niches for stem cells carrying the same oncogenic driver affect pathogenesis and therapy response in myeloproliferative neoplasms]]></title>
        <id>pubmed:37550517</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37550517/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230810204637&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-08-07T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Aging facilitates the expansion of hematopoietic stem cells (HSCs) carrying clonal hematopoiesis-related somatic mutations and the development of myeloid malignancies, such as myeloproliferative neoplasms (MPNs). While cooperating mutations can cause transformation, it is unclear whether distinct bone marrow (BM) HSC-niches can influence the growth and therapy response of HSCs carrying the same oncogenic driver. Here we found different BM niches for HSCs in MPN subtypes. JAK-STAT signaling...]]></summary>
        <author>
            <name>Elodie Grockowiak</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Short-term western diet causes rapid and lasting alterations of bone marrow physiology]]></title>
        <id>pubmed:37549687</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37549687/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230810204637&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-08-07T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Dietary factors have a significant impact on overall health and western diet (WD) disrupts arterial homeostasis, thereby promoting atherosclerosis. In our study, we investigated the effects of short-term WD on bone marrow vasculature and hematopoiesis in hypercholesterolemic mice. We found that WD rapidly remodels bone marrow arterioles, and these alterations persist even after WD cessation. The proximity between hematopoietic stem cells (HSCs) and arterioles increased with short-term WD, which...]]></summary>
        <author>
            <name>Mariaelvy Bianchini</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Immune dysregulation and potential targeted therapy in myelodysplastic syndrome]]></title>
        <id>pubmed:37547364</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37547364/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230810204637&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-08-07T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Myelodysplastic syndrome (MDS) is a heterogeneous group of clonal hematological diseases and a high risk for transformation to acute myeloid leukemia (AML). The identification of key genetic alterations in MDS has enhanced our understanding of the pathogenesis and evolution. In recent years, it has been found that both innate and adaptive immune signaling are activated in the hematopoietic niche of MDS with aberrant cytokine secretion in the bone marrow microenvironment. It is also clear that...]]></summary>
        <author>
            <name>Xiaoying Zhang</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Leukocytes carrying <em>Clonal Hematopoiesis of Indeterminate Potential</em> (CHIP) Mutations invade Human Atherosclerotic Plaques]]></title>
        <id>pubmed:37546840</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37546840/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230810204637&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-08-07T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSIONS: Deep-DNA-sequencing reveals a high prevalence of CHIP mutations in whole blood of CAD patients. CHIP-affected leukocytes invade plaques in human coronary arteries. RNAseq data obtained from macrophages of CHIP-affected patients suggest that pro-atherosclerotic signaling differs depending on the underlying mutations. Further studies are necessary to understand whether specific pathways affected by CHIP mutations may be targeted for personalized treatment.]]></summary>
        <author>
            <name>Moritz von Scheidt</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Cigarette smoke stimulates clonal expansion of Jak2<sup>V617F</sup> and Tet2<sup>-/-</sup> cells]]></title>
        <id>pubmed:37546389</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37546389/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230810204637&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-08-07T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSION: Altogether, these findings demonstrate that CS results in an inflamed bone marrow environment that provides a selection pressure for existing CHIP mutations such as Jak2V617F and Tet2 loss-of-function.]]></summary>
        <author>
            <name>Gajalakshmi Ramanathan</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Different niches for stem cells carrying the same oncogenic driver affect pathogenesis and therapy response in myeloproliferative neoplasms]]></title>
        <id>pubmed:37550517</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37550517/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230809205914&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-08-07T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Aging facilitates the expansion of hematopoietic stem cells (HSCs) carrying clonal hematopoiesis-related somatic mutations and the development of myeloid malignancies, such as myeloproliferative neoplasms (MPNs). While cooperating mutations can cause transformation, it is unclear whether distinct bone marrow (BM) HSC-niches can influence the growth and therapy response of HSCs carrying the same oncogenic driver. Here we found different BM niches for HSCs in MPN subtypes. JAK-STAT signaling...]]></summary>
        <author>
            <name>Elodie Grockowiak</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Short-term western diet causes rapid and lasting alterations of bone marrow physiology]]></title>
        <id>pubmed:37549687</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37549687/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230809205914&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-08-07T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Dietary factors have a significant impact on overall health and western diet (WD) disrupts arterial homeostasis, thereby promoting atherosclerosis. In our study, we investigated the effects of short-term WD on bone marrow vasculature and hematopoiesis in hypercholesterolemic mice. We found that WD rapidly remodels bone marrow arterioles, and these alterations persist even after WD cessation. The proximity between hematopoietic stem cells (HSCs) and arterioles increased with short-term WD, which...]]></summary>
        <author>
            <name>Mariaelvy Bianchini</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Immune dysregulation and potential targeted therapy in myelodysplastic syndrome]]></title>
        <id>pubmed:37547364</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37547364/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230809205914&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-08-07T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Myelodysplastic syndrome (MDS) is a heterogeneous group of clonal hematological diseases and a high risk for transformation to acute myeloid leukemia (AML). The identification of key genetic alterations in MDS has enhanced our understanding of the pathogenesis and evolution. In recent years, it has been found that both innate and adaptive immune signaling are activated in the hematopoietic niche of MDS with aberrant cytokine secretion in the bone marrow microenvironment. It is also clear that...]]></summary>
        <author>
            <name>Xiaoying Zhang</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Leukocytes carrying <em>Clonal Hematopoiesis of Indeterminate Potential</em> (CHIP) Mutations invade Human Atherosclerotic Plaques]]></title>
        <id>pubmed:37546840</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37546840/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230809205914&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-08-07T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSIONS: Deep-DNA-sequencing reveals a high prevalence of CHIP mutations in whole blood of CAD patients. CHIP-affected leukocytes invade plaques in human coronary arteries. RNAseq data obtained from macrophages of CHIP-affected patients suggest that pro-atherosclerotic signaling differs depending on the underlying mutations. Further studies are necessary to understand whether specific pathways affected by CHIP mutations may be targeted for personalized treatment.]]></summary>
        <author>
            <name>Moritz von Scheidt</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Cigarette smoke stimulates clonal expansion of Jak2<sup>V617F</sup> and Tet2<sup>-/-</sup> cells]]></title>
        <id>pubmed:37546389</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37546389/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230809205914&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-08-07T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSION: Altogether, these findings demonstrate that CS results in an inflamed bone marrow environment that provides a selection pressure for existing CHIP mutations such as Jak2V617F and Tet2 loss-of-function.]]></summary>
        <author>
            <name>Gajalakshmi Ramanathan</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Different niches for stem cells carrying the same oncogenic driver affect pathogenesis and therapy response in myeloproliferative neoplasms]]></title>
        <id>pubmed:37550517</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37550517/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230808205751&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-08-07T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Aging facilitates the expansion of hematopoietic stem cells (HSCs) carrying clonal hematopoiesis-related somatic mutations and the development of myeloid malignancies, such as myeloproliferative neoplasms (MPNs). While cooperating mutations can cause transformation, it is unclear whether distinct bone marrow (BM) HSC-niches can influence the growth and therapy response of HSCs carrying the same oncogenic driver. Here we found different BM niches for HSCs in MPN subtypes. JAK-STAT signaling...]]></summary>
        <author>
            <name>Elodie Grockowiak</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Short-term western diet causes rapid and lasting alterations of bone marrow physiology]]></title>
        <id>pubmed:37549687</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37549687/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230808205751&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-08-07T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Dietary factors have a significant impact on overall health and western diet (WD) disrupts arterial homeostasis, thereby promoting atherosclerosis. In our study, we investigated the effects of short-term WD on bone marrow vasculature and hematopoiesis in hypercholesterolemic mice. We found that WD rapidly remodels bone marrow arterioles, and these alterations persist even after WD cessation. The proximity between hematopoietic stem cells (HSCs) and arterioles increased with short-term WD, which...]]></summary>
        <author>
            <name>Mariaelvy Bianchini</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Immune dysregulation and potential targeted therapy in myelodysplastic syndrome]]></title>
        <id>pubmed:37547364</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37547364/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230808205751&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-08-07T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Myelodysplastic syndrome (MDS) is a heterogeneous group of clonal hematological diseases and a high risk for transformation to acute myeloid leukemia (AML). The identification of key genetic alterations in MDS has enhanced our understanding of the pathogenesis and evolution. In recent years, it has been found that both innate and adaptive immune signaling are activated in the hematopoietic niche of MDS with aberrant cytokine secretion in the bone marrow microenvironment. It is also clear that...]]></summary>
        <author>
            <name>Xiaoying Zhang</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Leukocytes carrying <em>Clonal Hematopoiesis of Indeterminate Potential</em> (CHIP) Mutations invade Human Atherosclerotic Plaques]]></title>
        <id>pubmed:37546840</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37546840/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230808205751&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-08-07T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSIONS: Deep-DNA-sequencing reveals a high prevalence of CHIP mutations in whole blood of CAD patients. CHIP-affected leukocytes invade plaques in human coronary arteries. RNAseq data obtained from macrophages of CHIP-affected patients suggest that pro-atherosclerotic signaling differs depending on the underlying mutations. Further studies are necessary to understand whether specific pathways affected by CHIP mutations may be targeted for personalized treatment.]]></summary>
        <author>
            <name>Moritz von Scheidt</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Cigarette smoke stimulates clonal expansion of Jak2<sup>V617F</sup> and Tet2<sup>-/-</sup> cells]]></title>
        <id>pubmed:37546389</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37546389/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230808205751&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-08-07T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSION: Altogether, these findings demonstrate that CS results in an inflamed bone marrow environment that provides a selection pressure for existing CHIP mutations such as Jak2V617F and Tet2 loss-of-function.]]></summary>
        <author>
            <name>Gajalakshmi Ramanathan</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Immune dysregulation and potential targeted therapy in myelodysplastic syndrome]]></title>
        <id>pubmed:37547364</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37547364/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230807205649&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-08-07T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Myelodysplastic syndrome (MDS) is a heterogeneous group of clonal hematological diseases and a high risk for transformation to acute myeloid leukemia (AML). The identification of key genetic alterations in MDS has enhanced our understanding of the pathogenesis and evolution. In recent years, it has been found that both innate and adaptive immune signaling are activated in the hematopoietic niche of MDS with aberrant cytokine secretion in the bone marrow microenvironment. It is also clear that...]]></summary>
        <author>
            <name>Xiaoying Zhang</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Leukocytes carrying <em>Clonal Hematopoiesis of Indeterminate Potential</em> (CHIP) Mutations invade Human Atherosclerotic Plaques]]></title>
        <id>pubmed:37546840</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37546840/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230807205649&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-08-07T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSIONS: Deep-DNA-sequencing reveals a high prevalence of CHIP mutations in whole blood of CAD patients. CHIP-affected leukocytes invade plaques in human coronary arteries. RNAseq data obtained from macrophages of CHIP-affected patients suggest that pro-atherosclerotic signaling differs depending on the underlying mutations. Further studies are necessary to understand whether specific pathways affected by CHIP mutations may be targeted for personalized treatment.]]></summary>
        <author>
            <name>Moritz von Scheidt</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Cigarette smoke stimulates clonal expansion of Jak2<sup>V617F</sup> and Tet2<sup>-/-</sup> cells]]></title>
        <id>pubmed:37546389</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37546389/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230807205649&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-08-07T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSION: Altogether, these findings demonstrate that CS results in an inflamed bone marrow environment that provides a selection pressure for existing CHIP mutations such as Jak2V617F and Tet2 loss-of-function.]]></summary>
        <author>
            <name>Gajalakshmi Ramanathan</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Blockade of IL-6 signaling alleviates atherosclerosis in <em>Tet2</em>-deficient clonal hematopoiesis]]></title>
        <id>pubmed:37539077</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37539077/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230817204642&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-08-04T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Clonal hematopoiesis (CH) increases the risk of atherosclerotic cardiovascular disease possibly due to increased plaque inflammation. Human studies suggest that limitation of interleukin-6 (IL-6) signaling could be beneficial in people with large CH clones, particularly in TET2 CH. Here we show that IL-6 receptor antibody treatment reverses the atherosclerosis promoted by Tet2 CH, with reduction of monocytosis, lesional macrophage burden and macrophage colony-stimulating factor 1 receptor...]]></summary>
        <author>
            <name>Wenli Liu</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Blockade of IL-6 signaling alleviates atherosclerosis in <em>Tet2</em>-deficient clonal hematopoiesis]]></title>
        <id>pubmed:37539077</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37539077/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230816204601&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-08-04T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Clonal hematopoiesis (CH) increases the risk of atherosclerotic cardiovascular disease possibly due to increased plaque inflammation. Human studies suggest that limitation of interleukin-6 (IL-6) signaling could be beneficial in people with large CH clones, particularly in TET2 CH. Here we show that IL-6 receptor antibody treatment reverses the atherosclerosis promoted by Tet2 CH, with reduction of monocytosis, lesional macrophage burden and macrophage colony-stimulating factor 1 receptor...]]></summary>
        <author>
            <name>Wenli Liu</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Blockade of IL-6 signaling alleviates atherosclerosis in <em>Tet2</em>-deficient clonal hematopoiesis]]></title>
        <id>pubmed:37539077</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37539077/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230815204647&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-08-04T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Clonal hematopoiesis (CH) increases the risk of atherosclerotic cardiovascular disease possibly due to increased plaque inflammation. Human studies suggest that limitation of interleukin-6 (IL-6) signaling could be beneficial in people with large CH clones, particularly in TET2 CH. Here we show that IL-6 receptor antibody treatment reverses the atherosclerosis promoted by Tet2 CH, with reduction of monocytosis, lesional macrophage burden and macrophage colony-stimulating factor 1 receptor...]]></summary>
        <author>
            <name>Wenli Liu</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Blockade of IL-6 signaling alleviates atherosclerosis in <em>Tet2</em>-deficient clonal hematopoiesis]]></title>
        <id>pubmed:37539077</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37539077/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230814204719&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-08-04T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Clonal hematopoiesis (CH) increases the risk of atherosclerotic cardiovascular disease possibly due to increased plaque inflammation. Human studies suggest that limitation of interleukin-6 (IL-6) signaling could be beneficial in people with large CH clones, particularly in TET2 CH. Here we show that IL-6 receptor antibody treatment reverses the atherosclerosis promoted by Tet2 CH, with reduction of monocytosis, lesional macrophage burden and macrophage colony-stimulating factor 1 receptor...]]></summary>
        <author>
            <name>Wenli Liu</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Blockade of IL-6 signaling alleviates atherosclerosis in <em>Tet2</em>-deficient clonal hematopoiesis]]></title>
        <id>pubmed:37539077</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37539077/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230813204802&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-08-04T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Clonal hematopoiesis (CH) increases the risk of atherosclerotic cardiovascular disease possibly due to increased plaque inflammation. Human studies suggest that limitation of interleukin-6 (IL-6) signaling could be beneficial in people with large CH clones, particularly in TET2 CH. Here we show that IL-6 receptor antibody treatment reverses the atherosclerosis promoted by Tet2 CH, with reduction of monocytosis, lesional macrophage burden and macrophage colony-stimulating factor 1 receptor...]]></summary>
        <author>
            <name>Wenli Liu</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Blockade of IL-6 signaling alleviates atherosclerosis in <em>Tet2</em>-deficient clonal hematopoiesis]]></title>
        <id>pubmed:37539077</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37539077/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230812205008&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-08-04T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Clonal hematopoiesis (CH) increases the risk of atherosclerotic cardiovascular disease possibly due to increased plaque inflammation. Human studies suggest that limitation of interleukin-6 (IL-6) signaling could be beneficial in people with large CH clones, particularly in TET2 CH. Here we show that IL-6 receptor antibody treatment reverses the atherosclerosis promoted by Tet2 CH, with reduction of monocytosis, lesional macrophage burden and macrophage colony-stimulating factor 1 receptor...]]></summary>
        <author>
            <name>Wenli Liu</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Blockade of IL-6 signaling alleviates atherosclerosis in <em>Tet2</em>-deficient clonal hematopoiesis]]></title>
        <id>pubmed:37539077</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37539077/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230811204531&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-08-04T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Clonal hematopoiesis (CH) increases the risk of atherosclerotic cardiovascular disease possibly due to increased plaque inflammation. Human studies suggest that limitation of interleukin-6 (IL-6) signaling could be beneficial in people with large CH clones, particularly in TET2 CH. Here we show that IL-6 receptor antibody treatment reverses the atherosclerosis promoted by Tet2 CH, with reduction of monocytosis, lesional macrophage burden and macrophage colony-stimulating factor 1 receptor...]]></summary>
        <author>
            <name>Wenli Liu</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Blockade of IL-6 signaling alleviates atherosclerosis in <em>Tet2</em>-deficient clonal hematopoiesis]]></title>
        <id>pubmed:37539077</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37539077/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230810204637&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-08-04T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Clonal hematopoiesis (CH) increases the risk of atherosclerotic cardiovascular disease possibly due to increased plaque inflammation. Human studies suggest that limitation of interleukin-6 (IL-6) signaling could be beneficial in people with large CH clones, particularly in TET2 CH. Here we show that IL-6 receptor antibody treatment reverses the atherosclerosis promoted by Tet2 CH, with reduction of monocytosis, lesional macrophage burden and macrophage colony-stimulating factor 1 receptor...]]></summary>
        <author>
            <name>Wenli Liu</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Blockade of IL-6 signaling alleviates atherosclerosis in <em>Tet2</em>-deficient clonal hematopoiesis]]></title>
        <id>pubmed:37539077</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37539077/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230809205914&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-08-04T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Clonal hematopoiesis (CH) increases the risk of atherosclerotic cardiovascular disease possibly due to increased plaque inflammation. Human studies suggest that limitation of interleukin-6 (IL-6) signaling could be beneficial in people with large CH clones, particularly in TET2 CH. Here we show that IL-6 receptor antibody treatment reverses the atherosclerosis promoted by Tet2 CH, with reduction of monocytosis, lesional macrophage burden and macrophage colony-stimulating factor 1 receptor...]]></summary>
        <author>
            <name>Wenli Liu</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Blockade of IL-6 signaling alleviates atherosclerosis in <em>Tet2</em>-deficient clonal hematopoiesis]]></title>
        <id>pubmed:37539077</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37539077/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230808205751&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-08-04T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Clonal hematopoiesis (CH) increases the risk of atherosclerotic cardiovascular disease possibly due to increased plaque inflammation. Human studies suggest that limitation of interleukin-6 (IL-6) signaling could be beneficial in people with large CH clones, particularly in TET2 CH. Here we show that IL-6 receptor antibody treatment reverses the atherosclerosis promoted by Tet2 CH, with reduction of monocytosis, lesional macrophage burden and macrophage colony-stimulating factor 1 receptor...]]></summary>
        <author>
            <name>Wenli Liu</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Blockade of IL-6 signaling alleviates atherosclerosis in <em>Tet2</em>-deficient clonal hematopoiesis]]></title>
        <id>pubmed:37539077</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37539077/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230807205649&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-08-04T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Clonal hematopoiesis (CH) increases the risk of atherosclerotic cardiovascular disease possibly due to increased plaque inflammation. Human studies suggest that limitation of interleukin-6 (IL-6) signaling could be beneficial in people with large CH clones, particularly in TET2 CH. Here we show that IL-6 receptor antibody treatment reverses the atherosclerosis promoted by Tet2 CH, with reduction of monocytosis, lesional macrophage burden and macrophage colony-stimulating factor 1 receptor...]]></summary>
        <author>
            <name>Wenli Liu</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Blockade of IL-6 signaling alleviates atherosclerosis in <em>Tet2</em>-deficient clonal hematopoiesis]]></title>
        <id>pubmed:37539077</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37539077/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230806205822&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-08-04T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Clonal hematopoiesis (CH) increases the risk of atherosclerotic cardiovascular disease possibly due to increased plaque inflammation. Human studies suggest that limitation of interleukin-6 (IL-6) signaling could be beneficial in people with large CH clones, particularly in TET2 CH. Here we show that IL-6 receptor antibody treatment reverses the atherosclerosis promoted by Tet2 CH, with reduction of monocytosis, lesional macrophage burden and macrophage colony-stimulating factor 1 receptor...]]></summary>
        <author>
            <name>Wenli Liu</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Blockade of IL-6 signaling alleviates atherosclerosis in <em>Tet2</em>-deficient clonal hematopoiesis]]></title>
        <id>pubmed:37539077</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37539077/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230805205329&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-08-04T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Clonal hematopoiesis (CH) increases the risk of atherosclerotic cardiovascular disease possibly due to increased plaque inflammation. Human studies suggest that limitation of interleukin-6 (IL-6) signaling could be beneficial in people with large CH clones, particularly in TET2 CH. Here we show that IL-6 receptor antibody treatment reverses the atherosclerosis promoted by Tet2 CH, with reduction of monocytosis, lesional macrophage burden and macrophage colony-stimulating factor 1 receptor...]]></summary>
        <author>
            <name>Wenli Liu</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Blockade of IL-6 signaling alleviates atherosclerosis in <em>Tet2</em>-deficient clonal hematopoiesis]]></title>
        <id>pubmed:37539077</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37539077/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230804205603&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-08-04T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Clonal hematopoiesis (CH) increases the risk of atherosclerotic cardiovascular disease possibly due to increased plaque inflammation. Human studies suggest that limitation of interleukin-6 (IL-6) signaling could be beneficial in people with large CH clones, particularly in TET2 CH. Here we show that IL-6 receptor antibody treatment reverses the atherosclerosis promoted by Tet2 CH, with reduction of monocytosis, lesional macrophage burden and macrophage colony-stimulating factor 1 receptor...]]></summary>
        <author>
            <name>Wenli Liu</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[The winner takes it all: Competition drives clonal selection in gliomagenesis]]></title>
        <id>pubmed:37541246</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37541246/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230831205203&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-08-04T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[The exact mechanisms that govern clonal dynamics and selection during early tumorigenesis remain largely elusive. Ceresa et al. provide experimental and mathematical evidence that MYC-dependent competition between individual clones is one driving force of brain tumor evolution, adding a winner/loser aspect to the picture that complements existing concepts.]]></summary>
        <author>
            <name>Frank Winkler</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[The winner takes it all: Competition drives clonal selection in gliomagenesis]]></title>
        <id>pubmed:37541246</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37541246/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230830204850&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-08-04T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[The exact mechanisms that govern clonal dynamics and selection during early tumorigenesis remain largely elusive. Ceresa et al. provide experimental and mathematical evidence that MYC-dependent competition between individual clones is one driving force of brain tumor evolution, adding a winner/loser aspect to the picture that complements existing concepts.]]></summary>
        <author>
            <name>Frank Winkler</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Early clonal extinction in glioblastoma progression revealed by genetic barcoding]]></title>
        <id>pubmed:37541243</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37541243/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230830204850&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-08-04T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Glioblastoma progression in its early stages remains poorly understood. Here, we transfer PDGFB and genetic barcodes in mouse brain to initiate gliomagenesis and enable direct tracing of glioblastoma evolution from its earliest possible stage. Unexpectedly, we observe a high incidence of clonal extinction events and progressive divergence in clonal sizes, even after the acquisition of malignant phenotype. Computational modeling suggests these dynamics result from clonal-based cell-cell...]]></summary>
        <author>
            <name>Davide Ceresa</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[The winner takes it all: Competition drives clonal selection in gliomagenesis]]></title>
        <id>pubmed:37541246</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37541246/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230829204824&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-08-04T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[The exact mechanisms that govern clonal dynamics and selection during early tumorigenesis remain largely elusive. Ceresa et al. provide experimental and mathematical evidence that MYC-dependent competition between individual clones is one driving force of brain tumor evolution, adding a winner/loser aspect to the picture that complements existing concepts.]]></summary>
        <author>
            <name>Frank Winkler</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Early clonal extinction in glioblastoma progression revealed by genetic barcoding]]></title>
        <id>pubmed:37541243</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37541243/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230829204824&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-08-04T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Glioblastoma progression in its early stages remains poorly understood. Here, we transfer PDGFB and genetic barcodes in mouse brain to initiate gliomagenesis and enable direct tracing of glioblastoma evolution from its earliest possible stage. Unexpectedly, we observe a high incidence of clonal extinction events and progressive divergence in clonal sizes, even after the acquisition of malignant phenotype. Computational modeling suggests these dynamics result from clonal-based cell-cell...]]></summary>
        <author>
            <name>Davide Ceresa</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[The winner takes it all: Competition drives clonal selection in gliomagenesis]]></title>
        <id>pubmed:37541246</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37541246/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230828204854&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-08-04T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[The exact mechanisms that govern clonal dynamics and selection during early tumorigenesis remain largely elusive. Ceresa et al. provide experimental and mathematical evidence that MYC-dependent competition between individual clones is one driving force of brain tumor evolution, adding a winner/loser aspect to the picture that complements existing concepts.]]></summary>
        <author>
            <name>Frank Winkler</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Early clonal extinction in glioblastoma progression revealed by genetic barcoding]]></title>
        <id>pubmed:37541243</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37541243/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230828204854&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-08-04T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Glioblastoma progression in its early stages remains poorly understood. Here, we transfer PDGFB and genetic barcodes in mouse brain to initiate gliomagenesis and enable direct tracing of glioblastoma evolution from its earliest possible stage. Unexpectedly, we observe a high incidence of clonal extinction events and progressive divergence in clonal sizes, even after the acquisition of malignant phenotype. Computational modeling suggests these dynamics result from clonal-based cell-cell...]]></summary>
        <author>
            <name>Davide Ceresa</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[The winner takes it all: Competition drives clonal selection in gliomagenesis]]></title>
        <id>pubmed:37541246</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37541246/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230827204908&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-08-04T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[The exact mechanisms that govern clonal dynamics and selection during early tumorigenesis remain largely elusive. Ceresa et al. provide experimental and mathematical evidence that MYC-dependent competition between individual clones is one driving force of brain tumor evolution, adding a winner/loser aspect to the picture that complements existing concepts.]]></summary>
        <author>
            <name>Frank Winkler</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Early clonal extinction in glioblastoma progression revealed by genetic barcoding]]></title>
        <id>pubmed:37541243</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37541243/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230827204908&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-08-04T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Glioblastoma progression in its early stages remains poorly understood. Here, we transfer PDGFB and genetic barcodes in mouse brain to initiate gliomagenesis and enable direct tracing of glioblastoma evolution from its earliest possible stage. Unexpectedly, we observe a high incidence of clonal extinction events and progressive divergence in clonal sizes, even after the acquisition of malignant phenotype. Computational modeling suggests these dynamics result from clonal-based cell-cell...]]></summary>
        <author>
            <name>Davide Ceresa</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[The winner takes it all: Competition drives clonal selection in gliomagenesis]]></title>
        <id>pubmed:37541246</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37541246/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230826205107&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-08-04T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[The exact mechanisms that govern clonal dynamics and selection during early tumorigenesis remain largely elusive. Ceresa et al. provide experimental and mathematical evidence that MYC-dependent competition between individual clones is one driving force of brain tumor evolution, adding a winner/loser aspect to the picture that complements existing concepts.]]></summary>
        <author>
            <name>Frank Winkler</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Early clonal extinction in glioblastoma progression revealed by genetic barcoding]]></title>
        <id>pubmed:37541243</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37541243/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230826205107&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-08-04T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Glioblastoma progression in its early stages remains poorly understood. Here, we transfer PDGFB and genetic barcodes in mouse brain to initiate gliomagenesis and enable direct tracing of glioblastoma evolution from its earliest possible stage. Unexpectedly, we observe a high incidence of clonal extinction events and progressive divergence in clonal sizes, even after the acquisition of malignant phenotype. Computational modeling suggests these dynamics result from clonal-based cell-cell...]]></summary>
        <author>
            <name>Davide Ceresa</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[The winner takes it all: Competition drives clonal selection in gliomagenesis]]></title>
        <id>pubmed:37541246</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37541246/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230825204602&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-08-04T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[The exact mechanisms that govern clonal dynamics and selection during early tumorigenesis remain largely elusive. Ceresa et al. provide experimental and mathematical evidence that MYC-dependent competition between individual clones is one driving force of brain tumor evolution, adding a winner/loser aspect to the picture that complements existing concepts.]]></summary>
        <author>
            <name>Frank Winkler</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Early clonal extinction in glioblastoma progression revealed by genetic barcoding]]></title>
        <id>pubmed:37541243</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37541243/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230825204602&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-08-04T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Glioblastoma progression in its early stages remains poorly understood. Here, we transfer PDGFB and genetic barcodes in mouse brain to initiate gliomagenesis and enable direct tracing of glioblastoma evolution from its earliest possible stage. Unexpectedly, we observe a high incidence of clonal extinction events and progressive divergence in clonal sizes, even after the acquisition of malignant phenotype. Computational modeling suggests these dynamics result from clonal-based cell-cell...]]></summary>
        <author>
            <name>Davide Ceresa</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[The winner takes it all: Competition drives clonal selection in gliomagenesis]]></title>
        <id>pubmed:37541246</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37541246/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230824204824&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-08-04T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[The exact mechanisms that govern clonal dynamics and selection during early tumorigenesis remain largely elusive. Ceresa et al. provide experimental and mathematical evidence that MYC-dependent competition between individual clones is one driving force of brain tumor evolution, adding a winner/loser aspect to the picture that complements existing concepts.]]></summary>
        <author>
            <name>Frank Winkler</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Early clonal extinction in glioblastoma progression revealed by genetic barcoding]]></title>
        <id>pubmed:37541243</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37541243/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230824204824&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-08-04T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Glioblastoma progression in its early stages remains poorly understood. Here, we transfer PDGFB and genetic barcodes in mouse brain to initiate gliomagenesis and enable direct tracing of glioblastoma evolution from its earliest possible stage. Unexpectedly, we observe a high incidence of clonal extinction events and progressive divergence in clonal sizes, even after the acquisition of malignant phenotype. Computational modeling suggests these dynamics result from clonal-based cell-cell...]]></summary>
        <author>
            <name>Davide Ceresa</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[The winner takes it all: Competition drives clonal selection in gliomagenesis]]></title>
        <id>pubmed:37541246</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37541246/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230823204708&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-08-04T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[The exact mechanisms that govern clonal dynamics and selection during early tumorigenesis remain largely elusive. Ceresa et al. provide experimental and mathematical evidence that MYC-dependent competition between individual clones is one driving force of brain tumor evolution, adding a winner/loser aspect to the picture that complements existing concepts.]]></summary>
        <author>
            <name>Frank Winkler</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Early clonal extinction in glioblastoma progression revealed by genetic barcoding]]></title>
        <id>pubmed:37541243</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37541243/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230823204708&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-08-04T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Glioblastoma progression in its early stages remains poorly understood. Here, we transfer PDGFB and genetic barcodes in mouse brain to initiate gliomagenesis and enable direct tracing of glioblastoma evolution from its earliest possible stage. Unexpectedly, we observe a high incidence of clonal extinction events and progressive divergence in clonal sizes, even after the acquisition of malignant phenotype. Computational modeling suggests these dynamics result from clonal-based cell-cell...]]></summary>
        <author>
            <name>Davide Ceresa</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[The winner takes it all: Competition drives clonal selection in gliomagenesis]]></title>
        <id>pubmed:37541246</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37541246/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230822204709&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-08-04T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[The exact mechanisms that govern clonal dynamics and selection during early tumorigenesis remain largely elusive. Ceresa et al. provide experimental and mathematical evidence that MYC-dependent competition between individual clones is one driving force of brain tumor evolution, adding a winner/loser aspect to the picture that complements existing concepts.]]></summary>
        <author>
            <name>Frank Winkler</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Early clonal extinction in glioblastoma progression revealed by genetic barcoding]]></title>
        <id>pubmed:37541243</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37541243/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230822204709&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-08-04T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Glioblastoma progression in its early stages remains poorly understood. Here, we transfer PDGFB and genetic barcodes in mouse brain to initiate gliomagenesis and enable direct tracing of glioblastoma evolution from its earliest possible stage. Unexpectedly, we observe a high incidence of clonal extinction events and progressive divergence in clonal sizes, even after the acquisition of malignant phenotype. Computational modeling suggests these dynamics result from clonal-based cell-cell...]]></summary>
        <author>
            <name>Davide Ceresa</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[The winner takes it all: Competition drives clonal selection in gliomagenesis]]></title>
        <id>pubmed:37541246</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37541246/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230821204801&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-08-04T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[The exact mechanisms that govern clonal dynamics and selection during early tumorigenesis remain largely elusive. Ceresa et al. provide experimental and mathematical evidence that MYC-dependent competition between individual clones is one driving force of brain tumor evolution, adding a winner/loser aspect to the picture that complements existing concepts.]]></summary>
        <author>
            <name>Frank Winkler</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Early clonal extinction in glioblastoma progression revealed by genetic barcoding]]></title>
        <id>pubmed:37541243</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37541243/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230821204801&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-08-04T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Glioblastoma progression in its early stages remains poorly understood. Here, we transfer PDGFB and genetic barcodes in mouse brain to initiate gliomagenesis and enable direct tracing of glioblastoma evolution from its earliest possible stage. Unexpectedly, we observe a high incidence of clonal extinction events and progressive divergence in clonal sizes, even after the acquisition of malignant phenotype. Computational modeling suggests these dynamics result from clonal-based cell-cell...]]></summary>
        <author>
            <name>Davide Ceresa</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[The winner takes it all: Competition drives clonal selection in gliomagenesis]]></title>
        <id>pubmed:37541246</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37541246/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230820204715&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-08-04T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[The exact mechanisms that govern clonal dynamics and selection during early tumorigenesis remain largely elusive. Ceresa et al. provide experimental and mathematical evidence that MYC-dependent competition between individual clones is one driving force of brain tumor evolution, adding a winner/loser aspect to the picture that complements existing concepts.]]></summary>
        <author>
            <name>Frank Winkler</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Early clonal extinction in glioblastoma progression revealed by genetic barcoding]]></title>
        <id>pubmed:37541243</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37541243/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230820204715&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-08-04T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Glioblastoma progression in its early stages remains poorly understood. Here, we transfer PDGFB and genetic barcodes in mouse brain to initiate gliomagenesis and enable direct tracing of glioblastoma evolution from its earliest possible stage. Unexpectedly, we observe a high incidence of clonal extinction events and progressive divergence in clonal sizes, even after the acquisition of malignant phenotype. Computational modeling suggests these dynamics result from clonal-based cell-cell...]]></summary>
        <author>
            <name>Davide Ceresa</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[The winner takes it all: Competition drives clonal selection in gliomagenesis]]></title>
        <id>pubmed:37541246</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37541246/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230819204952&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-08-04T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[The exact mechanisms that govern clonal dynamics and selection during early tumorigenesis remain largely elusive. Ceresa et al. provide experimental and mathematical evidence that MYC-dependent competition between individual clones is one driving force of brain tumor evolution, adding a winner/loser aspect to the picture that complements existing concepts.]]></summary>
        <author>
            <name>Frank Winkler</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Early clonal extinction in glioblastoma progression revealed by genetic barcoding]]></title>
        <id>pubmed:37541243</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37541243/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230819204952&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-08-04T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Glioblastoma progression in its early stages remains poorly understood. Here, we transfer PDGFB and genetic barcodes in mouse brain to initiate gliomagenesis and enable direct tracing of glioblastoma evolution from its earliest possible stage. Unexpectedly, we observe a high incidence of clonal extinction events and progressive divergence in clonal sizes, even after the acquisition of malignant phenotype. Computational modeling suggests these dynamics result from clonal-based cell-cell...]]></summary>
        <author>
            <name>Davide Ceresa</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[The winner takes it all: Competition drives clonal selection in gliomagenesis]]></title>
        <id>pubmed:37541246</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37541246/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230818204446&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-08-04T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[The exact mechanisms that govern clonal dynamics and selection during early tumorigenesis remain largely elusive. Ceresa et al. provide experimental and mathematical evidence that MYC-dependent competition between individual clones is one driving force of brain tumor evolution, adding a winner/loser aspect to the picture that complements existing concepts.]]></summary>
        <author>
            <name>Frank Winkler</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Early clonal extinction in glioblastoma progression revealed by genetic barcoding]]></title>
        <id>pubmed:37541243</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37541243/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230818204446&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-08-04T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Glioblastoma progression in its early stages remains poorly understood. Here, we transfer PDGFB and genetic barcodes in mouse brain to initiate gliomagenesis and enable direct tracing of glioblastoma evolution from its earliest possible stage. Unexpectedly, we observe a high incidence of clonal extinction events and progressive divergence in clonal sizes, even after the acquisition of malignant phenotype. Computational modeling suggests these dynamics result from clonal-based cell-cell...]]></summary>
        <author>
            <name>Davide Ceresa</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[The winner takes it all: Competition drives clonal selection in gliomagenesis]]></title>
        <id>pubmed:37541246</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37541246/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230817204642&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-08-04T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[The exact mechanisms that govern clonal dynamics and selection during early tumorigenesis remain largely elusive. Ceresa et al. provide experimental and mathematical evidence that MYC-dependent competition between individual clones is one driving force of brain tumor evolution, adding a winner/loser aspect to the picture that complements existing concepts.]]></summary>
        <author>
            <name>Frank Winkler</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Early clonal extinction in glioblastoma progression revealed by genetic barcoding]]></title>
        <id>pubmed:37541243</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37541243/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230817204642&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-08-04T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Glioblastoma progression in its early stages remains poorly understood. Here, we transfer PDGFB and genetic barcodes in mouse brain to initiate gliomagenesis and enable direct tracing of glioblastoma evolution from its earliest possible stage. Unexpectedly, we observe a high incidence of clonal extinction events and progressive divergence in clonal sizes, even after the acquisition of malignant phenotype. Computational modeling suggests these dynamics result from clonal-based cell-cell...]]></summary>
        <author>
            <name>Davide Ceresa</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[The winner takes it all: Competition drives clonal selection in gliomagenesis]]></title>
        <id>pubmed:37541246</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37541246/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230816204600&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-08-04T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[The exact mechanisms that govern clonal dynamics and selection during early tumorigenesis remain largely elusive. Ceresa et al. provide experimental and mathematical evidence that MYC-dependent competition between individual clones is one driving force of brain tumor evolution, adding a winner/loser aspect to the picture that complements existing concepts.]]></summary>
        <author>
            <name>Frank Winkler</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Early clonal extinction in glioblastoma progression revealed by genetic barcoding]]></title>
        <id>pubmed:37541243</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37541243/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230816204600&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-08-04T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Glioblastoma progression in its early stages remains poorly understood. Here, we transfer PDGFB and genetic barcodes in mouse brain to initiate gliomagenesis and enable direct tracing of glioblastoma evolution from its earliest possible stage. Unexpectedly, we observe a high incidence of clonal extinction events and progressive divergence in clonal sizes, even after the acquisition of malignant phenotype. Computational modeling suggests these dynamics result from clonal-based cell-cell...]]></summary>
        <author>
            <name>Davide Ceresa</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[The winner takes it all: Competition drives clonal selection in gliomagenesis]]></title>
        <id>pubmed:37541246</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37541246/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230815204647&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-08-04T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[The exact mechanisms that govern clonal dynamics and selection during early tumorigenesis remain largely elusive. Ceresa et al. provide experimental and mathematical evidence that MYC-dependent competition between individual clones is one driving force of brain tumor evolution, adding a winner/loser aspect to the picture that complements existing concepts.]]></summary>
        <author>
            <name>Frank Winkler</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Early clonal extinction in glioblastoma progression revealed by genetic barcoding]]></title>
        <id>pubmed:37541243</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37541243/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230815204647&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-08-04T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Glioblastoma progression in its early stages remains poorly understood. Here, we transfer PDGFB and genetic barcodes in mouse brain to initiate gliomagenesis and enable direct tracing of glioblastoma evolution from its earliest possible stage. Unexpectedly, we observe a high incidence of clonal extinction events and progressive divergence in clonal sizes, even after the acquisition of malignant phenotype. Computational modeling suggests these dynamics result from clonal-based cell-cell...]]></summary>
        <author>
            <name>Davide Ceresa</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[The winner takes it all: Competition drives clonal selection in gliomagenesis]]></title>
        <id>pubmed:37541246</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37541246/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230814204719&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-08-04T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[The exact mechanisms that govern clonal dynamics and selection during early tumorigenesis remain largely elusive. Ceresa et al. provide experimental and mathematical evidence that MYC-dependent competition between individual clones is one driving force of brain tumor evolution, adding a winner/loser aspect to the picture that complements existing concepts.]]></summary>
        <author>
            <name>Frank Winkler</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Early clonal extinction in glioblastoma progression revealed by genetic barcoding]]></title>
        <id>pubmed:37541243</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37541243/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230814204719&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-08-04T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Glioblastoma progression in its early stages remains poorly understood. Here, we transfer PDGFB and genetic barcodes in mouse brain to initiate gliomagenesis and enable direct tracing of glioblastoma evolution from its earliest possible stage. Unexpectedly, we observe a high incidence of clonal extinction events and progressive divergence in clonal sizes, even after the acquisition of malignant phenotype. Computational modeling suggests these dynamics result from clonal-based cell-cell...]]></summary>
        <author>
            <name>Davide Ceresa</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[The winner takes it all: Competition drives clonal selection in gliomagenesis]]></title>
        <id>pubmed:37541246</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37541246/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230813204802&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-08-04T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[The exact mechanisms that govern clonal dynamics and selection during early tumorigenesis remain largely elusive. Ceresa et al. provide experimental and mathematical evidence that MYC-dependent competition between individual clones is one driving force of brain tumor evolution, adding a winner/loser aspect to the picture that complements existing concepts.]]></summary>
        <author>
            <name>Frank Winkler</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Early clonal extinction in glioblastoma progression revealed by genetic barcoding]]></title>
        <id>pubmed:37541243</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37541243/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230813204802&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-08-04T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Glioblastoma progression in its early stages remains poorly understood. Here, we transfer PDGFB and genetic barcodes in mouse brain to initiate gliomagenesis and enable direct tracing of glioblastoma evolution from its earliest possible stage. Unexpectedly, we observe a high incidence of clonal extinction events and progressive divergence in clonal sizes, even after the acquisition of malignant phenotype. Computational modeling suggests these dynamics result from clonal-based cell-cell...]]></summary>
        <author>
            <name>Davide Ceresa</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[The winner takes it all: Competition drives clonal selection in gliomagenesis]]></title>
        <id>pubmed:37541246</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37541246/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230812205008&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-08-04T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[The exact mechanisms that govern clonal dynamics and selection during early tumorigenesis remain largely elusive. Ceresa et al. provide experimental and mathematical evidence that MYC-dependent competition between individual clones is one driving force of brain tumor evolution, adding a winner/loser aspect to the picture that complements existing concepts.]]></summary>
        <author>
            <name>Frank Winkler</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Early clonal extinction in glioblastoma progression revealed by genetic barcoding]]></title>
        <id>pubmed:37541243</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37541243/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230812205008&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-08-04T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Glioblastoma progression in its early stages remains poorly understood. Here, we transfer PDGFB and genetic barcodes in mouse brain to initiate gliomagenesis and enable direct tracing of glioblastoma evolution from its earliest possible stage. Unexpectedly, we observe a high incidence of clonal extinction events and progressive divergence in clonal sizes, even after the acquisition of malignant phenotype. Computational modeling suggests these dynamics result from clonal-based cell-cell...]]></summary>
        <author>
            <name>Davide Ceresa</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[The winner takes it all: Competition drives clonal selection in gliomagenesis]]></title>
        <id>pubmed:37541246</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37541246/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230811204539&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-08-04T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[The exact mechanisms that govern clonal dynamics and selection during early tumorigenesis remain largely elusive. Ceresa et al. provide experimental and mathematical evidence that MYC-dependent competition between individual clones is one driving force of brain tumor evolution, adding a winner/loser aspect to the picture that complements existing concepts.]]></summary>
        <author>
            <name>Frank Winkler</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Early clonal extinction in glioblastoma progression revealed by genetic barcoding]]></title>
        <id>pubmed:37541243</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37541243/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230811204539&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-08-04T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Glioblastoma progression in its early stages remains poorly understood. Here, we transfer PDGFB and genetic barcodes in mouse brain to initiate gliomagenesis and enable direct tracing of glioblastoma evolution from its earliest possible stage. Unexpectedly, we observe a high incidence of clonal extinction events and progressive divergence in clonal sizes, even after the acquisition of malignant phenotype. Computational modeling suggests these dynamics result from clonal-based cell-cell...]]></summary>
        <author>
            <name>Davide Ceresa</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[The winner takes it all: Competition drives clonal selection in gliomagenesis]]></title>
        <id>pubmed:37541246</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37541246/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230810204637&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-08-04T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[The exact mechanisms that govern clonal dynamics and selection during early tumorigenesis remain largely elusive. Ceresa et al. provide experimental and mathematical evidence that MYC-dependent competition between individual clones is one driving force of brain tumor evolution, adding a winner/loser aspect to the picture that complements existing concepts.]]></summary>
        <author>
            <name>Frank Winkler</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Early clonal extinction in glioblastoma progression revealed by genetic barcoding]]></title>
        <id>pubmed:37541243</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37541243/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230810204637&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-08-04T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Glioblastoma progression in its early stages remains poorly understood. Here, we transfer PDGFB and genetic barcodes in mouse brain to initiate gliomagenesis and enable direct tracing of glioblastoma evolution from its earliest possible stage. Unexpectedly, we observe a high incidence of clonal extinction events and progressive divergence in clonal sizes, even after the acquisition of malignant phenotype. Computational modeling suggests these dynamics result from clonal-based cell-cell...]]></summary>
        <author>
            <name>Davide Ceresa</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[The winner takes it all: Competition drives clonal selection in gliomagenesis]]></title>
        <id>pubmed:37541246</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37541246/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230809205914&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-08-04T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[The exact mechanisms that govern clonal dynamics and selection during early tumorigenesis remain largely elusive. Ceresa et al. provide experimental and mathematical evidence that MYC-dependent competition between individual clones is one driving force of brain tumor evolution, adding a winner/loser aspect to the picture that complements existing concepts.]]></summary>
        <author>
            <name>Frank Winkler</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Early clonal extinction in glioblastoma progression revealed by genetic barcoding]]></title>
        <id>pubmed:37541243</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37541243/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230809205914&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-08-04T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Glioblastoma progression in its early stages remains poorly understood. Here, we transfer PDGFB and genetic barcodes in mouse brain to initiate gliomagenesis and enable direct tracing of glioblastoma evolution from its earliest possible stage. Unexpectedly, we observe a high incidence of clonal extinction events and progressive divergence in clonal sizes, even after the acquisition of malignant phenotype. Computational modeling suggests these dynamics result from clonal-based cell-cell...]]></summary>
        <author>
            <name>Davide Ceresa</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[The winner takes it all: Competition drives clonal selection in gliomagenesis]]></title>
        <id>pubmed:37541246</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37541246/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230808205751&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-08-04T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[The exact mechanisms that govern clonal dynamics and selection during early tumorigenesis remain largely elusive. Ceresa et al. provide experimental and mathematical evidence that MYC-dependent competition between individual clones is one driving force of brain tumor evolution, adding a winner/loser aspect to the picture that complements existing concepts.]]></summary>
        <author>
            <name>Frank Winkler</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Early clonal extinction in glioblastoma progression revealed by genetic barcoding]]></title>
        <id>pubmed:37541243</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37541243/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230808205751&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-08-04T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Glioblastoma progression in its early stages remains poorly understood. Here, we transfer PDGFB and genetic barcodes in mouse brain to initiate gliomagenesis and enable direct tracing of glioblastoma evolution from its earliest possible stage. Unexpectedly, we observe a high incidence of clonal extinction events and progressive divergence in clonal sizes, even after the acquisition of malignant phenotype. Computational modeling suggests these dynamics result from clonal-based cell-cell...]]></summary>
        <author>
            <name>Davide Ceresa</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[The winner takes it all: Competition drives clonal selection in gliomagenesis]]></title>
        <id>pubmed:37541246</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37541246/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230807205649&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-08-04T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[The exact mechanisms that govern clonal dynamics and selection during early tumorigenesis remain largely elusive. Ceresa et al. provide experimental and mathematical evidence that MYC-dependent competition between individual clones is one driving force of brain tumor evolution, adding a winner/loser aspect to the picture that complements existing concepts.]]></summary>
        <author>
            <name>Frank Winkler</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Early clonal extinction in glioblastoma progression revealed by genetic barcoding]]></title>
        <id>pubmed:37541243</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37541243/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230807205649&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-08-04T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Glioblastoma progression in its early stages remains poorly understood. Here, we transfer PDGFB and genetic barcodes in mouse brain to initiate gliomagenesis and enable direct tracing of glioblastoma evolution from its earliest possible stage. Unexpectedly, we observe a high incidence of clonal extinction events and progressive divergence in clonal sizes, even after the acquisition of malignant phenotype. Computational modeling suggests these dynamics result from clonal-based cell-cell...]]></summary>
        <author>
            <name>Davide Ceresa</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[The winner takes it all: Competition drives clonal selection in gliomagenesis]]></title>
        <id>pubmed:37541246</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37541246/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230806205822&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-08-04T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[The exact mechanisms that govern clonal dynamics and selection during early tumorigenesis remain largely elusive. Ceresa et al. provide experimental and mathematical evidence that MYC-dependent competition between individual clones is one driving force of brain tumor evolution, adding a winner/loser aspect to the picture that complements existing concepts.]]></summary>
        <author>
            <name>Frank Winkler</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Early clonal extinction in glioblastoma progression revealed by genetic barcoding]]></title>
        <id>pubmed:37541243</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37541243/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230806205822&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-08-04T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Glioblastoma progression in its early stages remains poorly understood. Here, we transfer PDGFB and genetic barcodes in mouse brain to initiate gliomagenesis and enable direct tracing of glioblastoma evolution from its earliest possible stage. Unexpectedly, we observe a high incidence of clonal extinction events and progressive divergence in clonal sizes, even after the acquisition of malignant phenotype. Computational modeling suggests these dynamics result from clonal-based cell-cell...]]></summary>
        <author>
            <name>Davide Ceresa</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[The winner takes it all: Competition drives clonal selection in gliomagenesis]]></title>
        <id>pubmed:37541246</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37541246/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230805205329&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-08-04T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[The exact mechanisms that govern clonal dynamics and selection during early tumorigenesis remain largely elusive. Ceresa et al. provide experimental and mathematical evidence that MYC-dependent competition between individual clones is one driving force of brain tumor evolution, adding a winner/loser aspect to the picture that complements existing concepts.]]></summary>
        <author>
            <name>Frank Winkler</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Early clonal extinction in glioblastoma progression revealed by genetic barcoding]]></title>
        <id>pubmed:37541243</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37541243/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230805205329&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-08-04T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Glioblastoma progression in its early stages remains poorly understood. Here, we transfer PDGFB and genetic barcodes in mouse brain to initiate gliomagenesis and enable direct tracing of glioblastoma evolution from its earliest possible stage. Unexpectedly, we observe a high incidence of clonal extinction events and progressive divergence in clonal sizes, even after the acquisition of malignant phenotype. Computational modeling suggests these dynamics result from clonal-based cell-cell...]]></summary>
        <author>
            <name>Davide Ceresa</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clonal Hematopoiesis and Acute Ischemic Stroke Outcomes]]></title>
        <id>pubmed:37532684</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37532684/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230816204601&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-08-02T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[OBJECTIVE: The effect of clonal hematopoiesis of indeterminate potential (CHIP) on the manifestation and clinical outcomes of acute ischemic stroke (AIS) has not been fully elucidated.]]></summary>
        <author>
            <name>Eung-Joon Lee</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clonal Hematopoiesis and Acute Ischemic Stroke Outcomes]]></title>
        <id>pubmed:37532684</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37532684/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230815204647&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-08-02T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[OBJECTIVE: The effect of clonal hematopoiesis of indeterminate potential (CHIP) on the manifestation and clinical outcomes of acute ischemic stroke (AIS) has not been fully elucidated.]]></summary>
        <author>
            <name>Eung-Joon Lee</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clonal Hematopoiesis and Acute Ischemic Stroke Outcomes]]></title>
        <id>pubmed:37532684</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37532684/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230814204719&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-08-02T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[OBJECTIVE: The effect of clonal hematopoiesis of indeterminate potential (CHIP) on the manifestation and clinical outcomes of acute ischemic stroke (AIS) has not been fully elucidated.]]></summary>
        <author>
            <name>Eung-Joon Lee</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clonal Hematopoiesis and Acute Ischemic Stroke Outcomes]]></title>
        <id>pubmed:37532684</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37532684/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230813204802&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-08-02T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[OBJECTIVE: The effect of clonal hematopoiesis of indeterminate potential (CHIP) on the manifestation and clinical outcomes of acute ischemic stroke (AIS) has not been fully elucidated.]]></summary>
        <author>
            <name>Eung-Joon Lee</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clonal Hematopoiesis and Acute Ischemic Stroke Outcomes]]></title>
        <id>pubmed:37532684</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37532684/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230812205008&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-08-02T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[OBJECTIVE: The effect of Clonal hematopoiesis of indeterminate potential (CHIP) on the manifestation and clinical outcomes of acute ischemic stroke (AIS) has not been fully elucidated.]]></summary>
        <author>
            <name>Eung-Joon Lee</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clonal Hematopoiesis and Acute Ischemic Stroke Outcomes]]></title>
        <id>pubmed:37532684</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37532684/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230811204531&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-08-02T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[OBJECTIVE: The effect of Clonal hematopoiesis of indeterminate potential (CHIP) on the manifestation and clinical outcomes of acute ischemic stroke (AIS) has not been fully elucidated.]]></summary>
        <author>
            <name>Eung-Joon Lee</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clonal Hematopoiesis and Acute Ischemic Stroke Outcomes]]></title>
        <id>pubmed:37532684</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37532684/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230810204637&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-08-02T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[OBJECTIVE: The effect of Clonal hematopoiesis of indeterminate potential (CHIP) on the manifestation and clinical outcomes of acute ischemic stroke (AIS) has not been fully elucidated.]]></summary>
        <author>
            <name>Eung-Joon Lee</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clonal Hematopoiesis and Acute Ischemic Stroke Outcomes]]></title>
        <id>pubmed:37532684</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37532684/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230809205914&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-08-02T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[OBJECTIVE: The effect of Clonal hematopoiesis of indeterminate potential (CHIP) on the manifestation and clinical outcomes of acute ischemic stroke (AIS) has not been fully elucidated.]]></summary>
        <author>
            <name>Eung-Joon Lee</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clonal Hematopoiesis and Acute Ischemic Stroke Outcomes]]></title>
        <id>pubmed:37532684</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37532684/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230808205751&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-08-02T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[OBJECTIVE: The effect of Clonal hematopoiesis of indeterminate potential (CHIP) on the manifestation and clinical outcomes of acute ischemic stroke (AIS) has not been fully elucidated.]]></summary>
        <author>
            <name>Eung-Joon Lee</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clonal Hematopoiesis and Acute Ischemic Stroke Outcomes]]></title>
        <id>pubmed:37532684</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37532684/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230807205649&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-08-02T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[OBJECTIVE: The effect of Clonal hematopoiesis of indeterminate potential (CHIP) on the manifestation and clinical outcomes of acute ischemic stroke (AIS) has not been fully elucidated.]]></summary>
        <author>
            <name>Eung-Joon Lee</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clonal Hematopoiesis and Acute Ischemic Stroke Outcomes]]></title>
        <id>pubmed:37532684</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37532684/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230806205822&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-08-02T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[OBJECTIVE: The effect of Clonal hematopoiesis of indeterminate potential (CHIP) on the manifestation and clinical outcomes of acute ischemic stroke (AIS) has not been fully elucidated.]]></summary>
        <author>
            <name>Eung-Joon Lee</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clonal Hematopoiesis and Acute Ischemic Stroke Outcomes]]></title>
        <id>pubmed:37532684</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37532684/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230805205329&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-08-02T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[OBJECTIVE: The effect of Clonal hematopoiesis of indeterminate potential (CHIP) on the manifestation and clinical outcomes of acute ischemic stroke (AIS) has not been fully elucidated.]]></summary>
        <author>
            <name>Eung-Joon Lee</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clonal Hematopoiesis and Acute Ischemic Stroke Outcomes]]></title>
        <id>pubmed:37532684</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37532684/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230804205603&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-08-02T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[OBJECTIVE: The effect of Clonal hematopoiesis of indeterminate potential (CHIP) on the manifestation and clinical outcomes of acute ischemic stroke (AIS) has not been fully elucidated.]]></summary>
        <author>
            <name>Eung-Joon Lee</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clonal Hematopoiesis and Acute Ischemic Stroke Outcomes]]></title>
        <id>pubmed:37532684</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37532684/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230803205941&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-08-02T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[OBJECTIVE: The effect of Clonal hematopoiesis of indeterminate potential (CHIP) on the manifestation and clinical outcomes of acute ischemic stroke (AIS) has not been fully elucidated.]]></summary>
        <author>
            <name>Eung-Joon Lee</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Foxm1 haploinsufficiency drives clonal hematopoiesis and promotes a stress-related transition to hematologic malignancy in mice]]></title>
        <id>pubmed:37526082</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37526082/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230815204647&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-08-01T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Clonal hematopoiesis plays a critical role in the initiation and development of hematologic malignancies. In patients with del(5q) myelodysplastic syndrome (MDS), the transcription factor FOXM1 is frequently downregulated in CD34+ cells. In this study, we demonstrated that Foxm1 haploinsufficiency disturbed normal hematopoiesis and conferred a competitive repopulation advantage for a short period. However, it impaired the long-term self-renewal capacity of hematopoietic stem cells,...]]></summary>
        <author>
            <name>Chunjie Yu</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Foxm1 haploinsufficiency drives clonal hematopoiesis and promotes a stress-related transition to hematologic malignancy in mice]]></title>
        <id>pubmed:37526082</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37526082/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230814204719&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-08-01T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Clonal hematopoiesis plays a critical role in the initiation and development of hematologic malignancies. In patients with del(5q) myelodysplastic syndrome (MDS), the transcription factor FOXM1 is frequently downregulated in CD34+ cells. In this study, we demonstrated that Foxm1 haploinsufficiency disturbed normal hematopoiesis and conferred a competitive repopulation advantage for a short period. However, it impaired the long-term self-renewal capacity of hematopoietic stem cells,...]]></summary>
        <author>
            <name>Chunjie Yu</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Foxm1 haploinsufficiency drives clonal hematopoiesis and promotes a stress-related transition to hematologic malignancy in mice]]></title>
        <id>pubmed:37526082</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37526082/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230813204802&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-08-01T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Clonal hematopoiesis plays a critical role in the initiation and development of hematologic malignancies. In patients with del(5q) myelodysplastic syndrome (MDS), the transcription factor FOXM1 is frequently downregulated in CD34+ cells. In this study, we demonstrated that Foxm1 haploinsufficiency disturbed normal hematopoiesis and conferred a competitive repopulation advantage for a short period. However, it impaired the long-term self-renewal capacity of hematopoietic stem cells,...]]></summary>
        <author>
            <name>Chunjie Yu</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Foxm1 haploinsufficiency drives clonal hematopoiesis and promotes a stress-related transition to hematologic malignancy in mice]]></title>
        <id>pubmed:37526082</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37526082/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230812205008&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-08-01T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Clonal hematopoiesis plays a critical role in the initiation and development of hematologic malignancies. In patients with del(5q) myelodysplastic syndrome (MDS), the transcription factor FOXM1 is frequently downregulated in CD34+ cells. In this study, we demonstrated that Foxm1 haploinsufficiency disturbed normal hematopoiesis and conferred a competitive repopulation advantage for a short period. However, it impaired the long-term self-renewal capacity of hematopoietic stem cells,...]]></summary>
        <author>
            <name>Chunjie Yu</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Foxm1 haploinsufficiency drives clonal hematopoiesis and promotes a stress-related transition to hematologic malignancy in mice]]></title>
        <id>pubmed:37526082</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37526082/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230811204531&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-08-01T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Clonal hematopoiesis plays a critical role in the initiation and development of hematologic malignancies. In patients with del(5q) myelodysplastic syndrome (MDS), the transcription factor FOXM1 is frequently downregulated in CD34+ cells. In this study, we demonstrated that Foxm1 haploinsufficiency disturbed normal hematopoiesis and conferred a competitive repopulation advantage for a short period. However, it impaired the long-term self-renewal capacity of hematopoietic stem cells,...]]></summary>
        <author>
            <name>Chunjie Yu</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Foxm1 haploinsufficiency drives clonal hematopoiesis and promotes a stress-related transition to hematologic malignancy in mice]]></title>
        <id>pubmed:37526082</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37526082/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230810204637&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-08-01T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Clonal hematopoiesis plays a critical role in the initiation and development of hematologic malignancies. In patients with del(5q) myelodysplastic syndrome (MDS), the transcription factor FOXM1 is frequently downregulated in CD34+ cells. In this study, we demonstrated that Foxm1 haploinsufficiency disturbed normal hematopoiesis and conferred a competitive repopulation advantage for a short period. However, it impaired the long-term self-renewal capacity of hematopoietic stem cells,...]]></summary>
        <author>
            <name>Chunjie Yu</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Foxm1 haploinsufficiency drives clonal hematopoiesis and promotes a stress-related transition to hematologic malignancy in mice]]></title>
        <id>pubmed:37526082</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37526082/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230809205914&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-08-01T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Clonal hematopoiesis plays a critical role in the initiation and development of hematologic malignancies. In patients with del(5q) myelodysplastic syndrome (MDS), the transcription factor FOXM1 is frequently downregulated in CD34+ cells. In this study, we demonstrated that Foxm1 haploinsufficiency disturbed normal hematopoiesis and conferred a competitive repopulation advantage for a short period. However, it impaired the long-term self-renewal capacity of hematopoietic stem cells,...]]></summary>
        <author>
            <name>Chunjie Yu</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Foxm1 haploinsufficiency drives clonal hematopoiesis and promotes a stress-related transition to hematologic malignancy in mice]]></title>
        <id>pubmed:37526082</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37526082/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230808205751&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-08-01T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Clonal hematopoiesis plays a critical role in the initiation and development of hematologic malignancies. In patients with del(5q) myelodysplastic syndrome (MDS), the transcription factor FOXM1 is frequently downregulated in CD34+ cells. In this study, we demonstrated that Foxm1 haploinsufficiency disturbed normal hematopoiesis and conferred a competitive repopulation advantage for a short period. However, it impaired the long-term self-renewal capacity of hematopoietic stem cells,...]]></summary>
        <author>
            <name>Chunjie Yu</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Foxm1 haploinsufficiency drives clonal hematopoiesis and promotes a stress-related transition to hematologic malignancy in mice]]></title>
        <id>pubmed:37526082</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37526082/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230807205649&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-08-01T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Clonal hematopoiesis plays a critical role in the initiation and development of hematologic malignancies. In patients with del(5q) myelodysplastic syndrome (MDS), the transcription factor FOXM1 is frequently downregulated in CD34+ cells. In this study, we demonstrated that Foxm1 haploinsufficiency disturbed normal hematopoiesis and conferred a competitive repopulation advantage for a short period. However, it impaired the long-term self-renewal capacity of hematopoietic stem cells,...]]></summary>
        <author>
            <name>Chunjie Yu</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Foxm1 haploinsufficiency drives clonal hematopoiesis and promotes a stress-related transition to hematologic malignancy in mice]]></title>
        <id>pubmed:37526082</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37526082/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230806205822&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-08-01T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Clonal hematopoiesis plays a critical role in the initiation and development of hematologic malignancies. In patients with del(5q) myelodysplastic syndrome (MDS), the transcription factor FOXM1 is frequently downregulated in CD34+ cells. In this study, we demonstrated that Foxm1 haploinsufficiency disturbed normal hematopoiesis and conferred a competitive repopulation advantage for a short period. However, it impaired the long-term self-renewal capacity of hematopoietic stem cells,...]]></summary>
        <author>
            <name>Chunjie Yu</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Foxm1 haploinsufficiency drives clonal hematopoiesis and promotes a stress-related transition to hematologic malignancy in mice]]></title>
        <id>pubmed:37526082</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37526082/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230805205329&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-08-01T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Clonal hematopoiesis plays a critical role in the initiation and development of hematologic malignancies. In patients with del(5q) myelodysplastic syndrome (MDS), the transcription factor FOXM1 is frequently downregulated in CD34+ cells. In this study, we demonstrated that Foxm1 haploinsufficiency disturbed normal hematopoiesis and conferred a competitive repopulation advantage for a short period. However, it impaired the long-term self-renewal capacity of hematopoietic stem cells,...]]></summary>
        <author>
            <name>Chunjie Yu</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Foxm1 haploinsufficiency drives clonal hematopoiesis and promotes a stress-related transition to hematologic malignancy in mice]]></title>
        <id>pubmed:37526082</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37526082/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230804205603&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-08-01T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Clonal hematopoiesis plays a critical role in the initiation and development of hematologic malignancies. In patients with del(5q) myelodysplastic syndrome (MDS), the transcription factor FOXM1 is frequently downregulated in CD34+ cells. In this study, we demonstrated that Foxm1 haploinsufficiency disturbed normal hematopoiesis and conferred a competitive repopulation advantage for a short period. However, it impaired the long-term self-renewal capacity of hematopoietic stem cells,...]]></summary>
        <author>
            <name>Chunjie Yu</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Foxm1 haploinsufficiency drives clonal hematopoiesis and promotes a stress-related transition to hematologic malignancy in mice]]></title>
        <id>pubmed:37526082</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37526082/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230803205941&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-08-01T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Clonal hematopoiesis plays a critical role in the initiation and development of hematologic malignancies. In patients with del(5q) myelodysplastic syndrome (MDS), the transcription factor FOXM1 is frequently downregulated in CD34+ cells. In this study, we demonstrated that Foxm1 haploinsufficiency disturbed normal hematopoiesis and conferred a competitive repopulation advantage for a short period. However, it impaired the long-term self-renewal capacity of hematopoietic stem cells,...]]></summary>
        <author>
            <name>Chunjie Yu</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Foxm1 haploinsufficiency drives clonal hematopoiesis and promotes a stress-related transition to hematologic malignancy in mice]]></title>
        <id>pubmed:37526082</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37526082/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230802205831&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-08-01T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Clonal hematopoiesis plays a critical role in the initiation and development of hematologic malignancies. In patients with del(5q) myelodysplastic syndrome (MDS), the transcription factor FOXM1 is frequently downregulated in CD34+ cells. In this study, we demonstrated that Foxm1 haploinsufficiency disturbed normal hematopoiesis and conferred a competitive repopulation advantage for a short period. However, it impaired the long-term self-renewal capacity of hematopoietic stem cells,...]]></summary>
        <author>
            <name>Chunjie Yu</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Foxm1 haploinsufficiency drives clonal hematopoiesis and promotes a stress-related transition to hematologic malignancy in mice]]></title>
        <id>pubmed:37526082</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37526082/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230801205540&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-08-01T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Clonal hematopoiesis plays a critical role in the initiation and development of hematologic malignancies. In patients with del(5q) myelodysplastic syndrome (MDS), the transcription factor FOXM1 is frequently downregulated in CD34+ cells. In this study, we demonstrated that Foxm1 haploinsufficiency disturbed normal hematopoiesis and conferred a competitive repopulation advantage for a short period. However, it impaired the long-term self-renewal capacity of hematopoietic stem cells,...]]></summary>
        <author>
            <name>Chunjie Yu</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Foxm1 haploinsufficiency drives clonal hematopoiesis and promotes a stress-related transition to hematologic malignancy in mice]]></title>
        <id>pubmed:37526082</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37526082/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230828204854&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-08-01T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Clonal hematopoiesis plays a critical role in the initiation and development of hematologic malignancies. In patients with del(5q) myelodysplastic syndrome (MDS), the transcription factor FOXM1 is frequently downregulated in CD34+ cells. In this study, we demonstrated that Foxm1 haploinsufficiency disturbed normal hematopoiesis and conferred a competitive repopulation advantage for a short period. However, it impaired the long-term self-renewal capacity of hematopoietic stem cells,...]]></summary>
        <author>
            <name>Chunjie Yu</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Foxm1 haploinsufficiency drives clonal hematopoiesis and promotes a stress-related transition to hematologic malignancy in mice]]></title>
        <id>pubmed:37526082</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37526082/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230827204908&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-08-01T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Clonal hematopoiesis plays a critical role in the initiation and development of hematologic malignancies. In patients with del(5q) myelodysplastic syndrome (MDS), the transcription factor FOXM1 is frequently downregulated in CD34+ cells. In this study, we demonstrated that Foxm1 haploinsufficiency disturbed normal hematopoiesis and conferred a competitive repopulation advantage for a short period. However, it impaired the long-term self-renewal capacity of hematopoietic stem cells,...]]></summary>
        <author>
            <name>Chunjie Yu</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Foxm1 haploinsufficiency drives clonal hematopoiesis and promotes a stress-related transition to hematologic malignancy in mice]]></title>
        <id>pubmed:37526082</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37526082/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230826205107&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-08-01T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Clonal hematopoiesis plays a critical role in the initiation and development of hematologic malignancies. In patients with del(5q) myelodysplastic syndrome (MDS), the transcription factor FOXM1 is frequently downregulated in CD34+ cells. In this study, we demonstrated that Foxm1 haploinsufficiency disturbed normal hematopoiesis and conferred a competitive repopulation advantage for a short period. However, it impaired the long-term self-renewal capacity of hematopoietic stem cells,...]]></summary>
        <author>
            <name>Chunjie Yu</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Foxm1 haploinsufficiency drives clonal hematopoiesis and promotes a stress-related transition to hematologic malignancy in mice]]></title>
        <id>pubmed:37526082</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37526082/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230825204602&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-08-01T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Clonal hematopoiesis plays a critical role in the initiation and development of hematologic malignancies. In patients with del(5q) myelodysplastic syndrome (MDS), the transcription factor FOXM1 is frequently downregulated in CD34+ cells. In this study, we demonstrated that Foxm1 haploinsufficiency disturbed normal hematopoiesis and conferred a competitive repopulation advantage for a short period. However, it impaired the long-term self-renewal capacity of hematopoietic stem cells,...]]></summary>
        <author>
            <name>Chunjie Yu</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Foxm1 haploinsufficiency drives clonal hematopoiesis and promotes a stress-related transition to hematologic malignancy in mice]]></title>
        <id>pubmed:37526082</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37526082/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230824204824&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-08-01T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Clonal hematopoiesis plays a critical role in the initiation and development of hematologic malignancies. In patients with del(5q) myelodysplastic syndrome (MDS), the transcription factor FOXM1 is frequently downregulated in CD34+ cells. In this study, we demonstrated that Foxm1 haploinsufficiency disturbed normal hematopoiesis and conferred a competitive repopulation advantage for a short period. However, it impaired the long-term self-renewal capacity of hematopoietic stem cells,...]]></summary>
        <author>
            <name>Chunjie Yu</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Foxm1 haploinsufficiency drives clonal hematopoiesis and promotes a stress-related transition to hematologic malignancy in mice]]></title>
        <id>pubmed:37526082</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37526082/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230823204708&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-08-01T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Clonal hematopoiesis plays a critical role in the initiation and development of hematologic malignancies. In patients with del(5q) myelodysplastic syndrome (MDS), the transcription factor FOXM1 is frequently downregulated in CD34+ cells. In this study, we demonstrated that Foxm1 haploinsufficiency disturbed normal hematopoiesis and conferred a competitive repopulation advantage for a short period. However, it impaired the long-term self-renewal capacity of hematopoietic stem cells,...]]></summary>
        <author>
            <name>Chunjie Yu</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Foxm1 haploinsufficiency drives clonal hematopoiesis and promotes a stress-related transition to hematologic malignancy in mice]]></title>
        <id>pubmed:37526082</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37526082/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230822204709&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-08-01T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Clonal hematopoiesis plays a critical role in the initiation and development of hematologic malignancies. In patients with del(5q) myelodysplastic syndrome (MDS), the transcription factor FOXM1 is frequently downregulated in CD34+ cells. In this study, we demonstrated that Foxm1 haploinsufficiency disturbed normal hematopoiesis and conferred a competitive repopulation advantage for a short period. However, it impaired the long-term self-renewal capacity of hematopoietic stem cells,...]]></summary>
        <author>
            <name>Chunjie Yu</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Foxm1 haploinsufficiency drives clonal hematopoiesis and promotes a stress-related transition to hematologic malignancy in mice]]></title>
        <id>pubmed:37526082</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37526082/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230821204801&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-08-01T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Clonal hematopoiesis plays a critical role in the initiation and development of hematologic malignancies. In patients with del(5q) myelodysplastic syndrome (MDS), the transcription factor FOXM1 is frequently downregulated in CD34+ cells. In this study, we demonstrated that Foxm1 haploinsufficiency disturbed normal hematopoiesis and conferred a competitive repopulation advantage for a short period. However, it impaired the long-term self-renewal capacity of hematopoietic stem cells,...]]></summary>
        <author>
            <name>Chunjie Yu</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Foxm1 haploinsufficiency drives clonal hematopoiesis and promotes a stress-related transition to hematologic malignancy in mice]]></title>
        <id>pubmed:37526082</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37526082/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230820204715&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-08-01T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Clonal hematopoiesis plays a critical role in the initiation and development of hematologic malignancies. In patients with del(5q) myelodysplastic syndrome (MDS), the transcription factor FOXM1 is frequently downregulated in CD34+ cells. In this study, we demonstrated that Foxm1 haploinsufficiency disturbed normal hematopoiesis and conferred a competitive repopulation advantage for a short period. However, it impaired the long-term self-renewal capacity of hematopoietic stem cells,...]]></summary>
        <author>
            <name>Chunjie Yu</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Foxm1 haploinsufficiency drives clonal hematopoiesis and promotes a stress-related transition to hematologic malignancy in mice]]></title>
        <id>pubmed:37526082</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37526082/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230819204952&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-08-01T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Clonal hematopoiesis plays a critical role in the initiation and development of hematologic malignancies. In patients with del(5q) myelodysplastic syndrome (MDS), the transcription factor FOXM1 is frequently downregulated in CD34+ cells. In this study, we demonstrated that Foxm1 haploinsufficiency disturbed normal hematopoiesis and conferred a competitive repopulation advantage for a short period. However, it impaired the long-term self-renewal capacity of hematopoietic stem cells,...]]></summary>
        <author>
            <name>Chunjie Yu</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Foxm1 haploinsufficiency drives clonal hematopoiesis and promotes a stress-related transition to hematologic malignancy in mice]]></title>
        <id>pubmed:37526082</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37526082/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230818204446&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-08-01T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Clonal hematopoiesis plays a critical role in the initiation and development of hematologic malignancies. In patients with del(5q) myelodysplastic syndrome (MDS), the transcription factor FOXM1 is frequently downregulated in CD34+ cells. In this study, we demonstrated that Foxm1 haploinsufficiency disturbed normal hematopoiesis and conferred a competitive repopulation advantage for a short period. However, it impaired the long-term self-renewal capacity of hematopoietic stem cells,...]]></summary>
        <author>
            <name>Chunjie Yu</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Foxm1 haploinsufficiency drives clonal hematopoiesis and promotes a stress-related transition to hematologic malignancy in mice]]></title>
        <id>pubmed:37526082</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37526082/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230817204642&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-08-01T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Clonal hematopoiesis plays a critical role in the initiation and development of hematologic malignancies. In patients with del(5q) myelodysplastic syndrome (MDS), the transcription factor FOXM1 is frequently downregulated in CD34+ cells. In this study, we demonstrated that Foxm1 haploinsufficiency disturbed normal hematopoiesis and conferred a competitive repopulation advantage for a short period. However, it impaired the long-term self-renewal capacity of hematopoietic stem cells,...]]></summary>
        <author>
            <name>Chunjie Yu</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Foxm1 haploinsufficiency drives clonal hematopoiesis and promotes a stress-related transition to hematologic malignancy in mice]]></title>
        <id>pubmed:37526082</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37526082/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230816204600&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-08-01T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Clonal hematopoiesis plays a critical role in the initiation and development of hematologic malignancies. In patients with del(5q) myelodysplastic syndrome (MDS), the transcription factor FOXM1 is frequently downregulated in CD34+ cells. In this study, we demonstrated that Foxm1 haploinsufficiency disturbed normal hematopoiesis and conferred a competitive repopulation advantage for a short period. However, it impaired the long-term self-renewal capacity of hematopoietic stem cells,...]]></summary>
        <author>
            <name>Chunjie Yu</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Foxm1 haploinsufficiency drives clonal hematopoiesis and promotes a stress-related transition to hematologic malignancy in mice]]></title>
        <id>pubmed:37526082</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37526082/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230815204647&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-08-01T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Clonal hematopoiesis plays a critical role in the initiation and development of hematologic malignancies. In patients with del(5q) myelodysplastic syndrome (MDS), the transcription factor FOXM1 is frequently downregulated in CD34+ cells. In this study, we demonstrated that Foxm1 haploinsufficiency disturbed normal hematopoiesis and conferred a competitive repopulation advantage for a short period. However, it impaired the long-term self-renewal capacity of hematopoietic stem cells,...]]></summary>
        <author>
            <name>Chunjie Yu</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Foxm1 haploinsufficiency drives clonal hematopoiesis and promotes a stress-related transition to hematologic malignancy in mice]]></title>
        <id>pubmed:37526082</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37526082/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230814204719&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-08-01T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Clonal hematopoiesis plays a critical role in the initiation and development of hematologic malignancies. In patients with del(5q) myelodysplastic syndrome (MDS), the transcription factor FOXM1 is frequently downregulated in CD34+ cells. In this study, we demonstrated that Foxm1 haploinsufficiency disturbed normal hematopoiesis and conferred a competitive repopulation advantage for a short period. However, it impaired the long-term self-renewal capacity of hematopoietic stem cells,...]]></summary>
        <author>
            <name>Chunjie Yu</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Foxm1 haploinsufficiency drives clonal hematopoiesis and promotes a stress-related transition to hematologic malignancy in mice]]></title>
        <id>pubmed:37526082</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37526082/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230813204802&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-08-01T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Clonal hematopoiesis plays a critical role in the initiation and development of hematologic malignancies. In patients with del(5q) myelodysplastic syndrome (MDS), the transcription factor FOXM1 is frequently downregulated in CD34+ cells. In this study, we demonstrated that Foxm1 haploinsufficiency disturbed normal hematopoiesis and conferred a competitive repopulation advantage for a short period. However, it impaired the long-term self-renewal capacity of hematopoietic stem cells,...]]></summary>
        <author>
            <name>Chunjie Yu</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Foxm1 haploinsufficiency drives clonal hematopoiesis and promotes a stress-related transition to hematologic malignancy in mice]]></title>
        <id>pubmed:37526082</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37526082/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230812205008&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-08-01T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Clonal hematopoiesis plays a critical role in the initiation and development of hematologic malignancies. In patients with del(5q) myelodysplastic syndrome (MDS), the transcription factor FOXM1 is frequently downregulated in CD34+ cells. In this study, we demonstrated that Foxm1 haploinsufficiency disturbed normal hematopoiesis and conferred a competitive repopulation advantage for a short period. However, it impaired the long-term self-renewal capacity of hematopoietic stem cells,...]]></summary>
        <author>
            <name>Chunjie Yu</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Foxm1 haploinsufficiency drives clonal hematopoiesis and promotes a stress-related transition to hematologic malignancy in mice]]></title>
        <id>pubmed:37526082</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37526082/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230811204539&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-08-01T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Clonal hematopoiesis plays a critical role in the initiation and development of hematologic malignancies. In patients with del(5q) myelodysplastic syndrome (MDS), the transcription factor FOXM1 is frequently downregulated in CD34+ cells. In this study, we demonstrated that Foxm1 haploinsufficiency disturbed normal hematopoiesis and conferred a competitive repopulation advantage for a short period. However, it impaired the long-term self-renewal capacity of hematopoietic stem cells,...]]></summary>
        <author>
            <name>Chunjie Yu</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Foxm1 haploinsufficiency drives clonal hematopoiesis and promotes a stress-related transition to hematologic malignancy in mice]]></title>
        <id>pubmed:37526082</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37526082/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230810204637&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-08-01T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Clonal hematopoiesis plays a critical role in the initiation and development of hematologic malignancies. In patients with del(5q) myelodysplastic syndrome (MDS), the transcription factor FOXM1 is frequently downregulated in CD34+ cells. In this study, we demonstrated that Foxm1 haploinsufficiency disturbed normal hematopoiesis and conferred a competitive repopulation advantage for a short period. However, it impaired the long-term self-renewal capacity of hematopoietic stem cells,...]]></summary>
        <author>
            <name>Chunjie Yu</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Foxm1 haploinsufficiency drives clonal hematopoiesis and promotes a stress-related transition to hematologic malignancy in mice]]></title>
        <id>pubmed:37526082</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37526082/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230809205914&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-08-01T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Clonal hematopoiesis plays a critical role in the initiation and development of hematologic malignancies. In patients with del(5q) myelodysplastic syndrome (MDS), the transcription factor FOXM1 is frequently downregulated in CD34+ cells. In this study, we demonstrated that Foxm1 haploinsufficiency disturbed normal hematopoiesis and conferred a competitive repopulation advantage for a short period. However, it impaired the long-term self-renewal capacity of hematopoietic stem cells,...]]></summary>
        <author>
            <name>Chunjie Yu</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Foxm1 haploinsufficiency drives clonal hematopoiesis and promotes a stress-related transition to hematologic malignancy in mice]]></title>
        <id>pubmed:37526082</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37526082/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230808205751&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-08-01T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Clonal hematopoiesis plays a critical role in the initiation and development of hematologic malignancies. In patients with del(5q) myelodysplastic syndrome (MDS), the transcription factor FOXM1 is frequently downregulated in CD34+ cells. In this study, we demonstrated that Foxm1 haploinsufficiency disturbed normal hematopoiesis and conferred a competitive repopulation advantage for a short period. However, it impaired the long-term self-renewal capacity of hematopoietic stem cells,...]]></summary>
        <author>
            <name>Chunjie Yu</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Foxm1 haploinsufficiency drives clonal hematopoiesis and promotes a stress-related transition to hematologic malignancy in mice]]></title>
        <id>pubmed:37526082</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37526082/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230807205649&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-08-01T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Clonal hematopoiesis plays a critical role in the initiation and development of hematologic malignancies. In patients with del(5q) myelodysplastic syndrome (MDS), the transcription factor FOXM1 is frequently downregulated in CD34+ cells. In this study, we demonstrated that Foxm1 haploinsufficiency disturbed normal hematopoiesis and conferred a competitive repopulation advantage for a short period. However, it impaired the long-term self-renewal capacity of hematopoietic stem cells,...]]></summary>
        <author>
            <name>Chunjie Yu</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Foxm1 haploinsufficiency drives clonal hematopoiesis and promotes a stress-related transition to hematologic malignancy in mice]]></title>
        <id>pubmed:37526082</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37526082/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230806205822&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-08-01T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Clonal hematopoiesis plays a critical role in the initiation and development of hematologic malignancies. In patients with del(5q) myelodysplastic syndrome (MDS), the transcription factor FOXM1 is frequently downregulated in CD34+ cells. In this study, we demonstrated that Foxm1 haploinsufficiency disturbed normal hematopoiesis and conferred a competitive repopulation advantage for a short period. However, it impaired the long-term self-renewal capacity of hematopoietic stem cells,...]]></summary>
        <author>
            <name>Chunjie Yu</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Foxm1 haploinsufficiency drives clonal hematopoiesis and promotes a stress-related transition to hematologic malignancy in mice]]></title>
        <id>pubmed:37526082</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37526082/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230805205329&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-08-01T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Clonal hematopoiesis plays a critical role in the initiation and development of hematologic malignancies. In patients with del(5q) myelodysplastic syndrome (MDS), the transcription factor FOXM1 is frequently downregulated in CD34+ cells. In this study, we demonstrated that Foxm1 haploinsufficiency disturbed normal hematopoiesis and conferred a competitive repopulation advantage for a short period. However, it impaired the long-term self-renewal capacity of hematopoietic stem cells,...]]></summary>
        <author>
            <name>Chunjie Yu</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Foxm1 haploinsufficiency drives clonal hematopoiesis and promotes a stress-related transition to hematologic malignancy in mice]]></title>
        <id>pubmed:37526082</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37526082/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230804205603&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-08-01T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Clonal hematopoiesis plays a critical role in the initiation and development of hematologic malignancies. In patients with del(5q) myelodysplastic syndrome (MDS), the transcription factor FOXM1 is frequently downregulated in CD34+ cells. In this study, we demonstrated that Foxm1 haploinsufficiency disturbed normal hematopoiesis and conferred a competitive repopulation advantage for a short period. However, it impaired the long-term self-renewal capacity of hematopoietic stem cells,...]]></summary>
        <author>
            <name>Chunjie Yu</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Foxm1 haploinsufficiency drives clonal hematopoiesis and promotes a stress-related transition to hematologic malignancy in mice]]></title>
        <id>pubmed:37526082</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37526082/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230803205941&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-08-01T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Clonal hematopoiesis plays a critical role in the initiation and development of hematologic malignancies. In patients with del(5q) myelodysplastic syndrome (MDS), the transcription factor FOXM1 is frequently downregulated in CD34+ cells. In this study, we demonstrated that Foxm1 haploinsufficiency disturbed normal hematopoiesis and conferred a competitive repopulation advantage for a short period. However, it impaired the long-term self-renewal capacity of hematopoietic stem cells,...]]></summary>
        <author>
            <name>Chunjie Yu</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Foxm1 haploinsufficiency drives clonal hematopoiesis and promotes a stress-related transition to hematologic malignancy in mice]]></title>
        <id>pubmed:37526082</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37526082/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230802205831&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-08-01T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Clonal hematopoiesis plays a critical role in the initiation and development of hematologic malignancies. In patients with del(5q) myelodysplastic syndrome (MDS), the transcription factor FOXM1 is frequently downregulated in CD34+ cells. In this study, we demonstrated that Foxm1 haploinsufficiency disturbed normal hematopoiesis and conferred a competitive repopulation advantage for a short period. However, it impaired the long-term self-renewal capacity of hematopoietic stem cells,...]]></summary>
        <author>
            <name>Chunjie Yu</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Progressive disruption of hematopoietic architecture from clonal hematopoiesis to MDS]]></title>
        <id>pubmed:37520699</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37520699/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230813204802&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-07-31T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Clonal hematopoiesis of indeterminate potential (CHIP) describes the age-related acquisition of somatic mutations in hematopoietic stem/progenitor cells (HSPC) leading to clonal blood cell expansion. Although CHIP mutations drive myeloid malignancies like myelodysplastic syndromes (MDS) it is unknown if clonal expansion is attributable to changes in cell type kinetics, or involves reorganization of the hematopoietic hierarchy. Using computational modeling we analyzed differentiation and...]]></summary>
        <author>
            <name>Michle C Buck</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Progressive disruption of hematopoietic architecture from clonal hematopoiesis to MDS]]></title>
        <id>pubmed:37520699</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37520699/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230812205008&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-07-31T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Clonal hematopoiesis of indeterminate potential (CHIP) describes the age-related acquisition of somatic mutations in hematopoietic stem/progenitor cells (HSPC) leading to clonal blood cell expansion. Although CHIP mutations drive myeloid malignancies like myelodysplastic syndromes (MDS) it is unknown if clonal expansion is attributable to changes in cell type kinetics, or involves reorganization of the hematopoietic hierarchy. Using computational modeling we analyzed differentiation and...]]></summary>
        <author>
            <name>Michle C Buck</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Progressive disruption of hematopoietic architecture from clonal hematopoiesis to MDS]]></title>
        <id>pubmed:37520699</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37520699/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230811204531&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-07-31T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Clonal hematopoiesis of indeterminate potential (CHIP) describes the age-related acquisition of somatic mutations in hematopoietic stem/progenitor cells (HSPC) leading to clonal blood cell expansion. Although CHIP mutations drive myeloid malignancies like myelodysplastic syndromes (MDS) it is unknown if clonal expansion is attributable to changes in cell type kinetics, or involves reorganization of the hematopoietic hierarchy. Using computational modeling we analyzed differentiation and...]]></summary>
        <author>
            <name>Michle C Buck</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Progressive disruption of hematopoietic architecture from clonal hematopoiesis to MDS]]></title>
        <id>pubmed:37520699</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37520699/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230810204637&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-07-31T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Clonal hematopoiesis of indeterminate potential (CHIP) describes the age-related acquisition of somatic mutations in hematopoietic stem/progenitor cells (HSPC) leading to clonal blood cell expansion. Although CHIP mutations drive myeloid malignancies like myelodysplastic syndromes (MDS) it is unknown if clonal expansion is attributable to changes in cell type kinetics, or involves reorganization of the hematopoietic hierarchy. Using computational modeling we analyzed differentiation and...]]></summary>
        <author>
            <name>Michle C Buck</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Progressive disruption of hematopoietic architecture from clonal hematopoiesis to MDS]]></title>
        <id>pubmed:37520699</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37520699/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230809205914&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-07-31T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Clonal hematopoiesis of indeterminate potential (CHIP) describes the age-related acquisition of somatic mutations in hematopoietic stem/progenitor cells (HSPC) leading to clonal blood cell expansion. Although CHIP mutations drive myeloid malignancies like myelodysplastic syndromes (MDS) it is unknown if clonal expansion is attributable to changes in cell type kinetics, or involves reorganization of the hematopoietic hierarchy. Using computational modeling we analyzed differentiation and...]]></summary>
        <author>
            <name>Michle C Buck</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Progressive disruption of hematopoietic architecture from clonal hematopoiesis to MDS]]></title>
        <id>pubmed:37520699</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37520699/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230808205751&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-07-31T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Clonal hematopoiesis of indeterminate potential (CHIP) describes the age-related acquisition of somatic mutations in hematopoietic stem/progenitor cells (HSPC) leading to clonal blood cell expansion. Although CHIP mutations drive myeloid malignancies like myelodysplastic syndromes (MDS) it is unknown if clonal expansion is attributable to changes in cell type kinetics, or involves reorganization of the hematopoietic hierarchy. Using computational modeling we analyzed differentiation and...]]></summary>
        <author>
            <name>Michle C Buck</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Progressive disruption of hematopoietic architecture from clonal hematopoiesis to MDS]]></title>
        <id>pubmed:37520699</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37520699/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230807205649&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-07-31T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Clonal hematopoiesis of indeterminate potential (CHIP) describes the age-related acquisition of somatic mutations in hematopoietic stem/progenitor cells (HSPC) leading to clonal blood cell expansion. Although CHIP mutations drive myeloid malignancies like myelodysplastic syndromes (MDS) it is unknown if clonal expansion is attributable to changes in cell type kinetics, or involves reorganization of the hematopoietic hierarchy. Using computational modeling we analyzed differentiation and...]]></summary>
        <author>
            <name>Michle C Buck</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Progressive disruption of hematopoietic architecture from clonal hematopoiesis to MDS]]></title>
        <id>pubmed:37520699</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37520699/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230806205822&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-07-31T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Clonal hematopoiesis of indeterminate potential (CHIP) describes the age-related acquisition of somatic mutations in hematopoietic stem/progenitor cells (HSPC) leading to clonal blood cell expansion. Although CHIP mutations drive myeloid malignancies like myelodysplastic syndromes (MDS) it is unknown if clonal expansion is attributable to changes in cell type kinetics, or involves reorganization of the hematopoietic hierarchy. Using computational modeling we analyzed differentiation and...]]></summary>
        <author>
            <name>Michle C Buck</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Progressive disruption of hematopoietic architecture from clonal hematopoiesis to MDS]]></title>
        <id>pubmed:37520699</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37520699/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230805205329&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-07-31T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Clonal hematopoiesis of indeterminate potential (CHIP) describes the age-related acquisition of somatic mutations in hematopoietic stem/progenitor cells (HSPC) leading to clonal blood cell expansion. Although CHIP mutations drive myeloid malignancies like myelodysplastic syndromes (MDS) it is unknown if clonal expansion is attributable to changes in cell type kinetics, or involves reorganization of the hematopoietic hierarchy. Using computational modeling we analyzed differentiation and...]]></summary>
        <author>
            <name>Michle C Buck</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Progressive disruption of hematopoietic architecture from clonal hematopoiesis to MDS]]></title>
        <id>pubmed:37520699</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37520699/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230804205603&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-07-31T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Clonal hematopoiesis of indeterminate potential (CHIP) describes the age-related acquisition of somatic mutations in hematopoietic stem/progenitor cells (HSPC) leading to clonal blood cell expansion. Although CHIP mutations drive myeloid malignancies like myelodysplastic syndromes (MDS) it is unknown if clonal expansion is attributable to changes in cell type kinetics, or involves reorganization of the hematopoietic hierarchy. Using computational modeling we analyzed differentiation and...]]></summary>
        <author>
            <name>Michle C Buck</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Progressive disruption of hematopoietic architecture from clonal hematopoiesis to MDS]]></title>
        <id>pubmed:37520699</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37520699/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230803205941&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-07-31T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Clonal hematopoiesis of indeterminate potential (CHIP) describes the age-related acquisition of somatic mutations in hematopoietic stem/progenitor cells (HSPC) leading to clonal blood cell expansion. Although CHIP mutations drive myeloid malignancies like myelodysplastic syndromes (MDS) it is unknown if clonal expansion is attributable to changes in cell type kinetics, or involves reorganization of the hematopoietic hierarchy. Using computational modeling we analyzed differentiation and...]]></summary>
        <author>
            <name>Michle C Buck</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Progressive disruption of hematopoietic architecture from clonal hematopoiesis to MDS]]></title>
        <id>pubmed:37520699</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37520699/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230802205831&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-07-31T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Clonal hematopoiesis of indeterminate potential (CHIP) describes the age-related acquisition of somatic mutations in hematopoietic stem/progenitor cells (HSPC) leading to clonal blood cell expansion. Although CHIP mutations drive myeloid malignancies like myelodysplastic syndromes (MDS) it is unknown if clonal expansion is attributable to changes in cell type kinetics, or involves reorganization of the hematopoietic hierarchy. Using computational modeling we analyzed differentiation and...]]></summary>
        <author>
            <name>Michle C Buck</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Progressive disruption of hematopoietic architecture from clonal hematopoiesis to MDS]]></title>
        <id>pubmed:37520699</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37520699/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230801205540&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-07-31T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Clonal hematopoiesis of indeterminate potential (CHIP) describes the age-related acquisition of somatic mutations in hematopoietic stem/progenitor cells (HSPC) leading to clonal blood cell expansion. Although CHIP mutations drive myeloid malignancies like myelodysplastic syndromes (MDS) it is unknown if clonal expansion is attributable to changes in cell type kinetics, or involves reorganization of the hematopoietic hierarchy. Using computational modeling we analyzed differentiation and...]]></summary>
        <author>
            <name>Michle C Buck</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Progressive disruption of hematopoietic architecture from clonal hematopoiesis to MDS]]></title>
        <id>pubmed:37520699</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37520699/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230731210325&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-07-31T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Clonal hematopoiesis of indeterminate potential (CHIP) describes the age-related acquisition of somatic mutations in hematopoietic stem/progenitor cells (HSPC) leading to clonal blood cell expansion. Although CHIP mutations drive myeloid malignancies like myelodysplastic syndromes (MDS) it is unknown if clonal expansion is attributable to changes in cell type kinetics, or involves reorganization of the hematopoietic hierarchy. Using computational modeling we analyzed differentiation and...]]></summary>
        <author>
            <name>Michle C Buck</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[A pilot study of donor-engrafted clonal hematopoiesis evolution and clinical outcomes in allogeneic hematopoietic cell transplant recipients using a national registry]]></title>
        <id>pubmed:37517612</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37517612/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230813204802&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-07-30T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSION: CH in older HLA-matched sibling donors is relatively common and successfully engrafts and persists in recipients. In a homogenous population (myeloid malignancies, older donors and recipients, reduced-intensity conditioning, non-cyclophosphamide-containing GVHD prophylaxis), we did not detect a difference in cGVHD risk or other secondary outcomes by donor CH status. Subgroup analyses suggest potential of differential effects by clinical characteristics and CH mutations. Larger...]]></summary>
        <author>
            <name>Nancy Gillis</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[A pilot study of donor-engrafted clonal hematopoiesis evolution and clinical outcomes in allogeneic hematopoietic cell transplant recipients using a national registry]]></title>
        <id>pubmed:37517612</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37517612/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230812205008&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-07-30T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSION: CH in older HLA-matched sibling donors is relatively common and successfully engrafts and persists in recipients. In a homogenous population (myeloid malignancies, older donors and recipients, reduced-intensity conditioning, non-cyclophosphamide-containing GVHD prophylaxis), we did not detect a difference in cGVHD risk or other secondary outcomes by donor CH status. Subgroup analyses suggest potential of differential effects by clinical characteristics and CH mutations. Larger...]]></summary>
        <author>
            <name>Nancy Gillis</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[A pilot study of donor-engrafted clonal hematopoiesis evolution and clinical outcomes in allogeneic hematopoietic cell transplant recipients using a national registry]]></title>
        <id>pubmed:37517612</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37517612/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230811204531&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-07-30T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSION: CH in older HLA-matched sibling donors is relatively common and successfully engrafts and persists in recipients. In a homogenous population (myeloid malignancies, older donors and recipients, reduced-intensity conditioning, non-cyclophosphamide-containing GVHD prophylaxis), we did not detect a difference in cGVHD risk or other secondary outcomes by donor CH status. Subgroup analyses suggest potential of differential effects by clinical characteristics and CH mutations. Larger...]]></summary>
        <author>
            <name>Nancy Gillis</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[A pilot study of donor-engrafted clonal hematopoiesis evolution and clinical outcomes in allogeneic hematopoietic cell transplant recipients using a national registry]]></title>
        <id>pubmed:37517612</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37517612/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230810204637&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-07-30T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSION: CH in older HLA-matched sibling donors is relatively common and successfully engrafts and persists in recipients. In a homogenous population (myeloid malignancies, older donors and recipients, reduced-intensity conditioning, non-cyclophosphamide-containing GVHD prophylaxis), we did not detect a difference in cGVHD risk or other secondary outcomes by donor CH status. Subgroup analyses suggest potential of differential effects by clinical characteristics and CH mutations. Larger...]]></summary>
        <author>
            <name>Nancy Gillis</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[A pilot study of donor-engrafted clonal hematopoiesis evolution and clinical outcomes in allogeneic hematopoietic cell transplant recipients using a national registry]]></title>
        <id>pubmed:37517612</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37517612/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230809205914&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-07-30T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSION: CH in older HLA-matched sibling donors is relatively common and successfully engrafts and persists in recipients. In a homogenous population (myeloid malignancies, older donors and recipients, reduced-intensity conditioning, non-cyclophosphamide-containing GVHD prophylaxis), we did not detect a difference in cGVHD risk or other secondary outcomes by donor CH status. Subgroup analyses suggest potential of differential effects by clinical characteristics and CH mutations. Larger...]]></summary>
        <author>
            <name>Nancy Gillis</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[A pilot study of donor-engrafted clonal hematopoiesis evolution and clinical outcomes in allogeneic hematopoietic cell transplant recipients using a national registry]]></title>
        <id>pubmed:37517612</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37517612/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230808205751&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-07-30T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSION: CH in older HLA-matched sibling donors is relatively common and successfully engrafts and persists in recipients. In a homogenous population (myeloid malignancies, older donors and recipients, reduced-intensity conditioning, non-cyclophosphamide-containing GVHD prophylaxis), we did not detect a difference in cGVHD risk or other secondary outcomes by donor CH status. Subgroup analyses suggest potential of differential effects by clinical characteristics and CH mutations. Larger...]]></summary>
        <author>
            <name>Nancy Gillis</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[A pilot study of donor-engrafted clonal hematopoiesis evolution and clinical outcomes in allogeneic hematopoietic cell transplant recipients using a national registry]]></title>
        <id>pubmed:37517612</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37517612/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230807205649&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-07-30T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSION: CH in older HLA-matched sibling donors is relatively common and successfully engrafts and persists in recipients. In a homogenous population (myeloid malignancies, older donors and recipients, reduced-intensity conditioning, non-cyclophosphamide-containing GVHD prophylaxis), we did not detect a difference in cGVHD risk or other secondary outcomes by donor CH status. Subgroup analyses suggest potential of differential effects by clinical characteristics and CH mutations. Larger...]]></summary>
        <author>
            <name>Nancy Gillis</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[A pilot study of donor-engrafted clonal hematopoiesis evolution and clinical outcomes in allogeneic hematopoietic cell transplant recipients using a national registry]]></title>
        <id>pubmed:37517612</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37517612/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230806205822&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-07-30T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSION: CH in older HLA-matched sibling donors is relatively common and successfully engrafts and persists in recipients. In a homogenous population (myeloid malignancies, older donors and recipients, reduced-intensity conditioning, non-cyclophosphamide-containing GVHD prophylaxis), we did not detect a difference in cGVHD risk or other secondary outcomes by donor CH status. Subgroup analyses suggest potential of differential effects by clinical characteristics and CH mutations. Larger...]]></summary>
        <author>
            <name>Nancy Gillis</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[A pilot study of donor-engrafted clonal hematopoiesis evolution and clinical outcomes in allogeneic hematopoietic cell transplant recipients using a national registry]]></title>
        <id>pubmed:37517612</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37517612/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230805205329&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-07-30T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSION: CH in older HLA-matched sibling donors is relatively common and successfully engrafts and persists in recipients. In a homogenous population (myeloid malignancies, older donors and recipients, reduced-intensity conditioning, non-cyclophosphamide-containing GVHD prophylaxis), we did not detect a difference in cGVHD risk or other secondary outcomes by donor CH status. Subgroup analyses suggest potential of differential effects by clinical characteristics and CH mutations. Larger...]]></summary>
        <author>
            <name>Nancy Gillis</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[A pilot study of donor-engrafted clonal hematopoiesis evolution and clinical outcomes in allogeneic hematopoietic cell transplant recipients using a national registry]]></title>
        <id>pubmed:37517612</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37517612/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230804205603&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-07-30T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSION: CH in older HLA-matched sibling donors is relatively common and successfully engrafts and persists in recipients. In a homogenous population (myeloid malignancies, older donors and recipients, reduced-intensity conditioning, non-cyclophosphamide-containing GVHD prophylaxis), we did not detect a difference in cGVHD risk or other secondary outcomes by donor CH status. Subgroup analyses suggest potential of differential effects by clinical characteristics and CH mutations. Larger...]]></summary>
        <author>
            <name>Nancy Gillis</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[A pilot study of donor-engrafted clonal hematopoiesis evolution and clinical outcomes in allogeneic hematopoietic cell transplant recipients using a national registry]]></title>
        <id>pubmed:37517612</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37517612/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230803205941&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-07-30T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSION: CH in older HLA-matched sibling donors is relatively common and successfully engrafts and persists in recipients. In a homogenous population (myeloid malignancies, older donors and recipients, reduced-intensity conditioning, non-cyclophosphamide-containing GVHD prophylaxis), we did not detect a difference in cGVHD risk or other secondary outcomes by donor CH status. Subgroup analyses suggest potential of differential effects by clinical characteristics and CH mutations. Larger...]]></summary>
        <author>
            <name>Nancy Gillis</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[A pilot study of donor-engrafted clonal hematopoiesis evolution and clinical outcomes in allogeneic hematopoietic cell transplant recipients using a national registry]]></title>
        <id>pubmed:37517612</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37517612/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230802205831&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-07-30T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSION: CH in older HLA-matched sibling donors is relatively common and successfully engrafts and persists in recipients. In a homogenous population (myeloid malignancies, older donors and recipients, reduced-intensity conditioning, non-cyclophosphamide-containing GVHD prophylaxis), we did not detect a difference in cGVHD risk or other secondary outcomes by donor CH status. Subgroup analyses suggest potential of differential effects by clinical characteristics and CH mutations. Larger...]]></summary>
        <author>
            <name>Nancy Gillis</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[A pilot study of donor-engrafted clonal hematopoiesis evolution and clinical outcomes in allogeneic hematopoietic cell transplant recipients using a national registry]]></title>
        <id>pubmed:37517612</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37517612/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230801205540&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-07-30T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSION: CH in older HLA-matched sibling donors is relatively common and successfully engrafts and persists in recipients. In a homogenous population (myeloid malignancies, older donors and recipients, reduced-intensity conditioning, non-cyclophosphamide-containing GVHD prophylaxis), we did not detect a difference in cGVHD risk or other secondary outcomes by donor CH status. Subgroup analyses suggest potential of differential effects by clinical characteristics and CH mutations. Larger...]]></summary>
        <author>
            <name>Nancy Gillis</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[A pilot study of donor-engrafted clonal hematopoiesis evolution and clinical outcomes in allogeneic hematopoietic cell transplant recipients using a national registry]]></title>
        <id>pubmed:37517612</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37517612/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230731210325&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-07-30T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSION: CH in older HLA-matched sibling donors is relatively common and successfully engrafts and persists in recipients. In a homogenous population (myeloid malignancies, older donors and recipients, reduced-intensity conditioning, non-cyclophosphamide-containing GVHD prophylaxis), we did not detect a difference in cGVHD risk or other secondary outcomes by donor CH status. Subgroup analyses suggest potential of differential effects by clinical characteristics and CH mutations. Larger...]]></summary>
        <author>
            <name>Nancy Gillis</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Single-Cell Analysis in the <em>Omics</em> Era: Technologies and Applications in Cancer]]></title>
        <id>pubmed:37510235</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37510235/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230827204908&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-07-29T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Cancer molecular profiling obtained with conventional bulk sequencing describes average alterations obtained from the entire cellular population analyzed. In the era of precision medicine, this approach is unable to track tumor heterogeneity and cannot be exploited to unravel the biological processes behind clonal evolution. In the last few years, functional single-cell omics has improved our understanding of cancer heterogeneity. This approach requires isolation and identification of single...]]></summary>
        <author>
            <name>Michele Massimino</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Extreme Gradient Boosting Tuned with Metaheuristic Algorithms for Predicting Myeloid NGS Onco-Somatic Variant Pathogenicity]]></title>
        <id>pubmed:37508780</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37508780/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230827204908&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-07-29T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[The advent of next-generation sequencing (NGS) technologies has revolutionized the field of bioinformatics and genomics, particularly in the area of onco-somatic genetics. NGS has provided a wealth of information about the genetic changes that underlie cancer and has considerably improved our ability to diagnose and treat cancer. However, the large amount of data generated by NGS makes it difficult to interpret the variants. To address this, machine learning algorithms such as Extreme Gradient...]]></summary>
        <author>
            <name>Eric Pellegrino</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Single-Cell Analysis in the <em>Omics</em> Era: Technologies and Applications in Cancer]]></title>
        <id>pubmed:37510235</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37510235/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230826205107&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-07-29T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Cancer molecular profiling obtained with conventional bulk sequencing describes average alterations obtained from the entire cellular population analyzed. In the era of precision medicine, this approach is unable to track tumor heterogeneity and cannot be exploited to unravel the biological processes behind clonal evolution. In the last few years, functional single-cell omics has improved our understanding of cancer heterogeneity. This approach requires isolation and identification of single...]]></summary>
        <author>
            <name>Michele Massimino</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Extreme Gradient Boosting Tuned with Metaheuristic Algorithms for Predicting Myeloid NGS Onco-Somatic Variant Pathogenicity]]></title>
        <id>pubmed:37508780</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37508780/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230826205107&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-07-29T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[The advent of next-generation sequencing (NGS) technologies has revolutionized the field of bioinformatics and genomics, particularly in the area of onco-somatic genetics. NGS has provided a wealth of information about the genetic changes that underlie cancer and has considerably improved our ability to diagnose and treat cancer. However, the large amount of data generated by NGS makes it difficult to interpret the variants. To address this, machine learning algorithms such as Extreme Gradient...]]></summary>
        <author>
            <name>Eric Pellegrino</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Single-Cell Analysis in the <em>Omics</em> Era: Technologies and Applications in Cancer]]></title>
        <id>pubmed:37510235</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37510235/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230825204602&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-07-29T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Cancer molecular profiling obtained with conventional bulk sequencing describes average alterations obtained from the entire cellular population analyzed. In the era of precision medicine, this approach is unable to track tumor heterogeneity and cannot be exploited to unravel the biological processes behind clonal evolution. In the last few years, functional single-cell omics has improved our understanding of cancer heterogeneity. This approach requires isolation and identification of single...]]></summary>
        <author>
            <name>Michele Massimino</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Extreme Gradient Boosting Tuned with Metaheuristic Algorithms for Predicting Myeloid NGS Onco-Somatic Variant Pathogenicity]]></title>
        <id>pubmed:37508780</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37508780/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230825204602&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-07-29T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[The advent of next-generation sequencing (NGS) technologies has revolutionized the field of bioinformatics and genomics, particularly in the area of onco-somatic genetics. NGS has provided a wealth of information about the genetic changes that underlie cancer and has considerably improved our ability to diagnose and treat cancer. However, the large amount of data generated by NGS makes it difficult to interpret the variants. To address this, machine learning algorithms such as Extreme Gradient...]]></summary>
        <author>
            <name>Eric Pellegrino</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Mathematical Modeling of Clonal Interference by Density-Dependent Selection in Heterogeneous Cancer Cell Lines]]></title>
        <id>pubmed:37508513</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37508513/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230825204602&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-07-29T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Many cancer cell lines are aneuploid and heterogeneous, with multiple karyotypes co-existing within the same cell line. Karyotype heterogeneity has been shown to manifest phenotypically, thus affecting how cells respond to drugs or to minor differences in culture media. Knowing how to interpret karyotype heterogeneity phenotypically would give insights into cellular phenotypes before they unfold temporally. Here, we re-analyzed single cell RNA (scRNA) and scDNA sequencing data from eight stomach...]]></summary>
        <author>
            <name>Thomas Veith</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Single-Cell Analysis in the <em>Omics</em> Era: Technologies and Applications in Cancer]]></title>
        <id>pubmed:37510235</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37510235/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230824204824&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-07-29T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Cancer molecular profiling obtained with conventional bulk sequencing describes average alterations obtained from the entire cellular population analyzed. In the era of precision medicine, this approach is unable to track tumor heterogeneity and cannot be exploited to unravel the biological processes behind clonal evolution. In the last few years, functional single-cell omics has improved our understanding of cancer heterogeneity. This approach requires isolation and identification of single...]]></summary>
        <author>
            <name>Michele Massimino</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Extreme Gradient Boosting Tuned with Metaheuristic Algorithms for Predicting Myeloid NGS Onco-Somatic Variant Pathogenicity]]></title>
        <id>pubmed:37508780</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37508780/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230824204824&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-07-29T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[The advent of next-generation sequencing (NGS) technologies has revolutionized the field of bioinformatics and genomics, particularly in the area of onco-somatic genetics. NGS has provided a wealth of information about the genetic changes that underlie cancer and has considerably improved our ability to diagnose and treat cancer. However, the large amount of data generated by NGS makes it difficult to interpret the variants. To address this, machine learning algorithms such as Extreme Gradient...]]></summary>
        <author>
            <name>Eric Pellegrino</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Mathematical Modeling of Clonal Interference by Density-Dependent Selection in Heterogeneous Cancer Cell Lines]]></title>
        <id>pubmed:37508513</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37508513/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230824204824&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-07-29T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Many cancer cell lines are aneuploid and heterogeneous, with multiple karyotypes co-existing within the same cell line. Karyotype heterogeneity has been shown to manifest phenotypically, thus affecting how cells respond to drugs or to minor differences in culture media. Knowing how to interpret karyotype heterogeneity phenotypically would give insights into cellular phenotypes before they unfold temporally. Here, we re-analyzed single cell RNA (scRNA) and scDNA sequencing data from eight stomach...]]></summary>
        <author>
            <name>Thomas Veith</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Single-Cell Analysis in the <em>Omics</em> Era: Technologies and Applications in Cancer]]></title>
        <id>pubmed:37510235</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37510235/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230823204708&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-07-29T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Cancer molecular profiling obtained with conventional bulk sequencing describes average alterations obtained from the entire cellular population analyzed. In the era of precision medicine, this approach is unable to track tumor heterogeneity and cannot be exploited to unravel the biological processes behind clonal evolution. In the last few years, functional single-cell omics has improved our understanding of cancer heterogeneity. This approach requires isolation and identification of single...]]></summary>
        <author>
            <name>Michele Massimino</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Extreme Gradient Boosting Tuned with Metaheuristic Algorithms for Predicting Myeloid NGS Onco-Somatic Variant Pathogenicity]]></title>
        <id>pubmed:37508780</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37508780/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230823204708&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-07-29T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[The advent of next-generation sequencing (NGS) technologies has revolutionized the field of bioinformatics and genomics, particularly in the area of onco-somatic genetics. NGS has provided a wealth of information about the genetic changes that underlie cancer and has considerably improved our ability to diagnose and treat cancer. However, the large amount of data generated by NGS makes it difficult to interpret the variants. To address this, machine learning algorithms such as Extreme Gradient...]]></summary>
        <author>
            <name>Eric Pellegrino</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Mathematical Modeling of Clonal Interference by Density-Dependent Selection in Heterogeneous Cancer Cell Lines]]></title>
        <id>pubmed:37508513</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37508513/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230823204708&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-07-29T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Many cancer cell lines are aneuploid and heterogeneous, with multiple karyotypes co-existing within the same cell line. Karyotype heterogeneity has been shown to manifest phenotypically, thus affecting how cells respond to drugs or to minor differences in culture media. Knowing how to interpret karyotype heterogeneity phenotypically would give insights into cellular phenotypes before they unfold temporally. Here, we re-analyzed single cell RNA (scRNA) and scDNA sequencing data from eight stomach...]]></summary>
        <author>
            <name>Thomas Veith</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Single-Cell Analysis in the <em>Omics</em> Era: Technologies and Applications in Cancer]]></title>
        <id>pubmed:37510235</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37510235/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230822204709&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-07-29T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Cancer molecular profiling obtained with conventional bulk sequencing describes average alterations obtained from the entire cellular population analyzed. In the era of precision medicine, this approach is unable to track tumor heterogeneity and cannot be exploited to unravel the biological processes behind clonal evolution. In the last few years, functional single-cell omics has improved our understanding of cancer heterogeneity. This approach requires isolation and identification of single...]]></summary>
        <author>
            <name>Michele Massimino</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Extreme Gradient Boosting Tuned with Metaheuristic Algorithms for Predicting Myeloid NGS Onco-Somatic Variant Pathogenicity]]></title>
        <id>pubmed:37508780</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37508780/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230822204709&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-07-29T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[The advent of next-generation sequencing (NGS) technologies has revolutionized the field of bioinformatics and genomics, particularly in the area of onco-somatic genetics. NGS has provided a wealth of information about the genetic changes that underlie cancer and has considerably improved our ability to diagnose and treat cancer. However, the large amount of data generated by NGS makes it difficult to interpret the variants. To address this, machine learning algorithms such as Extreme Gradient...]]></summary>
        <author>
            <name>Eric Pellegrino</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Mathematical Modeling of Clonal Interference by Density-Dependent Selection in Heterogeneous Cancer Cell Lines]]></title>
        <id>pubmed:37508513</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37508513/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230822204709&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-07-29T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Many cancer cell lines are aneuploid and heterogeneous, with multiple karyotypes co-existing within the same cell line. Karyotype heterogeneity has been shown to manifest phenotypically, thus affecting how cells respond to drugs or to minor differences in culture media. Knowing how to interpret karyotype heterogeneity phenotypically would give insights into cellular phenotypes before they unfold temporally. Here, we re-analyzed single cell RNA (scRNA) and scDNA sequencing data from eight stomach...]]></summary>
        <author>
            <name>Thomas Veith</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Single-Cell Analysis in the <em>Omics</em> Era: Technologies and Applications in Cancer]]></title>
        <id>pubmed:37510235</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37510235/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230821204801&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-07-29T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Cancer molecular profiling obtained with conventional bulk sequencing describes average alterations obtained from the entire cellular population analyzed. In the era of precision medicine, this approach is unable to track tumor heterogeneity and cannot be exploited to unravel the biological processes behind clonal evolution. In the last few years, functional single-cell omics has improved our understanding of cancer heterogeneity. This approach requires isolation and identification of single...]]></summary>
        <author>
            <name>Michele Massimino</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Extreme Gradient Boosting Tuned with Metaheuristic Algorithms for Predicting Myeloid NGS Onco-Somatic Variant Pathogenicity]]></title>
        <id>pubmed:37508780</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37508780/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230821204801&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-07-29T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[The advent of next-generation sequencing (NGS) technologies has revolutionized the field of bioinformatics and genomics, particularly in the area of onco-somatic genetics. NGS has provided a wealth of information about the genetic changes that underlie cancer and has considerably improved our ability to diagnose and treat cancer. However, the large amount of data generated by NGS makes it difficult to interpret the variants. To address this, machine learning algorithms such as Extreme Gradient...]]></summary>
        <author>
            <name>Eric Pellegrino</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Mathematical Modeling of Clonal Interference by Density-Dependent Selection in Heterogeneous Cancer Cell Lines]]></title>
        <id>pubmed:37508513</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37508513/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230821204801&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-07-29T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Many cancer cell lines are aneuploid and heterogeneous, with multiple karyotypes co-existing within the same cell line. Karyotype heterogeneity has been shown to manifest phenotypically, thus affecting how cells respond to drugs or to minor differences in culture media. Knowing how to interpret karyotype heterogeneity phenotypically would give insights into cellular phenotypes before they unfold temporally. Here, we re-analyzed single cell RNA (scRNA) and scDNA sequencing data from eight stomach...]]></summary>
        <author>
            <name>Thomas Veith</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Single-Cell Analysis in the <em>Omics</em> Era: Technologies and Applications in Cancer]]></title>
        <id>pubmed:37510235</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37510235/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230820204715&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-07-29T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Cancer molecular profiling obtained with conventional bulk sequencing describes average alterations obtained from the entire cellular population analyzed. In the era of precision medicine, this approach is unable to track tumor heterogeneity and cannot be exploited to unravel the biological processes behind clonal evolution. In the last few years, functional single-cell omics has improved our understanding of cancer heterogeneity. This approach requires isolation and identification of single...]]></summary>
        <author>
            <name>Michele Massimino</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Extreme Gradient Boosting Tuned with Metaheuristic Algorithms for Predicting Myeloid NGS Onco-Somatic Variant Pathogenicity]]></title>
        <id>pubmed:37508780</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37508780/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230820204715&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-07-29T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[The advent of next-generation sequencing (NGS) technologies has revolutionized the field of bioinformatics and genomics, particularly in the area of onco-somatic genetics. NGS has provided a wealth of information about the genetic changes that underlie cancer and has considerably improved our ability to diagnose and treat cancer. However, the large amount of data generated by NGS makes it difficult to interpret the variants. To address this, machine learning algorithms such as Extreme Gradient...]]></summary>
        <author>
            <name>Eric Pellegrino</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Mathematical Modeling of Clonal Interference by Density-Dependent Selection in Heterogeneous Cancer Cell Lines]]></title>
        <id>pubmed:37508513</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37508513/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230820204715&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-07-29T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Many cancer cell lines are aneuploid and heterogeneous, with multiple karyotypes co-existing within the same cell line. Karyotype heterogeneity has been shown to manifest phenotypically, thus affecting how cells respond to drugs or to minor differences in culture media. Knowing how to interpret karyotype heterogeneity phenotypically would give insights into cellular phenotypes before they unfold temporally. Here, we re-analyzed single cell RNA (scRNA) and scDNA sequencing data from eight stomach...]]></summary>
        <author>
            <name>Thomas Veith</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Single-Cell Analysis in the <em>Omics</em> Era: Technologies and Applications in Cancer]]></title>
        <id>pubmed:37510235</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37510235/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230819204952&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-07-29T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Cancer molecular profiling obtained with conventional bulk sequencing describes average alterations obtained from the entire cellular population analyzed. In the era of precision medicine, this approach is unable to track tumor heterogeneity and cannot be exploited to unravel the biological processes behind clonal evolution. In the last few years, functional single-cell omics has improved our understanding of cancer heterogeneity. This approach requires isolation and identification of single...]]></summary>
        <author>
            <name>Michele Massimino</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Extreme Gradient Boosting Tuned with Metaheuristic Algorithms for Predicting Myeloid NGS Onco-Somatic Variant Pathogenicity]]></title>
        <id>pubmed:37508780</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37508780/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230819204952&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-07-29T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[The advent of next-generation sequencing (NGS) technologies has revolutionized the field of bioinformatics and genomics, particularly in the area of onco-somatic genetics. NGS has provided a wealth of information about the genetic changes that underlie cancer and has considerably improved our ability to diagnose and treat cancer. However, the large amount of data generated by NGS makes it difficult to interpret the variants. To address this, machine learning algorithms such as Extreme Gradient...]]></summary>
        <author>
            <name>Eric Pellegrino</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Mathematical Modeling of Clonal Interference by Density-Dependent Selection in Heterogeneous Cancer Cell Lines]]></title>
        <id>pubmed:37508513</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37508513/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230819204952&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-07-29T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Many cancer cell lines are aneuploid and heterogeneous, with multiple karyotypes co-existing within the same cell line. Karyotype heterogeneity has been shown to manifest phenotypically, thus affecting how cells respond to drugs or to minor differences in culture media. Knowing how to interpret karyotype heterogeneity phenotypically would give insights into cellular phenotypes before they unfold temporally. Here, we re-analyzed single cell RNA (scRNA) and scDNA sequencing data from eight stomach...]]></summary>
        <author>
            <name>Thomas Veith</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Single-Cell Analysis in the <em>Omics</em> Era: Technologies and Applications in Cancer]]></title>
        <id>pubmed:37510235</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37510235/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230818204446&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-07-29T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Cancer molecular profiling obtained with conventional bulk sequencing describes average alterations obtained from the entire cellular population analyzed. In the era of precision medicine, this approach is unable to track tumor heterogeneity and cannot be exploited to unravel the biological processes behind clonal evolution. In the last few years, functional single-cell omics has improved our understanding of cancer heterogeneity. This approach requires isolation and identification of single...]]></summary>
        <author>
            <name>Michele Massimino</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Extreme Gradient Boosting Tuned with Metaheuristic Algorithms for Predicting Myeloid NGS Onco-Somatic Variant Pathogenicity]]></title>
        <id>pubmed:37508780</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37508780/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230818204446&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-07-29T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[The advent of next-generation sequencing (NGS) technologies has revolutionized the field of bioinformatics and genomics, particularly in the area of onco-somatic genetics. NGS has provided a wealth of information about the genetic changes that underlie cancer and has considerably improved our ability to diagnose and treat cancer. However, the large amount of data generated by NGS makes it difficult to interpret the variants. To address this, machine learning algorithms such as Extreme Gradient...]]></summary>
        <author>
            <name>Eric Pellegrino</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Mathematical Modeling of Clonal Interference by Density-Dependent Selection in Heterogeneous Cancer Cell Lines]]></title>
        <id>pubmed:37508513</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37508513/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230818204446&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-07-29T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Many cancer cell lines are aneuploid and heterogeneous, with multiple karyotypes co-existing within the same cell line. Karyotype heterogeneity has been shown to manifest phenotypically, thus affecting how cells respond to drugs or to minor differences in culture media. Knowing how to interpret karyotype heterogeneity phenotypically would give insights into cellular phenotypes before they unfold temporally. Here, we re-analyzed single cell RNA (scRNA) and scDNA sequencing data from eight stomach...]]></summary>
        <author>
            <name>Thomas Veith</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Single-Cell Analysis in the <em>Omics</em> Era: Technologies and Applications in Cancer]]></title>
        <id>pubmed:37510235</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37510235/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230817204642&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-07-29T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Cancer molecular profiling obtained with conventional bulk sequencing describes average alterations obtained from the entire cellular population analyzed. In the era of precision medicine, this approach is unable to track tumor heterogeneity and cannot be exploited to unravel the biological processes behind clonal evolution. In the last few years, functional single-cell omics has improved our understanding of cancer heterogeneity. This approach requires isolation and identification of single...]]></summary>
        <author>
            <name>Michele Massimino</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Extreme Gradient Boosting Tuned with Metaheuristic Algorithms for Predicting Myeloid NGS Onco-Somatic Variant Pathogenicity]]></title>
        <id>pubmed:37508780</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37508780/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230817204642&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-07-29T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[The advent of next-generation sequencing (NGS) technologies has revolutionized the field of bioinformatics and genomics, particularly in the area of onco-somatic genetics. NGS has provided a wealth of information about the genetic changes that underlie cancer and has considerably improved our ability to diagnose and treat cancer. However, the large amount of data generated by NGS makes it difficult to interpret the variants. To address this, machine learning algorithms such as Extreme Gradient...]]></summary>
        <author>
            <name>Eric Pellegrino</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Mathematical Modeling of Clonal Interference by Density-Dependent Selection in Heterogeneous Cancer Cell Lines]]></title>
        <id>pubmed:37508513</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37508513/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230817204642&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-07-29T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Many cancer cell lines are aneuploid and heterogeneous, with multiple karyotypes co-existing within the same cell line. Karyotype heterogeneity has been shown to manifest phenotypically, thus affecting how cells respond to drugs or to minor differences in culture media. Knowing how to interpret karyotype heterogeneity phenotypically would give insights into cellular phenotypes before they unfold temporally. Here, we re-analyzed single cell RNA (scRNA) and scDNA sequencing data from eight stomach...]]></summary>
        <author>
            <name>Thomas Veith</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Single-Cell Analysis in the <em>Omics</em> Era: Technologies and Applications in Cancer]]></title>
        <id>pubmed:37510235</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37510235/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230816204600&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-07-29T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Cancer molecular profiling obtained with conventional bulk sequencing describes average alterations obtained from the entire cellular population analyzed. In the era of precision medicine, this approach is unable to track tumor heterogeneity and cannot be exploited to unravel the biological processes behind clonal evolution. In the last few years, functional single-cell omics has improved our understanding of cancer heterogeneity. This approach requires isolation and identification of single...]]></summary>
        <author>
            <name>Michele Massimino</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Extreme Gradient Boosting Tuned with Metaheuristic Algorithms for Predicting Myeloid NGS Onco-Somatic Variant Pathogenicity]]></title>
        <id>pubmed:37508780</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37508780/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230816204600&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-07-29T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[The advent of next-generation sequencing (NGS) technologies has revolutionized the field of bioinformatics and genomics, particularly in the area of onco-somatic genetics. NGS has provided a wealth of information about the genetic changes that underlie cancer and has considerably improved our ability to diagnose and treat cancer. However, the large amount of data generated by NGS makes it difficult to interpret the variants. To address this, machine learning algorithms such as Extreme Gradient...]]></summary>
        <author>
            <name>Eric Pellegrino</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Mathematical Modeling of Clonal Interference by Density-Dependent Selection in Heterogeneous Cancer Cell Lines]]></title>
        <id>pubmed:37508513</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37508513/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230816204600&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-07-29T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Many cancer cell lines are aneuploid and heterogeneous, with multiple karyotypes co-existing within the same cell line. Karyotype heterogeneity has been shown to manifest phenotypically, thus affecting how cells respond to drugs or to minor differences in culture media. Knowing how to interpret karyotype heterogeneity phenotypically would give insights into cellular phenotypes before they unfold temporally. Here, we re-analyzed single cell RNA (scRNA) and scDNA sequencing data from eight stomach...]]></summary>
        <author>
            <name>Thomas Veith</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Single-Cell Analysis in the <em>Omics</em> Era: Technologies and Applications in Cancer]]></title>
        <id>pubmed:37510235</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37510235/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230815204647&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-07-29T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Cancer molecular profiling obtained with conventional bulk sequencing describes average alterations obtained from the entire cellular population analyzed. In the era of precision medicine, this approach is unable to track tumor heterogeneity and cannot be exploited to unravel the biological processes behind clonal evolution. In the last few years, functional single-cell omics has improved our understanding of cancer heterogeneity. This approach requires isolation and identification of single...]]></summary>
        <author>
            <name>Michele Massimino</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Extreme Gradient Boosting Tuned with Metaheuristic Algorithms for Predicting Myeloid NGS Onco-Somatic Variant Pathogenicity]]></title>
        <id>pubmed:37508780</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37508780/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230815204647&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-07-29T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[The advent of next-generation sequencing (NGS) technologies has revolutionized the field of bioinformatics and genomics, particularly in the area of onco-somatic genetics. NGS has provided a wealth of information about the genetic changes that underlie cancer and has considerably improved our ability to diagnose and treat cancer. However, the large amount of data generated by NGS makes it difficult to interpret the variants. To address this, machine learning algorithms such as Extreme Gradient...]]></summary>
        <author>
            <name>Eric Pellegrino</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Mathematical Modeling of Clonal Interference by Density-Dependent Selection in Heterogeneous Cancer Cell Lines]]></title>
        <id>pubmed:37508513</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37508513/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230815204647&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-07-29T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Many cancer cell lines are aneuploid and heterogeneous, with multiple karyotypes co-existing within the same cell line. Karyotype heterogeneity has been shown to manifest phenotypically, thus affecting how cells respond to drugs or to minor differences in culture media. Knowing how to interpret karyotype heterogeneity phenotypically would give insights into cellular phenotypes before they unfold temporally. Here, we re-analyzed single cell RNA (scRNA) and scDNA sequencing data from eight stomach...]]></summary>
        <author>
            <name>Thomas Veith</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Single-Cell Analysis in the <em>Omics</em> Era: Technologies and Applications in Cancer]]></title>
        <id>pubmed:37510235</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37510235/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230814204719&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-07-29T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Cancer molecular profiling obtained with conventional bulk sequencing describes average alterations obtained from the entire cellular population analyzed. In the era of precision medicine, this approach is unable to track tumor heterogeneity and cannot be exploited to unravel the biological processes behind clonal evolution. In the last few years, functional single-cell omics has improved our understanding of cancer heterogeneity. This approach requires isolation and identification of single...]]></summary>
        <author>
            <name>Michele Massimino</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Extreme Gradient Boosting Tuned with Metaheuristic Algorithms for Predicting Myeloid NGS Onco-Somatic Variant Pathogenicity]]></title>
        <id>pubmed:37508780</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37508780/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230814204719&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-07-29T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[The advent of next-generation sequencing (NGS) technologies has revolutionized the field of bioinformatics and genomics, particularly in the area of onco-somatic genetics. NGS has provided a wealth of information about the genetic changes that underlie cancer and has considerably improved our ability to diagnose and treat cancer. However, the large amount of data generated by NGS makes it difficult to interpret the variants. To address this, machine learning algorithms such as Extreme Gradient...]]></summary>
        <author>
            <name>Eric Pellegrino</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Mathematical Modeling of Clonal Interference by Density-Dependent Selection in Heterogeneous Cancer Cell Lines]]></title>
        <id>pubmed:37508513</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37508513/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230814204719&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-07-29T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Many cancer cell lines are aneuploid and heterogeneous, with multiple karyotypes co-existing within the same cell line. Karyotype heterogeneity has been shown to manifest phenotypically, thus affecting how cells respond to drugs or to minor differences in culture media. Knowing how to interpret karyotype heterogeneity phenotypically would give insights into cellular phenotypes before they unfold temporally. Here, we re-analyzed single cell RNA (scRNA) and scDNA sequencing data from eight stomach...]]></summary>
        <author>
            <name>Thomas Veith</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Single-Cell Analysis in the <em>Omics</em> Era: Technologies and Applications in Cancer]]></title>
        <id>pubmed:37510235</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37510235/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230813204802&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-07-29T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Cancer molecular profiling obtained with conventional bulk sequencing describes average alterations obtained from the entire cellular population analyzed. In the era of precision medicine, this approach is unable to track tumor heterogeneity and cannot be exploited to unravel the biological processes behind clonal evolution. In the last few years, functional single-cell omics has improved our understanding of cancer heterogeneity. This approach requires isolation and identification of single...]]></summary>
        <author>
            <name>Michele Massimino</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Extreme Gradient Boosting Tuned with Metaheuristic Algorithms for Predicting Myeloid NGS Onco-Somatic Variant Pathogenicity]]></title>
        <id>pubmed:37508780</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37508780/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230813204802&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-07-29T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[The advent of next-generation sequencing (NGS) technologies has revolutionized the field of bioinformatics and genomics, particularly in the area of onco-somatic genetics. NGS has provided a wealth of information about the genetic changes that underlie cancer and has considerably improved our ability to diagnose and treat cancer. However, the large amount of data generated by NGS makes it difficult to interpret the variants. To address this, machine learning algorithms such as Extreme Gradient...]]></summary>
        <author>
            <name>Eric Pellegrino</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Mathematical Modeling of Clonal Interference by Density-Dependent Selection in Heterogeneous Cancer Cell Lines]]></title>
        <id>pubmed:37508513</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37508513/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230813204802&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-07-29T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Many cancer cell lines are aneuploid and heterogeneous, with multiple karyotypes co-existing within the same cell line. Karyotype heterogeneity has been shown to manifest phenotypically, thus affecting how cells respond to drugs or to minor differences in culture media. Knowing how to interpret karyotype heterogeneity phenotypically would give insights into cellular phenotypes before they unfold temporally. Here, we re-analyzed single cell RNA (scRNA) and scDNA sequencing data from eight stomach...]]></summary>
        <author>
            <name>Thomas Veith</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Single-Cell Analysis in the <em>Omics</em> Era: Technologies and Applications in Cancer]]></title>
        <id>pubmed:37510235</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37510235/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230812205008&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-07-29T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Cancer molecular profiling obtained with conventional bulk sequencing describes average alterations obtained from the entire cellular population analyzed. In the era of precision medicine, this approach is unable to track tumor heterogeneity and cannot be exploited to unravel the biological processes behind clonal evolution. In the last few years, functional single-cell omics has improved our understanding of cancer heterogeneity. This approach requires isolation and identification of single...]]></summary>
        <author>
            <name>Michele Massimino</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Extreme Gradient Boosting Tuned with Metaheuristic Algorithms for Predicting Myeloid NGS Onco-Somatic Variant Pathogenicity]]></title>
        <id>pubmed:37508780</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37508780/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230812205008&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-07-29T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[The advent of next-generation sequencing (NGS) technologies has revolutionized the field of bioinformatics and genomics, particularly in the area of onco-somatic genetics. NGS has provided a wealth of information about the genetic changes that underlie cancer and has considerably improved our ability to diagnose and treat cancer. However, the large amount of data generated by NGS makes it difficult to interpret the variants. To address this, machine learning algorithms such as Extreme Gradient...]]></summary>
        <author>
            <name>Eric Pellegrino</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Mathematical Modeling of Clonal Interference by Density-Dependent Selection in Heterogeneous Cancer Cell Lines]]></title>
        <id>pubmed:37508513</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37508513/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230812205008&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-07-29T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Many cancer cell lines are aneuploid and heterogeneous, with multiple karyotypes co-existing within the same cell line. Karyotype heterogeneity has been shown to manifest phenotypically, thus affecting how cells respond to drugs or to minor differences in culture media. Knowing how to interpret karyotype heterogeneity phenotypically would give insights into cellular phenotypes before they unfold temporally. Here, we re-analyzed single cell RNA (scRNA) and scDNA sequencing data from eight stomach...]]></summary>
        <author>
            <name>Thomas Veith</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Single-Cell Analysis in the <em>Omics</em> Era: Technologies and Applications in Cancer]]></title>
        <id>pubmed:37510235</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37510235/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230811204539&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-07-29T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Cancer molecular profiling obtained with conventional bulk sequencing describes average alterations obtained from the entire cellular population analyzed. In the era of precision medicine, this approach is unable to track tumor heterogeneity and cannot be exploited to unravel the biological processes behind clonal evolution. In the last few years, functional single-cell omics has improved our understanding of cancer heterogeneity. This approach requires isolation and identification of single...]]></summary>
        <author>
            <name>Michele Massimino</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Extreme Gradient Boosting Tuned with Metaheuristic Algorithms for Predicting Myeloid NGS Onco-Somatic Variant Pathogenicity]]></title>
        <id>pubmed:37508780</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37508780/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230811204539&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-07-29T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[The advent of next-generation sequencing (NGS) technologies has revolutionized the field of bioinformatics and genomics, particularly in the area of onco-somatic genetics. NGS has provided a wealth of information about the genetic changes that underlie cancer and has considerably improved our ability to diagnose and treat cancer. However, the large amount of data generated by NGS makes it difficult to interpret the variants. To address this, machine learning algorithms such as Extreme Gradient...]]></summary>
        <author>
            <name>Eric Pellegrino</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Mathematical Modeling of Clonal Interference by Density-Dependent Selection in Heterogeneous Cancer Cell Lines]]></title>
        <id>pubmed:37508513</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37508513/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230811204539&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-07-29T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Many cancer cell lines are aneuploid and heterogeneous, with multiple karyotypes co-existing within the same cell line. Karyotype heterogeneity has been shown to manifest phenotypically, thus affecting how cells respond to drugs or to minor differences in culture media. Knowing how to interpret karyotype heterogeneity phenotypically would give insights into cellular phenotypes before they unfold temporally. Here, we re-analyzed single cell RNA (scRNA) and scDNA sequencing data from eight stomach...]]></summary>
        <author>
            <name>Thomas Veith</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Single-Cell Analysis in the <em>Omics</em> Era: Technologies and Applications in Cancer]]></title>
        <id>pubmed:37510235</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37510235/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230810204637&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-07-29T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Cancer molecular profiling obtained with conventional bulk sequencing describes average alterations obtained from the entire cellular population analyzed. In the era of precision medicine, this approach is unable to track tumor heterogeneity and cannot be exploited to unravel the biological processes behind clonal evolution. In the last few years, functional single-cell omics has improved our understanding of cancer heterogeneity. This approach requires isolation and identification of single...]]></summary>
        <author>
            <name>Michele Massimino</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Extreme Gradient Boosting Tuned with Metaheuristic Algorithms for Predicting Myeloid NGS Onco-Somatic Variant Pathogenicity]]></title>
        <id>pubmed:37508780</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37508780/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230810204637&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-07-29T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[The advent of next-generation sequencing (NGS) technologies has revolutionized the field of bioinformatics and genomics, particularly in the area of onco-somatic genetics. NGS has provided a wealth of information about the genetic changes that underlie cancer and has considerably improved our ability to diagnose and treat cancer. However, the large amount of data generated by NGS makes it difficult to interpret the variants. To address this, machine learning algorithms such as Extreme Gradient...]]></summary>
        <author>
            <name>Eric Pellegrino</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Mathematical Modeling of Clonal Interference by Density-Dependent Selection in Heterogeneous Cancer Cell Lines]]></title>
        <id>pubmed:37508513</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37508513/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230810204637&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-07-29T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Many cancer cell lines are aneuploid and heterogeneous, with multiple karyotypes co-existing within the same cell line. Karyotype heterogeneity has been shown to manifest phenotypically, thus affecting how cells respond to drugs or to minor differences in culture media. Knowing how to interpret karyotype heterogeneity phenotypically would give insights into cellular phenotypes before they unfold temporally. Here, we re-analyzed single cell RNA (scRNA) and scDNA sequencing data from eight stomach...]]></summary>
        <author>
            <name>Thomas Veith</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Single-Cell Analysis in the <em>Omics</em> Era: Technologies and Applications in Cancer]]></title>
        <id>pubmed:37510235</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37510235/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230809205914&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-07-29T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Cancer molecular profiling obtained with conventional bulk sequencing describes average alterations obtained from the entire cellular population analyzed. In the era of precision medicine, this approach is unable to track tumor heterogeneity and cannot be exploited to unravel the biological processes behind clonal evolution. In the last few years, functional single-cell omics has improved our understanding of cancer heterogeneity. This approach requires isolation and identification of single...]]></summary>
        <author>
            <name>Michele Massimino</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Extreme Gradient Boosting Tuned with Metaheuristic Algorithms for Predicting Myeloid NGS Onco-Somatic Variant Pathogenicity]]></title>
        <id>pubmed:37508780</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37508780/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230809205914&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-07-29T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[The advent of next-generation sequencing (NGS) technologies has revolutionized the field of bioinformatics and genomics, particularly in the area of onco-somatic genetics. NGS has provided a wealth of information about the genetic changes that underlie cancer and has considerably improved our ability to diagnose and treat cancer. However, the large amount of data generated by NGS makes it difficult to interpret the variants. To address this, machine learning algorithms such as Extreme Gradient...]]></summary>
        <author>
            <name>Eric Pellegrino</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Mathematical Modeling of Clonal Interference by Density-Dependent Selection in Heterogeneous Cancer Cell Lines]]></title>
        <id>pubmed:37508513</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37508513/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230809205914&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-07-29T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Many cancer cell lines are aneuploid and heterogeneous, with multiple karyotypes co-existing within the same cell line. Karyotype heterogeneity has been shown to manifest phenotypically, thus affecting how cells respond to drugs or to minor differences in culture media. Knowing how to interpret karyotype heterogeneity phenotypically would give insights into cellular phenotypes before they unfold temporally. Here, we re-analyzed single cell RNA (scRNA) and scDNA sequencing data from eight stomach...]]></summary>
        <author>
            <name>Thomas Veith</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Single-Cell Analysis in the <em>Omics</em> Era: Technologies and Applications in Cancer]]></title>
        <id>pubmed:37510235</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37510235/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230808205751&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-07-29T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Cancer molecular profiling obtained with conventional bulk sequencing describes average alterations obtained from the entire cellular population analyzed. In the era of precision medicine, this approach is unable to track tumor heterogeneity and cannot be exploited to unravel the biological processes behind clonal evolution. In the last few years, functional single-cell omics has improved our understanding of cancer heterogeneity. This approach requires isolation and identification of single...]]></summary>
        <author>
            <name>Michele Massimino</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Extreme Gradient Boosting Tuned with Metaheuristic Algorithms for Predicting Myeloid NGS Onco-Somatic Variant Pathogenicity]]></title>
        <id>pubmed:37508780</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37508780/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230808205751&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-07-29T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[The advent of next-generation sequencing (NGS) technologies has revolutionized the field of bioinformatics and genomics, particularly in the area of onco-somatic genetics. NGS has provided a wealth of information about the genetic changes that underlie cancer and has considerably improved our ability to diagnose and treat cancer. However, the large amount of data generated by NGS makes it difficult to interpret the variants. To address this, machine learning algorithms such as Extreme Gradient...]]></summary>
        <author>
            <name>Eric Pellegrino</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Mathematical Modeling of Clonal Interference by Density-Dependent Selection in Heterogeneous Cancer Cell Lines]]></title>
        <id>pubmed:37508513</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37508513/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230808205751&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-07-29T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Many cancer cell lines are aneuploid and heterogeneous, with multiple karyotypes co-existing within the same cell line. Karyotype heterogeneity has been shown to manifest phenotypically, thus affecting how cells respond to drugs or to minor differences in culture media. Knowing how to interpret karyotype heterogeneity phenotypically would give insights into cellular phenotypes before they unfold temporally. Here, we re-analyzed single cell RNA (scRNA) and scDNA sequencing data from eight stomach...]]></summary>
        <author>
            <name>Thomas Veith</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Single-Cell Analysis in the <em>Omics</em> Era: Technologies and Applications in Cancer]]></title>
        <id>pubmed:37510235</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37510235/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230807205649&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-07-29T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Cancer molecular profiling obtained with conventional bulk sequencing describes average alterations obtained from the entire cellular population analyzed. In the era of precision medicine, this approach is unable to track tumor heterogeneity and cannot be exploited to unravel the biological processes behind clonal evolution. In the last few years, functional single-cell omics has improved our understanding of cancer heterogeneity. This approach requires isolation and identification of single...]]></summary>
        <author>
            <name>Michele Massimino</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Extreme Gradient Boosting Tuned with Metaheuristic Algorithms for Predicting Myeloid NGS Onco-Somatic Variant Pathogenicity]]></title>
        <id>pubmed:37508780</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37508780/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230807205649&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-07-29T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[The advent of next-generation sequencing (NGS) technologies has revolutionized the field of bioinformatics and genomics, particularly in the area of onco-somatic genetics. NGS has provided a wealth of information about the genetic changes that underlie cancer and has considerably improved our ability to diagnose and treat cancer. However, the large amount of data generated by NGS makes it difficult to interpret the variants. To address this, machine learning algorithms such as Extreme Gradient...]]></summary>
        <author>
            <name>Eric Pellegrino</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Mathematical Modeling of Clonal Interference by Density-Dependent Selection in Heterogeneous Cancer Cell Lines]]></title>
        <id>pubmed:37508513</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37508513/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230807205649&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-07-29T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Many cancer cell lines are aneuploid and heterogeneous, with multiple karyotypes co-existing within the same cell line. Karyotype heterogeneity has been shown to manifest phenotypically, thus affecting how cells respond to drugs or to minor differences in culture media. Knowing how to interpret karyotype heterogeneity phenotypically would give insights into cellular phenotypes before they unfold temporally. Here, we re-analyzed single cell RNA (scRNA) and scDNA sequencing data from eight stomach...]]></summary>
        <author>
            <name>Thomas Veith</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Single-Cell Analysis in the <em>Omics</em> Era: Technologies and Applications in Cancer]]></title>
        <id>pubmed:37510235</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37510235/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230806205822&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-07-29T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Cancer molecular profiling obtained with conventional bulk sequencing describes average alterations obtained from the entire cellular population analyzed. In the era of precision medicine, this approach is unable to track tumor heterogeneity and cannot be exploited to unravel the biological processes behind clonal evolution. In the last few years, functional single-cell omics has improved our understanding of cancer heterogeneity. This approach requires isolation and identification of single...]]></summary>
        <author>
            <name>Michele Massimino</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Extreme Gradient Boosting Tuned with Metaheuristic Algorithms for Predicting Myeloid NGS Onco-Somatic Variant Pathogenicity]]></title>
        <id>pubmed:37508780</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37508780/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230806205822&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-07-29T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[The advent of next-generation sequencing (NGS) technologies has revolutionized the field of bioinformatics and genomics, particularly in the area of onco-somatic genetics. NGS has provided a wealth of information about the genetic changes that underlie cancer and has considerably improved our ability to diagnose and treat cancer. However, the large amount of data generated by NGS makes it difficult to interpret the variants. To address this, machine learning algorithms such as Extreme Gradient...]]></summary>
        <author>
            <name>Eric Pellegrino</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Mathematical Modeling of Clonal Interference by Density-Dependent Selection in Heterogeneous Cancer Cell Lines]]></title>
        <id>pubmed:37508513</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37508513/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230806205822&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-07-29T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Many cancer cell lines are aneuploid and heterogeneous, with multiple karyotypes co-existing within the same cell line. Karyotype heterogeneity has been shown to manifest phenotypically, thus affecting how cells respond to drugs or to minor differences in culture media. Knowing how to interpret karyotype heterogeneity phenotypically would give insights into cellular phenotypes before they unfold temporally. Here, we re-analyzed single cell RNA (scRNA) and scDNA sequencing data from eight stomach...]]></summary>
        <author>
            <name>Thomas Veith</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Single-Cell Analysis in the <em>Omics</em> Era: Technologies and Applications in Cancer]]></title>
        <id>pubmed:37510235</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37510235/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230805205329&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-07-29T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Cancer molecular profiling obtained with conventional bulk sequencing describes average alterations obtained from the entire cellular population analyzed. In the era of precision medicine, this approach is unable to track tumor heterogeneity and cannot be exploited to unravel the biological processes behind clonal evolution. In the last few years, functional single-cell omics has improved our understanding of cancer heterogeneity. This approach requires isolation and identification of single...]]></summary>
        <author>
            <name>Michele Massimino</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Extreme Gradient Boosting Tuned with Metaheuristic Algorithms for Predicting Myeloid NGS Onco-Somatic Variant Pathogenicity]]></title>
        <id>pubmed:37508780</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37508780/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230805205329&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-07-29T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[The advent of next-generation sequencing (NGS) technologies has revolutionized the field of bioinformatics and genomics, particularly in the area of onco-somatic genetics. NGS has provided a wealth of information about the genetic changes that underlie cancer and has considerably improved our ability to diagnose and treat cancer. However, the large amount of data generated by NGS makes it difficult to interpret the variants. To address this, machine learning algorithms such as Extreme Gradient...]]></summary>
        <author>
            <name>Eric Pellegrino</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Mathematical Modeling of Clonal Interference by Density-Dependent Selection in Heterogeneous Cancer Cell Lines]]></title>
        <id>pubmed:37508513</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37508513/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230805205329&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-07-29T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Many cancer cell lines are aneuploid and heterogeneous, with multiple karyotypes co-existing within the same cell line. Karyotype heterogeneity has been shown to manifest phenotypically, thus affecting how cells respond to drugs or to minor differences in culture media. Knowing how to interpret karyotype heterogeneity phenotypically would give insights into cellular phenotypes before they unfold temporally. Here, we re-analyzed single cell RNA (scRNA) and scDNA sequencing data from eight stomach...]]></summary>
        <author>
            <name>Thomas Veith</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Single-Cell Analysis in the <em>Omics</em> Era: Technologies and Applications in Cancer]]></title>
        <id>pubmed:37510235</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37510235/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230804205603&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-07-29T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Cancer molecular profiling obtained with conventional bulk sequencing describes average alterations obtained from the entire cellular population analyzed. In the era of precision medicine, this approach is unable to track tumor heterogeneity and cannot be exploited to unravel the biological processes behind clonal evolution. In the last few years, functional single-cell omics has improved our understanding of cancer heterogeneity. This approach requires isolation and identification of single...]]></summary>
        <author>
            <name>Michele Massimino</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Extreme Gradient Boosting Tuned with Metaheuristic Algorithms for Predicting Myeloid NGS Onco-Somatic Variant Pathogenicity]]></title>
        <id>pubmed:37508780</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37508780/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230804205603&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-07-29T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[The advent of next-generation sequencing (NGS) technologies has revolutionized the field of bioinformatics and genomics, particularly in the area of onco-somatic genetics. NGS has provided a wealth of information about the genetic changes that underlie cancer and has considerably improved our ability to diagnose and treat cancer. However, the large amount of data generated by NGS makes it difficult to interpret the variants. To address this, machine learning algorithms such as Extreme Gradient...]]></summary>
        <author>
            <name>Eric Pellegrino</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Mathematical Modeling of Clonal Interference by Density-Dependent Selection in Heterogeneous Cancer Cell Lines]]></title>
        <id>pubmed:37508513</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37508513/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230804205603&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-07-29T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Many cancer cell lines are aneuploid and heterogeneous, with multiple karyotypes co-existing within the same cell line. Karyotype heterogeneity has been shown to manifest phenotypically, thus affecting how cells respond to drugs or to minor differences in culture media. Knowing how to interpret karyotype heterogeneity phenotypically would give insights into cellular phenotypes before they unfold temporally. Here, we re-analyzed single cell RNA (scRNA) and scDNA sequencing data from eight stomach...]]></summary>
        <author>
            <name>Thomas Veith</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Single-Cell Analysis in the <em>Omics</em> Era: Technologies and Applications in Cancer]]></title>
        <id>pubmed:37510235</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37510235/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230803205941&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-07-29T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Cancer molecular profiling obtained with conventional bulk sequencing describes average alterations obtained from the entire cellular population analyzed. In the era of precision medicine, this approach is unable to track tumor heterogeneity and cannot be exploited to unravel the biological processes behind clonal evolution. In the last few years, functional single-cell omics has improved our understanding of cancer heterogeneity. This approach requires isolation and identification of single...]]></summary>
        <author>
            <name>Michele Massimino</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Extreme Gradient Boosting Tuned with Metaheuristic Algorithms for Predicting Myeloid NGS Onco-Somatic Variant Pathogenicity]]></title>
        <id>pubmed:37508780</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37508780/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230803205941&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-07-29T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[The advent of next-generation sequencing (NGS) technologies has revolutionized the field of bioinformatics and genomics, particularly in the area of onco-somatic genetics. NGS has provided a wealth of information about the genetic changes that underlie cancer and has considerably improved our ability to diagnose and treat cancer. However, the large amount of data generated by NGS makes it difficult to interpret the variants. To address this, machine learning algorithms such as Extreme Gradient...]]></summary>
        <author>
            <name>Eric Pellegrino</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Mathematical Modeling of Clonal Interference by Density-Dependent Selection in Heterogeneous Cancer Cell Lines]]></title>
        <id>pubmed:37508513</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37508513/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230803205941&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-07-29T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Many cancer cell lines are aneuploid and heterogeneous, with multiple karyotypes co-existing within the same cell line. Karyotype heterogeneity has been shown to manifest phenotypically, thus affecting how cells respond to drugs or to minor differences in culture media. Knowing how to interpret karyotype heterogeneity phenotypically would give insights into cellular phenotypes before they unfold temporally. Here, we re-analyzed single cell RNA (scRNA) and scDNA sequencing data from eight stomach...]]></summary>
        <author>
            <name>Thomas Veith</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Single-Cell Analysis in the <em>Omics</em> Era: Technologies and Applications in Cancer]]></title>
        <id>pubmed:37510235</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37510235/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230802205831&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-07-29T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Cancer molecular profiling obtained with conventional bulk sequencing describes average alterations obtained from the entire cellular population analyzed. In the era of precision medicine, this approach is unable to track tumor heterogeneity and cannot be exploited to unravel the biological processes behind clonal evolution. In the last few years, functional single-cell omics has improved our understanding of cancer heterogeneity. This approach requires isolation and identification of single...]]></summary>
        <author>
            <name>Michele Massimino</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Extreme Gradient Boosting Tuned with Metaheuristic Algorithms for Predicting Myeloid NGS Onco-Somatic Variant Pathogenicity]]></title>
        <id>pubmed:37508780</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37508780/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230802205831&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-07-29T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[The advent of next-generation sequencing (NGS) technologies has revolutionized the field of bioinformatics and genomics, particularly in the area of onco-somatic genetics. NGS has provided a wealth of information about the genetic changes that underlie cancer and has considerably improved our ability to diagnose and treat cancer. However, the large amount of data generated by NGS makes it difficult to interpret the variants. To address this, machine learning algorithms such as Extreme Gradient...]]></summary>
        <author>
            <name>Eric Pellegrino</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Mathematical Modeling of Clonal Interference by Density-Dependent Selection in Heterogeneous Cancer Cell Lines]]></title>
        <id>pubmed:37508513</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37508513/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230802205831&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-07-29T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Many cancer cell lines are aneuploid and heterogeneous, with multiple karyotypes co-existing within the same cell line. Karyotype heterogeneity has been shown to manifest phenotypically, thus affecting how cells respond to drugs or to minor differences in culture media. Knowing how to interpret karyotype heterogeneity phenotypically would give insights into cellular phenotypes before they unfold temporally. Here, we re-analyzed single cell RNA (scRNA) and scDNA sequencing data from eight stomach...]]></summary>
        <author>
            <name>Thomas Veith</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Single-Cell Analysis in the <em>Omics</em> Era: Technologies and Applications in Cancer]]></title>
        <id>pubmed:37510235</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37510235/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230801205540&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-07-29T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Cancer molecular profiling obtained with conventional bulk sequencing describes average alterations obtained from the entire cellular population analyzed. In the era of precision medicine, this approach is unable to track tumor heterogeneity and cannot be exploited to unravel the biological processes behind clonal evolution. In the last few years, functional single-cell omics has improved our understanding of cancer heterogeneity. This approach requires isolation and identification of single...]]></summary>
        <author>
            <name>Michele Massimino</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Extreme Gradient Boosting Tuned with Metaheuristic Algorithms for Predicting Myeloid NGS Onco-Somatic Variant Pathogenicity]]></title>
        <id>pubmed:37508780</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37508780/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230801205540&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-07-29T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[The advent of next-generation sequencing (NGS) technologies has revolutionized the field of bioinformatics and genomics, particularly in the area of onco-somatic genetics. NGS has provided a wealth of information about the genetic changes that underlie cancer and has considerably improved our ability to diagnose and treat cancer. However, the large amount of data generated by NGS makes it difficult to interpret the variants. To address this, machine learning algorithms such as Extreme Gradient...]]></summary>
        <author>
            <name>Eric Pellegrino</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Mathematical Modeling of Clonal Interference by Density-Dependent Selection in Heterogeneous Cancer Cell Lines]]></title>
        <id>pubmed:37508513</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37508513/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230801205540&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-07-29T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Many cancer cell lines are aneuploid and heterogeneous, with multiple karyotypes co-existing within the same cell line. Karyotype heterogeneity has been shown to manifest phenotypically, thus affecting how cells respond to drugs or to minor differences in culture media. Knowing how to interpret karyotype heterogeneity phenotypically would give insights into cellular phenotypes before they unfold temporally. Here, we re-analyzed single cell RNA (scRNA) and scDNA sequencing data from eight stomach...]]></summary>
        <author>
            <name>Thomas Veith</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Single-Cell Analysis in the <em>Omics</em> Era: Technologies and Applications in Cancer]]></title>
        <id>pubmed:37510235</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37510235/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230731210325&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-07-29T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Cancer molecular profiling obtained with conventional bulk sequencing describes average alterations obtained from the entire cellular population analyzed. In the era of precision medicine, this approach is unable to track tumor heterogeneity and cannot be exploited to unravel the biological processes behind clonal evolution. In the last few years, functional single-cell omics has improved our understanding of cancer heterogeneity. This approach requires isolation and identification of single...]]></summary>
        <author>
            <name>Michele Massimino</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Extreme Gradient Boosting Tuned with Metaheuristic Algorithms for Predicting Myeloid NGS Onco-Somatic Variant Pathogenicity]]></title>
        <id>pubmed:37508780</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37508780/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230731210325&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-07-29T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[The advent of next-generation sequencing (NGS) technologies has revolutionized the field of bioinformatics and genomics, particularly in the area of onco-somatic genetics. NGS has provided a wealth of information about the genetic changes that underlie cancer and has considerably improved our ability to diagnose and treat cancer. However, the large amount of data generated by NGS makes it difficult to interpret the variants. To address this, machine learning algorithms such as Extreme Gradient...]]></summary>
        <author>
            <name>Eric Pellegrino</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Mathematical Modeling of Clonal Interference by Density-Dependent Selection in Heterogeneous Cancer Cell Lines]]></title>
        <id>pubmed:37508513</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37508513/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230731210325&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-07-29T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Many cancer cell lines are aneuploid and heterogeneous, with multiple karyotypes co-existing within the same cell line. Karyotype heterogeneity has been shown to manifest phenotypically, thus affecting how cells respond to drugs or to minor differences in culture media. Knowing how to interpret karyotype heterogeneity phenotypically would give insights into cellular phenotypes before they unfold temporally. Here, we re-analyzed single cell RNA (scRNA) and scDNA sequencing data from eight stomach...]]></summary>
        <author>
            <name>Thomas Veith</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Single-Cell Analysis in the <em>Omics</em> Era: Technologies and Applications in Cancer]]></title>
        <id>pubmed:37510235</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37510235/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230730205823&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-07-29T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Cancer molecular profiling obtained with conventional bulk sequencing describes average alterations obtained from the entire cellular population analyzed. In the era of precision medicine, this approach is unable to track tumor heterogeneity and cannot be exploited to unravel the biological processes behind clonal evolution. In the last few years, functional single-cell omics has improved our understanding of cancer heterogeneity. This approach requires isolation and identification of single...]]></summary>
        <author>
            <name>Michele Massimino</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Extreme Gradient Boosting Tuned with Metaheuristic Algorithms for Predicting Myeloid NGS Onco-Somatic Variant Pathogenicity]]></title>
        <id>pubmed:37508780</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37508780/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230730205823&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-07-29T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[The advent of next-generation sequencing (NGS) technologies has revolutionized the field of bioinformatics and genomics, particularly in the area of onco-somatic genetics. NGS has provided a wealth of information about the genetic changes that underlie cancer and has considerably improved our ability to diagnose and treat cancer. However, the large amount of data generated by NGS makes it difficult to interpret the variants. To address this, machine learning algorithms such as Extreme Gradient...]]></summary>
        <author>
            <name>Eric Pellegrino</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Mathematical Modeling of Clonal Interference by Density-Dependent Selection in Heterogeneous Cancer Cell Lines]]></title>
        <id>pubmed:37508513</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37508513/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230730205823&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-07-29T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Many cancer cell lines are aneuploid and heterogeneous, with multiple karyotypes co-existing within the same cell line. Karyotype heterogeneity has been shown to manifest phenotypically, thus affecting how cells respond to drugs or to minor differences in culture media. Knowing how to interpret karyotype heterogeneity phenotypically would give insights into cellular phenotypes before they unfold temporally. Here, we re-analyzed single cell RNA (scRNA) and scDNA sequencing data from eight stomach...]]></summary>
        <author>
            <name>Thomas Veith</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Single-Cell Analysis in the <em>Omics</em> Era: Technologies and Applications in Cancer]]></title>
        <id>pubmed:37510235</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37510235/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230729205947&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-07-29T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Cancer molecular profiling obtained with conventional bulk sequencing describes average alterations obtained from the entire cellular population analyzed. In the era of precision medicine, this approach is unable to track tumor heterogeneity and cannot be exploited to unravel the biological processes behind clonal evolution. In the last few years, functional single-cell omics has improved our understanding of cancer heterogeneity. This approach requires isolation and identification of single...]]></summary>
        <author>
            <name>Michele Massimino</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Extreme Gradient Boosting Tuned with Metaheuristic Algorithms for Predicting Myeloid NGS Onco-Somatic Variant Pathogenicity]]></title>
        <id>pubmed:37508780</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37508780/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230729205947&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-07-29T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[The advent of next-generation sequencing (NGS) technologies has revolutionized the field of bioinformatics and genomics, particularly in the area of onco-somatic genetics. NGS has provided a wealth of information about the genetic changes that underlie cancer and has considerably improved our ability to diagnose and treat cancer. However, the large amount of data generated by NGS makes it difficult to interpret the variants. To address this, machine learning algorithms such as Extreme Gradient...]]></summary>
        <author>
            <name>Eric Pellegrino</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Mathematical Modeling of Clonal Interference by Density-Dependent Selection in Heterogeneous Cancer Cell Lines]]></title>
        <id>pubmed:37508513</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37508513/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230729205947&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-07-29T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Many cancer cell lines are aneuploid and heterogeneous, with multiple karyotypes co-existing within the same cell line. Karyotype heterogeneity has been shown to manifest phenotypically, thus affecting how cells respond to drugs or to minor differences in culture media. Knowing how to interpret karyotype heterogeneity phenotypically would give insights into cellular phenotypes before they unfold temporally. Here, we re-analyzed single cell RNA (scRNA) and scDNA sequencing data from eight stomach...]]></summary>
        <author>
            <name>Thomas Veith</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Prevalence and significance of DDX41 gene variants in the general population]]></title>
        <id>pubmed:37506341</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37506341/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230812205008&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-07-28T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Germline variants in the DDX41 gene have been linked to myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML) development. However, the risks associated with different variants remain unknown, as do the basis of their leukemogenic properties, impact on steady-state hematopoiesis and links to other cancers. Here, we investigate the frequency and significance of DDX41 variants in 454,792 United Kingdom Biobank (UKB) participants and identify 452 unique non-synonymous DNA variants in...]]></summary>
        <author>
            <name>Sruthi Cheloor Kovilakam</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Prevalence and significance of DDX41 gene variants in the general population]]></title>
        <id>pubmed:37506341</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37506341/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230811204531&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-07-28T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Germline variants in the DDX41 gene have been linked to myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML) development. However, the risks associated with different variants remain unknown, as do the basis of their leukemogenic properties, impact on steady-state hematopoiesis and links to other cancers. Here, we investigate the frequency and significance of DDX41 variants in 454,792 United Kingdom Biobank (UKB) participants and identify 452 unique non-synonymous DNA variants in...]]></summary>
        <author>
            <name>Sruthi Cheloor Kovilakam</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Prevalence and significance of DDX41 gene variants in the general population]]></title>
        <id>pubmed:37506341</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37506341/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230810204637&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-07-28T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Germline variants in the DDX41 gene have been linked to myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML) development. However, the risks associated with different variants remain unknown, as do the basis of their leukemogenic properties, impact on steady-state hematopoiesis and links to other cancers. Here, we investigate the frequency and significance of DDX41 variants in 454,792 United Kingdom Biobank (UKB) participants and identify 452 unique non-synonymous DNA variants in...]]></summary>
        <author>
            <name>Sruthi Cheloor Kovilakam</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Detection of Age-Related Somatic Alterations in Canine Blood Using Next-Generation Sequencing-Based Liquid Biopsy: An Analysis of over 4800 Dogs]]></title>
        <id>pubmed:37505860</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37505860/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230810204637&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-07-28T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Age-related somatic genomic alterations in hematopoietic cell lines have been well characterized in humans; however, this phenomenon has not been well studied in other species. Next-generation sequencing-based liquid biopsy testing for cancer detection was recently developed for dogs and has been used to study the genomic profiles of blood samples from thousands of canine patients since 2021. In this study, 4870 client-owned dogs with and without a diagnosis or suspicion of cancer underwent...]]></summary>
        <author>
            <name>Kristina M Kruglyak</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Management of Patients with Lower-Risk Myelodysplastic Neoplasms (MDS)]]></title>
        <id>pubmed:37504319</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37504319/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230810204637&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-07-28T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Myelodysplastic neoplasms (MDS) are a heterogenous group of clonal hematologic disorders characterized by morphologic dysplasia, ineffective hematopoiesis, and cytopenia. In the past year, the classification of MDS has been updated in the 5th edition of the World Health Organization (WHO) Classification of Haematolymphoid Tumours and the International Consensus Classification (ICC) of Myeloid Neoplasms and Acute Leukemia with incorporation of morphologic, clinical, and genomic data. Furthermore,...]]></summary>
        <author>
            <name>Josephine Lucero</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Prevalence and significance of DDX41 gene variants in the general population]]></title>
        <id>pubmed:37506341</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37506341/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230809205914&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-07-28T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Germline variants in the DDX41 gene have been linked to myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML) development. However, the risks associated with different variants remain unknown, as do the basis of their leukemogenic properties, impact on steady-state hematopoiesis and links to other cancers. Here, we investigate the frequency and significance of DDX41 variants in 454,792 United Kingdom Biobank (UKB) participants and identify 452 unique non-synonymous DNA variants in...]]></summary>
        <author>
            <name>Sruthi Cheloor Kovilakam</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Detection of Age-Related Somatic Alterations in Canine Blood Using Next-Generation Sequencing-Based Liquid Biopsy: An Analysis of over 4800 Dogs]]></title>
        <id>pubmed:37505860</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37505860/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230809205914&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-07-28T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Age-related somatic genomic alterations in hematopoietic cell lines have been well characterized in humans; however, this phenomenon has not been well studied in other species. Next-generation sequencing-based liquid biopsy testing for cancer detection was recently developed for dogs and has been used to study the genomic profiles of blood samples from thousands of canine patients since 2021. In this study, 4870 client-owned dogs with and without a diagnosis or suspicion of cancer underwent...]]></summary>
        <author>
            <name>Kristina M Kruglyak</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Management of Patients with Lower-Risk Myelodysplastic Neoplasms (MDS)]]></title>
        <id>pubmed:37504319</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37504319/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230809205914&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-07-28T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Myelodysplastic neoplasms (MDS) are a heterogenous group of clonal hematologic disorders characterized by morphologic dysplasia, ineffective hematopoiesis, and cytopenia. In the past year, the classification of MDS has been updated in the 5th edition of the World Health Organization (WHO) Classification of Haematolymphoid Tumours and the International Consensus Classification (ICC) of Myeloid Neoplasms and Acute Leukemia with incorporation of morphologic, clinical, and genomic data. Furthermore,...]]></summary>
        <author>
            <name>Josephine Lucero</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Unlocking the Role of Endothelial MPL Receptor and JAK2V617F Mutation: Insights into Cardiovascular Dysfunction in MPNs and CHIP]]></title>
        <id>pubmed:37503259</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37503259/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230809205914&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-07-28T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Patients with JAK2V617F-positive myeloproliferative neoplasms (MPNs) and clonal hematopoiesis of indeterminate potential (CHIP) are at a significantly higher risk of cardiovascular diseases (CVDs). Endothelial cells (ECs) carrying the JAK2V617F mutation can be detected in many MPN patients. Here, we investigated the impact of endothelial JAK2V617F mutation on CVD development using both transgenic murine models and human induced pluripotent stem cell lines. Our findings revealed that JAK2V617F...]]></summary>
        <author>
            <name>Haotian Zhang</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Oncostatin M is a Master Regulator of an Inflammatory Network in <em>Dnmt3a</em> -Mutant Hematopoietic Stem Cells]]></title>
        <id>pubmed:37502912</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37502912/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230809205914&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-07-28T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Age-associated clonal hematopoiesis (CH) occurs due to somatic mutations accrued in hematopoietic stem cells (HSCs) that confer a selective advantage in the context of aging. The mechanisms by which CH-mutant HSCs gain this advantage with aging are not comprehensively understood. Using unbiased transcriptomic approaches, we identify Oncostatin M (OSM) signaling as a candidate contributor to aging-driven Dnmt3a -mutant CH. We find that Dnmt3a -mutant HSCs from young mice do not functionally...]]></summary>
        <author>
            <name>Logan S Schwartz</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Prevalence and significance of DDX41 gene variants in the general population]]></title>
        <id>pubmed:37506341</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37506341/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230808205751&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-07-28T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Germline variants in the DDX41 gene have been linked to myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML) development. However, the risks associated with different variants remain unknown, as do the basis of their leukemogenic properties, impact on steady-state hematopoiesis and links to other cancers. Here, we investigate the frequency and significance of DDX41 variants in 454,792 United Kingdom Biobank (UKB) participants and identify 452 unique non-synonymous DNA variants in...]]></summary>
        <author>
            <name>Sruthi Cheloor Kovilakam</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Detection of Age-Related Somatic Alterations in Canine Blood Using Next-Generation Sequencing-Based Liquid Biopsy: An Analysis of over 4800 Dogs]]></title>
        <id>pubmed:37505860</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37505860/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230808205751&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-07-28T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Age-related somatic genomic alterations in hematopoietic cell lines have been well characterized in humans; however, this phenomenon has not been well studied in other species. Next-generation sequencing-based liquid biopsy testing for cancer detection was recently developed for dogs and has been used to study the genomic profiles of blood samples from thousands of canine patients since 2021. In this study, 4870 client-owned dogs with and without a diagnosis or suspicion of cancer underwent...]]></summary>
        <author>
            <name>Kristina M Kruglyak</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Management of Patients with Lower-Risk Myelodysplastic Neoplasms (MDS)]]></title>
        <id>pubmed:37504319</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37504319/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230808205751&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-07-28T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Myelodysplastic neoplasms (MDS) are a heterogenous group of clonal hematologic disorders characterized by morphologic dysplasia, ineffective hematopoiesis, and cytopenia. In the past year, the classification of MDS has been updated in the 5th edition of the World Health Organization (WHO) Classification of Haematolymphoid Tumours and the International Consensus Classification (ICC) of Myeloid Neoplasms and Acute Leukemia with incorporation of morphologic, clinical, and genomic data. Furthermore,...]]></summary>
        <author>
            <name>Josephine Lucero</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Unlocking the Role of Endothelial MPL Receptor and JAK2V617F Mutation: Insights into Cardiovascular Dysfunction in MPNs and CHIP]]></title>
        <id>pubmed:37503259</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37503259/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230808205751&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-07-28T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Patients with JAK2V617F-positive myeloproliferative neoplasms (MPNs) and clonal hematopoiesis of indeterminate potential (CHIP) are at a significantly higher risk of cardiovascular diseases (CVDs). Endothelial cells (ECs) carrying the JAK2V617F mutation can be detected in many MPN patients. Here, we investigated the impact of endothelial JAK2V617F mutation on CVD development using both transgenic murine models and human induced pluripotent stem cell lines. Our findings revealed that JAK2V617F...]]></summary>
        <author>
            <name>Haotian Zhang</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Oncostatin M is a Master Regulator of an Inflammatory Network in <em>Dnmt3a</em> -Mutant Hematopoietic Stem Cells]]></title>
        <id>pubmed:37502912</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37502912/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230808205751&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-07-28T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Age-associated clonal hematopoiesis (CH) occurs due to somatic mutations accrued in hematopoietic stem cells (HSCs) that confer a selective advantage in the context of aging. The mechanisms by which CH-mutant HSCs gain this advantage with aging are not comprehensively understood. Using unbiased transcriptomic approaches, we identify Oncostatin M (OSM) signaling as a candidate contributor to aging-driven Dnmt3a -mutant CH. We find that Dnmt3a -mutant HSCs from young mice do not functionally...]]></summary>
        <author>
            <name>Logan S Schwartz</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Prevalence and significance of DDX41 gene variants in the general population]]></title>
        <id>pubmed:37506341</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37506341/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230807205649&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-07-28T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Germline variants in the DDX41 gene have been linked to myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML) development. However, the risks associated with different variants remain unknown, as do the basis of their leukemogenic properties, impact on steady-state hematopoiesis and links to other cancers. Here, we investigate the frequency and significance of DDX41 variants in 454,792 United Kingdom Biobank (UKB) participants and identify 452 unique non-synonymous DNA variants in...]]></summary>
        <author>
            <name>Sruthi Cheloor Kovilakam</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Detection of Age-Related Somatic Alterations in Canine Blood Using Next-Generation Sequencing-Based Liquid Biopsy: An Analysis of over 4800 Dogs]]></title>
        <id>pubmed:37505860</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37505860/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230807205649&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-07-28T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Age-related somatic genomic alterations in hematopoietic cell lines have been well characterized in humans; however, this phenomenon has not been well studied in other species. Next-generation sequencing-based liquid biopsy testing for cancer detection was recently developed for dogs and has been used to study the genomic profiles of blood samples from thousands of canine patients since 2021. In this study, 4870 client-owned dogs with and without a diagnosis or suspicion of cancer underwent...]]></summary>
        <author>
            <name>Kristina M Kruglyak</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Management of Patients with Lower-Risk Myelodysplastic Neoplasms (MDS)]]></title>
        <id>pubmed:37504319</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37504319/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230807205649&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-07-28T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Myelodysplastic neoplasms (MDS) are a heterogenous group of clonal hematologic disorders characterized by morphologic dysplasia, ineffective hematopoiesis, and cytopenia. In the past year, the classification of MDS has been updated in the 5th edition of the World Health Organization (WHO) Classification of Haematolymphoid Tumours and the International Consensus Classification (ICC) of Myeloid Neoplasms and Acute Leukemia with incorporation of morphologic, clinical, and genomic data. Furthermore,...]]></summary>
        <author>
            <name>Josephine Lucero</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Unlocking the Role of Endothelial MPL Receptor and JAK2V617F Mutation: Insights into Cardiovascular Dysfunction in MPNs and CHIP]]></title>
        <id>pubmed:37503259</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37503259/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230807205649&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-07-28T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Patients with JAK2V617F-positive myeloproliferative neoplasms (MPNs) and clonal hematopoiesis of indeterminate potential (CHIP) are at a significantly higher risk of cardiovascular diseases (CVDs). Endothelial cells (ECs) carrying the JAK2V617F mutation can be detected in many MPN patients. Here, we investigated the impact of endothelial JAK2V617F mutation on CVD development using both transgenic murine models and human induced pluripotent stem cell lines. Our findings revealed that JAK2V617F...]]></summary>
        <author>
            <name>Haotian Zhang</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Oncostatin M is a Master Regulator of an Inflammatory Network in <em>Dnmt3a</em> -Mutant Hematopoietic Stem Cells]]></title>
        <id>pubmed:37502912</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37502912/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230807205649&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-07-28T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Age-associated clonal hematopoiesis (CH) occurs due to somatic mutations accrued in hematopoietic stem cells (HSCs) that confer a selective advantage in the context of aging. The mechanisms by which CH-mutant HSCs gain this advantage with aging are not comprehensively understood. Using unbiased transcriptomic approaches, we identify Oncostatin M (OSM) signaling as a candidate contributor to aging-driven Dnmt3a -mutant CH. We find that Dnmt3a -mutant HSCs from young mice do not functionally...]]></summary>
        <author>
            <name>Logan S Schwartz</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Subclones with variants of uncertain clinical significance might contribute to ineffective hemopoiesis and leukemia predisposition]]></title>
        <id>pubmed:37501402</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37501402/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230807205649&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-07-28T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSIONS: In conclusions, we linked both pathogenic and VUS variants in AML-related genes to clonal hematopoiesis; therefore, we proposed to consider those variants as prognostic markers in leukemia and myelodysplasia. However, further studies in larger prospective cohorts are required to validate our results.]]></summary>
        <author>
            <name>Valentina Giudice</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Prevalence and significance of DDX41 gene variants in the general population]]></title>
        <id>pubmed:37506341</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37506341/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230806205822&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-07-28T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Germline variants in the DDX41 gene have been linked to myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML) development. However, the risks associated with different variants remain unknown, as do the basis of their leukemogenic properties, impact on steady-state hematopoiesis and links to other cancers. Here, we investigate the frequency and significance of DDX41 variants in 454,792 United Kingdom Biobank (UKB) participants and identify 452 unique non-synonymous DNA variants in...]]></summary>
        <author>
            <name>Sruthi Cheloor Kovilakam</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Detection of Age-Related Somatic Alterations in Canine Blood Using Next-Generation Sequencing-Based Liquid Biopsy: An Analysis of over 4800 Dogs]]></title>
        <id>pubmed:37505860</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37505860/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230806205822&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-07-28T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Age-related somatic genomic alterations in hematopoietic cell lines have been well characterized in humans; however, this phenomenon has not been well studied in other species. Next-generation sequencing-based liquid biopsy testing for cancer detection was recently developed for dogs and has been used to study the genomic profiles of blood samples from thousands of canine patients since 2021. In this study, 4870 client-owned dogs with and without a diagnosis or suspicion of cancer underwent...]]></summary>
        <author>
            <name>Kristina M Kruglyak</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Management of Patients with Lower-Risk Myelodysplastic Neoplasms (MDS)]]></title>
        <id>pubmed:37504319</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37504319/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230806205822&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-07-28T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Myelodysplastic neoplasms (MDS) are a heterogenous group of clonal hematologic disorders characterized by morphologic dysplasia, ineffective hematopoiesis, and cytopenia. In the past year, the classification of MDS has been updated in the 5th edition of the World Health Organization (WHO) Classification of Haematolymphoid Tumours and the International Consensus Classification (ICC) of Myeloid Neoplasms and Acute Leukemia with incorporation of morphologic, clinical, and genomic data. Furthermore,...]]></summary>
        <author>
            <name>Josephine Lucero</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Unlocking the Role of Endothelial MPL Receptor and JAK2V617F Mutation: Insights into Cardiovascular Dysfunction in MPNs and CHIP]]></title>
        <id>pubmed:37503259</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37503259/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230806205822&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-07-28T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Patients with JAK2V617F-positive myeloproliferative neoplasms (MPNs) and clonal hematopoiesis of indeterminate potential (CHIP) are at a significantly higher risk of cardiovascular diseases (CVDs). Endothelial cells (ECs) carrying the JAK2V617F mutation can be detected in many MPN patients. Here, we investigated the impact of endothelial JAK2V617F mutation on CVD development using both transgenic murine models and human induced pluripotent stem cell lines. Our findings revealed that JAK2V617F...]]></summary>
        <author>
            <name>Haotian Zhang</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Oncostatin M is a Master Regulator of an Inflammatory Network in <em>Dnmt3a</em> -Mutant Hematopoietic Stem Cells]]></title>
        <id>pubmed:37502912</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37502912/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230806205822&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-07-28T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Age-associated clonal hematopoiesis (CH) occurs due to somatic mutations accrued in hematopoietic stem cells (HSCs) that confer a selective advantage in the context of aging. The mechanisms by which CH-mutant HSCs gain this advantage with aging are not comprehensively understood. Using unbiased transcriptomic approaches, we identify Oncostatin M (OSM) signaling as a candidate contributor to aging-driven Dnmt3a -mutant CH. We find that Dnmt3a -mutant HSCs from young mice do not functionally...]]></summary>
        <author>
            <name>Logan S Schwartz</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Subclones with variants of uncertain clinical significance might contribute to ineffective hemopoiesis and leukemia predisposition]]></title>
        <id>pubmed:37501402</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37501402/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230806205822&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-07-28T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSIONS: In conclusions, we linked both pathogenic and VUS variants in AML-related genes to clonal hematopoiesis; therefore, we proposed to consider those variants as prognostic markers in leukemia and myelodysplasia. However, further studies in larger prospective cohorts are required to validate our results.]]></summary>
        <author>
            <name>Valentina Giudice</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Prevalence and significance of DDX41 gene variants in the general population]]></title>
        <id>pubmed:37506341</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37506341/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230805205329&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-07-28T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Germline variants in the DDX41 gene have been linked to myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML) development. However, the risks associated with different variants remain unknown, as do the basis of their leukemogenic properties, impact on steady-state hematopoiesis and links to other cancers. Here, we investigate the frequency and significance of DDX41 variants in 454,792 United Kingdom Biobank (UKB) participants and identify 452 unique non-synonymous DNA variants in...]]></summary>
        <author>
            <name>Sruthi Cheloor Kovilakam</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Detection of Age-Related Somatic Alterations in Canine Blood Using Next-Generation Sequencing-Based Liquid Biopsy: An Analysis of over 4800 Dogs]]></title>
        <id>pubmed:37505860</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37505860/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230805205329&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-07-28T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Age-related somatic genomic alterations in hematopoietic cell lines have been well characterized in humans; however, this phenomenon has not been well studied in other species. Next-generation sequencing-based liquid biopsy testing for cancer detection was recently developed for dogs and has been used to study the genomic profiles of blood samples from thousands of canine patients since 2021. In this study, 4870 client-owned dogs with and without a diagnosis or suspicion of cancer underwent...]]></summary>
        <author>
            <name>Kristina M Kruglyak</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Management of Patients with Lower-Risk Myelodysplastic Neoplasms (MDS)]]></title>
        <id>pubmed:37504319</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37504319/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230805205329&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-07-28T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Myelodysplastic neoplasms (MDS) are a heterogenous group of clonal hematologic disorders characterized by morphologic dysplasia, ineffective hematopoiesis, and cytopenia. In the past year, the classification of MDS has been updated in the 5th edition of the World Health Organization (WHO) Classification of Haematolymphoid Tumours and the International Consensus Classification (ICC) of Myeloid Neoplasms and Acute Leukemia with incorporation of morphologic, clinical, and genomic data. Furthermore,...]]></summary>
        <author>
            <name>Josephine Lucero</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Unlocking the Role of Endothelial MPL Receptor and JAK2V617F Mutation: Insights into Cardiovascular Dysfunction in MPNs and CHIP]]></title>
        <id>pubmed:37503259</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37503259/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230805205329&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-07-28T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Patients with JAK2V617F-positive myeloproliferative neoplasms (MPNs) and clonal hematopoiesis of indeterminate potential (CHIP) are at a significantly higher risk of cardiovascular diseases (CVDs). Endothelial cells (ECs) carrying the JAK2V617F mutation can be detected in many MPN patients. Here, we investigated the impact of endothelial JAK2V617F mutation on CVD development using both transgenic murine models and human induced pluripotent stem cell lines. Our findings revealed that JAK2V617F...]]></summary>
        <author>
            <name>Haotian Zhang</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Oncostatin M is a Master Regulator of an Inflammatory Network in <em>Dnmt3a</em> -Mutant Hematopoietic Stem Cells]]></title>
        <id>pubmed:37502912</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37502912/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230805205329&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-07-28T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Age-associated clonal hematopoiesis (CH) occurs due to somatic mutations accrued in hematopoietic stem cells (HSCs) that confer a selective advantage in the context of aging. The mechanisms by which CH-mutant HSCs gain this advantage with aging are not comprehensively understood. Using unbiased transcriptomic approaches, we identify Oncostatin M (OSM) signaling as a candidate contributor to aging-driven Dnmt3a -mutant CH. We find that Dnmt3a -mutant HSCs from young mice do not functionally...]]></summary>
        <author>
            <name>Logan S Schwartz</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Subclones with variants of uncertain clinical significance might contribute to ineffective hemopoiesis and leukemia predisposition]]></title>
        <id>pubmed:37501402</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37501402/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230805205329&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-07-28T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSIONS: In conclusions, we linked both pathogenic and VUS variants in AML-related genes to clonal hematopoiesis; therefore, we proposed to consider those variants as prognostic markers in leukemia and myelodysplasia. However, further studies in larger prospective cohorts are required to validate our results.]]></summary>
        <author>
            <name>Valentina Giudice</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Prevalence and significance of DDX41 gene variants in the general population]]></title>
        <id>pubmed:37506341</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37506341/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230804205603&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-07-28T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Germline variants in the DDX41 gene have been linked to myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML) development. However, the risks associated with different variants remain unknown, as do the basis of their leukemogenic properties, impact on steady-state hematopoiesis and links to other cancers. Here, we investigate the frequency and significance of DDX41 variants in 454,792 United Kingdom Biobank (UKB) participants and identify 452 unique non-synonymous DNA variants in...]]></summary>
        <author>
            <name>Sruthi Cheloor Kovilakam</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Detection of Age-Related Somatic Alterations in Canine Blood Using Next-Generation Sequencing-Based Liquid Biopsy: An Analysis of over 4800 Dogs]]></title>
        <id>pubmed:37505860</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37505860/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230804205603&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-07-28T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Age-related somatic genomic alterations in hematopoietic cell lines have been well characterized in humans; however, this phenomenon has not been well studied in other species. Next-generation sequencing-based liquid biopsy testing for cancer detection was recently developed for dogs and has been used to study the genomic profiles of blood samples from thousands of canine patients since 2021. In this study, 4870 client-owned dogs with and without a diagnosis or suspicion of cancer underwent...]]></summary>
        <author>
            <name>Kristina M Kruglyak</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Management of Patients with Lower-Risk Myelodysplastic Neoplasms (MDS)]]></title>
        <id>pubmed:37504319</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37504319/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230804205603&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-07-28T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Myelodysplastic neoplasms (MDS) are a heterogenous group of clonal hematologic disorders characterized by morphologic dysplasia, ineffective hematopoiesis, and cytopenia. In the past year, the classification of MDS has been updated in the 5th edition of the World Health Organization (WHO) Classification of Haematolymphoid Tumours and the International Consensus Classification (ICC) of Myeloid Neoplasms and Acute Leukemia with incorporation of morphologic, clinical, and genomic data. Furthermore,...]]></summary>
        <author>
            <name>Josephine Lucero</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Unlocking the Role of Endothelial MPL Receptor and JAK2V617F Mutation: Insights into Cardiovascular Dysfunction in MPNs and CHIP]]></title>
        <id>pubmed:37503259</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37503259/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230804205603&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-07-28T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Patients with JAK2V617F-positive myeloproliferative neoplasms (MPNs) and clonal hematopoiesis of indeterminate potential (CHIP) are at a significantly higher risk of cardiovascular diseases (CVDs). Endothelial cells (ECs) carrying the JAK2V617F mutation can be detected in many MPN patients. Here, we investigated the impact of endothelial JAK2V617F mutation on CVD development using both transgenic murine models and human induced pluripotent stem cell lines. Our findings revealed that JAK2V617F...]]></summary>
        <author>
            <name>Haotian Zhang</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Oncostatin M is a Master Regulator of an Inflammatory Network in <em>Dnmt3a</em> -Mutant Hematopoietic Stem Cells]]></title>
        <id>pubmed:37502912</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37502912/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230804205603&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-07-28T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Age-associated clonal hematopoiesis (CH) occurs due to somatic mutations accrued in hematopoietic stem cells (HSCs) that confer a selective advantage in the context of aging. The mechanisms by which CH-mutant HSCs gain this advantage with aging are not comprehensively understood. Using unbiased transcriptomic approaches, we identify Oncostatin M (OSM) signaling as a candidate contributor to aging-driven Dnmt3a -mutant CH. We find that Dnmt3a -mutant HSCs from young mice do not functionally...]]></summary>
        <author>
            <name>Logan S Schwartz</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Subclones with variants of uncertain clinical significance might contribute to ineffective hemopoiesis and leukemia predisposition]]></title>
        <id>pubmed:37501402</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37501402/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230804205603&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-07-28T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSIONS: In conclusions, we linked both pathogenic and VUS variants in AML-related genes to clonal hematopoiesis; therefore, we proposed to consider those variants as prognostic markers in leukemia and myelodysplasia. However, further studies in larger prospective cohorts are required to validate our results.]]></summary>
        <author>
            <name>Valentina Giudice</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Prevalence and significance of DDX41 gene variants in the general population]]></title>
        <id>pubmed:37506341</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37506341/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230803205941&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-07-28T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Germline variants in the DDX41 gene have been linked to myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML) development. However, the risks associated with different variants remain unknown, as do the basis of their leukemogenic properties, impact on steady-state hematopoiesis and links to other cancers. Here, we investigate the frequency and significance of DDX41 variants in 454,792 United Kingdom Biobank (UKB) participants and identify 452 unique non-synonymous DNA variants in...]]></summary>
        <author>
            <name>Sruthi Cheloor Kovilakam</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Detection of Age-Related Somatic Alterations in Canine Blood Using Next-Generation Sequencing-Based Liquid Biopsy: An Analysis of over 4800 Dogs]]></title>
        <id>pubmed:37505860</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37505860/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230803205941&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-07-28T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Age-related somatic genomic alterations in hematopoietic cell lines have been well characterized in humans; however, this phenomenon has not been well studied in other species. Next-generation sequencing-based liquid biopsy testing for cancer detection was recently developed for dogs and has been used to study the genomic profiles of blood samples from thousands of canine patients since 2021. In this study, 4870 client-owned dogs with and without a diagnosis or suspicion of cancer underwent...]]></summary>
        <author>
            <name>Kristina M Kruglyak</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Management of Patients with Lower-Risk Myelodysplastic Neoplasms (MDS)]]></title>
        <id>pubmed:37504319</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37504319/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230803205941&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-07-28T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Myelodysplastic neoplasms (MDS) are a heterogenous group of clonal hematologic disorders characterized by morphologic dysplasia, ineffective hematopoiesis, and cytopenia. In the past year, the classification of MDS has been updated in the 5th edition of the World Health Organization (WHO) Classification of Haematolymphoid Tumours and the International Consensus Classification (ICC) of Myeloid Neoplasms and Acute Leukemia with incorporation of morphologic, clinical, and genomic data. Furthermore,...]]></summary>
        <author>
            <name>Josephine Lucero</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Unlocking the Role of Endothelial MPL Receptor and JAK2V617F Mutation: Insights into Cardiovascular Dysfunction in MPNs and CHIP]]></title>
        <id>pubmed:37503259</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37503259/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230803205941&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-07-28T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Patients with JAK2V617F-positive myeloproliferative neoplasms (MPNs) and clonal hematopoiesis of indeterminate potential (CHIP) are at a significantly higher risk of cardiovascular diseases (CVDs). Endothelial cells (ECs) carrying the JAK2V617F mutation can be detected in many MPN patients. Here, we investigated the impact of endothelial JAK2V617F mutation on CVD development using both transgenic murine models and human induced pluripotent stem cell lines. Our findings revealed that JAK2V617F...]]></summary>
        <author>
            <name>Haotian Zhang</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Oncostatin M is a Master Regulator of an Inflammatory Network in <em>Dnmt3a</em> -Mutant Hematopoietic Stem Cells]]></title>
        <id>pubmed:37502912</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37502912/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230803205941&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-07-28T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Age-associated clonal hematopoiesis (CH) occurs due to somatic mutations accrued in hematopoietic stem cells (HSCs) that confer a selective advantage in the context of aging. The mechanisms by which CH-mutant HSCs gain this advantage with aging are not comprehensively understood. Using unbiased transcriptomic approaches, we identify Oncostatin M (OSM) signaling as a candidate contributor to aging-driven Dnmt3a -mutant CH. We find that Dnmt3a -mutant HSCs from young mice do not functionally...]]></summary>
        <author>
            <name>Logan S Schwartz</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Subclones with variants of uncertain clinical significance might contribute to ineffective hemopoiesis and leukemia predisposition]]></title>
        <id>pubmed:37501402</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37501402/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230803205941&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-07-28T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSIONS: In conclusions, we linked both pathogenic and VUS variants in AML-related genes to clonal hematopoiesis; therefore, we proposed to consider those variants as prognostic markers in leukemia and myelodysplasia. However, further studies in larger prospective cohorts are required to validate our results.]]></summary>
        <author>
            <name>Valentina Giudice</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Prevalence and significance of DDX41 gene variants in the general population]]></title>
        <id>pubmed:37506341</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37506341/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230802205831&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-07-28T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Germline variants in the DDX41 gene have been linked to myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML) development. However, the risks associated with different variants remain unknown, as do the basis of their leukemogenic properties, impact on steady-state hematopoiesis and links to other cancers. Here, we investigate the frequency and significance of DDX41 variants in 454,792 United Kingdom Biobank (UKB) participants and identify 452 unique non-synonymous DNA variants in...]]></summary>
        <author>
            <name>Sruthi Cheloor Kovilakam</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Detection of Age-Related Somatic Alterations in Canine Blood Using Next-Generation Sequencing-Based Liquid Biopsy: An Analysis of over 4800 Dogs]]></title>
        <id>pubmed:37505860</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37505860/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230802205831&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-07-28T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Age-related somatic genomic alterations in hematopoietic cell lines have been well characterized in humans; however, this phenomenon has not been well studied in other species. Next-generation sequencing-based liquid biopsy testing for cancer detection was recently developed for dogs and has been used to study the genomic profiles of blood samples from thousands of canine patients since 2021. In this study, 4870 client-owned dogs with and without a diagnosis or suspicion of cancer underwent...]]></summary>
        <author>
            <name>Kristina M Kruglyak</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Management of Patients with Lower-Risk Myelodysplastic Neoplasms (MDS)]]></title>
        <id>pubmed:37504319</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37504319/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230802205831&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-07-28T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Myelodysplastic neoplasms (MDS) are a heterogenous group of clonal hematologic disorders characterized by morphologic dysplasia, ineffective hematopoiesis, and cytopenia. In the past year, the classification of MDS has been updated in the 5th edition of the World Health Organization (WHO) Classification of Haematolymphoid Tumours and the International Consensus Classification (ICC) of Myeloid Neoplasms and Acute Leukemia with incorporation of morphologic, clinical, and genomic data. Furthermore,...]]></summary>
        <author>
            <name>Josephine Lucero</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Unlocking the Role of Endothelial MPL Receptor and JAK2V617F Mutation: Insights into Cardiovascular Dysfunction in MPNs and CHIP]]></title>
        <id>pubmed:37503259</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37503259/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230802205831&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-07-28T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Patients with JAK2V617F-positive myeloproliferative neoplasms (MPNs) and clonal hematopoiesis of indeterminate potential (CHIP) are at a significantly higher risk of cardiovascular diseases (CVDs). Endothelial cells (ECs) carrying the JAK2V617F mutation can be detected in many MPN patients. Here, we investigated the impact of endothelial JAK2V617F mutation on CVD development using both transgenic murine models and human induced pluripotent stem cell lines. Our findings revealed that JAK2V617F...]]></summary>
        <author>
            <name>Haotian Zhang</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Oncostatin M is a Master Regulator of an Inflammatory Network in <em>Dnmt3a</em> -Mutant Hematopoietic Stem Cells]]></title>
        <id>pubmed:37502912</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37502912/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230802205831&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-07-28T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Age-associated clonal hematopoiesis (CH) occurs due to somatic mutations accrued in hematopoietic stem cells (HSCs) that confer a selective advantage in the context of aging. The mechanisms by which CH-mutant HSCs gain this advantage with aging are not comprehensively understood. Using unbiased transcriptomic approaches, we identify Oncostatin M (OSM) signaling as a candidate contributor to aging-driven Dnmt3a -mutant CH. We find that Dnmt3a -mutant HSCs from young mice do not functionally...]]></summary>
        <author>
            <name>Logan S Schwartz</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Subclones with variants of uncertain clinical significance might contribute to ineffective hemopoiesis and leukemia predisposition]]></title>
        <id>pubmed:37501402</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37501402/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230802205831&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-07-28T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSIONS: In conclusions, we linked both pathogenic and VUS variants in AML-related genes to clonal hematopoiesis; therefore, we proposed to consider those variants as prognostic markers in leukemia and myelodysplasia. However, further studies in larger prospective cohorts are required to validate our results.]]></summary>
        <author>
            <name>Valentina Giudice</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Prevalence and significance of DDX41 gene variants in the general population]]></title>
        <id>pubmed:37506341</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37506341/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230801205540&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-07-28T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Germline variants in the DDX41 gene have been linked to myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML) development. However, the risks associated with different variants remain unknown, as do the basis of their leukemogenic properties, impact on steady-state hematopoiesis and links to other cancers. Here, we investigate the frequency and significance of DDX41 variants in 454,792 United Kingdom Biobank (UKB) participants and identify 452 unique non-synonymous DNA variants in...]]></summary>
        <author>
            <name>Sruthi Cheloor Kovilakam</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Detection of Age-Related Somatic Alterations in Canine Blood Using Next-Generation Sequencing-Based Liquid Biopsy: An Analysis of over 4800 Dogs]]></title>
        <id>pubmed:37505860</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37505860/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230801205540&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-07-28T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Age-related somatic genomic alterations in hematopoietic cell lines have been well characterized in humans; however, this phenomenon has not been well studied in other species. Next-generation sequencing-based liquid biopsy testing for cancer detection was recently developed for dogs and has been used to study the genomic profiles of blood samples from thousands of canine patients since 2021. In this study, 4870 client-owned dogs with and without a diagnosis or suspicion of cancer underwent...]]></summary>
        <author>
            <name>Kristina M Kruglyak</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Management of Patients with Lower-Risk Myelodysplastic Neoplasms (MDS)]]></title>
        <id>pubmed:37504319</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37504319/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230801205540&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-07-28T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Myelodysplastic neoplasms (MDS) are a heterogenous group of clonal hematologic disorders characterized by morphologic dysplasia, ineffective hematopoiesis, and cytopenia. In the past year, the classification of MDS has been updated in the 5th edition of the World Health Organization (WHO) Classification of Haematolymphoid Tumours and the International Consensus Classification (ICC) of Myeloid Neoplasms and Acute Leukemia with incorporation of morphologic, clinical, and genomic data. Furthermore,...]]></summary>
        <author>
            <name>Josephine Lucero</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Unlocking the Role of Endothelial MPL Receptor and JAK2V617F Mutation: Insights into Cardiovascular Dysfunction in MPNs and CHIP]]></title>
        <id>pubmed:37503259</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37503259/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230801205540&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-07-28T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Patients with JAK2V617F-positive myeloproliferative neoplasms (MPNs) and clonal hematopoiesis of indeterminate potential (CHIP) are at a significantly higher risk of cardiovascular diseases (CVDs). Endothelial cells (ECs) carrying the JAK2V617F mutation can be detected in many MPN patients. Here, we investigated the impact of endothelial JAK2V617F mutation on CVD development using both transgenic murine models and human induced pluripotent stem cell lines. Our findings revealed that JAK2V617F...]]></summary>
        <author>
            <name>Haotian Zhang</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Oncostatin M is a Master Regulator of an Inflammatory Network in <em>Dnmt3a</em> -Mutant Hematopoietic Stem Cells]]></title>
        <id>pubmed:37502912</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37502912/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230801205540&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-07-28T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Age-associated clonal hematopoiesis (CH) occurs due to somatic mutations accrued in hematopoietic stem cells (HSCs) that confer a selective advantage in the context of aging. The mechanisms by which CH-mutant HSCs gain this advantage with aging are not comprehensively understood. Using unbiased transcriptomic approaches, we identify Oncostatin M (OSM) signaling as a candidate contributor to aging-driven Dnmt3a -mutant CH. We find that Dnmt3a -mutant HSCs from young mice do not functionally...]]></summary>
        <author>
            <name>Logan S Schwartz</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Subclones with variants of uncertain clinical significance might contribute to ineffective hemopoiesis and leukemia predisposition]]></title>
        <id>pubmed:37501402</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37501402/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230801205540&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-07-28T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSIONS: In conclusions, we linked both pathogenic and VUS variants in AML-related genes to clonal hematopoiesis; therefore, we proposed to consider those variants as prognostic markers in leukemia and myelodysplasia. However, further studies in larger prospective cohorts are required to validate our results.]]></summary>
        <author>
            <name>Valentina Giudice</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Prevalence and significance of DDX41 gene variants in the general population]]></title>
        <id>pubmed:37506341</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37506341/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230731210325&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-07-28T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Germline variants in the DDX41 gene have been linked to myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML) development. However, the risks associated with different variants remain unknown, as do the basis of their leukemogenic properties, impact on steady-state hematopoiesis and links to other cancers. Here, we investigate the frequency and significance of DDX41 variants in 454,792 United Kingdom Biobank (UKB) participants and identify 452 unique non-synonymous DNA variants in...]]></summary>
        <author>
            <name>Sruthi Cheloor Kovilakam</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Detection of Age-Related Somatic Alterations in Canine Blood Using Next-Generation Sequencing-Based Liquid Biopsy: An Analysis of over 4800 Dogs]]></title>
        <id>pubmed:37505860</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37505860/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230731210325&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-07-28T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Age-related somatic genomic alterations in hematopoietic cell lines have been well characterized in humans; however, this phenomenon has not been well studied in other species. Next-generation sequencing-based liquid biopsy testing for cancer detection was recently developed for dogs and has been used to study the genomic profiles of blood samples from thousands of canine patients since 2021. In this study, 4870 client-owned dogs with and without a diagnosis or suspicion of cancer underwent...]]></summary>
        <author>
            <name>Kristina M Kruglyak</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Management of Patients with Lower-Risk Myelodysplastic Neoplasms (MDS)]]></title>
        <id>pubmed:37504319</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37504319/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230731210325&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-07-28T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Myelodysplastic neoplasms (MDS) are a heterogenous group of clonal hematologic disorders characterized by morphologic dysplasia, ineffective hematopoiesis, and cytopenia. In the past year, the classification of MDS has been updated in the 5th edition of the World Health Organization (WHO) Classification of Haematolymphoid Tumours and the International Consensus Classification (ICC) of Myeloid Neoplasms and Acute Leukemia with incorporation of morphologic, clinical, and genomic data. Furthermore,...]]></summary>
        <author>
            <name>Josephine Lucero</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Unlocking the Role of Endothelial MPL Receptor and JAK2V617F Mutation: Insights into Cardiovascular Dysfunction in MPNs and CHIP]]></title>
        <id>pubmed:37503259</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37503259/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230731210325&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-07-28T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Patients with JAK2V617F-positive myeloproliferative neoplasms (MPNs) and clonal hematopoiesis of indeterminate potential (CHIP) are at a significantly higher risk of cardiovascular diseases (CVDs). Endothelial cells (ECs) carrying the JAK2V617F mutation can be detected in many MPN patients. Here, we investigated the impact of endothelial JAK2V617F mutation on CVD development using both transgenic murine models and human induced pluripotent stem cell lines. Our findings revealed that JAK2V617F...]]></summary>
        <author>
            <name>Haotian Zhang</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Oncostatin M is a Master Regulator of an Inflammatory Network in <em>Dnmt3a</em> -Mutant Hematopoietic Stem Cells]]></title>
        <id>pubmed:37502912</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37502912/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230731210325&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-07-28T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Age-associated clonal hematopoiesis (CH) occurs due to somatic mutations accrued in hematopoietic stem cells (HSCs) that confer a selective advantage in the context of aging. The mechanisms by which CH-mutant HSCs gain this advantage with aging are not comprehensively understood. Using unbiased transcriptomic approaches, we identify Oncostatin M (OSM) signaling as a candidate contributor to aging-driven Dnmt3a -mutant CH. We find that Dnmt3a -mutant HSCs from young mice do not functionally...]]></summary>
        <author>
            <name>Logan S Schwartz</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Subclones with variants of uncertain clinical significance might contribute to ineffective hemopoiesis and leukemia predisposition]]></title>
        <id>pubmed:37501402</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37501402/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230731210325&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-07-28T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSIONS: In conclusions, we linked both pathogenic and VUS variants in AML-related genes to clonal hematopoiesis; therefore, we proposed to consider those variants as prognostic markers in leukemia and myelodysplasia. However, further studies in larger prospective cohorts are required to validate our results.]]></summary>
        <author>
            <name>Valentina Giudice</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Prevalence and significance of DDX41 gene variants in the general population]]></title>
        <id>pubmed:37506341</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37506341/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230730205823&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-07-28T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Germline variants in the DDX41 gene have been linked to myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML) development. However, the risks associated with different variants remain unknown, as do the basis of their leukemogenic properties, impact on steady-state hematopoiesis and links to other cancers. Here, we investigate the frequency and significance of DDX41 variants in 454,792 United Kingdom Biobank (UKB) participants and identify 452 unique non-synonymous DNA variants in...]]></summary>
        <author>
            <name>Sruthi Cheloor Kovilakam</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Detection of Age-Related Somatic Alterations in Canine Blood Using Next-Generation Sequencing-Based Liquid Biopsy: An Analysis of over 4800 Dogs]]></title>
        <id>pubmed:37505860</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37505860/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230730205823&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-07-28T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Age-related somatic genomic alterations in hematopoietic cell lines have been well characterized in humans; however, this phenomenon has not been well studied in other species. Next-generation sequencing-based liquid biopsy testing for cancer detection was recently developed for dogs and has been used to study the genomic profiles of blood samples from thousands of canine patients since 2021. In this study, 4870 client-owned dogs with and without a diagnosis or suspicion of cancer underwent...]]></summary>
        <author>
            <name>Kristina M Kruglyak</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Management of Patients with Lower-Risk Myelodysplastic Neoplasms (MDS)]]></title>
        <id>pubmed:37504319</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37504319/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230730205823&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-07-28T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Myelodysplastic neoplasms (MDS) are a heterogenous group of clonal hematologic disorders characterized by morphologic dysplasia, ineffective hematopoiesis, and cytopenia. In the past year, the classification of MDS has been updated in the 5th edition of the World Health Organization (WHO) Classification of Haematolymphoid Tumours and the International Consensus Classification (ICC) of Myeloid Neoplasms and Acute Leukemia with incorporation of morphologic, clinical, and genomic data. Furthermore,...]]></summary>
        <author>
            <name>Josephine Lucero</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Unlocking the Role of Endothelial MPL Receptor and JAK2V617F Mutation: Insights into Cardiovascular Dysfunction in MPNs and CHIP]]></title>
        <id>pubmed:37503259</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37503259/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230730205823&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-07-28T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Patients with JAK2V617F-positive myeloproliferative neoplasms (MPNs) and clonal hematopoiesis of indeterminate potential (CHIP) are at a significantly higher risk of cardiovascular diseases (CVDs). Endothelial cells (ECs) carrying the JAK2V617F mutation can be detected in many MPN patients. Here, we investigated the impact of endothelial JAK2V617F mutation on CVD development using both transgenic murine models and human induced pluripotent stem cell lines. Our findings revealed that JAK2V617F...]]></summary>
        <author>
            <name>Haotian Zhang</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Oncostatin M is a Master Regulator of an Inflammatory Network in <em>Dnmt3a</em> -Mutant Hematopoietic Stem Cells]]></title>
        <id>pubmed:37502912</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37502912/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230730205823&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-07-28T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Age-associated clonal hematopoiesis (CH) occurs due to somatic mutations accrued in hematopoietic stem cells (HSCs) that confer a selective advantage in the context of aging. The mechanisms by which CH-mutant HSCs gain this advantage with aging are not comprehensively understood. Using unbiased transcriptomic approaches, we identify Oncostatin M (OSM) signaling as a candidate contributor to aging-driven Dnmt3a -mutant CH. We find that Dnmt3a -mutant HSCs from young mice do not functionally...]]></summary>
        <author>
            <name>Logan S Schwartz</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Subclones with variants of uncertain clinical significance might contribute to ineffective hemopoiesis and leukemia predisposition]]></title>
        <id>pubmed:37501402</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37501402/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230730205823&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-07-28T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSIONS: In conclusions, we linked both pathogenic and VUS variants in AML-related genes to clonal hematopoiesis; therefore, we proposed to consider those variants as prognostic markers in leukemia and myelodysplasia. However, further studies in larger prospective cohorts are required to validate our results.]]></summary>
        <author>
            <name>Valentina Giudice</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Prevalence and significance of DDX41 gene variants in the general population]]></title>
        <id>pubmed:37506341</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37506341/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230729205947&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-07-28T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Germline variants in the DDX41 gene have been linked to myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML) development. However, the risks associated with different variants remain unknown, as do the basis of their leukemogenic properties, impact on steady-state hematopoiesis and links to other cancers. Here, we investigate the frequency and significance of DDX41 variants in 454,792 United Kingdom Biobank (UKB) participants and identify 452 unique non-synonymous DNA variants in...]]></summary>
        <author>
            <name>Sruthi Cheloor Kovilakam</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Detection of Age-Related Somatic Alterations in Canine Blood Using Next-Generation Sequencing-Based Liquid Biopsy: An Analysis of over 4800 Dogs]]></title>
        <id>pubmed:37505860</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37505860/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230729205947&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-07-28T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Age-related somatic genomic alterations in hematopoietic cell lines have been well characterized in humans; however, this phenomenon has not been well studied in other species. Next-generation sequencing-based liquid biopsy testing for cancer detection was recently developed for dogs and has been used to study the genomic profiles of blood samples from thousands of canine patients since 2021. In this study, 4870 client-owned dogs with and without a diagnosis or suspicion of cancer underwent...]]></summary>
        <author>
            <name>Kristina M Kruglyak</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Management of Patients with Lower-Risk Myelodysplastic Neoplasms (MDS)]]></title>
        <id>pubmed:37504319</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37504319/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230729205947&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-07-28T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Myelodysplastic neoplasms (MDS) are a heterogenous group of clonal hematologic disorders characterized by morphologic dysplasia, ineffective hematopoiesis, and cytopenia. In the past year, the classification of MDS has been updated in the 5th edition of the World Health Organization (WHO) Classification of Haematolymphoid Tumours and the International Consensus Classification (ICC) of Myeloid Neoplasms and Acute Leukemia with incorporation of morphologic, clinical, and genomic data. Furthermore,...]]></summary>
        <author>
            <name>Josephine Lucero</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Unlocking the Role of Endothelial MPL Receptor and JAK2V617F Mutation: Insights into Cardiovascular Dysfunction in MPNs and CHIP]]></title>
        <id>pubmed:37503259</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37503259/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230729205947&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-07-28T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Patients with JAK2V617F-positive myeloproliferative neoplasms (MPNs) and clonal hematopoiesis of indeterminate potential (CHIP) are at a significantly higher risk of cardiovascular diseases (CVDs). Endothelial cells (ECs) carrying the JAK2V617F mutation can be detected in many MPN patients. Here, we investigated the impact of endothelial JAK2V617F mutation on CVD development using both transgenic murine models and human induced pluripotent stem cell lines. Our findings revealed that JAK2V617F...]]></summary>
        <author>
            <name>Haotian Zhang</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Oncostatin M is a Master Regulator of an Inflammatory Network in <em>Dnmt3a</em> -Mutant Hematopoietic Stem Cells]]></title>
        <id>pubmed:37502912</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37502912/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230729205947&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-07-28T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Age-associated clonal hematopoiesis (CH) occurs due to somatic mutations accrued in hematopoietic stem cells (HSCs) that confer a selective advantage in the context of aging. The mechanisms by which CH-mutant HSCs gain this advantage with aging are not comprehensively understood. Using unbiased transcriptomic approaches, we identify Oncostatin M (OSM) signaling as a candidate contributor to aging-driven Dnmt3a -mutant CH. We find that Dnmt3a -mutant HSCs from young mice do not functionally...]]></summary>
        <author>
            <name>Logan S Schwartz</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Subclones with variants of uncertain clinical significance might contribute to ineffective hemopoiesis and leukemia predisposition]]></title>
        <id>pubmed:37501402</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37501402/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230729205947&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-07-28T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSIONS: In conclusions, we linked both pathogenic and VUS variants in AML-related genes to clonal hematopoiesis; therefore, we proposed to consider those variants as prognostic markers in leukemia and myelodysplasia. However, further studies in larger prospective cohorts are required to validate our results.]]></summary>
        <author>
            <name>Valentina Giudice</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Prevalence and significance of DDX41 gene variants in the general population]]></title>
        <id>pubmed:37506341</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37506341/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230728205723&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-07-28T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Germline variants in the DDX41 gene have been linked to myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML) development. However, the risks associated with different variants remain unknown, as do the basis of their leukemogenic properties, impact on steady-state hematopoiesis and links to other cancers. Here, we investigate the frequency and significance of DDX41 variants in 454,792 United Kingdom Biobank (UKB) participants and identify 452 unique non-synonymous DNA variants in...]]></summary>
        <author>
            <name>Sruthi Cheloor Kovilakam</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Detection of Age-Related Somatic Alterations in Canine Blood Using Next-Generation Sequencing-Based Liquid Biopsy: An Analysis of over 4800 Dogs]]></title>
        <id>pubmed:37505860</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37505860/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230728205723&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-07-28T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Age-related somatic genomic alterations in hematopoietic cell lines have been well characterized in humans; however, this phenomenon has not been well studied in other species. Next-generation sequencing-based liquid biopsy testing for cancer detection was recently developed for dogs and has been used to study the genomic profiles of blood samples from thousands of canine patients since 2021. In this study, 4870 client-owned dogs with and without a diagnosis or suspicion of cancer underwent...]]></summary>
        <author>
            <name>Kristina M Kruglyak</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Management of Patients with Lower-Risk Myelodysplastic Neoplasms (MDS)]]></title>
        <id>pubmed:37504319</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37504319/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230728205723&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-07-28T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Myelodysplastic neoplasms (MDS) are a heterogenous group of clonal hematologic disorders characterized by morphologic dysplasia, ineffective hematopoiesis, and cytopenia. In the past year, the classification of MDS has been updated in the 5th edition of the World Health Organization (WHO) Classification of Haematolymphoid Tumours and the International Consensus Classification (ICC) of Myeloid Neoplasms and Acute Leukemia with incorporation of morphologic, clinical, and genomic data. Furthermore,...]]></summary>
        <author>
            <name>Josephine Lucero</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Unlocking the Role of Endothelial MPL Receptor and JAK2V617F Mutation: Insights into Cardiovascular Dysfunction in MPNs and CHIP]]></title>
        <id>pubmed:37503259</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37503259/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230728205723&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-07-28T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Patients with JAK2V617F-positive myeloproliferative neoplasms (MPNs) and clonal hematopoiesis of indeterminate potential (CHIP) are at a significantly higher risk of cardiovascular diseases (CVDs). Endothelial cells (ECs) carrying the JAK2V617F mutation can be detected in many MPN patients. Here, we investigated the impact of endothelial JAK2V617F mutation on CVD development using both transgenic murine models and human induced pluripotent stem cell lines. Our findings revealed that JAK2V617F...]]></summary>
        <author>
            <name>Haotian Zhang</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Oncostatin M is a Master Regulator of an Inflammatory Network in <em>Dnmt3a</em> -Mutant Hematopoietic Stem Cells]]></title>
        <id>pubmed:37502912</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37502912/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230728205723&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-07-28T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Age-associated clonal hematopoiesis (CH) occurs due to somatic mutations accrued in hematopoietic stem cells (HSCs) that confer a selective advantage in the context of aging. The mechanisms by which CH-mutant HSCs gain this advantage with aging are not comprehensively understood. Using unbiased transcriptomic approaches, we identify Oncostatin M (OSM) signaling as a candidate contributor to aging-driven Dnmt3a -mutant CH. We find that Dnmt3a -mutant HSCs from young mice do not functionally...]]></summary>
        <author>
            <name>Logan S Schwartz</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Subclones with variants of uncertain clinical significance might contribute to ineffective hemopoiesis and leukemia predisposition]]></title>
        <id>pubmed:37501402</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37501402/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230728205723&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-07-28T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSIONS: In conclusions, we linked both pathogenic and VUS variants in AML-related genes to clonal hematopoiesis; therefore, we proposed to consider those variants as prognostic markers in leukemia and myelodysplasia. However, further studies in larger prospective cohorts are required to validate our results.]]></summary>
        <author>
            <name>Valentina Giudice</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Head and neck cancer with synchronous nodules of the lung as a diagnostic and therapeutic challenge - A systematic review]]></title>
        <id>pubmed:37506514</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37506514/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230822204709&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-07-28T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Head and neck squamous cell carcinoma (HNSCC) often presents with synchronous nodules of the lung (sNL), which may be benign nodules, second primary malignancies or metastases of HNSCC. We sought to gain an insight into the incidence of sNL and synchronous second primary of the lung (sSPML) in HNSCC patients and current opinions on useful diagnostic and therapeutic approaches. We conducted a systematic search of the PubMed database for articles that reported the simultaneous detection of HNSCC...]]></summary>
        <author>
            <name>Marc Mller</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Head and neck cancer with synchronous nodules of the lung as a diagnostic and therapeutic challenge - A systematic review]]></title>
        <id>pubmed:37506514</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37506514/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230821204801&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-07-28T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Head and neck squamous cell carcinoma (HNSCC) often presents with synchronous nodules of the lung (sNL), which may be benign nodules, second primary malignancies or metastases of HNSCC. We sought to gain an insight into the incidence of sNL and synchronous second primary of the lung (sSPML) in HNSCC patients and current opinions on useful diagnostic and therapeutic approaches. We conducted a systematic search of the PubMed database for articles that reported the simultaneous detection of HNSCC...]]></summary>
        <author>
            <name>Marc Mller</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Head and neck cancer with synchronous nodules of the lung as a diagnostic and therapeutic challenge - A systematic review]]></title>
        <id>pubmed:37506514</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37506514/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230820204715&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-07-28T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Head and neck squamous cell carcinoma (HNSCC) often presents with synchronous nodules of the lung (sNL), which may be benign nodules, second primary malignancies or metastases of HNSCC. We sought to gain an insight into the incidence of sNL and synchronous second primary of the lung (sSPML) in HNSCC patients and current opinions on useful diagnostic and therapeutic approaches. We conducted a systematic search of the PubMed database for articles that reported the simultaneous detection of HNSCC...]]></summary>
        <author>
            <name>Marc Mller</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Prevalence and significance of DDX41 gene variants in the general population]]></title>
        <id>pubmed:37506341</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37506341/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230820204715&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-07-28T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Germline variants in the DDX41 gene have been linked to myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML) development. However, the risks associated with different variants remain unknown, as do the basis of their leukemogenic properties, impact on steady-state hematopoiesis and links to other cancers. Here, we investigate the frequency and significance of DDX41 variants in 454,792 United Kingdom Biobank (UKB) participants and identify 452 unique non-synonymous DNA variants in...]]></summary>
        <author>
            <name>Sruthi Cheloor Kovilakam</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Coordinated inheritance of extrachromosomal DNA species in human cancer cells]]></title>
        <id>pubmed:37503111</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37503111/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230820204715&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-07-28T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[The chromosomal theory of inheritance has dominated human genetics, including cancer genetics. Genes on the same chromosome segregate together while genes on different chromosomes assort independently, providing a fundamental tenet of Mendelian inheritance. Extrachromosomal DNA (ecDNA) is a frequent event in cancer that drives oncogene amplification, dysregulated gene expression and intratumoral heterogeneity, including through random segregation during cell division. Distinct ecDNA sequences,...]]></summary>
        <author>
            <name>King L Hung</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Head and neck cancer with synchronous nodules of the lung as a diagnostic and therapeutic challenge - A systematic review]]></title>
        <id>pubmed:37506514</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37506514/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230819204952&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-07-28T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Head and neck squamous cell carcinoma (HNSCC) often presents with synchronous nodules of the lung (sNL), which may be benign nodules, second primary malignancies or metastases of HNSCC. We sought to gain an insight into the incidence of sNL and synchronous second primary of the lung (sSPML) in HNSCC patients and current opinions on useful diagnostic and therapeutic approaches. We conducted a systematic search of the PubMed database for articles that reported the simultaneous detection of HNSCC...]]></summary>
        <author>
            <name>Marc Mller</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Prevalence and significance of DDX41 gene variants in the general population]]></title>
        <id>pubmed:37506341</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37506341/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230819204952&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-07-28T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Germline variants in the DDX41 gene have been linked to myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML) development. However, the risks associated with different variants remain unknown, as do the basis of their leukemogenic properties, impact on steady-state hematopoiesis and links to other cancers. Here, we investigate the frequency and significance of DDX41 variants in 454,792 United Kingdom Biobank (UKB) participants and identify 452 unique non-synonymous DNA variants in...]]></summary>
        <author>
            <name>Sruthi Cheloor Kovilakam</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Coordinated inheritance of extrachromosomal DNA species in human cancer cells]]></title>
        <id>pubmed:37503111</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37503111/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230819204952&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-07-28T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[The chromosomal theory of inheritance has dominated human genetics, including cancer genetics. Genes on the same chromosome segregate together while genes on different chromosomes assort independently, providing a fundamental tenet of Mendelian inheritance. Extrachromosomal DNA (ecDNA) is a frequent event in cancer that drives oncogene amplification, dysregulated gene expression and intratumoral heterogeneity, including through random segregation during cell division. Distinct ecDNA sequences,...]]></summary>
        <author>
            <name>King L Hung</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Head and neck cancer with synchronous nodules of the lung as a diagnostic and therapeutic challenge - A systematic review]]></title>
        <id>pubmed:37506514</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37506514/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230818204446&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-07-28T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Head and neck squamous cell carcinoma (HNSCC) often presents with synchronous nodules of the lung (sNL), which may be benign nodules, second primary malignancies or metastases of HNSCC. We sought to gain an insight into the incidence of sNL and synchronous second primary of the lung (sSPML) in HNSCC patients and current opinions on useful diagnostic and therapeutic approaches. We conducted a systematic search of the PubMed database for articles that reported the simultaneous detection of HNSCC...]]></summary>
        <author>
            <name>Marc Mller</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Prevalence and significance of DDX41 gene variants in the general population]]></title>
        <id>pubmed:37506341</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37506341/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230818204446&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-07-28T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Germline variants in the DDX41 gene have been linked to myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML) development. However, the risks associated with different variants remain unknown, as do the basis of their leukemogenic properties, impact on steady-state hematopoiesis and links to other cancers. Here, we investigate the frequency and significance of DDX41 variants in 454,792 United Kingdom Biobank (UKB) participants and identify 452 unique non-synonymous DNA variants in...]]></summary>
        <author>
            <name>Sruthi Cheloor Kovilakam</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Coordinated inheritance of extrachromosomal DNA species in human cancer cells]]></title>
        <id>pubmed:37503111</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37503111/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230818204446&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-07-28T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[The chromosomal theory of inheritance has dominated human genetics, including cancer genetics. Genes on the same chromosome segregate together while genes on different chromosomes assort independently, providing a fundamental tenet of Mendelian inheritance. Extrachromosomal DNA (ecDNA) is a frequent event in cancer that drives oncogene amplification, dysregulated gene expression and intratumoral heterogeneity, including through random segregation during cell division. Distinct ecDNA sequences,...]]></summary>
        <author>
            <name>King L Hung</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Prevalence and significance of DDX41 gene variants in the general population]]></title>
        <id>pubmed:37506341</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37506341/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230817204642&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-07-28T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Germline variants in the DDX41 gene have been linked to myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML) development. However, the risks associated with different variants remain unknown, as do the basis of their leukemogenic properties, impact on steady-state hematopoiesis and links to other cancers. Here, we investigate the frequency and significance of DDX41 variants in 454,792 United Kingdom Biobank (UKB) participants and identify 452 unique non-synonymous DNA variants in...]]></summary>
        <author>
            <name>Sruthi Cheloor Kovilakam</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Coordinated inheritance of extrachromosomal DNA species in human cancer cells]]></title>
        <id>pubmed:37503111</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37503111/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230817204642&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-07-28T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[The chromosomal theory of inheritance has dominated human genetics, including cancer genetics. Genes on the same chromosome segregate together while genes on different chromosomes assort independently, providing a fundamental tenet of Mendelian inheritance. Extrachromosomal DNA (ecDNA) is a frequent event in cancer that drives oncogene amplification, dysregulated gene expression and intratumoral heterogeneity, including through random segregation during cell division. Distinct ecDNA sequences,...]]></summary>
        <author>
            <name>King L Hung</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Prevalence and significance of DDX41 gene variants in the general population]]></title>
        <id>pubmed:37506341</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37506341/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230816204600&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-07-28T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Germline variants in the DDX41 gene have been linked to myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML) development. However, the risks associated with different variants remain unknown, as do the basis of their leukemogenic properties, impact on steady-state hematopoiesis and links to other cancers. Here, we investigate the frequency and significance of DDX41 variants in 454,792 United Kingdom Biobank (UKB) participants and identify 452 unique non-synonymous DNA variants in...]]></summary>
        <author>
            <name>Sruthi Cheloor Kovilakam</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Coordinated inheritance of extrachromosomal DNA species in human cancer cells]]></title>
        <id>pubmed:37503111</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37503111/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230816204600&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-07-28T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[The chromosomal theory of inheritance has dominated human genetics, including cancer genetics. Genes on the same chromosome segregate together while genes on different chromosomes assort independently, providing a fundamental tenet of Mendelian inheritance. Extrachromosomal DNA (ecDNA) is a frequent event in cancer that drives oncogene amplification, dysregulated gene expression and intratumoral heterogeneity, including through random segregation during cell division. Distinct ecDNA sequences,...]]></summary>
        <author>
            <name>King L Hung</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Prevalence and significance of DDX41 gene variants in the general population]]></title>
        <id>pubmed:37506341</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37506341/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230815204647&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-07-28T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Germline variants in the DDX41 gene have been linked to myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML) development. However, the risks associated with different variants remain unknown, as do the basis of their leukemogenic properties, impact on steady-state hematopoiesis and links to other cancers. Here, we investigate the frequency and significance of DDX41 variants in 454,792 United Kingdom Biobank (UKB) participants and identify 452 unique non-synonymous DNA variants in...]]></summary>
        <author>
            <name>Sruthi Cheloor Kovilakam</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Coordinated inheritance of extrachromosomal DNA species in human cancer cells]]></title>
        <id>pubmed:37503111</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37503111/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230815204647&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-07-28T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[The chromosomal theory of inheritance has dominated human genetics, including cancer genetics. Genes on the same chromosome segregate together while genes on different chromosomes assort independently, providing a fundamental tenet of Mendelian inheritance. Extrachromosomal DNA (ecDNA) is a frequent event in cancer that drives oncogene amplification, dysregulated gene expression and intratumoral heterogeneity, including through random segregation during cell division. Distinct ecDNA sequences,...]]></summary>
        <author>
            <name>King L Hung</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Prevalence and significance of DDX41 gene variants in the general population]]></title>
        <id>pubmed:37506341</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37506341/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230814204719&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-07-28T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Germline variants in the DDX41 gene have been linked to myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML) development. However, the risks associated with different variants remain unknown, as do the basis of their leukemogenic properties, impact on steady-state hematopoiesis and links to other cancers. Here, we investigate the frequency and significance of DDX41 variants in 454,792 United Kingdom Biobank (UKB) participants and identify 452 unique non-synonymous DNA variants in...]]></summary>
        <author>
            <name>Sruthi Cheloor Kovilakam</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Coordinated inheritance of extrachromosomal DNA species in human cancer cells]]></title>
        <id>pubmed:37503111</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37503111/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230814204719&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-07-28T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[The chromosomal theory of inheritance has dominated human genetics, including cancer genetics. Genes on the same chromosome segregate together while genes on different chromosomes assort independently, providing a fundamental tenet of Mendelian inheritance. Extrachromosomal DNA (ecDNA) is a frequent event in cancer that drives oncogene amplification, dysregulated gene expression and intratumoral heterogeneity, including through random segregation during cell division. Distinct ecDNA sequences,...]]></summary>
        <author>
            <name>King L Hung</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Prevalence and significance of DDX41 gene variants in the general population]]></title>
        <id>pubmed:37506341</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37506341/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230813204802&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-07-28T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Germline variants in the DDX41 gene have been linked to myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML) development. However, the risks associated with different variants remain unknown, as do the basis of their leukemogenic properties, impact on steady-state hematopoiesis and links to other cancers. Here, we investigate the frequency and significance of DDX41 variants in 454,792 United Kingdom Biobank (UKB) participants and identify 452 unique non-synonymous DNA variants in...]]></summary>
        <author>
            <name>Sruthi Cheloor Kovilakam</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Coordinated inheritance of extrachromosomal DNA species in human cancer cells]]></title>
        <id>pubmed:37503111</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37503111/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230813204802&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-07-28T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[The chromosomal theory of inheritance has dominated human genetics, including cancer genetics. Genes on the same chromosome segregate together while genes on different chromosomes assort independently, providing a fundamental tenet of Mendelian inheritance. Extrachromosomal DNA (ecDNA) is a frequent event in cancer that drives oncogene amplification, dysregulated gene expression and intratumoral heterogeneity, including through random segregation during cell division. Distinct ecDNA sequences,...]]></summary>
        <author>
            <name>King L Hung</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Prevalence and significance of DDX41 gene variants in the general population]]></title>
        <id>pubmed:37506341</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37506341/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230812205008&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-07-28T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Germline variants in the DDX41 gene have been linked to myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML) development. However, the risks associated with different variants remain unknown, as do the basis of their leukemogenic properties, impact on steady-state hematopoiesis and links to other cancers. Here, we investigate the frequency and significance of DDX41 variants in 454,792 United Kingdom Biobank (UKB) participants and identify 452 unique non-synonymous DNA variants in...]]></summary>
        <author>
            <name>Sruthi Cheloor Kovilakam</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Coordinated inheritance of extrachromosomal DNA species in human cancer cells]]></title>
        <id>pubmed:37503111</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37503111/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230812205008&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-07-28T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[The chromosomal theory of inheritance has dominated human genetics, including cancer genetics. Genes on the same chromosome segregate together while genes on different chromosomes assort independently, providing a fundamental tenet of Mendelian inheritance. Extrachromosomal DNA (ecDNA) is a frequent event in cancer that drives oncogene amplification, dysregulated gene expression and intratumoral heterogeneity, including through random segregation during cell division. Distinct ecDNA sequences,...]]></summary>
        <author>
            <name>King L Hung</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Prevalence and significance of DDX41 gene variants in the general population]]></title>
        <id>pubmed:37506341</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37506341/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230811204539&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-07-28T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Germline variants in the DDX41 gene have been linked to myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML) development. However, the risks associated with different variants remain unknown, as do the basis of their leukemogenic properties, impact on steady-state hematopoiesis and links to other cancers. Here, we investigate the frequency and significance of DDX41 variants in 454,792 United Kingdom Biobank (UKB) participants and identify 452 unique non-synonymous DNA variants in...]]></summary>
        <author>
            <name>Sruthi Cheloor Kovilakam</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Coordinated inheritance of extrachromosomal DNA species in human cancer cells]]></title>
        <id>pubmed:37503111</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37503111/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230811204539&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-07-28T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[The chromosomal theory of inheritance has dominated human genetics, including cancer genetics. Genes on the same chromosome segregate together while genes on different chromosomes assort independently, providing a fundamental tenet of Mendelian inheritance. Extrachromosomal DNA (ecDNA) is a frequent event in cancer that drives oncogene amplification, dysregulated gene expression and intratumoral heterogeneity, including through random segregation during cell division. Distinct ecDNA sequences,...]]></summary>
        <author>
            <name>King L Hung</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Prevalence and significance of DDX41 gene variants in the general population]]></title>
        <id>pubmed:37506341</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37506341/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230810204637&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-07-28T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Germline variants in the DDX41 gene have been linked to myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML) development. However, the risks associated with different variants remain unknown, as do the basis of their leukemogenic properties, impact on steady-state hematopoiesis and links to other cancers. Here, we investigate the frequency and significance of DDX41 variants in 454,792 United Kingdom Biobank (UKB) participants and identify 452 unique non-synonymous DNA variants in...]]></summary>
        <author>
            <name>Sruthi Cheloor Kovilakam</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Coordinated inheritance of extrachromosomal DNA species in human cancer cells]]></title>
        <id>pubmed:37503111</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37503111/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230810204637&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-07-28T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[The chromosomal theory of inheritance has dominated human genetics, including cancer genetics. Genes on the same chromosome segregate together while genes on different chromosomes assort independently, providing a fundamental tenet of Mendelian inheritance. Extrachromosomal DNA (ecDNA) is a frequent event in cancer that drives oncogene amplification, dysregulated gene expression and intratumoral heterogeneity, including through random segregation during cell division. Distinct ecDNA sequences,...]]></summary>
        <author>
            <name>King L Hung</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Prevalence and significance of DDX41 gene variants in the general population]]></title>
        <id>pubmed:37506341</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37506341/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230809205914&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-07-28T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Germline variants in the DDX41 gene have been linked to myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML) development. However, the risks associated with different variants remain unknown, as do the basis of their leukemogenic properties, impact on steady-state hematopoiesis and links to other cancers. Here, we investigate the frequency and significance of DDX41 variants in 454,792 United Kingdom Biobank (UKB) participants and identify 452 unique non-synonymous DNA variants in...]]></summary>
        <author>
            <name>Sruthi Cheloor Kovilakam</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Coordinated inheritance of extrachromosomal DNA species in human cancer cells]]></title>
        <id>pubmed:37503111</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37503111/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230809205914&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-07-28T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[The chromosomal theory of inheritance has dominated human genetics, including cancer genetics. Genes on the same chromosome segregate together while genes on different chromosomes assort independently, providing a fundamental tenet of Mendelian inheritance. Extrachromosomal DNA (ecDNA) is a frequent event in cancer that drives oncogene amplification, dysregulated gene expression and intratumoral heterogeneity, including through random segregation during cell division. Distinct ecDNA sequences,...]]></summary>
        <author>
            <name>King L Hung</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Prevalence and significance of DDX41 gene variants in the general population]]></title>
        <id>pubmed:37506341</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37506341/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230808205751&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-07-28T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Germline variants in the DDX41 gene have been linked to myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML) development. However, the risks associated with different variants remain unknown, as do the basis of their leukemogenic properties, impact on steady-state hematopoiesis and links to other cancers. Here, we investigate the frequency and significance of DDX41 variants in 454,792 United Kingdom Biobank (UKB) participants and identify 452 unique non-synonymous DNA variants in...]]></summary>
        <author>
            <name>Sruthi Cheloor Kovilakam</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Coordinated inheritance of extrachromosomal DNA species in human cancer cells]]></title>
        <id>pubmed:37503111</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37503111/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230808205751&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-07-28T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[The chromosomal theory of inheritance has dominated human genetics, including cancer genetics. Genes on the same chromosome segregate together while genes on different chromosomes assort independently, providing a fundamental tenet of Mendelian inheritance. Extrachromosomal DNA (ecDNA) is a frequent event in cancer that drives oncogene amplification, dysregulated gene expression and intratumoral heterogeneity, including through random segregation during cell division. Distinct ecDNA sequences,...]]></summary>
        <author>
            <name>King L Hung</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Prevalence and significance of DDX41 gene variants in the general population]]></title>
        <id>pubmed:37506341</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37506341/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230807205649&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-07-28T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Germline variants in the DDX41 gene have been linked to myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML) development. However, the risks associated with different variants remain unknown, as do the basis of their leukemogenic properties, impact on steady-state hematopoiesis and links to other cancers. Here, we investigate the frequency and significance of DDX41 variants in 454,792 United Kingdom Biobank (UKB) participants and identify 452 unique non-synonymous DNA variants in...]]></summary>
        <author>
            <name>Sruthi Cheloor Kovilakam</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Coordinated inheritance of extrachromosomal DNA species in human cancer cells]]></title>
        <id>pubmed:37503111</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37503111/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230807205649&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-07-28T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[The chromosomal theory of inheritance has dominated human genetics, including cancer genetics. Genes on the same chromosome segregate together while genes on different chromosomes assort independently, providing a fundamental tenet of Mendelian inheritance. Extrachromosomal DNA (ecDNA) is a frequent event in cancer that drives oncogene amplification, dysregulated gene expression and intratumoral heterogeneity, including through random segregation during cell division. Distinct ecDNA sequences,...]]></summary>
        <author>
            <name>King L Hung</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Prevalence and significance of DDX41 gene variants in the general population]]></title>
        <id>pubmed:37506341</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37506341/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230806205822&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-07-28T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Germline variants in the DDX41 gene have been linked to myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML) development. However, the risks associated with different variants remain unknown, as do the basis of their leukemogenic properties, impact on steady-state hematopoiesis and links to other cancers. Here, we investigate the frequency and significance of DDX41 variants in 454,792 United Kingdom Biobank (UKB) participants and identify 452 unique non-synonymous DNA variants in...]]></summary>
        <author>
            <name>Sruthi Cheloor Kovilakam</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Coordinated inheritance of extrachromosomal DNA species in human cancer cells]]></title>
        <id>pubmed:37503111</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37503111/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230806205822&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-07-28T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[The chromosomal theory of inheritance has dominated human genetics, including cancer genetics. Genes on the same chromosome segregate together while genes on different chromosomes assort independently, providing a fundamental tenet of Mendelian inheritance. Extrachromosomal DNA (ecDNA) is a frequent event in cancer that drives oncogene amplification, dysregulated gene expression and intratumoral heterogeneity, including through random segregation during cell division. Distinct ecDNA sequences,...]]></summary>
        <author>
            <name>King L Hung</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Prevalence and significance of DDX41 gene variants in the general population]]></title>
        <id>pubmed:37506341</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37506341/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230805205329&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-07-28T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Germline variants in the DDX41 gene have been linked to myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML) development. However, the risks associated with different variants remain unknown, as do the basis of their leukemogenic properties, impact on steady-state hematopoiesis and links to other cancers. Here, we investigate the frequency and significance of DDX41 variants in 454,792 United Kingdom Biobank (UKB) participants and identify 452 unique non-synonymous DNA variants in...]]></summary>
        <author>
            <name>Sruthi Cheloor Kovilakam</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Coordinated inheritance of extrachromosomal DNA species in human cancer cells]]></title>
        <id>pubmed:37503111</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37503111/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230805205329&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-07-28T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[The chromosomal theory of inheritance has dominated human genetics, including cancer genetics. Genes on the same chromosome segregate together while genes on different chromosomes assort independently, providing a fundamental tenet of Mendelian inheritance. Extrachromosomal DNA (ecDNA) is a frequent event in cancer that drives oncogene amplification, dysregulated gene expression and intratumoral heterogeneity, including through random segregation during cell division. Distinct ecDNA sequences,...]]></summary>
        <author>
            <name>King L Hung</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Prevalence and significance of DDX41 gene variants in the general population]]></title>
        <id>pubmed:37506341</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37506341/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230804205603&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-07-28T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Germline variants in the DDX41 gene have been linked to myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML) development. However, the risks associated with different variants remain unknown, as do the basis of their leukemogenic properties, impact on steady-state hematopoiesis and links to other cancers. Here, we investigate the frequency and significance of DDX41 variants in 454,792 United Kingdom Biobank (UKB) participants and identify 452 unique non-synonymous DNA variants in...]]></summary>
        <author>
            <name>Sruthi Cheloor Kovilakam</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Coordinated inheritance of extrachromosomal DNA species in human cancer cells]]></title>
        <id>pubmed:37503111</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37503111/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230804205603&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-07-28T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[The chromosomal theory of inheritance has dominated human genetics, including cancer genetics. Genes on the same chromosome segregate together while genes on different chromosomes assort independently, providing a fundamental tenet of Mendelian inheritance. Extrachromosomal DNA (ecDNA) is a frequent event in cancer that drives oncogene amplification, dysregulated gene expression and intratumoral heterogeneity, including through random segregation during cell division. Distinct ecDNA sequences,...]]></summary>
        <author>
            <name>King L Hung</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Prevalence and significance of DDX41 gene variants in the general population]]></title>
        <id>pubmed:37506341</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37506341/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230803205941&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-07-28T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Germline variants in the DDX41 gene have been linked to myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML) development. However, the risks associated with different variants remain unknown, as do the basis of their leukemogenic properties, impact on steady-state hematopoiesis and links to other cancers. Here, we investigate the frequency and significance of DDX41 variants in 454,792 United Kingdom Biobank (UKB) participants and identify 452 unique non-synonymous DNA variants in...]]></summary>
        <author>
            <name>Sruthi Cheloor Kovilakam</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Coordinated inheritance of extrachromosomal DNA species in human cancer cells]]></title>
        <id>pubmed:37503111</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37503111/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230803205941&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-07-28T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[The chromosomal theory of inheritance has dominated human genetics, including cancer genetics. Genes on the same chromosome segregate together while genes on different chromosomes assort independently, providing a fundamental tenet of Mendelian inheritance. Extrachromosomal DNA (ecDNA) is a frequent event in cancer that drives oncogene amplification, dysregulated gene expression and intratumoral heterogeneity, including through random segregation during cell division. Distinct ecDNA sequences,...]]></summary>
        <author>
            <name>King L Hung</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Prevalence and significance of DDX41 gene variants in the general population]]></title>
        <id>pubmed:37506341</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37506341/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230802205831&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-07-28T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Germline variants in the DDX41 gene have been linked to myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML) development. However, the risks associated with different variants remain unknown, as do the basis of their leukemogenic properties, impact on steady-state hematopoiesis and links to other cancers. Here, we investigate the frequency and significance of DDX41 variants in 454,792 United Kingdom Biobank (UKB) participants and identify 452 unique non-synonymous DNA variants in...]]></summary>
        <author>
            <name>Sruthi Cheloor Kovilakam</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Coordinated inheritance of extrachromosomal DNA species in human cancer cells]]></title>
        <id>pubmed:37503111</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37503111/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230802205831&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-07-28T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[The chromosomal theory of inheritance has dominated human genetics, including cancer genetics. Genes on the same chromosome segregate together while genes on different chromosomes assort independently, providing a fundamental tenet of Mendelian inheritance. Extrachromosomal DNA (ecDNA) is a frequent event in cancer that drives oncogene amplification, dysregulated gene expression and intratumoral heterogeneity, including through random segregation during cell division. Distinct ecDNA sequences,...]]></summary>
        <author>
            <name>King L Hung</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Prevalence and significance of DDX41 gene variants in the general population]]></title>
        <id>pubmed:37506341</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37506341/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230801205540&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-07-28T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Germline variants in the DDX41 gene have been linked to myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML) development. However, the risks associated with different variants remain unknown, as do the basis of their leukemogenic properties, impact on steady-state hematopoiesis and links to other cancers. Here, we investigate the frequency and significance of DDX41 variants in 454,792 United Kingdom Biobank (UKB) participants and identify 452 unique non-synonymous DNA variants in...]]></summary>
        <author>
            <name>Sruthi Cheloor Kovilakam</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Coordinated inheritance of extrachromosomal DNA species in human cancer cells]]></title>
        <id>pubmed:37503111</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37503111/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230801205540&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-07-28T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[The chromosomal theory of inheritance has dominated human genetics, including cancer genetics. Genes on the same chromosome segregate together while genes on different chromosomes assort independently, providing a fundamental tenet of Mendelian inheritance. Extrachromosomal DNA (ecDNA) is a frequent event in cancer that drives oncogene amplification, dysregulated gene expression and intratumoral heterogeneity, including through random segregation during cell division. Distinct ecDNA sequences,...]]></summary>
        <author>
            <name>King L Hung</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Prevalence and significance of DDX41 gene variants in the general population]]></title>
        <id>pubmed:37506341</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37506341/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230731210325&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-07-28T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Germline variants in the DDX41 gene have been linked to myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML) development. However, the risks associated with different variants remain unknown, as do the basis of their leukemogenic properties, impact on steady-state hematopoiesis and links to other cancers. Here, we investigate the frequency and significance of DDX41 variants in 454,792 United Kingdom Biobank (UKB) participants and identify 452 unique non-synonymous DNA variants in...]]></summary>
        <author>
            <name>Sruthi Cheloor Kovilakam</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Coordinated inheritance of extrachromosomal DNA species in human cancer cells]]></title>
        <id>pubmed:37503111</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37503111/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230731210325&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-07-28T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[The chromosomal theory of inheritance has dominated human genetics, including cancer genetics. Genes on the same chromosome segregate together while genes on different chromosomes assort independently, providing a fundamental tenet of Mendelian inheritance. Extrachromosomal DNA (ecDNA) is a frequent event in cancer that drives oncogene amplification, dysregulated gene expression and intratumoral heterogeneity, including through random segregation during cell division. Distinct ecDNA sequences,...]]></summary>
        <author>
            <name>King L Hung</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Prevalence and significance of DDX41 gene variants in the general population]]></title>
        <id>pubmed:37506341</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37506341/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230730205823&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-07-28T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Germline variants in the DDX41 gene have been linked to myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML) development. However, the risks associated with different variants remain unknown, as do the basis of their leukemogenic properties, impact on steady-state hematopoiesis and links to other cancers. Here, we investigate the frequency and significance of DDX41 variants in 454,792 United Kingdom Biobank (UKB) participants and identify 452 unique non-synonymous DNA variants in...]]></summary>
        <author>
            <name>Sruthi Cheloor Kovilakam</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Coordinated inheritance of extrachromosomal DNA species in human cancer cells]]></title>
        <id>pubmed:37503111</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37503111/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230730205823&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-07-28T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[The chromosomal theory of inheritance has dominated human genetics, including cancer genetics. Genes on the same chromosome segregate together while genes on different chromosomes assort independently, providing a fundamental tenet of Mendelian inheritance. Extrachromosomal DNA (ecDNA) is a frequent event in cancer that drives oncogene amplification, dysregulated gene expression and intratumoral heterogeneity, including through random segregation during cell division. Distinct ecDNA sequences,...]]></summary>
        <author>
            <name>King L Hung</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Prevalence and significance of DDX41 gene variants in the general population]]></title>
        <id>pubmed:37506341</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37506341/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230729205947&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-07-28T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Germline variants in the DDX41 gene have been linked to myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML) development. However, the risks associated with different variants remain unknown, as do the basis of their leukemogenic properties, impact on steady-state hematopoiesis and links to other cancers. Here, we investigate the frequency and significance of DDX41 variants in 454,792 United Kingdom Biobank (UKB) participants and identify 452 unique non-synonymous DNA variants in...]]></summary>
        <author>
            <name>Sruthi Cheloor Kovilakam</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Coordinated inheritance of extrachromosomal DNA species in human cancer cells]]></title>
        <id>pubmed:37503111</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37503111/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230729205947&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-07-28T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[The chromosomal theory of inheritance has dominated human genetics, including cancer genetics. Genes on the same chromosome segregate together while genes on different chromosomes assort independently, providing a fundamental tenet of Mendelian inheritance. Extrachromosomal DNA (ecDNA) is a frequent event in cancer that drives oncogene amplification, dysregulated gene expression and intratumoral heterogeneity, including through random segregation during cell division. Distinct ecDNA sequences,...]]></summary>
        <author>
            <name>King L Hung</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Prevalence and significance of DDX41 gene variants in the general population]]></title>
        <id>pubmed:37506341</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37506341/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230728205723&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-07-28T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Germline variants in the DDX41 gene have been linked to myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML) development. However, the risks associated with different variants remain unknown, as do the basis of their leukemogenic properties, impact on steady-state hematopoiesis and links to other cancers. Here, we investigate the frequency and significance of DDX41 variants in 454,792 United Kingdom Biobank (UKB) participants and identify 452 unique non-synonymous DNA variants in...]]></summary>
        <author>
            <name>Sruthi Cheloor Kovilakam</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Coordinated inheritance of extrachromosomal DNA species in human cancer cells]]></title>
        <id>pubmed:37503111</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37503111/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230728205723&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-07-28T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[The chromosomal theory of inheritance has dominated human genetics, including cancer genetics. Genes on the same chromosome segregate together while genes on different chromosomes assort independently, providing a fundamental tenet of Mendelian inheritance. Extrachromosomal DNA (ecDNA) is a frequent event in cancer that drives oncogene amplification, dysregulated gene expression and intratumoral heterogeneity, including through random segregation during cell division. Distinct ecDNA sequences,...]]></summary>
        <author>
            <name>King L Hung</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[@NatureRevCancer: NEW content online! Nodal interferon exposure drives tumour-specific tolerance]]></title>
        <id>72a3a11d39c217b1a80cbb551444e6f6</id>
        <link href="https://twitter.com/NatureRevCancer/status/1533878403463405569"/>
        <updated>2022-06-06T18:28:04.000Z</updated>
        <summary type="html"><![CDATA[NEW content online! Nodal interferon exposure drives tumour-specific tolerance https://t.co/FT4NeBcFTg pic.twitter.com/NRHkVDUsOr
 NatureReviewsCancer (@NatureRevCancer) June 6, 2022]]></summary>
        <author>
            <name>@NatureRevCancer</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[@VIBConferences: #Cancer #immunotherapy has become a crucial pillar of anticancer therapy. 19 leading researchers at #ImmunoOnco22 will give new insights into the immune response to tumors and tackle unresolved questions.Registration Deadline: Thursday 2 June. Read more]]></title>
        <id>bb6bc242bcbc356c4a38db850e74d812</id>
        <link href="https://twitter.com/VIBConferences/status/1531132720952266752"/>
        <updated>2022-05-30T04:37:42.000Z</updated>
        <summary type="html"><![CDATA[#Cancer #immunotherapy has become a crucial pillar of anticancer therapy. 19 leading researchers at #ImmunoOnco22 will give new insights into the immune response to tumors and tackle unresolved questions.
Registration Deadline: Thursday 2 June. Read more https://t.co/cc0HC5cj6W pic.twitter.com/u8LFuzBbsV
 VIB Conferences (@VIBConferences) May 30, 2022]]></summary>
        <author>
            <name>@VIBConferences</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[@NatureRevCancer: NEW content online! Nonsense-mediated RNA decay: an emerging modulator of malignancy]]></title>
        <id>ed6c996dc1a718afb523de6229a53131</id>
        <link href="https://twitter.com/NatureRevCancer/status/1530198403686072320"/>
        <updated>2022-05-27T14:45:03.000Z</updated>
        <summary type="html"><![CDATA[NEW content online! Nonsense-mediated RNA decay: an emerging modulator of malignancy https://t.co/wjuHplkpof pic.twitter.com/1SoKYhRsPO
 NatureReviewsCancer (@NatureRevCancer) May 27, 2022]]></summary>
        <author>
            <name>@NatureRevCancer</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[@NatureRevCancer: Our June issue, out NOW! With articles on #therapyresistance, #senescence & targeting CDK4 & CDK6 in #cancer! Plus, a Comment on cancer mRNA vaccines as well as the launch of our new Tools of the Trade articles #NRCToT. So much content ]]></title>
        <id>d15a3a4b24853812d7fa21fd56de5815</id>
        <link href="https://twitter.com/NatureRevCancer/status/1530174481313972224"/>
        <updated>2022-05-27T13:10:00.000Z</updated>
        <summary type="html"><![CDATA[Our June issue, out NOW! With articles on #therapyresistance, #senescence & targeting CDK4 & CDK6 in #cancer! Plus, a Comment on cancer mRNA vaccines as well as the launch of our new Tools of the Trade articles #NRCToT. So much content 
 https://t.co/Fo6XRWV3OZ@natrescancer pic.twitter.com/rbxRPqLV6g
 NatureReviewsCancer (@NatureRevCancer) May 27, 2022]]></summary>
        <author>
            <name>@NatureRevCancer</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[@UlrikeHarjes: This Review by @MarcusDGon @cantleylab is part of the @NatureRevCancer series on #Diet & #SystemicMetabolism in cancer:  do love this topic in general plus I am handling research at @NatureMedicine now.. get in touch if you have something of interest]]></title>
        <id>fe13755a2693ea65459e5e21df097d2a</id>
        <link href="https://twitter.com/UlrikeHarjes/status/1529747629936193537"/>
        <updated>2022-05-26T08:53:50.000Z</updated>
        <summary type="html"><![CDATA[This Review by @MarcusDGon @cantleylab is part of the @NatureRevCancer series on #Diet & #SystemicMetabolism in cancer: https://t.co/p3Y2cdNhco
I do love this topic in general plus I am handling research at @NatureMedicine now.. get in touch if you have something of interest https://t.co/qWH2dTv8j9
 Ulrike Harjes (@UlrikeHarjes) May 26, 2022]]></summary>
        <author>
            <name>@UlrikeHarjes</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[@NatureRevCancer: NEW content online! Developing dietary interventions as therapy for cancer]]></title>
        <id>9ba5279424b31b0122a4ae20c18e6d03</id>
        <link href="https://twitter.com/NatureRevCancer/status/1529516411059437568"/>
        <updated>2022-05-25T17:35:04.000Z</updated>
        <summary type="html"><![CDATA[NEW content online! Developing dietary interventions as therapy for cancer https://t.co/ijuqctk1wJ pic.twitter.com/KHPpMKnCFa
 NatureReviewsCancer (@NatureRevCancer) May 25, 2022]]></summary>
        <author>
            <name>@NatureRevCancer</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[@NatureRevCancer: NEW content online! Digging for treasures in the tumour interactome]]></title>
        <id>611d40f2e6ea2796b028bebda41a86dd</id>
        <link href="https://twitter.com/NatureRevCancer/status/1526928478490095616"/>
        <updated>2022-05-18T14:11:32.000Z</updated>
        <summary type="html"><![CDATA[NEW content online! Digging for treasures in the tumour interactome https://t.co/NhHYAwUgLE
 NatureReviewsCancer (@NatureRevCancer) May 18, 2022]]></summary>
        <author>
            <name>@NatureRevCancer</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[@NatureRevCancer: As part of our overall commitment to diversity, equity and inclusion at Springer Nature, wed like to better understand what DEI means within the global research community. Take the survey here]]></title>
        <id>9590a971b00448cd312078183965b21d</id>
        <link href="https://twitter.com/NatureRevCancer/status/1526560254091313156"/>
        <updated>2022-05-17T13:48:21.000Z</updated>
        <summary type="html"><![CDATA[As part of our overall commitment to diversity, equity and inclusion at Springer Nature, wed like to better understand what DEI means within the global research community. Take the survey here https://t.co/03yLiUxFTq
 NatureReviewsCancer (@NatureRevCancer) May 17, 2022]]></summary>
        <author>
            <name>@NatureRevCancer</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[@NatureRevCancer: Newsflash! We have a new article type in the journal - Tools of the Trade #NRCToT   where we hope to enable more #ECRs to interact with the editorial team & have a bigger voice in our content. For more info, check out the Editorial ]]></title>
        <id>aa38ff4245b93e964773f191844ddc7a</id>
        <link href="https://twitter.com/NatureRevCancer/status/1524772831904509953"/>
        <updated>2022-05-12T15:25:46.000Z</updated>
        <summary type="html"><![CDATA[Newsflash! We have a new article type in the journal - Tools of the Trade #NRCToT   where we hope to enable more #ECRs to interact with the editorial team & have a bigger voice in our content. For more info, check out the Editorial  https://t.co/VbyoUJmTRJ
 NatureReviewsCancer (@NatureRevCancer) May 12, 2022]]></summary>
        <author>
            <name>@NatureRevCancer</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[@NatureRevCancer: NEW content online! Tools for the next generation]]></title>
        <id>65aca76b9f794aaa668d84ad32dca4a0</id>
        <link href="https://twitter.com/NatureRevCancer/status/1524068259712036864"/>
        <updated>2022-05-10T16:46:03.000Z</updated>
        <summary type="html"><![CDATA[NEW content online! Tools for the next generation https://t.co/lEzTPFYDf5
 NatureReviewsCancer (@NatureRevCancer) May 10, 2022]]></summary>
        <author>
            <name>@NatureRevCancer</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[@NatureRevCancer: NEW content online! Hunting down rare drug-tolerant cycling cells with Watermelon]]></title>
        <id>afa9b6784b4ccc7c05ed4efd26ddfb2d</id>
        <link href="https://twitter.com/NatureRevCancer/status/1524022709386190856"/>
        <updated>2022-05-10T13:45:03.000Z</updated>
        <summary type="html"><![CDATA[NEW content online! Hunting down rare drug-tolerant cycling cells with Watermelon https://t.co/XXT0c9SAYX
 NatureReviewsCancer (@NatureRevCancer) May 10, 2022]]></summary>
        <author>
            <name>@NatureRevCancer</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[@VarunVenkatara2: Very happy that our latest Perspective is now online @NatureRevCancer ! We discuss implications of malignant, multicellular networks and potential therapeutic strategies how to disconnect them. Thanks to everyone involved ! #CancerNeuroscience #TumorMicrotubes #neurotwitter]]></title>
        <id>43e2d5ccebc9030f737d656f47ac9d98</id>
        <link href="https://twitter.com/VarunVenkatara2/status/1520050291986604033"/>
        <updated>2022-04-29T14:40:05.000Z</updated>
        <summary type="html"><![CDATA[Very happy that our latest Perspective is now online @NatureRevCancer ! We discuss implications of malignant, multicellular networks and potential therapeutic strategies how to disconnect them. Thanks to everyone involved ! #CancerNeuroscience #TumorMicrotubes #neurotwitter https://t.co/S55cKTGNFd
 Varun Venkataramani (@VarunVenkatara2) April 29, 2022]]></summary>
        <author>
            <name>@VarunVenkatara2</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[@NatureRevCancer: NEW content online! An inhospitable site]]></title>
        <id>9f6b8644378881f4c2e6b6833c93fc2f</id>
        <link href="https://twitter.com/NatureRevCancer/status/1520020349068316673"/>
        <updated>2022-04-29T12:41:06.000Z</updated>
        <summary type="html"><![CDATA[NEW content online! An inhospitable site https://t.co/0dvqIKCWxh pic.twitter.com/PtY8J9Fz7r
 NatureReviewsCancer (@NatureRevCancer) April 29, 2022]]></summary>
        <author>
            <name>@NatureRevCancer</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[@NatureRevCancer: NEW content online! Disconnecting multicellular networks in brain tumours]]></title>
        <id>f6d91efcd60dae769e2722585bdfa8df</id>
        <link href="https://twitter.com/NatureRevCancer/status/1520020340201598978"/>
        <updated>2022-04-29T12:41:04.000Z</updated>
        <summary type="html"><![CDATA[NEW content online! Disconnecting multicellular networks in brain tumours https://t.co/LJrzy8bRma pic.twitter.com/CO7BnooP0r
 NatureReviewsCancer (@NatureRevCancer) April 29, 2022]]></summary>
        <author>
            <name>@NatureRevCancer</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[@NatureRevCancer: Our May issue, out NOW! With Reviews on #CRISPR in cancer biology & #therapy, ROS in tumour development & progression, and cancer #proteogenomics, and Comments on esophageal cancer research in Eastern Africa and on Critical Race Theory.]]></title>
        <id>76e3b436bc8e43ad21366a80c120e395</id>
        <link href="https://twitter.com/NatureRevCancer/status/1519678964364623872"/>
        <updated>2022-04-28T14:04:34.000Z</updated>
        <summary type="html"><![CDATA[Our May issue, out NOW! With Reviews on #CRISPR in cancer biology & #therapy, ROS in tumour development & progression, and cancer #proteogenomics, and Comments on esophageal cancer research in Eastern Africa and on Critical Race Theory.
 https://t.co/vQwHFJhpwv@natrescancer pic.twitter.com/6kYgjRYhdT
 NatureReviewsCancer (@NatureRevCancer) April 28, 2022]]></summary>
        <author>
            <name>@NatureRevCancer</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[@tmurraystewart: Our latest publication on #polyamines is online!@HopkinsMedicine]]></title>
        <id>fdf224ea293cdf039086d16e5699a59a</id>
        <link href="https://twitter.com/tmurraystewart/status/1519413460978704384"/>
        <updated>2022-04-27T20:29:33.000Z</updated>
        <summary type="html"><![CDATA[Our latest publication on #polyamines is online!@HopkinsMedicine https://t.co/ehRGgN1w9R
 Tracy Murray Stewart (@tmurraystewart) April 27, 2022]]></summary>
        <author>
            <name>@tmurraystewart</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[@NatureRevCancer: NEW content online! Polyamines in cancer: integrating organismal metabolism and antitumour immunity]]></title>
        <id>4f43226ec4dc8e531ff6e64a9c5ab8e6</id>
        <link href="https://twitter.com/NatureRevCancer/status/1519381375874265088"/>
        <updated>2022-04-27T18:22:03.000Z</updated>
        <summary type="html"><![CDATA[NEW content online! Polyamines in cancer: integrating organismal metabolism and antitumour immunity https://t.co/YCJX1hRQLO pic.twitter.com/zRUCRNXyxH
 NatureReviewsCancer (@NatureRevCancer) April 27, 2022]]></summary>
        <author>
            <name>@NatureRevCancer</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[@NatureRevCancer: NEW #ResearchHighlight! Lv, Liu, Mo & co demonstrate that in pancreatic #PDAC cells, gasdermin E transports YBX1 to the nucleus, which promotes mucin expression, thereby providing tumour cells with a barrier against digestive enzymes.]]></title>
        <id>a44ed79b9f76aad377b9272fb392f553</id>
        <link href="https://twitter.com/NatureRevCancer/status/1519317944995569664"/>
        <updated>2022-04-27T14:10:00.000Z</updated>
        <summary type="html"><![CDATA[NEW #ResearchHighlight! Lv, Liu, Mo & co demonstrate that in pancreatic #PDAC cells, gasdermin E transports YBX1 to the nucleus, which promotes mucin expression, thereby providing tumour cells with a barrier against digestive enzymes.
 https://t.co/JTUhX0DHQ1@natrescancer pic.twitter.com/2PdCmsDu2p
 NatureReviewsCancer (@NatureRevCancer) April 27, 2022]]></summary>
        <author>
            <name>@NatureRevCancer</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[@NatureRevCancer: In the April issue of @NatureRevCancer | Comment, Reimagining cancer research with art, by @CancerSciArtist, Stefani Shoreibah & @tdanino  @natrescancer @Columbia]]></title>
        <id>06ff7641d8f5fcc0dff91f835ac3bbc1</id>
        <link href="https://twitter.com/NatureRevCancer/status/1518967636561956865"/>
        <updated>2022-04-26T14:58:00.000Z</updated>
        <summary type="html"><![CDATA[In the April issue of @NatureRevCancer | Comment, Reimagining cancer research with art, by @CancerSciArtist, Stefani Shoreibah & @tdanino
 https://t.co/GeTVCMJQsp @natrescancer
 @Columbia pic.twitter.com/ZXW6A0Fe0c
 NatureReviewsCancer (@NatureRevCancer) April 26, 2022]]></summary>
        <author>
            <name>@NatureRevCancer</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[@NatureRevCancer: NEW content online! Tracking dormant disseminated tumour cells]]></title>
        <id>96b2ddff4eb269cf343213c6a1b1ce95</id>
        <link href="https://twitter.com/NatureRevCancer/status/1518563607440621569"/>
        <updated>2022-04-25T12:12:32.000Z</updated>
        <summary type="html"><![CDATA[NEW content online! Tracking dormant disseminated tumour cells https://t.co/kSXyWAvCxF
 NatureReviewsCancer (@NatureRevCancer) April 25, 2022]]></summary>
        <author>
            <name>@NatureRevCancer</name>
        </author>
    </entry>
</feed>